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INTRODUCTION
The landmark Synergy between Percutaneous Coronary Intervention with Taxus and 
Cardiac Surgery (SYNTAX) Trial1-4 has aided in reducing the area of uncertainty in deci-
sion making between percutaneous coronary intervention (PCI) and coronary artery 
bypass graft (CABG) surgery in patients with complex coronary artery disease.5-8 
As part of the SYNTAX Trial, quantification of the coronary artery disease burden was 
undertaken with the anatomical SYNTAX Score (www.syntaxscore.com),9-11 and has since 
been implemented in international revascularisation guidelines.5-8 In addition, recognis-
ing the importance of quantifying coronary artery disease burden in decision-making 
between CABG and PCI, the US Food and Drugs Association mandates the SYNTAX 
Score as entry criteria in ongoing contemporary stent and structural heart disease trials. 
Namely, the EXCEL (Evaluation of XIENCE PRIME™ or XIENCE V® Everolimus Eluting Stent 
System Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascular-
ization) Trial (ClinicalTrials.gov identifier: NCT01205776), and SURTAVI (Safety and Effi-
cacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic 
Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement) Trial 
(ClinicalTrials.gov identifier: NCT01586910).
The SYNTAX Trial was conceived in an era when the potential benefits of drug eluting 
stents were first being realised between 2002-2006.12-19 After multiple prior attempts 
comparing CABG against PCI using older technologies – namely plain ‘old’ balloon 
angioplasty (POBA) and bare metal stents (BMS)  – in over 20 randomised trials,20, 21 
including the Bypass Angioplasty Revascularization Investigation (BARI)22 and Coronary 
Angioplasty versus Bypass Revascularisation Investigation (CABRI)23 trials, the time had 
once again come to rechallenge the cardiac surgeons in the management of complex 
coronary artery disease.
Historically one of the major criticisms of randomised trial design comparing CABG 
against PCI was that the trials enrolled highly selected, “cherry-picked,” patients, with 
approximately 2-12% of screened subjects actually randomised in most trials, and thus 
being largely unrepresentative of conventional clinical practice.20, 24 At the time of the 
SYNTAX Trial design, one of the key requirements put forth by seven cardiac surgeons, 
dubbed the “magnificent seven,” and fully endorsed by the clinical and interventional 
cardiologists at the time, was the need for an ‘all-comers’ trial design, free from selection 
bias.
One of the unique aspects of the SYNTAX Trial was that a Heart Team  – consisting 
of at least a cardiac surgeon and an interventional cardiologist  – were required to use 
the SYNTAX Score as an objective anatomical scoring tool that forced the Heart Team 
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to systematically analyse the coronary angiogram, and agree that equivalent anatomic 
revascularisation between CABG and PCI could be achieved, based on a vessel size 
of 1.5 mm. Subjects were randomised if the Heart Team agreed that equivalent ana-
tomic revascularisation could be achieved; subjects not suitable for randomisation were 
nested in CABG (PCI-ineligible patients) and PCI (CABG-ineligible patients) registries and 
followed up.4 Notably, at the time of the SYNTAX Trial, the potential importance of the 
SYNTAX Score in stratifying patient outcomes and guiding decision making between 
CABG and PCI was unknown.
The aim of the thesis was to systematically study all aspects of the SYNTAX Trial, in or-
der to better understand the results of this landmark trial, and its potential implications 
for current and future clinical practice. In addition, the development and/or validation 
of various SYNTAX based clinical tools are examined.
In Part I we explore the progress made prior to the thesis, and describe contemporary 
and evolving anatomical, myocardial jeopardy, and clinical risk scoring systems, to aid 
in identifying higher risk subjects undergoing coronary revascularisation, and decision 
making between CABG and PCI. 
In Part II we show, through examination of the randomised and nested registries (more 
representative of an all-comers population) of the SYNTAX Trial, that incomplete revas-
cularisation has a negative impact on long term mortality in both CABG and PCI treated 
patients. In addition, we show that the clinical impact of incomplete revascularisation 
is dependent on the complexity of the baseline coronary disease and risk profile of the 
CABG and PCI populations. 
In Part III we develop and validate SYNTAX based clinical tools that objectively define 
levels of incomplete revascularisation. These tools may aid the clinician in determining 
a level of reasonable incomplete revascularisation which would not have an adverse 
effect on long term morbidity and mortality.
In Part IV we explore the use of novel intravascular imaging modalities to help further 
understand the complexities of the coronary bifurcation and stenting of this unique 
structure. In addition, we explore left main bifurcation angulation, and its relationship 
to the systolic and diastolic part of the cardiac cycle, and how this appears to impact on 
clinical outcomes in patients undergoing left main PCI. 
In Part V we move to understanding the mechanisms of drug eluting stent and bypass 
graft failure, through exploring mechanisms and clinical sequelae of stent thrombosis 
and graft occlusion in the SYNTAX Trial, and understanding the mechanisms leading to 
in-stent restenosis.
In Part VI we examine the role of peri-procedural cardiac enzyme elevation on clinical 
outcome reporting and its prognostic implications in the SYNTAX Trial.
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In Part VII we examine predictors of mortality in the PCI and CABG arms of the SYNTAX 
Trial and discover some unexpected findings, such as female gender being shown to an 
independent predictor of mortality in the PCI arm of the SYNTAX Trial.
In Part VIII we describe the process of the development and validation of the SYNTAX 
Score II, through augmenting the anatomical SYNTAX Score with clinical factors, and the 
move away from categorical based decision making between CABG and PCI (i.e. low, 
intermediate or high risk) to individualised decision making.
Part IX offers several editorials and letters on the author’s viewpoints relating to 
diabetics, trial design and hypotheses relating to what if the SYNTAX Trial had been 
conducted using contemporary drug eluting stents. 
Lastly, Part X offers a summary and conclusion of the thesis’s contents, as well as future 
perspectives, including prospective validation studies of the anatomical SYNTAX Score 
and SYNTAX Score II in ongoing and planned contemporary drug eluting stent trials. The 
Appendix details the finalised protocol of the SYNTAX II Trial investigating the treatment 
of de novo three vessel disease. The SYNTAX II Trial will use the newly developed SYNTAX 
Score II as a tool to recruit subjects on the grounds of patient safety.
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Contemporary and evolving risk scoring algorithms for
percutaneous coronary intervention
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ABSTRACT
Risk stratification is an essential part of appropriately
informing patients electing to undergo percutaneous
coronary intervention (PCI). This process is also an
integral part of the SYNTAX (Synergy between PCI with
Taxus and Cardiac Surgery)-pioneered heart team
approach in determining the most appropriate
revascularisation modality for patients with complex
coronary artery disease. The SYNTAX score was
pioneered as an anatomical-based risk score to aid in this
decision-making process; the lack of clinical variables in
this score has, however, been its main limitation. This
review examines the important established and evolving
contemporary risk models used to aid this
risk-stratification process. Risk scores based on clinical
and anatomical variables alone and in combinationdthe
latter of which is the subject of continuing researchdare
all explored. Other areas of discussion include risk scores
based on the completeness of revascularisation and
emerging concepts such as functional anatomical risk
scores and the patient-empowered risk-benefit
trade-off between PCI and coronary artery bypass
grafting, to help personalise the choice of
revascularisation modality.
INTRODUCTION
Risk stratification is an essential component of
appropriately informing patients electing to have
percutaneous coronary intervention (PCI). This
process is also an integral part of the Synergy
between PCI with Taxus and Cardiac Surgery
(SYNTAX) Trial-pioneered heart team approach in
selecting the most appropriate revascularisation
modality (coronary artery bypass grafting (CABG)
or PCI) in patients with complex (three-vessel
disease (3VD) or left main stem (LMS) disease)
coronary artery disease. Despite the landmark
SYNTAX Trial having established that surgery is
the standard of care for patients with LMS disease
or 3VD, an important finding from this study was
that patients with less complex disease had equiv-
alent outcomes to surgical and percutaneous
revascularisation at up to 3 years follow-up.1e4 The
heart team approach in managing patients with
complex coronary disease has therefore recently
been incorporated as a class I recommendation in
recent European myocardial revascularisation
guidelines.5
In cardiothoracic surgical practice, the use of risk
models to appropriately risk-stratify patients is
well established. These risk scores are predomi-
nantly related to clinical variables alone, with
scores such as the EuroSCORE6 7 or Society of
Thoracic Surgery Score8 being in widespread
contemporary use. The use of anatomical variables
for cardiothoracic risk models, eg, the SYNTAX
Score, has been shown not to provide any addi-
tional predictive benefit over clinical variables. This
is likely to be related to bypass grafts being anas-
tomosed distal to the coronary disease, regardless of
the complexity of the proximal segments, provided
that there are suitable graftable targets.4 9
The SXscore was pioneered as an anatomical-
based score to aid the heart team decision-making
processdits main application being identification
of less complex coronary artery disease, which
would be equally amenable to surgery or PCI in
terms of efficacy and safety. However, criticism
emerged that clinical factors were not being taken
into account in the risk stratification of the PCI
patient, and potentially important morbidity and
prognostic information may be missing.4 10e13
Several risk scores have consequently attempted to
merge the SXscore with clinically based risk scores,
such as the Clinical SYNTAX Score (a combination
of the SXscore and the modified ACEF (age, creat-
inine clearance, ejection fraction) Score) and the
Global Risk (a combination of the SXscore and the
EuroSCORE). These are discussed later in this
review.
The purpose of this review article is to give the
clinician a concise overview of the important
established and evolving contemporary risk models
for risk-stratifying patients electing to undergo PCI.
Risk scores based on clinical and anatomical vari-
ables alone and in combination, and on the
completeness of revascularisation are all discussed.
Furthermore, attention is drawn to which clinical
outcomesdand over what time period (ie, in-
hospital, short or long term)dthe risk model is
stratifying risk for, and also if the risk model is
validated in a population other than that from
which it was derived (table 1). Emerging concepts
such as functional anatomical risk scores, based on
invasive and non-invasive assessments, and the
novel concept of patient-empowered riskebenefit
trade-off between CABG and PCI to help person-
alise the choice of revascularisation modality are
also explored.
ANATOMY-BASED RISK SCORES
In 1981, Leaman et al44 developed a scoring system
that assessed the severity and extent of the under-
lying coronary artery disease. This system was
based on the severity of luminal diameter
narrowing and weighted according to the usual
flow to the left ventricle in each coronary vessel.
Consequently, the most weight was given to the
LMS, followed by the left anterior descending,
circumflex, and right coronary arteries. This early
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Table 1 Summary of a selection of established and contemporary risk models categorised by anatomical, clinical or combined types, for the
assessment of risk in patients proposing to undergo percutaneous coronary intervention
Clinical risk score
Number of variables
used to calculate risk
PCI outcomes (surgical outcomes in italics)Clinical Angiographic
Anatomy-based scores
ACC/AHA lesion
classification*
0 11 (per lesion) Pre-DES era: predictive of angiographic
success of PCI and prognostic effect on
early and late clinical outcomes. Conflicting
results in the DES era.14e18
SYNTAX score (SXscore) 0 11 (per lesion) Quantifies coronary artery disease
complexity by tertiles of SXscore: correlated
with clinical outcomes (Death, MACCE) at 1 year.2 4
Subsequently validated in multiple other populations.16 19 20
Functional anatomy-based scores
Functional Syntax Score 0 11 (per lesion) FFR-guided SXscore calculation improved
prognostic ability of the SXscore in a retrospective study: Death/MI,
MACE at 1 year.21 Validation in larger All-Comers
populations, including patients with LMS and 3VD, are awaited.
Myocardial Jeopardy Scores
Duke Jeopardy Score 0 Coronary tree divided into six segments: LAD, diagonal, septal perforating branches, LCx, OM and
PDA, with a segment distal to $70% considered at risk. Each segment assigned 2 points with
a maximum number of 12 points.y 22 23
Myocardial Jeopardy Index (BARI) 0 Distal terminating portions of LAD, LCx, RCA and major branch vessels (diagonals, OM, ramus, PDA
and LV branches) assigned units of 1, 2 or 3 on basis of length/size of vessel. Septal perforators
arbitrarily assigned a maximum of 3 units. Extent of jeopardy defined by units jeopardised by$50%
stenosis summated and divided by total LV territory.y 23 24
APPROACH Lesion Score 0 Based on principle from autopsy studies that the LAD generally subtends 41% of the LV, with the
LCx and RCA supplying the remainder, dependent on vessel dominance. Score calculated by % of
myocardium supplied by a vessel or its branches, jeopardised territories supplied by vessels with
$70% stenosis ($50% in the LMS)dmaximum score 100.y 23
Clinically based scores
New Mayo Clinic Risk Score* 7 0 Procedural Death and MACE for PCI; model
has been externally validated for Death.25 26
(In-hospital death with CABG).27
Parsonnet Score 14 0 Independent predictor of long-term MACE after
LMS PCI in two registry populations.19 28
(Operative mortality after open-heart surgery).29
EuroSCORE (additive or logistic) 17 0 Evidence for predicting Death or MACCE in
high-risk tertiles for PCI.10e12 30 (Operative
mortality for all forms of cardiothoracic surgery).6 7
NCDR CathPCI Risk Score* 8 0 Developed from 181 775 procedures performed
in Medicare patients; in-hospital and 30-day mortality
after all PCI patient types; internally validated in two
separate cohorts.31
ACEF Score (age, creatinine, ejection fraction) 3 0 Predictor of Cardiac Death and MI at 1 year
after PCI, inferior to the SXscore at predicting
overall MACE and repeat revascularisation in two
separate populations.32 33 (Operative mortality in elective
cardiac operations).34 35
Combined (anatomy and clinically based) risk scores
Global Risk 17 11 (per lesion) Predictive of Death and MACCE, at up to
3 years, in 3VD and LMS patients from the
randomised and All-Comers populations of the
SYNTAX Trial. Application of the model to other
populations is required.36 37
EuroHeart PCI Score* 10 6 Developed from 46 000 patients from the Euro
Heart Survey; in-hospital mortality in all PCI patient
types; internally validated. The score has strong applicability
for European practice.38
New Risk Classification Score (NERS) 17 Angiographic: 33
Procedural: 4z
6-month Cardiac Death and cumulative MACE after
unprotected LMS PCI. Although internally validateddapplication
to larger All-Comers population required (see text).39
Parsonnet + SYNTAX Score 14 11 Addition of the Parsonnet Score as a covariate to the
SYNTAX Score improved the long-term (w4 years)
predictive ability of the score in predicting MACCE after LMS PCI.19
Clinical SYNTAX Score 3 11 (per lesion) MACCE and Death in patients with complex
coronary disease treated with PCI at 5 years,40
and 2 year follow-up after LMS PCI.33
Not predictive of low-risk population, thereby limiting its clinical use.
Continued
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pioneering work, with further information derived from adverse
characteristics of coronary lesions from the American College of
Cardiology/American Heart Association (ACC/AHA) lesion
classification system,45 46 and the modified Duke/Institut
Cardiovasculaire Paris Sud (ICPS) System classification for
bifurcation lesions,14 47 ultimately formed the basis of the
SXscore.4 48 49
ACC/AHA lesion classification system
The ACC/AHA lesion classification system was one of the first
angiography scoring systems developed, comprising 11 angio-
graphic variables with all lesions categorised into types (A, B1,
B2 and C).45 46 This system predicts the angiographic success of
PCI with a subsequent prognostic effect on the early and late
clinical outcomes in the pre-drug-eluting stent era (box 1).50
Registry data from the drug-eluting stent era have, however, had
conflicting results. The German Cypher Registry (n¼6755) failed
to show any significant association with clinical outcomes at
6 months;15 conversely, data from a small registry (n¼255) was
potentially predictive of mortality in unprotected LMS PCI at
1-year follow-up.16
SYNTAX Score
The SXscore is an anatomical-based risk score that takes into
account features such as bifurcations, total occlusions,
thrombus, calcification and small vessels (figure 1). Each coro-
nary lesion with a >50% luminal obstruction in vessels
$1.5 mm is scored separately and the scores summated to
provide the overall SXscore. This is calculated using dedicated
software that integrates the number of lesions with their specific
weighting factors, based on the amount of myocardium distal to
the lesion and the morphological features of each lesion.4 44 48 49
In the SYNTAX Trial,1 the distribution of the SXscore was
found to be Gaussian in the randomised CABG and PCI popu-
lations, with the curves almost superimposable on each other
(figure 2). When the scores of the randomised SYNTAX popu-
lation were divided into tertiles, the upper boundary of the
lowest tertile was 22 (low risk), the second tertile ranged from
23 to 32 (intermediate risk), and the lower boundary for the
highest tertile was equal to or greater than 33 (high risk).
The SXscore has since consistently been shown to identify
poorer outcomes and to be an independent predictor of major
adverse cardiovascular and cerebrovascular events (MACCE) in
the high-tertile group of risk for PCI at 1 year,4 19 51 and in the
Arterial Revascularization Therapies Study II (ARTS II) popu-
lation (a population with two (46%) or three (54%) vessel
disease) at up to 5 years of follow-up (figure 3).52 53 Furthermore,
the 3-year SYNTAX Trial showed that a low SXscore (ie, <23) in
the 3VD cohort and loweintermediate SXscore (ie, <33) in the
LMS disease cohort were able to identify a subset of patients
who could safely and efficaciously be treated with CABG or PCI
and have comparable clinical outcomes in terms of death and
MACCE.2
Early-submitted results from the 3-year SYNTAX Trial have,
however, indicated that the SXscore appears to be poorly
predictive of clinical events in the 3VD cohort, unless combined
with clinical variables; the high SXscore was, however,
predictive of clinical events in the LMS disease population at
3 years.36 37 It was hypothesised that a high SXscore in patients
with LMS disease and an intermediateehigh SXscore in patients
with 3VD were markers of a more adverse risk profile. This is
supported by the 10-year predicted Framingham risk scores,
which were recently shown to have a significant and direct
relationship to the prevalence and magnitude of coronary artery
calcium scores.54 Furthermore, the ankleebrachial index and
common carotid intimaemedia thickness have both previously
been reported to be associated with the extent and severity of
coronary artery disease.55e57 Consequently, not only is the
presence of a higher SXscore associated with anatomical
complexities, such as multiple bifurcations and the presence of
total occlusionsdwhich would potentially make PCI more
technically challenging with consequent increased procedural
riskdbut the apparent association with clinical comorbidity
would also place these patients at greater long-term risk. As was
clearly demonstrated in the SYNTAX Trial, patients with
a higher SXscore would be better managed by CABG provided
that an acceptable threshold of risk for the patient and surgeon
was achievable.36 37 The reason for this is that CABG protects
the entire coronary vessel compared with PCI which treats the
individual.
With the next generation drug-eluting stent in the All-
Comers LEADERS (Limus Eluted from A Durable vs ERodable
Stent coating)58 and All-Comers Resolute59 randomised
populations undergoing PCI for a broad spectrum of indica-
tions, it has been shown that the highest tertile of the SXscore
was associated with a significantly higher incidence of
mortality and major adverse cardiac events (MACE). Moreover,
in the MULTISTRATEGY and STRATEGY Registries,
composed of patients presenting with a ST-elevation myocar-
dial infarction (MI), it was reported that the SXscore was an
Table 1 Continued
Clinical risk score
Number of variables
used to calculate risk
PCI outcomes (surgical outcomes in italics)Clinical Angiographic
New York PCI Risk Score* 8 1 In-hospital Death after PCI. Developed on the
basis of data from 46 090 procedures in 2002
and validated from 50 046 procedures in 2003 in New York.41
Excellent predictive ability in validation cohort (c-statistic 0.905).
The Texas Heart Institute Risk Score* 8 Angiographic: 2
Procedural: 1x
Predictors of in-hospital MACE after PCI or CABG.
Developed in 9494 patients (BMS era) and validated in 5545
patients (DES era).42
Mayo Clinic Risk Score* 6 2 In-hospital Death, Q-wave myocardial infarction,
emergent or urgent CABG or CVA after PCI; validated using the
NHLBI Registry.43
*These risk models include prediction of in-hospital mortality or MACE.
yAll myocardial jeopardy scores validated in one population-based cohort consisting of>20 000 patients and were predictive of 1 year mortality in patients treated with PCI (or medically).22e24
zNeed for intra-aortic balloon pump (IABP), 2-stent technique, intravascular ultrasound (IVUS) guidance.
xNumber of stents.
CABG, coronary artery bypass grafting; DES, drug-eluting stent; FFR, fractional flow reserve; LAD, left anterior descending artery; LCx, left circumflex artery; LMS, left main stem; LV, left
ventricle; MACE, mortality and major adverse cardiac events; MACCE, major adverse cardiovascular and cerebrovascular events; MI, myocardial infarction; NCDR, National Cardiovascular Data
Registry; NHLBI, National Heart, Lung, and Blood Institute; OM, obtuse marginal artery; PCI, percutaneous coronary intervention; PDA, posterior descending artery; RCA, right coronary artery.
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independent predictor of mortality, MACE, and stent throm-
bosis at 1-year follow-up; when however the SXscore was
combined with clinical variables, the risk model proved
significantly more predictive of adverse clinical events at 1
year.60
FUNCTIONAL ANATOMY-BASED RISK SCORES
Functional SXscore
Fractional flow reserve (FFR) is a technique that uses a pressure
wire to assess physiological variables that reflect both the
severity of epicardial stenosis and the amount of myocardium
supplied.61 This was investigated in the The FFR versus Angi-
ography for Guiding PCI in Patients with Multivessel Evaluation
(FAME) Study, which determined the potential prognostic
impact of PCI guided by FFR measurements to determine the
functional significance of an individual coronary lesion before
intervention.62 63
Consequently, by incorporating FFR measurements into the
SXscore to form the recently dubbed ‘Functional SXscore’, it was
shown in a retrospective sub-analysis of almost 500 patients
with multivessel disease from the FFR-guided arm of the FAME
Study that this improved the risk stratification of patients
compared with the conventional angiography-based approach to
the calculation of the SXscore.21 The primary benefit appeared
to be in reclassifying a significant proportion of the higher-risk
groups into lower-risk categories while still maintaining
a significantly higher event rate (death/MI and MACE at 1 year)
in the high-risk groups. It should, however, be emphasised that
no patients with LMS disease were involved in this study, and
prospective validation of the Functional SXscore in LMS disease
and multivessel disease is required.
One further caveat to the Functional SXscore approach is that
two-dimensional (2D) and three-dimensional (3D) quantitative
coronary angiography (QCA) have been shown to be far more
reliable than visual estimation of vessel size, the latter being
associated with poor reproducibility and often overestimation of
lesion significance.17 64e67 Yong et al65 recently showed that 3D
QCA assessment of the minimum lumen area was superior to
the 2D QCA-derived minimum lumen diameter in determining
the functional significance of a coronary lesion as assessed by
FFR. The 3D QCA measurements of the minimum lumen area
were derived from two orthogonal angiographic views of the
target lesion, enabling better assessment of vessel tortuosity and
coronary lesion asymmetry compared with 2D QCA.
If 2D QCA and, in particular, 3D QCA had been used to assess
vessel size to calculate the SXscore, this may have reduced the
benefits of the Functional SXscore compared with the SXscore
derived from visual estimation. Visual assessment of vessel/
lesion size is, however, representative of real-life practice and
was also the basis for calculation of the SXscores in the
SYNTAX Trial. It should also be emphasised that, although FFR
may be regarded as the ‘gold standard’ method for detecting
reversible ischaemia, the ischaemic potential of the small grey
zone of FFR (between 0.75 and 0.80) remains unclear, and an
abnormal FFR (ie, >0.80) excludes ischaemia in 90% of
cases.68e70 Further study is required to validate the Functional
SXscore compared with a visually or QCA derived SXscore.
Non-invasive Functional SXscore
Novel techniques in development to potentially simplify the
generation of the newly developed Functional SXscore include
the use of non-invasive coronary CTangiography (CTA), which
allows the simultaneous assessment of anatomy and measure-
ment of the haemodynamic significance of lesionsdto permit
non-invasive computation of FFRdusing computational fluid
dynamic techniques applied to the coronary CTA (Heartflow,
Redwood City, California, USA) (figure 4). Preliminary valida-
tion of this technique was recently reported in the DISCOVER
FLOW Trial,71 where it was found that the non-invasive FFR
technique could dramatically improve the diagnostic accuracy of
CT imaging without any immediate need for invasive
FFR imaging. The larger-scale multicentre DeFACTO (Deter-
mination of Fractional Flow Reserve by Anatomic Computed
Tomographic Angiography) Trial (NCT01233518) is ongoing.
Limitations of anatomy-based and functional anatomy-based risk
scores
The progressive development of anatomical-based risk scores
culminating in the Functional SXscore has undoubtedly
improved the performance of these risk models in terms of risk
stratification for the individual patient. However, a limiting
factor is the inevitable intervariability in coronary angiogram
assessment if visual assessment is used to assess the vessel/lesion
size.4 With the potential use of the QCA-derived SXscore or
Functional SXscore, this problem may be circumvented.
Another limiting factor is that no clinical variables are used,
which are less subjective than angiographic variables; this is of
Box 1 Characteristics of American College of Cardiology/
American Heart Association (ACC/AHA) type A, B and C
lesions50
Type A lesions (high success, >85%; low risk)
Discrete (<10 mm length)
Concentric
Readily accessible
Non-angulated segment <458
Smooth contour
Little or no calcification
Less than totally occlusive
Not ostial in location
No major branch involvement
Absence of thrombus
Type B lesions (moderate success, 60e85%; moderate
risk)
Tubular (10e20 mm length)
Eccentric
Moderate tortuosity of proximal segment
Moderately angulated segment, 45e908
Irregular contour
Moderate to heavy calcification
Ostial in location
Bifurcation lesions requiring double guidewires
Some thrombus present
Total occlusion <3 months old
Subdivided into type B1 (one type B characteristic) and B2
(two type B characteristics) types
Type C lesions (low success, <60%; high risk)
Diffuse (>2 cm length)
Excessive tortuosity of proximal segment
Extremely angulated segments, >908
Inability to protect major side branches
Degenerated vein grafts with friable lesions
Total occlusion >3 months old
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paramount importance given that the lack of clinical variables is
likely to reduce the predictive ability of the risk model if
anatomical variables alone are relied on.
MYOCARDIAL JEOPARDY SCORES
Myocardial jeopardy scores are used to estimate the amount of
myocardium at risk on the basis of assessment of both the
severity of the coronary artery lesion and the volume of
myocardium it supplies. Examples of such scores include the
Duke Jeopardy Score, the Myocardial Jeopardy Index from the
Bypass Angioplasty Revascularization Investigation (BARI)
Score, and the Alberta Provincial Project for Outcome Assessment
in Coronary Heart Disease (APPROACH) Score (figure 5;
table 1). The Duke and BARI Scores were developed and validated
in relatively small populations. All three models have since
been validated in one population-based cohort consisting of
>20 000 patients and were found to be predictive of 1-year
mortality in patients treated with PCI (or medically); in this
population, all three scores also had similar risk model perfor-
mance measures with only minor differences in c-statistics
evident.22e24
The Jeopardy Score has since been shown to be an indepen-
dent predictor of adverse clinical outcomes (ie, death/MI) in
medically treated patients with acute coronary syndromes at up
to 1 year, in the post hoc Acute Catheterization and Urgent
Intervention Triage Strategy (ACUITY) Trial.72
The recently described BCIS-1 Myocardial Jeopardy Score,
a variant of the Duke Jeopardy Score which has been reported to
be simpler to use, has been shown to have a strong correlation
with the myocardial ischaemia burden as assessed by cardiac
magnetic resonance perfusion imaging.73 74 A BCIS-1 Jeopardy
Score of 10e12 and a Revascularisation Index (pre- minus post-
procedural Jeopardy Scores divided by pre-procedural Jeopardy
Score, with 1 indicating complete revascularisation) of 0e0.33
were both shown to be highly predictive of mortality after
contemporary PCI in a single UK centre experience involving
over 600 patients.75 Larger-scale, multicentre trials are, however,
required. A correlation with the underlying complexity of
coronary anatomy (SXscore), which appears to have different
prognostic outcomes as previously described, and the correlation
between QCA- and FFR-derived jeopardy scores should in our
opinion be incorporated into future trials.
CLINICALLY BASED RISK SCORES
The main advantages of these scores are that they are poten-
tially easier to perform and less subjective than purely
anatomical-based scores, which require interpretation of the
coronary angiogram. They can also be performed relatively
quickly and often at the bedside if necessary.
Figure 1 SYNTAX Score (SXscore)
algorithm. The algorithm is applied to
each individual coronary lesion that
has a diameter stenosis >50% and
located in a vessel >1.5 mm in
diameter. The individual lesion scores
are added together to give the final
SXscore.3 4 48 49 LAD, left anterior
descending artery; LCx, left circumflex
artery; LM, left main stem; RCA, right
coronary artery. Reproduced, with
permission, from Serruys et al.4
Figure 2 Distribution of the SYNTAX Score (SXscore) in the
randomised controlled trial (RCT) and nested registry percutaneous
coronary intervention (PCI) and coronary artery bypass grafting (CABG)
populations from the SYNTAX Trial. Note how the distributions for both
the RCT, CABG and PCI populations are almost superimposable on each
other, whereas the nested registriesdconsisting of patients with more
complex coronary diseasedare shifted to the right.1 4 Adapted and
reprinted from EuroIntervention, Serruys PW et al, Assessment of the
SYNTAX score in the Syntax study. Copyright 2009, with permission
from Europa Edition.4
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New Mayo Clinic Risk Score
The New Mayo Clinic Risk Score was designed to replace the
Mayo Clinic Risk Score by predominantly excluding angio-
graphic variables, namely the presence of LMS or multivessel
disease, and a few of the interaction effects of specific clinical
variables.25 26 43
The New Mayo Clinic Risk Score is based solely on baseline
clinical and non-invasive assessments and incorporates seven
pre-procedural variables (age, serum creatinine, left ventricular
ejection fraction, MI #24 h, pre-procedural shock, congestive
heart failure and peripheral vascular disease) for the prediction of
procedural Death or MACE. The risk model had c-statistics of
0.74 and 0.89 for MACE and procedural death, respectively, in
the population from which the risk model was derived.25 26 The
risk model has since been validated for in-hospital mortality in
the National Cardiovascular Data Registry (NCDR);26 it has,
however, not been validated for MACE. The New Mayo Clinic
Risk Score has also been shown to be predictive of in-hospital
mortality after CABG surgery.27
CathPCI Risk Score System
The NCDR CathPCI Risk Score System was developed from
181 775 procedures performed in Medicare patients over a 2-year
period (table 2); the model was independently validated in two
separate validation cohorts.31 The risk model was based on eight
key pre-procedural factors and was found to have excellent
discriminative ability in predicting in-hospital mortality
(c-statistic 0.89), with the model still able to have good predic-
tive ability for 30-day mortality after PCI (c-statistic 0.83). A full
risk model, from which this model was derived (incorporating 35
pre-procedural and angiographic features), resulted in a margin-
ally better risk model (c-statistic 0.90 and 0.86 for in-hospital
and 30-day mortality, respectively).
European system for cardiac operative risk evaluation
(EuroSCORE)
The EuroSCORE is an established risk model, using 17 clinical
variables, in cardiothoracic surgical practice for predicting oper-
ative mortality and has been validated in many populations
around the world.6 7 76 In use since 1999, the model was derived
from almost 20 000 consecutive patients from 128 hospitals in
eight European countries. The additive EuroSCORE assigns an
individual score to 17 clinical variables (table 3), with a low
EuroSCORE risk tertile ranging from 1 to 2, intermediate risk
tertile from 3 to 5, and a high risk tertile of 6+.
The subsequently developed logistic EuroSCORE has been
suggested to allow a more accurate risk prediction in the CABG
cohort, in particular for the high-risk population, where the
additive model was found to lead to a potential underestimation
of risk.6 7 76 77 Conversely, the logistic EuroSCORE has
been shown to potentially overestimate observed mortality,
with its accuracy for predicting risk varying in different surgical
subgroups.77 78
Kim et al first demonstrated that the high-risk tertile of the
additive EuroSCORE was an independent predictor of Death/
MI after unprotected LMS intervention with sirolimus-eluting
stents.11 Subsequently, Romangoli et al applied the additive
EuroSCORE to predict in-hospital mortality in 1173 consecu-
tive patients undergoing PCI in a single high-volume centre and
correlated the higher-risk tertiles of the EuroSCORE with
in-hospital mortality; the study population also included
patients who had undergone unprotected LMS PCI.10 In addi-
tion, several studies have since all identified the additive
EuroSCORE as an independent predictor of MACCE in patients
with unprotected LMS PCI at up to 4 years follow-up.11 12 30
Only one study has examined the logistic EuroSCORE in PCI
patients, with few differences being demonstrated in stratifying
risk when compared with the additive EuroSCORE.10 Our
group has recently applied the additive and logistic Euro-
SCOREs to the SYNTAX PCI population; risk model perfor-
mance measures79 80 suggested that the additive EuroSCORE
was superior to the logistic EuroSCORE in risk-stratifying PCI
patients.36 37
Figure 4 The principle of non-invasive CT angiography that allows the
simultaneous assessment of anatomy and measurement of the
haemodynamic significance of lesions by fractional flow reserve (FFR)
guidance. This principle can allow for the non-invasive assessment of
the Functional Syntax Score. In this clinical case example, tandem
lesions in the left anterior descending artery (LAD) are evident, the
haemodynamic significance of which was unclear from the CT coronary
angiogram: non-invasive FFR in the distal LAD was 0.60 and therefore
haemodynamically significant, but FFR just proximal to the distal lesion
was 0.80, indicating that the proximal LAD lesion was not
haemodynamically significant; FFR at the ostial LAD was normal
(0.98, not illustrated).
Figure 3 KaplaneMeier curves of freedom protocol-defined major
adverse cardiac and cerebrovascular event (MACCE) rate according to
SYNTAX Score tertiles, from the 5-year clinical outcomes of the ARTS II
(Arterial Revascularization Therapies Study II) Trial. Reproduced, with
permission, from Serruys et al.53 MACCE, major adverse cardiovascular
and cerebrovascular events; interm., intermediate; SES, sirolimus eluting
stent.
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ACEF Score
Ranucci et al demonstrated a relatively simple risk model
(consisting of only three clinical variables, namely age, preop-
erative serum creatinine value and left ventricular ejection
fraction) for assessing operative mortality risk in elective cardiac
operations. It is noteworthy that, despite the simplicity of the
model, its clinical performance appeared to be comparable to
either the additive or the logistic EuroSCORE.34 35
The ACEF Score is calculated using the formula:
ACEF ¼ ½Age=Ejection fraction ð%Þ�
þ ½1 ðif creatinine> 2 mg=dlÞ�
From this score, a mortality risk can be calculated from a graphic
relationship of the score with an operative risk or an equation.34 35
The ACEF model was recently applied to PCI patients from
the All-Comers LEADERS population at 1-year follow-up.32
Despite the ACEF Score being demonstrated to be superior to
the SXscore alone as a predictor of cardiac death and MI after
PCI, it was found to be inferior to the SXscore at predicting
overall MACE and the risk of repeat revascularisation, reflecting
the observation that anatomical and clinical variables appear to
be necessary requirements for a comprehensive risk model in
predicting clinical outcomes with PCI. It should however be
emphasised that the ACEF model has not been validated in the
PCI population.
Limitations of clinically based risk scores
The main limitations of the clinically based risk scores, apart
from not incorporating anatomical-based variables, are that they
rely on predominantly registry datadproposed to be more
representative of contemporary ‘real-life’ practice. The potential
for selection bias in patients receiving coronary angiogra-
phydfor example, in limiting the number of octogenar-
iansdmay lead to the risk model potentially underestimating
risk in these patient subsets.
COMBINED (ANATOMICAL AND CLINICAL BASED)
RISK SCORES
SXscore and Parsonnet Score
Combining the Parsonnet Score, an operative risk score
published in 1989 consisting of 14 clinical variables,29 with the
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Figure 5 Example of a Myocardial Jeopardy Score. The APPROACH
Lesion Score illustrating the weighting factors for myocardial regions is
illustrated. LAD, left anterior descending artery; RV, right ventricle; PDA,
posterior decending artery; PL, posterolateral. Reproduced, with
permission, from Graham et al.23
Table 2 NCDR CathPCI Risk Score System
Variable Scoring response categories Total points Risk of in-patient mortality
Age <60 $60, <70 $70, <80 $80 0 0.0
0 4 8 14 5 0.1
Cardiogenic shock No Yes 10 0.1
0 25 15 0.2
Prior CHF No Yes 20 0.3
0 5 25 0.6
Peripheral vascular disease No Yes 30 1.1
0 5 35 2.0
Chronic lung disease No Yes 40 3.6
0 4 45 6.3
GFR <30 30e60 60e90 >90 50 10.9
18 10 6 0 55 18.3
NYHA functional class IV No Yes 60 29.0
0 4 65 42.7
PCI status (STEMI) Elective Urgent Emergent Salvage 70 57.6
12 15 20 38 75 71.2
PCI status (no STEMI) Elective Urgent Emergent Salvage 80 81.0
0 8 20 42 85 89.2
90 93.8
95 96.5
100 98.0
Reproduced, with permission, from Peterson et al.31
CHF, chronic heart failure; GFR, glomerular filtration rate; NCDR, National Cardiovascular Data Registry; NYHA, New York Heart Association; PCI, percutaneous coronary intervention;
STEMI, ST-elevation myocardial infarction.
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SXscore has been shown to potentially improve the performance
of the SXscore alone.
In 2005, Valgimigli et al showed that the Parsonnet Score was
an independent long-term (w3 years) predictor of MACE after
LMS intervention from the Rotterdam RESEARCH and
T-SEARCH Registries.28 More recently, Chakravarty et al
showed that adding the Parsonnet Score as a covariate to the
SXscore improved the long-term (w4 years) predictive ability of
the score in predicting MACCE after LMS PCI.19
Clinical SYNTAX Score
The underlying rationale for the Clinical SXscore was to
combine the SXscore and a variant of the ACEF Score (modified
ACEF Score).34 35 The modified ACEF Score was used instead of
the ACEF Score in this model because it had previously been
shown to potentially allow a more accurate assessment of the
underlying renal function, and had subsequently improved the
accuracy of cardiac prediction models such as the EuroSCORE in
patients receiving CABG.40 81 82 The modified ACEF Score is
calculated using the formula: age/ejection fraction +1 point for
every 10 ml/min reduction in creatinine clearance below 60 ml/
min/1.73 m2 (up to a maximum of 6 points).
This model was applied to the ARTS II population treated
with sirolimus-eluting stents for multivessel (two or three)
coronary artery disease.40 83 By dividing the calculated Clinical
SXscores into tertiles of risk, it was demonstrated that the risk
model for predicting outcomes for MACCE and death at 5 years
was superior to the SXscore or modified ACEF Score alone. One
of the limiting factors of the Clinical SXscore that has prevented
its clinical use is that, despite being able to potentially predict
events more accurately in the high-risk tertile, the risk model was
unable to differentiate between the clinical events for the low-
and intermediate-risk tertiles40; this was also demonstrated when
applied to a different similar-sized registry by another group.33
New Risk Classification Score (NERS)
NERS39 is a risk model developed within four centres in China
(n¼260) to predict long-term outcomes after unprotected LMS
PCI. Reflecting the long time period over which this registry was
performed (w10 years), the patients included either had bare
metal or drug-eluting stent implantation. The model was
subsequently tested (internally validated) in a different consec-
utive group of patients in the same registry all treated with
drug-eluting stents (n¼337).
This risk model consists of 54 variables (17 clinical, four
procedural and 33 angiographic features). A substantially higher
c-statistic was evident for NERS compared with the SXscore
(0.89 vs 0.69, respectively), indicating that it had excellent
discriminatory ability. When NERS was separated into two
groups of risk (high and low) and clinical outcomes were
assessed, the NERS model was able to identify a high-risk
population for MACE, at 30 days and at over 5 years follow-up.
Importantly, the high-risk NERS group was shown to be
significantly more predictive of MACE compared with the
intermediate or high SXscore tertiles.
Conversely, in the low-risk NERS group, outcomes were
similar to the low SXscore group, suggesting, at least from this
study, that anatomical variables alone may be sufficient to
predict clinical outcomes in the low-risk group. One of the main
limitations of this risk model is that comorbidity in the NERS
patient population was significantly less prevalent compared
with the All-Comers SYNTAX population;1 3 the latter was
Table 3 Additive EuroSCORE, calculated by summating the individual scores from 17 different variables6
Factor Description Score
Patient factors
Age Per 5 years or part thereof over the
age of 60 years
1
Sex Female 1
Chronic pulmonary disease Long-term use of bronchodilators or
steroids for respiratory disease
1
Peripheral arteriopathy Claudication/carotid stenosis >50%/previous
or planned intervention on the abdominal aorta,
limb arteries or carotids
2
Neurological dysfunction Severely affected mobility or day-to-day function 2
Previous cardiac surgery Previous opening of the pericardium 3
Serum creatinine >200 mmol/l before surgery 2
Active endocarditis Antibiotic therapy at time of surgery 3
Critical preoperative state Preoperative cardiac arrest, ventilation,
renal failure, inotropic support, intra-aortic
balloon pump use, ventricular arrhythmia
3
Cardiac factors
Unstable angina Rest pain requiring IV nitrates 2
Left ventricular function Moderate (30e50%) 1
Poor (<30%) 3
Recent MI Within 90 days 2
Pulmonary hypertension Systolic pulmonary artery pressure
>60 mm Hg
2
Operative factors
Emergency operation Performed before the start of next working
day
2
Other than isolated CABG Major cardiac procedure other than or in addition
to CABG
2
Surgery on thoracic aorta 3
Post-infarct septal rupture 4
CABG, coronary artery bypass grafting; IV, intravenous; MI, myocardial infarction.
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designed to overcome many of the limitations/selection bias
inherent in small registries. Validation of the NERS risk model in
a much larger All-Comers type population is therefore required
to overcome many of these issues.
Global Risk
The SYNTAX Trial established a complex interaction between
the EuroSCORE and SXscore in preliminary unpublished
data.84 Given that the EuroSCORE has been shown to be an
independent predictor of MACE for either CABG or PCI as
previously described,30 85 the need to combine the angiography
and clinical scores into a single approach has become evident.86
One of the main advantages of potentially combining the
EuroSCORE and SXscore to give a ‘Global Risk’ assessment is
that the same risk model can be used during the heart team
approach in selecting the optimal revascularisation modality for
the patient. To facilitate this process, it is our opinion that the
historically accepted cut-offs for the level of risk (low, inter-
mediate and high) for the additive EuroSCORE, each of which
have previously been demonstrated to have a different prog-
nostic value,4 6 7 48 49 and the SYNTAX Trial-defined anatomical
SXscore ranges4 48 should be incorporated into the Global Risk
model (table 4).
In variants of this model using differing and inconsistent cut-
off levels of risk for the SXscore and/or additive EuroSCORE in
a non-randomised population, it has recently been shown
that this may potentially improve the ability to predict
outcomes in patients undergoing surgical or percutaneous LMS
revascularisation.33 87
The main goal of using the Global Risk model is therefore to
combine anatomical and clinical variables to potentially further
aid risk stratification of patients with 3VD or LMS disease
considering revascularisation, and to identify a low-risk group of
surgically or percutaneously treated patients who would have
comparable outcomes in terms of safety and efficacy. This
concept has recently been applied by our group to the rando-
mised and All-Comers SYNTAX population, and proved to be
potentially useful in the identification of the previously
described low-risk population in the LMS disease cohort. In the
SYNTAX 3VD cohort, the interaction between anatomical and
clinical variables proved to be more complex; the Global Risk
model, however, still proved to be clinically useful when inter-
preted through a treatment algorithm. The results of these
studies are forthcoming.36 37
EuroHeart Score
On the basis of the Euro Heart Survey (a European PCI registry
consisting of over 46 000 patients from 176 European centres
who underwent PCI for different indications), a logistic regres-
sion model comprising 10 clinical variables and six anatomical
variables was developed (figure 6).38 The risk model was shown
to be highly predictive of in-hospital mortality (c-statistic 0.91).
Figure 6 EuroHeart PCI Score.
STE-ACS, ST-elevation acute coronary
syndrome; NSTE-ACS, non ST-elevation
acute coronary syndrome; BMI, body
mass index; CABG, coronary artery
bypass grafting; LAD, left anterior
descending artery; PCI, percutaneous
coronary intervention; TIMI flow,
thrombolysis in myocardial infarction
flow. Reproduced, with permission,
from de Mulder et al.38
Table 4 The Global Risk approach, combining historically defined tertiles of risk for the EuroSCORE and the SYNTAX Trial-defined ranges for
SXscore36 37
Low SXscore (£22) Intermediate SXscore (23e32) High SXscore (‡33)
Low additive EuroSCORE (0e2) Low risk Low risk Intermediate risk
Intermediate additive EuroSCORE (3e5) Low risk Low risk Intermediate risk
High additive EuroSCORE ($6) Intermediate risk Intermediate risk High risk
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The strengths of the risk model are that it was internally vali-
dated in the registry population and it retained its discrimina-
tory power (c-statistic 0.90).
RISKeBENEFIT ANALYSIS
Undoubtedly, both CABG and PCI result in an improvement in
the quality of life of the patient. One of the main drawbacks of
using contemporary risk models for both CABG and PCI is that
the role of the individual patient and their personal preferences
and perception of risk may be underestimated. To address this
issue, the novel concept of a clinical model that balances the
risks and benefits of the proposed revascularisation procedure
has recently emerged.88
Remaining active in their professional/personal lives may be
vital for some people, and they would thus be more prepared to
accept the longer-term risks of PCI (in particular an increased
risk of repeat revascularisation) in order to remain at their
present functional state, compared with the short-term
morbidity effects associated with CABG, the latter being
predominantly related to the intrinsically more invasive nature
of the CABG procedure (eg, thoracotomy and vein harvesting
and subsequent sternotomy and leg pain, etc).89 90
Individual patients may, however, value this riskebenefit
trade-off differently. For some, exchanging the increased risk of
repeat PCI or CABG to obtain short-term pain relief and a rapid
return to full mobility will be acceptable, while others may
prefer to endure short-term pain to obtain a higher probability of
avoiding a subsequent revascularisation. Some patients may also
prefer to risk undergoing multiple PCI procedures compared
with a single CABG, or they may prefer to avoid the risk of
requiring CABG subsequent to PCI and instead have CABG
initially. Consequently, from the patient’s perspective, the
balance between these conflicting considerations plays a crucial
role in selecting the preferred revascularisation strategy.
Federspiel et al recently applied this concept to the ARTS II
population, by quantifying the trade-off between the risks and
benefits of PCI versus CABG, such as freedom of chest pain and
improvement in health-related quality of life measures, for
patients with multivessel disease (figure 7).83 88 Although this
study was performed on data that were over 10 years old, in
a population who had implantation of bare metal stents, the
results nevertheless supported this concept and have allowed, for
the first time, quantification of a level of risk that a patient
would be able to accept in order to maintain their present
functional state. Data from the SYNTAX Trial on this concept,
reflecting more contemporary practice with drug-eluting stents,
are forthcoming.
CONCLUSION
It would appear that a combination of clinical and anatomical
variables is required for an effective, clinically useful risk model
for patients. The SXscore, while prognostically useful in risk-
stratifying patients proposing to undergo PCI, in itself appears
to carry important information on clinical comorbidity and
outcomes for the individual patient. However, this clearly is not
the whole picture, and it is our view that the incremental value
of adding clinical variables to the SXscore, as demonstrated with
risk models such as Global Risk, will ultimately prove to be more
clinically useful compared with the SXscore alone. Ongoing and
future risk models may answer these questions. Novel concepts
such as the Functional SXscore, performed invasively or non-
invasively as discussed, and the patient-empowered riskebenefit
trade-off are all further areas in current development where
additional clinically relevant information may become available.
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CLINICAL RESEARCH Coronary Revascularization
The Negative Impact of Incomplete Angiographic
Revascularization on Clinical Outcomes and
Its Association With Total Occlusions
The SYNTAX (Synergy Between Percutaneous Coronary Intervention
with Taxus and Cardiac Surgery) Trial
Vasim Farooq, MBCHB,* Patrick W. Serruys, MD, PHD,* Hector M. Garcia-Garcia, MD, PHD,*
Yaojun Zhang, MD,* Christos V. Bourantas, MD, PHD,* David R. Holmes, MD,†
Michael Mack, MD,‡ Ted Feldman, MD,§ Marie-Claude Morice, MD, Elisabeth Ståhle, MD,¶
Stefan James, MD,¶ Antonio Colombo, MD,# Roberto Diletti, MD,*
Michail I. Papafaklis, MD, PHD,** Ton de Vries MSC,†† Marie-angèle Morel, BSC,††
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Objectives The study sought to evaluate the clinical impact of angiographic complete (CR) and incomplete (ICR) revascular-
ization and its association with the presence of total occlusions (TO), after percutaneous coronary intervention
(PCI) or coronary artery bypass graft (CABG) surgery in the “all-comers” SYNTAX (Synergy Between Percutaneous
Coronary Intervention with Taxus and Cardiac Surgery) trial.
Background In patients with complex coronary artery disease undergoing PCI or CABG, the long-term prognostic implications
of CR versus ICR is unsettled.
Methods In this post hoc study, consisting of randomized (n  1,800) and nested PCI (n  198) and CABG (n  649) reg-
istries, 4-year clinical outcomes were compared in groups, with and without angiographic CR, in the PCI and
CABG arms. Clinical outcomes were analyzed with Kaplan-Meier estimates, log-rank comparisons, and Cox re-
gression analyses. Multivariate predictors of ICR were determined. Similar analyses were undertaken in the TO
and non-TO treated groups of both study arms.
Results Angiographic CR was achieved in 52.8% of the PCI arm and 66.9% of the CABG arm. Within the PCI and CABG
arms, ICR (compared with CR) seemed to be a surrogate marker of a greater burden of anatomical coronary
complexity and clinical comorbidity and was associated with significantly higher frequencies of 4-year mortality,
all-cause revascularization, stent thrombosis (PCI arm), and major adverse cardiac and cerebrovascular events.
The presence of a TO was the strongest independent predictor of ICR after PCI (hazard ratio: 2.70, 95% confi-
dence interval: 1.98 to 3.67, p  0.001). Eight hundred and forty patients (PCI: 26.3%, CABG: 36.4%, p 
0.001) were identified to have 1,007 TOs, with 68.1% of TOs located in the proximal-mid coronary vasculature.
The findings associating ICR (compared with CR) with higher frequencies of 4-year mortality and major adverse
cardiac and cerebrovascular events remained consistent in the TO-treated groups in the PCI and CABG arms.
Conclusions Within the PCI and CABG arms of the all-comers SYNTAX trial, angiographically determined ICR has a detrimen-
tal impact on long-term clinical outcomes, including mortality. This effect remained consistent in patients with
and without TOs. (J Am Coll Cardiol 2013;61:282–94) © 2013 by the American College of Cardiology
Foundation
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In patients with complex coronary artery disease—namely,
unprotected left main coronary artery (ULMCA) or de novo
3-vessel disease—undergoing coronary artery bypass graft
(CABG) surgery or percutaneous coronary intervention
(PCI), the long-term prognostic implications of complete
(CR) versus incomplete (ICR) revascularization is unsettled
(1–12). In addition, recent studies have suggested that
angiographic CR after CABG revascularization might not
be associated with a significant improvement in long-term
clinical outcomes (6,7).
The impact of successful or unsuccessful treatment of
total occlusion (TO) and its association with completeness
of revascularization in PCI- or CABG-treated patients with
ULMCA and/or multivessel disease also remains unde-
fined. Although multiple registries have associated success-
ful complete TO PCI with improved long-term mortality,
these studies were conducted in patients with less complex
coronary disease (13–17). Only 1 retrospective registry study
has examined CTO PCI in patients with predominantly
multivessel disease and associated successful CTO PCI in
the context of CR with a survival advantage, compared with
patients with ICR (18).
The purpose of this study was to report the long-term
(4-year) clinical impact of complete and incomplete angio-
graphic revascularization in the All-Comers SYNTAX
(Synergy Between Percutaneous Coronary Intervention
with Taxus and Cardiac Surgery) Trial. The All-Comers
SYNTAX Trial provided an opportunity for the assessment
of patients where selection bias in enrolling patients was
minimal and therefore was potentially more representative
of contemporary clinical practice. Secondly, the presence of
TOs to influence the ability of PCI or CABG to achieve
CR was examined, on the basis of the hypothesis that failure
to treat TOs would have a significantly detrimental impact
on long-term clinical outcomes in PCI- and CABG-treated
patients.
Methods
The All-Comers SYNTAX Trial is a randomized, prospec-
tive, multicenter trial (n  3,075) investigating patients
with ULMCA disease (isolated
or associated with 1-, 2-, or
3-vessel disease) or de novo
3-vessel coronary artery disease
and has previously been de-
scribed (19–21). In brief, exclu-
sion criteria were appropriately
limited and consisted of patients
with prior coronary revascular-
ization, the requirement of con-
comitant cardiac surgery, or on-
going acute myocardial infarction.
During the local Heart Team
meeting, the interventional car-
diologist and cardiac surgeon
specified the number of coronary
lesions requiring treatment and
their angiographic location and
characteristics with the SYN-
TAX Score as a tool to aid in this
process (22–24). All patients
considered as potentially achiev-
ing “equivalent anatomic” revas-
cularization with percutaneous or
surgical revascularization by the
Heart Team were randomized on
a 1:1 basis (n  1,800) to either
PCI with TAXUS Express paclitaxel-eluting stents (Boston
Scientific Corporation, Natick, Massachusetts) or CABG.
Patients unsuitable for randomization were nested into PCI
(CABG ineligible patients, n  198) and CABG registries
(PCI ineligible patients, n  1,077) (Fig. 1). All random-
ized patients underwent planned follow-up. Within the
nested registries, all PCI patients and 649 randomly allo-
cated CABG patients underwent follow-up on the basis of
the original study protocol (20,21).
An independent Clinical Events Committee, including
cardiologists, cardiac surgeons, and a neurologist reviewed
all the primary clinical endpoints (20,21). Baseline and peri-
and post-procedural data were prospectively collected by the
individual participating centers. Pre-procedural left ventric-
ular ejection fraction (LVEF) was defined as the percentage
LVEF taken by transthoracic echocardiography or diagnos-
tic coronary angiogram and was categorized as good
(50%), moderate (30% to 49%), or poor (30%). Four-
year clinical outcomes were compared in groups with and
without angiographic CR in the PCI and CABG arms, with
analyses repeated in the respective TO/non-TO groups.
Clinical outcomes. Clinical outcomes included all-cause
death, cardiac death, major adverse cardiac and cerebrovas-
cular events (MACCE) (a composite of all-cause death,
myocardial infarction, stroke, and all-cause revasculariza-
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tion) and its components, stent thrombosis, and graft
occlusion. Direct comparisons between the All-Comers
PCI and CABG arms were not undertaken due to the
previously reported outcomes of the SYNTAX trial
(19,20,25,26) and the presence of greater clinical comorbid-
ity and more complex anatomical coronary disease in the
nested PCI and CABG registries, respectively, which were
the predominant reasons for entry (27,28).
SYNTAX score and TO. The calculation of the SYNTAX
Score was undertaken by the study sites and an independent
core laboratory (Cardialysis BV, Rotterdam, the Nether-
lands) blinded to the treatment assignment (22–24). The
age and angiographic characteristics of TOs were specified
as part of the SYNTAX Score calculation. The definition of
the TOs required that there was absolutely no flow through
the lesion (Thrombolysis In Myocardial Infarction flow
grade 0). Antegrade flow beyond the TO maintained by
bridging collaterals and/or ipsi-collaterals was permitted.
Core laboratory-calculated SYNTAX Scores are reported in
this study. Procedural success rates of recanalization/bypass
of TOs were available in the electronic case records of the
randomized SYNTAX population and are reported.
Completeness of revascularization. Completeness of re-
vascularization was prospectively determined after the re-
vascularization procedure by the operator, on the basis of
the intended “equivalent anatomic” revascularization agreed
during the local Heart Team conference before revascular-
ization. The degree of revascularization was angiographic,
on the basis of segment numbering of vessels with a
diameter 1.5 mm used in the calculation of the SYNTAX
Score (22–24). The exact definition of CR defined in the
original trial protocol (NCT00114972) is detailed in the
following text.
The interventional cardiologist and surgeon during the local
Heart Team conference will specify the number of lesions
and locations requiring treatment to achieve “equivalent
anatomic” revascularization (decision). Complete revascu-
Figure 1 Flow Chart of Frequency of CR versus ICR in PCI and CABG Arms of “All-Comers” SYNTAX Population
The “All-Comers” population incorporates the randomized and nested registries of the percutaneous coronary intervention (PCI) and coronary artery bypass grafting
(CABG) arms. *Of the 1,077 CABG patients, 649 were randomly allocated for follow-up on the basis of the original study protocol (21). CR  complete revascularization;
ICR  incomplete revascularization.
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larization is defined as the treatment of any lesion with more
than 50% diameter stenosis in vessels1.5 mm as estimated
on the diagnostic angiogram during the local Heart Team
conference. Outcomes will be documented by the operator
based on whether the intended equivalent anatomic revas-
cularization was achieved.
Statistical analysis. The means  SD for continuous
variables were compared with the Student t test. Binary
variables are reported as counts and/or percentages and
compared with the chi-square test. Four-year clinical out-
comes were compared in groups with and without angio-
graphic CR and expressed as Kaplan-Meier estimates, with
curves examined visually. Comparisons were made with Cox
proportional hazard ratios (HRs) and the log-rank test. In
addition, TO and non-TO group-specific HRs for all
recorded 4-year clinical outcomes were obtained. The sig-
nificance of the interaction effect between CR versus ICR in
the PCI and CABG arms and the respective TO and
Baseline and Procedural Characteristics for “All-Comers” CABG and PCI PopulationsStratified by Completeness of Reva cularizationTable 1 Baseline and Pr cedu al Characteristics for “All-Comers” ABG and PCI PopulationsStratified by Completeness of Revascularization
PCI (n  1,095) CABG (n  1,541)
CR ICR p Value CR ICR p Value
Baseline clinical characteristics
Age (yrs) 65.7 9.6 67.2 10.5 0.01 64.9 9.6 66.1 9.7 0.020
Male 73.4% 77.8% 0.086 80.2% 79.5% 0.75
BMI (kg/m2) 28.2 5.0 28.0 4.9 0.42 28.0 4.6 27.8 4.3 0.63
Diabetes 25.6% 34.1% 0.002 27.3% 31.1% 0.13
Hypertension 73.0% 75.9% 0.28 73.3% 79.7% 0.007
Hyperlipidemia 74.4% 79.0% 0.077 77.2% 76.3% 0.71
Peripheral vascular disease 8.1% 12.9% 0.009 10.7% 14.5% 0.032
Current smoker 18.6% 15.7% 0.21 22.5% 21.0% 0.54
Unstable angina 28.7% 32.4% 0.19 22.7% 31.5% 0.001
Prior MI 33.4% 33.7% 0.93 31.8% 36.7% 0.063
LVEF
Good (50%) 80.6% 71.4% 0.001 76.5% 72.3% 0.073
Moderate (30%–49%) 15.6% 22.7% 0.003 18.1% 23.4% 0.017
Poor (30%) 1.6% 2.7% 0.17 3.3% 3.1% 0.84
Baseline anatomical and clinical scores
SYNTAX score 26.3 10.5 32.0 12.2 0.001 32.2 13.0 34.0 12.7 0.011
Total Parsonnet score 8.8 7.2 10.5 8.3 0.001 8.2 6.6 9.6 7.5 0.001
Additive EuroSCORE 3.9 2.7 4.4 3.0 0.001 3.6 2.6 4.2 2.9 0.001
Logistic EuroSCORE 4.0% 5.1 5.1% 6.4 0.002 3.6% 4.1 4.6% 5.0 0.001
Anatomical characteristics
TOs present 16.9% 36.8% 0.001 35.0% 40.3% 0.048
Number of TOs — — 0.001 — — 0.085
1 15.9% 31.0% — 27.3% 33.4% —
2 0.9% 5.7% — 6.8% 6.1% —
3 0.2% 0.0% — 0.9% 0.8% —
Diffuse disease or small vessels 18.9% 26.9% 0.002 23.6% 30.0% 0.009
Number of lesions 3.4 1.6 4.6 1.5 0.001 4.0 1.7 5.0 1.8 0.001
Left main disease 45.2% 33.3% 0.001 46.9% 34.0 % 0.001
Bifurcation 58.3% 66.9% 0.004 63.4% 67.2% 0.15
Trifurcation 6.1% 9.2% 0.049 8.8% 10.6% 0.28
Aorto-ostial 16.8% 13.8% 0.19 16.9% 14.2% 0.18
Any thrombus 2.4% 2.8% 0.74 3.9% 2.3% 0.10
Heavy calcification 47.3% 54.0% 0.03 53.3% 56.2% 0.30
Any severe tortuosity 60.9% 72.3% 0.001 67.8% 71.6% 0.14
Any lesion length 20 mm 48.5% 67.8% 0.001 61.5% 74.7% 0.001
Left arterial dominance 16.3% 20.6% 0.066 13.4% 19.5% 0.003
Procedural characteristics
Total number of stents implanted 4.5 2.4 4.2 2.1 0.009 — — —
Total length of stents implanted (mm) 85.5 51.5 76.4 43.1 0.002 — — —
Post-procedural hospital stay (days) 3.6 7.1 3.7 6.0 0.71 8.7 5.9 9.4 9.3 0.13
Procedure time (h) 1.6 0.9 1.7 0.9 0.11 3.5 1.1 3.4 1.1 0.034
Values are mean  SD or %.
BMI  body mass index; CABG  coronary artery bypass graft surgery; CR  complete revascularization; ICR  incomplete revascularization; LVEF  left ventricular ejection fraction; MI  myocardial
infarction; PCI  percutaneous coronary intervention; TO  total occlusion.
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non-TO groups were tested with the chi-square test. This
was undertaken to assess whether the HR of all 4-year
clinical outcomes for CR versus ICR was different across the
TO and non-TO groups.
Binary logistic regression analyses were undertaken to
identify univariate predictors of ICR with baseline char-
acteristics (20) and components of the SYNTAX Score,
respectively. The variables examined are detailed in Table 1.
The SYNTAX Score was excluded from these analyses to
allow for the appropriate identification of its components
(e.g., TO, calcification) associated with ICR. Univariate
predictors of ICR were entered into a multivariable model.
The enter method was implemented to determine indepen-
dent predictors, with a variable entry/stay criteria of 0.05/
0.1. Similar analyses for ICR were repeated in the TO
treated groups. A 2-sided p value  0.05 was considered
significant for all tests. Analyses were conducted with SPSS
(version 19.0, SPSS, Inc., Chicago Illinois) and STATA
(version 11.0, StataCorp, College Station, Texas).
Results
Baseline characteristics of the randomized and nested reg-
istry arms (All-Comers population) of the SYNTAX Trial
have previously been described (20,28). Within the All-
Comers population (n  2,636), angiographic CR was
Figure 2 Four-Year Clinical Outcomes in Patients by Complete Versus Incomplete Revascularization
Comparisons (Kaplan-Meier analyses) of 4-year clinical outcomes by completeness of revascularization in the All-Comers PCI (A) and All-Comers coronary artery bypass
grafting (B) populations. CVA  cerebrovascular accident; MACCE  major adverse cardiac and cerebrovascular events; MI  myocardial infarction.
286 Farooq et al. JACC Vol. 61, No. 3, 2013
Incomplete Angiographic Revascularization January 22 2013:282–94
46 Chapter 2
achieved in 52.8% of the PCI arm (n  1,095) and 66.9%
of the CABG arm (n  1,541) (Fig. 1).
Baseline and procedural characteristics on the basis of
CR and ICR. Baseline and procedural characteristics of
CR and ICR in the PCI (n  1,095) and CABG (n 
1,541) arms are shown (Table 1). Within the PCI and
CABG arms, more anatomically complex disease (higher
SYNTAX Score)—including the presence of TOs, greater
clinical comorbidity (higher EuroSCORE [29] and Parsonnet
Score [30]), and a reduced prevalence of ULMCA disease—
were evident in patients with ICR compared with CR.
Clinical outcomes on the basis of completeness of revas-
cularization. Within the PCI and CABG arms, ICR (com-
pared with CR) was associated with significantly higher
frequencies of 4-year mortality, all-cause revascularization,
stent thrombosis (PCI arm), and MACCE (Fig. 2).
Predictors of ICR. Multivariate analyses of ICR in the
PCI and CABG arms are shown (Table 2). The strongest
independent predictor of ICR in the PCI arm was the
presence of a TO (HR: 2.70, 95% confidence interval [CI]:
1.98 to 3.67, p  0.001). The strongest independent
predictor of ICR in the CABG arm was left arterial
dominance (HR: 2.19, 95% CI: 1.05 to 4.57, p  0.038).
Left arterial dominance, any right coronary artery lesion,
number of lesions, and clinical variables (EuroSCORE/
Parsonnet Score) were common independent predictors of
ICR in the PCI and CABG arms.
TO. Baseline and procedural characteristics of patients
with and without TOs in the PCI (n  1,095) and CABG
(n  1,541) arms are shown (Table 3). Eight hundred and
forty patients (PCI: 26.3%, CABG: 36.4%, p 0.001) were
identified to have 1,007 TOs. All patients with TOs (PCI
and CABG arms) were significantly more likely to have had
a previous myocardial infarction, a lower LVEF, diffuse or
small vessel disease, more coronary lesions, lesion length
20 mm, and a reduced prevalence of ULMCA disease.
Patients with TOs were less likely to achieve CR in the PCI
and CABG arms (CR PCI: non-TO 59.8%, TO 34.3%,
p  0.001; CR CABG: non-TO 69.8%, TO 64.8%, p 
0.048).
Table 4 shows the baseline angiographic characteristics of
the TOs in the entire SYNTAX population and PCI and
CABG arms. The age of the TOs was documented as 3
months or unknown in 95.6% of the study population.
Approximately two-thirds of TOs (68.1%) were located in
the proximal-mid coronary vessels on coronary angiography
(Fig. 3).
Procedural success rates of TO. Figure 4 demonstrates
the procedural success rates of TOs (n  543) on an
intention to treat basis by the study sites in the randomized
SYNTAX population. More TOs were successfully treated
with CABG compared with PCI (68.1% vs. 49.4%, p 
0.001).
Clinical outcomes on the basis of completeness of revas-
cularization in the TO groups. Figure 5 demonstrates com-
parisons of HRs for CR versus ICR in the PCI and CABG
arms for all 4-year clinical endpoints in the respective TO
and non-TO groups. The findings associating ICR (com-
pared with CR) with higher frequencies of 4-year adverse
clinical outcomes, as seen in the CABG and PCI arms of
the SYNTAX population, remained consistent in the re-
spective TO groups (nonsignificant p values for interaction),
with a few notable exceptions.
Within the PCI arm (p value for interaction 0.001),
CR in patients with TOs was associated with substantially
fewer episodes of 4-year stent thrombosis compared with
ICR (CR: 0%, n  0; ICR: 4.6%, n  7; no HR available
as 0 events in patients with CR) (Fig. 5). Within the CABG
arm (p value for interaction  0.0008), CR in patients with
TOs was related to a significantly lower risk of 4-year graft
occlusion, compared with ICR (CR 2.7% vs. ICR 7.6%;
HR: 0.34, 95% CI: 0.14 to 0.84, p  0.019); conversely, in
patients with CR without TOs, the risk of 4-year graft
occlusion was substantially higher (CR 5.2% vs. ICR 0.86%;
HR: 6.22, 95% CI: 1.49 to 26.07, p  0.012).
Despite limitations of power in the TO groups, signifi-
cant reductions in 4-year MACCE were evident in patients
with TOs who achieved CR (vs. ICR) treated with either
PCI or CABG (Fig. 6).
Predictors of ICR in TO groups. Table 5 lists indepen-
dent predictors of ICR in the TO groups of PCI- and
CABG-treated patients. Within the cohort of TO treated
PCI patients, heavy calcification and long lesions were
additional independent predictors of ICR compared with
the main study findings (Table 2).
Independent Predictors of ICR inAll-Comers PCI and CABG PopulationsTable 2 Ind pendent Predictors of ICR inAll-Comers PCI and CABG Populations
Anatomical/Clinical Characteristic OR (95% CI) p Value
PCI-treated patients
TO 2.70 (1.98–3.67) 0.001
Any RCA lesion 2.12 (1.33–3.38) 0.002
Left arterial dominance 1.81 (1.26–2.60) 0.001
Additive EuroSCORE 6 1.58 (1.18–2.13) 0.002
Number of lesions* 1.44 (1.29–1.59) 0.001
Hyperlipidemia 1.49 (1.08–2.06) 0.015
Any tortuosity 1.39 (1.04–1.86) 0.025
Total bifurcation/trifurcations* 1.32 (1.13–1.53) 0.001
CABG-treated patients*
Left arterial dominance 1.99 (1.45–2.73) 0.001
Any RCA lesion 1.89 (1.16–3.06) 0.010
Unstable angina 1.59 (1.23–2.05) 0.001
Peripheral vascular disease 1.34 (0.95–1.88) 0.092
Number of lesions* 1.30 (1.21–1.40) 0.001
Parsonnet score* 1.02 (1.00–1.04) 0.027
Left main coronary artery disease 0.70 (0.55–0.90) 0.005
Independent predictors of ICR in the All-Comers PCI (n 1095) and CABG (n 1541) populations.
*Continuous variables/unit increase.
CI confidence interval; OR odds ratio; RCA right coronary artery; other abbreviations as in
Table 1.
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Discussion
In this post hoc study of the All-Comers SYNTAX Trial,
there were several notable findings. First, within the PCI
and CABG arms, ICR (compared with CR) seemed to be
a surrogate marker of a greater burden of anatomical
coronary complexity and clinical comorbidity and was asso-
ciated with a significant increase in 4-year mortality, all-
cause revascularization, MACCE, and stent thrombosis
(PCI arm). Second, the presence of a TO was less likely to
result in CR in the PCI and CABG arms, with this effect
being substantially more pronounced in the PCI arm, where
the presence of a TO was shown to be the strongest
independent predictor of ICR. Third, ICR (compared with
CR) was associated with poorer clinical outcomes (4-year
mortality and MACCE) across the TO and non-TO
groups.
The low rate of CR in the PCI arm (34.3%) compared
with the CABG arm (64.8%) was predominantly related to
the lack of procedural success of TO PCI, as evident by a
49.4% recanalization rate in the randomized SYNTAX
Baseline and Procedural Characteristics for All-Comers PCI and CABG and Populations Stratified by the Presence of TOsTable 3 Baseline and Procedural Characteristics for All-Comers PCI and CABG and Populations Stratified by the Presence of TOs
PCI (n  1,095) CABG (n  1,541)
Non-TO TO p Value Non-TO TO p Value
Baseline clinical characteristics
Age (yrs) 66.4 9.9 65.9 10.6 0.47 65.4 9.4 64.9 10.0 0.31
Male 74.6% 77.6% 0.31 76.8% 84.7% 0.001
BMI (kg/m2) 28.0 4.8 28.5 5.2 0.17 27.8 4.5 28.3 4.7 0.04
Diabetes 28.9% 31.5% 0.41 28.0% 30.9% 0.24
Hypertension 73.7% 75.7% 0.50 75.7% 75.0% 0.76
Hyperlipidemia 75.8% 79.4% 0.21 76.5% 78.3% 0.44
Peripheral vascular disease 9.9% 11.5% 0.43 10.2% 14.8% 0.008
Current smoker 17.9% 15.1% 0.29 21.7% 22.6% 0.67
Unstable angina 29.9% 31.8% 0.54 27.1% 22.6% 0.051
Prior MI 31.4% 39.4% 0.015 30.3% 39.7% 0.001
LVEF
Good (50%) 80.3% 65.0% 0.001 81.6% 64.4% 0.001
Moderate (30%–49%) 16.5% 25.9% 0.001 15.2% 27.1% 0.001
Poor (30%) 1.0% 5.2% 0.001 2.2% 5.4% 0.001
Baseline clinical scores
Total Parsonnet score 9.5 7.8 9.9 7.9 0.42 8.5 7.0 8.9 6.9 0.30
Additive EuroSCORE 4.1 2.7 4.3 3.1 0.27 3.8 2.7 3.8 2.7 0.96
Logistic EuroSCORE 4.2% 5.1 5.2% 7.4 0.047 3.9% 4.3 4.0% 4.6 0.72
Anatomical characteristics
Number of TOs — — — — — —
1 — 87.8% — — 79.8% —
2 — 11.9% — — 17.9% —
3 — 0.3% — — 2.4% —
Diffuse disease or small vessels 20.9% 26.9% 0.035 20.9% 33.0% 0.001
Number of lesions 3.9 1.7 4.2 1.3 0.001 4.2 1.9 4.7 1.6 0.001
Left main disease 44.1% 26.9% 0.001 48.0% 32.9% 0.001
Bifurcation 61.9% 63.6% 0.60 65.7% 63.4% 0.36
Trifurcation 8.4% 4.9% 0.055 10.0% 8.8% 0.45
Aorto-ostial 16.0% 15.0% 0.70 18.2% 12.5% 0.003
Any thrombus 2.5% 2.8% 0.79 3.9% 2.7% 0.21
Heavy calcification 49.4% 52.4% 0.37 52.7% 56.5% 0.16
Any severe tortuosity 65.5% 67.5% 0.54 68.7% 70.4% 0.48
Left dominance 17.8% 18.9% 0.37 15.9% 14.8% 0.16
Procedural characteristics
Lesion length 20 mm 49.0% 80.8% 0.001 53.1% 87.2% 0.001
Total number of stents implanted 4.4 2.3 4.4 2.0 0.82 — — —
Total length of stents implanted (mm) 80.6 49.1 84.2 44.3 0.29 — — —
Post-procedural hospital stay (days) 3.6 7.1 3.8 5.2 0.63 8.8 5.7 9.2 9.1 0.30
Procedure time (h) 1.6 0.9 1.7 1.0 0.012 3.5 1.1 3.6 1.0 0.025
Completeness of revascularization
Complete revascularization 59.8% 34.3% 0.001 69.8% 64.8% 0.048
Values are mean  SD or %.
Abbreviations as in Table 1.
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population (compared with procedural success rate of 68.1%
in the CABG arm) on an intention-to-treat basis (Fig. 4).
Furthermore, the clinical impact of failure to recanalize TOs
by PCI would potentially have been greater, because two-
thirds of TOs were located in the proximal-mid coronary
major epicardial vessels (Fig. 3). Comparatively, other
anatomical factors associated with ICR in the PCI and
CABG arms might be of lesser importance, because the
amount of jeopardized myocardium would have been lower
compared with a TO—for example, a diseased side branch
of a coronary bifurcation. Previous studies have shown that
myocardial territory with 10% reversible ischemia derives
the greatest clinical benefit from revascularization (31–33).
In the CABG arm, CR was achieved less frequently in
patients with TOs compared with patients without TOs
(non-TO: 69.8%, TO: 64.8%, p  0.048). Notably, a
similar phenomenon was reported in the ARTS (Arterial
Revascularization Therapies Study) (34). A potential expla-
nation for this finding might be related to the presence of a
TO being associated with more diffuse or small vessel
disease (non-TO: 20.9%, TO: 33.0%, p  0.001) and
consequently hindering the anastomosis of a bypass graft
distally (Fig. 4).
Completeness of revascularization. One of the reasons
the long-term prognostic implications of completeness of
revascularization has historically remained controversial
has been a lack of consistency in the definition of ICR
(1,4–6,8,10,11). For example, variations in the size of
coronary vessels included and diameter stenosis on the basis
of coronary angiography have made results difficult to
Baseline Angiographic Characteristics of TOs on the Basis ofP rameters From SYNTAX Score Calculation From All-Comers SYNTAX TrialTable 4 Baseline Angiograph c Characteristics of TOs on the Basis ofParameters From SYNTAX Score Calculation From All-Comers SYNTAX Trial
SYNTAX Score Parameter for TO on Lesion Level in
All-Comers SYNTAX Trial*
All Treated TOs
(n  1,007)
PCI-Treated TOs
(n  324)
CABG-Treated TOs
(n  683)
Age of TO
3 months/unknown 963 (95.6%) 304 (93.8%) 659 (96.5%)
3 months 44 (3.4%) 20 (6.2%) 24 (3.5%)
Blunt stump 231 (22.9%) 78 (24.1%) 153 (22.4%)
Bridging occlusion 105 (10.4%) 40 (12.3%) 65 (9.5%)
Ostial lesion 34 (3.4%) 12 (3.7%) 22 (3.2%)
Severe tortuosity 224 (22.2%) 77 (23.8%) 147 (21.5%)
Heavy calcification 241 (23.9%) 71 (21.9%) 170 (24.9%)
Thrombus 7 (0.7%) 2 (0.6%) 5 (0.7%)
Length 20 mm 647 (64.3%) 192 (59.3%) 455 (66.6%)
Non-visible segments beyond TO† 226 (22.4%) 85 (26.2%) 141 (20.6%)
Side-branch at the origin of the TO
No 317 (31.5%) 110 (34.0%) 207 (30.3%)
Yes, side-branches 1.5mm 512 (50.8%) 158 (48.8%) 354 (51.8%)
Yes side-branches 1.5 mm 208 (20.7%) 66 (20.4%) 142 (20.8%)
Baseline angiographic characteristics of the TOs on the basis of parameters from the SYNTAX Score calculation from the All-Comers SYNTAX Trial
(n  2,636) (22–24). Lesion level data shown (n  1,007). Percentages relate to proportions/column. *Analyzed lesions include serial stenoses
(diameter stenosis 50% in vessels 1.5 mm) 3 vessel reference diameters apart. †Visualized by antegrade or retrograde contrast.
Abbreviations as in Table 1.
Figure 3 Location of Total Occlusions in All-Comers SYNTAX Population
Total occlusions (n  1,007 lesions) in the All-Comers SYNTAX population (n  2,636). Left main, proximal, and mid vessels (highlighted in red)
accounted for over two-thirds (68.1%) of total occlusions.
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compare. Furthermore, inconsistencies in defining the clin-
ical endpoints, quality of clinical endpoint monitoring and
adjudication, and selection biases in observational registries
have compounded this issue (1,5).
The strength of the present study was that the
angiographic-based definition of CR/ICR was prospectively
and rigorously systematically applied across all PCI- and
CABG-treated patients in an All-Comers setting. Al-
though more anatomically complex patients were enrolled
into the nested CABG registry and more with clinical
comorbidity were enrolled in the nested PCI registry
(27,28), this is representative of contemporary clinical prac-
tice. Within the present study, the decision to use a 1.5-mm
vessel as the minimum size of vessel that could be revascu-
larized was devised during the design of the SYNTAX Trial
to reflect the ability of the cardiac surgeon to anastomose
bypass grafts to vessels of this size. To allow appropriate
randomization of the patient, the interventional cardiologist
was required to match this practice.
In patients treated with PCI or CABG, ICR seemed to
be a surrogate marker of a greater burden of anatomical
coronary complexity and clinical comorbidity and was asso-
ciated with a poorer long-term prognosis in PCI- and
CABG-treated patients. These findings are not unexpected,
given the historical association of more extensive baseline
preoperative coronary disease with reduced long-term sur-
vival in the CASS (Coronary Artery Surgery Study) (35)
and Rotterdam (36) registries. Furthermore, within the
BARI (Bypass Angioplasty Revascularization Investigation)
trial (37)—consisting of patients treated with PCI or
CABG who underwent entry and 5-year coronary angio-
graphic follow-up—native coronary disease progression
(and not the extent of initial revascularization) was shown to
be the predominant determinant of recurrence of angina and
jeopardized myocardium at 5 years. Notably in this study,
two-thirds of the increase in myocardial jeopardy was in
previously untreated coronary vessels.
Moreover, the findings of the present study directly
contradict that reported from the 3-year randomized
SYNTAX trial (7), where no differences in clinical out-
comes between CR and ICR were seen in the CABG
population. Similar findings were shown in the 4-year
randomized data (unpublished data). The disparity in re-
sults seems to reflect the fact that the nested CABG registry
Figure 4 Treatment of Total Occlusions on an Intention to Treat Basis by Study Sites in Randomized SYNTAX Population
*Specified as “total occlusion” on the electronic case records without specific reason given for unsuccessful treatment of total occlusion.
Abbreviations as in Figure 1.
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Figure 5 Four-Year Clinical Outcomes in Patients Stratified by Presence of CR and ICR With and Without TOs
Hazard ratios (HR) represent CR versus ICR for each 4-year clinical endpoint. A nonsignificant p value for interaction indicates that the HR of CR versus ICR in the PCI
and CABG arms remained similar across the respective TO and non-TO groups. CI  confidence interval; Revasc  revascularization; TO  total occlusion; other abbrevi-
ations as in Figures 1 and 2.
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contains more anatomically complex patients compared
with the randomized CABG cohort (SYNTAX Score:
nested CABG registry 37.8  13.3, randomized CABG
29.1  11.4, p  0.002) (27,28). The ICR in the All-
Comers CABG population therefore potentially resulted in
more jeopardized myocardium, secondary to more anatom-
ically complex coronary artery disease and greater clinical
comorbidity (higher EuroSCORE and Parsonnet Scores)
and their association with a likely increase in coronary
atherosclerotic burden (4) and adverse long-term clinical
outcomes as previously discussed. Within the PCI arm,
potentially more jeopardized myocardium remained in pa-
tients with ICR compared with CABG, secondary to the
failure to recanalize TOs or other (perhaps lesser important)
anatomical factors, such as the presence of bifurcations, in
addition to the similar factors associated with ICR in
CABG patients.
Clinical impact of PCI- and CABG-treated TO. Beyond
the main study findings of increased stent thrombosis
associated with ICR in the PCI arm (CR 3.7%, ICR 6.5%,
p  0.046), further analyses indicated that there was a
substantial increase in stent thrombosis in patients with
TOs who had ICR (CR: 0 episodes [0%], ICR: 7 episodes
[4.6%]). Notably, patients with ICR had fewer stents (p 
0.009) and shorter total length of stents implanted (p 
0.002) (Table 1). Attempting to understand the mecha-
nisms underlying this possible phenomenon are speculative.
As to whether episodes of stent thrombosis are secondary to
neoatherosclerosis (38) related to the more adverse clinical
comorbidity in patients with ICR: stent under-deployment
due to greater coronary calcification associated with ICR,
failure to fully expand a TO after successful coronary wire
passage (Fig. 4), or the potential risk of delayed re-
endothelialization—particularly if a subintimal technique of
coronary wire passage is undertaken (39)—are all hypothet-
ical mechanisms that require further study.
In the present study, the graft occlusion rate was substan-
tially lower when CR was achieved in patients with TOs
(and greater when CR was achieved in patients without
TOs). These findings are consistent with previous studies,
where early graft failure has been shown to be higher when
anastomosed to functionally nonsignificant lesions or where
competitive filling with the treated native vessel is seen
(40–43).
Potential recommendations. Recently the concept of “rea-
sonable” or “appropriate” ICR has been highlighted (1,3–5).
This is either anatomically guided, on the basis of revascu-
larizing most of the major epicardial vessels, or functionally/
physiologically guided (on the basis of the burden of residual
ischemia). The underlying principle is that, even if CR was
technically possible and achievable (i.e., in all vessels 1.5
mm in diameter), this would not necessarily improve clinical
outcomes—given the small territory a small side branch
would, for example, supply. Future studies, possibly using a
Figure 6 Four-Year MACCE Stratified by
Presence of ICR Versus CR in Patients With TOs
A significant increase in MACCE was evident in PCI- and CABG-treated TO
patients with ICR. These findings reflect the findings seen in both the PCI and
CABG arms, where ICR was associated with poorer 4-year clinical outcomes
compared with CR (Fig. 2). Abbreviations as in Figures 1 and 2.
Independent Predictors of ICR in TO PatientsWithin All-Com rs PCI and CABG PopulationsTable 5 Independent Pred ctors of ICR in TO PatientsWithin All-Comers PCI and CABG Populations
Anatomical/Clinical Characteristic OR (95% CI) p Value
PCI-treated TO patients
Left arterial dominance 2.19 (1.05–4.57) 0.038
Additive EuroSCORE 6 2.13 (1.16–3.88) 0.014
Any heavy calcification 2.02 (1.19–3.43) 0.009
Any lesion 20 mm 1.84 (0.96–3.53) 0.068
Total bifurcations/trifurcations* 1.37 (0.98–1.91) 0.067
Number of lesions* 1.36 (1.09–1.71) 0.006
CABG-treated TO patients
Left arterial dominance 2.50 (1.53–4.09) 0.001
Number of lesions* 1.25 (1.11–1.40) 0.001
Parsonnet score* 1.03 (1.01–1.06) 0.013
PCI (n  554) and CABG (n  554) populations. *Continuous variables/unit increase.
Abbreviations as in Tables 1 and 2.
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noninvasive functional approach (44,45), might help best
distinguish what acceptable level of revascularization is appro-
priate that would have a significant impact on long-term
clinical outcomes. The newly devised Residual SYNTAX (46)
and CABG SYNTAX (47) Scores each allows for more
objective assessment of the degree of revascularization and
residual anatomical disease complexity post-PCI or -CABG.
Use of these methodologies might in the future aid in deter-
mining a “reasonable” threshold of revascularization.
Study limitations. The present study represents a post hoc
analysis of the SYNTAX trial, and the results should be
considered as hypothesis-generating. There was limited
statistical power in the TO-treated patients and for the
comparison of low-frequency events, such as stroke, graft
occlusion, and stent thrombosis. The age of TOs could not
be clearly defined, with most cases being unknown. Further
procedural details of recanalization of TOs are not available
beyond what is reported in the study. Core laboratory
assessment of CR/ICR was not undertaken, because no
post-operative (CABG) coronary angiograms were man-
dated in the SYNTAX trial. The possibility of other
unmeasured adverse clinical characteristics to have con-
founded the data toward ICR cannot be excluded, although
the intention of the study was to achieve CR in all study
patients. The “All-Comers” concept of the SYNTAX trial,
although more representative of contemporary clinical prac-
tice compared with the randomized approach, has been
reported to potentially not result in the inclusion of consec-
utive patients, predominantly due to the inability to gain
appropriate informed consent and refusal to participate
(48,49). Although the SYNTAX trial was based on con-
temporary revascularization practice at the time, improve-
ments in technology in PCI and CABG might yield
differences in clinical outcomes in future trials.
Conclusions
Within the PCI and CABG arms of the All-Comers
SYNTAX Trial, angiographically determined ICR seemed
to be a surrogate marker of a greater burden of anatomical
coronary complexity and clinical comorbidity and had a
detrimental impact on long-term clinical outcomes, includ-
ing mortality. This effect remained consistent in patients
with and without TOs.
The impact of ICR on clinical outcomes is dependent
on the complexity of coronary disease and risk profile of
the study population, on the basis of the observations
associating ICR with: 1) no effect on long-term clinical
outcomes (randomized CABG population); and 2) more
adverse long-term clinical outcomes (All-Comers CABG
population).
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Incomplete revascularization (ICR) has recently been shown to be a surrogate marker of a greater burden of anatomic coronary 
complexity and clinical comorbidity in patients undergoing 
percutaneous or surgical based revascularization in a post hoc 
analysis1 of the Synergy Between Percutaneous Coronary 
Intervention With Taxus and Cardiac Surgery (SYNTAX) Trial.2–5 
In addition, ICR has been linked to adverse short- and longer term 
morbidity and mortality.6–14 Recently, the concept of reasonable 
incomplete revascularization has been proposed,7,8,11,13,15 
the underlying principle being that an acceptable burden of 
obstructive coronary artery disease post revascularization to be 
associated with similar outcomes to subjects in whom complete 
revascularization (CR) was achieved.
Editorial see p 95 
Clinical Perspective on p 151
Background—The residual Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery 
(SYNTAX) Score is an objective measure of the degree and complexity of residual stenosis after percutaneous coronary 
intervention (PCI).
Methods and Results—In the randomized PCI cohort of the SYNTAX Trial (n=903), the baseline and residual SYNTAX 
Scores were calculated. Subjects with a residual SYNTAX Score of 0 were defined as having undergone complete 
revascularization (CR), and a residual SYNTAX Score >0 as incomplete revascularization (ICR). Five-year clinical 
outcomes were stratified by CR and ICR (tertiles of the residual SYNTAX Score: >0–4, >4–8, and >8). In the PCI cohort, 
the mean baseline and residual SYNTAX Scores were 28.4±11.5 and 4.5±6.9, respectively. The mean Δ SYNTAX Score 
(representative of the burden of disease removed by PCI) was 23.8±10.9. The residual SYNTAX Score was distributed as 
follows: CR, 0 (n=386, 42.7%); ICR, >0 to 4 (n=184, 20.4%), >4 to 8 (n=167, 18.5%), >8 (n=153, 16.9%). A progressively 
higher residual SYNTAX Score was shown to be a surrogate marker of increasing clinical comorbidity and anatomic 
complexity. Subjects with CR or residual SYNTAX Scores ≤8 had comparable 5-year mortality (CR, 8.5%; residual 
SYNTAX Score >0–4, 8.7%; >4–8, 11.4%; P=0.60). A residual SYNTAX Score >8 was associated with 35.3% all-cause 
mortality at 5-years (P<0.001). Stratified analyses in the predefined medical treated diabetic and left main subgroups 
yielded similar results.
Conclusions—The residual SYNTAX Score was shown to be a powerful indicator of 5-year mortality in the SYNTAX Trial. 
The residual SYNTAX Score may aid in determining a reasonable level of revascularization.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00114972.   (Circulation. 2013;128:141-151.)
Key Words: coronary disease ◼ drug-eluting stents ◼ myocardial ischemia  
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The recently developed residual SYNTAX Score is an 
objective, quantitative measure of the degree and complex-
ity of residual stenosis after percutaneous coronary interven-
tion (PCI).16 In a post hoc analysis of the ACUITY (Acute 
Catheterization and Urgent Intervention Triage Strategy) 
Trial,16 consisting of subjects with moderate to high-risk acute 
coronary syndrome undergoing PCI, and substantially less 
complex coronary artery disease compared with the SYNTAX 
Trial, a residual SYNTAX Score of >8.0 after PCI was asso-
ciated with adverse 1-year mortality. The purpose of this 
study was to assess the prognostic significance of the residual 
SYNTAX Score in the randomized all-comers SYNTAX Trial 
at the final 5-year follow-up.
Methods
The all-comers SYNTAX Trial is a randomized, prospective, mul-
ticenter trial investigating subjects with unprotected left main coro-
nary artery (ULMCA) disease (isolated or associated with 1-, 2-, or 
3-vessel disease), or de novo 3-vessel (3VD) coronary artery dis-
ease.3,5 In total, 1800 patients were recruited and randomized in 
PCI (n=903) and coronary artery bypass graft (CABG; n=897) arms 
from 85 centres in 18 countries from Europe and the United States. 
Exclusion criteria were limited, and consisted of subjects with prior 
coronary revascularization, the requirement of concomitant cardiac 
surgery (eg, valve surgery or resection of aortic or left ventricular 
aneurysm), or on-going acute myocardial infarction (MI). During the 
local Heart Team meeting, the interventional cardiologist and cardiac 
surgeon specified the number of coronary lesions requiring treat-
ment, and their angiographic location and characteristics using the 
anatomic SYNTAX Score—a quantitative measure of coronary artery 
complexity (http://www.syntaxscore.com)17–20—as a tool to aid in this 
process. All subjects considered as potentially achieving equivalent 
anatomic revascularization with percutaneous or surgical revascular-
ization by the Heart Team were randomized on a 1:1 basis (n=1800) 
to either PCI with Taxus Express paclitaxel-eluting stents (Boston 
Scientific Corporation, Natick, MA) or CABG. Patients unsuitable 
for randomization were nested into registries.5
Randomization of subjects was stratified by clinical site, the 
absence or presence of ULMCA disease, and medically treated diabe-
tes mellitus (requiring oral medications or insulin), to ensure approxi-
mately equal allocation to the 2 revascularization methods at each site 
and within each stratum.5 The Parsonnet21 and EuroSCORE22,23 were 
assessed by the Heart Team before randomization. Baseline, peri-, 
and postprocedural data were prospectively collected by the individ-
ual participating centres.
Baseline, Residual, and Δ SYNTAX Scores
The calculation of the baseline SYNTAX Score17–20 was carried 
out by the Heart Team before randomization and corroborated by 
an independent core laboratory (Cardialysis BV, Rotterdam, The 
Netherlands) blinded to the treatment assignment. Baseline and pro-
cedural coronary angiograms were centrally stored. The baseline and 
procedural coronary angiogram were analyzed side by side by a panel 
of 3 interventional cardiologists blinded to the clinical outcomes. The 
baseline SYNTAX Score and its components, including anatomic 
location of all lesions, recorded by the core laboratory in calculation 
of the original SYNTAX Score, were used to identify all coronary 
lesions in the baseline and procedural coronary angiogram. The resid-
ual SYNTAX Score was calculated based on the remaining obstruc-
tive coronary disease after treatment with PCI. The intraobserver 
variability for calculation of the residual SYNTAX Score (quartile 
partitioning), based on reanalyzing 50 cases at a 3-month interval, 
indicated a high level of agreement (κ statistic=0.89; 95% confidence 
interval [CI], 0.79 – 0.99; P<0.001).17,24 The high level of agreement 
was attributable to the panel having preknowledge of all coronary 
lesion locations before PCI. The Δ SYNTAX Score, representative of 
the burden of disease removed by PCI, was calculated by subtracting 
the residual from the baseline SYNTAX Score.16
Clinical Outcomes
Clinical outcomes included all-cause death, all-cause death/MI/
cerebrovascular accident, major adverse cardiac and cerebrovascu-
lar events (MACCE; a composite of all-cause death, MI, cerebrovas-
cular accident, and all-cause revascularization) and its components, 
and stent thrombosis using the Academic Research Consortium 
definition.25 An independent Clinical Events Committee, including 
Figure 1. Correlation between the baseline and residual Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac 
Surgery (SYNTAX) Score. Relationship between the baseline (x axis) and residual (y axis) SYNTAX Score, for individual patients in the 
randomized percutaneous coronary intervention (PCI) arm of the SYNTAX Trial. Paired data were available in 886/903 subjects (98.1%). 
Each point can be used to assess the baseline and residual SYNTAX Scores for individual patients from the SYNTAX Trial. Each point 
may represent >1 value.
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Table 1. Baseline and Procedural Characteristics According to Complete (Residual SYNTAX Score 0) and Incomplete 
Revascularization (Tertiles of the Residual SYNTAX Score)
 
Residual SYNTAX  Score (n=890)
0 (n=386) >0–4 (n=184) >4–8 (n=167) >8 (n=153)
P Value for 
Linear Trends*
Clinical characteristics
 Age, y 64.6±9.8 64.8±8.7 66.0±9.8 66.7±9.8 0.015
 Male 72.5% 81.0% 82.0% 73.9% 0.25
 Diabetes mellitus 22.0% 31.0% 29.3% 39.9% <0.0001
 Medically treated diabetes mellitus (oral medications or insulin)† 20.5% 26.6% 26.3% 37.3% 0.0001
 HbA1c ≥7% 13.6% 18.1% 7.3% 22.6% 0.24
 Body mass index, kg/m2 28.0±4.7 28.4±5.2 27.6±4.6 28.7±4.6 0.53
 Hypertension 71.5% 77.6% 70.7% 80.8% 0.099
 Hyperlipidemia 77.9% 75.8% 80.7% 82.7% 0.19
 Peripheral vascular disease 8.3% 6.0% 9.6% 15.0% 0.025
 Current smoker 20.5% 15.2% 16.2% 19.6% 0.54
 Unstable angina 25.9% 34.8% 29.3% 28.8% 0.44
 Previous myocardial infarction 29.8% 31.9% 28.8% 37.9% 0.17
 History of GI bleeding/peptic ulcer disease 4.4% 1.6% 3.0% 7.3% 0.32
 COPD 8.8% 6.0% 8.4% 7.8% 0.75
 LVEF (continuous variable), % 60.3±12.2 59.8±12.9 57.4±13.9 56.5±13.4 0.0058
 Good LVEF (≥50%) 82.6% 84.2% 73.1% 67.3% <0.0001
 Moderate LVEF (30%-49%) 13.2% 14.1% 22.2% 28.1% <0.0001
 Poor LVEF (<30%) 0.8% 0.5% 2.4% 2.6% 0.046
 Creatinine clearance, ml/min‡ 87.2±32.0 92.4±48.2 83.6±28.2 81.3±32.9 0.059
Baseline anatomical and clinical scores
 Baseline SYNTAX Score 23.6±10.0 29.0±10.2 31.7±9.8 35.9±12.4 <0.0001
 Residual SYNTAX Score 0.0±0.0 3.0±1.0 6.2±1.1 15.7±9.4 <0.0001
 Δ SYNTAX Score¶ 23.6±10.0 26.0±10.1 25.4±9.9 20.1±13.7 0.04
 Total Parsonnet Score 8.2±7.1 7.8±5.9 8.6±6.8 10.5±7.6 0.002
 Additive EuroSCORE 3.6±2.7 3.6±2.4 3.8±2.5 4.2±2.6 0.02
 Logistic EuroSCORE 3.8±5.5 3.3±2.9 3.7±3.6 4.3±4.2 0.34
Anatomical characteristics
 Left main disease§† 42.5% 34.8% 40.1% 39.2% 0.48
 De novo 3VD 57.5% 65.2% 59.9% 60.8% 0.48
 Number of lesions 3.5±1.7 4.1±1.6 4.3±1.6 4.5±1.6 <0.0001
 Any total occlusions 12.3% 22.3% 28.3% 50.7% <0.0001
 Number of total occlusions
 1 TO 12.0% 22.3% 25.3% 42.8% <0.0001
 2 TO 0.3% 0.0% 3.0% 7.9% <0.0001
 Any bifurcation lesion 57.3% 66.3% 62.9% 70.6% 0.0056
 Any trifurcation lesion 7.3% 6.0% 10.2% 6.5% 0.77
 Any bifurcation or trifurcation 62.2% 68.5% 70.1% 71.9% 0.015
 Diffuse or small vessel disease 18.4% 26.1% 20.4% 28.1% 0.034
 Any aorto-ostial lesion 17.3% 13.6% 11.5% 17.1% 0.48
 Any angiographically visible thrombus 2.6% 2.2% 2.4% 2.6% 0.97
 Any heavy calcification 42.7% 47.3% 53.0% 64.5% <0.0001
 Any severe tortuosity 55.8% 74.5% 74.7% 71.7% <0.0001
 Left arterial dominance 16.8% 19.6% 19.8% 16.3% 0.85
(Continued)
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cardiologists, cardiac surgeons, and a neurologist, reviewed all the 
primary clinical end points.3,5 A separate independent Clinical Events 
Committee adjudicated the Academic Research Consortium stent 
thrombosis events.
Statistical Analysis
Analyses were performed by intention to treat. Binary variables are 
reported as counts or percentages, continuous data are expressed 
as means±SD. All variables were stratified according to a residual 
SYNTAX Score 0 (CR), and tertiles of the residual SYNTAX Score 
>0 (ICR). For the baseline characteristics, testing for linear trends 
across residual SYNTAX Score groups was performed using general-
ized linear models with the residual SYNTAX Score class as a covari-
able for continuous variables, and the Cochran-Armitage test for 
trends in categorical data. Time-to-event variables are presented as 
Kaplan–Meier curves and compared using Cox proportional hazard 
ratios (HR) and the log-rank test. Multivariable analyses were con-
ducted with a Cox regression model using the forced enter method. 
Previously determined anatomic and clinical variables, shown to be 
independent predictors of long-term mortality in the SYNTAX Trial 
(P<0.1),26 were entered into the model, with no exit criteria. There 
was no departure from the proportionality of hazards assumption 
using the global proportional hazards test based on Schoenfeld resid-
uals.27 Area under the curve for the baseline and residual SYNTAX 
Scores for 5-year all-cause death and 5-year MACCE were computed 
by logistic regression and compared using the nonparametric method 
of deLong et al.28 Area under the curve performed with and without 
censored data removed had a negligible difference. A 2-sided proba-
bility value <0.05 was considered significant for all tests. All analyses 
were conducted using SPSS 20.0 (SPSS Inc, Chicago IL) and SAS 
System Software Version 9.2 (SAS Institute, Cary, NC)
Results
In the randomized PCI cohort (n=903), the baseline SYNTAX 
Score was available in 899/903 subjects (99.6%). The 
mean baseline SYNTAX Score was 28.4±11.5. The residual 
Table 1. Continued
Residual SYNTAX Score (n=890)
0 (n=386) >0–4 (n=184) >4–8 (n=167) >8 (n=153)
P Value for 
Linear Trends*
 Proximal LAD (segment 6) lesion 52.3% 62.0% 61.1% 64.7% 0.0047
 Any circumflex lesion 77.7% 92.9% 88.0% 92.2% <0.0001
 Any right coronary artery lesion 74.9% 83.7% 87.4% 91.5% <0.0001
 Any lesion length >20 mm 46.1% 57.6% 62.1% 70.4% <0.0001
Procedural characteristics
 Total number of stents implanted 4.5±2.4 4.9±2.2 4.7±2.0 4.6±2.1 0.73
 Total length of stents implanted, mm 85.8±51.6 91.0±47.9 84.3±42.5 82.2±42.1 0.44
 Stent length >100 mm 35.1% 36.1% 28.7% 29.6% 0.12
 Postprocedural hospital stay, d 3.0±4.3 2.9±3.4 2.9±2.4 5.1±7.1 0.0001
 Procedure time, h 1.6±0.9 1.7±0.8 1.9±0.9 1.9±1.0 <0.0001
3VD indicates 3-vessel disease; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; HbA1c, hemoglobin A1c; LAD, left anterior descending artery; LVEF, 
left ventricular ejection function; MI, myocardial infarction; PCI, percutaneous coronary intervention; SYNTAX, Synergy Between Percutaneous Coronary Intervention With 
Taxus and Cardiac Surgery; and TO, total occlusion.
*Testing for (linear) trends was performed using generalized linear models with the residual SYNTAX Score class as a covariable for continuous variables and the 
Cochran-Armitage test for trends in categorical data.
†Prespecified patient subsets at randomization.
‡Cockcroft and Gault formula.
Δ SYNTAX Score represents the burden of disease removed by PCI.
§Isolated or associated with 1, 2, or 3VD.
Figure 2. Complete (residual Synergy Between 
Percutaneous Coronary Intervention With Taxus 
and Cardiac Surgery [SYNTAX] Score 0) and 
incomplete (tertiles of the residual SYNTAX Score 
[residual SYNTAX Score >0]) revascularization, 
stratified according to tertiles of the baseline 
SYNTAX Score. Note the progressive increase 
in the frequency of a residual SYNTAX Score >8 
across conventional tertiles of the baseline SYNTAX 
Score.
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SYNTAX Score was available in 890/903 subjects (98.6%). 
The correlation (Spearman coefficient 0.414, P<0.001) and 
distribution of the baseline and residual SYNTAX Score is 
illustrated in Figure 1. CR (residual SYNTAX Score 0) was 
evident in 42.7% of the PCI arm (n=386), and ICR in 55.8% 
of the PCI arm (n=504) (residual SYNTAX Score: >0 to 4 
(20.4% [n=184]), >4 to 8 (18.5% [n=167]), and >8 (16.9% 
[n=153]). The mean Δ SYNTAX Score (representative of the 
burden of disease removed by PCI) was 23.8±10.9. The mean 
residual SYNTAX Score was 4.5±6.9.
Baseline Characteristics
Baseline characteristics of CR (residual SYNTAX Score 0) 
and ICR (tertiles of the residual SYNTAX Score) are shown 
in Table 1. A higher residual SYNTAX Score was associated 
with progressively increasing clinical comorbidity; namely, 
older age (P=0.015), medically treated diabetes mellitus 
(P=0.0001), peripheral vascular disease (P=0.025), reduced 
left ventricular ejection fraction (P=0.0058), reduced creatinine 
clearance (P=0.059), greater Parsonnet Score (P=0.0020), 
and additive EuroSCORE (P=0.020). Similarly, a greater 
residual SYNTAX Score was associated with progressively 
higher baseline SYNTAX score (P<0.0001), with a residual 
SYNTAX Score of >8 associated with significantly more 
total occlusions (TO; 50.7%, P<0.0001), bifurcations (70.6%, 
P=0.0056), diffuse or small vessel disease (28.1%, P=0.034), 
heavy calcification (64.5%, P<0.0001), severe tortuosity 
(71.7%, P<0.0001), and long lesions (70.4%, P<0.0001). 
Stent length was not associated with an increase in the 
residual SYNTAX Score (P=0.44). Notably, the Δ SYNTAX 
Score was lower in subjects with a residual SYNTAX Score 
>8 (20.1±13.7) compared with CR (23.6±10.0, P=0.040).
Distribution of Residual SYNTAX Score per Tertiles 
of the Baseline SYNTAX Score
Figure 2 illustrates the distribution of the residual SYNTAX 
Score per tertile of the baseline SYNTAX Score. The fre-
quency of subjects with a residual SYNTAX Score >8 pro-
gressively increased across tertiles of the baseline SYNTAX 
Score (0–22: 7.1% versus 23–32: 14.3% versus ≥33: 30.9%, 
P value for linear trend <0.0001).
5-Year Clinical Outcomes
Figure 3 illustrates the HRs for categories of the residual 
SYNTAX Score for differing clinical outcomes, using CR 
(residual SYNTAX Score 0) as a reference. Subjects with 
CR or lower residual SYNTAX Scores (≤8) had compara-
ble 5-year mortality (CR [n=386]: 8.5%, residual SYNTAX 
Score >0–4 [n=184]: 8.7%, >4–8 [n=167]: 11.4%, P=0.60). 
At 5 years, a residual SYNTAX Score >8 was associated with 
significantly increased all-cause mortality (35.3%, P<0.001), 
MACCE (59.5%, P<0.001), MI (17.0%, P<0.001), all-cause 
revascularization (32.0%, P<0.001), and definite/probable 
stent thrombosis (16.0%, P=0.005) (Figure 4).
Tertiles of the Baseline SYNTAX Score
Figure 5 demonstrates the impact of ICR (tertiles of the resid-
ual SYNTAX Score) according to the conventional tertiles of 
the baseline SYNTAX Score. From low (0-22), to intermedi-
ate (23–32) and high (≥33) baseline SYNTAX Scores, there 
was an incremental rise in the 5-year mortality impact of a 
residual SYNTAX Score >8 (low: 23.8%, P=0.022; interme-
diate: 34.1%, P<0.001; high: 39.1%, P<0.001).
Stratified Analyses
Stratified analyses (Table 2) in the subgroups of medically 
treated diabetes mellitus (n=231/903 [26%], P value for inter-
action 0.84), ULMCA disease (n=357/903 [40%], P value 
for interaction 0.91), and impaired left ventricular function 
(n=172/903 [19%], P value for interaction 0.36) indicated that 
a residual SYNTAX Score >8 was similarly associated with 
adverse 5-year mortality. In the subgroup consisting of TOs 
(n=217/903 [24%]), a residual SYNTAX Score of >8 was asso-
ciated with a more modest effect on mortality (HR, 2.17; 95% 
CI, 0.80–5.88; P=0.13), compared with a more pronounced 
effect in subjects without TOs (HR, 8.51; 95% CI, 5.20–13.94; 
P<0.0001; P value for interaction 0.015).
Discriminative and Predictive Value of the Baseline 
and Residual SYNTAX Scores
Compared with the baseline SYNTAX Score, the residual 
SYNTAX Score demonstrated greater discrimination for 
5-year all-cause mortality (0.619 [95% CI, 0.568–0.671] 
Figure 3. Five-year clinical outcomes stratified 
by tertiles of the residual Synergy Between 
Percutaneous Coronary Intervention With Taxus 
and Cardiac Surgery (SYNTAX) Score (incomplete 
revascularization, >0). Hazard ratios (HR) are 
relative to complete revascularization (Reference 
Line, residual SYNTAX Score 0). HR for tertiles of 
the residual SYNTAX Score (>0) are shown. The 
error bars represent 95% confidence intervals. A 
residual SYNTAX Score 10.0 was associated with 
a doubling of 5-year all-cause death. A residual 
SYNTAX Score of 10.7 and 11.3 respectively lead 
to a doubling of 5 year all-cause death/MI/CVA 
and 5 year MACCE. CVA indicates cerebrovascular 
accident; MACCE, major adverse cardiac and 
cerebrovascular events; and MI, myocardial 
infarction.
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versus 0.687 [95% CI, 0.630–0.744]; P=0.024) and MACCE 
(0.570 [95% CI, 0.531–0.610] versus 0.634 [95% CI, 0.597–
0.672]; P=0.0026). Notably, a residual SYNTAX Score >8 
was highly specific in its association with 5-year clinical out-
comes (specificity: all cause death, 88%; MACCE, 90%).
Multivariable Analysis
Multivariable analysis (Table 3) demonstrated the resid-
ual SYNTAX Score to be an independent predictor of 
5-year all-cause death (HR, 1.65; 95% CI, 1.41–1.92; 
P<0.001)
Figure 4. Kaplan–Meier curves showing cumulative event rates through to 5 years based on complete (residual Synergy Between 
Percutaneous Coronary Intervention With Taxus and Cardiac Surgery [SYNTAX] Score 0) and incomplete (tertiles of the residual SYNTAX 
Score) revascularization. All-cause death, all-cause death/myocardial infarction (MI)/cerebrovascular accident (CVA), major adverse 
cardiac and cerebrovascular events (MACCE), MI, all-cause revascularization, definite stent thrombosis and, definite/probable stent 
thrombosis, are illustrated. For all clinical outcomes, with the exception of definite stent thrombosis, a residual SYNTAX Score >8 was 
associated with adverse events. ST indicates stent thrombosis.
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Discussion
The main findings of this study are the following, at 5 years: (1) 
A progressively higher residual SYNTAX Score was shown to be 
a surrogate marker of increasing clinical comorbidity and more 
anatomically complex disease; (2) a residual SYNTAX Score 
of ≤8 was associated with long-term mortality comparable with 
subjects with CR; (3) a residual SYNTAX Score of >8 was asso-
ciated with progressively increasing adverse long-term clinical 
outcomes, including mortality—an effect that remained consistent 
across all conventional tertiles of the baseline SYNTAX Score; 
(4) The findings of a residual SYNTAX Score >8 to be associated 
with adverse long-term mortality were equally applicable in the 
predefined subgroups of ULMCA disease and medically treated 
diabetes mellitus, and the subgroup with impaired left ventricular 
ejection function; (5) In the TO subgroup, a residual SYNTAX 
Score >8 was associated with a more modest effect on long-term 
mortality, compared with a pronounced effect in subjects without 
TOs; and (6) the residual SYNTAX Score was shown to be a pow-
erful indicator of long-term mortality and other clinical outcomes 
in subjects with ULMCA disease or de novo 3VD.
Previous predominantly registry studies investigating the clin-
ical impact of CR and ICR have lacked standardized definitions. 
These studies have for example used the number of treated ves-
sels/treated important vessels based on varying degrees of steno-
sis, and have analyzed IR with or without the presence of TOs, 
or on revascularization of all vessels with a size ≥1.5 mm.1,6–
14,29
 Such varying definitions of ICR have made comparisons 
between studies problematic. In addition, the unavoidable selec-
tion bias inherent to all registries has added to the difficulties in 
interpreting these studies.7,8 Even using multivariate and propen-
sity score adjustments of baseline characteristics to control for 
selection bias would be potentially misleading, because ICR was 
Table 2. Stratified Analyses of Complete (Residual SYNTAX Score 0) Versus Incomplete Revascularization (Residual SYNTAX Score 
>0–8 and >8), for 5-Year All-Cause Death in Subjects With and Without Medically Treated Diabetes Mellitus, Unprotected Left Main 
Coronary Artery Disease, Total Occlusions, and Impaired Left Ventricular Ejection Fraction
CR (rSS=0) ICR (rSS>0) Hazard Ratio (95% CI) P Value Pinteraction
rSS 0 vs. rSS >0-8 rSS=0 rSS >0-8
All-cause death 33/369 (9%) 35/348 (10%) 1.13 (0.71–1.83) 0.60 0.31
 Medically treated diabetes mellitus*† 10/76 (13%) 9/91 (10%) 0.75 (0.31–1.85) 0.54
 No medically treated diabetes mellitus 23/293 (8%) 26/257 (10%) 1.30 (0.74–2.28) 0.36
All-cause death 33/369 (9%) 35/348 (10%) 1.13 (0.71–1.83) 0.60 0.11
 Unprotected left main† 11/157 (7%) 16/130 (12%) 1.83 (0.85–3.95) 0.12
 De novo 3VD 22/212 (10%) 19/218 (9%) 0.83 (0.45–1.53) 0.55
All-cause death 33/365 (9%) 35/347 (10%) 1.12 (0.70–1.81) 0.63 0.32
 Total occlusion 5/44 (11%) 7/88 (8%) 0.67 (0.21–2.11) 0.49
 No total occlusion 28/321 (9%) 28/259 (11%) 1.26 (0.75–2.13) 0.38
All-cause death 32/356 (9%) 33/342 (10%) 1.08 (0.67–1.76) 0.76 0.20
 LVEF Not Impaired (≥50%) 27/306 21/274 (8%) 0.86 (0.49–1.52) 0.61
 LVEF Impaired (<50%) 5/50 (10%) 12/68 (18%) 1.85 (0.65–5.26) 0.25
rSS 0 vs. rSS >8 rSS=0 rSS >8
All-cause death 33/369 (9%) 54/145 (37%) 5.12 (3.32–7.90) <0.0001 0.84
 Medically treated diabetes mellitus*† 10/76 (13%) 25/52 (48%) 5.01 (2.40–10.44) <0.0001
 No medically treated diabetes mellitus 23/293 (8%) 29/93 (31%) 4.60 (2.66–7.95) <0.0001
All-cause death 33/369 (9%) 54/145 (37%) 5.12 (3.32–7.90) <0.0001 0.91
 Unprotected left main† 11/157 (7%) 17/58 (29%) 4.93 (2.31–10.53) <0.0001
 De novo 3VD 22/212 (10%) 37/87 (43%) 5.16 (3.04–8.76) <0.0001
All-cause death 33/365 (9%) 54/144 (38%) 5.11 (3.31–7.88) <0.0001 0.015
 Total occlusion 5/44 (11%) 17/73 (23%) 2.17 (0.80–5.88) 0.13
 No total occlusion 28/321 (9%) 37/71 (52%) 8.51 (5.20–13.94) <0.0001
All-cause death 32/356 (9%) 54/142 (38%) 5.22 (3.37–8.09) <0.0001 0.36
 LVEF not impaired (<50%) 27/306 (9%) 31/98 (32%) 4.25 (2.53–7.12) <0.0001
 LVEF impaired (<50%) 5/50 (10%) 23/44 (52%) 6.96 (2.64–18.34) <0.0001
Data are (n/N [%]). Interaction P value is for the test on the difference in HR between CR (rSS 0) vs ICR (rSS >0) in the respective diabetic/non diabetic groups, 
unprotected left main/non unprotected left main groups, total occlusion/non total occlusion groups and LVEF impaired/not impaired groups. 
3VD indicates 3-vessel disease; CI, confidence interval; CR, complete revascularization; ICR, incomplete revascularization; LVEF, left ventricular ejection function; rSS, 
residual SYNTAX Score; and SYNTAX, Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery.
*Insulin or oral hypoglycemics.
†Prestratified at randomization.
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demonstrated to be a surrogate marker of sicker patients with 
more anatomically complex baseline coronary artery disease.11
Conversely, the residual SYNTAX Score allowed for an 
objective, quantitative assessment of the extent of ICR in PCI 
treated subjects in the randomized all-comers population of the 
SYNTAX Trial, in which selection bias would have been mini-
mal. Furthermore, the residual SYNTAX Score allowed for a 
threshold value of ICR to be determined that would not have a 
negative impact on long-term mortality (ie, the concept of reason-
able incomplete revascularization).7,8,11,13,15 This concept, using 
the residual SYNTAX Score, has recently been described in the 
ACUITY Trial,16 the main differences being that the ACUITY 
Trial recruited subjects solely presenting with non-ST elevation 
acute coronary syndrome, followed up for 1-year, and impor-
tantly, with substantially lesser complex coronary artery disease 
(primarily single or double vessel disease, median SYNTAX 
Score 9.0, interquartile range 5.0–16.0). Comparatively, the 
SYNTAX Trial recruited subjects with substantially more com-
plex coronary artery disease (left main or de novo 3VD, median 
SYNTAX Score 28, interquartile range 20.0–36.0), and validated 
the findings of a residual SYNTAX Score >8 to be associated 
with adverse outcomes at up to 5 years, in an all-comers random-
ized population, and in several clinical and anatomic subgroups.
Reducing the Ischemia Burden
The residual SYNTAX Score is principally a marker of the resid-
ual ischemia burden, dependent on the location of the coronary 
lesion and the anatomic complexity (eg, calcification, bifurcation, 
long lesion, etc) associated with the obstructive disease. This is 
attributable to the fact that most of the points of the SYNTAX 
Score are accrued from the severity of luminal diameter narrowing 
and its weighting according to the usual blood flow to the left ven-
tricle in each vessel or vessel segment.17,18,30 More proximal coro-
nary artery disease therefore scores more highly on the SYNTAX 
Score, particularly if the obstructive disease is more complex. 
From a prognostic perspective this is important because MIs have 
been shown to cluster in the proximal third of major epicardial 
vessels,31 and a large plaque burden and small luminal area have 
both been linked to the highest risk of future cardiac events.32,33
Reducing the ischemia burden of the patient would undoubt-
edly improve long-term prognosis, as exemplified by previous 
studies associating a short- and long-term survival benefit in 
Table 3. Univariable and Multivariable Cox Regression Analyses, Incorporating the Residual SYNTAX Score, Using Clinical 
Variables Previously Shown to be Independent Predictors of Long-Term Mortality in the SYNTAX Trial26
Univariable Analyses Multivariable Analyses
HR (95% CI) P Value HR (95% CI) P Value
Residual SYNTAX Score (4 groups)* 1.76 (1.50, 2.06) <0.001 1.65 (1.41, 1.92) <0.001
Baseline SYNTAX Score (tertiles)† 1.50 (1.20, 1.88) <0.001 — —
Preprocedural poor (<30%) LVEF 5.60 (2.61, 12.02) <0.001 5.04 (2.30, 11.04) <0.001
Peripheral vascular disease 3.31 (2.15, 5.11) <0.001 2.92 (1.88, 4.52) <0.001
History of GI bleeding or peptic ulcer disease 2.08 (1.05, 4.09) 0.035 1.89 (0.95, 3.76) 0.069
Age per increase in 10 yr 1.79 (1.46, 2.20) <0.001 1.61 (1.30, 1.99) <0.001
Female sex 1.70 (1.17, 2.47) 0.006 1.57 (1.06, 2.33) 0.023
CI indicates confidence interval; CR, complete revascularization; GI, gastrointestinal; HR, hazard ratio; ICR, incomplete revascularization; LVEF, left ventricular ejection 
function; and SYNTAX, Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery.
*Four groups comprising CR (residual SYNTAX Score 0) and ICR (tertiles of the residual SYNTAX Score >0 to 4, >4 to 8, >8).
†Conventional tertiles of the baseline SYNTAX Score (low 0–22, intermediate 23–32, high ≥33).17
*†Correlation of 0.4 precluded entry of baseline SYNTAX Score into multivariable model.
Figure 5. Completeness of revascularization stratified to conventional tertiles of the baseline Synergy Between Percutaneous Coronary 
Intervention With Taxus and Cardiac Surgery (SYNTAX) Score using the residual SYNTAX Score. Kaplan–Meier curves showing cumulative 
event rates through to 5 years, based on complete (residual SYNTAX Score 0) and incomplete (tertiles of residual SYNTAX Score) 
revascularization, in the low (0–22), intermediate (23–32), and high (≥33) baseline SYNTAX Scores. Note the progressive rise in the 5-year 
mortality impact of a residual SYNTAX Score >8 with increasing anatomic complexity.
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patients with moderate to large amounts of inducible ischemia 
who were revascularized.34–36 Specifically, in the nuclear sub-
study of the Clinical Outcomes Utilizing Revascularization 
and Aggressive Drug Evaluation (COURAGE) Trial,35 ≥10% 
reversible ischemia was associated with adverse 5-year mor-
tality if treated medically.
Strikingly, the frequency of a high residual SYNTAX Score 
(ie, >8), and its association with more severe baseline ana-
tomic complexity such as calcification, bifurcations, TOs, 
and tortuosity (Table 1), was shown to progressively increase 
across the conventional tertiles of the baseline SYNTAX 
Score (Figure 2), which in turn was linked to an incremental 
rise in 5-year all-cause mortality (Figure 5). In addition, the 
most pronounced effect of the long-term adverse prognos-
tic effects of a residual SYNTAX Score >8 were in subjects 
without TOs (Table 2). These findings perhaps epitomize the 
need for appropriate myocardial viability testing to ensure that 
revascularization of the TO is clinically justified.37–42
Notably in the high baseline SYNTAX Scores, despite the 
greater anatomic complexity, the Δ SYNTAX Score (representa-
tive of burden of coronary disease removed by PCI) was less than 
that seen in subjects with CR. These results suggest the potential 
difficulties the interventional cardiologist may face in the treat-
ment of highly complex coronary artery disease. Advances in 
PCI technology, with more deliverable newer generation drug-
eluting stents, adjunctive devices to aid stent delivery, crossing 
and re-entry systems to aid TO revascularization, functional 
assessment of lesions, intravascular ultrasound guidance to 
ensure adequate stent expansion, and dedicated specialists for 
specific anatomic subsets, may improve long-term prognosis by 
ensuring major epicardial vessels are fully revascularized.43–47
Surrogate Marker of Anatomic Complexity and 
Clinical Comorbidity
The findings associating ICR with sicker patients, more ana-
tomically complex coronary artery disease, and consequent 
poorer long-term clinical outcomes, are supported by the his-
torical data as detailed below.
First, that very long term follow-up data (>10 years) of 
CABG treated patients in 2 separate registries48,49 have associ-
ated more extensive baseline preoperative disease with adverse 
mortality. Second, in the Bypass Angioplasty Revascularization 
Investigation (BARI) Trial,50 where jeopardized myocardium 
and recurrence of angina were shown to occur more frequently 
secondary to native coronary artery disease progression, a 
reflection of the clinical risk profile of the patient, compared 
with failed revascularization in both PCI- and CABG-treated 
subjects at 5 year follow-up. Findings that have also been 
observed in other studies,51,52 with baseline comorbidities, 
such as diabetes mellitus, having been shown to be a predic-
tor of native coronary disease progression. Third, that coronary 
artery calcification has been linked to adverse all-cause mortal-
ity at 10 years, independent of other risk factors.53,54 Notably, 
heavy calcification was present in almost two-thirds (64.5%) of 
subjects with a residual SYNTAX Score >8 (Table 1).
Decision-Making Between CABG and PCI
The recently developed and validated SYNTAX Score 
II55 combines anatomic (including the SYNTAX Score) 
and clinical variables that directly affect decision making 
between CABG and PCI. This is based on the provision that 
the cardiologist and cardiac surgeon agree, before revascular-
ization, that equivalent anatomic revascularization could be 
achieved. Incorporation of quantitative factors of complete-
ness of revascularization in the SYNTAX Score II would 
however have a limited role in decision-making between 
CABG and PCI, because this is a clinical outcome. This is 
typified in the SYNTAX Trial, where, despite the mandatory 
requirement of the interventional cardiologist and cardiac 
surgeon to agree that equivalent anatomic revascularization 
could be achieved to allow the patient to be randomized, 
CR was realized in 56.7% and 63.2% of the PCI and CABG 
arms, respectively.29
Study Limitations
The present study represents a post hoc analysis of the 
SYNTAX Trial, and the results should be considered as 
hypothesis-generating. Although a core laboratory under-
took baseline SYNTAX Scores prospectively, the residual 
SYNTAX Score was retrospectively assessed by a panel of 
3 interventional cardiologists. Despite this limitation, anal-
yses were performed with the identification of the lesions 
recorded by the core-laboratory, with consequent excel-
lent reproducibility (κ statistic 0.89). It is entirely plau-
sible that the residual SYNTAX Score could be improved 
through enhanced identification of functionally significant 
lesions with fractional flow reserve47,56 or viability assess-
ment of the supplied myocardium.37–42 Although multivari-
able adjustments were performed for significant confounders 
(P<0.1), the possibility of other unmeasured confounders to 
have affected the results cannot be excluded. Although the 
SYNTAX Trial was based on contemporary revasculariza-
tion practice at the time, improvements in technology in PCI 
and CABG may yield differences in clinical outcomes in 
future trials.
Conclusions
The residual SYNTAX Score was shown to be a powerful 
indicator of 5-year clinical outcomes, including mortality, 
after PCI with drug-eluting stents in subjects with left main 
or de novo 3VD. The residual SYNTAX Score may aid deter-
mining a reasonable level of revascularization.
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CLINICAL PERSPECTIVE
Interpreting the long-term prognostic impact of incomplete revascularization (ICR) in patients with complex coronary artery 
disease has historically remained difficult. The lack of standardized definitions of ICR, lack of randomized data, unavoidable 
selection bias inherent to all registry studies, and quality of monitoring and adjudication of outcomes, have led to conflicting 
results in the literature. The residual Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery 
(SYNTAX) Score is based on the principle of being a measure of the myocardial ischemia burden, dependent on the loca-
tion of the coronary disease, its importance in supplying blood to the myocardium, and the anatomic complexity associated 
with the obstructive disease. Importantly, the residual SYNTAX Score allowed for the determination of an objective level 
of reasonable ICR, whereby a threshold value of ICR could be determined (≤8) that would not have a negative impact on 
long-term mortality and other clinical outcomes. The residual SYNTAX Score was validated in a randomized, all-comers 
population, consisting of subjects with complex coronary artery disease (unprotected left main coronary artery or de novo 
3-vessel-disease) who had undergone 5-year follow-up. Notably, progressively higher residual SYNTAX Scores were shown 
to be a surrogate marker of sicker patients, with greater baseline clinical comorbidity and anatomic complexity, with con-
sequent adverse long-term clinical outcomes, including all-cause mortality. Results that were equally applicable in subjects 
with unprotected left main coronary artery disease and medically-treated diabetes mellitus. Such findings are of value in 
guiding the clinician to reduce the level of reversible myocardial ischemia by treating obstructive lesions to stay within the 
threshold of reasonable ICR.
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Abstract
Aims: The SYNTAX Score (SXscore) has established itself as an important prognostic tool in patients under-
going percutaneous coronary intervention (PCI). A limitation of the SXscore is the inability to differentiate 
outcomes in patients who have undergone prior coronary artery bypass graft (CABG) surgery. The CABG 
SXscore was devised to address this limitation.
Methods and results: In the SYNTAX-LE MANS substudy 115 patients with unprotected left main coronary 
artery disease (isolated or associated with one, two or three-vessel disease) treated with CABG were prospectively 
assigned to undergo a 15-month coronary angiogram. An independent core laboratory analysed the baseline SXscore 
prior to CABG. The 15-month CABG SXscore was calculated by a panel of three interventional cardiologists. The 
CABG SXscore was calculated by determining the standard SXscore in the “native” coronary vessels (“native 
SXscore”) and deducting points based on the importance of the diseased coronary artery segment (Leaman score) 
that have a functioning bypass graft anastomosed distally. Points relating to intrinsic coronary disease, such as bifur-
cation disease or calcification, remain unaltered. The mean 15-month CABG SXscore was significantly lower 
compared to the mean baseline SXscore (baseline SXscore 31.6, SD 13.1; 15-month CABG SXscore 21.2, SD 11.1; 
p<0.001). Reproducibility analyses  (kappa [k] statistics) indicated a substantial agreement between CABG SXscore 
measurements (k=0.70; 95% CI [0.50-0.90], p<0.001), with the points deducted to calculate the CABG SXscore the 
most reproducible measurement (k=0.74; 95% CI [0.53-0.95], p<0.001). Despite the limited power of the study, 
four-year outcome data (Kaplan-Meier curves) demonstrated a trend towards reduced all-cause death (9.1% vs. 1.8%, 
p=0.084) and death/CVA/MI (16.4% vs. 7.0%, p=0.126) in the low compared to the high CABG SXscore group.
Conclusions: In this pilot study the calculation of the CABG SXscore appeared feasible, reproducible and 
may have a long-term prognostic role in patients with complex coronary disease undergoing surgical revas-
cularisation. Validation of this new scoring methodology is required.
KEYWORDS
• CABG
• PCI
• SYNTAX Score
•  CABG SYNTAX 
Score
• Leaman score
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Introduction
The SYNTAX Score (SXscore) (http://www.syntaxscore.com)1-5 has 
established itself as an important prognostic tool in risk stratifying 
patients being considered for revascularisation, and has been vali-
dated in patients undergoing percutaneous coronary intervention 
(PCI) at one-year follow-up6-11. In addition, the SXscore has been 
applied to contemporary drug-eluting stent trials enrolling “all-com-
ers” type populations, and has been shown to be an independent 
predictor of one-year mortality and major adverse cardiac events 
(MACE)12-14.
As a consequence, the SXscore is now advocated in both the 
European and the US revascularisation guidelines in aiding the risk 
stratification of patients with complex coronary artery disease to the 
most appropriate revascularisation modality15-17. Furthermore, the US 
FDA (Food and Drug Administration) recommends the application of 
the SXscore in selecting low-intermediate SXscore patients with 
unprotected left main coronary artery disease in the ongoing EXCEL 
Trial (ClinicalTrials.gov Identifier: NCT01205776), and low SXscore 
patients suitable for transcatheter aortic valve implantation in the 
SURTAVI Trial (ClinicalTrials.gov Identifier: NCT01586910). 
However, a limitation of the SXscore is the inability to apply it usefully 
to patients who have previously undergone CABG.
Based on the principles first defined by Leaman et al (Leaman 
score)18, the SXscore takes into account both the coronary anatomy 
and also the importance of the diseased coronary artery segment 
supplying the myocardium – termed “vessel-segment weighting”. 
Although the baseline SXscore, calculated prior to surgical revas-
cularisation, has been shown not to have any effect on the short to 
long-term prognosis after CABG3,4,7,19,20, it was hypothesised that a 
suitably developed CABG SXscore that takes into account native 
coronary disease anatomy, including features such as calcification, 
bifurcation disease and the effects of surgical revascularisation on 
the vessel-segment weighting, may have potential clinical and 
research applications. The purpose of this pilot study is to examine 
the feasibility of the newly developed CABG SXscore in the 
SYNTAX-LE MANS angiographic substudy21.
Methods
The overall study design of the all-comers SYNTAX Trial3,5,22 and 
the SYNTAX-LE MANS substudy21 have previously been 
described. In brief, SYNTAX-LE MANS was a predefined sub-
study of patients from the randomised SYNTAX Trial who pro-
vided a separate written, informed consent for the substudy entry21. 
Eligible patients were those with left main disease (isolated or asso-
ciated with one, two or three-vessel disease) who did not have renal 
dysfunction (defined as creatinine >2.0 mg/dL [150 μmol/L]) or 
hypersensitivity to contrast agents that could not be adequately pre-
medicated. Per protocol, the time window for the 15-month angio-
gram was set between 14 and 16 months post-allocation. Patients 
enrolled in the study who had a clinically driven angiogram from 9 
to 13 months (inclusive) after treatment allocation were permitted 
to use the earlier coronary angiogram to fulfil the 15-month angio-
graphic requirement.
CABG SYNTAX SCORE ANALYSIS
Baseline and 15-month coronary angiograms were analysed side by 
side by a panel of three interventional cardiologists to calculate the 
15-month CABG SXscore. All reviewers were blinded to the clini-
cal outcomes of the patient analyses and to the baseline SXscore, 
undertaken prior to CABG by an independent core laboratory (Car-
dialysis BV, Rotterdam, The Netherlands) as part of the original 
SYNTAX Trial3.
The CABG SXscore calculation was repeated on 30 randomly 
selected cases at a three-month interval with the reviewers blinded 
to the original baseline and CABG SXscores. Intraobserver repro-
ducibility analyses were undertaken.
CABG SYNTAX SCORE
The CABG SXscore is essentially the SXscore of the “native” coro-
nary vessels (“native SXscore”), with points deducted based on the 
vessel-segment weighting of the bypassed coronary vessel as previ-
ously proposed by Leaman et al18.
SYNTAX SCORE
In brief, the SXscore1-4 was developed by combining the impor-
tance of a diseased coronary artery segment by the vessel-segment 
weighting (Leaman score)18, adverse characteristics of such a lesion 
for revascularisation (ACC/AHA lesion classification)23,24 and the 
Medina classification system for bifurcation lesions25. Each vessel 
segment, 1.5 mm in diameter or greater (Figure 1, labelled 1 to 16), 
with a ≥50% diameter stenosis by visual estimation, is awarded 
a multiplication factor related to coronary lesion location and sever-
ity (Figure 2). Further characterisation of the coronary lesions leads 
to the addition of more points, which includes features of total 
occlusions (duration, length, blunt stump, presence of bridging col-
laterals or side branch), presence of bifurcation (based on the 
Medina classification) or trifurcation disease (number of diseased 
branches involved), side branch angulation, aorto-ostial lesion, 
severe tortuosity, lesion length >20 mm, heavy calcification, throm-
bus and diffuse or small vessel disease. An online SXscore algo-
rithm1 automatically summates each of these features to calculate 
the final total SXscore.
LEAMAN SCORE
The Leaman score is based on the severity of luminal diameter nar-
rowing, and is weighted according to the usual blood flow to the left 
ventricle (LV) in each vessel or vessel segment based on whether 
the coronary system is right or left dominant18.
In a right dominant system the right coronary artery (RCA) sup-
plies approximately 16% and the left coronary artery (LCA) 
approximately 84% of the blood flow to the LV. This 84% is nor-
mally directed 66% to the left anterior descending (LAD) and 33% 
to the left circumflex (LCx) vessels. Thus the LAD and LCx respec-
tively carry approximately 3.5 times and 1.5 times as much blood as 
the RCA. In a left dominant system the LV receives all of its blood 
supply from the LCA; consequently, the RCA is not weighted and 
its value is assigned to the LCA, thereby leading to a heavier vessel-
segment weighting of the LAD and LCx compared to a right domi-
nant system18,26-28. These principles ultimately formed the basis of 
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the segment-weighting factors that were incorporated into the 
SXscore (Table 1)1-4.
CALCULATION OF THE CABG SYNTAX SCORE
In order to allow consistency and reproducibility in the application 
of the CABG SXscore, five rules were adhered to in calculating the 
CABG SXscore.
1.  The SXscore of the native coronary vessels (native SXscore) was 
analysed using the standard methodology (http://www.syntax-
score.com)1, utilising the bypass graft angiogram as necessary to 
allow visualisation of the entire vessel.
2.  All the bypass grafts were analysed to establish the vessel-seg-
ment weighting of the “protection” conferred by the bypass grafts 
(Figure 1, Table 1).
3.  Based on the presence of obstructive or non-obstructive bypass 
disease by visual assessment, segment-weighting points were 
deducted from the native SXscore:
a.  Patent bypass graft to a significant coronary lesion: segment-
weighting points for the coronary lesion were deducted, pro-
vided there was no intervening significant coronary disease 
(Figure 3).
Figure 1. The effect of right and left arterial dominance on the segment numbering – refer to Table 1 for the segment-weighting for the 
respective arterial segments. Anatomical description of the segment numbers has previously been described2 and is included in the 
supplementary appendix. 
Figure 2. Segment-weighting multiplication factors utilised in the SYNTAX Score – used to calculate the points required to deduct from the 
“native SXscore” to calculate the CABG SYNTAX Score.
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b.  Occluded bypass graft: native SXscore remained unaltered 
(Figure 3).
c.  Bypass graft with obstructive (50-99%) disease (Figure 4):
 i.  obstructive native coronary lesion (50-99%): no segment-
weighting points deducted;
ii.  occluded native coronary lesion (100%, TIMI 0 flow): x3 
segment-weighting points deducted.
With an obstructive native coronary lesion (50-99%), it is 
assumed that a significantly diseased graft (50-99%) would confer 
no additional benefit to the blood supply to the affected coronary 
vessel; consequently, there would be no net gain or loss in the seg-
ment-weighting points to the native SXscore. Conversely, if the 
coronary vessel was occluded, then a diseased graft (50-99%) 
would provide “ischaemic protection” to the territory supplied by 
the occluded lesion. Consequently, the segment-weighting factor 
Figure 3. Example of the calculation of the CABG SXscore in a 
patient with distal left main trifurcation disease and an occluded mid 
RCA. The native SXscore was 23 (upper images). A patent LIMA to 
the LAD with no intervening obstructive coronary disease (lower left 
image) led to the deduction of 3.5×2 points (x2 segment-weighting 
due to ischaemic LAD) from the native SXscore. An occluded SVG to 
the intermediate led to no points being deducted (inset lower left 
image). A patent SVG to the distal RCA led to 1×5 points (x5 
segment-weighting due to occluded mid RCA) deducted from the 
native SXscore. Final CABG SXscore was therefore 23-7-5=11 points.
LIMA: left internal mammary artery; SVG: saphenous vein graft; 
RCA: right coronary artery. Black arrows indicate obstructive native 
coronary disease; white arrows indicate patent anastomosis sites of 
grafts to vessels
Table 1. Coronary vessel segment-weighting based on the 
principles first established by Leaman et al18 and incorporated 
into the SYNTAX Score2. Refer to Figure 1 for location of segment 
numbers on the coronary tree based on arterial dominance.
Segment number
Right 
dominance
Left 
dominance
1  (RCA proximal) 1 0
2  (RCA mid) 1 0
3  (RCA distal) 1 0
4  (Posterior descending artery) 1 n/a
16  (Posterolateral branch from RCA) 0.5 n/a
16a  (Posterolateral branch from RCA) 0.5 n/a
16b (Posterolateral branch from RCA) 0.5 n/a
16c (Posterolateral branch from RCA) 0.5 n/a
5 (Left main) 5 6
6 (LAD proximal) 3.5 3.5
7 (LAD mild) 2.5 2.5
8 (LAD apical) 1 1
9 (First diagonal) 1 1
9a (First diagonal) 1 1
10 (Second diagonal) 0.5 0.5
10a (Second diagonal) 0.5 0.5
11 (Proximal circumflex artery) 1.5 2.5
12 (Intermediate/anterolateral artery) 1 1
12a (Obtuse marginal) 1 1
12b (Obtuse marginal) 1 1
13 (Distal circumflex artery) 0.5 1.5
14 (Left posterolateral) 0.5 1
14a (Left posterolateral) 0.5 1
14b (Left posterolateral) 0.5 1
15 (Posterior descending artery) n/a 1
RCA: right coronary artery; LAD: left anterior descending artery; n/a: not 
applicable
would be reduced from x5 (occluded vessel) to x2 (non-occluded 
vessel with a significant lesion [50-99%]), i.e., a deduction of x3 
segment-weighting factor from the native SXscore.
4.  Any further native coronary disease clearly identified through the 
angiograms of the bypass grafts were added to the native 
SXscore. Lesions ≥3 reference vessel diameters were viewed as 
two separate lesions and within this distance as one lesion.
5.  If an obstructive coronary lesion interferes with the blood flow to the 
vessel being protected by the bypass graft, then the points deducted 
were for the segment weighting of the lesion only (Figure 5).
Points related to the lesion characteristics of the “native” coronary 
disease, such as calcification, bifurcation disease, total occlusion, 
etc., would remain unaltered as these reflect the native coronary anat-
omy. Further detail on the SXscore/Leaman score and applications of 
the CABG SXscore are provided in the Supplementary Appendix.
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Figure 4. Principle of “ischaemic protection” in the CABG SXscore. 
Upper image: occluded mid RCA (segment 2 - black arrows) with 
bridging collaterals: native SXscore for the RCA is 8. Lower image: 
SVG anastomosed to distal RCA (white arrow). If the SVG was free of 
obstructive disease then the CABG SXscore would be 8 minus 
(1×5)=3 points. If the SVG was diseased with an obstructive lesion as 
illustrated (lower image, black arrow) the distal RCA would be under 
“ischaemic protection”. Consequently x2 weighting factor for the 
RCA should remain – therefore x3 weighting needs to be deducted 
leading to a CABG SXscore of 8 minus (1×3) points=5 points. If the 
SVG was occluded then the CABG SXscore would remain unaltered 
at 8 points. RCA: right coronary artery; SVG: saphenous vein graft
STATISTICAL ANALYSIS
Continuous variables are expressed as means±SD. Comparisons of 
means and four-year outcomes (Kaplan-Meier curves) were performed 
with the paired t-test and log-rank test respectively. Intraobserver 
variability (tertile partitioning) was determined with kappa statistics 
(<0 none, 0-0.20 slight, 0.21-0.40 fair, 0.41-0.60 moderate, 0.61-0.80 
substantial, 0.81-1.00 almost perfect) on the native SXscore, deducted 
points and CABG SXscore4. A two-sided p-value <0.05 was consid-
ered significant for all tests. Analyses were conducted with SAS Sys-
tem Software Version 8.0+ (SAS Institute, Cary, NC, USA) and 
SPSS 17.0 (SPSS Inc., Chicago, IL, USA).
Results
In total, 271 patients were enrolled in the SYNTAX-LE MANS 
study, 115 of whom were enrolled in the CABG arm. Available 
15-month coronary angiograms were suitable for analysis in 113 of 
115 (97.4%) CABG patients. No patients died in the CABG arm 
from baseline to undergoing the 15-month coronary angiogram. 
One patient had no angiographic films available and a further 
patient did not have native coronary vessels filmed. Baseline char-
acteristics for the SYNTAX-LE MANS substudy have been pub-
lished previously21.
COMPARISONS OF THE BASELINE SYNTAX SCORE AND 
15-MONTH CABG SYNTAX SCORE
Comparisons of the baseline SXscores and 15-month CABG 
SXscores demonstrated a significant decline in the mean value of 
the 15-month CABG SXscores (Figure 6). Both the baseline 
SXscore and the 15-month CABG SXscore appeared to be broadly 
normally distributed with the mean 15-month CABG SXscore sig-
nificantly moved to the left (Figure 7). The mean 15-month CABG 
SXscore was significantly lower compared to the mean baseline 
SXscore (baseline SXscore 31.6, SD 13.1; 15-month CABG 
SXscore 21.2, SD 11.1; p<0.001) (Figure 7).
Comparisons of the baseline SXscore and 15-month native 
SXscore did not demonstrate any significant statistical differences 
(baseline SXscore 31.6, SD 13.1; 15-month native SXscore 31.1, 
SD 12.2; p=0.50). The mean number of points deducted from the 
15-month native SXscore to derive the CABG SXscore was 9.9 
(SD 5.3) (Figure 8).
REPRODUCIBILITY ANALYSES
The intraobserver variability for the 15-month native SXscore 
(k=0.70; 95% CI: 0.50-0.91, p<0.001), points deducted from the 
native SXscore to derive the 15-month CABG SXscore (k=0.74; 
95% CI: 0.53-0.95, p<0.001) and the final 15-month CABG 
SXscore (k=0.70; 95% CI: 0.50-0.90, p<0.001) were all substantial. 
The number of points deducted to derive the 15-month CABG 
SXscore was the most reproducible measurement.
CLINICAL OUTCOMES
Due to limited power the present outcome analyses should be inter-
preted as exploratory and hypothesis-generating. The CABG 
SXscores were separated into two groups, divided by the median of 
the normally distributed 15-month CABG SXscores into low (0-21) 
(n=58) and high-risk groups (≥22) (n=55).
Four-year clinical outcome data demonstrated a trend towards an 
increased mortality in the high CABG SXscore group compared to 
the low CABG SXscore group (low CABG SXscore: 1.8%, high 
CABG SXscore: 9.1%, p=0.084) (Figure 9). Furthermore, an 
increase in the composite of all-cause death/cerebrovascular acci-
dent (CVA)/ myocardial infarction (MI) at four years was also evi-
dent in the high CABG SXscore group compared to the low CABG 
SXscore group (low CABG SXscore: 7.0%, high CABG SXscore: 
16.4%, p=0.126).
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Figure 6. Reduction in the CABG SYNTAX Score at scheduled 
coronary angiography at 15 months, compared to the baseline 
SYNTAX Score (n=113).
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Figure 7. Distribution of the baseline SYNTAX Scores and the 
15-month CABG SYNTAX Scores (n=113). Note the significant 
decrease in the mean CABG SYNTAX Score compared to the mean 
baseline SYNTAX Score (p<0.001). SD: standard deviation.
Figure 5. Example of the calculation of the CABG SXscore in a patient with mid left main and two-vessel coronary disease. Native SXscore was 21. 
A patent LIMA anastomosed to the mid LAD, with upstream native mid LAD disease, and led to the segment-weighting (2.5×2 points) of the mid 
LAD (segment 7) being deducted from the native SXscore (left image). The LCx was protected by two OM SVGs leading to a deduction of 1.5×2 
points from the native SXscore (middle image). The occluded PLV was protected by an SVG leading to the deduction of 0.5×5 points from the native 
SXscore (right image). Final CABG SXscore was therefore 21-5-3-2.5=10.5 points. LAD: left anterior descending artery; LCx: left circumflex; OM: 
obtuse marginal; RCA: right coronary artery; PLV: posterior left ventricular branch of the RCA; LIMA: left internal mammary artery; SVG 
saphenous vein graft. Black arrows indicate obstructive native coronary disease; white arrows indicate patent anastomosis sites of grafts to vessels.
Notably, the Kaplan-Meier curves for all clinical outcomes in the 
low and high CABG SXscores did not start to separate until after 
one year of follow-up, with continued separation of the curves up 
to four years of follow-up. A peak in the incidence of all-cause 
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revascularisation was observed at approximately 15 months sec-
ondary to the scheduled study coronary angiogram triggering repeat 
revascularisation (Figure 9).
Discussion
The main findings of this pilot study are: 1) that the application of 
the newly developed CABG SXscore appears feasible; 2) that the 
15-month CABG SXscore demonstrated a significant decrease in 
value compared to the baseline SXscore (prior to CABG), second-
ary to a deduction in points attributed to the segment-weighting of 
the revascularised coronary vessels; 3) that the CABG SXscore 
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Figure 8. Distribution of the deducted points from the native SXscore 
to calculate the CABG SXscore (n=113). SD: standard deviation.
appears to be a reproducible technique when performed by a panel 
of interventional cardiologists experienced in the reporting of the 
SXscore; 4) that the deduction of the segment-weighting related 
points due to the presence of bypass grafts was the most reproduc-
ible technique; and 5) that the CABG SXscore may have a long-
term prognostic role. Further validation of this newly developed 
score is required.
The findings from this present study are consistent with the 
methodology adopted by Leaman et al when applying the Leaman 
score to patients pre and post CABG18, namely that the segment-
weighting for the treated vessel would be deducted if it had a func-
tioning bypass graft anastomosed distal to the treated lesion. In 
comparison to the baseline SXscore, a clear and significant reduc-
tion in the 15-month CABG SXscore was evident. The main differ-
ence between the CABG SXscore and the Leaman score was that 
the points relating to lesion characteristics in the CABG SXscore 
remained.
One of the unavoidable limitations of the present study was that 
the coronary angiograms were taken 15 months post CABG and the 
results compared to the baseline SXscore taken prior to surgery. The 
mean baseline SXscore and the 15-month native SXscore did how-
ever not differ significantly (baseline SXscore 31.6, SD 13.1; 
15-month native SXscore 31.1, SD 12.2; p=0.50), making the poten-
tial effects of native coronary disease progression at 15 months likely 
to be of lesser significance.
Conversely, as reported in the SYNTAX-LE MANS substudy, 
over a quarter of the CABG patients (27.2%) had a significantly 
diseased (≥50% to <100%) or obstructed (100%) bypass graft at 
15 months21. These findings may have led to the underestimation of 
the 15-month CABG SXscore compared to if the CABG SXscore 
had been performed post CABG surgery. Although it has previously 
been reported that early bypass graft occlusion rates may be associated 
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Figure 9. Clinical outcomes separated by the median of the CABG SYNTAX Score into low (0-21) (n=58) and high (≥22) (n=55) score groups. 
A non-significant trend towards higher mortality (left image) and all-cause death/CVA/MI (middle image) were evident in the high CABG 
SYNTAX Score group at four years. The peak in repeat all-cause revascularisation between years one and two (right image) were secondary to 
patients undergoing scheduled coronary angiography, the findings of which triggered repeat revascularisation. CVA: cerebrovascular 
accident; MI: myocardial infarction
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with adverse clinical events29-31, the reported loss of the bypass 
grafts in SYNTAX-LE MANS were not significantly associated 
with early MACCE21.
It may be speculated that a proportion of these bypass grafts 
may potentially have been unnecessary. Early bypass graft 
patency rates for functionally significant native coronary lesions 
have been shown to be significantly higher compared to those for 
bypass grafts with functionally insignificant native coronary 
lesions32-34. Furthermore, angiographically defined percentage 
diameter stenoses or the minimum lumen diameter of native coro-
nary vessels29,35 and grafts that have competitive filling with the 
treated native vessel36,37 have been shown to be predictors of 
insufficient flow and/or early graft failure. Consequently, despite 
the limitations, the 15-month CABG SXscore may potentially be 
representative of patients who have been surgically revascularised 
at baseline.
ASSOCIATION OF THE CABG SYNTAX SCORE WITH CLINICAL 
OUTCOMES
The SXscore taken prior to surgery has consistently been shown not 
to have any significant effect on the short to long-term prognosis 
after CABG2-4,7,19,20. It has previously been suggested that this obser-
vation may be related to the fact that bypass grafts are anastomosed 
distal to the proximal disease regardless of the complexity of the 
native coronary disease, providing there are suitable graftable tar-
gets4,38. With the CABG SXscore this concept is potentially chal-
lenged, with the observation of a non-significant trend towards 
a higher longer-term mortality and death/MI/CVA in the high (com-
pared to the low) CABG SXscore group. MACCE was not exam-
ined as the 15-month scheduled coronary angiogram triggered 
repeat revascularisation (Figure 9).
PREVIOUS STUDIES
Alderman et al39 previously demonstrated in The Bypass Angio-
plasty Revascularisation Investigation (BARI) trial – consisting 
of patients treated with percutaneous or surgical revascularisation 
who underwent entry and five-year coronary angiographic fol-
low-up – that native coronary disease progression (and not the 
extent of initial revascularisation) was the predominant determi-
nant of the recurrence of angina and jeopardised myocardium at 
five years. Notably within the BARI Trial two thirds of the 
increase in myocardial jeopardy at five years was in previously 
untreated coronary vessels.
Although other studies have suggested that incomplete surgical 
revascularisation may be associated with short and long-term 
adverse outcomes40,41, further predominantly more contemporary 
studies have suggested that “reasonable” incomplete surgical revas-
cularisation does not have an adverse effect on long-term clinical 
outcomes42-45. Furthermore, the long-term survival of patients 
treated with surgical revascularisation in the CASS (Coronary 
Artery Surgery Study)46 and Rotterdam47 registries has been shown 
to be associated with more extensive preoperative coronary disease, 
which in turn was linked to the higher prevalence and severity of 
other clinical risk factors.
In addition, the Duke graft index48 – an anatomical-based scoring 
system for patients who had previously undergone CABG – was 
demonstrated to be significantly more associated with long-term 
prognosis compared to the native coronary anatomy prior to CABG. 
Remarkably, the Duke graft index had a design concept that in prin-
ciple was similar to the CABG SXscore, namely associating anatom-
ical coronary disease (Duke Graft index: based on the number of 
diseased coronary territories; CABG SXscore: a more sophisticated 
assessment of the coronary anatomy as previously described) with 
the level of protection to the diseased territories conferred by bypass 
grafts in both scores.
IMPLICATIONS OF THE CABG SYNTAX SCORE FOR CLINICAL 
PRACTICE
The CABG SXscore may thus be regarded as both a marker of ana-
tomical coronary disease complexity, and of the degree of revascu-
larisation secondary to the deduction of segment-weighting points 
related to the bypass grafts. Furthermore, it may be speculated that 
the CABG SXscore consisting of anatomical characteristics of the 
coronary vessel – such as bifurcation disease, calcification, total 
occlusions, etc. – may reflect the clinical risk profile of the patient 
and the likelihood of native coronary (and possibly non-coronary as 
detailed below) atherosclerotic disease progression which, impor-
tantly, may actually target the bypass grafts.
It has previously been suggested that the SXscore is a marker of 
patients with a more adverse clinical risk profile who have evi-
dence of systemic atherosclerotic disease, and are thus at greater 
longer-term cardiovascular and cerebrovascular risk19,20,49. This 
hypothesis is supported by the significant and direct relationship 
of the 10-year predicted Framingham risk scores with the preva-
lence and magnitude of coronary artery calcium scores50. In addi-
tion, the ankle-brachial index51-54 and common carotid 
intima-media thickness55-58, both markers of extra-cardiac disease, 
have been correlated with the severity of coronary artery disease 
and even clinical events.
Notably, the clinical outcomes in the present study did not start to 
separate until after one year, and continued to separate at up to four 
years (Figure 9). It may be further hypothesised that the curves 
would continue to separate in the longer term where the clinical 
manifestations of continued native atherosclerotic coronary disease 
progression, and importantly bypass graft disease progression par-
ticularly with SVG, would become more apparent. Consistent with 
these hypotheses are the findings that SVGs have been shown to be 
protective in the first seven years, and that thereafter mortality 
increases significantly in parallel to the gradual loss of SVG 
patency47,59. 
POTENTIAL CLINICAL AND RESEARCH APPLICATIONS OF 
THE CABG SYNTAX SCORE
Potential clinical applications of the CABG SXscore include long-
term risk stratification of patients who have previously undergone 
CABG to aid in the identification of a group at high risk for future 
clinical events and repeat revascularisation. Even without the use of 
a CABG SXscore, it may be further postulated that higher SXscore 
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patients may benefit more from undergoing revascularisation with 
more durable grafts that have a proven long-term patency (e.g., 
LIMA and RIMA) compared to SVG60,61.
Although aggressive risk factor control would undoubtedly improve 
the prognosis of all these patients, perhaps future study may target 
patients with a higher SXscore/CABG SXscore who may potentially 
benefit from more aggressive risk factor control with established and 
emerging drugs that cause atherosclerotic disease regression.
Other potential applications of the CABG SXscore in a research 
setting include the allowance of the incorporation of CABG patients 
into contemporary stent trials measuring the SXscore, where such 
patients are at present excluded.
STUDY LIMITATIONS
As previously discussed, apart from the time frame at which the 
CABG SXscore was taken, the main limitation of this study is that 
there was limited power to examine long-term clinical outcomes. 
Despite this limitation, a non-significant trend towards more 
adverse clinical outcomes in the higher CABG SXscore group was 
seen, which is further supported by the concept of the Duke graft 
index, as previously discussed48.
One other limitation is that the CABG SXscore does not account 
for the type of graft anastomosed and the characteristics of the graft 
disease (if present), except if there is obstructive graft disease or not. 
This is perhaps more notable with the LIMA bypass graft given its 
proven higher long-term patency rates compared to other types of 
bypass graft60,61. The hypothesis central to the CABG SXscore does, 
however, relate to the native SXscore and its apparent association 
with clinical comorbidity, with the additional “protection” conferred 
by the bypass grafts. Furthermore, reducing the CABG SXscore by 
an arbitrary number of points based on the type and numerous ana-
tomical complexities of the bypass graft would substantially increase 
the complexity of the analyses, making this impractical.
FUTURE DIRECTIONS
Potentially, the integration of the CABG SXscore into an online 
algorithm, as is currently available with the SXscore1, may serve to 
simplify the calculation of the CABG SXscore. The functional 
SYNTAX Score – a fractional flow reserve (FFR) guided SYNTAX 
scoring methodology – has recently been demonstrated to improve 
the diagnostic accuracy of the SXscore62. Furthermore, the feasibil-
ity of undertaking non-invasive anatomical and fractional flow 
measurements has since been proven, utilising computational 
fluid dynamics applied to coronary computed tomography (CT) 
angiography63. The application of this emerging technology to the 
CABG SXscore may improve the diagnostic accuracy and repro-
ducibility of the CABG SXscore. In addition, the non-invasive 
combined coronary CT and FFR technology may potentially allow 
for the automatic adjustment of the vessel-segment weighting for 
coronary vessels based on actual measured blood flow, in order to 
calculate a more “physiological” functional CABG SXscore.
Conclusion
The calculation of the CABG SXscore is feasible, reproducible and 
may have a long-term prognostic role in the assessment of risk in 
patients undergoing coronary artery bypass grafting. Confirmation 
and validation of the findings from this pilot study are required in 
larger studies.
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Scores
LEAMAN SCORE
The Leaman Score64 is based on the severity of luminal diameter 
narrowing and is weighted according to the usual blood flow to the 
left ventricle in each vessel or vessel segment. In a right dominant 
system, the right coronary artery (RCA) supplies approximately 
16% and the left coronary artery approximately 84% of the blood 
flow to the left ventricle. This 84% is normally directed 66% 
towards the left anterior descending (LAD) and 33% to the left cir-
cumflex (LCx) vessels. Consequently, the LMS, LAD and LCx 
supply approximately x5, x3.5 (84/16 x0.66) and x1.5 respectively 
as much blood as the RCA to the left ventricle, the values of which 
are designated as the respective vessel’s segment-weighting factors. 
In a left dominant system, the RCA does not contribute to the blood 
supply of the left ventricle, which is instead supplied by the LCx. 
Thus the LMS supplies 100% of the blood flow to the left ventricle. 
Hence the LAD provides 58% (segment-weighting factor x3.5) and 
the LCx 42% (segment-weighting factor x2.5) of the total blood 
flow to the LV. These concepts ultimately formed the basis of the 
segment-weighting factors that were incorporated into the now 
validated SXscore65-73.
APPLICATION OF THE LEAMAN SCORE IN PATIENTS 
UNDERGOING CABG. Leaman et al previously applied the Lea-
man Score, derived from the segment-weighting factors, to patients 
at baseline and post CABG surgery64. This concept was based on 
the principle that the segment-weighting for the treated vessel 
would be deducted if it had a functioning bypass graft anastomosed 
distal to the treated lesion. For example, a significant mid RCA 
lesion would score a segment-weighting factor of 1x2 (2 points) if 
the lesion was significantly (non-total) diseased, or 1x5 (5 points) if 
the lesion was occluded. Post-surgery, if the graft to the RCA was 
patent, the respective segment-weighting points for the treated ves-
sel would be deducted. Conversely, if the graft was occluded, the 
points would remain unaltered.
SYNTAX SCORE
The SXscore methodology has previously been described74-77. In 
brief, the SXscore was developed by combining the importance of 
a diseased coronary artery segment by the vessel-segment weight-
ing (modified Leaman Score)64, adverse characteristics of such a 
lesion for revascularisation (ACC/AHA lesion classification)78,79 
and the Medina classification system for bifurcation lesions80,81.
Each vessel segment, 1.5 mm in diameter or greater, with a ≥50% 
diameter stenosis by visual estimation, is awarded a multiplication 
factor related to the location of the lesion, and the severity of the 
stenosis (non-total vs. total occlusion). Further characterisation of 
the coronary lesions leads to the addition of more points. These 
include features of total occlusions (duration, length, blunt stump, 
presence of bridging collaterals or side branch), the presence of 
bifurcation (based on the Medina classification) or trifurcation dis-
ease (number of diseased branches involved), side branch angula-
tion, aorto-ostial lesion, severe tortuosity, lesion length >20 mm, 
heavy calcification, thrombus and diffuse or small vessel disease. 
 
Online Figure 1. Example of the calculation of the CABG SXscore in 
a patient with an occluded LMS. Black arrows indicate obstructive 
native coronary disease; white arrows indicate patent anastomosis 
sites of grafts to vessels, # occluded LMS. LMS: left main stem; 
RCA: right coronary artery; LIMA: left internal mammary artery; 
OM: obtuse marginal; LAD: left anterior descending artery; SVG: 
saphenous vein graft
The above information is entered into the online available SXscore 
algorithm75 which automatically sums each of these features to cal-
culate the total SXscore.
DEFINITIONS OF VESSEL SEGMENTS. A table of vessel seg-
ments relating to the SYNTAX Score is detailed hereafter (Online 
Table 1).
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Further illustrative examples of the application 
of the CABG SXscore
CASE 1
Occluded LMS (#) in a left dominant system gave a native SXscore 
of 39 (upper image). The ostial involvement of the LAD (black 
arrow) was regarded as part of the LMS lesion as it was located 
within ≥3 vessel reference diameters from the occluded LMS 
lesion. A patent LIMA inverse Y graft anastomosed to the mid LAD 
(upper white arrow), with sequential anastomoses to the 1st, 2nd and 
3rd OM branches (lower three white arrows) are shown. Based on 
the segment-weighting 30 points were deducted from the native 
SXscore. Final CABG SXscore was therefore 39–17.5–12.5=9 
points (Online Figure 1).
CASE 2
Upper images: native SXscore was 35.5 with distal LMS disease 
(Medina 1.1.1), distal RCA disease, and an occluded ostial LCx (#).
Lower images: distal RCA protected by SVG (left image), therefore 
1x2 points were deducted from the native SXscore. Occluded ostial 
LCx is under “ischaemic protection” by the RIMA to the distal OM 
(middle image) secondary to disease more proximal to the anastomo-
sis. Therefore 1.5x3 points are deducted from the native SXscore (no 
points are added for the OM disease as it is protected by the RIMA 
graft). The ostial LAD disease is protected by the LIMA (right image) 
anastomosed to the distal LAD with no intervening obstructive disease, 
so 3.5x2 points are deducted from the native SXscore. Final CABG 
SXscore was therefore 35.5–2–4.5–7=22 points (Online Figure 2).
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Table 1. Definitions of segments.
1. RCA proximal From ostium to one half the distance to the acute margin 
of the heart.
2. RCA mid From end of first segment to acute margin of heart.
3. RCA distal From the acute margin of the heart to the origin of the 
posterior descending artery.
4. Posterior descending 
artery
Running in the posterior interventricular groove.
16. Posterolateral branch 
from RCA
Posterolateral branch originating from the distal 
coronary artery distal to the crux.
16a. Posterolateral branch 
from RCA
First posterolateral branch from segment 16.
16b. Posterolateral branch 
from RCA
Second posterolateral branch from segment 16.
16c. Posterolateral branch 
from RCA
Third posterolateral branch from segment 16.
5. Left main From the ostium of the LCA through bifurcation into left 
anterior descending and left circumflex branches.
6. LAD proximal Proximal to and including first major septal branch.
7. LAD mid LAD immediately distal to origin of first septal branch 
and extending to to the point where LAD forms an angle 
(RAO view). If this angle is not identifiable this segment 
ends at one half the distance from the first septal to the 
apex of the heart.
8. LAD apical Terminal portion of LAD, beginning at the end of previous 
segment and extending to or beyond the apex.
9. First diagonal The first diagonal originating from segment 6 or 7.
9a. First diagonal a Additional first diagonal originating from segment 6 or 
7, before segment 8.
10. Second diagonal Second diagonal originating from segment 8 or the 
transition between segment 7 and 8.
10a. Second diagonal a Additional second diagonal originating from segment 8.
11. Proximal circumflex 
artery
Main stem of circumflex from its origin of left main to 
and including origin of (first and second) obtuse 
marginal branch(es).
12. Intermediate/
anterolateral artery
Branch from trifurcating left main other than proximal 
LAD or LCx. Belongs to the circumflex territory.
12a. Obtuse marginal a First side branch of circumflex running in general to the 
area of obtuse margin of the heart.
12b. Obtuse marginal b Second additional branch of circumflex running in the 
same direction as 12.
13. Distal circumflex 
artery
The stem of the circumflex distal to the origin of the 
most distal obtuse marginal branch and running along 
the posterior left atrioventricular grooves. Calibre may be 
small or artery absent.
14. Left posterolateral Running to the posterolateral surface of the left ventricle. 
May be absent or a division of obtuse marginal branch.
14a. Left posterolateral a Distal from 14 and running in the same direction.
14b. Left posterolateral b Distal from 14 and 14a and running in the same 
direction.
15. Posterior descending Most distal part of dominant left circumflex when present. 
Gives origin to septal branches. When this artery is 
present, segment 4 is usually absent.
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We recently reported the coronary artery bypass graft (CABG) 
SYNTAX Score, an objective measure of anatomical complexity 
and revascularisation post coronary artery bypass graft (CABG) sur-
gery1. At four-year follow-up, a non-significant trend towards more 
adverse clinical outcomes, including all-cause death, was reported 
in the higher CABG SYNTAX group (≥22)1. The final five-year out-
comes of the SYNTAX trial have recently been reported2,3. We report 
the five-year outcomes of the CABG SYNTAX Score from the CABG 
arm of the SYNTAX-LE MANS left main angiographic substudy.
At five years, significantly greater all-cause death was seen in 
the high CABG SYNTAX Score group (≥22) compared to the low 
CABG SYNTAX Score group (<22) (14.5% vs. 9.1%, log rank 
p-value=0.012) (Figure 1). Similarly, significantly greater five-year 
all-cause death/cerebrovascular accident (CVA)/myocardial infarction 
(MI) (log rank p-value=0.025) and MACCE (major adverse cardiac 
and cerebrovascular events) (log rank p-value=0.050) were reported.
Incomplete revascularisation (ICR) has recently been hypothe-
sised and shown to be a surrogate marker of a greater burden and 
complexity of coronary disease, other vascular disease, and clinical 
comorbidity, in both CABG and PCI (percutaneous coronary inter-
vention) treated patients4,5. Specifically, in the all-comers CABG 
and PCI arms of the SYNTAX trial, adverse long-term (four-year) 
clinical outcomes  – including mortality, all-cause revascularisation, 
and MACCE – were shown to occur more frequently in patients 
who were incompletely revascularised.
The CABG SYNTAX Score and its PCI equivalent, the residual 
SYNTAX Score6, both provide objective measures of the complex-
ity of the residual disease and level of revascularisation. These scores 
may aid in determining a level of “reasonable revascularisation” 
after undergoing surgical or percutaneous-based revascularisation7, 
and may have a long-term prognostic role in identifying high-risk 
patients undergoing CABG or PCI. Validation studies are awaited.
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Figure 1. Outcomes (Kaplan-Meier curves) separated by the median of the CABG SYNTAX Score into low (0-21) (n=58) and high (≥22) 
(n=55) score groups. At 5 years, significantly greater all-cause mortality (left image), significantly greater all-cause death/CVA/MI (middle 
image) and MACCE (right image) were evident in the high CABG SYNTAX Score group compared to the low CABG SYNTAX Score group. 
Note the peak in MACCE at approximately 18 months secondary to patients undergoing scheduled coronary angiography, the findings of 
which triggered repeat revascularisation. Log rank p-values are shown.
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Coronary artery bifurcations are a common challenging lesion subset accounting for approximately
10% to 20% of all percutaneous coronary interventions. The provisional T-stenting approach is gener-
ally recommended as the first-line management of most lesions. Carina shift is suggested to be the
predominant mechanism of side-branch pinching during provisional T-stenting and has been indirectly
inferred from bench work and other intravascular imaging modalities. Offline 3-dimensional (3D) recon-
structions of patients studied in the first-in-man trial of the high-frequency (160 frames/s) Terumo opti-
cal frequency domain imaging system were undertaken using volume-rendering software. Through a
series of 3D reconstructions, several novel hypothesis-generating concepts are presented. (J Am Coll
Cardiol Intv 2011;4:921–31) © 2011 by the American College of Cardiology Foundation
Coronary bifurcations are a challenging lesion
subset accounting for approximately 10% to 20% of
all percutaneous coronary interventions (PCI).
Historically, they have been associated with lower
rates of procedural success, higher restenosis rates,
in particular at the ostium, and adverse events
compared with the treatment of simpler, nonbifur-
cation lesions (1–3).
The current prevailing opinion in their man-
agement is one of a “simpler is better” approach,
with provisional T-stenting recommended as the
first-line strategy in most lesions (1,2). The
traditional concept of plaque shift as the pre-
dominant mechanism in the pinching of the side
branch (SideB) during this technique has re-
cently been challenged and replaced by carina
shift, with the suggestion that up to 30% of
bifurcations have involvement of plaque shift,
since atheroma is rarely seen at the carina alone
because of it being a high wall shear stress area
(2,4). The concept of carina shift has been
indirectly inferred from bench work, in vivo
longitudinal and cross-sectional intravascular ul-
trasound intravascular (IVUS) imaging, and
computed tomography (CT) imaging modalities
(1,4 –8).
Both IVUS (image resolution: 100 to 150 m)
and CT (resolution: 300 to 500 m) lack the
imaging resolution to fully appreciate the complex
architecture of the bifurcation compared with op-
tical coherence tomography (OCT; image resolu-
tion: 10 to 20 m). Fusion of CT and IVUS in
obtaining 3D reconstructions of human coronary
bifurcation have previously successfully been un-
dertaken to allow for wall shear stress analyses; this
system, however, lacks the resolution obtainable
with OCT (9).
Current-generation Fourier-domain OCT (FD-
OCT) allows rapid pullback speeds and has al-
lowed visualization of the coronary bifurcation
with 2-dimensional (2D) images in great detail
(10–12). One of the major limitations of this
technology, however, has been the lack of 3-dimensional
(3D) images. Trying to mentally reconstruct a
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complex 3D structure from 2D images is difficult; 2D
imaging may not allow a full appreciation of the anatomic
features of the bifurcation and the effects of PCI.
Three-dimensional, offline FD-OCT reconstructions
were first described by Tearney et al. (13) and more recently
by Okamura et al. (14) in the assessment of jailed SideB by
bioresorbable vascular scaffolds.
Prototypes of current-generation “real-time” (i.e., peripro-
cedural) 3D FD-OCT are experimental, have not yet entered
conventional clinical practice, and appear to have a limited
resolution compared with the offline 3D optical frequency
domain imaging (OFDI) reconstructions; this may be related
to the lower frame rate of commercially available systems: the
intracoronary Terumo OFDI sys-
tem (Terumo Corporation, To-
kyo, Japan) is currently the only
system with a frame rate as high as
160 frames/s (11,14,15).
Through a series of images
demonstrating 3D OFDI recon-
structions of coronary artery
bifurcations, we aim to demon-
strate several novel, hypothesis-
generating concepts with regard
to the anatomic characteristics of
this complex structure.
Methodology
Three-dimensional reconstruc-
tions of patients who underwent
conventional PCI from the orig-
inal first-in-man study of the
intracoronary Terumo OFDI
system were undertaken (15).
The high-speed Terumo OFDI
system is capable of acquiring
160 frames/s during the catheter
pullback up to a maximum speed
of 40 mm/s; all images were
acquired with a pullback speed
of 20 mm/s. The 3D coronary angiography images were
constructed from their respective biplane 2D images
(CAAS 5.9, Pie Medical Imaging, Maastricht, the Nether-
lands) (16). All patients studied had stable angina; 3D
reconstructions of coronary bifurcations and the consequent
effects of provisional T-stenting were performed.
The methodology for the 3D reconstructions has previ-
ously been described (14). In brief, offline bitmap sequences
(704  704 pixels) were generated from prior 2D OFDI
imaging. Manual detection of every strut in each 2D cross
section were undertaken, and 3D reconstructions of the
coronary vessel pre- and post-intervention were performed
using volume-rendering software (INTAGE Realia, KGT,
Tokyo, Japan).
Nomenclature for 3D FD-OCT reconstructions. “Fly-through”
views indicate a selected still image of an internal view of a
vessel looking either downstream (proximal-to-distal vessel)
or upstream (distal-to-proximal vessel). An “orientation”
figure is located as an inset figure within the 3D reconstruc-
tion to best illustrate where the endoluminal point of view is
electronically located, and in which direction it is pointing.
In 3D reconstructions, the 3D rendering software provides
x-, y-, and z-axes within the coronary vessel to allow precise
assessment of the location of the endoluminal point of view.
Longitudinal and, in some cases, cross-sectional 2D OFDI
frames of the vessel and bifurcation, with a blue arrow
superimposed on it, are used to orient the reader within the
vessel: the base and direction of the blue arrow indicates
from and in which direction, respectively, the 3D image is
visualized from within the 2D plane(s).
3D Reconstructions
Anatomy of the left main stem, circumflex, left anterior
descending, diagonal, and septal branches. Figure 1A dem-
onstrates a fly-through view, looking downstream, from the
distal left main stem showing the ostia of the left anterior
descending coronary artery (LAD), circumflex, first diago-
nal (Fig. 1A, D1), and septal branches. Note the appearance
of the opening of the diagonal vessel and its relationship to
the LAD vessel opening. The main branch (MainB) and
SideB appear to diverge parallel to each other at their
respective origins, with the carina (labeled) appearing to be
“interposed” between both vessel openings at this point of
divergence.
Figure 1B demonstrates a close-up fly-through view of
the same vessel looking downstream from the proximal
LAD and aimed towards the diagonal ostium (upper right
image); the left circumflex coronary artery (LCx) orifice
appears between 12 and 3 o’clock in relation to the diagonal
ostium. For comparison, note the corresponding 2D OFDI
frames (lower image). The slit-like, elliptical appearance of
the diagonal opening is clearly visible, and when bifurcation
is viewed perpendicular to the vessel wall (inset left image—
use the orientation figure to allow assessment of the endo-
luminal point of view), the carina is predominantly visual-
ized, with the proximal course of the diagonal vessel
appearing to be hidden behind the rim of the carina so
that the diagonal orifice appears, in-depth, as a dead end.
This is further suggestive of the proximal parallel course
of the diagonal with the LAD at the point of divergence.
The yellow arrows in the fly-through and perpendicular
views are pointing in identical directions, namely, the
direction of the opening of the diagonal vessel.
Figure 1C demonstrates a fly-through view looking
further downstream into the same LAD (upper left image).
Abbreviations
and Acronyms
2D  2-dimensional
3D  3-dimensional
CT  computed tomography
FD-OCT  Fourier-domain
optical coherence
tomography
IVUS  intravascular
ultrasound intravascular
KBPD  kissing balloon
post-dilation
LAD  left anterior
descending coronary artery
LCx  left circumflex
coronary artery
MainB  main branch
OCT  optical coherence
tomography
OFDI  optical frequency
domain imaging
PCI  percutaneous
coronary intervention
RV  right ventricular
SideB  side branch
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Observe the large septal branch orifice opening; when
viewed perpendicular to the vessel wall (upper right image),
and contrary to the observations made with the diagonal
branch, the endoluminal opening of the septal branch is
entirely visible and does not appear to be concealed behind the
carina. This corresponds to the characteristic, almost perpen-
dicular takeoff of the septal branch from the LAD. Corre-
sponding 2D OFDI frames are displayed below the panel.
Anatomy of the proximal, mid, and distal LAD–diagonal
branches. Figure 2A demonstrates downstream fly-through
views of the LAD, looking distally (Image 1) and aimed
towards the proximal diagonal ostium (Image 2). When the
bifurcation is visualized perpendicular to the vessel wall
(Image 3), the diagonal orifice appears to have a circular
appearance with the rim of the carina appearing to be
concealing the proximal course of diagonal, so that the
diagonal orifice once again appears, in-depth, as a dead
end. Yellow arrows (Images 2 and 3) point in identical
directions at the opening of the same diagonal vessel.
Corresponding 2D OFDI frames are shown below the
panel for comparison.
Figure 2B demonstrates fly-through views (looking
downstream) of the mid (D2, left image) and distal (D3,
right image) LAD–diagonal bifurcations; yellow arrows
point at the diagonal vessel openings. The corresponding
2D OFDI frames of each bifurcation are displayed below
their respective 3D reconstructions.
All of these images are further suggestive of the proximal
parallel course of the diagonal vessels relative to the LAD at
their point of divergence.
Anatomy of diagonal branch originating perpendicular to the
LAD. Figure 3 demonstrates a coronary angiogram (left
image), suggesting the diagonal vessel (asterisk) originates
almost perpendicular to the LAD at the point of divergence
of both vessel origins. The 3D coronary angiography images
(left inset figures) confirmed these findings with a bifurca-
tion angle of 85°. A fly-through view of the LAD looking
downstream (upper right image) demonstrates the diagonal
vessel opening (asterisk), note the elliptical shape of the
vessel opening and the observation that the diagonal vessel
opening is fully visible, and not concealed by the carina,
when visualized perpendicular to the vessel wall (lower right
image). Observe how the stent is able to divide the opening
of the diagonal vessel into at least 3 segments. Effectively,
the diagonal branch with an almost perpendicular takeoff
appears to have similar characteristics to the septal branch as
described in Figure 1C.
The right ventricular branch of the right coronary artery.
Figure 4 demonstrates how the right ventricular (RV)
branch of the right coronary artery (RCA) appears to
exhibit the phenomenon of a “parallel bifurcation” as
described for the diagonal vessel. The downstream fly-
through view of the proximal RCA demonstrates the
opening of the RV branch (upper left image); note how
the opening of the RV branch (yellow arrows) appears to be
concealed behind the proximal rim of the carina in the
perpendicular (upper middle image) and retrograde (upper
right image) endoluminal point of views. In support of this
concept is that the bifurcation angle is 57° on the corre-
sponding 2D and 3D coronary angiograms (lower left
images). Corresponding 2D OFDI frames are displayed
(lower right images).
Bifurcation treated with provisional-T approach: comparing
the diagonal and septal branches on 2D and 3D FD-OCT.
Figure 5A demonstrates a long segment of disease in the
proximal-mid LAD (upper left image) extending across the
bifurcation with a diagonal branch. This was treated with 2
overlapping Xience V stents (Abbott Vascular, Abbott Park,
Illinois) that lead to “pinching” of the SideB ostium with
Thrombolysis In Myocardial Infarction flow grade 3 (mid-
dle left image with corresponding 3D coronary angiogram).
Kissing balloon post-dilation (KBPD) was subsequently
successfully performed with improvements in the pinched
angiographic appearances (lower left image with corre-
sponding 3D coronary angiograms) (Online Video 1). In
the fly-through view (looking downstream) of the LAD
post-intervention (right image), note the characteristic per-
pendicular and parallel takeoffs of the septal (asterisk) and
diagonal (white arrow) branches at the point of divergence
from the LAD lumen, respectively.
Figure 5B demonstrates fly-through views looking down-
stream at the diagonal and septal branches; note the
differences between both branches as a more perpendicular
view of the vessel wall is seen. Parallel yellow arrows
represent the parallel courses of the diagonal and LAD
vessels at their point of divergence. Medina et al. (6) have
previously hypothesized the concept of carina shift pinching
the SideB by the displacement of the carina so that it
appears as an “eye-brow” sign on longitudinal 2D IVUS
imaging (17). As shown on the 3D reconstruction, this
effect can be more easily appreciated and may be hypothe-
sized to have led to the near closure of the diagonal ostium
following post-dilation of the MainB stent; subsequent
KBPD may have reopened the SideB ostium by displacing
the carina towards the lumen of the MainB. This principle
may not be applicable to the septal branch because of the
differing appearances of the carina.
Figure 5C demonstrates the corresponding 2D OFDI
frames of the septal (asterisks) and diagonal branches
(arrows). The almost parallel course of the diagonal vessel
(yellow arrow indicates the diagonal vessel in cross-sectional
view) in relation to the LAD lumen at the point of
divergence appears to determine the 2D FD-OCT charac-
teristics; without careful observation, the diagonal vessel
may have been misinterpreted as an area of stent malappo-
sition on the 2D FD-OCT imaging. With the septal
branch, this appears to originate perpendicular to the vessel
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wall giving its characteristic 2D FD-OCT appearances as
shown (yellow asterisk).
Bifurcation treated with provisional-T approach: the concept
of a parallel bifurcation and carina shift. Figure 6A demon-
strates the concept of carina shift with pre- and post-
intervention images: the solid line indicates the position of the
carina pre-intervention (left image); broken lines demonstrate
the position of the carina pre- (left image) and post- (right
image) intervention. Two-dimensional (Online Video 2) and
3D coronary angiograms (inset images) demonstrate disease of
the LAD with involvement of the diagonal ostium not evident
on subsequent 3D reconstruction.
Implantation of a Xience V stent (Abbott Vascular) in the
mid LAD led to angiographic “pinching” of the SideB
ostium with Thrombolysis In Myocardial Infarction flow
grade 3 maintained in the SideB. Post-dilation of the
Figure 1. Anatomy of the Left Main Stem, Circumflex, Left Anterior Descending, Diagonal, and Septal Branches
(A) Fly-through view looking downstream from the distal left main stem (LMS). (B) Close-up view of the LAD–proximal diagonal “parallel bifurcation.” Per-
pendicular (left inset) and downstream (right) fly-through views aimed at the first diagonal vessel opening (D1) are illustrated. Corresponding 2D OFDI
frames are shown below.
Continued on the next page
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 4 , N O . 8 , 2 0 1 1
A U G U S T 2 0 1 1 : 9 2 1 – 3 1
Farooq et al.
3D FD-OCT Imaging of the Coronary Bifurcation
924
103Chapter 4.1
MainB alone was performed with the deploying stent
balloon; no KBPD was performed. The angiographic ap-
pearance of the pinching of SideB ostium improved (Online
Video 2).
Figure 6B (upper images) demonstrates the appearance of
the SideB opening when viewed perpendicular to the vessel
wall (Image 3), illustrating the principle of a “parallel
bifurcation” with the concealment of most of the opening of
the diagonal vessel by the rim of the carina. It may be
speculated that continued post-dilation of the MainB stent
alone, especially with larger balloons, may have risked
further carina shift and SideB closure.
Note how the MainB struts appear to overhang the carina
over the SideB opening, especially evident in the perpen-
dicular view (Image 3), because of the structure of the
parallel bifurcation and carina. For comparison, the 2D
OFDI frames (lower images) with the stent struts at the
SideB ostium are illustrated. Asterisk indicates thrombus
and the shadow it casts on the vessel wall, in both the 2D
and 3D FD-OCT imaging.
Discussion
On the basis of the offline 3D OFDI reconstructions, we
have proposed several hypothesis-generating concepts relat-
ing to bifurcation anatomy and the effects of PCI: 1) the
concept of the parallel or perpendicular bifurcations and the
corresponding 2D and 3D appearances—a reassessment of
current interpretations of the 2D FD-OCT imaging of
the bifurcation may be warranted; 2) the hypothesis that
the angle of divergence between the MainB and SideB at
their respective origins will ultimately determine the
anatomic features of the carina and how it potentially
interacts with the SideB vessel orifice during MainB
stenting; and 3) the potential clinical application of
instantaneous 3D FD-OCT in coronary bifurcation
treatment.
Based on the appearances of the carina on the 3D
reconstructions and the effects of PCI, a more perpendicular
takeoff of the SideB from the MainB may be less prone to
the effects of carina shift whereas a shallower angle of
divergence appears to be more susceptible to the effects of
carina shift. This concept is supported by a study suggesting
a specific measure of SideB angulation on the coronary
angiogram is associated with a higher incidence of SideB
compromise (18). Asakaura et al. (19) also demonstrated, in
a small case series, that a shallower angle, with a cutoff of
80°, between the LCx and LAD was predictive of LCx
ostial impairment after stenting within the LAD ostial
region—the authors had presumed at the time that the
mechanism of SideB (LCx) closure was secondary to plaque
shift or coronary dissection. Both of the aforementioned
studies are, however, limited by a lack of 3D quantitative
coronary angiography to calculate the bifurcation angulation
(16). An awareness of the potential increased risk of SideB
closure during MainB stenting of coronary bifurcations with
a shallower bifurcation angle may be justified—further study
into this phenomenon is required.
Angiographic appearances of the SideB ostium after
MainB stenting has previously been demonstrated to be
unreliable, with only a quarter (27%) of cases with a residual
Figure 1. Continued
(C) Anatomy of the LAD–septal “perpendicular bifurcation.” Downstream fly-through (left) and perpendicular (right) views are illustrated. Corresponding 2D
OFDI frames are shown below. 2D  2-dimensional; DIST  distal; LAD  left anterior descending artery; LCx  left circumflex; OFDI  optical frequency
domain imaging; PROX  proximal.
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angiographic narrowing of 75% in the SideB being found
to have a functionally significant narrowing in pressure wire
studies (1,8). The main limitation of this technique is the
potential risk of dissecting the SideB ostium with a less
flexible, less torquable, and less hydrophilic pressure wire
and the increase in procedural time in rewiring the SideB
through the MainB stent. As the 3D FD-OCT reconstruc-
tions can visualize the carina shift and the SideB vessel
opening, quantification of the SideB opening as an area may
allow the operator to assess whether the SideB ostium is
hemodynamically compromised, without the need to per-
form a pressure wire study. The addition of quantitative
measurements to the 3D software as well as the requirement
for instantaneous online 3D FD-OCT availability of a
high-enough resolution would, however, be necessary re-
quirements.
Within the parallel bifurcation, the positioning and geomet-
ric relationship of the MainB stent over the SideB opening
suggested “overhanging” of the struts over the edge of the
carina (Fig. 7); this was especially evident in the views perpen-
dicular to the vessel wall (Figs. 5B and 6B) and contrary to the
appearances on the corresponding 2D images where a “jailed”
appearance of the stent struts covering the SideB opening was
suggested; the jailed appearance of the struts covering the
SideB ostium was, however, evident with perpendicular bifur-
cations (Figs. 3 and 5).
Figure 2. Anatomy of the Proximal, Mid, and Distal LAD–Diagonal Branches
(A) Further example of the LAD–proximal diagonal parallel bifurcation. Downstream fly-through (top left) aimed at the first diagonal (top middle) and perpen-
dicular (top right) views are illustrated. Corresponding 2D OFDI frames are shown below. (B) Anatomy of the mid and distal LAD–diagonal parallel bifurcations.
Downstream and perpendicular views of the mid (upper left) and distal (upper right) LAD–diagonal bifurcations are illustrated. Corresponding 2D OFDI frames
are shown below. D2  second diagonal; D3  third diagonal; other abbreviations as in Figure 1.
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Figure 3. Anatomy of Diagonal Branch Originating Perpendicular to the LAD: Perpendicular Bifurcation
Two-dimensional and 3-dimensional (3D) coronary angiograms (left) and 3D reconstructions (right) are illustrated. An asterisk indicates the endoluminal open-
ing of diagonal branch, a tilde, small diagonal branch, and a hash mark, septal branch. CRA  cranial; LAO  left anterior oblique; RAO  right anterior
oblique.
Figure 4. Anatomy of the RCA RV Branch Demonstrating a Parallel Bifurcation
Three-dimensional (3D) reconstructions (top) with the perpendicular view. Two-dimensional (2D) and 3D quantitative coronary angiography (bottom left) and corre-
sponding 2D OFDI frames (bottom right). RCA  right coronary artery; RV right ventricular; other abbreviations as in Figures 1 and 3.
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Current recommendations during provisional T-stenting
suggest the recrossing of the coronary wire (after MainB
stenting) into the SideB through the most distal cell of the
MainB stent covering the SideB opening (11,20,21). If the
coronary wire is passed through a proximal cell into the SideB,
this may potentially provide no scaffolding to the SideB ostium
and leave many struts unopposed adjacent to the carina. The
adoption of this principle to bifurcations with 3D FD-OCT
has recently been shown to be potentially feasible in humans
(11,22). To help further appreciate this potential appli-
Figure 5. Bifurcation Treated With Provisional-T Approach: Comparing the Diagonal and Septal Branches on 2D and 3D FD-OCT
(A) LAD–diagonal bifurcation treated with the provisional-T approach. Angiographic findings (left) and downstream fly-through view of the LAD post-interven-
tion (right) illustrating the septal (white asterisks) and diagonal (white arrows) vessel openings. (B) The differences between the septal and diagonal vessels
based on perpendicular views. Progressively more perpendicular views of the diagonal (top) and septal (bottom) SideB openings. Parallel yellow arrows repre-
sent the parallel courses of the LAD–diagonal at their respective point of divergence.
Continued on the next page
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 4 , N O . 8 , 2 0 1 1
A U G U S T 2 0 1 1 : 9 2 1 – 3 1
Farooq et al.
3D FD-OCT Imaging of the Coronary Bifurcation
928
107Chapter 4.1
cation, a 3D OFDI reconstruction was performed in a
patient separate from this study, utilizing the OFDI
system from an ongoing trial (23): the case is of a
proximal LCx–obtuse marginal bifurcation in the context
of an acute coronary syndrome requiring manual aspira-
tion thrombectomy; malapposition was evident immedi-
ately after MainB stent implantation requiring further
post-dilation (not illustrated) (Fig. 7).
Based on the 3D reconstructions, the malapposed struts
located in close vicinity to the proximal ostial rim (i.e., in the
“takeoff” position) are overprojected on the true orifice of the
SideB, giving the illusion that the SideB orifice is jailed when
the orifice is viewed obliquely (Fig. 7A); this, however, appears
to be the ideal endoluminal point of view to best select the
distal cells of the stent over the parallel bifurcation to pass the
coronary wire and perform KBPD (white arrow, Fig. 7A).
When moving further downstream along the axis of the
MainB, the optical visual perspective of overprojection on the
orifice of the SideB is gradually reduced (Fig. 7B) and
eliminated when a downstream endoluminal point of view at
the level of the carina is selected (Fig. 7C). The struts located
in front of the edge of the carina are now seen prominently as
a metallic extension of the carina and not covering the SideB
opening. The potential to advance a coronary wire beneath the
malapposed struts in the proximal vicinity of the ostial rim
appears to be very real, and if SideB dilation or stenting were
performed, would result in multiple unappposed struts taking
off from the carina.
Other properties of 3D FD-OCT reconstructions that
may have a clinical application include the addition of tissue
characterization; this has previously been performed offline
(13,24,25). Tissue characterization within 3D FD-OCT
imaging (25) or fusion imaging of 2D FD-OCT and IVUS
virtual histology (26) would have the potential to aid in the
identification of clinically useful areas of interest such as
fibrocalcific plaque, lipid pools, and vulnerable plaque. A recent
study utilizing longitudinal high-resolution intravascular ultra-
sound has suggested that that the effects of carina shift may be
limited by the presence of fibro-calcific plaque at the carina,
presumably because of resistance to expansion—using 3D
FD-OCT, this concept appears easier to appreciate; tissue
characterization of intravascular imaging may ultimately aid
in identifying these areas (2,17).
Conclusions
The potential for the clinical application of 3D FD-OCT as
a complementary tool to 2D imaging is demonstrated. A
reassessment of the understanding of 2D FD-OCT imaging
may be warranted in light of the 3D findings. Real-time,
instantaneous, high-resolution 3D FD-OCT, with the
Figure 5. Continued
(C) Corresponding 2D OFDI images of the septal and diagonal branches. Highlighted OFDI frames demonstrate the diagonal (yellow arrow) and septal vessels
(yellow asterisk) when viewed in cross section. Also see Online Video 1. SideB  side branch; other abbreviations as in Figure 1.
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addition of quantitative and possible tissue characterization
properties, are required from industry to validate and apply
this technology in conventional PCI practice. This may aid
in the further understanding of the complexities of the
coronary bifurcation.
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Figure 6. Bifurcation Treated With Provisional-T Approach: The Concept of a Parallel Bifurcation and Carina Shift
(A) The principle of carina shift. Downsteam fly-through views pre- (left) and post- (right) intervention of the LAD–diagonal bifurcation are demonstrated; 3D
coronary angiograms are illustrated as inset figures. (B) Anatomy of the LAD–diagonal parallel bifurcation post-MainB (LAD) stenting. Top demonstrates a pro-
gressively more perpendicular view of the vessel. Bottom demonstrates the corresponding 2D OFDI images (Online Video 2). White asterisk indicates thrombus
on corresponding 2D and 3D images. MainB  main branch; other abbreviations as in Figures 1 and 4.
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APPENDIX
For supplementary videos, please see the online version of this article.
Figure 7. Provisional T-Stenting: The Principle of Recrossing the Coronary Wire (After MainB Stenting) Into the SideB Through the Most Distal Cell
Progressive downstream fly-through views culminating in the endoluminal point of view being located at the carina (A to C). White arrow indicates the most
distal cell where the coronary wire would be recommended to be passed; yellow arrows indicates the parallel courses of the left circumflex coronary artery
(LCx) and obtuse marginal (OM) vessels at their point of divergence. Abbreviations as in Figures 5 and 6.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 4 , N O . 8 , 2 0 1 1 Farooq et al.
A U G U S T 2 0 1 1 : 9 2 1 – 3 1 3D FD-OCT Imaging of the Coronary Bifurcation
931

Chapter 4.2
Unravelling the complexities of the coronary 
bifurcation: is this raising a few eyebrows?
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The coronary bifurcation has long proven to be a common but 
challenging lesion subset that the interventional cardiologist must 
face.1-3 Despite the general consensus that the “simpler is better 
approach” to be the preferred treatment strategy1,4 –as endorsed 
by the European Bifurcation Club2– practices amongst interven-
tional cardiologists in certain bifurcation lesion subtypes differ, 
with the quote that “the simplest approach is not always the best 
approach.”1 Specifically that in selected cases an upfront 2 stent 
strategy may be preferable to the relatively simple provisional 
T-stenting approach.
Improvements to the provisional T-stenting approach are increas-
ingly being reported in the literature: these range from the pressure 
wire assessment of jailed side branches (SideB);5 the passage of the 
coronary wire into the distal cell covering the SideB ostium after 
main branch (MainB) stenting to allow for kissing balloon post-
dilatation (KBPD) and subsequent clearance of over-hanging struts 
at the SideB ostium6-10; the proximal optimisation technique (POT)2 
to best avoid SideB compromise, facilitate coronary rewiring of the 
SideB and allow for appropriate stent apposition; fluoroscopic 
based assessment of stent expansion (such as Stent Boost)11; – the 
list continues to grow…
In this issue of EuroIntervention, two important papers are added 
to the expanding literature on undertaking the provisional T-stenting 
approach. Mylotte et al12 describe the clinical application of the 
novel technique – first reported by the European Bifurcation Club 
20102 – of utilising non-compliant balloons to undertake KBPD 
after MainB stenting. The use of non-compliant balloons to perform 
KBPD would theoretically minimise balloon over-expansion (a fea-
ture of compliant balloons) in the SideB with a consequent risk of 
vessel injury/restenosis, and stent under-expansion in the MainB 
stent. The lack of a control arm and the relatively small numbers 
(n=100) in this pilot study are obvious; the authors, however, do 
demonstrate the safety and feasibility of this technique, utilising the 
low profile Hiryu (Terumo Corporation, Tokyo, Japan) non-compli-
ant balloon. The take-home message is very practical and can be 
incorporated with relative ease into clinical practice. One perhaps 
notable critique of this study is that angiographic criteria alone were 
used for assessing the need for SideB stenting – noting that only 
a quarter (27%) of cases with a residual angiographic narrowing of 
≥75% in the SideB had a functionally significant narrowing in 
a previous classic pressure wire study.5 Furthermore, the require-
ment to make an angiographic acceptable appearance of the SideB 
ostium may have driven the operators to use higher pressure bal-
loon inflations or larger size balloons, with the consequent risk of 
inducing SideB ostial dissection and the need for two stents.
It is becoming increasingly clear that further adjunctive device(s) 
may be required to assess the ostium of the SideB. Two-dimensional 
axial intravascular ultrasound (IVUS), optical coherence tomography 
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(OCT) and pressure wire assessment have all proven feasible.5,6,13-15 
Furthermore, in this issue of EuroIntervention, Suárez de Lezo et 
al16 elegantly demonstrate the use of longitudinal IVUS studies to 
describe the ‘eyebrow’ sign, “a powerful predictor of ostial SideB 
damage after stent implantation in the MainB in bifurcation coro-
nary lesions without plaque involving the SideB.”
Article see p 1147
The eyebrow sign is impressively illustrated in the figures 
accompanying the paper. The concept being that MainB stenting 
during the provisional T-stenting approach can lead to carina shift 
and pinching of the SideB ostium, with subsequent SideB com-
promise. Furthermore, when KBPD is performed, the authors 
demonstrate the repositioning – “endoluminal displacement” – of 
the carina so that the SideB is no longer compromised. The 
authors use the term “damage” to describe the eyebrow phenom-
enon which is helpfully defined as “an increase of the percentage 
of ostial stenosis by QCA ≥30%”. Further adding to this novel con-
cept is that plaque located at the carina –which most often can 
occur when it grows from the opposite lower shear stress wall to the 
higher shear stress carina17– was significantly less likely to be asso-
ciated with the eyebrow sign. Presumably, the presence of more 
fibro-calcific plaque on the carina would make it more resistant to 
expansion and, subsequently, at a reduced risk of carina shift.
The authors then continue by  associating the presence of the 
eyebrow sign with shallower bifurcation angles, and the lack of the 
eyebrow sign with a more perpendicular bifurcation angle (62°±23° 
vs. 76°±24° respectively, p<0.05). These absolute values of the 
bifurcation angle, although statistically supportive of this concept, 
should be viewed as a guide given the lack of 3-dimensional quan-
titative coronary angiography, which would have improved the 
accuracy of the SideB angulation measurements.18,19
Yet when we interpret the results of this study and its implica-
tions for clinical practice, can we now be sure we fully understand 
the mechanisms of SideB closure? Not until recently has the con-
cept of carina shift as the predominant mechanism of SideB closure 
been widely accepted, with the previously long-held view that the 
so-called “snow-plough” effect, secondary to plaque shift, being 
the main aetiology. The latter does still occur, but to a substantially 
lesser degree than previously thought,1,5,14,17,20,21 and rarely in this 
reported study by Suárez de Lezo et al16.
3D-OCT
Recently 3-dimemsional OCT has demonstrated the potential 
application in improving our understanding of coronary bifurca-
tions and the effects of the provisional T-stenting approach.9,22-24 
Firstly, a proposal of classification was made based on the num-
ber of compartments the SideB orifice was divided into by the 
jailed stent struts.24 Secondly, hypotheses based on 3-OCT 
reconstructions during the provisional T-stenting approach were 
made, introducing concepts such as “parallel” (Figure 1) and 
“perpendicular” (Figure 2) bifurcations related to the SideB 
angulation with the MainB.9,22,23 The results of Suárez de Lezo et 
al16 further add to the evidence supporting these hypotheses. The 
eyebrow sign is related to shallower bifurcation angles, and fits 
into the concept of a parallel bifurcation, where the origin of the 
MainB and SideB take off parallel to each at the carina (Fig-
ure 1) until the SideB undergoes a change of direction. Conse-
quently, MainB stenting in a parallel bifurcation may compromise 
the SideB (with the resultant eyebrow sign), whereas with the 
perpendicular bifurcation (Figure 2) this may not be so apparent 
because of the differing appearances of the carina. In support of 
this hypothesis are studies associating smaller bifurcation angles 
with more carina shift.15,25-27 The implications of these findings 
may be that by simply assessing the bifurcation angle with QCA, 
a prediction could be made through which SideB may be at risk 
of carina shift and compromise, and thus need protecting with 
a coronary wire.
One interesting observation of the coronary bifurcation on 
3D-OCT is the ellipsoid or oval appearances of the SideB opening, 
which is especially notable in the illustrated LAD diagonal bifurca-
tion (Figure 2), and appears to be evident in most bifurcations, espe-
cially after MainB stenting.9,15,30 This observation perhaps warrants 
closer attention given the lack of any association between QCA and 
ostial SideB “lesions”.5,28,29,31 Once again, 3D-OCT may hold the 
answers to explaining this apparent paradox. It may be hypothesised 
that during coronary angiography, the plane of the angiography cuts 
the SideB in the narrower segment of the ellipsoid opening (which 
would be more likely to occur) rather than the longer segment given 
its oval shape, consequently the impression of angiographic SideB 
compromise is erroneously visualised.
Further adding to the potential appeal of 3D-OCT is the principle 
of passing the coronary wire into the distal cell of the struts cover-
ing the SideB after MainB stenting, during the provisional T-stenting 
approach. This is to reduce the likelihood of causing multiple 
malapposed struts if the coronary wire is passed into the more prox-
imal cells and KBPD performed as illustrated (Figure 3). If the cor-
onary wire is passed into the most distal cell, then KBPD would 
subsequently displace the struts covering the SideB ostium so that 
they opposed the SideB vessel wall opposite the carina (akin to the 
“skirt” technique30).
In addition, 3D-OCT may potentially allow for the visualisation 
of the final result after a 2-stent bifurcation stent approach. This 
may guide the need for passage of the coronary wire into the appro-
priate cell to allow for further post-dilatation to clear any malap-
posed struts, guide the size of the angioplasty balloons needed to 
clear malapposed struts and ensure adequate ostial expansion, even 
if KBPD had already been performed as illustrated (Figure 4).
The technology of 3D-OCT is rapidly progressing. If features like 
real-time 3D-OCT to allow for its immediate use in the catheterisa-
tion laboratory to assess the results of the bifurcation intervention, the 
introduction of quantitative measurements to allow for a more objec-
tive assessment of the SideB ostium and the need for further interven-
tion, then the potential for the research and clinical application of 
3D-OCT would be very promising.22 Perhaps then, 3D-OCT may be 
seen more as an important adjunctive tool in the catheterisation labo-
ratory, rather than an instrument to create visually appealing images.
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Figure 1. Principle of a “parallel bifurcation”. Downstream (proximal to distal) fly-through view of the right coronary artery (RCA) – right 
ventricular (RV) branch bifurcation (upper image). Note the characteristics of the carina interposed between the parallel origins of the MainB and 
SideB. Further note the progressive more perpendicular endoluminal views of the RV branch opening (middle image: numbers 1-4) culminating in 
the almost apparent concealment of the RV branch opening behind the proximal rim of the carina. With more retrograde endoluminal views (middle 
image: numbers 5-6), this leads to the apparent “disappearance” of the RV branch opening. The bifurcation angle is 57° on the corresponding 
3-dimensional QCA (CAAS 5.9, Pie Medical Imaging, Maastricht, The Netherlands) (lower images). Longitudinal and cross-sectional 2D OCT 
images of the bifurcation, with a blue arrow superimposed on it are used to orientate the reader within the vessel – the base and direction of the blue 
arrow indicates from and in which direction respectively the 3D image is visualised from in 2D plane(s). Adapted and reproduced from Farooq et al.9 
(with kind permission from Elsevier)
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Figure 2. Principle of a “perpendicular bifurcation”. The take-off the SideB (diagonal vessel) from the MainB (left anterior descending 
artery - LAD) originates perpendicular to the LAD at the point of divergence of both vessel origins, with a bifurcation angle of 85° demonstrated 
on 3-dimensional QCA.19 A downstream fly-through view (proximal to distal) of the LAD (upper right image) demonstrates the diagonal vessel 
opening (asterisked), note the elliptical shape of the vessel opening and the observation that the diagonal vessel opening is fully visible, and not 
concealed by the carina, when visualised perpendicular to the vessel wall (lower right image). Reproduced from Farooq et al.9 *indicates 
diagonal branch, ~ small diagonal branch, # septal branch.
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Objectives This study sought to investigate the impact of left main coronary artery (LMCA)
3-dimensional (3D) bifurcation angle (BA) parameters on 5-year clinical outcomes of patients
randomized to LMCA percutaneous coronary intervention (PCI) in the SYNTAX (Synergy Between
Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) trial.
Background BA can affect outcome after bifurcation PCI; 3D angiographic analysis provides reliable
BA measurements.
Methods The diastolic distal BA (between left anterior descending and left circumflex) and its systolic-
diastolic range were explored. A stratified post-hoc survival analysis was performed for 5-year major
adverse cardiac and cardiovascular events (MACCE) (all-cause death, cerebrovascular accident,
myocardial infarction, or repeat revascularization), a safety endpoint (all-cause death, cerebrovascular
accident, or myocardial infarction), and repeat revascularization. Analysis was performed in patients
where 3D BA was available pre- and post-PCI.
Results Of 266 patients eligible for analysis, 185 underwent bifurcation PCI (group B); 1 stent was
used in 75 patients (group B1), whereas �2 stents were used in 110 patients (group B2). Stratification
across pre-PCI diastolic distal BA tertiles (<82�, 82� to 106�, �107�) failed to show any difference in
MACCE rates either in the entire study population (p ¼ 0.99) or in group B patients (p ¼ 0.78). Group B
patients with post-PCI systolic-diastolic range <10� had significantly higher MACCE rates (50.8% vs.
22.7%, p < 0.001); repeat revascularization and safety endpoint rates were also higher (37.4% vs.
15.5%, p ¼ 0.002, and 25.4% vs. 14.1%, p¼0.055, respectively). Post-PCI systolic-diastolic range <10�
was an independent predictor of MACCE (hazard ratio: 2.65; 95% confidence interval: 1.55 to 4.52;
p < 0.001) in group B patients.
Conclusions A restricted post-procedural systolic-diastolic distal BA range resulted in higher 5-year
adverse event rates after LMCA bifurcation PCI. Pre-PCI BA value did not affect the clinical
outcome. (J Am Coll Cardiol Intv 2013;6:1250–60) ª 2013 by the American College of Cardiology
Foundation
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Conclusions A restricted post-procedural systolic-diastolic distal BA range resulted in higher 5-year
adverse event rates after LMCA bifurcation PCI. Pre-PCI BA value did not affect the clinical
outcome. (J Am Coll Cardiol Intv 2013;6:1250–60) ª 2013 by the American College of Cardiology
Foundation
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Percutaneous coronary intervention (PCI) for unprotected
left main coronary artery (LMCA) disease is emerging as
a reasonable treatment option alternative to coronary artery
bypass graft surgery, especially when concomitant coronary
artery disease is limited and comorbidities are present (1,2).
Data from major randomized trials (3–7) and many regis-
tries have led to the upgrade of PCI as a means of revas-
cularization for LMCA ostial and/or shaft stenosis to a class
IIa recommendation. However, bifurcation LMCA PCI was
assigned a class IIb recommendation; it was deemed to be of
considerably higher risk for adverse clinical outcomes than
surgery (1,2). Issues such as the choice of (drug-eluting)
stent, the number of stents used and individual techniques,
SYNTAX (Synergy Between Percutaneous Coronary
Intervention With Taxus and Cardiac Surgery) score, and
plaque distribution have all been addressed (8). However,
whereas the impact of bifurcation angle (BA) on immediate
post-procedural and especially the long-term outcome has
been studied in non-LMCA lesions (9–11), its relation to the
LMCA PCI is unclear. The studies reporting on this subject
were largely on the basis of BA measurements derived from
2-dimensional (2D) quantitative coronary angiography
(QCA) and therefore were prone to error; moreover, these
studies had a small sample size and/or limited outcome
data (12–14).
We have previously explored the 3-dimensional (3D)
QCA-based distribution of the LMCA BA variables (dia-
stolic and systolic values, pre- and post-PCI) in a report on
the basis of patients that were randomized to PCI in the
context of the SYNTAX trial; furthermore, we have
provided 12-month outcome data stratified across the distal
BA tertile values (15). At that time, the analysis did not
show enough evidence to support 3D BA as a potential
predictor of outcome; however, there was a weak trend
indicating higher adverse event rates in patients with wider
distal LMCA angles when �2 stents were implanted in the
LMCA bifurcation. Now having 5-year outcome data
available (16), we investigate once more the topic to attempt
to get conclusive evidence on the impact of 3D BA on very
long-term outcome after LMCA PCI and, if possible, to
gain insight into the possible mechanisms whereby this
effect is mediated.
Methods
Study population. This is a substudy of the SYNTAX trial
(4), which was a randomized, prospective, multicenter,
all-comers clinical trial with the overall goal of assessing
the optimum revascularization treatment for patients
with de novo 3-vessel disease or LMCA disease (either
isolated or in combination with 1-, 2-, or 3-vessel disease).
Patients (N ¼ 1,800) amenable to either treatment option
were randomized to PCI with polymer-based, paclitaxel-
eluting Taxus Express (Boston Scientific Corporation,
Natick, Massachusetts) stents or coronary artery bypass
graft surgery; they were also stratified according to the
presence or absence of LMCA disease. For the purpose of
this study, we reviewed the cineangiograms of the 354
patients who actually underwent PCI of the LMCA stem
(5). Patients with both distal
and nondistal LMCA lesions
were evaluated; the ones in
whom 3D angiographic recon-
struction could be performed to
derive the LMCA BA parame-
ters both pre- and post-proce-
dure constituted our original
study population (Fig. 1) (15).
This study was not pre-specified
in the SYNTAX trial protocol
and was not subsidized by the
official sponsor of the trial,
Boston Scientific Corporation.
Nevertheless, previous permis-
sion was sought and granted by
the steering committee to access
and analyze this dataset.
Treatment. Procedures were
performed according to local
practice and at the investigator’s
discretion. In the Taxus arm,
clopidogrel was mandated for at least 6 months after the
procedure, whereas patients were advised to maintain aspirin
therapy indefinitely. Recommended procedural techniques
included complete coverage of lesions with stent overlapping
(where required) at both margins byw4 mm and use of final
kissing balloons inflation after bifurcation stenting (5).
Endpoints and definitions. The primary endpoint of the
SYNTAX trial was a composite of major adverse cardiac and
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Abbreviations
and Acronyms
BA = bifurcation angle
CI = confidence interval(s)
HR = hazard ratio(s)
LMCA = left main coronary
artery
MACCE = major adverse
cardiac and cardiovascular
events
MI = myocardial infarction
PCI = percutaneous coronary
intervention
QCA = quantitative coronary
angiography
SB = side branch
SDR = systolic-diastolic
range
2D = 2-dimensional
3D = 3-dimensional
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cardiovascular events (MACCE) (all-cause death, cere-
brovascular accident, myocardial infarction [MI], or repeat
revascularization) throughout the 12-month period following
treatment allocation. Definitions of clinical events have been
previously described in detail (4,17). All adverse events were
adjudicated by an independent clinical events committee;
stent thrombosis has been adjudicated according to the study
protocol. Patient follow-up has been conducted on an annual
basis until 5 years after treatment allocation.
Angiographic analysis. 3D reconstruction was performed
offline by 2 experienced operators (C.G. and Y.O.), who
were blinded to individual patient data and clinical outcome,
with a validated program for 3D QCA (CardiOp-B system,
version 2.1.0.151, Paieon Medical Ltd., Rosh Ha’ayin,
Israel). The distal BA was measured between the left ante-
rior descending and the left circumflex coronary arteries
designated as the distal main vessel and the side branch
(SB), respectively; 3D reconstructions were performed at
end diastole and end systole, both pre- and post-procedure.
In this study, the diastolic distal BA and its systolic-diastolic
range (SDR) were explored pre- and post-procedure. The
latter variable (SDR) was defined as the absolute difference
between diastolic and systolic distal BA values. On occasion,
systolic values exceeded the diastolic ones; however, only
absolute (positive) terms were studied. To prospectively
grade the complexity of coronary artery disease, the
Angiographic Core Laboratory (Cardialysis BV, Rotterdam,
the Netherlands) scored the angiograms according to the
SYNTAX score algorithm (18). LMCA bifurcation lesion
type was adjudicated according to Medina; [1,1,1], [1,0,1],
and [0.1,1] lesion types are summarily called true bifurcation
lesions. Because the staff of the angiographic core laboratory
was blinded to site information, adjudicated lesions for the
SYNTAX score derivation could not be matched between
core laboratory and site; we chose to report bifurcation type
per site to be concordant with the choice of stenting
technique.
Study design. Tertile and/or median values of the afore-
mentioned angulation variables were used to stratify clinical
outcomes. Pre-procedural values were explored over the
entire study population, that is patients with nondistal
(group A) and distal LMCA PCI (group B) (Fig. 1).
However, regarding the post-procedure values and the
change in LMCA bifurcation geometry conferred by PCI, it
was deemed more meaningful to study their association with
clinical outcomes only for patients in group B, whether they
had 1 stent (group B1) or �2 stents (group B2) placed across
the LMCA bifurcation.
Statistical analysis. Statistical analysis was performed using
SPSS for Windows (version 19.0, SPSS Inc., Chicago,
Illinois). Continuous variables are expressed as mean � SD
and compared between groups by the unpaired Student
t test; paired Student t test was employed for within-group
comparisons. Categorical variables are presented as counts
and/or percentages; comparisons were performed with the
chi-square test and the Fisher exact test as appropriate.
Cumulative 5-year event rates for MACCE, a safety
composite endpoint (all-cause death, cerebrovascular acci-
dent, or MI) and stent thrombosis were calculated according
to the Kaplan-Meier method. Event rates were compared
according to the Cox proportional hazards model. Inde-
pendent predictors of 5-year MACCE, repeat revasculari-
zation, and the safety endpoint were sought among variables
significant beyond the level of p ¼ 0.10 in univariable
analysis. Potential predictors were checked for collinearity
before entering a Cox regression multivariable backward
stepwise model; variables with a variance inflation factor
>2.5 were disqualified. Crude and adjusted hazard ratios
(HRs) and corresponding 95% confidence intervals (CIs)
are reported for qualifying variables. All statistical tests were
2-sided and a p value of <0.05 was considered statistically
significant.
Results
Five-year clinical follow-up was attained for 259 (97.4%)
patients (median: 1,826 days, range: 4 to 2,082 days); 7
patients were lost to follow-up and were censored at days
389, 1,105, 1,442, 1,462, 1,462, 1,473, and 1,489,
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Figure 1. Flow Diagram Indicating the Entire Study Population Synthesis
and Subgroups
Out of the entire randomized study population of 1800 patients, 354 patients
actually underwent PCI of the LMCA stem; however, 3D angiographic recon-
struction could be performed both pre- and post-PCI in only 266 patients.
Thereof, 185 patients underwent distal LMCA PCI, wherein 2 stents or more
were placed in 110 patients. LMCA ¼ left main coronary artery;
PCI ¼ percutaneous coronary intervention; pts ¼ patients; SYNTAX ¼ Synergy
Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery;
3D ¼ 3-dimensional.
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respectively. The baseline characteristics of the study pop-
ulation are shown in Table 1 stratified according to LMCA
lesion location and bifurcation stenting technique (1 or �2
stents). Compared with group A patients, in group B
patients, coronary artery disease was significantly more
extensive as indicated by the increased SYNTAX score (32.6
� 13.5 vs. 23.5 � 10.5, p < 0.001) and percentage of
patients with LMCA plus 2- or 3-vessel disease (81.6% vs.
42.0%, p < 0.001). Complete revascularization rates were
comparable between groups A and B (67.9% vs. 64.3%, p ¼
0.68); 3.0 � 1.9 stents with a total length of 51.0� 39.0 mm
were used in the former, whereas 4.2� 2.4 stents with a total
length of 77.7 � 47.9 mm were used in the latter (p < 0.001
for both).
Complex stenting techniques were applied to patients
with more complex bifurcation disease; 85 of 108 true
bifurcation lesions were treated with �2 stents (Table 2).
However, in 19 cases of a [1,1,1] bifurcation lesion, provi-
sional T stenting was performed; in 14 of these cases, the
procedure was finished with a kissing balloon inflation.
Overall, final kissing balloon inflation was employed more
frequently after complex bifurcation stenting (p < 0.001).
BA variables. Angulation variables for patients with LMCA
bifurcation PCI are shown in Table 3. There is a significant
post-procedural decrease in the diastolic distal BA (D¼
�6.3�, p < 0.001), whereas SDR is only slightly decreased
(D ¼ �0.5�, p ¼ 0.50). On average, SDR is slightly
increased after single-stenting (D ¼ 0.7�, p ¼ 0.45), whereas
moderately decreased by complex stenting (D ¼ -1.3�,
p ¼ 0.17); however, direction and extent of change vary
significantly among 2-stent techniques (p < 0.01) (Fig. 2).
Impact on outcome. Stratification across pre-PCI diastolic
distal BA tertiles (<82�, 82� to 106�, �107�) failed to show
any difference in MACCE rates either in the entire study
population (37.1%, 37.7%, and 35.6%, respectively,
p ¼ 0.99), or in group B patients (33.7%, 40.3%, and 35.6%,
respectively, p ¼ 0.78). Kaplan-Meier curves slightly
diverged for patients in group B2 (p ¼ 0.41), mainly due to
relatively increased safety endpoint rates for patients in the
middle tertile; this was not the case for group B1 (Fig. 3).
Repeat revascularization rates did not show any significant
differences across tertiles (p ¼ 0.42 and 0.77 for groups B1
and B2, respectively) (Fig. 3); on the other hand, there was
a strong trend for increased MI rates for patients with BA
<82� in group B2 (17.5%, 16.8%, and 0.0% for low, mid-,
and high tertiles, respectively, p ¼ 0.06) that was not seen in
group B1 (5.3%, 4.2%, and 6.6%, respectively, p ¼ 0.91).
Stratification across post-PCI diastolic distal BA tertile
values (<79�, 79� to 98�, �99�) did not show any significant
difference in MACCE rates in group B (37.1%, 31.0%, and
42.0%, respectively, p ¼ 0.29). There was a trend for
increased safety endpoint rates in patients in the third tertile
(13.5%, 17.7%, and 27.7% for low, mid-, and high tertiles,
respectively, p ¼ 0.12); however, this was not the case for
Table 1. Baseline Clinical Characteristics in Patients With LMCA PCI (n ¼ 266)
Nondistal LMCA
Group A, (n ¼ 81)
Distal LMCA
Group B, (n ¼ 185) p Value
Distal 1 Stent
Group B1, (n ¼ 75)
Distal �2 Stents
Group B2, (n ¼ 110) p Value
Age, yrs 64.9 � 9.4 65.3 � 10.0 0.76 64.2 � 10.3 66.1 � 9.7 0.21
Male 54 (66.7) 142 (76.8) 0.10 61 (81.3) 81 (73.6) 0.29
BMI, kg/m2 28.3 � 5.2 28.1 � 4.9 0.72 28.0 � 4.7 28.2 � 5.1 0.81
Diabetes mellitus 22 (27.2) 41 (22.2) 0.43 15 (20.0) 26 (23.6) 0.59
Hypertension 55/79 (69.6) 126 (68.1) 0.89 52 (69.3) 74 (67.3) 0.87
Hyperlipidemia 65 (80.2) 149 (80.5) 1.00 59 (78.7) 90 (81.8) 0.71
Current smoker 18 (22.2) 36 (19.5) 0.62 19 (25.3) 17 (15.5) 0.13
Prior myocardial infarction 25 (30.9) 47 (25.5) 0.37 20 (26.7) 27 (24.8) 0.86
Unstable angina 25 (30.9) 54 (29.2) 0.77 21 (28.0) 33 (30.0) 0.87
LVEF <30% 1 (1.2) 4 (2.2) 1.00 3 (4.0) 1 (0.9) 0.31
Prior TIA 5 (6.2) 9 (4.9) 0.77 3 (4.0) 6 (5.5) 0.74
Creatinine >200 mmol/l 0 (0.0) 5 (2.7) 0.33 2 (2.7) 3 (2.7) 1.00
Emergent revascularization priority 3 (3.7) 5 (2.7) 0.70 0 (0.0) 5 (4.5) 0.08
Additive EuroSCORE 3.7 � 2.3 3.8 � 2.9 0.79 3.6 � 3.1 4.0 � 2.8 0.39
SYNTAX score* 23.5 � 10.5 32.6 � 13.5 <0.001 30.6 � 12.4 34.0 � 14.1 0.10
Lesion number 2.6 � 1.6 3.0 � 1.8 0.23 3.1 � 1.7 2.9 � 1.8 0.76
Isolated LMCA 20 (24.7) 12 (6.5) <0.001 5 (6.7) 7 (6.3) 1.00
LMCA þ 1 vessel 27 (33.3) 22 (11.9) <0.001 13 (17.3) 9 (8.2) 0.07
LMCA þ 2 vessels 20 (24.7) 86 (46.5) 0.001 32 (42.7) 54 (49.1) 0.45
LMCA þ 3 vessels 14 (17.3) 65 (35.1) 0.003 25 (33.3) 40 (36.4) 0.75
Values are mean � SD or n (%). *Calculated by the core laboratory.
BMI ¼ body mass index; EuroSCORE ¼ European System for Cardiac Operative Risk Evaluation; LMCA ¼ left main coronary artery; LVEF ¼ left ventricular ejection fraction; PCI ¼ percutaneous coronary
intervention; SYNTAX ¼ Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery; TIA ¼ transient ischemic attack.
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repeat revascularization rates (31.5%, 23.5%, and 23.8%,
respectively, p ¼ 0.55).
Systolic-diastolic BA range both pre- and post-procedure
had a median value of 10�. There was no significant
difference in MACCE rates for patients in group B with
pre-PCI SDR �10� (40.6% vs. 32.5%; HR: 1.25; 95% CI:
0.77 to 2.02; p ¼ 0.37). Conversely, patients with post-PCI
SDR <10� showed significantly higher MACCE rates for
group B (50.8% vs. 22.7%; HR: 2.65; 95% CI: 1.58 to 4.44;
p < 0.001), group B1 (46.9% vs. 16.4%; HR: 3.47; 95% CI:
1.41 to 8.55; p ¼ 0.01) and group B2 (52.8% vs. 28.0%;
HR: 2.16; 95% CI: 1.15 to 4.07; p ¼ 0.02). The event rates
for all different endpoints for the entire group B are reported
in Table 4 stratified across the post-PCI SDR median value.
Moreover, in both subgroups, higher event rates were
recorded for patients with post-PCI SDR <10� regarding
repeat revascularization (p ¼ 0.07 and 0.02 for groups B1
and B2) and the safety endpoint (p ¼ 0.08 and 0.35 for
groups B1 and B2) (Fig. 4). Finally, group B patients with
even minimally increased SDR post-procedure (DSDR ¼
post-PCI SDR minus pre-PCI SDR) showed significantly
lower MACCE rates (28.6% vs. 43.9%; HR: 0.60; 95% CI:
0.37 to 0.99, p ¼ 0.045), compared with patients with
DSDR �0.
Stent thrombosis. Per protocol, stent thrombosis was adju-
dicated in 13 patients in the entire study population (4.9%).
Of those 13, 9 had LMCA bifurcation PCI (4.9%); thereof
8 belonged to group B2. Among these 9 patients, 5 events
occurred early (�30 days), 1 event late (day 318), and 3
events very late (days 598, 835, and 1,594). If stratified
across diastolic distal BA, there was a trend for higher stent
thrombosis rates in the lowest angle tertiles (8.5%, 5.4%, and
1.6%, p ¼ 0.23, and 8.5%, 3.5%, and 3.3%, p ¼ 0.33, pre-
and post-PCI, respectively); however, difference was mainly
driven by early events (3 events each in the lowest angle
tertiles). There was also a trend for higher event rates for
patients with narrower post-PCI SDR (8.0% vs. 2.2%; HR:
3.75; 95% CI: 0.78 to 18.2, p ¼ 0.10) (Table 4), which
reflected a similar trend among group B2 patients with post-
PCI SDR <10� (12.2% vs. 2.0%; HR: 6.21; 95% CI: 0.77
to 50.0, p ¼ 0.09).
Multivariable analysis. In group B, next to a post-PCI SDR
of the distal BA <10�, a number of variables were signifi-
cantly associated with or showed a strong trend for (p < 0.10
in univariable analysis) higher MACCE rates (Table 5).
Total stent length was eliminated from analysis due to
collinearity with the total number of stents. The narrow
post-PCI SDR emerged as an independent predictor of
MACCE (HR: 2.65; 95% CI: 1.55 to 4.52, p < 0.001) next
to poor left ventricular ejection fraction (HR: 7.53; 95% CI:
2.63 to 21.6, p < 0.001) and the total number of stents
placed in a patient (HR: 1.13; 95% CI: 1.03 to 1.24,
p < 0.01). Following a similar analysis, a narrow post-PCI
SDR independently predicted increased rates for both repeat
revascularization (HR: 2.39; 95% CI: 1.26 to 4.52,
p < 0.01) next to the total number of stents (HR: 1.16; 95%
CI: 1.05 to 1.29, p < 0.01) and for the safety endpoint
(HR: 2.06; 95% CI: 1.03 to 4.12, p ¼ 0.04) next to previous
MI (HR: 2.93; 95% CI: 1.50 to 5.71, p < 0.01) and poor
left ventricular ejection fraction (HR: 4.78; 95% CI: 1.37 to
16.6, p ¼ 0.01).
Discussion
The following are the main findings of this study. 1) The
pre-procedural 3D QCA-derived diastolic distal BA of the
Table 2. Baseline Angiographic and Procedural Characteristics for
Patients With LMCA Bifurcation PCI (n ¼ 185)
Distal 1 Stent
Group B1,
(n ¼ 75)
Distal �2 Stents
Group B2,
(n ¼ 110) p Value
Bifurcation type per LMCA lesion <0.001
Medina 1,1,1 19 (25.3) 71 (64.5) <0.001
Medina 1,1,0 21 (28.0) 8 (7.3) <0.001
Medina 1,0,1 4 (5.4) 14 (12.7) 0.13
Medina 1,0,0 31 (41.3) 17 (15.5) <0.001
True bifurcation lesions 23 (30.7) 85 (77.3) <0.001
Nontrue bifurcation lesions 52 (69.3) 25 (22.7) <0.001
Bifurcation stenting technique N/A
Provisional T-stenting 75 (100.0) 0 (0.0)
Classic T-stenting,
main vessel first
0 (0.0) 36 (32.7)
Classic T-stenting,
side branch first
0 (0.0) 12 (10.9)
Modified T-stenting 0 (0.0) 6 (5.5)
Crush technique 0 (0.0) 18 (16.4)
Culotte technique 0 (0.0) 23 (20.9)
V stenting, kissing stents 0 (0.0) 13 (11.8)
Y stenting, touching stents 0 (0.0) 2 (1.8)
Final kissing balloon inflation 46 (61.3) 97 (88.2) <0.001
Complete revascularization 54 (72.0) 65 (59.1) 0.09
Total stents per patient 3.5 � 2.2 4.8 � 2.4 <0.001
Total stent length per
patient, mm
65.4 � 43.1 86.1 � 49.4 0.004
Values are n (%) or mean � SD.
N/A ¼ not applicable; other abbreviations as in Table 1.
Table 3. BA Variables for Patients With LMCA Bifurcation PCI
Distal 1 Stent
Group B1,
(n ¼ 75)
Distal �2 Stents
Group B2,
(n ¼ 110) p Value
Pre-PCI distal BA, diastolic � 99.2 � 23.7 93.3 � 23.3 0.10
Post-PCI distal BA, diastolic � 92.7 � 21.2 87.2 � 21.2 0.09
Pre-PCI SDR � 11.0 � 7.1 11.1 � 8.8 0.92
Post-PCI SDR � 11.7 � 7.8 9.8 � 7.6 0.12
Values are mean � SD.
BA ¼ bifurcation angle; SDR ¼ systolic-diastolic range (of distal BA); other abbreviations as in
Table 1.
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LMCA bifurcation could not predict long-term clinical
outcomes after PCI for LMCA coronary artery disease.
Even when patients with LMCA bifurcation PCI were
examined separately, there was still no significant impact of
this parameter on long-term clinical outcomes. 2) A narrow
(<10�) post-PCI systolic-diastolic range of this angle was
shown to be significantly associated with worse 5-year
clinical outcomes in patients undergoing LMCA bifurcation
PCI. Adjusted for various clinical, angiographic (including
extent of concomitant disease), and procedural variables, it
still proved an independent predictor of 5-year MACCE.
To our knowledge, this is the first study ever to report on
such long-term clinical outcomes of LMCA PCI stratified
across BA parameters exclusively derived from 3D angio-
graphic bifurcation analysis. The relative merits of 3D
angiography have already been stressed (15); regarding the
BA derivation, 3D angiographic analysis is of apparent
importance as the bifurcation is a 3D structure, and there-
fore its maximal opening can be accurately appreciated only
in a 3D space (19). Moreover, on the basis of a phantom
validation study, 3D QCA has recently been shown to
provide more accurate and precise BA measurements than
2D software does (20).
Effect of SDR. The idea that a decreased post-PCI systolic-
diastolic range of movement of the LMCA (or any) bifur-
cation is associated with higher event rates may on first
p
ri
n
t
&
w
e
b
4
C
=
F
P
O
Figure 2. Effect of Bifurcation Stenting on the SDR of the Distal BA
(A) Periprocedural change in systolic-diastolic range (SDR) according to the number of stents implanted. (B) Difference in SDR (DSDR ¼ post-PCI SDR – pre-PCI SDR)
according to bifurcation stenting technique. BA ¼ bifurcation angle; Mod-T ¼ modified T-stenting; PCI ¼ percutaneous coronary intervention; Prov-T ¼ provisional
T-stenting; V ¼ kissing stenting; Y ¼ touching stenting.
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inspection sound like a paradox. It would be assumed that in
the long term an increased range of torsion, flexion, and
stretching of any metallic structure would lead to metal
fatigue and eventually strut fracture (21,22). The premise we
are making is the same, only seen in a different perspective.
The diminished range of movement after the procedure,
even more pronounced after complex stenting (Fig. 2),
implies that the bifurcation has been “stiffened” by the stents
and forced into an unnatural configuration. Therefore, the
myocardium and hence the epicardial coronary arteries strive
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Figure 3. Impact of Pre-PCI Diastolic Distal BA on 5-Year MACCE, All-Cause Death, CVA, or MI (Safety Endpoint), and Repeat Revascularization
Kaplan-Meier curves shown for group B1 (A, C, E) and group B2 (B, D, F). CVA ¼ cerebrovascular accident; HR ¼ hazard ratio; LMCA ¼ left main coronary artery;
MACCE ¼ major adverse cardiac and cardiovascular events; MI ¼ myocardial infarction; other abbreviations as in Figures 1 and 2.
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to revert to the previous geometry (23,24), thereby exerting
increased and repetitive strain on the metallic scaffolds. It
has been reported that the Taxus Express metallic platform
is not prone to strut fractures at least to the same extent as
the Cypher stent (Cypher, Cordis, Johnson and Johnson
Corporation, Miami, Florida) (22). This has been attributed
to the Taxus Express open-cell design, which is said to
enhance its conformability around bends (23) as well as to its
diminished radiopacity, which makes fractures more difficult
to detect angiographically. Stent strut fractures have been
mostly explored in straight vessel segments; even there, high
vessel tortuosity and excessive vessel angulation during the
heart cycle were reported to be precipitating factors (24–26),
especially in the presence of long overlapping stents. Even
so, stent strut fractures seldom translate into stent throm-
bosis, MI, or sudden death (22), but rather in a hinge
motion associated with in-stent restenosis (26); however,
when seen in the context of the LMCA bifurcation,
otherwise occult restenotic lesions could very well lead to
catastrophic outcomes.
Effect of distal BA. Intuitively, the distal BA has been
associated with the risk of SB occlusion during stent
implantation in the main vessel (27); a shallow distal BA
makes a carina shift more probable, thereby resulting in
considerable residual stenosis (28). Moreover, for BA �70�,
classic T stenting cannot fully scaffold the SB ostium
without stent struts protruding into the main vessel (29);
dedicated techniques, such as the crush and the culotte, that
fully cover the SB ostium have been developed to address
this issue. However, a shallow angle necessitates an increased
stent cell size to avoid jailing the SB ostium after the crush
or causing a napkin ring stenosis in the ostium of the distal
main vessel after a culotte. Theoretically, for BA w60�,
a distal main vessel diameter of 3 mm and an SB diameter of
2.75 mm, a stent cell diameter of w3.3 mm would be
required (30), which could be achieved with the Taxus
Express metallic stent platform (31).
Moving to steeper angles, bench studies have shown that
for BA >80�, full stent strut apposition cannot be achieved
with the crush (32,33) or the culotte techniques despite
sequential kissing balloon inflations (34); straightening of
the LMCA curvature could cause added distortion.
Thereby, gaps in support and drug application are left at the
SB ostium, which probably translate into higher adverse
event rates for highly angulated bifurcations (9–12). At
the same time, increasing BA have been associated with
decreasing lower wall shear stress values and increased
oscillatory flow at the lateral walls opposite the carina
(35,36), which facilitate plaque proliferation and eventually
restenosis; contrary to sirolimus, paclitaxel cannot modify
the effect of low wall shear stress on neointima formation
(37). Expectedly, all these phenomena are exacerbated in the
presence of multiple stent strut layers, metallic neo-carinas,
and protruding and malapposed struts.
Implementation and clinical implications. A single 3D
angiographic reconstruction of a bifurcation requires 2
adequate images 30� apart with the least possible amount of
foreshortening and vessel overlap. For a given bifurcation,
there is usually 1 optimal view, whereas in any other direc-
tion certain features, usually the SB ostium, may be
obscured; retrospective collection of 2 adequate images can
be challenging. However, new software algorithms can
retrieve missing information even from 2 suboptimal images,
whereas the optimal view, if not among the images initially
acquired, can be suggested by a provisional 3D reconstruc-
tion on the basis of 2 suboptimal views (20). Moreover,
dedicated computation algorithms implemented in com-
mercially available 2D and 3D bifurcation QCA software
allow for accurate and reproducible BA calculation; time
requirements (<10 s for reconstruction of 2 images, <60 s
for 3 images) are not an issue.
The interventional cardiologist can do little to change the
geometrical configuration of the LMCA bifurcation after
the stent implantation, as long as this is done according to
sound clinical practice facilitating free access to SB and good
stent strut apposition to the vessel wall. Our findings may
suggest a lesser degree of bifurcation stiffening with single
bifurcation stenting; however, no solid recommendation
could be issued on the basis of a single study. Nevertheless,
in those cases where a decreased post-procedural range of
movement can be manifested, there would probably be
a need for potent and prolonged platelet inhibition and
increased clinical surveillance.
Study limitations. This study was not pre-specified in the
SYNTAX trial protocol and therefore was probably under-
powered regarding the detection of a plausible effect of
pre-PCI angulation parameters on clinical outcomes. Our
analysis may have been further confounded by marked
heterogeneity in bifurcation techniques, the number of stents
used, the bifurcation type, the extent of final kissing balloon
inflation, and other unforeseen and possibly unaccounted for
periprocedural phenomena. In addition, data on mainte-
nance of dual antiplatelet therapy were not available. On the
Table 4. Five-Year Clinical Outcomes Stratified Across Post-PCI SDR in
Patients With LMCA Bifurcation PCI (Univariable Analysis)
SDR < 10�
(n ¼ 92)
SDR � 10�
(n ¼ 93) <10� vs. �10�
p
Value
MACCE 50.8 22.7 2.65 (1.58–4.44) <0.001
Death, CVA, or MI 25.4 14.1 1.95 (0.99–3.85) 0.055
Death 17.7 7.6 2.48 (1.02–6.02) 0.045
Repeat revascularization 37.4 15.5 2.70 (1.44–5.05) 0.002
MI 12.4 6.6 1.98 (0.73–5.35) 0.18
Stent thrombosis,
per protocol
8.0 2.2 3.75 (0.78–18.2) 0.10
Values are % or hazard ratio (95% confidence interval).
CVA ¼ cerebrovascular accident; MACCE ¼ major adverse cardiac and cardiovascular events;
MI ¼ myocardial infarction; other abbreviations as in Tables 1 and 3.
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other hand, per SYNTAX trial design, repeat revasculari-
zation events have not been adjudicated as to their anatomic
location (5); therefore, clinical events cannot be necessarily
ascribed to the LMCA lesion treatment. However, specifi-
cally for SDR analysis, events have been adjusted in multi-
variable analysis for individual patient characteristics,
including additional vessel disease. Finally, Medina
classification according to visual assessment is less precise in
stratifying bifurcation lesion complexity; thus, detailed
subsegmental angiographic analysis would be warranted for
a better understanding of lesion complexity and possible
association with outcomes. As already mentioned, 3D QCA
analysis was not pre-specified in the SYNTAX trial
protocol; therefore, such detailed results are not available
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Figure 4. Impact of Post-PCI SDR of the Distal BA on 5-Year MACCE, All-Cause Death, CVA, or MI (Safety Endpoint), and Repeat Revascularization
Kaplan-Meier curves shown for group B1 (A, C, E) and group B2 (B, D, F). Abbreviations as Figures 1 to 3.
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from the current analysis. Angiographic analysis including
prospective collection of BA data in the ongoing EXCEL
(Evaluation of Xience Prime Everolimus Eluting Stent
System [EECSS] or Xience V EECSS or Xience Xpedition
EECSS of Xience Pro EECSS Versus Coronary Artery
Bypass Surgery for Effectiveness of Left Main Revasculari-
zation) trial on w3,100 patients undergoing LMCA PCI
could help us shed more light on this subject.
Conclusions
This study assessed the impact of 3D distal BA parameters
on 5-year clinical outcomes after LMCA PCI on the basis of
the largest randomized trial to date. A restricted post-
procedural systolic-diastolic distal BA range translated into
significantly higher adverse event rates 5 years after LMCA
bifurcation PCI; on the contrary, pre-procedural distal BA
did not affect the long-term clinical outcomes. It is possible
that this study provides us with new insights into the
biomechanics of stent failure in bifurcation lesions, the
LMCA bifurcation being the most important of all in
the human coronary tree.
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Objectives The aim of this study was to report the short-term and long-term clinical impact of stent thrombosis (ST) and graft
occlusion (GO) in thefinal 5-year outcomesof theSYNTAX (SYNergyBetweenPCIWith TAXUSandCardiacSurgery) trial.
Background The clinical effect of newer-generation drug-eluting stents and operative factors in complex coronary artery disease
is uncertain.
Methods The incidence of 5-year ST and GO, and their association with clinical outcomes, were analyzed in the randomized
percutaneous coronary intervention and coronary artery bypass graft cohorts. ST and GO were defined by the
SYNTAX protocol definitions (clinical presentation with acute coronary syndrome and angiographic/pathological
evidence), the Academic Research Consortium (ARC) definition for ST, and the newly devised “ARC-like” definition of
GO (i.e., definite, probable, or possible GO).
Results At 5 years, 871 of 903 patients (96.5%) in the percutaneous coronary intervention cohort and 805 of 897 patients
(89.7%) in the coronary artery bypass graft cohort completed follow-up. As compared with other vessel locations,
protocol ST (72 lesions) occurred more frequently in the left main (14 of 72; 19%) and proximal coronary vasculature
(37 of 72; 51%) andprotocol GO (41 lesions) with grafts anastomosed to the distal right coronary artery (17 of 41; 42%).
The incidence of 5-year ARCdefinite ST andARC-like definite GOdid not significantly differ (7% [n¼ 48] vs. 6% [n¼ 32],
log rank p¼ 0.34); landmark analyses indicated significantly increased ARC definite ST within 30 days (3% [n¼ 19] vs.
1% [n ¼ 6], log rank p ¼ 0.033) but not>30 days to 5 years (4.2% [n ¼ 29] vs. 4.5% [n ¼ 26], log rank p ¼ 0.78). At
presentation, ARC definite ST (n ¼ 48) and ARC-like definite GO (n ¼ 32) were adjudicated to be linked to 4 (8%) and
0 deaths, respectively. At 5 years, ARC definite ST (n¼ 48) and ARC definite/probable ST (n¼ 75) were associated with
17 (17 of48, 35.4%;median days to death: 0 days; interquartile range: 0 to 16days;maximum:321days) and31 (31 of
75, 41.3%; median: 0 days; interquartile range: 0 to 9 days; maximum: 721 days) cardiac deaths, respectively. At 5
years, ARC-like definite GO (n ¼ 32) and ARC-like definite/probable GO (n ¼ 53) were associated with 0 and 12 (12
of 52, 23.1%; median: 0 days; interquartile range: 0 to 14 days; maximum: 257 days) cardiac deaths, respectively.
Conclusions Although the incidence of ST and GO was similar at 5 years, the clinical impact of ST appeared greater, with
a negative impact on short-term to long-term mortality. (J Am Coll Cardiol 2013;62:2360–9) ª 2013 by the
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The final 5-year reporting of the SYNTAX (SYNergy
Between PCI With TAXUS and Cardiac Surgery) trial
showed that coronary artery bypass graft (CABG) surgery
remained the standard of care for patients with complex (left
main or 3-vessel) coronary artery disease compared with
percutaneous coronary intervention (PCI) with first-
generation drug-eluting stents (1,2). In subjects with lesser
complex coronary artery disease undergoing PCI, using the
anatomic SYNTAX Score to assess coronary artery
complexity (3) or the SYNTAX Score augmented with
clinical factors (SYNTAX Score II), (4,5) were shown to be
an acceptable alternative to CABG.
The clinical impact of stent thrombosis (ST) and graft
occlusion (GO) in the SYNTAX trial is unreported. The
purpose of the study was to report the incidence, timing,
predictors, and clinical impact of ST and GO in the
SYNTAX trial.
Methods
The SYNTAX trial is a randomized, prospective, multi-
center, “all-comers” trial investigating subjects with un-
protected left main coronary artery (ULMCA) disease
(isolated or associated with 1-, 2-, or 3-vessel disease) or de
novo 3-vessel disease and has previously been described
(1,2). In total, 1,800 subjects were randomized on a 1:1
basis to either PCI with Taxus Express paclitaxel-eluting
stents (Boston Scientific Cor-
poration, Natick, Massachusetts)
or CABG.
An independent clinical events
committee (CEC), including car-
diologists, cardiac surgeons, and
a neurologist, reviewed all the
primary clinical endpoints and
ST/GO events. All deaths were
subdivided into cardiovascular and
noncardiovascular deaths by the
CEC. Cardiac deaths were clas-
sified as related or unrelated to
a cardiac procedure by the CEC.
STandGO. Because theSYNTAX
trial began before publication of
the Academic Research Con-
sortium (ARC) definition, (6)
the SYNTAX trial instigated
a protocol definition for ST and
GO (Table 1). Subsequently, the
ARC criteria (6) for ST were
implemented and reported by a
separate CEC (see the Acknowledgments section). To allow
comparisons of ARC ST events to GO, “ARC-like” defi-
nitions were formulated for GO (i.e., definite, probable, or
possible GO) using adapted ARC definitions (Table 1).
Table 1 SYNTAX Protocol and ARC/ARC-Like Definitions of ST and GO
Stent Thrombosis Graft Occlusion
SYNTAX protocol definition
The occurrence of any of the following:
1. Clinical presentation of acute coronary syndrome with ST confirmed by
angiography, multi-slice CT, or autopsy
a. Angiographic documentation of a complete occlusion (TIMI flow grade
0 or 1) of a previously successfully treated artery (TIMI flow gade 2 to 3
immediately after stent placement and diameter stenosis �30) and/or
b. Documentation by angiography, multi-slice CT, or autopsy of flow-limiting
thrombus or complete luminal obstruction within or adjacent to
a previously successfully treated lesion
2. Q-wave MI in the territory of one or more of the treated vessels (LAD, LCX,
RCA) within the first 30 days (acute or subacute)
SYNTAX protocol definition
The occurrence of any of the following:
1. Clinical presentation of acute coronary syndrome with GO confirmed by
angiography, multi-slice CT, or autopsy
a. Angiographic documentation of occlusion (TIMI flow grade 0 or 1) of
a vascular graft and/or
b. Documentation by angiography, multi-slice CT, or autopsy of flow-limiting
thrombus or complete luminal obstruction within a bypass graft or a flow
limiting thrombus adjacent to the anastomosis of previously bypassed
coronary artery
2. Q-wave MI in the territory of one or more of the treated vessels (LAD, LCX,
RCA) within the first 30 days (acute or subacute)
ARC definite ST
1. Angiographic or pathological confirmation of partial or total thrombotic occlu-
sion within the peri-stent region and at least one of the following additional
criteria:
a. Acute ischemic symptoms
b. Ischemic electrocardiographic changes
c. Elevated cardiac biomarkers
ARC-like definite GO*
1. SYNTAX protocol definition as stated in the preceding text
ARC probable ST
1. Any unexplained death within 30 days of stent implantation
2. Any MI that is related to documented acute ischemia in the territory of the
implanted stent without angiographic confirmation of ST
ARC-like probable GOy
1. Any unexplained death within 30 days of graft
2. Any MI that is related to documented acute ischemia in the territory of the
anastomosed graft without angiographic confirmation of GO
ARC possible ST
1. Any unexplained death beyond 30 days
ARC-like possible GOz
1. Any unexplained death beyond 30 days
*The definitions of protocol GO and ARC-like definite GO were identical. yBecause subjects had left main or de novo 3-vessel disease, it was assumed that an MI in any of the 3-vessel territories for 3-vessel
disease or the left coronary system for unprotected left main coronary artery disease without subsequent angiographic confirmation of graft patency was classified as probable GO. zARC possible GO was
identical to ARC-like possible ST.
ARC ¼ Academic Research Consortium; CT ¼ computed tomography; GO ¼ graft occlusion; MI ¼ myocardial infarction; LAD ¼ left anterior descending artery; LCX ¼ left circumflex artery; RCA ¼ right
coronary artery; ST ¼ stent thrombosis; TIMI ¼ Thrombolysis in Myocardial Infarction.
Abbreviations
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ARC-like definitions for GO were retrospectively assessed
in conjunction with the safety reporting data obtained by the
CEC.
Statistical analysis. Continuous variables are expressed
as mean � SD and binary variables as counts and/or
percentages. Time-to-event variables are presented as
Kaplan-Meier (KM) estimates and compared using the log-
rank test. Corrected KM curves were constructed by
removing the ST adjudicated clinical event from the KM
curves (7). Multivariable analyses (Cox regression) were
conducted using the baseline characteristics (Online
Appendix) and the forced enter method (entry criteria
0.05, no exit criteria). There was no departure from the
proportionality of hazards assumption using the global
proportional hazards test based on Schoenfeld residuals (8).
Variables were screened for correlation before entry into
the multivariable model, and none were sufficiently corre-
lated to warrant removal. A 2-sided p value <0.05 was
considered significant for all tests. All analyses were con-
ducted using SPSS version 20.0 (SPSS Inc., Chicago, Illi-
nois) and SAS system software version 9.2 (SAS Institute,
Cary, North Carolina).
Results
Figure 1 shows the study design and frequency of ST and
GO using the SYNTAX protocol and ARC/ARC-like
definitions. At 5 years, 871 of 903 patients (96.5%) in the
PCI cohort and 805 of 897 patients (89.7%) in the CABG
cohort completed follow-up.
Antiplatelet compliance. Use of aspirin therapy was
significantly lower after CABG compared with PCI post-
procedurally (88.5% vs. 96.3%, p < 0.001) and at 1 year
(84.3% vs. 91.2%, p < 0.001) but not at 5 years (85.0% vs.
87.1%, p ¼ 0.24). Use of thienopyridine therapy was
significantly lower for CABG post-procedurally (19.4% vs.
96.7%, p < 0.001) and at 1 year (15.0% vs. 71.1%,
p < 0.001) and 5 years (12.1% vs. 32.0%, p < 0.001). Dual
antiplatelet use at 5 years was significantly higher with PCI
compared to CABG (9.1% vs. 27.4%, p < 0.001).
Anatomic location of ST and GO at 5 years of
follow-up. Protocol ST was confirmed in 47 subjects with
72 lesions (Fig. 2). Forty-three of 47 subjects had docu-
mented protocol ST confirmed by angiography (62 lesions),
3 subjects had documented protocol ST confirmed by
Figure 1 Flow Chart
SYNTAX trial design indicating the number of GO and ST cases using the protocol and ARC/ARC-like definitions. *In the PCI arm, 871 patients remained in the study at 5 years
(11 withdrew consent and 21 were lost to follow-up/other; in the CABG arm, 805 patients remained in the study at 5 years (50 withdrew consent and 41 were lost to follow-up/
other) (1). ARC ¼ Academic Research Consortium; CABG ¼ coronary artery bypass graft; Def ¼ definite; EU ¼ Europe; GO ¼ graft occlusion; LM ¼ left main; PCI ¼ percutaneous
coronary intervention; Poss ¼ possible; Prob ¼ probable; RCT ¼ randomized controlled trial; ST ¼ stent thrombosis; US ¼ United States; 3VD ¼ 3-vessel disease.
Farooq et al. JACC Vol. 62, No. 25, 2013
Stent Thrombosis and Graft Occlusion in the SYNTAX Trial December 24, 2013:2360–9
2362
ARC-like definitions for GO were retrosp ctively ass ssed
in conjunction with the safety reporting data obt ined by the
CEC.
Statistic l an lysis. Continu us variables re expressed
as me n � SD and bi ary variables s counts and/or
percentages. Time-to-event ariables are presented as
Kaplan-Meier (KM) estimates and compared using the log-
rank test. Corrected KM curves were constructed by
removing the ST adjudicated linical event from the KM
curves (7). Multivariable ana yses (Cox regression) were
condu ted using the bas line characteristi s (Online
Appendix) and the forc d enter method (entry criteria
0.05, no exit criteria). There was no departure from the
proporti nali y of hazards assumption using the global
proporti nal hazards test bas d on Schoenfeld residuals (8).
Variables were scre ned for correlation before nt y i to
the multivariable mod l, and no e were sufficiently corre-
lated to warrant removal. A 2-sided p value <0.05 was
considered significant for all tests. All analyses wer con-
ducted sing SPSS version 20.0 (SPSS Inc., Chicago, Illi-
nois) and SAS system software version 9.2 (SAS Institute,
Cary, No th Carolina).
Results
Figure 1 shows the study design and frequency of ST and
GO using the SYNTAX protocol and ARC/ -like
definitions. At 5 years, 871 of 903 patients (96.5%) in the
PCI cohort and 805 of 897 patients (89.7%) in the CABG
cohort completed follow-up.
Antiplatelet compliance. Use of aspirin therapy was
significantly lower after CABG compared with PCI post-
procedu ally (88.5% vs. 96.3%, p < 0.001) and at 1 year
(84.3% vs 91.2%, p < 0.001) but not at 5 years (85.0% vs
87.1%, p ¼ 0.24). Use of thienopyridine therapy w s
significantly lower f r CABG post-procedurally (19.4% vs.
96.7%, p < 0.001) and at 1 year (15.0% vs. 71.1%,
p < 0.001) and 5 years (12.1% vs 32.0%, p < 0.001). Dual
antiplatelet us a 5 years was significantly higher with PCI
compared to CABG (9.1% vs 27.4%, p < 0.001).
Anatomic location of ST and GO at 5 years of
follow-up. Protocol ST was confirmed in 47 subjects with
72 lesions (Fig. 2). Forty-three of 47 subjects had docu-
mented protocol ST confirmed by angiography (62 lesions),
3 subjects had documented protocol ST confirmed by
Figure 1 Flow Chart
SYNTAX trial design in icati g the number of GO and ST cases using the protocol and ARC/ARC-like definitions. *In the PC arm, 871 patients remai ed in the study at 5 years
(11 withdrew consent and 21 were lost to fol w-up/ ther; in the CABG arm, 805 patients remai ed in the study at 5 years (50 withdrew consent and 41 were lost to fol w-up/
other) (1). ARC ¼ Academic Res arch Consortium; CABG ¼ coronary artery b pass graft; Def ¼ definite; EU ¼ Europe; GO ¼ graft occlusion; LM ¼ left main; PCI ¼ percutaneous
coronary intervention; Poss ¼ pos ible; Prob ¼ probable; RCT ¼ randomized c ntrolled trial; ST ¼ stent thrombosis; US ¼ United States; 3VD ¼ 3-vessel dis a .
Farooq et al. JACC Vol. 62, No. 25, 2013
Stent Thrombosis and Graft Occlusion in the SYNTAX Trial December 24, 2013:2360–9
2362
142 Chapter 5.1
autopsy (7 lesions), and this was not recorded in one subject
(3 lesions). Protocol ST occurred more frequently in the left
main (14 of 72; 19.4%) and proximal (37 of 72; 51.4%)
coronary vasculature.
Protocol GO was confirmed in 32 subjects with 41 lesions
(Fig. 2). All 32 subjects had documented protocol GO
confirmed by angiography (41 lesions). Protocol GO
occurred more frequently with grafts anastomosed to the
distal right coronary artery (17 of 41; 42%) compared with
other vessel locations.
ARC/ARC-like definitions of ST and GO: incidence
and timing. The incidence and timing of ARC/ARC-like
ST and ARC/ARC-like GO are shown in Figures 3 and 4.
At 5 years (KM estimates), there was no significant
difference between ARC definite ST and ARC-like
definite GO (ARC ST: 6.8% [n ¼ 48]; ARC-like GO:
5.5% [n ¼ 32]; p ¼ 0.34), ARC definite/probable ST and
ARC-like definite/probable GO (p ¼ 0.48), and ARC
definite/probable/possible ST and ARC-like definite/
probable/possible GO (p ¼ 0.69).
Landmark analyses (Fig. 4) indicated significantly more
ARC definite ST within 30 days (ARC definite ST: 2.7%
[n ¼ 19]; ARC-like definite GO: 1.0% [n ¼ 6]; p ¼ 0.033)
but not >30 days to 5 years (ARC definite ST: 4.2%
[n ¼ 29]; ARC-like definite GO: 4.5% [n ¼ 26]; p ¼ 0.78).
Comparisons of ARC definite/probable ST and ARC-
like definite/probable GO showed no significant differ-
ences at intervals of 0 to 30 days (p ¼ 0.38), 30 days to
5 years (p ¼ 0.12), and 5 years (p ¼ 0.48). Comparisons of
ARC definite/probable/ possible ST and ARC-like definite/
probable/possible GO showed no significant differences at
30 days to 5 years (p ¼ 0.33) and 5 years (p ¼ 0.69).
ARC/ARC-like definitions of ST and GO: adjudicated
clinical outcomes. ARC definite ST (n ¼ 48) was adju-
dicated by the CEC to be linked to 4 deaths (4 of 48; 8.3%),
11 myocardial infarctions (MIs) (11 of 48; 22.9%), 23 cases
of all-cause revascularization (23 of 48; 47.9%), and 10 cases
with no clinical event (10 of 48; 20.8%). Corrected KM
curves with the clinical events, adjudicated to be associated
with the ARC definition of ST by the CEC, removed are
shown (Fig. 5). Notably, removal of ARC definite/probable
ST-related events would have led to a reduction of 5.1% in
cardiac death/MI/all-cause revascularization and a 1.5%
reduction in cardiac death at 5 years.
Figure 2 Coronary Anatomic Location Sites of Protocol ST and Anastomosis Sites of Protocol GO Until 5 Years
The location of per-protocol (clinical presentation with acute coronary syndrome and angiographic/pathological evidence) ST (upper panel) and GO (lower panel) on a lesion-
level basis is shown. ST pertains to the anatomic location in coronary arteries, and GO pertains to the anastomosis site of bypass graft to native coronary arteries. Percentages
are provided, and actual numbers are stated in parentheses. *Denotes ST (listed in the CABG arm on an intention-to-treat basis). N¼ number of patients; L ¼ number of lesions;
other abbreviations as in Figure 1.
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ARC-like definite GO (n ¼ 32) was adjudicated by the
CEC to be linked to 0 deaths, 7 MIs (7 of 32; 21.9%), 21
cases of all-cause revascularization (21 of 32; 65.6%), and 4
cases with no clinical event (4 of 32; 12.5%).
Long-term cardiac mortality associated with the index
ARC/ARC-like ST/GO events. The 5-year relationship
of cardiac mortality to the index ARC ST or ARC-like GO
events is shown (Table 2). At 5 years, ARC definite ST was
associated with 17 cardiac deaths (17 of 48; 35.4%) (median
number of days to cardiac death: 0; interquartile range:
0 to 16 days; maximum: 321 days) and ARC definite/
probable ST (n ¼ 75) with 31 cardiac deaths (31 of 75;
41.3%) (median number of days to death: 0; interquartile
range: 0 to 9 days; maximum: 721 days).
Comparatively, at 5 years, ARC-like definite GO was not
associated with any deaths and ARC-like definite/probable
GO (n ¼ 53) with 12 cardiac deaths (12 of 52; 23.1%)
(median number of days to death: 0; interquartile range: 0 to
14 days; maximum: 257 days).
Multivariable predictors of the ARC definition of ST.
Table 3 shows multivariable analyses of ARC definite/
probable ST. Model 1 incorporated components of the
SYNTAX Score and clinical- and procedural-related vari-
ables. Model 2 incorporated the SYNTAX Score and
EuroSCORE. Stent length (in millimeters) and number of
stents implanted were not univariable predictors of early or
late/very late ST.
EARLY ARC ST (WITHIN 30 DAYS). The presence of ULMCA
disease was not a univariable predictor of early ARC ST
(p ¼ 0.84). Lack of post-procedural antiplatelet therapy was
the strongest independent predictor of early ST (p < 0.001),
followed by peripheral vascular disease (p ¼ 0.054), heavy
calcification (p ¼ 0.054), and prior MI (p ¼ 0.037). Both
the SYNTAX Score (p ¼ 0.086) and additive EuroSCORE
(p ¼ 0.006) were predictors of early ST.
LATE/VERY LATE ARC ST (BEYOND 30 DAYS). The presence of
ULMCA disease showed a trend toward being protective
Figure 3 Comparison of Incidence of ARC Definition ST and ARC-Like Definition of GO Until 5 Years
ARC definite, probable, and possible ST (upper panel) and ARC-like definite, probable, and possible GO (lower panel) are illustrated. Patient-level data are shown. Abbreviations
as in Figure 1.
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against late/very late ARC ST on univariable analyses (hazard
ratio: 0.61; 95% confidence interval: 0.33 to 1.12; p ¼ 0.10).
The SYNTAX Score was not a univariable predictor of late/
very late ARC ST (p ¼ 0.71). Any baseline angiographically
visible thrombus (p ¼ 0.003) and trifurcation lesion
(p ¼ 0.048) were the strongest independent predictors.
In total, 23 of 903 subjects (2.5%) in the PCI cohort
were reported to have a baseline angiographically visible
thrombus, of which 7 of 23 subjects had ARC ST beyond 30
days (ARC definite ST: n ¼ 3; ARC possible ST: n ¼ 3;
ARC probable ST: n ¼ 1). Sixty-six of 903 subjects (7.3%)
in the PCI cohort were reported to have trifurcation lesions,
of which 12 of these 66 subjects had ARC ST (ARC
definite ST: n ¼ 5; ARC probable ST: n ¼ 5; ARC possible
ST: n ¼ 2). Three of the 12 cases of ARC ST occurred
in <30 days (2 in subjects with ULMCA disease), and 7
occurred in >30 days (6 in subjects with ULMCA disease).
Multivariable predictors of ARC-like definite GO. In
the CABG cohort, double left internal mammary artery
(LIMA)/right internal mammary artery (RIMA) and
complete arterial revascularization were reported to be used
in 236 of 897 subjects (26.3%) and 161 of 897 subjects
(17.9%), respectively. On univariable analyses, double
LIMA/RIMA (hazard ratio: 0.86; 95% confidence interval:
0.35 to 2.10; p ¼ 0.74), complete arterial revascularization
(hazard ratio: 0.81; 95% confidence interval: 0.31 to 2.11;
p ¼ 0.67), and ULMCA disease (p ¼ 0.66) were not
statistically associated with a reduction in ARC-like
Figure 4 Kaplan-Meier Estimates of ARC Definition ST and ARC-Like Definition GO Until 5 Years
Five-year outcomes (upper panels) and landmark analyses at 0 to 30 days and 31 days to 5 years (lower panels) are illustrated. Log-rank comparisons between ARC and ARC-
like definitions of ST and GO are shown. Definite: *p ¼ 0.34, **p ¼ 0.033, ***p ¼ 0.78. Definite/probable: yp ¼ 0.48, yyp ¼ 0.38, yyyp ¼ 0.12. Definite/probable/possible:
zp ¼ 0.69, zzp ¼ 0.33. Abbreviations as in Figure 1.
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definite GO. Any baseline angiographically visible thrombus
(n ¼ 31) (p ¼ 0.41) was not statistically associated with
a reduction in ARC-like definite GO.
Multivariable analyses indicated that other arterial/venous
conduits (i.e., no LIMA) to the left anterior descending
artery (LAD) (p ¼ 0.050) and the number of grafts (p ¼
0.017) were independent predictors of ARC-like definite
GO (Table 3). Of subjects with ARC-like definite GO
(n ¼ 32), 8 had no LIMA to the LAD and 25 were not on
pre-procedural aspirin therapy.
Discussion
In this post-hoc study of the randomized, all-comers
SYNTAX trial, the main findings were as follows. First,
although the incidence of ST and GO at 5 years was similar
using the ARC/ARC-like definitions, the clinical impact of
ST appeared greater, with a negative impact on short-term
to longer-term mortality. Second, independent predictors
of ST and GO were diverse and related to anatomic or
procedural- or clinical-related factors.
Stent thrombosis. The findings of ST in the SYNTAX
trial are notable in that early (<30 days) and late/very late
ARC definite ST (>30 days) were associated with short-
term and long-term mortality. It is important to empha-
size that the actual causes of death are multifactorial and not
easily directly attributed to ST. For example, although lack
of post-procedural antiplatelet therapy was the strongest
independent predictor of ST (Table 3), a recent substudy of
the SYNTAX trial showed that this was of multifactorial
origin (9). Factors precluding antiplatelet administration
were reported to include gastrointestinal bleeding, retro-
peritoneal bleeding from procedure-related femoral vascular
access, coronary perforation, or following surgical bailout for
PCI-related complications. Consequently, directly attrib-
uting ST to mortality is difficult, although it is clear there
was a strong causal link.
In addition, ST most frequently occurred in the left main
and proximal vasculature (>70% of cases). Accordingly, the
impact of ST on mortality is not only related to the
acute consequences of abrupt closure of the treated vessel
but also the short-term to longer-term complications of
MI, including heart failure, arrhythmias, or mechanical
complications (10). Indeed, previously reported analyses of
PCI-treated patients who had post-procedural creatine
kinase levels >2 times the upper limit of normal (with
corroborating elevation of creatine kinase MB fraction) in
the SYNTAX trial were shown to be associated with short-
term (<3 months) and longer-term (2 to 4 years) mortality
(11). Even selecting a time window (e.g., 1 day, 1 week, or 1
month) associating mortality with ST is arbitrary because, as
shown in this study, the interquartile range of cardiac death
after ARC definite ST ranged from 0 to 16 days, with
a maximum duration of 321 days, and cardiac death was
often of multifactorial origin. Consequently, determining
the potential impact on mortality of newer-generation drug-
eluting stents with proven reductions in ST (12,13) is
difficult to determine in the SYNTAX trial. Comparatively,
potential reductions in ST-related MI and all-cause revas-
cularization were easier to determine, as highlighted in
Figure 5.
Graft occlusion. The present study confirms the estab-
lished supremacy of the long-term durability of LIMA to
the LAD (14). Notably, double LIMA/RIMA was not
associated with a reduced risk of GO on univariable analyses,
despite being undertaken in more than one-fourth (27.6%)
of randomized patients undergoing CABG. It is important
to emphasize that the data related to double LIMA/RIMA
were underpowered to draw any firm conclusions and are in
contrast to the data in published reports (14,15). Ten-year
follow-up data from a large ongoing randomized trial are
awaited (16).
The finding of the number of grafts to be an indepen-
dent predictor of GO is consistent with reported studies
in that too extensive surgical revascularization has been
associated with the occurrence of major perioperative
complications and acute MI (17,18). Conversely, the
15-month angiographic substudy of the SYNTAX trial
(19) showed that more than one-fourth (27.2%) of subjects
undergoing CABG had at least one significantly diseased
(�50% to <100%) or occluded bypass graft at 15 months.
Notably, the reported angiographic loss of the bypass grafts
Figure 5 Corrected Kaplan-Meier Curves for ARC Definition ST
Kaplan-Meier estimates of cardiac death (black), cardiac death or MI (green), and
cardiac death, MI, or all-cause revascularization (red) according to the ARC defi-
nition (6). Broken lines indicate corrected Kaplan-Meier curves after ST-related
clinical events were excluded. ARC definite ST is superimposed on the Kaplan-
Meier curves as circles, ARC probable ST as squares, and ARC possible ST as
triangles. Removal of ARC ST-related events would lead to a reduction in cardiac
death/MI/all-cause revascularization (ARC definite ST: D2.9%; ARC definite/
probable ST: D5.1%; ARC definite/probable/possible ST: D8.1%), cardiac death/
MI (ARC definite ST: D1.3%; ARC definite/probable ST: D3.8%; ARC definite/
probable/possible ST: D7.7%), and cardiac death (ARC definite ST: D0.5%; ARC
definite/probable ST: D1.5%; ARC definite/probable/possible ST: D5.5%). MI ¼
myocardial infarction; other abbreviations as in Figure 1.
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was not significantly associated with early clinical events
(19), in contrast to GO in the current study (defined in the
context of clinical presentation with acute coronary
syndrome). Reasons to account for the “clinically silent” loss
of bypass grafts have included that they were anastomosed
to functionally insignificant lesions, with resultant com-
petitive filling to the native vessel, and were therefore
unnecessary (20).
Study limitations. The present study represents a post-hoc
analysis, and the results should be considered hypothesis
generating. Because ST and GO were defined in the context
of clinical presentation, the true occurrence is likely to be
higher, particularly if the ST occurs in a distal vessel (19). In
addition, saphenous vein grafts have been shown to be
protective in the first 7 years; thereafter, mortality and repeat
revascularization have been reported to increase signifi-
cantly, secondary to a gradual loss of graft patency (21).
Given that operative factors were linked to ARC-like
probable GO, ARC-like definite GO was used for the
multivariable analyses to identify long-term predictors of
GO. As exists with ARC possible ST, ARC-like possible
GO is likely to have a low specificity in identifying GO.
The exact anatomic segment number of the ST using the
ARC definite criteria is not available, because this was not
recorded by the CEC. There was limited statistical power
for further subanalyses in patients with ST or GO.
Although multivariable adjustments were performed for
significant confounders (p < 0.1), the possibility of other
unmeasured confounders cannot be excluded. The possi-
bility of overfitting in the multivariable analyses cannot be
excluded. Because the confidence intervals of these correlates
were relatively narrow, the risk would have been limited (22).
Given the unavoidable differences in follow-up between the
CABG and PCI cohorts, we cannot exclude the possibility
that this may have affected the results.
Conclusions
Although the incidence of ST and GO was similar at 5 years,
the clinical impact of ST appeared greater, with a negative
impact on short-term to longer-term mortality.
Table 2 Association of First ARC ST or ARC-Like GO Event With 5-Year Cardiac Death
Incidence
at 5 Yrs (%)
No. of Cardiac
Deaths Post-Event
Until 5 Yrs (%)
Time From Index Event to
Cardiac Death (Days)
Median
Interquartile
Range
Minimum to
Maximum
SYNTAX trial PCI arm (n ¼ 903)
ST ARC definition
Classification
Definite 48 (5.3) 17/48 (35.4) 0 0–16 0–321
Probable 27 (3.0) 14/27 (51.9) 0 0–4 0–721
Definite or probable 75 (8.3) 31/75 (41.3) 0 0–9 0–721
Possible 27 (3.0) 27/27 (100) d d d
Time frame (definite)
Acute/subacute (�30 days) 19 (2.1) 8/19 (42.1) 0 0–6 0–17
Late (31 days to 1 yr) 9 (1.0) 2/9 (22.2) 173 d 25–321
Very late (>1 yr) 20 (2.2) 7/20 (35.0) 0 0–14 0–17
Time frame (definite/probable)
Acute/subacute (�30 days) 24 (2.7) 12/24 (50.0) 0 0–17 0–721
Late (31 days to 1 yr) 15 (1.7) 7/15 (46.7) 0 0–44 0–87
Very late (>1 yr) 36 (4.0) 12/36 (33.3) 0 0–7 0–17
SYNTAX trial CABG arm (n ¼ 897)
GO ARC-like definition
Classification
Definite 32 (3.6) 0/31 (0) d d d
Probable 21 (2.3) 12/21 (57.1) 0 0–14 0–257
Definite or probable 53 (5.9) 12/52 (23.1) 0 0–14 0–257
Possible 31 (3.5) 31/31 (100) d d d
Time frame (definite)
Acute/subacute (�30 days) 6 (0.7) 0/6 (0) d d d
Late (31 days to 1 yr) 12 (1.3) 0/12 (0) d d d
Very late (>1 yr) 14 (1.6) 0/13 (0) d d d
Time frame (definite/probable)
Acute/subacute (�30 days) 25 (2.8) 10/25 (40.0) 0 0–6 0–15
Late (31 days to 1 yr) 14 (1.6) 2/14 (14.3) 214 d 170–257
Very late (>1 yr) 14 (1.6) 0/14 (0) d d d
Binary values are given.
Abbreviations as in Table 1. CABG ¼ coronary artery bypass graft; PCI ¼ percutaneous coronary intervention.
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Additive EuroSCOREy 1.22 (1.08–1.38) 0.001 1.20 (1.05–1.36) 0.006
Late/very late ST (>30 days) (n ¼ 51)
Model 1
Any baseline angiographically visible thrombusz (4 of 51, 7.8%) 3.74 (1.35–10.37) 0.011 4.86 (1.73–13.65) 0.003
Any circumflex lesion (49 of 51, 96.1%) 4.27 (1.04–17.55) 0.044 3.08 (0.73–13.01) 0.13
Any trifurcation lesion (7 of 51, 13.7%) 2.00 (0.90–4.43) 0.089 2.27 (1.01–5.12) 0.048
Any right coronary artery lesion (47 of 51, 92.2%) 2.72 (0.98–7.53) 0.055 2.18 (0.76–6.23) 0.15
Unstable angina (21 of 51, 41.2%) 1.85 (1.07–3.21) 0.028 1.49 (0.77–2.87) 0.23
Prior MI (24 of 51, 47.1%) 2.04 (1.19–3.52) 0.01 1.68 (0.94–2.99) 0.079
Additive EuroSCOREy 1.09 (0.99–1.20) 0.076 1.02 (0.91–1.16) 0.72
Model 2
SYNTAX Score (per 10-point increase) 0.96 (0.75–1.21) 0.71 d d
Additive EuroSCOREy 1.09 (0.99–1.20) 0.076 d d
ARC-like definite GO (n ¼ 32)
No LIMA to LAD (8 of 32, 25.8%) 2.68 (1.20–5.98) 0.017 2.30 (1.00–5.28) 0.050
Number of grafts per patienty 1.78 (1.08–2.93) 0.023 1.87 (1.12–3.12) 0.017
Lack of pre-procedural aspirin (25 of 32, 78.1%) 2.34 (1.01–5.41) 0.047 1.87 (0.79–4.40) 0.15
Peripheral vascular disease (6 of 32, 18.8%) 2.58 (1.06–6.27) 0.036 1.47 (0.54–4.00) 0.45
Body mass indexy (kg/m2) 0.92 (0.84–1.00) 0.062 0.93 (0.85–1.02) 0.13
Previous MI (5 of 32, 15.6%) 0.38 (0.15–0.98) 0.046 0.38 (0.15–1.01) 0.052
Incidence of variables is provided in parentheses. *Multiple persisting opacifications of the coronary wall visible in more than one projection surrounding the complete lumen of the coronary artery at the site
of the lesion. yContinuous variables per unit increase. zSpheric, ovoid, or irregular intraluminal filling defect or lucency surrounded on 3 sides by contrast medium seen just distal or within the coronary
stenosis in multiple projections or a visible embolization of intraluminal material downstream.
CI ¼ confidence interval; HR ¼ hazard ratio; LIMA ¼ left internal mammary artery; other abbreviations as in Table 1.
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APPENDIX  
 
Expanded Methods 
The SYNTAX Trial is a randomized, prospective, multicenter, ‘all-comers’ trial investigating 
subjects with unprotected left main coronary artery (ULMCA) disease (isolated or associated 
with 1-, 2-, or 3-vessel disease [3VD]) or de novo 3VD, and has previously been described. 
(1,2)  In total, 1800 subjects were recruited and randomized from 85 centers in 18 countries 
from Europe and the United States. Exclusion criteria were minimal, consisting of subjects 
with prior coronary revascularization, planned need for concomitant cardiac surgery (e.g. 
valve surgery or resection of aortic or left ventricular aneurysm), or on-going acute MI.  
During the local Heart Team meeting, the interventional cardiologist and cardiac surgeon 
specified the number of coronary lesions requiring treatment, and their angiographic location 
and characteristics utilizing the anatomical SYNTAX Score as a tool to aid in this process. 
(1-3) All subjects considered by the Heart Team as potentially achieving “equivalent 
anatomic” revascularization with percutaneous or surgical revascularization were 
randomized on a 1:1 basis (n=1800) to either PCI with TAXUS Express paclitaxel-eluting 
stents (Boston Scientific Corporation, Natick, Mass), or CABG. Patients unsuitable for 
randomization were nested into registries.  
The calculation of the anatomical SYNTAX Score, and recording of its individual 
components, were carried out by the Heart Team prior to randomization, and corroborated by 
an independent core laboratory (Cardialysis BV, Rotterdam, The Netherlands), blinded to the 
treatment assignment. An independent Clinical Events Committee (CEC), including 
cardiologists, cardiac surgeons, and a neurologist, reviewed all the primary clinical end points 
and ST/GO events. All deaths were subdivided into cardiovascular or non-cardiovascular 
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deaths by the CEC. Cardiac deaths were classified as related or unrelated to a cardiac 
procedure by the CEC. In the event of any uncertainty arising in the classification of a 
clinical event, the CEC assisted the investigator in reaching his/her final classification. The 
CEC decision was able to overrule the investigator’s classification.  
Stent Thrombosis and Graft Occlusion 
As the SYNTAX Trial was commenced prior to the publication of the Academic Research 
Consortium (ARC) Definition, (4) the SYNTAX Trial instigated a protocol definition for ST. 
To allow direct comparison between ST and GO, a similarly defined protocol definition of 
GO was devised (Table 2a). The protocol definitions of ST/GO required clinical presentation 
with acute coronary syndrome, and confirmation by coronary angiography, multislice 
computerized tomography or autopsy. 
Subsequently, the ARC criteria (4) for ST was implemented and reported by a separate CEC 
(see Acknowledgements), and is reported in the study. To allow comparisons of ARC ST 
events to GO, ‘ARC like’ definitions were formulated for GO (i.e. definite, probable or 
possible GO), using adapted ARC definitions (Table 2b). The definition of definite GO was 
identical to the protocol definition. Since subjects had left main or de novo 3VD, the 
assumption was made that a MI in any of the 3 vessel territories for 3VD, or the left coronary 
system for ULMCA disease, without subsequent angiographic confirmation of graft patency, 
was classified as a probable GO. Possible GO was identical to the ARC definition of possible 
ST (unexplained death beyond 30 days). ‘ARC like’ definitions for GO were retrospectively 
assessed in conjunction with the safety reporting data performed by the CEC.  
Statistical Analysis 
Continuous variables are expressed as means (±SD), binary variables as counts and/or 
percentages. Time-to-event variables are presented as Kaplan-Meier (KM) estimates, and 
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compared using the log-rank test. Corrected KM curves were constructed by removing the ST 
adjudicated clinical event from the KM curves, in line with that previously reported. (5) 
Multivariable analyses were conducted with Cox regression using the forced enter method 
(variable entry criteria 0.05, and no exit criteria). The variables examined are detailed in the 
baseline characteristics (Table 1). There was no departure from the proportionality of hazards 
assumption using the global proportional hazards test based on Schoenfeld residuals. (6) 
Variables were screened for correlation before entering into the multivariable model, none 
were sufficiently correlated to warrant removal. A 2-sided p-value <0.05 was considered 
significant for all tests. All analyses were conducted using SPSS 20.0 (SPSS Inc., Chicago 
IL, USA) and SAS System Software Version 9.2 (SAS Institute, Cary, North Carolina, USA). 
  
152 Chapter 5.1
Expanded Results 
Online Table 1 
Baseline characteristics of patients with and without definite stent thrombosis or definite graft 
occlusion.   
 Stent Thrombosis (ARC) Graft Occlusion (‘ARC like’) 
Definite ST 
(n=48) 
No Definite 
ST (n=855) 
p-value Definite GO 
(n=32) 
No Definite 
GO (n=865) 
p-
value 
Clinical Characteristics 
Age (years) 
Male 
BMI 
Diabetes 
Medically treated diabetes*† 
Hypertension 
Hyperlipidemia 
Peripheral vascular disease 
Current smoker 
Unstable angina 
Previous myocardial infarction 
GI Bleeding/Peptic ulcer disease 
COPD  
LVEF (%) 
Creatinine clearance (ml/min)‡ 
Total Parsonnet Score 
Additive EuroSCORE 
Logistic EuroSCORE 
 
64.4±11.2 
75.5% 
27.6±5.2 
28.6% 
26.5% 
58.3% 
73.5% 
12.2% 
24.5% 
38.8% 
46.9% 
6.1% 
8.2% 
54.1±14.2 
88.3±35.5 
8.1±6.6 
4.3±2.6 
4.1±3.1 
 
65.3±9.5 
76.4% 
28.2±4.8 
28.0% 
25.2% 
74.7% 
78.9% 
8.5% 
17.4% 
28.1% 
30.6% 
4.0% 
7.8% 
54.9±11.8 
86.5±35.6 
8.6±7.0 
3.7±2.6 
3.7±4.6 
 
0.51 
0.89 
0.42 
0.93 
0.84 
0.012 
0.37 
0.37 
0.21 
0.11 
0.017 
0.48 
0.93 
0.65 
0.74 
0.65 
0.15 
0.55 
 
64.1±9.3 
78.1%  
26.3±3.6 
31.2% 
25.0% 
76.7% 
78.1% 
18.8% 
31.2% 
34.4% 
15.6% 
3.1% 
9.4% 
60.7±12.1 
83.2±24.5 
7.3±6.3 
3.4±2.2 
2.9±2.0 
 
65.0±9.8 
79.0% 
28.0±4.6 
28.4% 
24.6% 
77.0% 
77.1% 
10.3% 
21.7% 
27.7% 
34.5% 
4.3% 
9.2% 
58.1±13.2 
86.7±28.7 
8.5±6.9 
3.8±2.7 
3.9±4.5 
 
0.61 
0.91 
0.042 
0.73 
0.96 
0.97 
0.90 
0.13 
0.20 
0.41 
0.027 
0.74 
0.98 
0.35 
0.52 
0.35 
0.42 
0.011 
Anatomical Characteristics 
SYNTAX Score 
Left Main Disease§†  
Number of lesions 
Any total occlusions   
Any bifurcation lesion 
Any trifurcation lesion 
Diffuse or small vessel disease 
Any aorto-ostial lesion 
Any angiographically visible thrombus 
Any heavy calcification 
Any severe tortuosity 
Left arterial dominance 
Proximal LAD (Segment 6) lesion 
Any circumflex lesion 
Any right coronary artery lesion 
Any lesion length >20 mm 
 
29.3±11.2 
34.7% 
4.0±1.4 
20.4% 
69.4% 
10.2% 
22.4% 
12.2% 
6.1% 
61.2% 
65.3% 
12.2% 
61.2% 
93.9% 
87.8% 
69.4% 
 
28.4±11.4 
40.1% 
4.0±1.7 
24.2% 
62.5% 
7.3% 
22.0% 
15.8% 
2.2% 
49.0% 
66.9% 
18.4% 
58.3% 
85.3% 
81.5% 
55.0% 
 
0.59 
0.46 
0.70 
0.55 
0.33 
0.45 
0.95 
0.50 
0.084 
0.095 
0.82 
0.28 
0.69 
0.094 
0.27 
0.048 
 
27.5±12.5 
43.8% 
3.9±1.8 
28.1% 
62.5% 
6.2% 
21.9% 
21.9% 
6.2% 
43.8% 
56.2% 
6.2% 
65.6% 
90.6% 
81.2% 
65.6% 
 
29.2±11.3 
38.7% 
4.0±1.7 
22.0% 
64.6% 
7.1% 
20.9% 
14.8% 
3.4% 
48.8% 
68.2% 
16.6% 
57.4% 
83.4% 
81.1% 
56.4% 
 
0.41 
0.56 
0.69 
0.42 
0.81 
0.86 
0.97 
0.27 
0.39 
0.57 
0.16 
0.29 
0.36 
0.28 
0.99 
0.30 
Peri-/Post- Procedural 
Characteristics 
Procedure Time (hours)  
Intra-aortic balloon pump 
Complete Revascularization|| 
Lack of pre-procedural antiplatelet therapy# 
Lack of post-procedural antiplatelet therapy# 
One post-procedural antiplatelet therapy** 
 
 
1.9±1.0 
0.0% 
42.9% 
2.0% 
6.1% 
4.1% 
 
 
1.7±0.9 
2.3% 
57.2% 
0.7% 
0.9% 
4.3% 
 
 
0.22 
0.28 
0.050 
0.32 
0.001 
0.95 
 
 
3.5±1.0 
3.1% 
78.1% 
21.9% 
3.1% 
- 
 
 
3.4±1.1 
0.9% 
62.6% 
35.4% 
8.6% 
- 
 
 
0.92 
0.22 
0.075 
0.11 
0.27 
- 
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Total number of stents  
Stent length (mm) 
Stent length >100 mm 
Off pump 
Blood cardioplegia 
Grafts per patient 
LIMA LAD 
LIMA/RIMA 
Complete arterial revascularization 
Complete venous revascularization 
At least one jump graft 
At least one Y graft 
Small/unsatisfactory vessel at anastomosis site 
Calcification at anastomosis site 
Endarterectomy performed 
4.8±2.1 
90.3±50.3 
29.2% 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
4.6±2.3 
86.3±47.9 
34.0% 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
0.62 
0.58 
0.50 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
25.0% 
43.8% 
2.7±0.7 
74.2% 
19.4% 
16.1% 
3.2% 
29.0% 
9.7% 
29.0% 
29.0% 
3.2% 
- 
- 
- 
13.9% 
47.7% 
3.0±0.7 
88.8% 
21.4% 
18.7% 
2.7% 
31.2% 
11.9% 
27.4% 
24.7% 
2.9% 
- 
- 
- 
0.20 
0.76 
0.024 
0.013 
0.79 
0.72 
0.85 
0.80 
0.71 
0.84 
0.58 
0.92 
 
*Medically treated diabetes is defined as diabetic patients requiring oral medications or insulin for glycemic 
control. 
†Prespecified patient subsets 
‡Cockcroft and Gault formula 
§Isolated or associated with 1, 2 or 3VD 
||SYNTAX protocol definition 
# Aspirin nor thienopyridine. Pre-procedurally, the study protocol mandated aspirin (>70 mg per day) at least 12 
hours pre-CABG, aspirin (>70 mg per day) at least 12 hours pre-PCI, and clopidogrel (300+ mg 24 hours pre-
PCI) or ticlopidine (2x250 mg daily 48 hours pre-PCI).(7) 
**Aspirin or thienopyridine. Post-procedurally, aspirin (>70 mg per day) was mandated in the CABG and PCI 
arms, and clopidogrel or ticlopidine (2 x 250 mg) for at least 6 months in the PCI arm.(7) 
 
Abbreviations: Abbreviations: ARC, Academic Research Consortium;(4) BMI body mass index; Def definite; 
LAD left anterior descending artery; LIMA left internal mammary artery; LVEF left ventricular ejection 
fraction; MI myocardial infarction; ml millimeter; mm millimeter; min minute; PCI percutaneous coronary 
intervention; Poss possible; Prob probable; RIMA right internal mammary artery; ST stent thrombosis; TO total 
occlusion 
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Online Table 2 
Association of adjudicated first ST event (Protocol definition) (a), or GO event (Protocol 
definition) (b) to 5-year cardiac death. Time frame (median, IQR, range) from ST /GO to 
cardiac death are also detailed. Binary values are given. 
a) Stent Thrombosis (Protocol Definition) 
SYNTAX Trial 
PCI Arm (n=903) 
Incidence of Stent 
Thrombosis at  
5 Years 
No. of Cardiac 
Deaths Post ST  
Until 5 years 
Time Elapsing From Index ST to 
Cardiac Death (Days) 
Median IQR Min-Max 
SYNTAX Protocol Definition 
Time Frame 
  Acute/subacute (≤30 days) 
  Late (31 days to 1 year) 
  Very Late (>1 year) 
47 (5.2%) 
 
19 (2.1%) 
8 (0.9%) 
20 (2.2%) 
15/47 (31.9%) 
 
8/19 (42.1%) 
2/8 (25.0%) 
5/20 (25.0%) 
0 
 
1 
- 
0 
0-17 
 
0-19 
- 
0-12 
0-321 
 
0-321 
- 
0-17 
 
b) Graft Occlusion (Protocol Definition) 
SYNTAX Trial 
CABG Arm (n=897) 
Incidence of Graft 
Occlusion  
at 5 Years 
No. of Cardiac 
Deaths Post ST  
Until 5 years 
Time Elapsing from Index GO to  
Cardiac Death (Days) 
Median IQR Min-Max 
SYNTAX Protocol Definition 
Time Frame 
  Acute/subacute (≤30 days) 
  Late (31 days to 1 year) 
  Very Late (>1 year) 
32 (3.6%) 
 
6 (0.7%) 
12 (1.3%) 
14 (1.6%) 
0/31 (0%) 
 
0/6 (0%) 
0/12 (0%) 
0/13 (0%) 
- 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
 
- 
- 
- 
 
 
 
 
 
 
  
Abbreviations: ARC, Academic Research Consortium; MI, myocardial infarction; IQR, interquartile 
range; and ST, stent thrombosis. 
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Association of adjudicate  first S  event (Protocol definition) (a), or GO event (Protocol 
definition) (b) to 5-year cardiac death. Time frame (median, IQR, range) from ST /GO to 
cardiac death are also detailed. Binary values are given. 
a) Stent Thrombosis (Protocol Definition) 
SYNTAX Trial 
PCI Arm (n=903) 
Incidence of Stent 
Thrombosis at  
5 Years 
No. of Cardiac 
Deaths Post ST  
Until 5 years 
Time Elapsing From Index ST to 
Cardiac Death (Days) 
Median IQR Min-Max 
SYNTAX Protocol Definition 
Time Frame 
  Acute/subacute (≤30 days) 
  Late (31 days to 1 year) 
  Very Late (>1 year) 
47 (5.2%) 
 
19 (2.1%) 
8 (0.9%) 
20 (2.2%) 
15/47 (31.9%) 
 
8/19 (42.1%) 
2/8 (25.0%) 
5/20 (25.0%) 
0 
 
1 
- 
0 
0-17 
 
0-19 
- 
0-12 
0-321 
 
0-321 
- 
0-17 
 
b) Graft Occlusion (Protocol Definition) 
SYNTAX Trial 
CABG Arm (n=897) 
Incidence of Graft 
Occlusion  
at 5 Years 
No. of Cardiac 
Deaths Post ST  
Until 5 years 
Time Elapsing from Index GO to  
Cardiac Death (Days) 
Median IQR Min- a  
SYNTAX Protocol Definition 
Time Frame 
  Acute/subacute (≤30 days) 
  Late (31 days to 1 year) 
  Very Late (>1 year) 
32 (3.6%) 
 
6 (0.7%) 
12 (1.3%) 
14 (1.6%) 
0/31 (0%) 
 
0/6 (0%) 
0/12 (0%) 
0/13 (0%) 
- 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
 
- 
- 
- 
 
 
 
 
 
 
  
Abbreviations: ARC, Academic Research Consortium; MI, myocardial infarction; IQR, interquartile 
range; and ST, stent thrombosis. 
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Association of adjudicated first ST event (Protocol definition) (a), or GO event (Protocol 
definition) (b) to 5-year cardiac death. Time frame (median, IQR, range) from ST /GO to 
cardiac death are also detailed. Binary values are given. 
a) Stent Thrombosis (Protocol Definition) 
SYNTAX Trial 
PCI Arm (n=903) 
Incidence of Stent 
Thromb sis at  
5 Years 
No. of Cardiac 
Deaths Post ST  
Un il 5 years 
Time Elapsing From Index ST to 
Cardiac Death (Days) 
Median IQR Min-Max 
SYNTAX Protocol Definition 
Time Frame 
  Acute/subacute (≤30 days) 
  Late (31 d ys to 1 year) 
  Very Late (>1 year) 
47 (5.2%) 
 
9 (2.1%) 
8 (0.9%) 
20 (2.2 ) 
15/47 (31.9%) 
 
8/19 (42.1%) 
2/8 (25.0 ) 
5/20 (25.0 ) 
0 
 
1 
-
0 
0-17
 
0-19 
- 
0-12 
0-321 
 
0-321 
- 
0-17 
 
b) Graft Occlusion (Protocol Definition) 
SYNTAX Trial 
CABG Arm (n=897) 
Incidence of Graft 
Occlusion  
at 5 Years
No. of Cardiac 
Deaths Post ST  
Un il 5 years 
Time Elapsing from Index GO to  
Cardiac Death (Days) 
Median IQR Min-Max 
SYNTAX Protocol Definition 
Time Frame 
  Acute/subacute (≤30 days) 
  L te (31 d ys to 1 year) 
  Very Late (>1 year) 
32 (3.6%) 
 
6 (0.7%) 
12 (1.3 ) 
4 6
0/31 (0%) 
 
0/6 (0%) 
0/12 (0 ) 
3
- 
 
- 
- 
 
- 
- 
 
- 
 
 
 
 
 
 
  
Abbreviations: ARC, Academic Research Consortium; MI, myocardial infarction; IQR, interquartile 
range; and ST, stent thrombosis. 
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Online Figure 1. Comparison of incidence of protocol defined stent thrombosis and 
graft occlusion at 5 years 
Patient level data shown. 
 
 
 
 
 
 
 
Abbreviations: ARC Academic Research Consortium(4), CABG coronary artery bypass graft surgery, PCI 
percutaneous coronary intervention, d days 
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Online Figure 2. Kaplan-Meier estimates of protocol defined stent thrombosis and protocol 
defined graft occlusion at 5 years 
5 year outcomes are illustrated (upper) with landmark analyses at 30 days and 31 days - 5 years 
(lower).  
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Despite the enormous progress made in reducing the inci-
dence of restenosis with first and second-generation drug-
eluting stents (DES), the incidence of in-stent restenosis 
(ISR) requiring target vessel revascularisation (TVR), so-
called “DES failure”, is approximately 5-10%, with one 
estimate suggesting approximately 200,000 repeat revascu-
larisations performed in the US alone. Emerging evidence 
is now challenging the traditionally held view that ISR 
is a benign phenomenon with between 30-60% of cases 
presenting with acute coronary syndrome. The underly-
ing mechanisms of DES restenosis are complex and can 
be broadly divided into 4 main causes, namely biological, 
arterial, stent and implantation factors. Evolving concepts 
concerning mechanisms relating to late restenosis and “neo-
atherosclerosis” are also discussed. The treatment of ISR 
and the determinant factors involved in the development of 
late stent thrombosis are well described elsewhere and are 
outside the scope of this review. In this review the numerous 
causes of DES restenosis are delineated to help identify the 
potentially controllable and non-controllable factors from 
the perspective of the interventional cardiologist intending 
to implant a DES. 
In-stent restenosis
VASIM FAROOQ, LORENZ RÄBER, BILL D. GOGAS, PATRICK W. SERRUYS
P A R T
III
CHAPTER 26
This chapter also includes supplementary data which 
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INTRODUCTION
In the last decade, tremendous progress has been made in reduc-
ing the incidence of restenosis with the advent of the drug-elut-
ing stent (DES). With “plain old balloon angioplasty” (POBA), 
rates of acute and chronic vessel restenosis were unacceptably 
high at approximately 30-60%, secondary to acute and chronic 
recoil and constrictive remodelling [1-3]. The advent of bare 
metal stents (BMS) appeared to eliminate the issue of acute and 
chronic recoil but introduced a new entity – neointimal hyper-
plasia (NIH) with classical manuscripts unequivocally demon-
strating a strong and linear relationship between NIH forma-
tion and late lumen loss (LLL) [4]. The restenosis rates with 
BMS were reported to be between 16-44% with higher rates 
of stenosis attributable to several risk factors, in particular long 
lesion length and small vessel calibre [3,5-7]. 
Consequently, attempts were made to limit the neointimal 
response after stent implantation with endovascular coro-
nary brachytherapy. This involved the use of either catheter 
based endovascular delivery of radiation or radioactive stents. 
The technology initially appeared feasible in leading to dose-
dependent reductions in restenosis. This technology resulted 
in an increased risk of stent thrombosis, and a significant edge 
vascular response leading to an “edge effect” or “candy-wrap-
per” phenomenon - secondary to the radioactive dose fall-off 
at the transition zones (proximal and distal stent edges) - pre-
cluding its widespread clinical use [8-10].
DES were thus conceived as the next step in tackling this 
iatrogenic entity of NIH, with large-scale reductions in reste-
nosis rates reported at 0% in highly selective lesions and up 
to 16% in a broader range of patients and lesions with first-
generation DES [3,6,11].
 In contrast to POBA [12] and BMS [13],where an almost 
classical Gaussian (normal) distribution of late loss is broadly 
seen post-procedurally, the distribution of LLL after DES 
implantation has been shown to follow a bimodal pattern of 
distribution with both paclitaxel- (PES) and sirolimus- (SES) 
eluting stents (  Figure 1) [14]. 
F I G U R E  1
The bimodal distribution of late lumen loss (LLL) (A, B) and percentage diameter stenosis (C, D) after Cypher (left) and Taxus (right) implantation. 
LLL indicates late lumen loss. Reproduced with permission from Byrne et al. [14] In each panel the observed frequency distribution curve (thin solid 
line), two subpopulations’ normal distribution curves (dashed lines) and the composite distribution curve (thick solid line) are displayed; the vertical 
dashed line denotes the intersection point between the two subpopulation distribution curves.
A
C
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Despite the significant advances in the technology to reduce 
restenosis, conservative estimates would, however, still sug-
gest the incidence of ISR requiring repeat revascularisation, 
so-called “DES failure,” to be approximately 5-10%, with 
one estimate suggesting approximately 200,000 repeat revas-
cularisations in the United States alone [15].
CLASSIFICATION SYSTEM OF IN-STENT 
RESTENOSIS
In 1999, Mehran et al [16] first described a classification sys-
tem for the patterns of restenosis seen with coronary stents. 
Two broad categories were described, namely focal and dif-
fuse restenosis, with multiple subtypes within each group. 
The pattern of restenosis seen with DES is usually focal, in 
contrast to BMS which is primarily diffuse. In one series, over 
60% of in-stent restenosis (ISR) cases with both PES and SES 
were focal, with the most common location for focal reste-
nosis appearing to be at the proximal DES edge [17]. Despite 
this, over one fifth of cases of ISR remains diffuse and approx-
imately 10-20% of cases are even occlusive (  Figure 2).
RISK FACTORS ASSOCIATED WITH IN-STENT 
RESTENOSIS
In 2004, there was the first reported description of the risk 
factors associated with DES restenosis in patients with the 
F I G U R E  2
The patterns of restenosis in SES and PES
The predominant pattern of restenosis is a focal pattern of restenosis, 
although diffuse and proliferative restenosis are still seen with DES. 
*P-value calculated for the overall observed difference in the pattern 
of restenosis in PES and SES groups. SES indicates sirolimus- elut-
ing stent; PES: paclitaxel-eluting stent; DES: drug-eluting stent. 
Reproduced with permission from Corbett et al [17].
p = 0.006*
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unrestricted use of SES since approval of its CE mark [18,19].
Despite the apparent differences in the distribution of LLL 
between BMS and DES as previously described, the main 
message of these and subsequent findings was that the usual 
patient characteristics, lesion types and procedural factors 
incriminated with restenosis in BMS were equally responsi-
ble with DES, with diabetes mellitus being implicated as one 
of the strongest risk factors for the development of restenosis 
[17-21]. It should, however, be emphasised that the distribu-
tion of restenosis with DES appears more attenuated com-
pared with BMS, especially in long lesions and small vessels, 
highlighting the importance of drug elution in potentially 
diminishing the NIH response. 
HISTOPATHOLOGICAL BASIS OF IN-STENT 
RESTENOSIS
The inflammatory reaction which occurs after arterial injury 
is a critical factor that influences the extent of neointimal 
response, with the persistence of this inflammatory response 
beyond 90 days being strongly associated with an increased 
level of neointimal thickness and consequent restenosis 
[3,22,23]. In keeping with these findings, it has been demon-
strated that restenotic lesions have a higher number of chronic 
inflammatory cells compared to non-restenotic lesions [22]. 
Histopathological analyses of ISR, involving samples taken 
by directional atherectomy at the time of reintervention, 
have been shown to be remarkably similar between BMS and 
DES. This is almost exclusively composed of proteoglycan-
rich smooth muscle cells (SMC) and fibrolipidic areas rich 
in collagen and reticular fibres. A more “immature” resten-
otic process, as evidenced by differences in SMC phenotypes, 
however, has been shown potentially to exist with certain 
types of DES compared with BMS [24,25]. Fibrinoid tissue, 
indicative of a persistent inflammatory and incomplete heal-
ing response, has also been reported with DES [26-30] and 
implicated in the subsequent risk of late stent thrombosis 
(LST) [28]. 
IN-STENT RESTENOSIS: A BENIGN ENTITY?
ISR has traditionally been suggested as being potentially 
less benign with the recurrence of anginal symptoms alone. 
Emerging evidence now suggests that between 30-60% of 
ISR cases perhaps present with an acute coronary syndrome 
(ACS), with unstable angina being the most common presen-
tation (  Figure 3) [31-41], and up to 5% of patients even 
being reported as presenting with an ST-elevation myocardial 
infarction (STEMI) [36,38-41].
Furthermore, as to whether a total vessel occlusion pre-
senting with acute ischaemia is related to a stent thrombo-
sis or a subtotal restenosis is often difficult to differentiate 
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factors from the perspective of the interventional cardiologist 
intending to implant a DES.
BIOLOGICAL FACTORS
Resistance to antiproliferative drugs
The underlying mechanisms of action and causes of resist-
ance to paclitaxel or sirolimus are well documented in the 
cancer literature and can either be present in genetically pre-
determined individuals or be acquired, following cytotoxic 
exposure to the drug [45,46]. 
The so-called “drug resistance gene expression pro-
gramme,” described for paclitaxel resistance from the cancer 
literature, best exemplifies the complex pathways involved 
in the aetiology of drug resistance [45]. Essentially, the cel-
lular context determines the genes that are expressed which 
contribute to drug resistance either in genetically predeter-
mined cells or primed for expression following the cytotoxic 
insult after exposure to the drug. These genes may operate 
in conventional pathways that are well known (drug deliv-
ery and metabolism, apoptosis regulation, DNA repair), but 
the temporal (i.e., pro- and anti-apoptotic gene activity) and 
spatial regulation (i.e., cell survival signalling pathways) of 
these gene products after exposure to the drug also appear 
to be important.
As examples, polymorphisms in the genes that encode 
mTOR or proteins involved in paclitaxel or sirolimus metab-
olism have been shown to confer drug resistance both in 
vitro and in vivo [10,11] : decreased binding of sirolimus to 
solely based on the clinical presentation and the angiographic 
findings. The consideration of the angiographic appear-
ances, the behaviour of the lesion during balloon inflation 
and the patient history (such as the type of stent previously 
implanted) can potentially aid in identifying the aetiology of 
the ischaemic event. Intravascular imaging can serve as an 
additional supportive diagnostic tool, although the differen-
tiation between thrombus and neointimal tissue is not always 
readily possible with currently available intravascular imag-
ing techniques (intravascular ultrasound [IVUS] and optical 
coherence tomography [OCT]). This rapidly evolving concept 
is discussed in the Late restenosis section of Arterial factors. 
OVERVIEW OF CHAPTER
The treatment of ISR and the determinant factors involved 
in the development of late stent thrombosis (LST) are well 
described elsewhere and are outside the scope of this chap-
ter [42-44]. The underlying mechanisms of restenosis with 
DES can broadly be divided into 4 main causes (  Table 1), 
namely biological, arterial, stent and implantation factors, 
accepting that this classification is somewhat arbitrary with 
mechanisms of restenosis being attributable to more than one 
factor. In this chapter we explore these 4 main mechanisms 
and identify the potentially controllable and non-controllable 
F I G U R E  3
The presence of intraluminal material (white arrow), most probably 
thrombus, visualised in a restenotic segment. The OCT images were 
obtained from a patient referred for coronary angiography for unstable 
angina. Reproduced with permission from Gonzalo et al [229].
F O C U S  B O X  1
 • Drug-eluting stents (DES) were conceived as the next step 
- after balloon angioplasty and bare metal stents (BMS) - in 
tackling the iatrogenic entity of neointimal hyperplasia
 • The distribution of late lumen loss (LLL) after drug-eluting 
stent implantation has been shown to follow a bimodal 
pattern of distribution with both paclitaxel  (PES) and 
sirolimus (SES) eluting stents
 • “DES failure” equates to approximately 5-10% of cases, 
with one estimate suggesting approximately 200,000 repeat 
revascularisations in the US alone [15]
 • The pattern of restenosis seen with DES is usually focal. By 
contrast, the pattern of restenosis with BMS is primarily 
diffuse
 • Persistence of the inflammatory response beyond 90 days 
after arterial injury is strongly associated with an increased 
level of neointimal thickness and consequent restenosis
 • In-stent restenosis (ISR) may not be as “benign” as once 
originally thought with 30-60% of ISR cases presenting with 
an acute coronary syndrome (ACS)
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mTOR due to mutations in FK-B12 and mTOR and muta-
tions of downstream effector molecules of mTOR may all 
cause resistance to sirolimus [11]. 
Potentially overcoming drug resistance through the 
delivery of higher doses of antiproliferative agent to the 
implantation site
Given the possibility that drug resistance is one poten-
tial mechanism of restenosis, attempts have been made to 
give much higher doses of oral sirolimus to patients with 
refractory ISR in the theoretical attempt of overcoming 
drug resistance and delivering increased amounts of drug 
to the implantation site. The OSIRIS study [47] investi-
gated the administration of higher doses of oral sirolimus 
to patients with refractory ISR and demonstrated a sig-
nificant correlation between the level of sirolimus concen-
tration in the bloodstream and rates of further late lumen 
loss (  Figure 4). Given that the patients received a short 
TA B L E  1
The underlying mechanisms of restenosis with DES
BIOLOGICAL FACTORS ARTERIAL FACTORS STENT FACTORS IMPLANTATION FACTORS
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Small vessels 
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cracking
Stent fractures
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Geographical miss
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Barotrauma to Unstented 
Segments
Incomplete lesion coverage
Deployment of DES in a clot-laden 
arterial segment
F I G U R E  4
The patterns of restenosis in SES and PES
The association of sirolimus blood concentrations at the time of repeat 
intervention and the angiographic late lumen loss at 6-month angio-
graphic follow-up from the OSIRIS study. Higher serum levels of siroli-
mus were found to correlate with the degree of 6-month angiographic 
late lumen loss. Reproduced with permission from Hausleiter et al [47].
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duration of oral sirolimus (7 days), it was unclear if these 
findings would be maintained at longer-term follow-up. 
It has been anecdotally reported that courses of sirolimus 
given for 30 days after POBA to the restenotic lesion, in 
the theoretical attempt to cover the injury period following 
POBA, can reduce restenosis in refractory restenosis cases 
[48]. Larger-scale studies are required to establish if this is 
feasible or practical. 
Furthermore, evidence has suggested that the concomitant 
administration of steroids to patients implanted with BMS, 
particularly in patients with a persistent inflammatory state, 
as indicated by elevated C-reactive protein, may reduce the 
incidence of ISR [49-53]. Further trials are needed, how-
ever, to assess the clinical utility of steroid therapy for the 
treatment of ISR after prior DES implantation.
Hypersensitivity reactions (the polymer)
Polymer layers in DES are used as both drug reservoirs 
and non-drug-coated external films to allow optimal drug 
release kinetics, as described in Stent Factors. As exam-
ples with the first-generation DES, the Cypher® (SES) 
stent (Cordis Corporation, Johnson & Johnson, Warren, 
NJ, USA) consists of a stainless steel platform covered 
with a basecoat formulation (67%) consisting of the poly-
mers PEVA (polyethylene vinyl acetate) and PBMA (poly 
n-butyl methacrylate) mixed with sirolimus (33%); a drug-
free PBMA topcoat is also applied over the polymer drug 
mixture to control drug release kinetics. The Taxus® (PES) 
stent (Boston Scientific, Natick, MA, USA) consists of a 
stainless steel platform with Translute™ (poly [styrene-b-
isobutylene-b-styrene]) polymer combined with paclitaxel 
without a primer or topcoat layer.
The inflammatory reaction that occurs after arterial injury 
is a critical factor which influences the extent of neointimal 
response, with the persistence of this inflammatory response 
beyond 90 days being strongly associated with delayed heal-
ing and implicated in an increased risk of LST and restenosis 
long term [13,14].
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The inflammatory and potential hypersensitivity 
response
Both PES and SES have been demonstrated to provoke dis-
tinctive inflammatory responses in animal models beyond 90 
days, with SES triggering giant cell infiltrations and PES caus-
ing eosinophilic reactions around stent struts [26-30]. The 
inflammatory responses associated with SES have been shown 
to persist beyond 180 days and up to 2 years (  Figure 5). 
This phenomenon has also been shown to be potentially fur-
ther exacerbated at sites of overlapping DES [28]. This is in 
contrast to BMS and the second-generation everolimus-eluting 
stent (EES; Xience V; Abbott Vascular, Santa Clara, CA, USA) 
with a more biocompatible polymer, where the inflammatory 
responses have been demonstrated to be limited to a period of 
90 days and 12 months, respectively (  Figure 5) [54].
Evidence of persistent inflammatory responses in humans 
have also been reported both in autopsy cases, with one case 
reported to involve up to one third of struts in first-gener-
ation DES at 3 months, and demonstrating signs of persis-
tent inflammation characterised by granuloma formation 
and extensive eosinophilic infiltration as seen in the animal 
models. Furthermore, evidence of persistent inflammation has 
been demonstrated from thrombus aspirates taken at the time 
of emergency PCI in patients presenting with very LST [55].
F I G U R E  5
The persistent inflammatory response to Cypher stents for a period of up to 2 years
The panels below show the persistent granulomatous inflammatory response to Cypher stents in sections at low and high power at various time 
points. Reproduced with permission from Nakazawa et al [54].
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Further details related to this “late restenosis” phenom-
enon are described in Arterial factors.
Hypersensitivity reactions (metallic stent platform) 
Koster et al [56] first reported an apparent association 
between the risk of restenosis and metal allergy, namely 
nickel and molybdenum, with BMS. This study has been con-
troversial, however, and the research methodology subjected 
to criticism, in particular the methodology of identifying 
nickel allergy [57-59]. Small-scale, predominantly retrospec-
tive studies have failed to show an association between metal 
allergy in BMS and restenosis [60,61]. Saito et al [62] did, 
however, report nickel allergy as being an independent pre-
dictor for refractory ISR in BMS (odds ratio 5.1, p=0.0033), 
with almost one fifth of patients with refractory ISR having 
a documented true allergy to nickel (24 of 128 patients). Of 
note is the fact that the nickel allergy assessment was per-
formed by an independent dermatologist blinded to the study 
results. Conversely, Lijima et al [63] suggested an associa-
tion between nickel allergy by patch test and the recurrence 
of ISR, in patients treated with POBA for ISR after BMS 
implantation. Within their study no association was found 
with BMS implantation and first presentation of ISR. 
The issue of ISR has also been linked to gold-coated stents, 
where several studies have associated these with contact 
allergy and a considerable increase in the risk of ISR [64-68].
Consequently, the use of gold in coronary stents has been 
abandoned. 
Whether the issue of nickel hypersensitivity is a potential 
issue with DES is both speculative and theoretical. To date, 
only one small study (Nakazawa et al [69]) has examined this 
issue and found no association between the risk of ISR and 
SES implantation. 
Inflammatory biomarkers and genetics
Inflammatory biomarkers
The inflammatory status, as assessed by C-reactive protein 
levels, has consistently failed to demonstrate any association 
with ISR after DES implantation, despite being associated 
with ISR after BMS implantation; C-reactive protein levels 
have, however, been implicated in the risk of stent thrombo-
sis [70,71].
Circulating matrix metalloproteinases (MMP) have been 
shown to be potentially useful in identifying patients at a 
greater risk of developing ISR following DES implantation 
[72]. It is well established that both MMP-2 and MMP-9 play 
fundamental roles in the migration of vascular SMCs and 
matrix remodelling during wound healing and are produced 
by vascular SMCs, endothelial cells, macrophages, lympho-
cytes and mast cells in response to mechanical injury [73-75]. 
Significant elevations in MMP-9 levels at baseline and 24 
hours post PCI, and MMP-2 levels 24 hours post PCI, have 
all proven to be strongly associated with the development 
of ISR following DES implantation [72].Conversely, in the 
same study, low and near-normal MMP-2 and MMP-9 levels 
were strongly associated with a lack of a significant restenotic 
response.
Furthermore, other inflammatory biomarkers such as 
serum levels of PAI-1 [76] and complement components (C3a 
and C5a) [77] have also been implicated with ISR after DES 
implantation.
Genetics
It would also appear that the effects of ISR are perhaps not 
immune from genetics. As to whether this is due to the resist-
ance (predetermined or acquired) to the drug as previously 
described, or due to biological mechanisms, in particular the 
inflammatory response of the restenosis process itself, is pres-
ently unclear. Inflammatory gene polymorphisms in 4 differ-
ing genes have been previously demonstrated to be associated 
with ISR [78]. For example, homozygosity of the 16/glycine 
variant in the beta2-adrenergic receptor (ADRB2), a medi-
ator of nitrous oxide synthetase, has been associated with 
ADRB2 receptor down-regulation and an increased risk of 
restenosis [78].Vogiatzi et al [79] have previously described 
a powerful association, by a factor of over 15-fold, between 
two functional polymorphisms of interleukin-8 (a strong 
mediator of inflammation) and the subsequent risk of reste-
nosis. These latter gene polymorphisms were relatively rare, 
which subsequently limited any clinical application. Other 
gene mutations have also previously been described as being 
associated with restenosis [80,81]. Conversely, genetic mark-
ers such as angiotensin-converting enzyme (ACE), despite 
showing initial promise, have failed to demonstrate a clinical 
role – perhaps due to the multifactorial nature of ISR [82]. 
Potential clinical application
The prospect of potentially being able to identify patients 
with a greater propensity to develop ISR after DES implanta-
tion may perhaps allow a more “personalised revascularisa-
tion” with, for example, DES which deliver higher drug con-
centrations to the vessel or even the prospect of considering 
surgical revascularisation in this cohort of patients. This indi-
vidualised approach to revascularisation based on individual 
genetic risk factor profiling is still in its infancy and extensive 
preclinical and clinical investigations are required before this 
can even be considered to enter conventional clinical practice. 
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ARTERIAL FACTORS
Wall shear stress 
Wall shear stress refers to the principle that fluid dynamics 
and vessel geometry may play a potential role in the cause 
of focal plaque or neointimal formation [83]. The concept 
of wall shear stress is that fluid (i.e., blood) does not move 
at the same velocity at every point within the vessel, with 
blood flowing fastest in the vessel centre (i.e., a high shear 
stress area) and slowest when closest to the vessel wall (i.e., 
a low shear stress area) due to frictional forces exerted by 
the vessel endothelium. For example, in coronary bifurca-
tions this phenomenon becomes more notable with a lower 
shear stress occurring at the ostium of a side branch [83-85]. 
This may subsequently lead to the accumulation of growth 
factors, mitogenic cytokines and platelets, which may pro-
mote either atherosclerosis or neointimal formation if the side 
branch undergoes “vessel injury,” such as after angioplasty or 
stenting [83,85-89]. Conversely, the carina of the side branch 
is a high shear stress area and atherosclerosis or restenosis 
rarely occurs here: indeed, animal models have shown that 
high shear stress areas can potentially directly inhibit SMC 
proliferation [90]. Other examples include differences in the 
shear stress in the inner and outer curvatures of a stented ves-
sel (  Figure 6) [89].
Clinical implications of wall shear stress
In a novel experiment in an animal model, Carlier et al [91] 
demonstrated that, through the implantation of a “flow 
divider” into the centre of a stent implanted in the iliac arter-
ies, they were able to modulate the local wall shear stress and 
the subsequent growth of NIH. The flow divider significantly 
increased the local wall shear stress and was consequently 
found to lead to a local reduction in inflammation and injury, 
with reduced NIH growth and subsequent late lumen loss. The 
closest human model of this example has been the use of the 
principle of simultaneous V-stenting (so-called “shotgun stent-
ing”) with the formation of a metallic neo-carina in the left 
main stem or other suitably sized vessels [92,93].Kim et al [92] 
demonstrated that in 36 consecutive patients (29 with left main 
stem interventions) using this technique with SES implantation, 
a 14% (5 patients) restenosis rate occurred over an average 
follow-up period of over 2 years. Interestingly, a “membra-
nous diaphragm” at the carina was identified in 14 patients 
(47%) with restenosis occurring in just one of these patients. 
Conversely, Stinis et al [94] showed that, in 74 consecutive 
patients with predominantly left anterior descending-diagonal 
lesions, the target lesion revascularisation rate was more than 
twice as high in the simultaneous V-stenting group (14 patients, 
40%), compared with the crush group (5 patients, 12.8%) at 
F I G U R E  6
Two-dimensional axial cross-section of a slightly curved stented coro-
nary segment (B). The results of a computation of velocity and shear 
stress distribution in this segment at follow-up show regions with low 
shear stress (A) that coincide with the shallow pits in (B). Along the 
inner curve, the region with lower shear stress, the pits are virtually 
absent and shear stress distribution is much more homogeneous (C). In 
some of the pits along the outside curve, flow reversal can be observed 
(inset and D). The areas containing negative axial velocity are indicated 
by the shaded boxed regions in (B). Reproduced (Figure and Figure leg-
end) with permission from Gijsen et al [89].
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F O C U S  B O X  2
 • Biological factors related to in-stent restenosis (ISR) can 
be secondary to resistance to antiproliferative drugs, 
hypersensitivity reactions to the polymer or metallic stent 
platform, and inflammatory biomarkers and genetics
 • ISR secondary to antiproliferative drugs can either be 
present in genetically predetermined individuals or be 
acquired following cytotoxic exposure to the drug. Limited 
evidence exists for using oral sirolimus to overcome drug 
resistance – further trials are required to establish if this is 
feasible or practical
 • Hypersensitivity to the polymer is well documented and has 
been associated with late restenosis (see Arterial factors) 
and stent thrombosis
 • Hypersensitivity to the metallic platform of drug-eluting 
stents remains hypothetical and unproven with nickel. 
Gold-coated stents have a proven association with contact 
allergy and have been linked to restenosis: consequently, 
coronary stents are no longer manufactured from gold
 • The identification of biomarkers (e.g., MMP) and genes 
associated with ISR is in its infancy – at the time of writing 
the clinical application is awaiting to be defined
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a follow-up of >3 years. Whether lesion location played a role 
in the disparity of these results remains unclear. Robust, ran-
domised controlled trials are therefore required to evaluate the 
feasibility of this technique. 
The issue as to whether the actual presence of the stent in the 
vessel wall negatively alters the wall shear stress sufficiently to 
promote restenosis has proven to be controversial, with con-
flicting evidence existing in the literature. In a more recent, 
larger, well-designed trial, Papafaklis et al [95] demonstrated 
the presence of significant numbers of “pockets” of low shear 
stress within stented segments, secondary to local geometric 
factors such as angulation or curvature, and showed that these 
pockets were significantly associated with NIH formation at 
6-month follow-up with BMS and PES. Interestingly, this was 
not seen with SES, suggesting that sirolimus significantly atten-
uated the neointimal response to low shear stress. Paclitaxel 
was unable to do this, perhaps because of its differing pharma-
cological mode of action or even its shorter drug-release kinet-
ics as discussed in Stent factors [3].
 “Thromborestenosis” phenomenon
“Thromborestenosis” is a term first described by Oikawa et 
al [96] to describe a novel theory in which chronic thrombus 
formation may play an integral part in the development of 
ISR following DES implantation. The uniqueness of this study 
was the combined use of intravascular ultrasound (IVUS), 
coronary angioscopy and histopathological analyses (taken by 
direct coronary atherectomy) in all patients who had presented 
with ISR following SES implantation. The major findings of 
this study were that, in patients presenting with ISR, the inci-
dence of thrombus and fibrin deposition were substantially 
more frequently observed within ISR lesions associated with 
SES implantation (12 of 13 cases), as compared to BMS (2 of 
8 cases), and that the thrombus seen was not only located at 
uncovered stent strut sites (if present) but also, more impor-
tantly, on covered stent strut sites (  Figure 7). A theory to 
explain the presence of neointimal thrombus put forward by 
the authors was that the neointima covering a SES strut site 
was potentially more thrombogenic. 
 Joner et al [26] have previously described evidence to sup-
port the concept of “thromborestenosis.” In 2 of 14 autopsy 
cases of patients who died of LST, evidence of ISR with super-
imposed thrombus was seen [26]. Further support comes from, 
Cook et al [55] who demonstrated evidence of the widespread 
presence of chronic thrombi, as evidenced by the presence of 
a chronic inflammatory response, within all thrombus aspi-
rates taken at the time of emergency percutaneous coronary 
intervention (PCI) in patients presenting with very LST. This 
was in addition to the acute thrombus seen in all samples 
and “hypereosinophilia” (likely to be secondary to polymeric 
 
hypersensitivity) observed in a proportion of aspirates [55].   
Conversely, Rittersma et al [97] also showed evidence of 
chronic thrombi which was days to weeks old in at least 50% of 
211 consecutive STEMI patients who had thrombus aspirates 
taken within 6 hours of onset of symptoms. Only 4 patients 
(2%) within the study group had prior PCI to the infarct-
related artery, with the theory for the presence of older thrombi 
being speculated to be related to “clinically silent non-occlusive 
atherothrombotic events” in the preceding days to weeks prior 
to the clinical presentation of occlusive thrombosis.
As to whether “clinically silent non-occlusive atherothrom-
botic events” is also an explanation for the presence of chronic 
thrombi seen with ISR, or if this is related to “thromboresteno-
sis”, is presently unclear. 
Vessel remodelling 
Implantation of DES in vessels that have previously under-
gone positive remodelling (the “Glagov” phenomenon [98]) 
secondary to a large plaque burden have been shown to be 
a significant predictor of restenosis (  Figure 8) [98-100]. 
Theoretically, the level of NIH formation would be the same 
between a non-remodelled and a remodelled vessel following 
stent implantation; however, the phenomenon of where the 
NIH would potentially grow post stent implantation would 
be significantly different between the two vessels. In vessels 
without positive remodelling, the NIH can be partially accom-
modated between the stent and the external elastic membrane 
(EEM), thereby limiting neointimal growth within the vessel 
lumen. Conversely, in a fully remodelled vessel, this process 
cannot occur to the same extent, and the bulk of the NIH 
growth would therefore preferentially occur within the stented 
lumen with a subsequent greater likelihood of restenosis.
Small vessels
This is discussed in Stent factors with strut thickness.
F O C U S  B O X  3
 • Wall shear stress refers to the principle that blood flow is 
fastest (high shear stress) in the vessel centre and slowest 
(low shear stress) when closest to the vessel wall due to 
frictional forces exerted by the vessel endothelium. Low 
shear stress areas lead to the local accumulation of growth 
factors, mitogenic cytokines and platelets which may 
promote either atherosclerosis or neointimal formation 
after vessel injury
 • SES, but not PES, are able to effectively inhibit the 
neointimal response in low shear stress areas
 • “Thromborestenosis” describes the theory in which chronic 
thrombus formation may play an integral part in the 
development of ISR
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Late restenosis
Whereas parallel neointimal proliferation and healing with 
BMS have been shown to be complete after 3 to 6 months 
[101], potentially followed by a late lumen enlargement 
beyond one year, a different pattern of healing has emerged 
with early-generation DES. This has been characterised 
by delayed healing with an ongoing neointimal growth 
beyond 30 days in experimental studies [102] as previously 
described (  Figure 5), and beyond 6 months in clinical 
studies [103]. 
Different mechanisms have been identified in the mecha-
nisms of delayed neointimal growth and these are elaborated 
in the following paragraphs.
Decreasing drug dose
The antiproliferative drug concentration diminishes over 
time according to the individual elution profile of the differ-
ent DES (see Stent factors): with decreasing drug dose, the 
antiproliferative inhibitive effect progressively declines. If the 
arterial healing is not terminated at the point in time when 
the drug elution has ceased, neointimal growth may continue 
to accrue (  Figure 9). 
Chronic inflammation
Chronic inflammation is a trigger for late neointimal growth. 
Animal studies have suggested that the inflammatory response 
among different DES is clearly distinct in terms of the pro-
F I G U R E  7
Evidence of the “Thromborestenosis” theory?
Upper image: in a patient with a diffuse long ISR in the mid circumflex (A-B), IVUS shows homogeneous isoechoic restenotic lesions (upper right 
images) and coronary angioscopy reveals flapping white thrombus attached to the restenotic segment (middle right images: yellow arrows). 
Lower image: histopathology of restenotic tissue taken by direct atherectomy from the restenotic site reveals (from left to right), homogeneous 
tissue and collagen matrix (seen on haematoxylin and eosin stain), smooth muscle cells in collagen matrix (black arrows) (a-SMA stain), few proteo-
glycans (versican and decorin stain) and rich fibrin corresponding to the homogeneous tissue. Reproduced with permission from Oikawa et al [96].
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F I G U R E  9
The different time courses of the neointimal growth (indicated by late lumen loss) for BMS, early and newer-generation DES are shown over a 
five-year period. Different mechanisms contributing to the late neointimal growth in DES are presented. In addition, a case example of a sirolimus-
eluting stent showing delayed neointimal growth is depicted. SMC M: smooth muscle cell migration into neointima. D and E: D and E domains of 
fibrinogen. Arrow in histological cross-section depicts peri-strut inflammatory cell infiltrates. Reproduced (Figure and Figure legend) with permis-
sion from Räber et al [231].
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F I G U R E  8
The phenomenon of the increased likelihood of restenosis occurring in positively remodelled vessels. Red arrow indicates position where NIH can 
potentially grow since the NIH cannot be accommodated between the stent and the external elastic membrane (EEM). Adapted and reproduced with 
permission from Spanos et al. [230].
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Neoatherosclerosis
Neoatherosclerosis is defined as the presence of atheroscle-
rotic disease within the neointima of a stented segment, 
ranging from pathological intimal thickening with presence 
of intercellular lipid accumulations to ruptured/unruptured 
thin-cap fibroatheroma. It has been speculated that the 
presence of neoatherosclerosis, namely ruptured thin-cap 
fibroatheromas, may be responsible for the acute clinical 
presentation of patients suffering from late restenosis.
Nakazawa et al described in a pathology registry the inci-
dence of neoatherosclerosis within 142 BMS, 81 SES and 76 
PES post-mortem specimens [108]. The incidence of neoathero-
sclerosis was higher in DES (31%) as compared to BMS (16%, 
p<0.001), whereas no meaningful differences were observed 
between the two early-generation DES. An important differ-
ence between BMS and early-generation DES was that the first 
occurrence of neoatherosclerosis occurred earlier with first-
generation DES compared to BMS. Vulnerable plaques, namely 
thin-cap fibroatheroma (TCFA), were found in 1-4% of lesions 
without differences among stent types, but with a delayed 
occurrence in BMS as compared to early-generation DES.
The underlying reason for the difference in the occurrence 
of neoatherosclerosis is currently speculative. The mecha-
nisms of neoatherosclerosis in DES are likely to be different 
from the ones observed in BMS. DES have been associated 
with impaired re-endothelialisation and with a disturbed 
functionality of the neoendothelium. This potentially leads 
to the initialisation of the atherosclerotic cascade commenc-
ing with monocyte adhesion and migration into the neoin-
tima and an increased permeability of the endothelium for 
circulatory lipid migrating into the subendothelial matrix. 
Conversely, re-endothelialisation is faster and the endothe-
lium exhibits a preserved functionality in BMS-treated seg-
ments, suggesting different mechanisms involved in the gen-
esis of neoatherosclerosis. Nakazawa et al [108] speculated 
whether shear stress may be a major contributing explana-
tory factor, as evidenced by some differences in the longi-
tudinal distribution of neoatherosclerosis, in particular an 
increased occurrence in the proximal part of BMS-treated 
segments.
Illustrative examples of histological cross-sections depict-
ing neoatherosclerosis are provided in  Figure 10 and two 
examples of OCT cross-sections displaying neoatheroscle-
rotic lesions are shown in  Figure 11.
To date, two in vivo studies have corroborated the afore-
mentioned histopathological findings. Takano et al compared 
the appearances of neointimal tissue in BMS-treated lesions at 
6 months and separate BMS-treated lesions more than 5 years 
previously [109]. Whereas neoatherosclerosis was absent in 
the early group, a transformation of the neointima during 
portion of giant cells, granulomas, eosinophils, lymphocytes 
and fibrin deposition as previously described [26-30]. Carter 
et al compared SES and BMS in a porcine coronary artery 
model and found late neointimal formation between 30 
and 90 days, which resulted in a similar amount of neointi-
mal area at 90 days between SES and BMS, thus mitigating 
the initial suppression achieved with SES at 30 days [102]. 
Histological data documented a progressive increase in 
injury and inflammation scores between 30 and 180 days, 
probably representative of a chronic inflammatory response 
with a predominantly lymphocytic reaction with giant cells.
The presence of inflammatory reactions during the long-
term time course following SES implantation was further 
corroborated by Virmani et al [104]. Histological evaluation 
of stented porcine coronary arteries demonstrated an intense 
circumferential granulomatous, eosinophil-rich inflamma-
tory response during long-term follow-up (90 and 180 days) 
in SES, and to a lesser extent PES; conversely, inflammation 
was absent with BMS. PES as opposed to SES was further 
characterised by an increase in fibrin deposition. The pres-
ence of fibrin - which has been described in the vicinity of 
stent struts in experimental [104] and autopsy studies [105] 
is an initiator of smooth muscle cell migration and prolif-
eration [106]. Porcine coronary models have demonstrated 
an increasing amount of fibrin in the long-term course (90 
days), [104] which is analogous to delayed wound healing 
and excessive scarring. Delayed fibrinolysis is a stimulus to 
smooth muscle cell proliferation and excessive collagenous 
matrix deposition, leading to late restenosis.
The most likely culprits for the prolonged inflammatory 
reactions of the vessel wall are hypersensitivity reactions to 
the durable polymer. Durable polymers serve as a standard 
component of early-generation DES and are of importance 
as they facilitate drug delivery over a certain time (see Stent 
factors) [107]. Animal data have demonstrated that a peak 
in hypersensitivity reactions occurs only after the complete 
release of the drug (>60 days), supporting the notion that the 
durable polymer may be the more important cause [28]. 
Taken together, early-generation SES and PES showed distinct 
long-term vessel responses, which have not been described in 
BMS. Whereas SES may cause a granulomatous and eosinophilic 
reaction, PES is mainly characterised by fibrin deposition. Both 
of these inflammatory reactions may trigger a continued neoin-
timal proliferation and thereby potentially cause late restenosis 
(  Figure 9). Inflammatory reactions are most likely caused by 
the durable polymers which have made them the consequent 
targets for improving stent designs. Whether the strategy of 
more biocompatible polymers or biodegradable polymers will 
result in a lower inflammatory response and consequent lower 
late neointimal proliferation has yet to be demonstrated. 
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long-term follow-up was noted with lipid-rich intima (68%), 
calcifications (10%), intimal disruptions (38%), thrombi, 
and neovascularisation (52%). These results were confirmed 
in another OCT study by Habara et al who evaluated the 
neointimal composition in BMS-treated patients presenting 
with early (<1 year) versus late (>1 year) clinical restenosis 
[110]. Whilst the neointima appeared to be relatively nor-
mal in the early restenosis group, a significant proportion of 
late restenosis lesions presented with atherosclerotic changes, 
thrombi or neointimal tears. An extension of these findings 
to DES was obtained by Kang et al [111] in 50 patients pre-
F I G U R E  1 0
(A) Foamy macrophage clusters in the peri-strut region of sirolimus-eluting stents (SES) implanted for 13 months ante mortem are seen. (B) 
Fibroatheroma with foamy macrophage-rich lesion and early necrotic core formation in SES of 13 months’ duration. (C) Fibroatheroma with peri-
strut early necrotic core, cholesterol clefts, surface foamy macrophages, and early calcification (arrows) in SES at 13 months. (D) Peri-strut late 
necrotic core in the neointima characterised by large aggregates of cholesterol cleft in SES at 17 months. (E) Fibroatheroma with calcification in the 
necrotic core in SES of 10 months’ duration. (F) A peri-strut calcification (arrows) with fibrin in SES of 7 months’ duration. (G and H) A low-power 
magnification image (H) of a severely narrowed bare metal stent (BMS) implanted 61 months with a thin-cap fibroatheroma. Note macrophage 
infiltration and a discontinuous thin fibrous cap in a high-power magnification image (G). (I) A low-power magnification image shows a plaque 
rupture with an acute thrombus that has totally occluded the lumen in BMS implanted for 61 months ante mortem. (J) A high-power magnification 
image shows a discontinuous thin-cap with occlusive luminal thrombus. Reproduced (Figure and Figure legend) with permission from Nakazawa 
et al [232].
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senting with clinical restenosis who underwent optical coher-
ence tomography (OCT), intravascular ultrasound (IVUS) 
and IVUS-VH (IVUS-virtual histology) after a mean duration 
of 32 months post DES implantation. The main finding was 
that 90% of all patients exhibited a lipid-rich intima, indi-
cating that atherosclerotic transformation was indeed highly 
predominant in delayed restenotic lesions. Whilst a majority 
of patients with stable angina presented with a structurally 
intact intima, more than 50% of patients presenting with 
unstable clinical symptoms showed evidence of a ruptured 
and thrombosed thin-cap fibroatheroma.
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Taken together, the evidence derived from histology and in 
vivo imaging studies suggests that neoatherosclerosis occurs 
during the long-term time course after both BMS and DES 
implantation and can contribute to late restenosis.
Furthermore, neoatherosclerosis seems to be more prevalent 
in lesions causing symptomatic restenosis. The neoatheroscle-
rotic transformation of the neointima potentially leads to the 
formation of (neo) thin-cap fibroatheromas, which can rupture 
and trigger an unstable clinical presentation. Therefore, in-
stent neoatherosclerosis should also be considered as a differ-
ential diagnosis in patients presenting with stent thrombosis.
TA B L E  2
Serial intravascular ultrasound (IVUS) assessment of neointimal volume in patients treated with BMS or DES during long-term follow-up
TRIAL 
OR FIRST 
AUTHOR
STENT TYPE PATIENT NUMBER
4-6 MONTHS 
(MM3)
1 YEAR
(MM3)
2 YEARS
(MM3)
4 YEARS
(MM3) P-VALUE
TAXUS II [216] BMS 77 28.7±33.2 na 23.9±25.1 na 0.02
Aoki et al [217] SES 23 2.1±1.7 3.8±3.3 7.0±6.7 8.4±5.8 <0.0001
TAXUS II [216] PES-SR 43 9.4±12.1 na 13.6±11.3 na 0.018
TAXUS II [216] PES-MR 41 10.7±15.8 na 16.9±17.3 na 0.013
Collet et al [218] SES 12 na 2.5±3.7 na 7.7±6.7 na
Collet et al [218] BES 13 1.2±2.0 na na 1.2±4.9 na
BMS: bare metal stent; SES: sirolimus-eluting stent; PES-SR: paclitaxel-eluting stent slow release; PES-MR: paclitaxel-eluting stent moderate release;
BES: biolimus-eluting stent using biodegradable polymer; na=not applicable.
F I G U R E  1 1
This figure depicts 2 OCT cross-sections obtained 5 years following 
implantation of a sirolimus-eluting stent (Panel A) and a paclitaxel-
eluting stent (Panel B). In Panel A, a signal-poor region between 4 and 
1 o’clock is noted, suggestive of a lipid pool/necrotic core that is cov-
ered by a thick fibrous cap with a high signal intensity (100 microns 
at the location indicated by arrows). Due to the high attenuation of the 
lipid pool/necrotic core (*), the underlying stent struts are displaying an 
unusual low signal without shadowing (S). Taken together, the image 
suggests the presence of a thick-cap fibroatheroma within neointimal 
tissue. Note the artefact (A) at 2 o’clock.
In Panel B, the stent struts are displaying a much more intense signal 
with a typical shadowing. Between three and 6 o’clock, a sharply deline-
ated region with low backscattering and low attenuation is noted, sug-
gesting a calcific pool within the neointimal tissue. 
Note that, in both images, there is no significant narrowing of the 
lumen, which refers to the fact that neoatherosclerosis does not neces-
sarily lead to late restenosis. Image courtesy of Dr Lorenz Räber and 
Professor S. Windecker, Bern, Switzerland.
A B
Angiographic and intravascular imaging data on late 
neointimal growth and restenosis in humans
Longitudinal angiographic and angioscopic follow-up series 
in patients implanted with BMS have observed late improve-
ments in lumen diameter and an increased transparency 
(defined according to the visibility of the majority of the stent) 
respectively at three years of follow-up, suggesting late lumen 
remodelling on the basis of fibrotic maturation and regression 
of the neointima. Kimura et al reported a significant improve-
ment in MLD from 1.94±0.48mm at 6 months to 2.09±0.48 
(p≤0.001) at 3 years [112]. A longitudinal angioscopic evalu-
ation in 12 patients following BMS implantation exhibited a 
change in neointimal appearance from 6 months to 3 years 
characterised by an increase in transparency [113]. A prolon-
gation of the angiographic follow-up of the above-mentioned 
study by Kimura et al demonstrated late re-narrowing beyond 
4 years, [114] suggesting a triphasic pattern following BMS 
implantation: 1) pronounced neointimal proliferation within 
the first 6 months, followed by 2) a lumen enlargement with 
maturation of the neointima, and finally 3) leading to a re-
narrowing, probably paralleled by an atherosclerotic trans-
formation as previously described (  Figure 9). 
In contrast to BMS, angiographic and IVUS studies of 
early-generation DES documented a continued increase in 
neointimal formation beyond the time point at which neoin-
timal proliferation is halted in BMS.  Table 2 provides 
an overview of IVUS studies that assessed serial changes in 
neointimal volumes among different stent types. Whereas 
in BMS no increase in neointimal volume was observed, 
early-generation DES have been associated with an on-going 
growth up to 4 years. Notably, all of these studies have only 
provided a snapshot within the first year after implantation, 
and at a single time point beyond one year (e.g., at 2, 3, or 
4 years). In view of this methodological limitation, there is 
no definite answer in respect to the exact dynamics of late 
neointimal growth, and presently it remains unclear whether 
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the continued growth is halted at 2, 3, or 4 years, or whether 
it continues beyond 4 years. Furthermore, serial IVUS data 
on newer-generation DES are, to date, scarce. 
 Angiographic data
 Table 3 provides an overview of angiographic long-term 
studies investigating delayed late loss, namely the difference 
in late loss between 6-12 months and at long-term follow-up 
beyond one year. 
In SIRTAX LATE, 293 patients underwent serial angi-
ography at baseline, 8 months and 5 years (SES=142, 
PES=151) [103]. Overall, an ongoing reduction of the 
minimal lumen diameter was noted between 8 months and 
5 years, resulting in a late loss of 0.33±0.66 mm. Whilst 
SES was superior in terms of late loss at 8 months, differ-
ences between PES and SES were balanced at five years. 
This was explained by a late catch-up observed with SES, 
namely a numerically higher delayed late loss with SES (SES 
0.37±0.73 mm, PES 0.29\0.59 mm, p=ns). In keeping with 
the findings from SIRTAX LATE, Byrne et al demonstrated 
in a large, unpaired angiographic patient cohort that the 
late loss at 6-8 months further accrued with first-generation 
DES (PES and SES) [115]. A numerically higher increase of 
late loss was consistently shown with SES (0.17±0.50 mm) 
compared to PES (0.13±0.50 mm). As the absolute increase 
in late loss from 8 months to 2 years observed by Byrne et 
al was numerically lower than the increase from 8 months 
to 5 years in SIRTAX LATE, one may speculate that neointi-
mal growth continued beyond 2 years. Interestingly, a third 
group in the study of Byrne et al, composed of polymer-
free DES, exhibited only a minimal delayed late loss of 
0.01±0.42 mm, suggesting that polymer-free stents may be 
less affected.
Newer-generation drug-eluting stents
Histological data comparing the long-term inflammatory 
responses of newer-generation DES using durable polymer 
are to date scarce. As they relate to devices using biodegrad-
able polymer technology for drug delivery, it will be of inter-
est to investigate how the bio-absorption process, which is 
TA B L E  3
Serial angiographic assessment of late loss following BMS or DES implantation during long-term follow-up
FIRST AUTHOR STENT TYPE NUMBER OF LESIONS
LATE LOSS SHORT 
TERM (BL-FUP1) 
(MM)
LATE LOSS LONG 
TERM (BL-FUP 2) 
(MM)
DELAYED LATE 
LOSS/GAIN (MM)
Asakura et al [113] BMS 12
6 mo
0.74 ± 0.32 
3 yrs
0.51 ± 0.26
gain : 0.23
Kimura et al [112] BMS 72
6 mo
0.61
3 yrs
0.46
gain : 0.15
Byrne et al [115] PF- RES
SES
PES
375
704
501
6-8 mo
0.46 ± 0.57
0.25 ± 0.50
0.46 ± 0.59
2 yrs
0.47 ± 0.59
0.37 ± 0.60
0.55 ± 0.66
loss : 0.01 ± 0.42
loss : 0.17 ± 0.50
loss : 0.13 ± 0.50
Räber et al [219] SES
PES
179
203
8 mo
0.09 ± 0.18
0.13 ± 0.22
5 yrs
0.45 ± 0.73
0.42 ± 0.62
loss : 0.37 ± 0.73
loss : 0.29 ± 0.59
Kyung Woo Park et al [220]
SES
PES
24
23
6-9 mo*
0.24
0.55
2 yrs*
0.50
0.65
loss : 0.26
loss : 0.10
Duk-Woo Park et al [221] BMS
LD-PES
HD-PES
17
18
20
6 mo*
0.80
0.50
0.30
2 yrs*
2 yrs*
0.70
0.90
gain : 0.40
loss : 0.20
loss : 0.60
Sousa et al [222]
FR-SES
SR-SES
13
13
1 yr
0.08 ± 0.31
0.08 ± 0.23
4 yrs
0.41 ± 0.49
0.09 ± 0.23
loss : 0.33
loss : 0.01
PF: polymer free; SES: sirolimus-eluting stent; PES: paclitaxel-eluting stent;  BMS: bare metal stent; LD: low dose;
HD: high dose; FR: fast release; SR: slow release; mo: months; yrs: years ; where SD is missing, values have been calculated using MLD.
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a known trigger for at least a transient inflammation, may 
enhance neointimal proliferation during the long-term fol-
low-up [116]. With polymer-free DES, few animal studies 
have reported a decrease in both inflammatory reactions and 
fibrin deposition up to 180 days, with a subsequent lower 
extent of angiographically defined delayed late loss [115].
Clinical significance of late catch-up
The most relevant question emerging from the angiographic 
and intravascular imaging data is whether delayed neointimal 
proliferation translates into a clinically meaningful need for 
target lesion revascularisation (TLR) during long-term follow-
up, reducing the early efficacy benefit of DES. Long-term results 
from randomised controlled trials of early and newer-genera-
tion DES consistently show a yearly TLR rate of less than 2% 
beyond one year, without meaningful differences compared 
to BMS (  Table 4). After subtraction of stent-thrombosis-
related TLR - which are at least in part not related to resteno-
sis - the annual TLR rate is as low as 1–1.5%. This relatively 
low frequency of late TLR is explainable by the magnitude of 
the delayed late loss (between 1 and 5 years = 0.30-0.40 mm), 
which is below the threshold that usually causes clinically sig-
nificant restenosis. Against this backdrop it is reasonable to 
conclude that early-generation DES delay neointimal forma-
tion and healing during the long-term course, but without sig-
nificantly compromising the early benefit in efficacy. Prolonged 
neointimal proliferation, however, may be a useful marker to 
assess the delay in healing. The presence of delayed healing 
TA B L E  4
Target lesion and stent thrombosis rates beyond one year in BMS, early and newer-generation DES
TRIAL ACRONYM
STENT 
TYPE AND 
NUMBER OF 
PATIENTS
CLINICAL 
SETTING
FOLLOW-UP 
PERIOD 
(YEARS)
 INCIDENCE 
OF TLR UP 
TO LATEST 
FOLLOW-UP 
(%)
INCIDENCE 
OF TLR 
BETWEEN 
1-5 YEARS 
(%)
ANNUAL 
TLR RATE 
BETWEEN 1 
YEAR AND 
MAXIMUM 
FOLLOW-UP 
(%)
ARC 
DEFINITION 
VLST UP TO 
MAXIMUM 
FOLLOW-UP 
(%)
ANNUAL 
VLST 
INCIDENCE 
(%) 
EARLY-GENERATION DES (RCTS WITH 5-YEAR FOLLOW-UP)
RAVEL [223] SES (n=120)
vs.
BMS (n=118)
Stable CAD 5 10.3 vs. 1.7*† 2.6 vs. 0.4*
0.8 vs. 0.8
p=1.0 0.2 vs. 0.2*
SIRIUS [224] SES (n=533)
vs.
BMS (n=525
Stable CAD 5
9.4 vs. 24.2 
p<0.001
4.5 vs. 4.0
p=0.76 1.1 vs. 1.0*
0.8 vs. 0.4 
p=0.56 0.2 vs. 0.1*
TAXUS IV-SR [225] PES (n=651)
vs.
BMS (n=643)
Stable and 
unstable 
CAD
5 16.4 vs. 4.3
p<0.001
6.0 vs. 8.0* 1.5 vs. 2.0
p=0.26
0.8 vs. 0.4* 0.2 vs. 0.1
p=0.49
SIRTAX LATE [103] SES (n=503)
vs.
PES (n=509)
Allcomers 5 13.1 vs. 15.1
p=0.29
7.4 vs. 4.9
p=0.16
2.0 vs. 1.4
p=0.17
2.6 vs. 2.4
p=0.83
0.7 vs. 0.6
p=0.85
NEWER-GENERATION DES (RCTS WITH AT LEAST 3 YEARS OF FOLLOW-UP)
LEADERS
{Wykrzykowska, 2011
 #30}
BES (n=857)
vs.
SES (n=850)
Allcomers 3 7.6 vs. 8.8
p=0.38
2.7 vs. 3.4
p=0.41
1.3 vs. 1.7
p=0.56
0.3 vs. 0.9
p=0.09
0.1 vs. 0.4
p=0.12
ENDEAVOR pooled 
[226]
ZES 
(n=2,132)
Stable and 
unstable 
CAD
3 6.7 1.3 0.65* 0.8‡ 0.4‡
SPIRIT II, III pooled 
[227]
EES (n=892) 
vs. PES 
(n=410)
Stable CAD 3 5.4 vs. 9.1 2.5 vs. 3.7
p=0.27
1.3 vs. 1.9* 0.2 vs. 0.5
p=0.59
01. vs. 0.3*
TLR is ischaemia-driven if available. *Unpublished data that was calculated using outcomes at 1 year and at the time point of the maximal follow-
up, therefore no p-values  † TLR between 9 months and 5 years. ‡ARC definite or probable stent thrombosis.
BMS: bare metal stent; SES: sirolimus-eluting stent; PES: paclitaxel-eluting stent; ZES: zotarolimus-eluting stent; na: not applicable; VLST: very 
late stent thrombosis; TLR: target lesion revascularisation; ENDEAVOR: randomised controlled trials of the Medtronic Endeavor drug-eluting 
coronary stent system. LEADERS: limus eluted from a durable versus erodible stent coating. RAVEL: a randomised comparison of a sirolimus-
eluting stent with a standard stent for coronary revascularisation. SIRIUS: sirolimus-eluting stent in de novo native coronary lesions. TAXUS II-SR: 
treatment of de novo coronary disease using a single paclitaxel-eluting slow release stent. SPIRIT: a clinical evaluation of the XIENCE V everolimus-
eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions. SIRTAX LATE: sirolimus versus paclitaxel-
eluting stent for coronary revascularisation LATE trial.
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may contribute to a mechanistic explanation of the ongoing 
risk of very late stent thrombosis as it has been identified as the 
principal pathological finding in an autopsy study distinguish-
ing late thrombosed from patent early-generation DES [117]. 
Newer-generation DES, such as an everolimus-eluting 
stent, have shown superior clinical safety and efficacy out-
comes when compared to PES up to 2 years [118,119]. The 
annual incidence of late (>1 year) TLR in patients included 
in SPIRIT IV amounted to 2.1% in EES and 2.9% in PES. 
Patients included in the allcomers study COMPARE showed 
0.9% late TLR in the EES and 1.5% in the PES-treated 
patient group, respectively. Although there was no significant 
statistical difference in late TLR in both studies, it is impor-
tant to note the continued separation of the TLR curves 
beyond 1 year. This continued separation suggests a potential 
decrease in late TLR with the use of newer-generation DES 
as compared to the early-generation PES, potentially due to a 
less extensive inflammatory reaction.
Functional stent coverage by endothelium and vasomotor 
response 
As a consequence of stent implantation, there is a substantial 
reduction in the integrity of the vessel endothelium within the 
treated vessel segment. Furthermore, histological studies have 
confirmed that recovery of the endothelial cellular layer is sig-
nificantly delayed following DES compared to BMS implanta-
tion [120]. It is commonly accepted that the delay in the recov-
ery of the endothelial cellular layer following DES implantation 
is a consequence of the applied antiproliferative drug, which 
non-selectively inhibits mitosis of smooth muscle cells, fibro-
blasts and endothelial cells. The endothelial cell layer of the 
vessel wall has, however, a vital role in mediating vasomotion 
of the vessel wall by the excretion of nitric oxide (NO).
Notably, several studies have associated a lower vasore-
activity in the vessel segments adjacent to implanted early-
generation DES compared to BMS [121-123]. Within these 
studies different methodologies have been used to induce vas-
omotion of the vessel segment edges, namely physical stress 
(e.g., bicycle stress test), rapid atrial pacing, and high dose 
acetylcholine infusion. Newer-generation DES, integrating 
features such as reduced strut thickness, lower drug dose and 
a more biocompatible polymer, have allowed for less trau-
matic delivery and improved biocompatibility of the stent. 
These features may be the reasons why further studies have 
shown an improvement in the vasoreactivity of the adjacent 
vessel segments in implanted newer-generation DES, com-
pared to earlier-generation DES [124,125].
To date, the magnitude of the correlation between endothe-
lial restoration within the stented segment of DES and the vaso-
motor response in the adjacent vessel segment remains unclear. 
The introduction of intravascular optical coherence tomogra-
phy (OCT) technology has permitted the assessment of vessel 
stent strut coverage, as an indicator of endothelial integrity. 
Fuji et al [126] assessed strut coverage 3 months after zotaroli-
mus-eluting stent implantation and demonstrated a correla-
tion between the degree of stent coverage and the vasomotor 
response assessed by acetylcholine infusion. Furthermore, an 
inverse correlation of the rate of uncovered struts with the 
vasomotor capacity of the vessel wall was shown, thus sup-
porting the hypothesis of a relationship between restoration of 
the stent vessel endothelialisation and vasomotor response fol-
lowing DES implantation.
F O C U S  B O X  4
 • Three principal factors may be responsible for the 
formation of late restenosis: 1) decreasing drug dose; 
2) chronic inflammatory reactions and persistent fibrin 
deposition; 3) neoatherosclerosis
 • Early-generation SES and PES, but not BMS, have been 
associated with chronic inflammation and fibrin deposition 
during the long-term time course
 • Neoatherosclerosis occurs earlier and more frequently in 
DES compared to BMS
 • Incomplete re-endothelialisation and impaired 
functionality of the endothelium may be the source of 
neoatherosclerosis in DES, whereas shear stress has been 
suggested to be a relevant contributor in BMS
 • Lipidic transformation of the neointima can lead to 
the formation of thin-cap fibroatheroma, which can be 
responsible for unstable presentations of restenosis
 • Early-generation SES and PES have been associated 
with a delayed late loss of 0.3-0.4 mm between 1-5 years 
in angiographic long-term studies without significant 
differences between the two devices. Data on newer-
generation DES are scarce
 • The small magnitude of delayed late loss observed with 
early-generation DES does not translate into clinically 
significant late TLR rates (incidence <1.5% per annum) and 
does not compromise the early benefit in efficacy achieved 
with the introduction of DES
 • Angiographic and clinical data suggest that some of the 
newer-generation DES (e.g., polymer-free DES) may be 
less vulnerable to late restenosis
STENT FACTORS
Polymer release kinetics
Polymer release kinetics play a key and fundamental role in 
the prevention of restenosis with the suggestion that it is not 
necessarily the total dosage of the antiproliferative drug deliv-
ered to the vessel wall that is important but more the kinetics 
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of the release of the drug. The PISCES trial [127] was the first 
human study to demonstrate this principle involving the use 
of the Conor stent and six different polymer-drug release for-
mulations. The main finding of the trial was that the duration 
of the drug release had a far greater impact on the inhibition 
of NIH than the dose of the drug delivered (  Figure 12).
The polymer-free biolimus A9-eluting stent, with 2 differ-
ing doses of biolimus, has been investigated in animal models 
[128] and the first-in-human BIOFREEDOM study [129]. 
Initial studies in animals indicated that the lower (112 µg/per 
14 mm of stent length) and higher dose (225 µg/per 14 mm 
of stent length) biolimus A9-eluting stents have equivalent 
effects on the NIH response and both have a superior late 
reduction in NIH as compared to SES at 180 days [128]. 
In the subsequent BIOFREEDOM study [129] in humans, 
powered to test for non-inferiority, statistical equivalency 
was achieved in all 3 groups with an in-stent late lumen loss 
reported as 0.17 mm (“standard-dose biolimus” group - 15.6 
µg/per mm of stent length), 0.22 mm (“low-dose biolimus” 
group - 7.8 µg/per mm of stent length) and 0.35 mm for the 
Taxus stent with no differences in MACE or reported cases 
of stent thrombosis in all 3 groups. 
It would therefore appear that a certain threshold of drug 
needs to be delivered to the vessel wall over a sustained, pro-
longed period of time, during the process of endothelialisa-
tion of the DES, in order to “dampen” down the inflamma-
tory response and limit NIH formation. This is supported by 
molecular biology studies which have suggested that genes 
responsible for the proliferative response potentially remain 
active for a period of up to 21 days after vessel injury [130]. 
Achieving the fine balance between the drug type, dosage and 
delivery over the appropriate time are therefore crucial fac-
tors in DES design. 
In addition, an early peak in drug release may theoreti-
cally be of importance to inhibit the early inflammatory reac-
tion of the vessel wall caused by the traumatic vessel wall 
injury following stent implantation. The early suppression of 
injury-induced inflammation may result in an antithrombotic 
effect, which may explain the decreased risk of acute stent 
thrombosis observed in a recent study comparing the newer-
F I G U R E  1 2
The PISCES trial involving the use of the Conor stent and six different polymer-drug-release formulations in humans
In this example, 10 mcg of paclitaxel released over 10 days (D3) following DES implantation appeared to have little effect on NIH production, whereas 
the same dosage of the drug released over a 30-day (D5) period led to a profound reduction in NIH, with a more than halving (57% reduction) of the 
rate of LLL. Interestingly, 30 mcg of the same drug released over a 10-day period (D4) was also less effective. Corresponding tables and graphs of 
the drug release kinetics are shown. The design of the Conor stent is also illustrated (lower right image).
Adapted and reproduced with permission from Serruys et al [127].
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generation everolimus-eluting stent with a bare metal stent 
for primary PCI [131]. 
Type of DES? Type of drug?
Differences relating to first-generation DES are discussed in 
the Late restenosis section of Arterial factors. Data from the 
SCAAR registry, involving >35,000 patients implanted with 
four different types of DES (ZES, SES, Taxus® Express® 
[Boston Scientific] and Liberté® [Boston Scientific]) in real-
world practice at 2-year follow-up, showed that the rates of 
restenosis with DES implantation were significantly higher 
in diabetics and that important differences existed in the effi-
cacy of differing brands of DES to reduce restenosis [21]. In 
particular, the restenosis rates with Endeavor® (Medtronic, 
Inc., Minneapolis, MN, USA) were twice as high in diabet-
ics as compared to other DES types. Higher restenosis rates 
were also evident in diabetics with Endeavor (RR: 1.77, 
95% CI: 1.29 to 2.43) and SES (RR: 1.25, 95% CI: 1.04 
to 1.51) when compared to non-diabetics. Five-year unpub-
lished follow-up data from the SCAAR registry continued 
to demonstrate differences in the efficacy of the first and 
second-generation DES in reducing rates of stenosis, with a 
trend for better outcomes seen after nearly 2 years’ use of the 
everolimus-eluting stent.
The EES releases 80% of the drug within 30 days and nearly 
all the drug within 4 months. In the Spirit I, II, and III trials, 
a LLL of 0.10, 0.16, and 0.33 mm and TVR rates of 3.8%, 
3.4%, and 4.6% were observed at 6, 12, and 24 months, 
respectively [43]. Conversely, the Endeavor reported a LLL 
of 0.60 mm and 0.67 mm and TVR of 6.3% and 4.5%, 
respectively, in the Endeavor III and IV trials at 12 months. 
The Endeavor, however, elutes 95% of its drug very rapidly 
(within 14 days): this is highly likely to be the main reason 
for the poorer results seen. 
The next-generation Endeavor® Resolute stent (Medtronic, 
Inc.), consisting of the same cobalt chromium metallic plat-
form (Driver BMS; Medtronic, Inc.) and the same drug 
(zotarolimus) as the Endeavor stent, but incorporating the 
BioLinx™ polymer - an enhanced triple polymer combining a 
hydrophobic coating covering the stent, a hydrophilic, more 
biocompatible polymer on the abluminal surface with a third 
polymer binding the previous two polymers – allowed for 
substantially longer polymer drug release kinetics (180 days), 
compared to 14 days with the Endeavor stent. The Endeavor 
Resolute stent reported an in-stent LLL of 0.12, 0.22, and 
0.27 mm at 4, 9, and 13 months, respectively, with angio-
graphic equivalency (LLL 0.19 mm) in terms of meeting the 
criteria for non-inferiority being met when compared with 
EES. Equivalency in the 12-month primary endpoint of tar-
get lesion failure (a composite of cardiac death, target vessel 
MI, and clinically driven target lesion revascularisation [8.2% 
versus 8.3%]) and a slight increase in the rate of definite stent 
thrombosis (1.2% versus 0.3%, p=0.01) were also seen [132].
Type of drug
Based on the vast experimental and clinical evidence associ-
ating inflammation with restenosis as previously discussed, 
multiple immunosuppressive and antiproliferative drugs 
– such as dexamethasone, actinomycin D, cytochalasin D, 
17-beta-estradiol, mycophenolic acid, and angiopeptin – 
have been investigated for their effect in inhibiting the path-
way of NIH [133,134]. As an example, methylprednisolone, 
although shown to be promising in a porcine model [135], 
demonstrated a restenosis (>50% diameter stenosis at fol-
low-up) rate of 13.3% and a LLL of 0.45 mm at follow-up 
in the STRIDE (Study of antirestenosis with BiodivYsio dex-
amethasone-eluting stent) European Study [136]. The very 
short release profile of the drug – almost completely eluted in 
the first 24 hours after deployment – no doubt had a strong 
influence on the clinical effect of the drug. 
The drugs that have been demonstrated to have superior 
performance in a consistent and reproducible fashion both 
in preclinical investigations and in clinical trials are siroli-
mus (rapamycin) and paclitaxel in first-generation stents, 
and the limus family of drugs (which includes sirolimus) in 
second-generation DES [133,134]. Although polymer release 
kinetics are crucial to the antiproliferative effects of these 
drugs as previously described, because of the differing and 
potentially more potent mechanisms of action of the limus 
family of drugs compared to paclitaxel, the limus family of 
drugs are thought to deliver a more sustained antiprolifera-
tive NIH effect [133,134]. Furthermore, in the randomised 
PAINT trial, Lemos et al. [137] conducted a head-to-head 
comparison of 2 DES with the same metallic stent platform 
and biodegradable-polymer carrier but releasing either siroli-
mus or paclitaxel, and a BMS of the same metallic platform. 
Nine-month in-stent late loss was significantly more favour-
able towards sirolimus (paclitaxel: 0.54-0.44 mm, sirolimus: 
0.32-0.43 mm, vs. BMS: 0.90-0.45 mm, respectively, p< 
0.01) in the 274 patients studied. 
New-generation DES, such as the everolimus-eluting stent 
(XIENCE; Abbott Vascular) has shown superiority compared 
to the Taxus PES and shown itself to be a powerful inde-
pendent predictor of 2-year freedom from ischaemia-driven 
target lesion revascularisation (hazard ratio: 0.59 [95% CI: 
0.47–0.74], p=0.0001), ischaemia-driven target vessel revas-
cularisation (0.70 [0.58,0.84]; p=0.0002), myocardial infarc-
tion (hazard ratio: 0.54 [95% CI: 0.41–0.71]; p=0.0001) and 
MACE (hazard ratio: 0.64 [0.54, 0.77]; p<0.0001) [138]. 
Furthermore, the biolimus-eluting stent with a biodegrad-
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able polymer has demonstrated non-inferiority to the SES 
(Cypher) at up to 4 years follow-up [139,140]. It is likely that 
a combination of favourable polymer release kinetics and the 
limus-based drug are reasons for the more advantageous clin-
ical effects seen. Conversely, the Endeavor DES, eluting the 
limus-based zotarolimus drug, led to unfavourable clinical 
outcomes due to the very short polymer release kinetics (14 
days) as previously discussed.
Stent gap, non-uniform strut distribution and drug 
deposition
Takebayashi et al [141] classically described the number and 
distribution of DES struts, as identified by IVUS, as being 
independent significant risk factors (fewer struts and non-
uniform stent strut distribution) for NIH formation and the 
subsequent risk of restenosis. Non-uniform DES strut distri-
bution has been suggested as being attributable to features 
such as stent design (e.g., open versus closed cell), stent gap, 
vessel curvature, coronary bifurcations, ostial lesions, stent 
underexpansion or overexpansion, polymer peeling, and 
stent fracture.
Small vessels and strut thickness
Small coronary artery disease is a recognised challenging sub-
set within the field of coronary artery intervention with sig-
nificant and unacceptable risks of restenosis seen with both 
POBA and BMS [142-145]. A meta-analysis [146] of the use 
of DES in small vessel disease demonstrated that both late 
loss and binary restenosis were largely dependent on the type 
of DES implanted (  Figure 13). 
Mechanisms suggested to explain the poorer outcomes 
associated with small vessels include: (1) a high degree of 
vessel stretch and injury, (2) a smaller post-procedural lumen 
area, and (3) a higher metal density [147]. The overstretch 
theory is, however, controversial, with evidence suggesting a 
possible adverse effect with increased NIH [119,120], no sig-
nificant effect [148], or even potential benefit [142,148]. The 
latter beneficial effects have been proposed to be related to a 
higher balloon-to-artery ratio, the so-called bigger is better 
paradigm (see Implantation factors), leading to appropriate 
apposition of the stent to the vessel wall.
Thicker stent struts have been linked to an increased risk of 
restenosis with BMS [149] and small vessels [147,150,151]. 
The underlying rationale is that a thinner stent strut would 
have less of a “footprint” on the vessel wall with a conse-
quential reduced inflammatory response. With DES, how-
ever, a complex relationship exists between the strut mate-
rial and characteristics, stent design, polymer type, and drug 
release kinetics. Both Cypher and XIENCE appear to have 
the lowest risk of binary restenosis in small vessels, despite 
a large disparity in stent strut thicknesses (approximately 
150 µm versus 90 µm); moreover, Endeavor had the worst 
outcomes despite its strut thickness being approximately 10 
microns more than the XIENCE V® [146]. A fairer com-
parison perhaps would be between the Taxus Liberté and 
Express as both contain identical metallic platform materi-
als, polymer coatings and drug concentrations (1 µg/mm2 
of paclitaxel), except that the Taxus Liberté contains thin-
ner struts, more flexible cell geometry, and uniform cell 
distribution. In the SCAAR registry, the Taxus Express was 
shown to have a mild but significantly higher adjusted risk 
of restenosis compared to Taxus Liberté (RR: 1.32, 95% CI: 
1.10-1.60).21
“On” and “off” label use of DES
The Strategic Transcatheter Evaluation of New Therapies 
(STENT) Group is the largest, multicentre, prospective 
registry involving >15,000 patients to have evaluated 
the late outcomes associated with DES implantation in 
the United States [152]. This compared on-label (short 
de novo lesions in coronary arteries measuring >2.5 mm 
and <3.5 mm for SES or <3.75 mm PES) and off-label 
(ostial, left main stem, chronic total occlusion, saphenous 
vein graft, small or large vessels/multivessel, STEMI, ISR 
lesions) indications for DES implantation. A near doubling 
in the TVR rate was seen in the off-label group at 9 months 
(5.7% versus 3.2%, p<0.0001) and 2 years (11.8% versus 
6.5%, p<0.0001) [153]. 
Data from the Synergy between Percutaneous Coronary 
Intervention with TAXUS and Cardiac Surgery (SYNTAX) 
F I G U R E  1 3
The modelling of the impact of different late losses on follow-up binary 
angiographic restenosis after PCI in coronary segments with small 
(<2.75 mm), medium (2.75–3.25 mm), and large (>3.25 mm) reference 
vessel diameter. Reproduced (Figure and Figure legend) with permis-
sion from Biondi-Zoccai et al [146].
181Chapter 5.2
PERCUTANEOUS INTERVENTIONAL CARDIOVASCULAR MEDICINE  THE PCR-EAPCI TEXTBOOK 805
F I G U R E  1 4
Polymer defects in first-generation DES
Polymer void and bridging on a Taxus Express stent and polymer void and peeling on a Cypher DES. Adapted and reproduced with permission from 
Otsuka et al [159].
Polymer void
Polymer void
Polymer brindging
Polymer peeling
study, reflecting a population of patients with highly com-
plex off-label use of DES in 3-vessel or left main stem dis-
ease, have reported even higher rates of TVR at 1, 2, 3 and 4 
years at 11.6%, 17.4%, 19.7% and 23%, respectively [154]. 
Furthermore, recent evidence has suggested that one of the 
main determinants of future clinical events, including revas-
cularisation, is the clinical risk profile of the patient. High 
EuroSCORE patients from the SYNTAX trial - in particu-
lar in the 3VD population - have been associated with more 
adverse clinical outcomes [155,156]. Registries have also sug-
gested these observations in patients with left main disease 
[157,158]. Further study is required to validate these findings.
Polymer disruption, peeling and cracking
Polymer disruption, peeling and cracking have been demon-
strated to occur in bench studies involving both first [159] 
(  Figure 14) and second (  Figure 15) generation DES, 
[160,161] using light or scanning electron microscopy. 
Although there is no direct evidence to suggest that the 
integrity of the polymer coating is a direct cause of resteno-
sis, there are sufficient theoretical concerns to warrant con-
cern through non-uniform local drug distribution or the dis-
rupted polymer potentially acting as a nidus for an ongoing 
inflammatory response with the subsequent risk of restenosis 
[27-29,54].
Other concerns with regard to the potential for polymer 
disruption involve the percutaneous coronary intervention 
procedure itself. Wiemer et al. [162,163] demonstrated that, 
in DES that had failed to be delivered to the intended implan-
tation site in tortuous calcified lesions, significant damage 
and cracking of the polymer had occurred to varying extents 
with multiple types of second-generation DES. Scanning 
electron microscopy revealed many cases of deep damage to 
the polymer with exposure of the bare metal: in particular, 
the Endeavor RX stents showed up to 20% damage to the 
surface area (  Figure 16). With polymer-free DES, a large 
proportion of the surface area was shown to be without any 
layer of drug (  Figure 16).
Bifurcation stenting, especially if very complex, has been 
hypothesised as possibly leading to polymer disruption, peel-
ing or even polymer void [159], with the consequent risk of 
non-uniform drug distribution and focal stenosis. In bench 
work utilising scanning electron microscopy of the polymer 
integrity of 5 different types of DES (Cypher, Cypher Select, 
Endeavor, Taxus Express, and Taxus Liberté) after undergo-
ing kissing balloon post-dilatation, Guerin et al. [164] dem-
onstrated significantly greater coating damage to the ostial 
struts, especially along the overstretched segments, with 
cracking of the polymer seen in all cases and even exposure 
of bare metal. Of note is that the Endeavor stent showed 
a subtotal destruction of its coating on the luminal surface 
in all segments, whereas the other DES demonstrated more 
focal localised abnormalities.
Stent fractures
Stent fracture related to DES implantation in coronary arteries 
was first reported in 2004 (  Figure 17) [165]. Subsequent 
retrospective and prospective registries have quoted restenosis 
rates ranging from 15% to 100% in patients identified as hav-
ing stent fractures [166]. In the only randomised controlled 
trial reporting the incidence of stent fracture and outcomes 
after DES implantation and subsequent mandatory angio-
graphic follow-up (LONG-DES-II study), a 14% incidence of 
restenosis was observed [167].
The pattern of restenosis associated with DES fractures 
appears to be focal, reflecting the local trauma sustained by 
the vessel at the fracture site once this has occurred. Due to the 
underlying mechanism of DES fracture (as explained below), 
restenosis tends to occur fairly late, and invariably after 
most if not all of the antiproliferative drug has been eluted. 
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F I G U R E  1 5
Polymer defects seen in second-generation DES
Adapted and reproduced with permission from Basalus et al [160].
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The subsequent healing response therefore occurs without 
any drug to suppress the NIH response, which in itself is 
exacerbated by further exposure of the vessel to the disrupted 
polymer. The aetiology of the DES fractures also appears to 
be relatively well understood and is related to two principal 
factors.
The first is the location of the implantation site of the DES. 
Mechanical fatigue of the metallic stent can occur due to 
excessive movement during cardiac contraction, especially at 
a “hinge point” where the potential for 2 opposing forces 
may occur at the same site [168]. In these situations, excessive 
movements can occur to the DES implanted in one part of a 
vessel during cardiac contraction, in particular in the right 
coronary artery or a saphenous vein graft, because of their 
greater propensity for angulation and tortuosity [166,168].
Secondly, the design of the DES itself has been strongly 
incriminated with causing DES fracture. A closed-cell design, 
such as occurs with SES, is less likely to be able to withstand 
the pressures related to excessive movements compared with 
the open-cell design of a PES. In a recent meta-analysis, [166] 
the incidence of stent fracture was reported to be less than 
0.1% with the open-cell PES and approximately 2.3% with 
the closed-cell SES.
Long stents, overlapping stents, tight lesions that have been 
“vigorously post-dilated and expanded,” [167] myocardial 
bridge sites, areas of significant curvature (due to the lack 
of conformability of certain DES, especially of closed-cell 
design) are all other factors which may predispose to DES 
fracture [165-173].
Newer-generation DES have consequently aimed to main-
tain the open-cell design and have thinner struts by using new 
metallic alloys. Although the radial strength has been pre-
served with next-generation DES - recent case reports have 
suggested that, with certain types of next-generation DES, 
F I G U R E  1 6
Polymer defects in second-generation DES that could not be delivered through calcified, tortuous vessels. Adapted and reproduced with permission 
from Wiemer et al [163].
A: unexpanded Janus Carbostent Flex (Sorin, Milan, Italy): small polymer irritations (black arrows) at the fringe (magnification x 200.
B: unexpanded Yukon Choice Stent (Translumina GmbH, Hechingen, Germany): very thin, irregular drug layer covering stent and balloon. A large 
area of the surface of the stent was found to be without drug coverage (black arrows) (magnification ? (x100)).
C: unexpanded Axxion (Biosensors International, Singapore): large continuous areas and spots without any drug coverage (white arrows) (magni-
fication (x80).
D: unexpanded XIENCE V®: typical wrinkling and cracking of polymer with bare metal exposure at loop region (black arrows) after failed attempt to 
pass the DES through a calcified vessel (magnification x 150.
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the longitudinal strength of the device may potentially be 
affected, increasing the likelihood for stent deformation (lon-
gitudinal elongation or compression) requiring post-dilation 
or further stent placement - episodes of late stent thrombo-
sis have also been reported [174-176]. Higher incidences of 
restenosis have, at the time of writing, not yet been reported. 
IMPLANTATION FACTORS 
Incomplete stent expansion
A smaller post-procedural minimal lumen diameter (MLD) 
and a greater residual stenosis (  Figure 17) have been 
associated with long-term DES patency and clinical out-
comes [177-187]. Evidence of stent underexpansion has been 
reported in 20-40% of cases when assessed by quantitative 
coronary angiography (QCA) and 38-70% of cases when 
assessed by IVUS [182-184]. However, what proportion of 
these cases with stent underexpansion are clinically relevant 
in causing restenosis remains unclear. Serial IVUS analyses 
from the SIRIUS trial [185] and other studies [186,187] 
investigating SES use, have demonstrated a cut-off of a post-
procedural MSA of between 5.0-5.5 mm2 as being the opti-
mal area to reduce the likelihood of restenosis.
In an important meta-analysis, Casella et al [188] com-
pared IVUS against angiographic-guided BMS implantation 
(n=2,972 patients) and demonstrated that, at 6 months fol-
low-up, there was reduced TVR (OR 0.62; 95% CI: 0.49-
0.78; p=0.00003), binary restenosis (OR 0.75; 95% CI: 
0.60-0.94; p=0.01) and MACE (OR 0.79; 95% CI: 0.64-
0.98; p=0.03) when an IVUS approach to BMS implantation 
was used. Since then, the only new published randomised 
controlled trials of IVUS versus angiographic-guided stent 
implantation were the AVID trial [189] for BMS and a small 
trial (Jakabcin et al [190]) for DES.
The AVID trial was published 10 years after the data collec-
tion and had mixed results, with no benefit in the incidence 
of 12-month TLR, a larger minimum stent area post BMS 
implantation and, on subgroup analysis, a lower 12-month 
TLR rate for vessels ≥2.5 mm or vessels with a high-grade 
pre-stent stenosis. With DES, Jakabcin et al failed to show 
any differences in the clinical endpoints of MACE (death, 
myocardial infarction and reintervention) at 18 months. 
F I G U R E  1 7
The first reported DES fracture in the literature made by our group in 2004
The initial RCA result (A) following implantation of 3 overlapping 3 mm Cypher DES (post-dilated with a 3.5 mm balloon). 5 months later the patient 
re-presented with unstable angina – 4 very focal lesions, giving the vessel a beaded appearance, were demonstrated on both coronary angiography 
(B-C) and IVUS C), indicative of DES fracture. Reproduced with permission from Sianos et al [165].
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tation would be more likely to be of significance in leading 
to a flow-limiting lesion. Conversely, if the MSA was larger, 
then the growth of the same amount of NIH would be clini-
cally less relevant in causing binary restenosis [193]. Other 
suggestions of DES underexpansion as a cause of ISR have 
been related to possible asymmetrical stent expansion, which 
may affect the pattern of neointimal growth through possible 
uneven drug delivery [194,195]. Numerous factors, includ-
ing “off-label” indications for DES implantation, as previ-
ously described, are involved in increasing the risk of subop-
timal stent deployment (  Table 5). 
Furthermore, the initial results of the AVIO (Angiographic 
Versus IVUS Optimisation) randomised, multicentre trial assess-
ing IVUS-guided DES implantation were presented in 2010 
[191,192]. In 142 patients with complex lesions implanted 
with IVUS-guided DES, no clinical benefit was demonstrated 
compared to controls, with comparable clinical outcomes in 
the combined endpoint of MI, target lesion revascularisation 
(TLR), TVR or cardiac death at 30 days and 9 months (85.9% 
vs. 83.1%, p=0.47). The primary endpoint of a higher MLD 
was seen in the IVUS-guided DES implantation group (2.70 mm 
vs. 2.51 mm, p=0.0002). As only 39% of patients had QCA 
at 9 months, no comments could be made as to whether this 
approach would potentially lead to a reduction in restenosis 
rates. Until large-scale trials unequivocally demonstrate the 
clinical efficacy of an IVUS-guided DES implantation approach, 
IVUS will remain to be used at the operator’s discretion.
The most plausible and the strongest theory to explain 
the underlying mechanism relating stent underexpansion to 
restenosis is the so-called “bigger-is-better” paradigm [193]. 
Effectively, if the minimum stent area (MSA) is smaller at 
baseline, then the expected NIH formation post DES implan-
TA B L E  5
Factors associated with an increased risk of suboptimal stent 
deployment [228]
LIST OF CONDITIONS ASSOCIATED WITH AN INCREASED RISK 
OF SUBOPTIMAL STENT DEPLOYMENT 
Low-pressure stent deployment (<12 atm)
Lesions with heavy calcification
Lesions with large plaque burden (severe stenosis)
Lesions with a mismatch of proximal and distal reference size
Ostial lesions
Bifurcation lesions treated with stenting of side branch
Long lesions requiring multiple stents 
Small vessel treatment 
Treatment of diffuse in-stent restenosis 
F O C U S  B O X  5
 • Polymer release kinetics – namely antiproliferative drug 
dose and time course of delivery – play a crucial role in the 
prevention of restenosis
 • The genes responsible for the proliferative response 
potentially remain active for a period of up to 21 days after 
vessel injury – a critical time period for antiproliferative 
drug delivery from DES
 • DES with shorter drug release kinetics, such as Endeavor 
(14 days), lead to greater restenosis compared to DES with 
longer drug release kinetics
 • Newer-generation DES with thinner struts, longer drug 
release kinetics, more biocompatible polymers have led to 
more effective neointima inhibition
 • Off-label use of DES, such as in ostial, left main stem, 
chronic total occlusion, saphenous vein graft, small 
or large vessels/multivessel, STEMI, ISR lesions, are 
associated with higher restenosis and revascularisation 
rates
 • Polymer disruption, peeling and cracking, either on the 
DES at baseline or induced by delivery or by interventional 
procedure, have been demonstrated with first and second-
generation DES. As to whether this is implicated in 
restenosis is theoretical
 • Stent fractures are more likely to occur with the closed-cell 
design of first-generation DES and in sites where there is 
greater angulation or tortuosity (i.e., hinge points). They 
tend to occur late, when there is little or no antiproliferative 
drug to cover the vessel injury
Geographical miss/barotrauma to unstented segments
Geographical miss (  Figure 18), as the name suggests, is 
essentially a failure to cover appropriately an injured vessel or 
atherosclerotic plaque. This may be a consequence of lesion 
predilatation, balloon-associated vessel barotrauma and the 
subsequent failure to cover the entire injured site with a DES, 
incomplete coverage of the diseased segment of the vessel with 
significant plaque remaining at the stent margins, or failure 
adequately to overlap DES in long segments of disease. 
Geographical miss has more accurately been described 
as longitudinal geographical miss (LGM: injured or dis-
eased stenotic segment not fully covered by DES) or axial 
geographical miss (AGM: balloon-artery size ratio <0.9 or 
>1.3 mismatch) (  Figure 19) [196]. Geographical miss, 
associated with the implantation of SES, was investigated in 
the STLLR study [196]. As a whole, geographical miss was 
observed in nearly two thirds of the study group (66.5%), 
with almost half the patients experiencing LGM (47.6%), 
over one third AGM (35.2%), and 16.5% a combination of 
the two. At 1-year follow-up, there was more than a 2-fold 
increase in TVR (5.1% vs. 2.5%; p=0.025) and a 3-fold 
increase in MI (2.4% vs. 0.8%; p=0.04) in patients with 
geographical miss. Subgroup analyses indicated that these 
findings were almost exclusively related to LGM (6.1% vs. 
2.6%; p=0.001), with two thirds of cases being second-
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F I G U R E  1 9
Geographical miss
Illustration of the mechanism of longitudinal (LGM) and axial geographical miss (AGM). Reproduced and adapted with permission from Costa et 
al [196].
F I G U R E  1 8
The potential benefit of IVUS-guided stent implantation
Comparison of angiographic and IVUS findings before and after high-pressure stent post-dilatation. Reproduced with permission from Romagnoli 
et al. [228]
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ary to balloon injury outside the stent margins, and AGM 
not seeming to be an important factor (4.2% vs. 4.3%; p 
non-significant). This latter finding has been corroborated, 
where it was shown that the balloon-to-artery ratio [148] 
or the occurrence of edge dissections (potentially associ-
ated with AGM) [197] did not have a significant impact 
on the risk of restenosis: this does perhaps argue against 
the practice of IVUS-guided DES implantation. The occur-
rence of edge dissections has, however, been linked to an 
increased periprocedural and 1-month MACE rate, driven 
primarily by an elevated risk of stent thrombosis and sub-
sequent TVR [198].
More recently, a substudy of the STLLR study demon-
strated that the clinical effects of balloon injury secondary to 
LGM were more pronounced in diabetics [199]. More than 
a four-fold increase (8%) in the need for target lesion revas-
cularisation in diabetics, and almost a two-fold increase in 
non-diabetics (3.8%), in the presence of LGM were reported 
compared to no LGM being present. 
The vascular response at the stent edges has been evalu-
ated with first-generation DES. It appears to be dependent 
on the implanted device and the periprocedural-induced 
vascular trauma, as a consequence of the geographical miss 
phenomenon, as described. [196] Within the IVUS substud-
ies of the E-SIRIUS and SIRIUS trials, both AGM and LGM 
were shown to be potentially reduced when periprocedural 
implantation parameters such as conservative pre-dilatation, 
less forceful stent implantation (~16 atm) and selective post-
dilatation with balloons shorter than the stent were under-
taken [200]. 
The landing zone of the implanted device may be a poten-
tial mechanism for restenosis. Failure to cover fully a sten-
otic lipid-core lesion due to LGM as described has poten-
tially been shown to increase the likelihood of DES failure 
due to plaque progression at the DES edge and subsequent 
edge restenosis (  Figure 20) [17,170,196,201,202]. Further 
studies are required to assess if the use of intracoronary imag-
ing to ensure full lesion/plaque coverage is undertaken and to 
assess whether this leads to improved clinical outcomes. 
Deployment of a DES in a clot-laden arterial segment 
Deployment of a DES in a clot-laden arterial segment 
has been shown in an ex vivo model to lead to signifi-
cant variability in arterial drug distribution [203] which 
may potentially affect clinical outcomes (  Figure 21). 
Essentially in this study it was shown that thrombus 
between the stent strut and vessel wall lead to a reduc-
tion in drug penetration into the vessel wall by a factor 
of up to 10-fold. Despite these theoretical concerns, mul-
tiple studies [204-212] and a meta-analysis of 13 trials 
(n=7,244) [213] have shown the significant short-term 
benefits of DES over BMS. Specifically in the meta-anal-
ysis by Piscione et al, [213] a reduction of TVR (5.11% 
versus 11.19%, p<0.00001) and recurrent MI (3.03% 
versus 3.70%, p=0.02) in patients with STEMI were dem-
onstrated up to 1 year. The widespread use of glycopro-
tein-IIb/IIIa inhibitors and aspiration thrombectomy may 
be the reasons why these concerns have not materialised 
in clinical trials in the short term. 
Concerns over the long-term safety of DES in STEMI do 
persist, however, because of the potential risk of late-acquired 
stent malapposition and consequent LST [214,215]. The con-
cerns about reduced absorption of the drug from DES should 
be borne in mind in a thrombus-laden vessel, especially when 
there has been inadequate resolution of thrombus and DES 
implantation is to be considered.
F I G U R E  2 0
Late drug-eluting stent (DES) failure
This report illustrates a case of incomplete stent coverage of a necrotic-
core plaque mass, despite adequate coverage of the angiographic ste-
nosis. Incomplete coverage of the lipid-core lesion with the DES at 
the index procedure (A, C) appeared to be associated with plaque pro-
gression leading to stent failure due to angiographic edge restenosis 
at 15 months (B, D). Corresponding 2D OCT images (not illustrated) 
demonstrated the mechanism of restenosis to be progression of the 
necrotic core rather than neointimal hyperplasia. Red colour indicates 
artery wall; green, macrophages; yellow, lipid core; blue, stent; white, 
calcium; purple, thrombus; grey, guidewire. White arrow denotes side 
branch in (C) and (D). *Guidewire shadow. Reproduced with permission 
from Waxman et al [201].
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F I G U R E  2 1
Deployment of a DES in a clot-laden arterial segment
This can potentially lead to variability in arterial drug distribution in ex 
vivo models, potentially affecting clinical outcomes. The concepts of 
drug diffusivities in clot (Dclot) and tissue (Dtiss), drug capacity of clot 
relative to solution (Kclot:sol), drug capacity of arterial tissue relative 
to clot (Ktiss:clot), drug capacity of arterial tissue relative to solution 
(Ktiss:sol) and drug convective velocities (V), as illustrated, demonstrate 
the complexity of stenting in acute myocardial infarction. Reproduced 
with permission from Hwang et al [203].
Despite the low incidence of DES restenosis, the burden of ISR in absolute numbers will probably continue to grow 
with the increasing uptake of second-generation DES in conventional percutaneous coronary intervention practice. 
Moreover, it is probable that these cases will select themselves as more resistant cases which may make treatment 
subsequently more challenging. Large-scale clinical trials and registries are required to translate these restenotic mecha-
nisms best into either enhanced DES design or further effective treatment options. For example, the pooled data of 
the randomised controlled trials investigating EES comprise almost 15,000 patients and, apart from mortality, would 
potentially be of sufficient power to detect rare events such as stent thrombosis. 
Although the treatment of ISR is beyond the scope of this review, an understanding of the mechanisms involved in 
DES restenosis and the controllable and non-controllable factors can give the practising interventional cardiologist 
further useful clinical information to reduce DES restenosis in his/her own practice. Apart from biological factors, 
there are potentially controllable factors within arterial and stent factors. However, it should be acknowledged that in 
the treatment of ISR the evidence for using a DES with a different drug remains unproven [44]. Ultimately, the implan-
tation factors are the most important controllable factors from the perspective of the interventional cardiologist.
F O C U S  B O X  6
 • Implantation factors are the most controllable factors for 
potentially reducing restenosis
 • A smaller post-procedural minimal lumen diameter 
(MLD) and a greater residual stenosis have been strongly 
associated with long-term DES patency and clinical 
outcomes
 • IVUS-guided BMS implantation has been associated 
with a reduced TVR and binary restenosis in classical 
meta-analyses
 • To date, no randomised controlled trial has demonstrated 
the clinical superiority of IVUS-guided DES implantation 
despite being associated with a post-procedural higher MLD
 • Longitudinal geographical miss has been associated with 
greater TVR and MI, an effect that may be pronounced in 
diabetics
 • Reductions in TVR and MI have been associated with DES 
implanted after STEMI at up to 1 year, despite theoretical 
concerns that thrombus may interfere with local drug 
absorption. Concerns over the long-term safety of DES in 
STEMI do persist
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Different cardiac biomarkers to detect peri-procedural
myocardial infarction in contemporary coronary stent
trials: impact on outcome reporting
Pascal Vranckx,1,2 Vasim Farooq,3 Scot Garg,3 Gerrit-Anne Van Es,2 Sigmund Silber,4
Stephan Windecker,5 Gregg W Stone,6 Patrick W Serruys3
ABSTRACT
Objective To assess the differential implications of
cardiac biomarker type on peri-procedural myocardial
infarction (PMI) reporting.
Setting The Resolute ‘All-Comers’ stent trial.
Interventions Blood samples for creatine kinase (CK),
CK-myoband (CK-MB) mass or cardiac troponin (cTn)
(optional) were collected before and at 6, 12 and 18 h
after the assigned percutaneous coronary intervention or
at discharge. PMIs were adjudicated using either the
2007 universal definition of MI (type-4a) or the extended
historical definition of MI.
Patients 2121/2292 patients (92.5%) had an analysable
dataset for either biomarker. 890/2121 patients (42%)
presented with an acute coronary syndrome (ACS). 267/
890 patients (30%) were within 24 h of an ST-segment
elevation MI.
Main outcome measures Type-4a MI was diagnosed
in 208/2121 patients (9.8%) when cTn was used (CK-
MB mass if cTn not available), and in 93/2121 of patients
(4.4%) when CK-MB mass was used (cTn if CK-MB
mass not available). With the extended historical
CK-based definition of MI, PMI was diagnosed in 65/
2121 patients (3.1%). Adjudication of type-4a MI in
patients with an ACS was problematic with <10% of the
potential type-4a MI being confirmed as an event, as
compared with approximately 95% in stable patients
undergoing elective PCI. Type-4a MI was not associated
with the subsequent hazard for cardiac mortality
(p¼0.6).
Conclusions The percentage of adjudicated PMI
events is driven by the MI-definition criteria and
biomarker type. Type-4a MI may not be a reliable
component of the primary composite end point in
coronary stent investigations which recruit patients with
ACS.
Trial registration number http://www.ClinicalTrials.
gov; Unique identifier: NCT00617084.
INTRODUCTION
In coronary stent investigations the reported inci-
dence of peri-procedural myocardial infarction
(PMI) may vary according to the metrics (ie, the
definition of MI used for adjudication and the
preferred cardiac biomarker) and the clinical
presentation of the patient at the time of the index
percutaneous coronary intervention (PCI).1e4 The
clinical and therapeutic implications of PMI remain
the subject of continuing debate.1e3
Contemporary all-comers coronary stent trials
reflect routine PCI practice.5e9 These studies
provide a unique opportunity to compare clinical
outcomes among patients presenting with and
without acute coronary syndromes (ACS). In the
Resolute ‘All-Comers’ (Resolute-AC) trial we
implemented two different sets of criteria to define
PMI, and sampled three different cardiac
biomarkers to detect myocardial injurydnamely,
creatine kinase (CK), CK-MB isoenzyme (mass) and
cardiac-specific troponin (cTn).5 6
The purpose of this prespecified subanalysis of
the Resolute-AC trial is to improve the under-
standing of the differential implications of cardiac
biomarker type on PMI reporting and the
associated death of patients.
METHODS
Study design
The design, detailed methods and end point defi-
nitions of the Resolute-AC trial (ClinicalTrials.gov
number: NCT00617084) have been detailed in
a previous publication.5 In brief the Resolute-AC is
a prospective, multicentre, drug-eluting stent
(DES)-versus-DES trial. Between 30 April 2008 and
28 October 2008 17 institutions enrolled a total of
2292 patients with symptomatic coronary artery
disease on an all-comers basis, including patients
with stable angina, silent angina and ACS. The
main outcome measure for this analysis was cardiac
death at 2 years.
All outcome measures in Resolute-AC, including
MI, were adjudicated by three members of an
independent clinical end points committee (CEC)
blinded to treatment assignment before locking the
database. The institutional review boards of all
participating institutions reviewed and approved
the protocol of the Resolute-AC trial. All enrolled
patients gave written informed consent.
Definitions of MI
MI was defined according to the 2007 universal
definition, using as the preferred biomarker either
cTn (CK-MB mass when cTn was not available) or
CK-MB (cTn when CK-MB mass was not available;
Academic Research Consortium (ARC) recom-
mendation), and the extended, historical (WHO)
CK-based definition.10e12
For the 2007 universal definition of MI, the joint
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of Cardiology, American Heart Association and World Heart
Foundation task force recently classified cardiac biomarker levels
above 33 the 99th centile of the upper reference limit (URL), as
indicative of PMI following PCI. Furthermore, the replacement
of CK-MB mass with cTn was recommended for the diagnosis of
a PMI in all cases. Although the 2007 universal definition of MI
was endorsed by the ARC, after long and intense discussions the
ARC recommended that CK-MB mass should remain the
preferred biomarker for the diagnosis of PMI.10 11
The historical (WHO) definition of MI was used to adjudicate
PMI in previous (Medtronic) stent trials in elective patients with
simple lesions. The historical definition was adapted (‘extended’)
to better accommodate ‘all-comers’ populations by considering
patients presenting with ACS.12 13 A hierarchical approach was
used for the adjudication of PMI based upon cardiac biomarker
availability when an analysable cardiac biomarker dataset was
missing (CK-MB mass when CK was not available, cTn when
CK and CK-MB mass were not available) (online supplementary
table 1). In order to be adjudicated as a trial end point, PMI had
to be new, and therefore distinguishable (ie, new clinical signs or
symptoms, angiographic flow-limiting complications) from the
index clinical event. Dependent on the clinical situation at the
time of the index procedure, PMI could be adjudicated consid-
ering either (new) symptoms suggestive of ischaemia/infarction
(>20 min), ECG changes, appropriate cardiac biomarker data or
pathological evidence of MI, or a mixture of these factors.
Ascertainment of peri-procedural myocardial infarction
Blood samples for cardiac biomarkersdCK and CK-MB
massdwere issued according to protocol (cTn was optional)
within 6 h before the index-PCI procedure, and at 6, 12 and 18 h
after the assigned study procedure or at hospital discharge,
whichever came first. Additional samples up to 48 h after the
index-PCI procedure were also considered in this analysis. An
analysable cardiac biomarker set consisted of a baseline value,
and at least one other measurement of the same biomarker in
the 48 h period after the index-PCI procedure.
Cardiac biomarkers were analysed at local site laboratories,
yielding a mixture of biomarker tests and upper limits of normal
(supplementary table 2, supplementary appendix). The limita-
tions of the analytical performance of commercial assays for
biomarkers were considered. A coefficient of variation at the MI
decision limit (99th centile of a healthy reference population)
was expected at <10% for CK-MB mass and cTn assays used
during this trial.14e17
Current analysis
For the purpose of this analysis the Resolute-AC study popula-
tion was assessed as a cohort. All patients with a reference
biomarker available before the index-PCI (baseline), and one or
more corresponding samples in the same biomarker family
(CPK, CK-MB, cTn) within 48 h after the index-PCI, were
suitable for analysis. Seven (7.1) per cent of patients (163/2290)
were excluded from the analysis, because either no baseline
(n¼81, 3.5%) or no samples within 48 h after the index-PCI
(n¼82, 3.5%) were taken. Six patients had no baseline and no
post-PCI biomarker of the same family. Two patients in the
study underwent coronary bypass graft surgery within 48 h of
the index-PCI procedure and were excluded from this analysis.
A comparison of the rates of PMI using the 2007 universal
definition, measuring either cTn (joint task force recommenda-
tion) or CK-MB mass (ARC recommendation) as the preferred
biomarker, with the extended historical definition, in the adju-
dication of PMI was undertaken. Subgroup analyses were
performed for patients with (n¼890, 42.0%) or without ACS
(n¼1231, 58.0%). Patients in this analysis were categorised as
having ACS at the time of the index-PCI procedure if they had
either a biomarker above the URL before the index-PCI proce-
dure and/or clinical signs and/or symptoms (>20 min) consis-
tent with continuing myocardial ischaemia as declared by the
investigator. The analysis was repeated in the cohort of patients
who had both an analysable cTn and CK-MB dataset (935,
n¼44.1%).
We assessed the 2-year cardiac mortality in patients with or
without PMI according to either the 2007 universal definition of
MI using either cTn or CK-MB as preferred biomarker (as
outlined earlier) or the extended historical definition of MI.
Statistics
All statistical analyses were exploratory. The counts of PMI are
summarised and tabulated according to frequency. Differences in
outcomes between patients with and without PMI are
compared by Fisher ’s exact test or c2 testing. For univariate
analyses, cumulative event rates of cardiac mortality for the
different types of PMI at up to 2 years were estimated with
KaplaneMeier analyses and Cox proportional HRs with 95%
CIs. Multivariable analyses evaluating the association between
PMI and mortality were performed by Cox proportional hazards
regression. Multivariable models considered the following base-
line covariates: age, sex and diabetes mellitus. Statistical analyses
were performed with the use of SAS software, version 9.2 by
a dedicated independent statistician. A two-sided p value <0.05
was considered to indicate statistical significance.
RESULTS
Two thousand one hundred and twenty-one of 2290 (92.5%)
patients from the Resolute-AC were suitable for analysis. Base-
line demographics and clinical characteristics are listed in
supplementary table 3. Over one-fifth of patients (n¼452,
21.3%) presented with an acute MI within 24 h of symptom
onset, including 267 patients (59.1%) with an ST elevation MI.
The mean SYNTAX Score was 14.769.2.
Availability of biomarkers of myocardial necrosis before and
within 48 h after the index-PCI
Figure 1A depicts the number of patients with available cardiac
biomarker of myocardial injury (BMI) sample values at baseline
and one or more sample values within 48 h (‘analysable cardiac
biomarker dataset’, n¼2121). The Venn diagrams illustrate the
availability of one BMI (CK or CK-MB mass or cTn), two BMI
(CK and CK-MB mass or CK and cTn or CK-MB mass and cTn)
or all three BMI (CK and CK-MB mass and cTn). Although cTn
sampling was an optional investigation in the Resolute-AC trial,
an analysable dataset for cTn was available in 55.3% (1173/
2121) patients. In addition 44.1% (935/2121) patients had an
analysable dataset for both cTn and CK-MB.
Figure 1B depicts all analysable cardiac biomarker sample
values datasets (n¼2121) in all patients in the analysis, stable
patients and patients presenting with ACS with at least one
cardiac biomarker sample value above the designated threshold
for defining a PMI. Notably, 19.0% (178/935) (figure 1A) of
patients with an analysable biomarker dataset available for both
cTn and CK-MB mass had a peak cTn >3 times 99th centile
URL, but a peak CK-MB#3 times 99th centile URL. Figure 1C is
limited to patients with an ACS at the time of the index-PCI
(n¼890). Figure 1D is limited to stable patients having an
elective PCI (n¼1231).
Heart 2012;98:1424e1430. doi:10.1136/heartjnl-2012-302267 1425
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Diagnosis of PMI based on selection of cardiac biomarkers
Elevated biomarkers of myocardial necrosis before and within 48 h
after the index-PCI
The number of stable patients undergoing elective PCI with
cardiac biomarker elevations above the designated threshold
required to define PMI was four times higher when measuring
cTn than when measuring CK (161 vs 46 patients), and double
when measuring CK-MB mass rather than CK (68 vs 46
patients). Conversely, the number of patients with an ACS at
the time of the index-PCI with cardiac biomarker elevations
above the designated threshold required to define PMI was only
1.5 times higher when measuring cTn compared with CK (47 vs
19 patients) (table 1).
PMI adjudicated by the CEC
For the 2007 universal definition of MI, type-4a MI was adju-
dicated by the CEC in 208/2121 patients (9.8%) when cTn was
used (CK-MB mass if cTn not available), and in 93/2121 of
patients (4.4%) when CK-MB mass was used (cTn if CK-MB
mass not available, ARC recommendation). With the extended
historical CK-based definition of MI, PMI was adjudicated in 65/
2121 patients (3.1%).
The percentage of the adjudicated PMI over the suspected
events based on cardiac biomarker elevations (‘event-to-trigger
percentages’) was predominantly driven by the clinical presen-
tation at the time of the index-PCI, with this percentage being
nearly 10-fold higher for stable patients undergoing elective PCI
than for patients presenting with an ACS. Adjudication of type-
4a MI in patients with a suspected ongoing MI was problematic
with <10% of the potential type-4a MI being confirmed as an
event by the CEC, as opposed to approximately 95% in stable
patients undergoing elective PCI.
PMI in patients with an analysable dataset for both CK-MB mass
and cTn
The trends outlined above are similar for the patient subpopu-
lation with analysable cardiac biomarker datasets for both CK-
MB and cTn (supplementary table 4). In the subset of patients,
in whom an analysable dataset for both cTn and CK-MB mass
was available (n¼935), myocardial injurydas defined by
a cardiac biomarker sample value >99th centile URLdwas
Figure 1 (A) Patients with an
analysable cardiac biomarker sets with
both a pre- (baseline) and one or more
post-PCI biomarker sample value(s) of
the same family. (BeD) Patients, either
with or without ongoing MI, with
a baseline cardiac biomarker sample
value (either for cTn, CK-MB mass, CK)
and an increase in the corresponding
6e48 h post-PCI biomarker sample
value above the predefined threshold to
qualify as a suspect PMI, before final
PMI-event adjudication by the clinical
end points committee (figure 2B). For
patients presenting with an acute
coronary syndrome a 20% increase in
cardiac biomarker sample value was
taken into account (see also figure 1,
flowchart). Patients with suspected
ongoing MI (figure 2C) at the time of
the index-PCI and stable patients
undergoing elective PCI (figure 2D) are
represented separately. CK-MB,
creatine kinase-myoband; CPK, creatine
kinase; cTn, cardiac troponin; PMI, peri-
procedural myocardial infarction; URL,
upper reference limit upper reference
limit.
CK-MB 
cTn 
CPK 
64 (3.0%) 
32 (1.5%) 
27 (1.2%) 
852 
(40.2%) 
211 
(9.9%) 
687 
(32.4%) 
248 
(11.7%) 
55.3% 85.8% 
85.5% 
All patients (n=2121) 
N=935  
19 (0.9%) 289 (13.6%) 
41 
(1.9%) 
173 
(8.2%) 
121 
(5.7%) 
All patients (n=2121) 
32 (1.5%) 
80 
(3.8%) 
No elevation above the pre-defined 
threshold to define PMI for any marker: 
1366 (64.4 %). 
cTn >3*URL 
(n=624)  
Of all patients 29.4% 
Of patients with analysable 
dataset cTn available 
53.2% 
CKMBmass >3*URL 
(n=393)  
All patients 18.5% 
Patients with analysable 
dataset CKMB available 
21.5% 
CK>2*URL+(cTN or 
CKMBmass>URL) 
(n=326)  
All patients 15.4% 
Patients with analysable 
dataset CK available 
18.0% 
A
B
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detected in 54.0% (505/935) measuring cTn and in 49.7% (465/
935) measuring CK-MB mass. Type-4a MI was diagnosed
in 11.0% (103/935) patients and 5.2% (49/935) patients,
respectively.
Associated 2-year cardiac mortality
During the 2-year follow-up 54 patients in Resolute-AC died
owing to cardiac causes, 51 of them are in the 2121 cohort. PMI
versus no PMI adjudicated by the extended historical definition
of MI was associated with 2-year crude cardiac mortality
(HR¼3.5; 95% CI 1.4 to 8.9; p¼0.007), but not type-4a when
cTn was used (HR¼1.2; 95% CI 0.5 to 2.9; p¼0.65) or when CK-
MB (HR¼1.4; 95% CI 0.4 to 4.4; p¼0.61) was used to adjudicate
MI (table 2, figure 2). After adjustment for baseline covariates,
PMI by the extended historical definition of MI, analysed as
dichotomous variable, remained a significant correlate of 2-year
mortality (HR¼3.7, 95% CI 1.4 to 9.2, p¼0.0065).
DISCUSSION
The Resolute-AC study design provided a unique opportunity to
study the implications of the use of different biomarkers for the
detection of myocardial injury in patients undergoing PCI, and
Figure 1 Continued
cTn >3*URL 
(n=443)  
All patients with ongoing MI 49.8% 
Patients with analysable 
dataset cTn available 
74.6% 
5 (0.6%) 161 (18.1%) 
26 
(2.9%) 
159 
(17.9%) 
97 
(10.9%) 
Patients with suspected ongoing spontaneous MI 
at the time of the index PCI. 
(n=890) 
22 (2.5%) 
75 
(8.4%) 
No elevation above the pre-defined 
threshold to define PMI for any marker: 
345 (38.8 %). 
CKMBmass >3*URL 
(n=336)  
All patients with ongoing MI 37.8% 
Patients with analysable 
dataset CKMB available 
41.1% 
CK>2*URL+(cTN or 
CKMBmass>URL) 
(n=282)  
All patients with ongoing MI 31.7% 
Patients with analysable 
dataset CK available 
42.1% 
cTn >3*URL 
(n=181)  
All stable, elective patients 14.7% 
Patients with analysable 
dataset cTn available 
17.8% 
14 (1.1%) 128 (10.4%) 
15 
(1.2%) 
14 
(1.2%) 
24 
(1.9%) 
10 (0.8%) 
5 
(0.4%) 
 
Patients without suspected ongoing spontaneous 
MI at the time of the index PCI.
(n=1231) 
No elevation above the pre-defined 
threshold to define PMI for any marker: 
1021 (82.9 %). 
CKMBmass >3*URL 
(n=57)  
All stable, elective patients 4.6% 
Patients with analysable 
dataset CKMB available 
4.8% 
CK>2*URL+(cTN or 
CKMBmass>URL) 
(n=44)  
All stable elective patients 3.6% 
Patients with analysable 
dataset CK available 
4.1% 
C
D
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the adjudication of unreported PMI among patients presenting
with or without an ACS at the time of the index procedure. The
main conclusions of this analysis are:
1. PMI constituted the majority of all MIs in the Resolute-AC
PCI trial. However, the PMI event count varied considerably
according to the choice of cardiac biomarker and/or the
criteria used for adjudication. Comparing the 2007 universal
definition of MI and the extended historical (WHO) CK-based
definition of MI, using cTn resulted in a tripling of the rate of
PMI. Applying the 2007 universal definition of MI with cTn
resulted in a doubling of the rate of PMI compared with
CK-MB mass.
2. The PMI ‘event-to-trigger ’ percentage was dependent on the
clinical presentation at the time of the index-PCI procedure,
rising from <9% in patients presenting with ACS at the time
of the index-PCI procedure, to >80% in patients undergoing
elective PCI for stable symptomatic coronary artery disease
regardless of which biomarker one uses.
3. The frequency of undetected MI with the 2007 universal
definition of MI was approximately five times higher than
the extended historical (WHO) CK-based definition of MI,
mainly reflecting the greater sensitivity of cTn to detect
myocardial injury (with subsequent investigator under-
reporting).
4. More than 50% of adjudicated PMI events in patients
undergoing elective PCI for stable symptomatic coronary
artery disease were unreported and only detected through
analysis of serial cardiac biomarker sample values.
5. In Resolute-AC, type-4a MI with the actual proposed
biomarker thresholds and regardless of the biomarker used,
was not associated with subsequent cardiac mortality at
2 years.
This analysis represents the largest prospective comparison of
the three most commonly used serum biomarkers for detection
of PMI. These findings are likely to be representative of
contemporary PCI practice, as patient-, lesion- and procedure-
related risk factors are all previously established predictors of
PMI,3 and the baseline and angiographic characteristics of
Resolute-AC have been reported to be consistent with other
recently reported ‘real-world’ coronary stent investigations.5e8 18
The stable patient subset undergoing elective PCI to treat stable
coronary lesions matched those recruited in historical stent
trials.
The diagnosis of acute, evolving or recent MI requires, in the
absence of pathological confirmation, a typical rise and/or fall of
biomarkers of myocardial necrosis in conjunction with clinical
evidence of myocardial ischaemia.10 A PMI is defined by
a typical new cardiac biomarker elevation above a predefined
threshold occurring during the immediate peri-procedural period
(<48 h), and an established causality to the index study proce-
dure. This causality may or may not be declared by the inves-
tigator (eg, coronary artery dissections, distal plaque
embolisation). With ACS the PMI must be identified as a new
event, clearly distinct from the index clinical event in the same
predefined peri-procedural period of 48 h. In the Resolute-AC
trial, most suspected PMIs were reported by the investigators at
clinical sites. Yet not all cardiac biomarker elevations above the
predefined threshold (‘triggers’) will identify new events.
The adjudication of PMI in an ‘All-Comers’ trial resembling
everyday PCI practice may be characterised by a signal-to-noise
problem. For this analysis we disentangled two specific clinical
situationsdpatients with or without an ACS at the time of the
index-PCI. The adjudication of type-4a MI, implementing the
2007 universal definition of MI, in patients with acute presen-
tations (ie, ACS) at the time of the index-PCI is problematic, and
exacerbated when measuring a sensitive biomarker such as
cTn.19 Unless there is a clear indication that the cardiac
biomarker sample values were falling after the index event and
then rising again (above the predefined thresholds) after the
index-PCI procedure, there would be insufficient biomarker data
Table 1 Peri-procedural myocardial infarction (PMI) adjudication upon cardiac biomarkers guided either by the 2007 universal (troponin based)-
myocardial infarction (MI) definition or the WHO (creatine kinase (CK)-based)-MI definition in counts and percentages (all patients; N¼2121)
2007 Universal-MI definition
WHO-MI definition extended
for AC trials
Primary marker cTn,
(CK-MB mass if cTn
unavailable)*
(ARC recommendation)
Primary marker CK-MB mass,
(cTn if CK-MB mass unavailable)*
Primary CK (with confirming cTn or CK-MB),
(CK-MB mass if CK unavailable, cTn if CK
and CK-MB mass unavailable)*
Stable angina (N¼1231)
Adjudicated PMI/triggery to PMI 161/190 (84.7) 68/75 (90.7) 46/52 (88.5)
Investigator reported 73/84 (86.9) 35/35 (100.0) 30/31 (96.8)
ACS (N¼890)
Adjudicated PMI/triggery to PMI 47/519 (9.1) 25/366 (6.8) 19/354 (5.4)
Investigator reported 12/20 (60.0) 7/12 (58.3) 6/10 (60.0)
*In 1533/2121 (72%), 1975/2121 (93%) and 1983/2121 (93.4%) cases the preferred biomarker, respectively cardiac specific troponin (cTn), creatine kinase (CK) and CK-myoband (MB), was
available for analysis.
yTrigger is defined as a suspected PMI based upon cardiac biomarker sample value elevation and/or clinical signs or symptoms consistent with myocardial ischaemia.
ACS, acute coronary syndrome; ARC, Academic Research Consortium.
Table 2 Two-year cardiac mortality according to the occurrence of procedure-related MI (different
definitions) or not
Primary
biomarker
KM estimate,
PMI* (%)
KM estimate,
no PMI* (%)
Log rank,
p value HR and 95% CIy
cTn 2.90 2.43 0.649 1.2 (0.5 to 2.9)
CK-MB 3.25 2.44 0.606 1.4 (0.4 to 4.4)
CK 7.74 2.31 0.007 3.5 (1.4 to 8.9)
*Percentage failure based on KaplaneMeier (KM) estimates.
yCox Model, assuming proportional Hazards.
CK-MB, creatine kinase-myoband; cTn, cardiac troponin; KM, KaplaneMeier; PMI peri-procedural myocardial infarction.
1428 Heart 2012;98:1424e1430. doi:10.1136/heartjnl-2012-302267
Interventional cardiology
 group.bmj.com on August 8, 2013 - Published by heart.bmj.comDownloaded from 
212 Chapter 6.1
to adjudicate a PMI.19 20 The critical challenge for the members
of the CEC is to distinguish whether a new MI was induced by
the index-PCI procedure (ie, additional component of an already
injured myocardial region, new procedural flow-limiting
complications), or if the cardiac biomarker release was still the
tail end of the continuing initial myocardial insult.1 19
In Resolute-AC, while the event-to-(biomarker) trigger ratio
was as low as 5% for the 2007 universal definition of MI, these
events proved to be numerically important and contributed to
half of the unreported PMIs (based on serial cardiac biomarker
sample value analyses only) (table 1). It should be emphasised
that including clinical information from the investigator, such as
evidence of new myocardial ischaemia and coronary artery flow-
limiting complications, resulted in a 10 times higher event-to-
trigger percentage, and may improve the signal-to-noise ratio
(table 1). Conversely, in stable patients undergoing uncompli-
cated contemporary elective PCI, >50% of PMIs were detected
upon review of serial cardiac biomarker sample values alone,
with >80% of all suspected type-4a MI adjudicated as an event.
On the basis of the traditional concept of PMI described here,
considering a high ‘trigger ’ and ‘trigger-to-event ratio’ in stable
patients undergoing elective PCI, the missing biomarker data
may affect outcome reporting and should be considered while
interpreting trial results.
The extent of myocardial injury following PCI, as detected by
release of CK and/or CK-MB mass, has been correlated with late
clinical outcomes in several studies.21e27 Despite these findings,
the threshold level of cTn associated with a prognostic signifi-
cance remains elusive.1 10 This analysis adds to the evidence that
type-4a MIs, as a class in real-world patients with the current set
biomarker thresholds, are not of significant prognostic impor-
tance after PCI using contemporary management strategies.
Cardiac biomarker elevation following PCI should therefore
always be interpreted in relation to the clinical presentation at
the time of the index procedure.
The lack of association between a CK-MB mass elevation
more than three times the diagnostic level based on the 2007
universal definition of MI, and 1-year mortality among patients
with moderate to high risk ACS undergoing PCI, was also
reported in the ACUITY trial.23 Conversely, in the EVENT
(Evaluation of drug eluting stents and ischaemic events) registry,
consisting of almost 5000 patients undergoing elective PCI, the
same degree of cardiac enzyme elevation independently
predicted 1-year mortality. In addition, the EVENT investigators
reported similar hazards for negative clinical outcomes related to
cTn, but only when 20 times the upper limit of normal was used
as decision limit.24 Patients in the subanalysis in the EVENT
registry were, however, not separated on the detection of
a baseline cTn level $99th centile of the URL.
In patients with ACS it is undisputed that an increased cTn
(baseline) is a marker of patients at increased risk.27 Further-
more, it appears that almost all the prognostic information is
contained in the baseline cardiac enzyme value, and that this
may be a reflection of the underlying coronary atherosclerotic
burden and/or plaque instability. At what level, if any, additional
cTn elevation following PCI contributes to the hazard for 1-year
negative outcomes remains unanswered.
This issue(s) and the stark variations in reported rates of PMI
call into question the inclusion of PMI as a component of the
primary composite end points of contemporary coronary device
trials, particularly when recruiting patients presenting with ACS.
Limitations
This study has several limitations. First, in 2008 cTn was not yet
widely implemented as cardiac biomarker to detect myocardial
injury, thereby according to protocol cTn sampling was optional
in Resolute-AC. Despite this limitation, up to 54% of patients
had an analysable cTn dataset and the major conclusions of the
study were unchanged when a subset of patients with both cTn
and CK-MB were sampled (supplementary table 3). While recent
advances in assay technology have led to more sensitive and
precise cTn assays, the issues raised in this manuscript towards
trial conduct and data interpretation remain, and may even be
accentuated.28
Figure 2 Cumulative cardiac mortality
according to PMI up to 2-years. Shown
are the KaplaneMeier curves for
cardiac mortality after the occurrence
of PMI according to either the extended
historical definition of MI (green) and
the 2007 universal definition of MI
measuring cTn (CK-MB if cTn is not
available) (red) or CK-MB (cTn if CK-MB
is not available, Academic Research
Consortium recommendation) (blue).
CK-MB, creatine kinase-myoband; cTn,
cardiac troponin; PMI, peri-procedural
myocardial infarction.
Kaplan–Meier-Plot - Cumulative incidence for cardiac death 
(N=6363 patients) 
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Our results did not include the direct metrics (eg, MRI) of the
extent of myocardial injury. The findings of the study do,
however, suggest that most MIs were small or moderate. We
cannot exclude the possibility of a slight variation in the results
if a central core laboratory had undertaken the analyses of the
cardiac biomarkers.29 The 99th centile of the reference medical
decision cut-off point for the cTn assays was determined in each
local laboratory by internal studies with the specific assay that is
used in clinical practice. The previous limitations do, however,
cause no concern in interpreting the major conclusions of this
analysis.
CONCLUSIONS
As currently defined, type-4a MI following PCI is not a valid
outcome measure in contemporary outcome trials. Meaningful
thresholds for individual cardiac biomarkers should be identified
based on large outcome trials. Adjudication of PMI in patients
with an ACS at the time of the index-PCI remains problematic.
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Resolute-AC 
N= 2292 
No BMI sample ≤48 hours post PCI 
N=82 
BMI sample pre- and 
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SUPPLEMENTARY APPENDIX: 
SUPPLEMENTAL FIGURE 1: PATIENTS INCLUDED IN THIS ANALYSIS. 
Patient flow diagram showing patients from the total Resolute-AC study cohort and reasons for 
exclusion from this analysis. BMI indicates biomarker of myocardial injury, CABG indicates 
coronary artery bypass grafting, MI indicates myocardial infarction,  
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SUPPLEMENTAL TABLE 1: CRITERIA FOR PERI-PROCEDURAL MYOCARDIAL INFARCTION 
FOLLOWING PERCUTANEOUS CORONARY INTERVENTION. 
 
 2007 UNIVERSAL 
DEFINITION OF MI 
EXTENDED HISTORICAL DEFINITION OF 
MI 
STABLE PATIENTS UNDERGOING AN ELECTIVE PCI  
 cTn (CKMBmass ,ARC 
recommendation) >3*URL  
 
New pathologic q waves in ≥ 2 contiguous ECG 
leads and 
- Any CKMBmass > 1*URL or 
- In the absence of CKMBmass: cTn >1*URL 
or  
- In the absence of CKMBmass and cTn: 
CK>1*URL or 
- In the absence of CKMBmass, cTn and CK: 
CEC decision upon clinical scenario 
Appropriate cardiac enzyme data: 
- CK ≥2*URL confirmed by: 
 CKMBmass or 
 In the absence of CKMBmass: cTn >1*URL 
or  
 In the absence of CKMBmass, cTn : CEC 
decision upon clinical scenario 
OR 
- In the absence of CK: CKMBmass >3*URL 
OR 
- In the absence of CK and CKMBmass: cTn 
>3*URL 
SIGNS AND/OR SYMPTOMS CONSISTENT WITH MYOCARDIAL ISCHEMIA 
OR 
ELEVATED CARDIAC BIOMARKERS OF MYOCARDIAL INJURY 
BIOMARKERS OF MYOCARDIAL 
INJURY HAVE NOT YET PEAKED 
If biomarkers increasing or 
peak not reached, then 
insufficient data to diagnose 
MI-extension/new myocardial 
infarction. 
 
Recurrent signs and/or symptoms >20minutes 
consistent with myocardial infarction 
And 
Appropriate cardiac enzyme data: 
- A rise of CK within 24hours of the index 
event >2*URL (confirmed by either 
CKMBmass or cTn>1*URL) and ≥50% 
above the previous level or 
- In the absence of CK: a post PCI rise of 
CKMBmass within 24 hours of the index 
event >3*URL and and ≥50% above the 
previous level or 
- In the absence of CK and CKMBmass: a 
post PCI rise in cTn within 24 hours of the 
index event <3*URL and and ≥50% above 
the previous level. 
BIOMARKERS OF MYOCARDIAL 
INJURY HAVE PEAKED, BUT DID 
NOT YET RETURNED <1*URL 
Stable or decreasing cTn 
(CKMBmass ,ARC 
recommendation) values on 2 
consecutive samples 
AND  
20% increase 3h – 6h after 
second sample. 
 
Appropriate cardiac enzyme data: 
- A rise of CK within 24hours of the index 
event >2*URL (confirmed by either 
CKMBmass or cTn>1*URL) and ≥50% 
above the previous level or 
- In the absence of CK: a post PCI rise of 
CKMBmass within 24 hours of the index 
event >3*URL and and ≥50% above the 
previous level or 
- In the absence of CK and CKMBmass: a 
post PCI rise in cTn within 24 hours of the 
index event <3*URL and and ≥50% above 
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the previous level. 
PCI denotes percutaneous coronary intervention, cTn denotes cardiac specific troponin, URL 
denotes the upper reference of normal, CEC denotes clinical event committee, ARC denotes 
academic research consortium. 
  
the previous level. 
PCI denotes percutaneous coronary intervention, cTn denotes cardiac specific troponin, URL 
denotes the upper reference of normal, CEC denotes clinical vent committe , ARC de tes 
academic research consortium. 
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SUPPLEMENTAL TABLE 2 : Resolute All-comers , cardiac troponin immune assays used 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Which cTn isoform (troponin T or I) were used was determined by local practice at each study 
site. The 99th percentile of a reference decision-limit (medical decision cutoff) for cTn assays 
was determined for each local laboratory as per guidelines. [25] 
  
Site cTn isoform 99th percentile of a normal 
reference population ng/ml 
(URL = upper reference limit).* 
10100 cTn T,  Roche Diagnostics, Elecsys 2010 
platform, fourth generation 
0.01 
10200 cTn T, Roche Diagnostics, Elecsys 2010 
platform, fourth generation 
0.01 
10300 cTn T, Roche Diagnostics, Elecsys 2010 
platform, fourth generation 
0.01 
10301 cTn T, Roche Diagnostics, Elecsys 2010 
platform, fourth generation 
0.01 
10500 I Beckman Access 0.04 
11000 I Bayer Centaur 0.16 
11001 I Bayer Centaur 0.16 
12000 I Bayer Centaur 0.16 
12001 cTn T, Roche Diagnostics, Elecsys 2010 
platform, fourth generation 
0.01 
12002 I  Dade-Behring Dimension RxL 0.03 
12003 cTn T, Roche Diagnostics, Elecsys 2010 
platform, fourth generation 
0.01 
13000 I  Beckman Access 0.04 
14001 I  Diagnostic Products Corporation, Immulite 
2000 
0.2 
15000 I  Beckman Access 0.04 
15900 cTn T, Roche Diagnostics, Elecsys 2010 
platform, fourth generation 
0.01 
40600 cTn T, Roche Diagnostics, Elecsys 2010 
platform, fourth generation 
0.01 
41000 none  
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SUPPLEMENTARY TABLE 3. BASELINE DEMOGRAPHICS AND CLINICAL CHARACTERISTICS 
(PER PATIENT)  
 
Patient Characteristics  
Total Ongoing MI No Ongoing MI    
  n 2121 890 1231 
 Age [yrs]   64.3±10.8 62.9±11.6 65.3±10.1 
Male 76.6% (1625/2121) 78.2% (696/890) 75.5% (929/1231) 
Diabetes Mellitus 23.3% (494/2121) 21.3% (190/890) 24.7% (304/1231) 
Hypertension 71.9% (1524/2121) 63.8% (568/890) 77.7% (956/1231) 
Current smoker 26.4% (559/2121) 36.1% (321/890) 19.3% (238/1231) 
Hyperlipidemia 65.9% (1398/2121) 54.8% (488/890) 73.9% (910/1231) 
Prior MI 29.9% (621/2075) 25.5% (224/877) 33.1% (397/1198) 
Prior PCI 32.2% (684/2121) 21.5% (191/890) 40.0% (493/1231) 
Prior CABG 9.6% (204/2121) 6.2% (55/890) 12.1% (149/1231) 
Revascularization for Angina or MI 88.1% (1869/2121) 95.5% (850/890) 82.8% (1019/1231) 
  Stable Angina 35.1% (744/2121) 10.6% (94/890) 52.8% (650/1231) 
  Unstable Angina 19.2% (408/2121) 4.4% (39/890) 30.0% (369/1231) 
  MI (pre-procedure <72 hours) 33.8% (717/2121) 80.6% (717/890) 0.0% (0/1231) 
    Acute MI (within 24 hours) 21.3% (452/2121) 50.8% (452/890) 0.0% (0/1231) 
    ST elevation (STEMI) 12.6% (267/2121) 30.0% (267/890) 0.0% (0/1231) 
    Non ST elevation (NSTEMI) 8.7% (185/2121) 20.8% (185/890) 0.0% (0/1231) 
Left Ventricular Ejection Fraction  
Mean ± SD 
55.8±11.7 54.2±11.6 56.8±11.7 
Multi vessel 25.4% (538/2121) 28.0% (249/890) 23.5% (289/1231) 
Small Vessel (<=2.75 mm) 67.3% (1210/1798) 66.4% (452/681) 67.9% (758/1117) 
Number of lesions treated  
  One 64.7% (1371/2119) 63.1% (562/890) 65.8% (809/1229) 
  Two 26.5% (561/2119) 26.2% (233/890) 26.7% (328/1229) 
  Three 6.5% (137/2119) 8.0% (71/890) 5.4% (66/1229) 
  >= Four 2.4% (50/2119) 2.7% (24/890) 2.1% (26/1229) 
Long Lesion (>18mm) 19.9% (358/1798) 22.9% (156/681) 18.1% (202/1117) 
Number of lesions treated Mean ± SD 1.5±0.7 1.5±0.8 1.4±0.7 
Off label 66.2% (1404/2121) 86.2% (767/890) 51.7% (637/1231) 
Mean SYNTAX SCORE Mean ± SD  
  n 1888 828 1060 
  Mean ± SD 14.7±9.2 16.0±9.3 13.7±8.9 
  (Min, Max) (0 - 55) (0 - 55) (0 - 49) 
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SUPPLEMENTAL TABLE 4: PATIENTS WITH ANALYSABLE CARDIAC BIOMARKER DATA SET FOR 
CARDIAC SPECIFIC TROPONIN (CTN)AND CRETANINE KINASE-MYOBAND (CKMB) (PRE AND 
POST PROCEDURE CTN AND CK-MB AVAILABLE, N=935). 
 2007 Universal-MI- definition WHO-MI-definition 
extended for AC-trials 
 Primary marker cTn, 
(CK-MB mass if cTn 
unavailable) 
 
(ARC- recommendation) 
Primary marker CK-MB 
mass, 
(cTn if CK-MB mass 
unavailable) 
Primary CK (with 
confirming trop or 
CKMB), 
(CK-MB mass if CK 
unavailable, cTn if CK and 
CK-MB mass unavailable) 
    
STABLE ANGINA   
(N=487) 
 
Adjudicated PMI/trigger** 
to PMI 
69/   73 (94.5) 34/ 36 (94.4) 23/ 26 (88.5) 
 Investigator reported 
 
41/  
  
42 
 
(97.6) 
 
23/ 
 
23 
 
(100) 
 
13/ 
 
14 
 
(92.9) 
 
ACS (N=448)       
Adjudicated PMI/trigger** 
to PMI 
34/  293 (11.6) 16/ 180 (8.8) 10/ 177 (5.6) 
 Investigator reported 
 
8/  
  
12 
 
(66.7) 
 
5/ 
 
8 
 
(62.5) 
 
3/ 
 
5 
 
(60.0) 
 
**Trigger is defined as a suspected PMI based upon cardiac biomarker sample elevation and/or 
clinical signs or symptoms consistent with myocardial ischaemia 
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Aims:The aimof thepresent investigationwas todetermine the long-termprognostic associationof post-procedural
cardiac enzyme elevation within the randomised Synergy between Percutaneous Coronary Intervention (PCI) with
TAXUS and Cardiac Surgery (SYNTAX) Trial.
Methods: 1800 patients with unprotected left main or de novo three-vessel coronary artery disease were
randomised to undergo coronary artery bypass graft (CABG) surgery or PCI. Per protocol patients underwent
post-procedural blood sampling with creatine kinase (CK), and the cardiac specific MB iso-enzyme (CK-MB) only
if the preceding CK ratiowas≥2× the upper limit of normal (ULN). An independent chemistry laboratory evaluated
all collected blood samples.
Results: Post-procedural CK sampling was available in 1629 of 1800 patients (90.5%). As per protocol, CK-MB anal-
yses were undertaken in 474 of 491 patients (96.5%) in the CABG arm, and 53 of 61 patients (86.9%) in the PCI arm.
Within the CABG arm, despite the limitations of incomplete data, a post-procedural CK-MB ratio b3/≥3 ULN sepa-
rated 4-year mortality into low- and high-risk groups (2.3% vs. 9.5%, p = 0.03). Additionally, in the CABG arm, a
post-procedural CK-MB ratio ≥3 ULN was associated with an increased frequency of a high SYNTAX Score (≥33)
tertile (high [≥33] SYNTAX Score: 39.5%, intermediate [23–32] SYNTAX Score 31.0%, low [≤22] SYNTAX Score
29.5%, p = 0.02). Within the PCI arm, a post-procedural CK ratio of b2 or ≥2 ULN separated 4-year mortality into
low- and high-risk groups (10.8% vs. 23.3%, p = 0.001). Notably, there was an early (within 6 months) and late
(after 2 years) peak in mortality in patients with a post-PCI CK ratio of ≥2 ULN. Lack of pre-procedural
thienopyridine, carotid artery disease, type 1 diabetes, and presence of coronary bifurcationswere independent cor-
relates of a CK ratio ≥2 ULN post-PCI.
Conclusion: Cardiac enzyme elevations post-CABG or post-PCI are associatedwith an adverse long-termmortality;
the causes of which are multifactorial.
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1. Introduction
Cardiac enzyme elevation post-coronary artery bypass graft
(CABG) or post-percutaneous coronary intervention (PCI) has
been demonstrated to have a detrimental impact on mortality
post-revascularisation [1–4]. The aims of the present investiga-
tion were to determine the incidence, correlates and prognostic
significance of post-procedural cardiac biomarker release follow-
ing surgical or percutaneous revascularisation in the SYNTAX
Trial [5–8].
2. Methods
The SYNTAX Trial is a randomised, prospective, multicentre trial that incorpo-
rated an ‘all-comers’ design, and consisted of prespecified left main (isolated or
associated with 1, 2 or 3 vessel disease [3VD]) and de novo 3VD cohorts [5–8]. Pa-
tients were randomised on a 1:1 basis by the Heart Team consensus to undergo
either CABG or PCI with Taxus Express paclitaxel-eluting stents (Boston Scientific
Corporation, Natick, Mass) (n = 1800). Patients considered unsuitable for
randomisation were nested in registries for CABG- or PCI-ineligible patients. Ex-
clusions were only limited to patients with prior coronary revascularisation, the
requirement of concomitant cardiac surgery, or on-going acute MI. The calculation
of the SYNTAX Score (http://www.syntaxscore.com) [9–13] was carried out by the
Heart Team prior to randomisation, and corroborated by an independent core lab-
oratory (Cardialysis BV, Rotterdam, The Netherlands), blinded to the treatment
assignment.
2.1. Cardiac enzymes
Per protocol randomised patients from the SYNTAX Trial were scheduled to un-
dergo blood sampling with creatine kinase (CK) pre- and post-revascularisation,
and the cardiac specific MB iso-enzyme (CK-MB) only if the CK ratio ≥2× the upper
limit of normal (ULN) [7,14]. If the CK ratio b2 ULN, CK-MB assessment was not man-
dated. Revascularisation with CABG or PCI was only permitted if the pre-procedural
cardiac enzymes were b2 ULN. All samples were evaluated locally and by an indepen-
dent central chemistry laboratory (Covance Inc., Geneva, Switzerland, and
Indianapolis, Ind). Data from the central chemistry laboratory was available in the
SYNTAX Trial database; local data was not collected in the SYNTAX Trial database.
For patients discharged N24 h post-procedure, three sets of CK (and CK-MB if CK
ratio ≥2 ULN) were mandated, at 6 and 12 h post-procedure, and as close to dis-
charge as possible. For patients discharged less than 24 h post-procedure, two sets
of CK (and CK-MB if CK ratio ≥2 ULN) were required, at 6 h post-procedure, and as
close to discharge as possible. In cases of chest pain, with or without ECG changes, ad-
ditional serial cardiac enzymes were required to be sampled immediately, and at 6
and 12 h (and CK-MB if CK ratio ≥2 ULN). For all CK and CK-MB analyses, the peak
(12-hour) post-procedural sample was used for the analyses — where this was not
available, either the 6 hour or discharge sample was used, whichever was greater.
Cardiac enzyme levels were categorised and differences in four-year mortality
determined.
Predictors of post-PCI CK releasewere determined, since therewas over 90% complete
data [15]. Predictors of CK or CK-MB release post-CABG, and CK-MB release post-PCI, were
not determined due to skeletalmuscle damage post-CABG confounding the CK analyses in
the CABG arm, and incomplete data for CK-MB sampling in the CABG and PCI arms due to
the study protocol mandating CK-MB sampling only if the CK ratio N2 ULN.
2.2. Statistical analysis
Categorical variables are presented as counts/percentages, and compared with
the Chi-square test. Continuous data are presented as medians and interquartile
ranges (IQR), and compared using the Mann–Whitney rank sum test. Different thresh-
olds of cardiac enzyme ratios were investigated to determine the best discrimination be-
tween groups. Comparisons of four-year clinical outcomes (Kaplan–Meier curves) were
performed with the log-rank test between cardiac enzyme groups in the CABG and PCI
arms. Relationships of post-PCI cardiac enzyme elevation to covariates (CK ratio ≥2 ULN
for PCI), utilising previously published baseline and peri-procedural related characteristics
[6], were investigated with univariate logistic regression models. Two models were
constructed, the first model incorporating the SYNTAX Score, and the secondmodel com-
ponents of the SYNTAX Score, to determine individual anatomical factors associated with
cardiac enzyme release. Correlates identified in univariable analyses were introduced into
a multivariable model using the forced enter method, with variable entry criteria of 0.05
and no exit criteria. A 2-sided p-value b0.05 was considered significant. All analyses
were conducted using SPSS 19.0 (SPSS Inc., Chicago IL).
3. Results
Within the randomised SYNTAX population (n = 1800), baseline
demographics and clinical characteristics for the treatment arms were
well balanced and have been described previously [6]. Aflowchart illus-
trates the availability of post-procedural cardiac enzyme levels (per
protocol) within the randomised SYNTAX population (Fig. 1).
3.1. Incidence and distribution of post-procedural CK/CK-MB release
Post-procedural CK sampling was available in 1629 out of 1800
patients (91%) (Fig. 1); CK-MB analyses were undertaken in 474 of
491 patients (97%) in the CABG arm, and 54 of 61 patients (89%) in
the PCI arm.
The distribution of the post-procedural CK and CK-MB ratios is illus-
trated (Fig. 2). The median CK ratio in the CABG arm was significantly
greater compared to the PCI arm (CABG: 2.5 ULN, IQR 1.6–4.1; PCI: 0.5
ULN, IQR 0.4–0.9; p b 0.001). The median CK-MB ratio in the PCI arm
Fig. 1. Flow chart of the post-procedural cardiac biomarker availability in the randomised SYNTAX Trial (n = 1800). Percentages in parentheses indicate the proportion of the entire
randomised SYNTAX population (n = 1800). *1 patient included with CK-MB level with no prior CK level assessment. Abbreviations: CABG coronary artery bypass surgery, PCI percuta-
neous coronary intervention, CK creatine kinase, CK-MB creatine kinase-MB fraction, hr hour.
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was significantly greater compared to the CABG arm (CABG: 6.2 ULN,
IQR 3.6–10.4; PCI: 12.6 ULN, IQR 6.8–28.1; p b 0.001).
3.2. Clinical outcomes based upon post-procedural cardiac enzyme release
3.2.1. Post-procedural CK-ratio
Within the CABG arm, a post-procedural CK ratio separated by b2
and ≥2 ULN demonstrated no significant differences in all-cause
death at four-years (Fig. 3). Within the PCI arm, a post-procedural CK
ratio separated by b2 and ≥2 ULN, divided patients into low- and
high-risk groups for all-cause death at 30 days (0.9% [7/765] vs. 10.0%
[6/60], p b 0.001), 6 months (2.2% [17/762] vs. 13.3% [8/60], log rank
p b 0.001) and 4 years (10.8% [81/750] vs. 23.3% [14/60], log rank
p = 0.001) (Fig. 3). Notably in the PCI arm, an early (within 6 months)
and late (after 2 years) peak in mortality was evident following a post-
procedural CK ratio ≥2 ULN.
3.2.2. Post-procedural CK-MB ratio
Since post-procedural CK-MB sampling in the CABG and PCI arms
was limited to patients with a prior CK ratio ≥2 ULN, as directed by
the study protocol [7], clinical outcomes based on post-procedural CK-
MB analyses should be interpreted with caution, due to the incomplete
data.
Within the CABG arm, a post-procedural CK-MB ratio b3 and ≥3
ULN separated 4-year mortality into low- and high-risk groups (CK-
MB ratio b3 ULN: 2.3% [2/87]; post-procedural CK-MB ratio group ≥3
ULN 9.5% [34/359], log rank p = 0.03) (Fig. 4a). Post-procedural CK-
MB ratios at higher thresholds (b5 and ≥5 ULN, b10 and ≥10 ULN)
did not separate 4-year mortality into low and high-risk groups.
Within the PCI arm, there was limited power for analyses due to a
low occurrence of a post-procedural CK ratio ≥2 ULN, and subsequent
per-protocol CK-MB analyses (n = 54/61 [3.0% of the study popula-
tion]). Nevertheless, significantly greater mortality was evident in the
high compared to the low post-procedural CK-MB ratio group (separat-
ed by the median CK-MB ratio of 12.6 ULN) at 4 years (7.4% [2/27] vs.
38.5% [10/26], log rank p = 0.006) (Fig. 4b).
3.3. Predictors of post-procedural cardiac enzyme release
3.3.1. CABG arm
A post-procedural CK-MB ratio≥3 ULNwas associatedwith a signif-
icantly increased frequency of a high SYNTAX Score tertile (≥33)
Fig. 2. Distribution of post-procedural CK ratios (n = 1629) (a) and post-procedural CK-
MB ratios (n = 528) (b) in the CABG and PCI cohorts of the randomised SYNTAX Trial.
Fig. 3. Four-year mortality stratified to post-procedural CK b2 ULN and post-procedural CK ≥2 ULN in patients undergoing CABG (n = 802) (left) or PCI (n = 827) (right) based
revascularisation. Inset right image are findings for six-month (180 days) mortality.
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compared to intermediate and low SYNTAX Score tertiles (b33) (p =
0.02) (Fig. 5). Due to incomplete data in post-procedural CK-MB
sampling within the CABG arm, determination as to whether a high
SYNTAX Score tertile was an independent correlate of cardiac enzyme
release post-CABG could not be determined.
3.3.2. PCI arm
Within the PCI arm, since N90% had post-procedural CK sampling
performed (n = 827/903, 91.7%), independent correlates of cardiac en-
zyme release (CK ratio≥2 ULN) could be determined (Table 1). Lack of
pre-procedural thienopyridinewas the strongest independent correlate
of a post-procedural CK ratio ≥2 ULN post-PCI (HR 8.49, CI 2.95–24.43,
p b 0.001), followed by carotid artery disease (HR 2.14, CI 21.00–4.60,
p = 0.052), type I diabetes (HR 3.38, CI 0.86–13.25, p = 0.081) and
SYNTAX Score per 10 points increase (HR 1.25, CI 1.00–1.57, p =
0.052).Within the SYNTAX Score, the presence of a coronary bifurcation
was an independent correlate of enzyme release (HR 2.17, CI 1.17–4.05,
p = 0.015), and the presence of diffuse coronary disease or small pe-
ripheral vessels appeared protective (HR 0.43, CI 0.19–0.95, p = 0.036).
4. Discussion
The main findings of this study are that: 1) cardiac enzyme eleva-
tion post-CABG or post-PCI (CK and subsequent CK-MB sampling)
Fig. 4. Four-year mortality stratified to categories of post-procedural CK-MB ratio in the CABG (a) and PCI (b) arms. Within the CABG arm (n = 474), 4-year mortality separated by a post-
procedural CK-MB ratio b/≥3, b/≥5, and b/≥10ULN are illustrated.Within the PCI arm (n = 54), due to limitations of power, 4-yearmortality data is shown separated by a post-procedural
CK-MB ratio b/≥median (12.60, IQR 6.8–28.1) ULN.
Fig. 5. Distribution of tertiles of the SYNTAX Score (low ≤22, intermediate 23–32,
high ≥33) within the randomised SYNTAX population, stratified by low and high post-
procedural CK-MB ratios (CK-MB ratio b3 and ≥3 ULN) in the CABG arm (n = 463).
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had a detrimental impact on long-term mortality in the SYNTAX
Trial; 2) that in the CABG arm, despite limitations of the data, a
post-procedural CK-MB ratio b3/≥3 ULN separated 4-year mortality
into low- and high-risk groups, and that a post-procedural CK-MB ratio
≥3 ULN appeared to be associated with a significantly increased fre-
quency of a high SYNTAX Score tertile (≥33); 3) a post-procedural CK-
ratio ≥2 ULN post-PCI was associated with an early (within 6 months)
and late (after 2 years) peak in mortality; and 4) a lack of pre-
procedural thienopyridine, carotid artery disease, type 1 diabetes, and
presence of coronary bifurcations were independent correlates of a CK
ratio ≥2 ULN post-PCI.
4.1. CABG arm
The requirement of a CK ratio ≥2 ULN to allow for CK-MB ratio
analyses in the present study was not supported by the clinical find-
ings in the CABG arm, namely that no differences in mortality were
seen between post-CABG CK ratios b2 or ≥2 ULN. This is likely to
be secondary to the fact that skeletal muscle damage, particularly
when undertaking a sternotomy, leads to post-operative rises in CK
levels [16]. At the time of the design of the SYNTAX Trial in 2004, it
was concluded that it was a reasonable strategy to determine the
CK-MB only if the CK ratio was ≥2 ULN [7,14]. In hindsight this prac-
tice underpowered the subsequent analyses on the CK-MB ratios.
Despite these limitations, a post-CABG CK-MB ratio of b3 or ≥3
ULN was still able to discriminate low and high risk groups for mor-
tality at up to four years.
Furthermore, these results are consistent with the findings from
Costa et al. who first associated minor cardiac enzyme elevation post-
CABGwith early mortality in the randomised Arterial Revascularization
Therapies Study (ARTS) [4]. Subsequently, Domanski et al. confirmed
these findings in a large meta-analysis of seven trials (n = 18,908)
[2]. Notably in this meta-analysis, the doubling of one-year mortality
was associatedwith a post-operative CK-MB ratio of 4.4 ULN, consistent
with the findings in the present study, where a substantial increase in
mortality occurred in patients with a post-CABG CK-MB ratio between
3 and 5 ULN (Fig. 4a).
As to the potential mechanism linking mortality (N1 year) with
minor elevations of CK-MB in CABG patients, this is more complex and
has not yet been clearly defined [2]. Due to the incomplete data collect-
ed on CK-MB analyses, as mandated by the study protocol, multivariate
analyses to determine independent correlates of post-operative cardiac
enzyme release could not be performed. Notably, the presence of a post-
operative CK-MB ratio ≥3 ULN was associated with a significant in-
crease in the frequency of a high SYNTAXScore tertile (Fig. 5). It is there-
fore possible that the CK-MB ratio ≥3 ULN may be confounding, and
potentially related tomore complex baseline coronary disease, and con-
sequent leakage of cardiac enzymes during administration of
cardioplegia solution during CABG [17]. This hypothesis is supported
by historical data associatingmore extensive baseline preoperative cor-
onary disease to longer-term (N10 years) mortality [18,19].
4.2. PCI arm
Historically, a post-PCI elevated CK ratio (≥2 ULN) has been associ-
ated with adverse long-termmortality [16,20,21]. As all patients within
the present study underwent PCI only if the pre-procedural CK-ratio
was ≤2 ULN, the elevation of the CK-ratio after PCI is highly likely to
be related to the presence of significant peri-procedural myocardial
necrosis; the only caveat perhaps being a groin haematoma as a compli-
cation of a femoral approach to PCI.
Furthermore, given the magnitude of cardiac enzyme release in pa-
tients with a CK ratio ≥2 ULN post-PCI (median CK-MB ratio: 12.6
ULN [IQR 6.6–28.1]), and that progressive rises in post-PCI CK-MB ratios
are clearly linked to an increase in mortality [1,22,23], it is not incon-
ceivable that a doubling of 4-year mortality was seen in patients with
a CK ratio ≥2 ULN. Notably, an early (within 6 months) and late peak
(N2 years) in mortality was evident in patients with a post-PCI CK
ratio ≥2 ULN (Fig. 3). These findings may be related to the clinical con-
sequences of an acuteMI in the short term, and complications related to
heart failure or arrhythmias in the long term.
In so far as preventing cardiac enzyme elevation post-PCI, the 2 po-
tentially reversible independent correlates of cardiac enzyme elevation
included lack of pre-procedural thienopyridine, and the presence of a
coronary bifurcation (Table 1). The coronary bifurcation (compared to
non-coronary bifurcations) has historically been associatedwith poorer
outcomes following PCI [24–27]. As compared to the one-stent
approach for the treatment of the coronary bifurcations, the two-stent
approach utilising first generation DES has been shown to be less
favourable, with a recommendation of a one-stent (provisional) strate-
gy wherever possible [28–30].
5. Study limitations
The present study represents a post hoc analysis of the SYNTAX Trial
and the results should be considered as hypothesis generating. The
main limitation of this study was the incomplete data on CK-MB ratios
due to the protocol defined reliance on amandatory CK-ratio performed
beforehand [7]. It has previously been reported that 10–20% of patients
with elevated CK-MB measurements have a normal total CK [31]. We
therefore cannot exclude the possibility of selection bias in patients in-
vestigatedwith elevated CK-MB. It is however unlikely that themyocar-
dial injury was of a sizable magnitude, as it would have been identified
Table 1
Univariate (selected variables shown) and independent correlates of post-procedural
cardiac enzyme release (CK ratio ≥2 ULN) following PCI based revascularisation. Model
1 incorporates the SYNTAX Score. Model 2 incorporates components of the SYNTAX Score.
PCI Odds ratio 95% C.I. p-Value
Univariate correlates of post-PCI CK ratio ≥2
SYNTAX Score per increase in 10 points 1.22 0.98, 1.52 0.072
Any coronary bifurcation 2.21 1.20, 4.07 0.011
Any heavy calcification 1.34 0.79, 2.26 0.28
Any aorto-ostial disease 1.28 0.64, 2.52 0.49
Any angiographically visible thrombus 1.20 0.27, 5.22 0.81
Any total occlusion 0.87 0.46, 1.65 0.68
Left main coronary artery disease 0.85 0.50, 1.47 0.57
Any severe tortuosity 0.84 0.49, 1.44 0.52
Diffuse disease or small peripheral vessels 0.49 0.23, 1.06 0.069
Lack of pre-procedural thienopyridinea 7.35 2.62, 20.62 b0.001
Type 1 diabetes 3.49 0.95, 12.86 0.060
Carotid artery disease 1.96 0.92, 4.17 0.079
Stent length N100 mm 1.37 0.78, 2.40 0.27
Peripheral vascular disease 1.25 0.55, 2.84 0.60
Poor left ventricular ejection fraction 1.24 0.16, 9.84 0.84
Moderate left ventricular ejection fraction 1.17 0.61, 2.27 0.63
Age per increase in 10 years 1.08 0.82, 1.41 0.60
Incomplete revascularisation 1.06 0.63, 1.79 0.82
Total stent length (mm) 1.00 1.00, 1.01 0.50
Type II diabetes 0.97 0.53, 1.74 0.91
Good left ventricular ejection fraction 0.91 0.49, 1.68 0.75
Model 1 — SYNTAX Score Odds ratio 95% C.I. p-Value
Independent correlates of post-PCI CK ratio ≥2
Lack of pre-procedural thienopyridinea 8.49 2.95, 24.43 b0.001
Carotid artery disease 2.14 1.00, 4.60 0.052
Type 1 diabetes 3.38 0.86, 13.25 0.081
SYNTAX Score per increase in 10 points 1.25 1.00, 1.57 0.052
Model 2 — components of the SYNTAX Score Odds ratio 95% C.I. p-Value
Independent correlates of post-PCI CK ratio ≥2
Lack of pre-procedural thienopyridinea 8.35 2.84, 24.57 b0.001
Type 1 diabetes 3.63 0.91, 14.52 0.068
Carotid artery disease 2.35 1.09, 5.08 0.030
Any coronary bifurcation 2.17 1.17, 4.05 0.015
Diffuse disease or small peripheral vessels 0.43 0.19, 0.95 0.036
a Clopidogrel or ticlopidine.
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by the total CK assessment. In addition, there was lack of troponin data
since the SYNTAX Trial was commenced prior to the Academic Research
Consortium publication of standardised definitions and clinical out-
comes [32]. Site reported data on cardiac enzymes was not collected.
The incomplete data on CK-MB sampling precluded multivariate analy-
ses for cardiac enzyme release and long-term mortality. Multivariable
correlates of long-termmortality, without inclusion of cardiac enzymes,
have however recently been reported [33].
6. Conclusion
Cardiac enzyme elevation post-CABG or post-PCI is associated with
an adverse long-term mortality; the causes of which are multifactorial.
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Aims The aim of this investigation was to determine the incidence and multivariable correlates of long-term (4-year)
mortality in patients treated with surgical or percutaneous revascularization in the synergy between percutaneous
coronary intervention (PCI) with TAXUS Express and Cardiac Surgery (SYNTAX) trial.
Methods and
results
A total of 1800 patients were randomized to undergo coronary artery bypass graft (CABG) surgery (n ¼ 897) or PCI
(n ¼ 903). Prospectively collected baseline and peri- and post-procedural data were used to determine independent
correlates of 4-year all-cause death in the CABG and the PCI arms (Cox proportional hazards model). Four-year
mortality rates in the CABG and the PCI arms were 9.0% [74 deaths (12 in-hospital)] and 11.8% [104 deaths (16
in-hospital)], respectively (log-rank P-value ¼ 0.063). Censored data comprised 78 patients (8.7%) in the CABG
arm, and 24 patients (2.7%) in the PCI arm (log-rank P-value , 0.001). Within the CABG arm, the strongest inde-
pendent correlates of 4-year mortality were lack of discharge aspirin [hazard ratio (HR) 3.56; 95% CI: 2.04, 6.21;
P, 0.001], peripheral vascular disease (PVD) (HR: 2.65; 95% CI: 1.49, 4.72; P ¼ 0.001), chronic obstructive pulmon-
ary disease, age, and serum creatinine. Within the PCI arm, the strongest independent correlate of 4-year mortality
was lack of post-procedural anti-platelet therapy (HR: 152.16; 95% CI: 53.57, 432.22; P, 0.001), with 10 reported
early (within 45 days) in-hospital deaths secondary to multifactorial causes precluding administration of anti-platelet
therapy. Other independent correlates of mortality in the PCI arm included amiodarone therapy on discharge, pre-
procedural poor left ventricular ejection fraction, a ‘history of gastrointestinal bleeding or peptic ulcer disease’, PVD
(HR: 2.13; 95% CI: 1.26, 3.60; P ¼ 0.005), age, female gender (HR: 1.60; 95% CI: 1.01, 2.56; P ¼ 0.048), and the
SYNTAX score (Per increase in 10 points: HR: 1.25; 95% CI: 1.06, 1.47; P ¼ 0.007).
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Conclusion Independent correlates of 4-year mortality in the SYNTAX trial were multifactorial. Lack of discharge aspirin and lack
of post-procedural anti-platelet therapy were the strongest independent correlates of mortality in the CABG and the
PCI arms, respectively. Peripheral vascular disease is a common independent correlate of 4-year mortality and may be
a marker of the severity of baseline coronary disease and risk of future native coronary disease (and extra-cardiac
disease) progression.
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Introduction
The SYNTAX trial has established a framework in which patients
with unprotected left main or 3-vessel coronary artery disease
are managed by the consensus of the Heart Team, in which the
cardiac surgeon and interventional cardiologist determine the
optimal revascularization modality for patients.1–6 The results
from the primary endpoint of the SYNTAX trial at 4 years have
recently been reported,7,8 with follow-up through to 5 years
planned. The aim of this study was to analyse the incidence and
multivariable correlates of all-cause death at 4 years following
surgical or percutaneous revascularization in the randomized
SYNTAX trial.
Methods
The SYNTAX trial is a randomized, prospective, multicentre trial that
incorporates an ‘All-Comers’ design and in this study, consisted of pre-
specified left main [isolated or associated with 1, 2, or 3 vessel disease
(3VD)] and 3VD arms.1,3,5 Patients were randomized on a 1:1 basis by
the Heart Team consensus to undergo either coronary artery bypass
graft (CABG) or percutaneous coronary intervention (PCI) with
TAXUS Express paclitaxel-eluting stents (Boston Scientific Corpor-
ation, Natick, MA, USA) (n ¼ 1800). Patients considered unsuitable
for randomization were entered in nested registries for CABG- or
PCI-ineligible patients. Exclusions were limited only to patients with
prior coronary revascularization, the requirement of concomitant
cardiac surgery, or on-going acute MI. An independent core laboratory
(Cardialysis BV, Rotterdam, the Netherlands), blinded to the treatment
assignment, calculated the SYNTAX score (http://www.syntaxscore.
com).3,4,6,9
Pre-procedurally, the study protocol mandated in the CABG arm
aspirin (.70 mg per day) at least 12 h pre-CABG, and in the PCI
arm aspirin (.70 mg per day) at least 12 h pre-PCI and clopidogrel
(300 + mg 24 h pre-PCI) or ticlopidine (2 × 250 mg daily 48 h
pre-PCI). Post-procedurally, aspirin (.70 mg/day) was mandated in
the CABG and the PCI arms, and clopidogrel (75 mg) or ticlopidine
(2 × 250 mg) for at least 6 months in the PCI arm. Within the
CABG and the PCI arms, it was recommended that optimal medical
treatment be continued long-term according to the ACC/AHA guide-
lines.10–12
Baseline and peri- and post-procedural data and blood samples were
prospectively collected by the individual participating centres. Post-
procedural and discharge medications encompassed specific medica-
tions (or lack of) immediately after revascularization (CABG or PCI)
and at hospital discharge, respectively. Pre- and post-revascularization
per protocol blood sampling with creatine kinase (CK) were under-
taken, with the cardiac-specific MB iso-enzyme (CK-MB) measured
only if the CK ratio ≥2× upper limit of normal (ULN).5 Revasculari-
zation with CABG or PCI was permitted only if the cardiac enzymes
were ,2× ULN. All the samples were evaluated by an independent
central chemistry laboratory (Covance, Inc., Geneva, Switzerland,
and Indianapolis, IN, USA).
Statistical analysis
In this article, continuous variables are presented as means+ standard
deviation (SD). Categorical variables are presented as counts or
percentages. Comparisons of 4-year clinical all-cause death (Kaplan–
Meier estimates) were performed with the log-rank test. Similar ana-
lyses were conducted for censored patients using the time to censored
event for all-cause death. Relationships of 4-year all-cause to covari-
ates, utilizing previously published baseline and peri- and post-
procedural characteristics,3 were investigated with univariate Cox
regression models. The correlates of worse prognosis identified in uni-
variable analyses were then introduced into a multivariable model
using the forced enter method, with a variable entry criterion of
0.05; all the variables were retained in the final model irrespective of
statistical significance. The proportionality of hazards (PH) assumption
was checked using the global PH test based on Schoenfeld residuals.13
There was no departure from the PH assumption in the CABG [x2 ¼
10.29, degrees of freedom (df) ¼ 10, P ¼ 0.42] and the PCI arms
(x2 ¼ 13.96, df ¼ 10, P ¼ 0.17). Intercorrelation between variables
was undertaken with the Pearson correlation coefficient where appro-
priate. A two-sided P-value of ,0.05 was considered significant for all
tests. All analyses were conducted using SPSS 19.0 (SPSS, Inc., Chicago,
IL, USA) and STATA 11.0 (Stata Corp., College Station, TX, USA).
Results
Within the randomized SYNTAX trial (n ¼ 1800), baseline demo-
graphics, and clinical characteristics for the CABG (n ¼ 897) and
the PCI (n ¼ 903) arms were well balanced and have previously
been described.3 At 4 years, clinical data were available in 819 of
897 patients in the CABG arm, and 879 of 903 patients in the
PCI arm. Censored data comprised 78 patients (8.7%) in the
CABG arm, and 24 patients (2.7%) in the PCI arm (log-rank
P-value , 0.001). The most common reason for censoring was
the withdrawal of consent after randomization [61 patients
(CABG n ¼ 50, PCI n ¼ 11)], with the remainder of patients pri-
marily lost to follow-up.
Four-year mortality was 9.0% (74 all-cause deaths) in the CABG
arm and 11.8% (104 all-cause Deaths) in the PCI arm (log-rank
P-value ¼ 0.063). Univariate and independent correlates of cumu-
lative 4-year mortality in the CABG and the PCI arms are shown in
Tables 1–4.
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Randomized coronary artery bypass
graft arm
Within the randomized CABG arm, incomplete revascularization
and on-pump CABG were not shown to be univariate correlates
of 4-year mortality (Table 1). Lack of pre-procedural aspirin was
not an independent correlate of mortality (Table 2). Lack of dis-
charge aspirin was the strongest independent correlate of 4-year
mortality [hazard ratio (HR) 3.56; 95% CI: 2.04, 6.21; P, 0.001].
Only a weak correlation was apparent between lack of pre-
procedural aspirin and lack of discharge aspirin (Pearson correl-
ation 0.14, P, 0.001). Twenty-seven out of 96 CABG-treated
patients (28.1%) not discharged on aspirin died within 4 years
(0 in-hospital deaths). Notably, 15 of the 27 deaths were cardiac
(n ¼ 13) or vascular (n ¼ 2) related and 12 deaths non-cardiac
related. A ‘history of gastrointestinal (GI) bleeding or peptic
ulcer disease’ demonstrated a trend towards significance of being
an independent correlate of 4-year mortality (P ¼ 0.085). A
‘history of GI bleeding or peptic ulcer disease’ had no correlation
with a lack of discharge aspirin therapy (Pearson correlation 0.03,
P ¼ 0.36).
Pre-procedural poor left ventricular ejection fraction (LVEF) was
not an independent correlate of 4-year mortality. Amiodarone
therapy on discharge demonstrated a trend towards being a
significant independent correlate of 4-year mortality (P ¼ 0.070).
No correlation of pre-procedural poor LVEF and amiodarone
therapy on dischargewas evident (Pearson correlation 0.01, P ¼ 0.76).
Other key independent correlates of 4-year mortality in the ran-
domized CABG arm included peripheral vascular disease (PVD)
(HR: 2.65; 95% CI: 1.49, 4.72; P ¼ 0.001)—with 21 of 87 patients
(24.1%) dying within 4-years (five in-hospital deaths), chronic ob-
structive pulmonary disease (HR: 2.44; 95% CI: 1.30, 4.60; P ¼
0.006), age, and renal function (Table 2).
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Table 1 Univariate (selected variables shown) correlates of 4-year mortality in the entire coronary artery bypass graft
population of the randomized SYNTAX trial (n 5 897)
CABG (n 5 897) univariate correlates of 4-year mortality Incidence of mortality: no./total (%) Hazard ratio (95% CI) P-value
Categorical variables (%)
Lack of discharge aspirin 27/96 (28.1) 5.03 (3.11–8.14) ,0.001
Peripheral vascular disease 21/87 (24.1) 3.72 (2.24–6.16) ,0.001
Pre-procedural poor LVEF 5/18 (27.8) 3.65 (1.47–9.05) 0.005
Chronic obstructive pulmonary disease 17/77 (22.1) 3.20 (1.86–5.50) ,0.001
History of GI bleeding or peptic ulcer disease 8/37 (21.6) 2.87 (1.38–5.98) 0.005
Amiodarone therapy on discharge 16/105 (15.2) 2.01 (1.16–3.51) 0.014
Hypertension 63/625 (10.1) 1.97 (1.01–3.84) 0.046
Lack of pre-procedural aspirin 56/535 (10.5) 1.91 (1.10–3.33) 0.023
Metabolic syndrome 33/292 (11.3) 1.57 (0.94–2.63) 0.084
Left main coronary artery disease 37/324 (11.4) 1.55 (0.98–2.45) 0.059
Diabetes 27/230 (11.7) 1.53 (0.95–2.46) 0.078
On pump CABG 63/687 (9.2) 1.45 (0.66–3.16) 0.36
Anterograde administration of cardioplegia 61/668 (9.1) 1.33 (0.66–2.67) 0.43
Crystalloid cardioplegia 27/263 (10.3) 1.29 (0.79–2.08) 0.31
Incomplete revascularization 31/306 (10.1) 1.28 (0.80–2.04) 0.3
Male 61/653 (9.3) 1.19 (0.66–2.17) 0.56
Current Smoker 16/172 (9.3) 1.07 (0.62–1.87) 0.81
High SYNTAX score tertile 25/294 (8.5) 0.90 (0.56–1.46) 0.67
Blood cardioplegia 34/405 (8.4) 0.91 (0.57–1.45) 0.69
Retrograde administration of cardioplegia 6/116 (5.2) 0.54 (0.23–1.24) 0.15
Continuous variablesa
Age per increase in 10 years 71+8 2.16 (1.64–2.86) ,0.001
Serum creatinine (mg/dL) 1.32+1.17 1.52 (1.27–1.82) ,0.001
SYNTAX score per increase in 10 points 30+13 1.10 (0.91–1.34) 0.34
Cross-clamp time (minutes) 54+23 1.00 (0.99–1.01) 0.89
BMI 27+5 0.97 (0.92–1.02) 0.25
Post-CABG peak CK–MB ratiob 17.63+39.8 1.02 (1.01–1.03) 0.002
GI, gastrointestinal; LVEF, left ventricular ejection fraction; CABG, coronary artery bypass graft surgery; CK-MB, creatine kinase myoglobin; BMI, body mass index.
aContinuous variables are presented as mean+ SD in patients who died within four years (age and SYNTAX score are presented as actual values).
bThe CK–MB ratio was not inserted in the multivariable model because of incomplete data as per the SYNTAX trial protocol (available in 474 of 897 patients—26.3% of study
population).
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Randomized percutaneous coronary
intervention arm
Within the randomized PCI arm, total number of stents, total
stent length, and stent length .100 mm were not shown to be
correlates of 4-year mortality (Table 3). The strongest independ-
ent correlate of mortality was lack of post-procedural anti-
platelet therapy (HR: 152.16, 95% CI: 53.57, 432.22, P, 0.001)
(Table 4). Further analyses indicated that 11 PCI-treated patients
had a lack of post-procedural anti-platelet therapy (neither aspirin
nor thienopyridine) with 10 reported early in-hospital deaths
(,45 days) and the 11th patient’s clinical outcome censored.
All 10 deaths were cardiac related and of multifactorial causes
which precluded anti-platelet administration. Two deaths were
related to GI bleeding, one death secondary to retroperitoneal
bleeding resulting from procedure-related femoral vascular
access, three deaths secondary to coronary perforation (two
cases requiring surgical intervention), and three further cases ne-
cessitating CABG after PCI-related complications following stent
implantation (two cases secondary to post-procedural acute
stent thrombosis and one case for extraction of ruptured
balloon catheter after stent implantation), with withdrawal of
treatment in one case due to poor prognosis. Detailed patient
narratives of these 10 deaths are available in the Supplementary
material online, Appendix.
Being discharged on one anti-platelet agent alone was not an in-
dependent correlate of mortality (n ¼ 39, one patient event cen-
sored), with no in-hospital deaths reported. There was no
correlation between a ‘history of GI bleeding or peptic ulcer
disease’ and a lack of post-procedural anti-platelet therapy
(Pearson correlation 20.02, P ¼ 0.51) or patients taking one anti-
platelet agent at discharge (Pearson correlation 0.04, P ¼ 0.28).
Amiodarone therapy on discharge [5 of 12 patients dying within
4 years (1 death in-hospital)] (HR: 4.49, 95% CI: 1.36, 14.83, P ¼
0.014) and pre-procedural poor left LVEF were independent
correlates of 4-year mortality. Both variables showed minor cor-
relation (Pearson correlation 0.3, P, 0.001).
Other independent correlates of 4-year mortality included a
‘history of GI bleeding or peptic ulcer disease,’ PVD [22 of 80
patients (27.5%) dying within 4 years (4 in-hospital deaths)]
(HR ¼ 2.13, 95% CI: 1.26, 3.60, P ¼ 0.005), age and female
gender [38 of 207 patients (18.4%) dying within 4 years (8
in-hospital deaths)] (HR: 1.60; 95% CI: 1.01, 2.56; P ¼ 0.048).
Female gender had a weak negative correlation with the
SYNTAX score (Pearson correlation coefficient: 20.09, P ¼
0.007) and a weak positive correlation with age (Pearson correl-
ation coefficient 0.18, P, 0.001).
The SYNTAX score was an independent correlate of 4-year
mortality in the PCI arm. For every 10-point-increase in the
SYNTAX score, this associated with a 1.25 times greater risk of
4-year mortality in the PCI-treated patients.
Discussion
The following are the main findings of this study: (i) within the
CABG arm, the lack of discharge aspirin therapy was the strongest
independent correlate of 4-year mortality; (ii) within the PCI arm,
clinical factors were more strongly associated with 4-year all-cause
death compared with anatomical factors (namely the SYNTAX
score); in addition procedural related factors, such as stent
number or length, were not correlates of 4-year mortality; (iii)
female gender was an independent correlate of 4-year mortality
in the PCI arm; (iv) PVD was a common independent correlate
of 4-year mortality in the CABG and the PCI arms—the presence
of which may be a marker of native coronary disease severity and
the risk of future coronary disease progression; and (v) the possi-
bility of the outcomes of the SYNTAX trial having been affected by
the significant differences in censored patient numbers between
the CABG and the PCI arms cannot be excluded.
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Table 2 Independent correlates of 4-year mortality in the entire coronary artery bypass graft population of the
randomized SYNTAX trial (n 5 897)
CABG (n 5 897) independent correlates of 4-year mortality
(variables with a P-value >0.05 italicized)
Hazard ratio 95% CI P-value
Lack of discharge aspirin 3.56 2.04–6.21 ,0.001
Peripheral vascular disease 2.65 1.49–4.72 0.001
Chronic obstructive pulmonary disease 2.44 1.30–4.60 0.006
History of GI bleeding or peptic ulcer disease 2.14 0.90–5.07 0.085
Age per increase in 10 years 1.95 1.41–2.69 ,0.001
Pre-procedural poor LVEF 1.86 0.65–5.33 0.25
Amiodarone therapy on discharge 1.79 0.95–3.35 0.07
Serum creatinine (mg/dL) 1.47 1.17–1.84 0.001
Hypertension 1.28 0.62–2.67 0.51
Lack of pre-procedural aspirin 1.18 0.64–2.19 0.59
CABG, coronary artery bypass graft surgery; GI, gastrointestinal; LVEF, left ventricular ejection fraction.
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Mechanism of late (4-year) mortality
in coronary artery bypass graft and
percutaneous coronary intervention
patients
Within the CABG and the PCI arms, PVD was an independent cor-
relate of 4-year Death. The presence and the severity of extra-
cardiac disease, defined by parameters such as carotid intima
media thickness (CIMT) and ankle brachial pressure index, have
previously been associated with more extensive baseline coronary
artery disease.14–21 For example, Ikeda et al.15 recently associated
the severity of the SYNTAX score with the CIMT. More complex
baseline coronary artery disease has in turn been associated with
adverse long-term prognosis as reported in the Coronary Artery
Surgery Study21 and Rotterdam18 registries. Within these regis-
tries, more extensive baseline preoperative coronary disease was
associated with long-term mortality (.10 years), which were
further linked to a higher prevalence and severity of other clinical
risk factors. Notably, within the Bypass Angioplasty Revasculariza-
tion Investigation trial, native coronary disease progression, and
not failed revascularization, was the predominant determinant of
jeopardized myocardium and recurrence of angina at 5-year
follow-up in CABG- or PCI-treated patients.22
Lack of discharge anti-platelet therapy
in the coronary artery bypass graft arm
The findings of lack of discharge aspirin after CABG to be an inde-
pendent correlate of 4-year mortality are contrasted by previous
studies that have potentially related aspirin therapy on the day of
surgery to a reduction in in-hospital or at most 30-day mortality.23
Historically, aspirin therapy on the day of surgery has been
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Table 3 Univariate (selected variables shown) correlates of 4-year mortality in the entire percutaneous coronary
intervention population of the randomized SYNTAX trial (n5 903)
PCI (n 5 903) univariate correlates of 4-year
mortality
Incidence of mortality:
no./total (%)
Hazard ratio (95% CI) P-value
Categorical variables (%)
No post-procedural anti-platelet therapya,b 10/10 (100)b 173.76 (71.24–423.78) ,0.001
Pre-procedural poor LVEF 6/12 (50) 5.37 (2.35–12.26) ,0.001
Amiodarone therapy on discharge 5/12 (41.7) 4.85 (1.97–11.91) 0.001
Peripheral vascular disease 22/80 (27.5) 3.05 (1.91–4.89) ,0.001
History of GI bleeding or peptic ulcer disease 9/37 (24.3) 2.42 (1.22–4.79) 0.011
Female gender 38/207 (18.4) 1.95 (1.31–2.91) 0.001
Lack of pre-procedural thienopyridinec 4/20 (20) 1.78 (0.66–4.85) 0.26
Diabetes 41/247 (16.6) 1.76 (1.19–2.61) 0.005
Hypertension 83/642 (12.9) 1.52 (0.93–2.48) 0.092
Metabolic syndrome 47/327 (14.4) 1.51 (0.99–2.32) 0.057
Incomplete angiographic revascularization 53/381 (13.9) 1.41 (0.96–2.08) 0.081
Single (aspirin or thienopyridinec) on discharge 6/39 (15.4) 1.34 (0.59–3.06) 0.49
Current smoking 23/161 (14.3) 1.29 (0.81–2.05) 0.28
Stent length .100 mm 35/287 (12.2%) 1.09 (0.72–1.65) 0.67
Any total occlusion 26/209 (12.4%) 1.05 (0.68–1.64) 0.82
Left main coronary disease 40/349 (11.5) 0.94 (0.64–1.40) 0.77
Continuous variablesd
Age per increase in 10 years 70+8 1.81 (1.45–2.26) ,0.001
SYNTAX score per increase in 10 points 32+12 1.33 (1.14–1.54) ,0.001
Serum creatinine (mg/dL) 1.13+0.43 1.29 (1.05–1.60) 0.018
Post-PCI peak CK ratioe 1.61+3.18 1.21 (1.13–1.29) ,0.001
Total number of stents 5+2 1.06 (0.97–1.15) 0.19
Total stent length (mm) 90+46 1.00 (1.00–1.01) 0.45
BMI 28+6 1.00 (0.96–1.04) 0.92
Post-PCI peak CK–MB ratioe 36.6+21.6 1.05 (1.02–1.07) ,0.001
PCI, percutaneous coronary intervention; GI, gastrointestinal; LVEF, left ventricular ejection fraction; CK, creatine kinase; CK-MB, creatine kinase myoglobin, BMI, body mass index.
aAspirin nor thienopyridine.
bAll deaths occurred in-hospital and within 45 days.
cClopidogrel or ticlopidine.
dContinuous variables are presented as mean+ SD in patients who died within four years (age and SYNTAX score are presented as actual values).
eThe CK ratio (available in 766 of 903 patients—84.8% of the study population) and the CK–MB ratio (available in 54 of 903 patients—3% of study population) were not inserted
in the multivariable model because of incomplete data as per the SYNTAX trial protocol.
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associated with a 50–70% reduction in early and late (up to
1-year) aorto-coronary vein-graft occlusion.24–26 Graft patency
at 1-year has, however, not translated into increased mortality.
Moreover within the angiographic sub-study of SYNTAX trial,27
despite over a quarter of the CABG patients (27.2%) found to
have significantly diseased (≥50 to,100%) or obstructed
(100%) bypass grafts at 15 months, this was not significantly asso-
ciated with early major adverse cardiovascular and cerebrovascu-
lar events. Potential reasons for this latter phenomenon have been
related to bypass grafts prematurely failing if anastomosed distal to
functionally non-significant lesions, because of competitive flow, or
the recurrence of anginal symptoms if bypass grafts to a function-
ally significant lesion failed.27–30
Why aspirin therapy in the present study was a strong independ-
ent correlate of 4-year mortality in the CABG arm is unclear. As
previously discussed, patients with more complex coronary
disease have been associated with the presence of extra-cardiac
arteriopathy.14–21 It may, therefore, be hypothesized that aspirin
therapy was potentially protective against ischaemic complications
arising from cardiac and systemic atherosclerotic disease (cerebral,
renal, and GI), which may perhaps be more likely to occur in the
study population.14–21 This hypothesis is supported by the findings
of most of the deaths in patients not on aspirin therapy at
discharge in the CABG arm to be cardiac or vascular related
(15 out of 27 deaths).
History of gastrointestinal bleeding or
peptic ulcer disease
A history of GI bleeding or peptic ulcer disease was an independ-
ent correlate of 4-year mortality in the PCI arm (P ¼ 0.004), with a
trend towards significance in the CABG arm (P ¼ 0.085). Aspirin
alone, clopidogrel alone, and their combination have all been asso-
ciated with an increased risk of GI bleeding.31–33 Consequently,
the association of a ‘history of GI bleeding or peptic ulcer
disease’ with mortality is perhaps not unexpected, given the
mandatory requirement of dual anti-platelet therapy after PCI to
prevent stent thrombosis, and the potential long-term protective
effect of aspirin therapy in CABG-treated patients as previously
discussed. Notably, Iakovou et al.,34 in a well-designed ‘real-world’
registry of first-generation DES (sirolimus- or paclitaxel-eluting
stents) (n ¼ 2229), demonstrated that the premature discontinu-
ation of anti-platelet therapy is strongly associated with acute
stent thrombosis at 9-months following DES implantation.
Within PCI patients, the use of concomitant proton pump inhi-
bitors with clopidogrel therapy for gastro-protection has been
controversial, because of a potential interaction with the anti-
platelet effect of clopidogrel. Until now, no study has convincingly
demonstrated any significant impact on adverse clinical outcomes,
although this effect cannot be excluded in certain subgroups, such
as poor metabolizers of clopidogrel.35–38 Further studies are
required to investigate the cost/risk–benefit ratio of selectively
or routinely adopting prophylactic gastro-protective therapy in
PCI (and possibly CABG)-treated patients.
Gender
Despite adjustments for risk factors, including age and the
SYNTAX score, female gender was an independent correlate of
4-year mortality in the PCI arm of the SYNTAX trial, a finding at
odds with other contemporary DES trials showing no gender
effect.39–43 The main difference being that females in the
SYNTAX trial had more complex baseline coronary disease (and
therefore potentially a greater atherosclerotic burden)—mean
SYNTAX score of 26.5+ 11.9—compared with 12.9 + 8.4 in
women from three pooled All-Comers randomized DES trials
(SIRTAX, LEADERS, RESOLUTE).39
A recent sub-study of the PROSPECT trial (Providing Regional
Observations to Study Predictors of Events in the Coronary
Tree)44,45 has shown that there may be a potential ‘gender
effect’ in the pathophysiology and composition of atherosclerotic
plaque leading to acute coronary syndrome. Women (compared
with men) were shown to have less extensive coronary artery
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 4 Independent correlates of 4-year mortality in the entire percutaneous coronary intervention population of the
randomized SYNTAX trial (n 5 903)
PCI (n5 903) independent correlates of 4-year mortality
(variables with a P- value >0.05 italicized)
Hazard ratio 95% CI P-value
No post-procedural anti-platelet therapya 152.16 53.57–432.22 ,0.001
Amiodarone therapy on discharge 4.49 1.36–14.83 0.014
Pre-procedural poor LVEF 3.31 1.03–10.64 0.045
History of GI bleeding or peptic ulcer disease 2.93 1.41–6.12 0.004
Peripheral vascular disease 2.13 1.26–3.60 0.005
Age per increase in 10 years 1.62 1.26–2.09 ,0.001
Female gender 1.6 1.01–2.56 0.048
Serum creatinine 1.28 0.95–1.72 0.11
Diabetes 1.28 0.83–2.00 0.27
SYNTAX score per increase in 10 points 1.25 1.06–1.47 0.007
PCI, percutaneous coronary intervention; CI, confidence interval; GI, gastrointestinal; LVEF, left ventricular ejection fraction.
aNeither aspirin nor thienopyridine.
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disease by angiographic and intravascular ultrasound assessments,
less plaque rupture, less necrotic core and calcium, similar
plaque burden, and smaller lumens. Conversely, the presence of
thin-cap fibroatheroma was demonstrated to be a stronger
marker of plaque vulnerability and risk of future clinical events in
women compared with men. Importantly, despite these differ-
ences, clinical outcomes were reported to be comparable
between the sexes in the PROSPECT trial, although most events
occurred in angiographically inapparent lesions. Patients from the
SYNTAX trial had substantially more complex coronary disease
compared with the PROSPECT trial (which excluded patients
with left main coronary artery disease and 3VD requiring PCI).
Thus, the possibility of more unfavourable plaque composition in
obstructive and non-obstructive lesions of females with advanced
atherosclerotic disease being a possible explanation for the poten-
tial increased mortality in the SYNTAX trial cannot be
dismissed.14,45,46
Study limitations
This study represents a post hoc analysis of the SYNTAX trial and
the results should be considered hypothesis generating. Since the
proportion of patients lost to follow-up varied between the two
study arms (CABG arm: 8.7%, PCI arm: 2.7%, P, 0.001), this po-
tential confounding factor should be considered when interpreting
the results. Although multivariable adjustments were performed
for significant confounders (P, 0.05), the possibility of other un-
measured confounders having affected the results cannot be
excluded. Within the CABG arm as all correlates that were signifi-
cantly associated with increased mortality on univariable analyses
(P, 0.05) were included in the multivariable model, this may
have resulted in over-fitting since there were 78 deaths. As the
confidence intervals of these correlates were narrow, this would
have limited this risk.47 In the PCI population, there were
enough events (104 deaths) to include all significant correlates.
The lack of CK–MB ratios in all study patients precluded its assess-
ment in the multivariable analyses.
Conclusion
Independent correlates of 4-year mortality in the SYNTAX trial
were multifactorial. Lack of discharge aspirin (CABG arm) and
female gender (PCI arm) are notable independent correlates of
4-year mortality that require confirmation in further studies. Per-
ipheral vascular disease is a common independent correlate of
4-year mortality and may be a marker of the severity of baseline
coronary disease and the risk of future native coronary disease
(and extra-cardiac disease) progression.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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Incidence and Multivariable Correlates of Long-Term (up to 4-Year) 
Mortality in Patients Treated with Surgical or Percutaneous 
Revascularisation in the Synergy Between PCI with TAXUS Express 
and Cardiac Surgery Trial 
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1.  Supplementary Methods 
Continuous data are presented as medians and interquartile range (IQR) and were 
compared with the Mann-Whitney rank sum test. Categorical variables were 
compared with the chi-square test. 
2.  Supplementary Tables 
Table 1 
Comparison of anatomical and clinical variables between patients with and without 
discharge antiplatelet therapy in the CABG arm (n=897). 
CABG 
 
No Antiplatelet Therapy 
on Discharge (n=100) 
Antiplatelet Therapy on 
Discharge (n=770) 
p-value 
Categorical Variables 
Peripheral vascular disease 
Pre-procedural poor LVEF 
COPD 
History of GI bleeding peptic ulcer disease 
Amiodarone therapy on discharge 
Hypertension 
Lack of pre-procedural aspirin 
Metabolic syndrome 
Left main coronary artery disease 
Diabetes 
On pump CABG 
Anterograde administration of cardioplegia 
Crystalloid cardioplegia 
Incomplete revascularisation 
Male 
Current Smoker 
High SYNTAX Score tertile 
Blood cardioplegia 
Retrograde administration of cardioplegia 
13/100 (13%) 
6/100 (6.0%) 
15/100 (15.0%) 
7/99 (7.1%) 
9/99 (9.1%) 
83/99 (83.8%) 
83/99 (83.8%) 
43/73 (58.9%) 
30/100 (30.0%) 
33/100 (33.0%) 
89/99 (89.0%) 
84/99 (84.8%) 
33/99 (33.0%) 
39/99 (39.4%) 
73/100 (73.0%) 
22/97 (22.7%) 
 33/99 (33.3%) 
45/99 (45.0%) 
14/99 (14.1%) 
78/770 (10.1%) 
14/770 (1.8%) 
66/770 (8.6%) 
31/764 (4.1%) 
102/770 (13.2%) 
581/765 (75.9%) 
482/770 (62.6%) 
270/616 (43.8%) 
313/769 (40.7%) 
208/770 (27.0%) 
635/753 (82.5%) 
618/754 (82.0%) 
244/753 (31.7%) 
280/770 (36.4%) 
618/770 (80.3%) 
168/768 (21.9%) 
275/766 (35.9%) 
382/753 (49.6%) 
109/754 (14.5%) 
0.38 
0.009 
0.037 
0.17 
0.24 
0.080 
<0.001 
0.014 
0.039 
0.21 
0.25 
0.48 
0.72 
0.56 
0.091 
0.86 
0.62 
0.45 
0.93 
Continuous Variables*** 
Age per increase in 10 years 
Creatinine (mg/dL) 
SYNTAX Score per increase in 10 points  
Cross-clamp time (minutes) 
BMI 
Post CABG peak CK-MB ratio 
 
69 (IQR 60-75) 
1.00 (IQR 0.90-1.20) 
27 (IQR 20-36) 
52 (IQR 37-64) 
28 (IQR 26-31) 
7.6 (IQR 4.4-11.9) 
66 (IQR 58-72) 
1.00 (IQR 0.85-1.10) 
28 (IQR 21-37) 
51 (IQR 38-67) 
27 (IQR 25-30) 
6.0 (IQR 3.5-10.3) 
0.26 
0.93 
0.95 
0.077 
0.91 
0.001 
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***Continuous variables are presented as mean±SD in patients who died within 4-years (age 
and SYNTAX Score are presented as actual values). 
Abbreviations: GI gastrointestinal; COPD chronic obstructive pulmonary disease; IQR 
interquartile range; LVEF left ventricular ejection fraction; CABG coronary artery bypass 
graft surgery; CK-MB creatine kinase myoglobin, BMI body mass index. 
Table 2 
Comparison of anatomical and clinical variables between patients with and without 
post-procedural antiplatelet therapy in the PCI arm (n=903). 
PCI 
 
No Post-Procedural 
Antiplatelet Therapy* (n=11) 
Antiplatelet Therapy 
on Discharge†* (n=885) 
p-value 
Categorical Variables 
Pre-procedural poor LVEF 
Amiodarone therapy on discharge 
Peripheral vascular disease 
History of GI bleeding or peptic ulcer disease 
Female gender 
Lack of pre-procedural thienopyridine**             
Diabetes 
Hypertension 
Metabolic syndrome 
Incomplete revascularisation 
Current smoking 
Stent length greater than 100 mm 
Any total occlusion 
Left main coronary disease 
  
0/11 (0%) 
0/11 (0%) 
2/11 (18.2%) 
0/10 (0%) 
6/11 (54.5%) 
2/11 (18.2%) 
6/11 (54.5%) 
9/11 (81.8%) 
6/9 (66.7%) 
7/11 (63.6%) 
3/11 (27.3%) 
5/8 (62.5%) 
2/11 (18.2%) 
4/11 (36.4%) 
 
12/885 (1.4%) 
13/885 (1.5%) 
80/885 (9.0%) 
37/881 (4.2%) 
204/885 (23.1%) 
26/885 (2.9%) 
248/885 (28.0%) 
649/878 (73.9%) 
331/722 (45.8%) 
381/885 (43.1%) 
163/885 (18.4%) 
286/869 (32.9%) 
212/879 (24.1%) 
348/885 (39.3%) 
0.70 
0.69 
0.30 
0.51 
0.014 
0.004 
0.052 
0.55 
0.21 
0.17 
0.45 
0.077 
0.65 
0.84 
 
Continuous Variables*** 
Age per increase in 10 years 
SYNTAX Score per increase in 10 points  
Serum creatinine (mg/dL) 
Post PCI peak CK ratio 
Total number of stents 
Total stent length (mm) 
BMI 
Post PCI peak CK-MB ratio 
73 (IQR 70-75) 
32 (IQR 17-39) 
1.00 (IQR 0.90-1.60) 
2.8 (IQR 0.5-4.9) 
7 (IQR 4-8) 
136 (IQR 64-148) 
25 (IQR 24-26) 
24.8 (IQR 14.3-32.8) 
 
66 (IQR 59-73) 
27 (IQR 20-35) 
1.00 (IQR 0.80-1.10) 
0.54 (IQR 0.35-0.91) 
4 (IQR 3-6) 
80 (IQR 52-112) 
27 (IQR 25-31) 
12.5 (IQR 6.2-20.3) 
 
0.012 
0.38 
0.46 
0.014 
0.12 
0.13 
0.10 
0.21 
 
*Aspirin or thienopyridine 
**Clopidogrel or ticlopidine      
***Continuous variables are presented as medians±IQR in patients who died within 4-years (age and 
SYNTAX Score are presented as actual values). 
Abbreviations: PCI percutaneous coronary intervention; GI gastrointestinal; IQR interquartile range;       
LVEF left ventricular ejection fraction; CK creatine kinase; CK-MB creatine kinase myoglobin, BMI 
body mass index. 
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***Continuous varables are preeted as meanSD in patiet who died wthin 4-years (age 
and SYNTAX Score are presented as actual values). 
Abbreviations: GI gastroitestinal; COPD chronic obstructive pulmoary disease; IQR 
interquartilerange; LVEF left ventricular ejectin fraction; CABG coronary arterybypass 
graft surgery; CK-MB creatine kinase myoglobin, BMI body mass index. 
Table 2 
Comparison of natomical nd clinical varibles between ptients with nd without 
post-procedural antiplatelet therapy in the PCI arm (n=903). 
PCI 
 
No Post-Procedural 
Antiplatelt Therapy* (n=11) 
Antiplatelet Therapy 
on Discharge†* (n=885) 
p-value 
Categoica Vaiables 
Pre-procedural poor LVEF 
Amiodarone therapy ondischarge 
Peripheral vascular disease 
History of GI bleeding or peptic ulcer disease 
Female gender
Lack of pre-procedural thienopyridine**            
Diabetes 
Hypertension 
Metabolic syndrome 
Incomplete revascularisation 
Current smoking 
Stent length greater than 100 mm 
Any total occlusion 
Left main coronary disease 
  
/11 (0%) 
/11 (0%) 
2/11 (18.2%) 
/10 (0%) 
6/11 (54.5%) 
2/11 (18.2%)
6/11 (54.5%) 
9/11 (81.8%) 
6/9 (66.7%) 
7/11 (63.6%) 
3/11 (27.3%) 
5/8 (62.5%) 
2/11 (18.2%) 
4/11 (36.4%) 
 
12/885 (1.4%) 
13/885(1.5%) 
80/885 (9.0%) 
37/881 (4.2%) 
204/885 (23.1%)
26/885 (2.9%) 
248/885 (28.0%) 
649/878 (73.9%) 
331/722 (45.8%) 
381/885 (43.1%) 
163/885 (18.4%) 
286/869 (32.9%) 
212/879 (24.1%) 
348/885 (39.3%) 
0.70 
0.69 
0.30 
0.51 
0.014 
0.004 
0.052 
0.55 
0.21 
0.17 
0.45 
0.077 
0.65 
0.84 
 
Continuous Variables*** 
Age per increase in 10 years
SYNTAX Score per increase in 10 points  
Serum creatinine (mg/dL) 
Post PCI peak CK ratio 
Total number of stents 
Total stent length (mm) 
BMI 
Post PCI peak CK-MBratio 
73 (IQR 70-75) 
32 (IQR 17-39) 
1.00 (IQR 0.90-1.60) 
2.8 IQR 0.5-4.9) 
7 (IQR 4-8) 
136 (IQR 64-148) 
25 (IQR 24-26) 
24.8 (IQR 14.3-32.8) 
 
66(IQR 59-73) 
27 (IQR 20-35) 
1.00 (IQR 0.80-1.10) 
0.54 (IQR 0.35-0.91) 
4 (IQR 3-6) 
80 (IQR 52-112) 
27 (IQR 25-31) 
12.5 (IQR6.2-20.3) 
 
0.012 
0.38 
0.46 
0.014 
0.12 
0.13 
0.10 
0.21 
 
*Aspirin or thienopyridine 
**Clopidogrel or ticlopidine      
***Continuous variables are presented as medians±IQR in patients who died within 4-years (age and 
SYNTAX Score are presented as actual values). 
Abbrviations: PCI percutaneous coronary intervetio; GI gastrointestinal; IQR interquartile rang;       
LVEF left ventricular ejection fraction; CK cratie kias; CK-MB creatine kinase myoglobin, BMI 
body mass index. 
 
245Chapter 7
	   4	  
3. Patient Narratives 
Table 3 
Known patient related events, as detailed in the patient narratives, preceding death in 
the 10 of the 11 patients not taking any anti-platelet therapy at the time of death.  
Age/ 
Gender 
SYNTAX 
Score 
Known Events Preceding Death (Autopsy Details Provided Where Available) 
79/F 
 
 
 
73/F 
 
 
 
 
74/M 
 
 
 
 
67/F 
 
 
 
 
81/F 
 
 
 
 
72/F 
 
 
 
 
 
71/M 
 
 
 
 
 
 
56/F 
 
 
 
 
 
75/M 
 
 
76/M 
 
13 
(LM + 2VD) 
 
 
15 
(3VD) 
 
 
 
64 
(LM + 3VD) 
 
 
 
17 
(3VD) 
 
 
 
31 
(3VD) 
 
 
 
39 
(3VD) 
 
 
 
 
38 
(LM + 3VD) 
 
 
 
 
 
32 
(3VD) 
 
 
 
 
65 
(LM + 3VD) 
 
33 
(3VD) 
Anaemia and thrombocytopenia (unknown cause), on warfarin long term (recurrent DVT/PE). Transfused 2 units 
packed red cells and platelets pre-procedure. 5 days post procedure melaena and anaemia. 9 days post index PCI, 
sudden cardiac arrest/death. No autopsy performed. 
 
24 hours post index PCI, a significant fall in haemoglobin necessitating 3 unit blood transfusion. Upper GI 
endoscopy demonstrated ‘duodenitis.’ 9 days post index procedure, developed sudden anterior infarct/cardiac arrest. 
Autopsy: “Taxus Express stents were deployed in the LM-LAD and LM-LCx bifurcations, so both stents extended to 
the proximal segment of these vessels (LAD and LCx). The stent thrombosis occurred in each of these stents.” 
 
Rapidly progressive hypotension and cardiac arrest during index PCI procedure with bleeding from right femoral 
puncture site. Patient was anticoagulated with coumadin preadmission and received abciximab. Computed 
tomography imaging of abdomen confirmed retroperitoneal bleeding as cause of haemorrhagic shock. Developed 
disseminated intravascular coagulopathy, multiorgan failure and expired 3 days post index procedure.  
 
Attempted RCA PCI - coronary dissection with inferior ST elevation (no stents implanted). Emergency CABG: 
SVG TO RCA and LCx OM branches. Cardiogenic shock post-procedure: patient expired within 6 hours. Autopsy: 
“acute myocardial infarction of the wall of the left ventricle…haemopericardium developed, this was the direct 
cause of death.” 
 
Peri-procedural small distal perforation conservatively treated: “small area of intramyocardial dye ‘staining’ 
probably due to a small distal perforation induced by the hydrophilic guidewire.” 6 hours post PCI developed 
sudden hypotension secondary to cardiac tamponade leading to death. Autopsy: cause of death haemopericardium, 
“...the examination of the 3 coronary vessels documented the presence of normally positioned and patent stents…” 
 
Left main, mid LAD stent implantation. Coronary perforation in LAD. Cardiac tamponade necessitating 
pericardiocentesis and cardiac surgery – bleeding site identified in right anterior wall next to proximal LAD. SVG 
to LAD, LCx and PDA. Developed systemic inflammatory response syndrome, “multi-organ failure with 
disseminated intravascular coagulation…massive liver failure, increasing lactic acidosis…” 13 days post index 
procedure patient expired. 
 
PCI to trifurcation lesion of left main (crush technique) and mid LAD. PCI to RCA 4 days later as staged procedure. 
Acute stent thrombosis 1 day post staged procedure – catheterisation revealed thrombotic occlusion of common 
trunk. “Using PTCA, partial rehabilitation of the anterior descending artery was obtained. Recanalization of the 
intermediate ramus and circumflex was not obtained.” Underwent emergency CABG: LIMA LAD, SVG D1 and 
OM (no RCA graft documented). Seven days post CABG, “suddenly…the blood pressure decreased…subsequently 
experienced refractory hypotension…patient expired.” No autopsy performed. 
 
Acute stent thrombosis/LAD abrupt closure 1 hour post 3VD PCI necessitating emergency PCI.  Over the following 
5 days developed respiratory sepsis, congestive heart failure and cardiogenic shock. New severe mitral regurgitation 
and worsening left ventricular function necessitating surgical mitral valve repair (no documented grafts) and 
biventricular assist device. Persistent ventricular failure and profound acidosis. Treatment withdrawn due to poor 
prognosis. Patient expired 17 days post index procedure. 
 
Patient became haemodynamically and electrically unstable during the procedure. Peri-procedural death despite 
placement of stent in the left main stem. No autopsy performed.  
 
Balloon catheter rupture during PCI to LCx (only 1 stent deployed) with retainment of material. Underwent 
emergency CABG for extraction of ruptured balloon catheter and SVG to PDA, LAD and OM. Patient developed 
cardiogenic shock a few hours post CABG requiring inotropic support. Patient expired 9 days post index procedure.  
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Abbreviations: 2VD 2 vessel disease; 3VD 3 vessel disease; CABG coronary artery bypass graft; DVT 
deep vein thrombosis; GI gastrointestinal; LCx left circumflex; LAD left anterior descending; LIMA 
left internal mammary artery graft; LM left main; OM obtuse marginal; PCI percutaneous coronary 
intervention; PE pulmonary embolism; PTCA percutaneous transluminal coronary angioplasty; RCA 
right coronary artery; SVG saphenous vein graft  
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A Global Risk Approach to Identify Patients With Left Main or
3-Vessel Disease Who Could Safely and Efficaciously Be Treated
With Percutaneous Coronary Intervention
The SYNTAX Trial at 3 Years
Objectives The aim of this study was to assess the additional value of the Global Risk—a combina-
tion of the SYNTAX Score (SXscore) and additive EuroSCORE—in the identification of a low-risk pop-
ulation, who could safely and efficaciously be treated with coronary artery bypass graft surgery
(CABG) or percutaneous coronary intervention (PCI).
Background PCI is increasingly acceptable in appropriately selected patients with left main stem or
3-vessel coronary artery disease.
Methods Within the SYNTAX Trial (Synergy between PCI with TAXUS and Cardiac Surgery Trial), all-
cause death and major adverse cardiac and cerebrovascular events (MACCE) were analyzed at 36 months in
low (GRCLOW) to high Global Risk groups, with Kaplan-Meier, log-rank, and Cox regression analyses.
Results Within the randomized left main stem population (n  701), comparisons between GRCLOW
groups demonstrated a significantly lower mortality with PCI compared with CABG (CABG: 7.5%, PCI:
1.2%, hazard ratio [HR]: 0.16, 95% confidence interval [CI]: 0.03 to 0.70, p  0.0054) and a trend to-
ward reduced MACCE (CABG: 23.1%, PCI: 15.8%, HR: 0.64, 95% CI: 0.39 to 1.07, p  0.088). Similar
analyses within the randomized 3-vessel disease population (n  1,088) demonstrated no statisti-
cally significant differences in mortality (CABG: 5.2%, PCI: 5.8%, HR: 1.14, 95% CI: 0.57 to 2.30, p  0.71)
or MACCE (CABG: 19.0%, PCI: 24.7%, HR: 1.35, 95% CI: 0.95 to 1.92, p  0.10). Risk-model performance
and reclassification analyses demonstrated that the EuroSCORE—with the added incremental benefit of
the SXscore to form the Global Risk—enhanced the risk stratification of all PCI patients.
Conclusions In comparison with the SXscore, the Global Risk, with a simple treatment algorithm, substan-
tially enhances the identification of low-risk patients who could safely and efficaciously be treated with CABG
or PCI. (J Am Coll Cardiol Intv 2012;5:606–17) © 2012 by the American College of Cardiology Foundation
The SYNTAX score (SXscore) (1–4) has established itself
as an important tool in the SYNTAX trial (The Synergy
between PCI with TAXUS and Cardiac Surgery Trial)
pioneered Heart Team approach, in which the cardiac
surgeon and interventional cardiologist determined the
optimal revascularization modality for patients with un-
treated left main stem (LMS) or 3-vessel (3VD) coronary
artery disease (1,5–7). The SXscore has since been validated
in the LMS percutaneous coronary intervention (PCI)
population at short- and long-term follow-up (8–11); the
3VD PCI population at short-term (1-year) follow-up
(12,13); and “All-Comers” patients undergoing PCI in
contemporary stent trials at 1-year follow-up (14,15). In
addition, both the current U.S. and European Guidelines on
myocardial revascularization (16–18) advocate the use of the
SXscore to determine the optimal revascularization modal-
ity in patients with unprotected left main or complex
coronary disease, without the explicit use of clinical vari-
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ables. Furthermore, the U.S. guidelines now gives surgical
revascularization for unprotected left main coronary disease
a Class 1B recommendation (16,17), compared with a Class
1A recommendation in previous guidelines (19).
Because the SXscore relies on the scoring of the coronary
anatomy in isolation to objectively select the appropriate
revascularization strategy for the individual patient, criti-
cism has emerged, due to potentially important prognostic
information being missing secondary to the absence of
clinical factors (20,21). The EuroSCORE (22,23), a cardiac
surgery-based clinical risk score, has been shown to have a
reliable impact on prognosis and to be an independent predic-
tor of major adverse cardiac events and mortality in surgical and
percutaneously treated patients in the SYNTAX trial, thus
confirming findings from previous studies (24–28).
Attempts have previously been made to combine the SX-
score and additive EuroSCORE
to form the Global Risk classifi-
cation (29,30) and have been
shown to potentially improve the
risk stratification of patients un-
dergoing surgical or percutaneous
LMS intervention, compared
with the SXscore alone. The
Global Risk categorical approach
reported in the present study,
adapted from the previously re-
ported Global Risk classification
(29,30), uses the historically ac-
cepted cutoff levels for tertiles of the
additive EuroSCORE (22,23)—of
which a high EuroSCORE ter-
tile has previously been shown to
be an independent predictor of
adverse outcomes after PCI
(24,26 –28)—and the now
broadly accepted tertiles of the
SXscore (Fig. 1) (1–4). There-
fore the goal of the Global Risk is to improve in the
identification of low-risk groups with LMS or 3VD, com-
pared with the SXscore, who would achieve comparable
surgical and percutaneous outcomes in terms of efficacy and
safety at 3 years.
Methods
The SYNTAX trial is a randomized, prospective, multi-
center trial that incorporated an “All-Comers” design and
consisted of pre-specified LMS (isolated or associated with 1-,
2-, or 3-vessel disease) and 3VD cohorts (1,6,7). Patients were
randomized on a 1:1 basis to undergo either coronary artery
bypass graft surgery (CABG) or PCI or placed in nested
registries when considered unsuitable for randomization by
the Heart Team (CABG nested registry for PCI-ineligible
patients and PCI nested registry for CABG-ineligible
patients). Exclusions were only limited to patients with
prior coronary revascularization, the requirement of con-
comitant cardiac surgery, or ongoing acute myocardial
infarction (MI). Recent MI with resolution of cardiac
enzymes (2 upper limit of normal) and unstable angina
(no elevation in biomarkers) were not exclusion criteria.
The PCI techniques between the randomized and nested
registry populations were similar except that TAXUS Ex-
press (Boston Scientific Corporation, Natick, Massachu-
setts) paclitaxel-eluting stents were only permitted in the
randomized population. Within the PCI nested registry the
implantation of any type of drug-eluting stent or bare-metal
stent (BMS) was permitted, although the use of TAXUS
paclitaxel-eluting stents was encouraged. Of the 589 stents
implanted within the PCI nested registry, 57% were
TAXUS Express or Liberté (Boston Scientific Corpora-
tion), 19% were another drug-eluting stent, and 24% were
BMS; 4 PCI nested registry patients did not receive a stent.
Conversely CABG techniques between the randomized and
nested registry were broadly similar, except that double left and
right internal mammary artery grafts were more frequently
performed in the randomized (27.6%) CABG population, com-
pared with the CABG nested registry (16.1%).
The Global Risk was calculated by combining the SX-
score (2–4)—calculated by an independent core laboratory
(Cardialysis BV, Rotterdam, the Netherlands)—and the
additive EuroSCORE, as assessed by the Heart Team
before randomization (22,23). The additive EuroSCORE
was used to form the Global Risk, because this was shown
Figure 1. The Proposed Global Risk
The Global Risk demonstrating recategorization of established tertiles of
risk for the SYNTAX Score and additive EuroSCORE to form low (GRCLOW),
intermediate (GRCINT), and high (GRCHIGH) Global Risk groups. Highlighted
(dashed) boxes indicate patients moved (reclassified) into or out of the
low SYNTAX Score group to form the low Global Risk group (GRCLOW).
Adapted from Capodanno et al. (29,30).
Abbreviations
and Acronyms
3VD  3-vessel disease
BMS  bare-metal stent(s)
CABG  coronary artery
bypass graft surgery
CI  confidence interval
GRCLOW  Low Global Risk
GRCINT  Intermediate
Global Risk
GRCHIGH  High Global Risk
HR  hazard ratio
LMS  left main stem
MACCE  major adverse
cardiac and cerebrovascular
event(s)
MI  myocardial infarction
PCI  percutaneous
coronary intervention
SXscore  SYNTAX Score
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to be more predictive of clinical outcomes in the PCI
population compared with the logistic EuroSCORE, find-
ings consistent with a previous study (29). Patients were
subsequently categorized into 3 classes of Global Risk, on
the basis of predefined anatomical and clinical-risk catego-
ries (low, intermediate, and high) for the SXscore (2–4) and
additive EuroSCORE, respectively (22,23) (Fig. 1).
Statistical methods. Comparisons of all-cause death and major
adverse cardiac and cerebrovascular events (MACCE) (a compos-
ite of all-cause death, MI, stroke, and all-cause revascular-
ization) (1,7) were performed (Kaplan-Meier curves) with
the log-rank test and Cox proportional hazard ratios be-
tween the low Global Risk (GRCLOW) groups for CABG
and PCI. This prognostic model-based approach to identify a
low subgroup of patients defined by prognostic factors is in
contrast to the traditional approach to subgroup analysis
(31–33). A logistic regression model that incorporated the
SXscore and EuroSCORE as covariates was used to give each
score proper relative weighting to each other within the Global
Risk. This analysis allowed for the assessment of the
predictive ability of the Global Risk: 1) the Hosmer–
Lemeshow test for calibration—the assessment of the cor-
rectness of the prediction by the risk model, with poor fit
indicated by a significant p value (0.05); 2) receiver
operator curves for discrimination (C-statistic)—the ability
of the risk model to appropriately assign the correct risk
prediction in patients who have the outcome, ranging from
0.50 (no discrimination) to 1.0 (perfect discrimination); 3) the
Brier score—an overall risk model performance measure cap-
turing both discrimination and calibration aspects of the risk
model, ranging from 0 to 1, with a lower value (closer to 0)
suggestive of a more predictive risk model (34–36). Compar-
isons were made with other risk models, namely, the SXscore
(2,4); age, creatinine, and ejection fraction/modified age, cre-
atinine, and ejection fraction scores (37,38); the Clinical
SXscore (39,40); and the additive/logistic EuroSCOREs
(22,23)—a brief description of which is enclosed in the Online
Appendix.
Analyses on those groups that were reclassified according
to the Global Risk compared with the SXscore alone were
undertaken, following the principles of Net Reclassification
Improvement (38,41) (Fig. 1). These reclassification analy-
ses were to test whether the low Global Risk group
(GRCLOW) appropriately risk-stratified patients, compared
with a low SXscore. Higher anatomical risk patients (i.e.,
intermediate SXscores with low-intermediate Euro-
SCOREs) would be appropriately reclassified as lower-risk
(GRCLOW) if they had comparable (or more favorable) PCI
outcomes, compared with CABG. Conversely lower ana-
tomical risk patients with a high clinical comorbidity (i.e.,
low SXscore with a high EuroSCORE) would only be
appropriately reclassified to a higher risk group (GRCINT) if
they had more favorable surgical outcomes, compared with
PCI. Further detailed methodology, including illustrative
figures describing the reclassification concepts, is included
in the Online Appendix. A 2-sided p value 0.05 was
considered significant for all tests. All analyses were con-
ducted with SAS System Software (version 8.0 or higher,
SAS Institute, Cary, North Carolina) and SPSS (version
17.0, SPSS, Inc., Chicago, Illinois).
Results
All randomized patients underwent planned follow-up.
Within the nested registries, all PCI patients underwent
planned follow-up, and 649 of the 1,077 CABG patients
were randomly allocated for follow-up, on the basis of the
original study protocol (1,7). Complete data, including
clinical outcomes relating to the Global Risk, were
available in 1,789 of 1,800 randomized patients (PCI, n  899;
CABG, n  890), and 2,610 of 3,075 “All-Comers”
patients (PCI, n  1,088; CABG, n  1,522) at 3-year
follow-up.
Within the randomized SYNTAX population baseline
demographic data and clinical characteristics for the treat-
ment arms have previously been described and were well-
balanced (1). Within the “All-Comers” population more
complex coronary anatomy was present in the CABG
population (mean SXscore  1 SD: CABG: 32.7  12.9,
PCI: 28.9  11.7, p  0.001) (Table 1). Conversely,
significantly more comorbidity was present in the “All-
Table 1. Comparison of Anatomical Factors (SXscore) and Clinical Risk Scores for the CABG and PCI Populations
Anatomical/Clinical
Risk Score
CABG PCI
p Value*
Randomized
(n  897)
Nested Registry
(n  644)
All-Comers
(n  1,541) p Value†
Randomized
(n  899)
Nested Registry
(n  195)
All-Comers
(n  1,094) p Value†
SXscore 29.1 11.4 37.8 13.3 32.7 12.9 0.001 28.4 11.5 31.3 12.5 28.9 11.7 0.002 0.001
Total Parsonnet score 8.4 6.8 9.0 7.1 8.7 6.9 0.15 8.5 7.0 14.4 9.5 9.6 7.8 0.001 0.001
Additive EuroSCORE 3.8 2.69 3.9 2.7 3.8 2.7 0.47 3.8 2.6 5.8 3.1 4.1 2.8 0.001 0.008
Logistic EuroSCORE, % 3.9 4.4 4.0 4.4 3.9 4.4 0.46 3.8 4.5 7.7 8.9 4.5 5.8 0.001 0.009
Mean score  1 SD. *p value represents comparisons between the All-Comers (randomized and nested registry) coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI)
populations. †p value represents comparisons between the randomized and nested registry populations for the CABG and PCI populations.
SXscore SYNTAX Score.
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Comers” PCI population, as evidenced by significantly
greater Parsonnet (42) and EuroSCOREs (Table 1).
Clinical outcomes with PCI. Within the randomized and
“All-Comers” LMS (Fig. 2) and 3VD (Fig. 3) PCI popu-
lations, a low Global Risk group (GRCLOW) could be
differentiated from the higher risk groups (GRCINT-HIGH)
for All-Cause death and MACCE. Furthermore, within the
LMS PCI population, the Global Risk demonstrated a clear
incremental increase in predictive ability (C-statistics and
overall risk model performance measures), compared with
either the SXscore or the EuroSCORE in isolation (Fig. 4).
Within the randomized and “All-Comers” 3VD PCI pop-
ulation, the additive EuroSCORE had a superior predictive
ability for all-cause death and MACCE compared with the
SXscore alone, with little or no additional improvements in
the predictive ability of the Global Risk compared with the
additive EuroSCORE (Fig. 4).
Clinical outcomes with CABG. At 36 months the Global
Risk could differentiate between the GRCINT-HIGH groups
only for all-cause death and MACCE in the randomized
and “All-Comers” CABG populations (Figs. 2 and 3). The
Global Risk added little or no improvement to the predic-
tive ability, compared with the additive EuroSCORE used
in isolation (Fig. 4).
Comparison of CABG and PCI: low-risk LMS population.
Within the GRCLOW group of the randomized LMS
population (n  701), CABG resulted in significantly
higher 3-year mortality compared with PCI (CABG: 7.5%,
PCI: 1.2%, HR: 0.16, 95% CI: 0.03 to 0.70, p  0.0054),
with a trend toward a lower incidence of MACCE (CABG:
23.1%, PCI: 15.8%, HR: 0.64, 95% CI: 0.39 to 1.07, p 
0.088) and stroke (CABG: 3.5%, PCI: 0.6%, HR: 0.17,
95% CI: 0.02 to 1.46, p 0.067). No statistically significant
differences in MI or all-cause revascularization were found.
Within the GRCLOW group of the “All-Comers” LMS
population (n  1,079), no statistically significant differ-
ences in mortality (CABG: 5.3%, PCI: 2.7%, HR: 0.51,
95% CI: 0.18 to 1.44, p  0.19) or MACCE (CABG:
18.0%, PCI: 18.5%, HR: 1.02, 95% CI: 0.65 to 1.60, p 
0.94) were observed. A significantly greater incidence of
stroke was evident with CABG (CABG: 4.0%, PCI: 0.6%,
HR: 0.13, 95% CI: 0.02 to 1.05, p  0.025), and a
significantly greater frequency of MI was evident with PCI
(CABG: 0.9%, PCI: 3.9%, HR: 4.30, 95% CI: 0.89 to
20.70, p  0.047). No statistically significant differences in
all-cause revascularization were seen (CABG: 10.7%, PCI:
14.8%, HR: 1.40, 95% CI: 0.81 to 2.42, p  0.23).
Comparison of CABG and PCI: low-risk 3VD population.
Within the GRCLOW group of the randomized 3VD popu-
lation (n  1,088), no statistically significant differences in
3-year mortality (CABG: 5.2%, PCI: 5.8%, HR: 1.14, 95%
CI: 0.57 to 2.30, p 0.71) orMACCE (CABG: 19.0%, PCI:
24.7%, HR: 1.35, 95% CI: 0.95 to 1.92, p  0.10) were
observed. Percutaneous coronary intervention was associated
with a significantly increased risk of all-cause revascularization
(CABG: 10.5%, PCI: 18.5%, HR: 1.88, 95% CI: 1.19 to 2.96,
p  0.0055). No statistically significant differences in the risk
of stroke were seen (CABG: 2.9%, PCI: 1.3%, HR: 0.45, 95%
CI: 0.13 to 1.49, p  0.18).
Within the “All-Comers” 3VD population (n  1,531)
no statistically significant differences in mortality were
observed (CABG: 5.1%, PCI: 5.9%, HR: 1.16, 95% CI:
0.62 to 2.17, p  0.65). A significantly higher incidence of
MACCE was evident with PCI (CABG: 17.9%, PCI:
24.4%, HR: 1.42, 95% CI: 1.03 to 1.96, p  0.031)
secondary to predominantly greater all-cause revasculariza-
tion (CABG: 9.1%, PCI: 18.5%, HR: 2.20, 95% CI: 1.44 to
3.35, p  0.0002). No statistically significant differences in
the incidences of stroke were seen (CABG: 3.2%, PCI:
1.5%, HR: 0.46, 95% CI: 0.16 to 1.30, p  0.13).
Analyses of reclassified patients. Within the LMS popula-
tion, patients (i.e., patients with an intermediate SXscore
and low-moderate EuroSCOREs) were appropriately re-
classified to the GRCLOW group (Fig. 1). More favorable
outcomes were seen with PCI, compared with CABG
(randomized population: 3-year all-cause death: CABG
10.8%, PCI 1.3%; 3-year MACCE: CABG 24.4%, PCI
15.6%). Conversely, patients reclassified to a higher-risk
(GRCINT) group (i.e., patients with a low SXscore and a
high EuroSCORE) had more favorable surgical outcomes
in the larger “All-Comers” population (Fig. 1), predomi-
nantly secondary to reduced MACCE with CABG (3-year
MACCE: CABG 20.4%, PCI 27.0%).
Within the 3VD population more favorable surgical outcomes
were evident in patients reclassified to the GRCLOW group.
Further analyses indicated that a GRCLOW with an intermediate
SXscore would remain better-managed by CABG, and a
GRCLOW with a low SXscore would have comparable surgical
and PCI outcomes. More favorable surgical outcomes were
evident in patients (i.e., with a low SXscore and a high Euro-
SCORE) reclassified to the higher-risk (GRCINT) group (ran-
domized population: 3-year death: CABG 9.6%, PCI 21.3%;
3-year MACCE: CABG 22.5%, PCI 39.1%). Further detailed
results of the reclassification analyses are included in the Online
Appendix.
Comparison of the Global Risk with other risk models. The
Global Risk was superior in predictive performance com-
pared with other combined anatomical/clinical scores (de-
rived from the SXscore) and their components. This in-
cluded the Clinical SXscore (39) (Fig. 4).
Discussion
The main findings of this study are: 1) clinical variables
(EuroSCORE) per se are more predictive of clinical outcomes
(all-cause death and MACCE), compared with anatomical
variables (SXscore) in the PCI population; 2) within the LMS
PCI population the Global Risk demonstrated a clear incre-
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 5 , N O . 6 , 2 0 1 2
J U N E 2 0 1 2 : 6 0 6 – 1 7
Serruys et al.
SYNTAX at 3 Years: LM or 3VD Treated With PCI
610
256 Chapter 8.1
Figure 2. Comparisons of Clinical Outcomes by Categories of Global Risk in the SYNTAX LMS Population
Kaplan-Meier curves for cumulative rate of death (A) and MACCE (B) at 3-year follow-up stratified according to the Global Risk group; event rate  1.5 SE.
CABG  coronary arty bypass grafting; GRCLOW  Low Global Risk; GRCINT  Intermediate Global Risk; GRCHIGH  High Global Risk; LMS  left main stem;
MACCE  major adverse cardiac and cerebrovascular event(s); PCI  percutaneous coronary intervention.
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Figure 3. Comparisons of Clinical Outcomes by Categories of Global Risk in the SYNTAX 3VD Population
Kaplan-Meier curves for cumulative rate of death (A) and MACCE (B), at 3-year follow-up stratified according to the Global Risk group; event rate  1.5 SE.
3VD  3-vessel disease; other abbreviations as in Figure 2.
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mental benefit in its predictive ability, compared with the
SXscore or EuroSCORE used in isolation; 3) within the
3VD PCI population, the Global Risk improved the risk
stratification of patients, compared with the SXscore alone,
by demonstrating that low SXscore patients with a high
EuroSCORE to attain a mortality benefit in undergoing
CABG compared to PCI; and 4) that the Global Risk
substantially enhanced the identification of a low-risk pop-
ulation who could safely and efficaciously be treated with
CABG or PCI at 3 years.
The application of the Global Risk to the SYNTAX
population was complicated by the differing prognostic and
morbidity outcomes between the LMS and 3VD popula-
tions. However, a low-risk population was identified with
outcomes comparable to CABG and PCI at 3 years in terms
of efficacy and safety, namely a GRCLOW group in the LMS
population and a GRCLOW group with a low SXscore in the
3VD population. Ultimately reclassification analyses proved
vital in ensuring the optimal revascularization modality in
specific groups of patients. For example, high-EuroSCORE
Figure 4. Comparison of Different Risk Models for the Randomized LMS and 3VD Populations for Death and MACCE at 3 Years
Comparison of different risk models for the randomized LMS and 3VD populations for death (A) and MACCE (B) at 3 years, with calibration (Hosmer–Lemeshow
test), discrimination (C-statistic, y axes), and overall model performance measures (Brier score, x axes) (36). Yellow arrows in the LMS cohort demonstrate the
incremental benefit, in terms of predictive ability, of the Global Risk compared with the additive EuroSCORE and SYNTAX Score as evidenced by a greater C-sta-
tistic and lower Brier score. Yellow arrows in the 3VD cohort demonstrate the incremental benefit of the additive EuroSCORE compared with the SYNTAX Score
with little/no improvement of the predictive ability of the Global Risk compared with the additive EuroSCORE, as evidenced by comparable C-statistics and Brier
scores. Note how even minor differences in the Brier score reflect overall improvements in the model performance and the different scales for the Brier scores
for death and MACCE reflecting the findings that the risk models are superior in predicting death. ACEF  age, creatinine, and ejection fraction (score); CSS 
clinical SYNTAX score; other abbreviations as in Figures 2 and 3.
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patients with a low SXscore were shown to confer a clear
mortality benefit from undergoing CABG in the 3VD
population, and intermediate-SXscore patients with low-
moderate EuroSCOREs were shown to confer a potential
survival advantage in undergoing PCI in the LMS population.
On the basis of these findings a treatment algorithm is
proposed to simplify these concepts, which admittedly will
require further validation in other unselected registries (Fig. 5).
The main strengths of the Global Risk are that the
additive EuroSCORE is a simple bedside calculation and
that the Global Risk can be applied across the entire
spectrum of surgical and percutaneously treated patients.
Within the “All-Comers” SYNTAX population the adop-
tion of this treatment algorithm (Fig. 5) would potentially
identify a smaller population of patients, compared with
using the SXscore alone, who would have similar outcomes
to CABG and PCI at 3 years in terms of efficacy and
safety—namely, 39% of the LMS population (compared
with 51% with low-moderate SXscores) and 21% of the
3VD population (compared with 26% with a low SXscore).
By identifying a low Global Risk (GRCLOW) group
within the randomized LMS population, a significant mor-
tality benefit and trend toward a reduction in MACCE was
evident for PCI at 3 years. This was not apparent in the
“All-Comers” population. Several factors might explain this
disparity in results. First, the “All-Comers” PCI population
had significantly greater comorbidity (Table 1)—factors
well known to be associated with in-hospital and long-term
adverse outcomes after PCI (24,26–28). Second, a low
EuroSCORE could not exclude nonadjustable characteris-
tics, such as the judgment of the treating clinician in
declining a patient for CABG and thus undergoing PCI
instead, such as patients with a short-term survival—as were
recruited within the “All-Comers” SYNTAX trial. Third,
the CABG nested registry might potentially have been
diluted with a proportion of lower-anatomical-risk patients
who might have been suitable for PCI, because the concept
of the clinical outcomes on the basis of tertiles of the
SXscore were unknown at the time of the SYNTAX trial.
Fourth, is the use of BMS in the nested PCI registries:
although specific data pertaining to the indications for use of
BMS were not collected, it is probable that a sizeable propor-
tion of these patients might have had comorbidities that
precluded the use of prolonged dual antiplatelet therapy. The
adoption of the “All-Comers” approach is nonetheless more
likely to mirror contemporary clinical practice and is perceived
by many as the recommended approach (18,43).
Adverse clinical comorbidity: CABG or PCI? In both the LMS
and 3VD populations the surgical benefit in the higher
comorbidity patients (i.e., with a low SXscore and high
EuroSCORE) was more pronounced, compared with PCI.
In particular a substantial mortality benefit favoring CABG
was evident in low-SXscore patients with a high Euro-
SCORE in the 3VD population. Although it has been
previously demonstrated that a high EuroSCORE is a
potential predictor of adverse outcomes after PCI (24,26–
28), conventional clinical practice has suggested that high-
comorbidity patients might be more suitable for PCI com-
pared with CABG. In contrast to this accepted clinical
practice, it seems that it is precisely these types of patients
who would potentially stand to gain more from CABG on
prognostic and morbidity grounds. These findings are prob-
ably related to PCI treating the individual lesion, whereas
CABG would potentially protect the entire treated vessel
from future cardiac events for the lifespan of the graft.
There is nevertheless a recognition that a certain threshold
of operative risk would have to be acceptable for the cardiac
surgeon and patient, and the latter of who may adamantly
refuse a surgical approach due to the anticipated prohibitive
risk of the proposed surgical intervention. It should, however,
Figure 5. Proposed Treatment Algorithm for the Management of LMS and 3VD Incorporating Clinical and Anatomical Variables
Proposed treatment algorithm for the management of LMS and 3VD incorporating clinical (additive EuroSCORE) and anatomical (SYNTAX Score) variables.
Although not explicitly stated PCI might be the preferred revascularization modality in low-risk patients subject to the Heart Team discussion. *If an acceptable
threshold of operative risk is exceeded for the patient and cardiac surgeon, consideration of PCI should be considered—appropriate discussion concerning risk
stratification should be undertaken. Abbreviations as in Figures 2 and 3.
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be recognized that PCI may potentially be more hazardous for
the patient with regard to long-term outcomes, compared with
CABG. A greater understanding of this phenomenon may
potentially reduce the threshold value for which surgical
revascularization is declined during theHeart Team discussion.
Anatomical and clinical variables in the LMS PCI population.
Before the introduction of the SXscore, heterogeneity of the
LMS anatomical description and its impact on clinical
outcomes were previously recognized by the use of classical
terminology describing isolated LMS or LMS  1-, 2-, or
3-vessel disease. The SXscore was an attempt to eliminate the
historical and arbitrarily defined subdivisions of the coronary
tree into LMS and 3VD and to create a common anatomical
denominator (2,3). It now seems that the LMS outcomes are
largely a reflection of the presence of distal LMS bifurcation
disease, clinical comorbidity, and importantly, the increasing
prevalence of 3VD and its association with clinical comorbidi-
ties (as discussed in the following) and anatomical complexi-
ties, such as multiple bifurcations and the presence of total
occlusions leading to higher SXscores.
Anatomical and clinical variables in the 3VD PCI population.
Within the 3VD PCI population the SXscore added very little
incremental benefit to the additive EuroSCORE in predicting
death andMACCE (Fig. 4). It might be hypothesized that the
severity of 3VD (as evidenced by a higher SXscore) might be
representative of patients with a more adverse risk profile who
have evidence of systemic atherosclerosis and therefore are at
greater longer-term cardiovascular and cerebrovascular risk. Con-
sequently these patients might potentially benefit fromCABGon
prognostic and morbidity grounds due to the bypass grafts
protecting the coronary vessel as discussed. This might also be an
explanation for the comparability in long-term stroke outcomes
betweenCABG and PCI for the 3VDSYNTAXpopulation (6).
This hypothesis is supported by the significant and direct
relationship of the 10-year predicted Framingham risk
scores with the prevalence and magnitude of coronary artery
calcium scores (44). Furthermore, the ankle-brachial pres-
sure index (45–49) and common carotid intima-media
thickness (50–53), both markers of peripheral vascular
disease, have been correlated with the severity of coronary
artery disease and clinical events.
Implications of the Global Risk for future trials. Given the
heterogeneity of the outcomes between LMS and 3VD,
the strategy for the future is to construct separate trials for
the LMS and 3VD populations that should incorporate
anatomical and clinical variables. Left main stem disease is
currently subject to the ongoing EXCEL (Evaluation of
Xience Prime or Xience V versus Coronary Artery Bypass
Surgery for Effectiveness of Left Main Revascularization) trial,
recruiting patients on anatomical entry criteria only—namely
low-moderate SXscores—and does not directly take into account
clinical variables except within the Heart Team discussion.
Within the 3VD population perhaps a more targeted
identification of patients by other markers of atherosclerotic
burden, such as ankle-brachial pressure index and common
carotid intima-media thickness as discussed, in conjunction
with the SXscore or Global Risk might prove beneficial.
Another recently described approach is the “Functional
SYNTAX Score”—utilizing the functional assessment of
coronary lesions—and has potentially been shown to im-
prove the identification of low and higher risk patients (54).
In addition, the potential noninvasive calculation of the Func-
tional SYNTAX Score, with computational fluid dynamics
applied to coronary computed tomography angiography, has
shown significant promise (55,56).
Summary of the potential clinical implications of the Global Risk.
The practical clinical application of the Global Risk is
summarized in a treatment algorithm in Figure 5. Although
validation of the Global Risk concept is required, the practi-
calities are that not only high-anatomical-risk patients but also
patients with significant comorbidity are best served by under-
going surgical revascularization, because they seem to be one of
the patient groups that stand to potentially gain more from
surgical revascularization on prognostic and morbidity grounds,
particularly if they have 3VD. Clearly a threshold of operative risk
for surgical revascularization should not be exceeded; therefore
these issues are vital in theHeart Team discussion in selecting the
most appropriate revascularization modality.
Study limitations. This study represents a post hoc analysis
of the original SYNTAX Trial, and the predictive models
were developed retrospectively at 3-year follow-up. The
further analyses undertaken in the LMS and 3VD cohorts
(1,7) should be considered as hypothesis-generating. Fur-
thermore, the focus of this study was on low Global risk
(GRCLOW) groups, because CABG is the standard of care
in the management of patients in the higher-Global Risk
groups (1,5,6). Comparisons between the higher-Global
Risk groups are nevertheless provided in the Online Ap-
pendix. In addition there was limited statistical power for
the comparison between CABG and PCI for events such as
stroke and MI and analyses of reclassified patients. Conse-
quently external validation of the proposed Global Risk is
required in unselected registries, with numbers greater than
the SYNTAX “All-Comers” population. The “All-Comers”
concept of the SYNTAX trial, although more representative
of contemporary clinical practice compared with the ran-
domized approach (18,43), has been reported to potentially
not result in the inclusion of consecutive patients, predom-
inantly due to the inability to gain appropriate informed
consent and refusal to participate (57).
It is not possible to judge and account for the decisions
made by the Heart Team in selecting a patient for random-
ization. However, this approach is representative of contem-
porary practice. It should also be acknowledged that, although
the SYNTAX Trial was based on contemporary revasculariza-
tion practice at the time, improvements in technology in both
CABG and PCI might yield differences in clinical outcomes in
future trials. Noninvasive or invasive carotid imaging to screen
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for the presence of significant carotid disease was undertaken
by the clinical consensus of the Heart Team to calculate the
EuroSCORE. The possibility of a small minority of patients
with clinically silent carotid disease cannot be excluded. The
cardiac-related comorbidities within the EuroSCORE are
more likely to reflect outcomes after PCI, whereas extracardiac
factors (e.g., the presence of chronic obstructive pulmonary
disease and poor neurological status) are unlikely to reflect
outcomes (24–28)—this point should be borne in mind when
interpreting the Global Risk. Furthermore, the use of the
EuroSCORE with a continuous approach might have affected
the results of the analysis. However, the categorical approach
was adopted from the outset to allow application of the same
risk model in CABG and PCI patients, given that a high
SXscore tertile has consistently been shown to be an indepen-
dent predictor of adverse outcomes after PCI (24,26–28). The
newly developed EuroSCORE II (58) cannot be applied to the
concept of the Global Risk, because this information was not
collected during the original SYNTAX trial.
Conclusions
In comparison with the SXscore, the Global Risk—with a
simplified treatment algorithm—substantially enhances the
identification of low-risk patients who could safely and
efficaciously be treated with CABG or PCI.
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The SYNTAX Trial at 3 Years: 
A Global Risk Approach to Identify Patients With 3-Vessel and/or Left Main 
Stem Disease Who Could Safely and Efficaciously Be Treated With 
Percutaneous Coronary Intervention 
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II. Supplementary Methods 
a) Definitions of Risk Scores  
SYNTAX Score (1-4)  
The SYNTAX Score Algorithm. (http://www.syntaxscore.com) 
The following algorithm is applied to each individual coronary lesion that has a 
diameter stenosis greater than 50% and located in a vessel that is larger than 1.5 mm 
in diameter – the individual lesion scores are added together to give the final 
SYNTAX score.  
The Syntax Score Algorithm 
1. Arterial dominance 
2. Arterial segments involved per lesion 
 
Lesion characteristics 
3. Total occlusion 
   i. Number of segments involved 
   ii. Age of the total occlusion (>3 months) 
   iii. Blunt stump 
   iv. Bridging collaterals 
   v. First segment beyond the occlusion visible by antegrade or retrograde filling 
   vi. Side branch involvement 
 4. Trifurcation 
   i. Number of segments diseased 
 5. Bifurcation 
   i. Medina type 
   ii. Angulation between the distal main vessel and the side branch <70° 
 6. Aorto-ostial lesion 
 7. Severe tortuosity 
 8. Length >20 mm 
 9. Heavy calcification 
10. Thrombus 
11. Diffuse disease/small vessels 
   i. Number of segments with diffuse disease/small vessels 
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I. Flow chart of patients from the SYNTAX trial demonstrating availability 
of data . 
Based on the original study protocol (1,29) 649 of the 1077 CABG nested registry 
patients were randomly allocated for follow up; data from 37 patients were 
unavailable (11 patients at baseline and a further 26 patients at follow up).  
Figure 1. Flow chart. 
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ACEF Score (5-7) 
The ACEF score is calculated using the formula:   
ACEF= [Age/Ejection fraction (%)] + [1 (if creatinine >2mg/dl)].  
The left ventricular ejection fraction (LVEF) is the value recorded prior to the index 
PCI procedure, and in the event of multiple available values, the lowest recorded 
figure. The serum creatinine value is the value recorded prior to the index PCI. 
Clinical SYNTAX score (8) 
The Clinical SYNTAX Score is calculated using the formula: Clinical SYNTAX 
Score = [SXscore] x [modified ACEF score]. The modified ACEF score is calculated 
using the formula: age/ejection fraction+1 point for every 10ml/min reduction in 
creatinine clearance below 60ml/min/1.73m2 (up to a maximum of 6 points). The 
LVEF is the value recorded prior to the index PCI and in the event of multiple 
available values the lowest recorded figure. Creatinine clearance is calculated using 
the Cockcroft-Gault equation using the patient’s age, weight, and serum creatinine 
values recorded prior to the index PCI. (9)  
Additive EuroSCORE (10) 
The additive EuroSCORE is calculated by summation of the individual scores from 
17 different clinical variables.  
Additive EuroSCORE 
Patient Factors 
Age 
Sex  
Chronic pulmonary disease 
 
Peripheral arteriopathy 
 
 
Neurological dysfunction 
Previous cardiac surgery 
Serum creatinine  
 
Per 5 years or part thereof over the age of 60 years 
Female  
Long-term use of bronchodilators or steroids for respiratory 
disease  
Claudication/carotid stenosis >50%/Previous or planned 
intervention on the abdominal aorta, limb arteries, or 
carotids  
Severely affected mobility or day-to-day function  
Previous opening of the pericardium 
Pre-operatively >200 µmol/l 
 
1 
1 
1 
 
2 
 
 
2 
3 
2 
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Active endocarditis  
Critical pre-operative state  
Antibiotic therapy at time of surgery 
Pre-operative cardiac arrest, ventilation, renal failure, 
inotropic support, intra-aortic balloon pump use, ventricular 
arrhythmia 
3 
3 
Cardiac factors 
Unstable angina  
Left ventricular function  
 
Recent MI  
Pulmonary hypertension 
 
Rest pain requiring IV nitrates 
Moderate (30%–50%) 
Poor (<30%) 
Within 90 days 
Systolic pulmonary artery pressure >60 mm Hg  
 
2 
1 
3 
2 
2 
Operative factors 
Emergency Operation  
Other than isolated CABG  
Surgery on thoracic aorta  
Post-infarct septal rupture  
 
Performed before the start of next working day 
Major cardiac procedure other than or in addition to CABG 
 
 
2 
2 
3 
4 
 
Logistic EuroSCORE (11) 
The logistic EuroSCORE utilises the EuroSCORE logistic regression equation and 
uses the same risk factors as the additive EuroSCORE.  
 
 
 
b) Additional Reclassification Methodology  
The SXscore and additive EuroSCORE consists of 3 categories of level of anatomical 
disease complexity (2-4) and clinical risk (10,11) respectively. By combining the two 
categorical based scores to form the Global Risk (GRC) 9 different risk groups were 
created. Based on the principle that comparable clinical outcomes, in patients with a 
low SXscore undergoing CABG or PCI, were evident at 3 years (1,12) it was 
hypothesised that patients without a high EuroSCORE and/or high SXscore would be 
a lower risk population (GRCLOW) population, who would be equally amenable to 
CABG or PCI in terms of efficacy and safety. 
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Figure 2: Comparability (or more favourable PCI outcomes) in Death and MACCE 
between CABG and PCI for the higher risk group (intermediate SXscore and low-
intermediate EuroSCOREs) reclassified to a lower risk (GRCLOW) group would be 
expected. 
 
 
 
 
Figure 3: More favourable clinical outcomes (Death or MACCE) would be expected 
with CABG compared to PCI, for the lower risk group (low SXscore and high 
EuroSCORE) reclassified to a higher (GRCINT) risk group. This is in keeping with 
previous findings of a high EuroSCORE to be an independent predictor of in-hospital 
mortality and MACCE after PCI. (13-16) 
 
 
 
 
 
 
 
 
 8 
The underlying principles of the reclassification analyses were therefore to ensure that 
– in the higher anatomical risk patients (i.e. with intermediate SXscores and low-
intermediate EuroSCORE) reclassified as low Global Risk (GRCLOW) – comparability 
(or more favourable PCI outcomes) in clinical outcomes between CABG and PCI 
would be maintained in this reclassified group. Conversely – in the lower anatomical 
risk patients with a high clinical comorbidity (i.e. low SXscore with a high 
EuroSCORE) reclassified as a higher Global Risk (GRCINT) – more favourable 
surgical clinical outcomes would be evident in this reclassified group. 
If reclassification analyses were not undertaken the main danger would be that higher 
(or lower risk) patients would be inappropriately reclassified to lower (or higher) risk 
groups. This may subsequently not be clinically apparent as the expected lower (or 
higher) clinical outcomes within the population the reclassified patients entered, 
would potentially dilute the clinical outcomes within the reclassified patients. 
Consequently, comparisons of clinical outcomes (between CABG and PCI) within the 
reclassified groups are required to ensure that the patients have been appropriately 
reclassified. Illustrative figures explaining these concepts are detailed below (Figures 
1-2). 
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b. Outcomes for the Global Risk for the endpoint of Death and MACCE in the 
randomised SYNTAX population 
Figure 5: Kaplan Meier curves for cumulative rates of Death (upper), and MACCE 
(lower) in the Global Randomised SYNTAX population at 3-year follow-up stratified 
according to the group of Global Risk, event rate ±1.5 SE. 
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III Additional Analyses for the Randomised  SYNTAX Population                                                                                                                                      
a. Outcomes by tertiles of the SYNTAX Score                                                                                                                         
Figure 4  
At 36-months within both the LMS and 3VD PCI cohorts, a low SXscore group could 
not be differentiated from the higher risk groups (low-intermediate SXscore) for 
Death and MACCE. Within the LMS PCI population a high SXscore group could 
only be differentiated from the lower SXscore groups (low to intermediate SXscore) 
for Death and MACCE. 
Title: Outcomes By Tertile of Risk of the SXscore in isolation within the Randomised 
LMS and 3VD PCI Population  
Caption: Kaplan Meier curves for cumulative rate of Death (upper) and MACCE 
(lower) at 3-year follow-up, stratified to tertile of the SXscore, event rate ±1.5 SE.  
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Tables 1-3: Comparisons (CABG and PCI) of low Global Risk Groups (GRCLOW) 
Table 1 
Principal effectiveness and safety results, summary of time-to-event analyses intent-
to-treat, comparing low Global Risk groups (GRCLOW) for the Global Randomised 
PCI and Global Randomised CABG population (N=921). 
Event 
CABG 
(N=443) 
PCI 
(N=478) 
Hazard Ratio 
[95% CI] Difference p-Value 
3 Year      
Post-Allocation MACCE  20.4% (86) 21.6% (102) 1.06 [0.80, 1.41] 1.2% 0.69 
 Death/Stroke/MI, Any 11.2% (47) 8.5% (40) 0.74 [0.49, 1.14] -2.7% 0.17 
  Death, Any 6.0% (25) 4.2% (20) 0.70 [0.39, 1.26] -1.8% 0.24 
  Cerebrovascular Event 
 (Stroke), Any 3.1% (13) 1.1% (5) 0.34 [0.12, 0.95] -2.0% 0.031 
  MI, Any 3.1% (13) 4.9% (23) 1.58 [0.80, 3.12] 1.8% 0.18 
 Revascularisation, Any 12.0% (49) 16.5% (77) 1.43 [1.00, 2.04] 4.6% 0.050 
  PCI 11.3% (46) 14.2% (66) 1.30 [0.89, 1.89] 2.9% 0.17 
  CABG 1.2% (5) 3.7% (17) 3.04 [1.12, 8.23] 2.5% 0.02 
Post-Procedure Stent 
Thrombosis/Graft Occlusion 3.9% (16) 3.9% (18) 0.99 [0.51, 1.95] 0.0% 0.99 
Table 2 
Principal effectiveness and safety results, summary of time-to-event analyses intent-
to-treat, comparing GRCLOW for the Global Randomised LMS population (N=318). 
Event 
CABG 
(N=152) 
PCI 
(N=166) 
Hazard Ratio 
[95% CI] Difference p-Value 
3 Year      
Post-Allocation MACCE  23.1% (34) 15.8% (26) 0.64 [0.39, 1.07] -7.3% 0.088 
 Death/Stroke/MI, Any 12.3% (18) 5.5% (9) 0.42 [0.19, 0.94] -6.8% 0.029 
  Death, Any 7.5% (11) 1.2% (2) 0.16 [0.03, 0.70] -6.3% 0.0054 
  Stroke, Any 3.5% (5) 0.6% (1) 0.17 [0.02, 1.46] -2.9% 0.067 
  MI, Any 1.4% (2) 3.7% (6) 2.59 [0.52, 12.82] 2.3% 0.23 
 Revascularisation, Any 14.6% (21) 12.8% (21) 0.85 [0.46, 1.56] -1.8% 0.60 
  PCI 13.3% (19) 10.9% (18) 0.81 [0.42, 1.54] -2.3% 0.51 
  CABG 1.3% (2) 3.0% (5) 2.20 [0.43, 11.36] 1.7% 0.33 
Post-Procedure Stent 
Thrombosis/Graft Occlusion 4.1% (6) 2.5% (4) 0.57 [0.16, 2.01] -1.6% 0.37 
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Figure 6: Comparison of different risk models for the Global Randomised SYNTAX 
population for Death (left) and MACCE (right), utilising calibration (Hosmer-
Lemeshow), discrimination (c-statistic) and overall model performances (Brier score). 
(17) 
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to-treat, comparing low Global Risk groups (GRCLOW) for the Global Randomised 
PCI and Global Randomised CABG population (N=921). 
Event 
CABG 
(N=443) 
PCI 
(N=478) 
Hazard Ratio 
[95% CI] Difference p-Value 
3 Year      
Post-Allocation MACCE  20.4% (86) 21.6% (102) 1.06 [0.80, 1.41] 1.2% 0.69 
 Death/Stroke/MI, Any 11.2% (47) 8.5% (40) 0.74 [0.49, 1.14] -2.7% 0.17 
  Death, Any 6.0% (25) 4.2% (20) 0.70 [0.39, 1.26] -1.8% 0.24 
  Cerebrovascular Event 
 (Stroke), Any 3.1% (13) 1.1% (5) 0.34 [0.12, 0.95] -2.0% 0.031 
  MI, Any 3.1% (13) 4.9% (23) 1.58 [0.80, 3.12] 1.8% 0.18 
 Revascularisation, Any 12.0% (49) 16.5% (77) 1.43 [1.00, 2.04] 4.6% 0.050 
  PCI 11.3% (46) 14.2% (66) 1.30 [0.89, 1.89] 2.9% 0.17 
  CABG 1.2% (5) 3.7% (17) 3.04 [1.12, 8.23] 2.5% 0.02 
Post-Procedure Stent 
Thrombosis/Graft Occlusion 3.9% (16) 3.9% (18) 0.99 [0.51, 1.95] 0.0% 0.99 
Table 2 
Principal effectiveness and safety results, summary of time-to-event analyses intent-
to-treat, comparing GRCLOW for the Global Randomised LMS population (N=318). 
Event 
CABG 
(N=152) 
PCI 
(N=166) 
Hazard Ratio 
[95% CI] Difference p-Value 
3 Year      
Post-Allocation MACCE  23.1% (34) 15.8% (26) 0.64 [0.39, 1.07] -7.3% 0.088 
 Death/Stroke/MI, Any 12.3% (18) 5.5% (9) 0.42 [0.19, 0.94] -6.8% 0.029 
  Death, Any 7.5% (11) 1.2% (2) 0.16 [0.03, 0.70] -6.3% 0.0054 
  Stroke, Any 3.5% (5) 0.6% (1) 0.17 [0.02, 1.46] -2.9% 0.067 
  MI, Any 1.4% (2) 3.7% (6) 2.59 [0.52, 12.82] 2.3% 0.23 
 Revascularisation, Any 14.6% (21) 12.8% (21) 0.85 [0.46, 1.56] -1.8% 0.60 
  PCI 13.3% (19) 10.9% (18) 0.81 [0.42, 1.54] -2.3% 0.51 
  CABG 1.3% (2) 3.0% (5) 2.20 [0.43, 11.36] 1.7% 0.33 
Post-Procedure Stent 
Thrombosis/Graft Occlusion 4.1% (6) 2.5% (4) 0.57 [0.16, 2.01] -1.6% 0.37 
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c. Outcomes for the Global Risk for the endpoint Death/MI/Stroke in the 
Randomised SYNTAX population 
Figure 7: Kaplan Meier curves for cumulative rates of Death/MI/Stroke in the 
Randomised LMS SYNTAX population at 3-year follow-up stratified according to 
the group of Global Risk, event rate ±1.5 SE. 
 
 
 
 
 
 
 
 
Figure 8: Kaplan Meier curves for cumulative rates of Death/MI/Stroke in the 
Randomised 3VD SYNTAX population at 3-year follow-up stratified according to the 
group of Global Risk, event rate ±1.5 SE. 
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Table 3 
Principal effectiveness and safety results, summary of time-to-event analyses intent-
to-treat, comparing GRCLOW for Global Randomised 3VD population (N=603). 
Event 
CABG 
(N=291) 
PCI 
(N=312) 
Hazard Ratio 
[95% CI] Difference p-Value 
3 Year      
Post-Allocation MACCE  19.0% (52) 24.7% (76) 1.35 [0.95, 1.92] 5.7% 0.10 
 Death/Stroke/MI, Any 10.6% (29) 10.0% (31) 0.95 [0.57, 1.58] -0.5% 0.85 
  Death, Any 5.2% (14) 5.8% (18) 1.14 [0.57, 2.30] 0.7% 0.71 
  Stroke, Any 2.9% (8) 1.3% (4) 0.45 [0.13, 1.49] -1.6% 0.18 
  MI, Any 4.0% (11) 5.6% (17) 1.40 [0.66, 2.99] 1.6% 0.38 
 Revascularisation, Any 10.5% (28) 18.5% (56) 1.88 [1.19, 2.96] 8.0% 0.0055 
  PCI 10.2% (27) 15.9% (48) 1.66 [1.04, 2.66] 5.7% 0.033 
  CABG 1.1% (3) 4.0% (12) 3.60 [1.02, 12.75] 2.9% 0.034 
Post-Procedure Stent 
Thrombosis/Graft Occlusion 3.7% (10) 4.6% (14) 1.25 [0.56, 2.81] 0.9% 0.59 
 
  
 15 
c. Outcomes for the Global Risk for the endpoint Death/MI/Stroke in the 
Randomised SYNTAX population 
Figure 7: Kaplan Meier curves for cumulative rates of Death/MI/Stroke in the 
Randomised LMS SYNTAX population at 3-year follow-up stratified according to 
the group of Global Risk, event rate ±1.5 SE. 
 
 
 
 
 
 
 
 
Figure 8: Kaplan Meier curves for cumulative rates of Death/MI/Stroke in the 
Randomised 3VD SYNTAX population at 3-year follow-up stratified according to the 
group of Global Risk, event rate ±1.5 SE. 
 
 
 
 
 
 
 
RANDOMISED DEATH/MI/STROKE - PCI RANDOMISED DEATH/MI/STROKE - CABG 
RANDOMISED DEATH/MI/STROKE - PCI RANDOMISED DEATH/MI/STROKE - CABG 
277Chapter 8.1
 15 
c. Outcomes for the Global Risk for the endpoint Death/MI/Stroke in the 
Randomised SYNTAX population 
Figure 7: Kaplan Meier curves for cumulative rates of Death/MI/Stroke in the 
Randomised LMS SYNTAX population at 3-year follow-up stratified according to 
the group of Global Risk, event rate ±1.5 SE. 
 
 
 
 
 
 
 
 
Figure 8: Kaplan Meier curves for cumulative rates of Death/MI/Stroke in the 
Randomised 3VD SYNTAX population at 3-year follow-up stratified according to the 
group of Global Risk, event rate ±1.5 SE. 
 
 
 
 
 
 
 
RANDOMISED DEATH/MI/STROKE - PCI RANDOMISED DEATH/MI/STROKE - CABG 
RANDOMISED DEATH/MI/STROKE - PCI RANDOMISED DEATH/MI/STROKE - CABG 
 15 
c. Outcomes for the Global Risk for the endpoint Death/MI/Stroke in the 
Randomised SYNTAX population 
Figure 7: Kaplan Meier curves for cumulative rates of Death/MI/Stroke in the 
Randomised LMS SYNTAX population at 3-year follow-up stratified according to 
the group of Global Risk, event rate ±1.5 SE. 
 
 
 
 
 
 
 
 
Figure 8: Kaplan Meier curves for cumulative rates of Death/MI/Stroke in the 
Randomised 3VD SYNTAX population at 3-year follow-up stratified according to the 
group of Global Risk, event rate ±1.5 SE. 
 
 
 
 
 
 
 
RANDOMISED DEATH/MI/STROKE - PCI RANDOMISED DEATH/MI/STROKE - CABG 
RANDOMISED DEATH/MI/STROKE - PCI RANDOMISED DEATH/MI/STROKE - CABG 
 15 
c. Outcomes for the Global Risk for the endpoint Death/MI/Stroke in the 
Randomised SYNTAX population 
Figure 7: Kaplan Meier curves for cumulative rates of Death/MI/Stroke in the 
Randomised LMS SYNTAX population at 3-year follow-up stratified according to 
the group of Global Risk, event rate ±1.5 SE. 
 
 
 
 
 
 
 
 
Figure 8: Kaplan Meier curves for mulative rates of D ath/MI/Stroke in the 
Randomised 3VD SYNTAX population at 3-year follow-up stratified according to the 
group of Global Risk, event rate ±1.5 SE. 
 
 
 
 
 
 
 
RANDOMISED DEATH/MI/STROKE - PCI RANDOMISED DEATH/MI/STROKE - CABG 
RANDOMISED DEATH/MI/STROKE - PCI RANDOMISED DEATH/MI/STROKE - CABG 
 15 
c. Outcomes for the Global Risk for the endpoint Death/MI/Stroke in the 
Randomised SYNTAX population 
Figure 7: Kaplan Meier curves for cumulative rates of Death/MI/Stroke in the 
Randomised LMS SYNTAX population at 3-year follow-up stratified according to 
the group of Global Risk, event rate ±1.5 SE. 
 
 
 
 
 
 
 
 
Figure 8: Kaplan Meier curves for cumulative rates of Death/MI/Stroke in the 
Randomised 3VD SYNTAX population at 3-year follow-up stratified according to the 
group of Global Risk, event rate ±1.5 SE. 
 
 
 
 
 
 
 
RANDOMISED DEATH/MI/STROKE - PCI RANDOMISED DEATH/MI/STROKE - CABG 
RANDOMISED DEATH/MI/STROKE - PCI RANDOMISED DEATH/MI/STROKE - CABG 
278 Chapter 8.1
 17 
Table 5 
Principal effectiveness and safety results, summary of time-to-event analyses intent-
to-treat, comparing GRCINT for the Randomised LMS population (N=290). 
Event 
CABG 
(N=143) 
TAXUS 
(N=147) 
Hazard Ratio 
[95% CI] Difference 
Relative 
% 
Change p-Value1 
3 Year       
Post-Allocation MACCE  19.3% (27) 35.6% (52) 2.00 [1.26, 3.19] 16.4% 84.9% 0.0028 
 Death/Stroke/MI, Any 12.1% (17) 17.8% (26) 1.49 [0.81, 2.75] 5.7% 46.8% 0.1959 
  Death, Any 5.7% (8) 11.0% (16) 1.96 [0.84, 4.59] 5.2% 91.2% 0.1123 
  Cerebrovascular Event 
 (Stroke), Any 2.2% (3) 0.7% (1) 0.33 [0.03, 3.14] -1.5% -66.9% 0.3076 
  MI, Any 6.3% (9) 11.1% (16) 1.73 [0.76, 3.91] 4.7% 74.3% 0.1837 
 Revascularization, Any 11.7% (16) 27.4% (39) 2.57 [1.44, 4.60] 15.7% 133.8% 0.0010 
  PCI 8.9% (12) 21.0% (30) 2.65 [1.36, 5.18] 12.1% 135.4% 0.0030 
  CABG 2.8% (4) 9.4% (13) 3.22 [1.05, 9.86] 6.6% 232.6% 0.0307 
Post-Procedure Stent 
Thrombosis/Graft 
Occlusion 
4.5% (6) 6.9% (10) 1.63 [0.59, 4.49] 2.5% 55.4% 0.3394 
 
Table 6 
Principal effectiveness and safety results, summary of time-to-event analyses intent-
to-treat, comparing GRCINT for the Randomised 3VD population (N=397). 
Event 
CABG 
(N=214) 
TAXUS 
(N=183) 
Hazard Ratio 
[95% CI] Difference 
Relative 
% 
Change p-Value1 
3 Year       
Post-Allocation MACCE  17.6% (36) 33.3% (60) 2.08 [1.38, 3.15] 15.7% 89.3% 0.0004 
 Death/Stroke/MI, Any 9.2% (19) 21.1% (38) 2.39 [1.38, 4.14] 11.8% 127.8% 0.0014 
  Death, Any 4.4% (9) 13.4% (24) 3.14 [1.46, 6.75] 9.0% 203.9% 0.0020 
  Cerebrovascular Event 
 (Stroke), Any 3.0% (6) 4.9% (8) 1.58 [0.55, 4.54] 1.9% 61.1% 0.3959 
  MI, Any 2.9% (6) 8.4% (15) 2.98 [1.16, 7.68] 5.6% 194.4% 0.0175 
 Revascularization, Any 10.0% (20) 18.9% (33) 2.06 [1.18, 3.59] 8.9% 89.1% 0.0092 
  PCI 9.1% (18) 16.2% (28) 1.92 [1.06, 3.47] 7.1% 77.8% 0.0280 
  CABG 0.9% (2) 3.4% (6) 3.54 [0.72, 17.56] 2.5% 260.3% 0.0980 
Post-Procedure Stent 
Thrombosis/Graft 
Occlusion 
2.1% (4) 2.8% (5) 1.46 [0.39, 5.43] 0.6% 29.9% 0.5716 
 16 
IV. Additional Comparative Analyses (CABG and PCI) for the GRCINT & 
GRCHIGH groups in the Global, LMS & 3VD Randomised SYNTAX Populations                                                                                                                       
 
Tables 4-6: Comparisons (CABG & PCI) for the GRCINT Groups  
Table 4 
Principal effectiveness and safety results, summary of time-to-event analyses intent-
to-treat, comparing GRCINT for the Global Randomised PCI and Global 
Randomised CABG patients (N=687) 
Event 
CABG 
(N=357) 
TAXUS 
(N=330) 
Hazard Ratio 
[95% CI] Difference 
Relative 
% 
Change p-Value1 
3 Year       
Post-Allocation MACCE  18.2% (63) 34.3% (112) 2.06 [1.51, 2.80] 16.1% 88.2% <.0001 
 Death/Stroke/MI, Any 10.4% (36) 19.6% (64) 1.95 [1.30, 2.94] 9.2% 88.9% 0.0010 
  Death, Any 4.9% (17) 12.3% (40) 2.57 [1.46, 4.53] 7.4% 148.9% 0.0007 
  Cerebrovascular Event 
 (Stroke), Any 2.7% (9) 3.0% (9) 1.09 [0.43, 2.75] 0.3% 11.7% 0.8515 
  MI, Any 4.3% (15) 9.6% (31) 2.26 [1.22, 4.19] 5.4% 125.7% 0.0076 
 Revascularization, Any 10.7% (36) 22.7% (72) 2.32 [1.56, 3.47] 12.1% 112.8% <.0001 
  PCI 9.0% (30) 18.3% (58) 2.24 [1.44, 3.48] 9.3% 103.4% 0.0002 
  CABG 1.7% (6) 6.1% (19) 3.48 [1.39, 8.71] 4.4% 259.6% 0.0045 
Post-Procedure Stent 
Thrombosis/Graft 
Occlusion 
3.1% (10) 4.6% (15) 1.62 [0.73, 3.62] 1.6% 50.8% 0.2304 
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Event 
CABG 
(N=214) 
TAXUS 
(N=183) 
Hazard Ratio 
[95% CI] Difference 
Relative 
% 
Change p-Value1 
3 Year       
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  Cerebrovascular Event 
 (Stroke), Any 3.0% (6) 4.9% (8) 1.58 [0.55, 4.54] 1.9% 61.1% 0.3959 
  MI, Any 2.9% (6) 8.4% (15) 2.98 [1.16, 7.68] 5.6% 194.4% 0.0175 
 Revascularization, Any 10.0% (20) 18.9% (33) 2.06 [1.18, 3.59] 8.9% 89.1% 0.0092 
  PCI 9.1% (18) 16.2% (28) 1.92 [1.06, 3.47] 7.1% 77.8% 0.0280 
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Table 9 
Principal effectiveness and safety results, summary of time-to-event analyses intent-
to-treat, comparing GRCHIGH for the Randomised 3VD population (N=88). 
Event 
CABG 
(N=40) 
TAXUS 
(N=48) 
Hazard Ratio 
[95% CI] Difference 
Relative 
% 
Change p-Value1 
3 Year       
Post-Allocation MACCE  25.4% (9) 37.9% (18) 1.71 [0.77, 3.80] 12.4% 49.0% 0.1850 
 Death/Stroke/MI, Any 19.8% (7) 23.2% (11) 1.28 [0.49, 3.29] 3.4% 17.0% 0.6146 
  Death, Any 17.1% (6) 19.0% (9) 1.16 [0.41, 3.26] 1.9% 11.3% 0.7772 
  Cerebrovascular Event 
 (Stroke), Any 2.8% (1) 2.3% (1) 0.76 [0.05, 12.20] -0.5% -16.3% 0.8480 
  MI, Any 0.0% (0) 12.7% (6) NA [NA, NA] 12.7% NA 0.0253 
 Revascularization, Any 6.0% (2) 26.1% (12) 4.87 [1.09, 21.76] 20.1% 332.2% 0.0217 
  PCI 6.0% (2) 22.2% (10) 4.01 [0.88, 18.30] 16.2% 268.1% 0.0525 
  CABG 0.0% (0) 4.4% (2) NA [NA, NA] 4.4% NA 0.2090 
Post-Procedure Stent 
Thrombosis/Graft 
Occlusion 
0.0% (0) 6.3% (3) NA [NA, NA] 6.3% NA 0.1341 
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Tables 7-9: Comparisons (CABG and PCI) for the GRCHIGH Groups 
Table 7 
Principal effectiveness and safety results, summary of time-to-event analyses intent-
to-treat, comparing GRCHIGH for the Global Randomised PCI and Global 
Randomised CABG patients (N=181). 
Event 
CABG 
(N=90) 
TAXUS 
(N=91) 
Hazard Ratio 
[95% CI] Difference 
Relative 
% 
Change p-Value1 
3 Year       
Post-Allocation MACCE  27.4% (23) 38.7% (35) 1.56 [0.92, 2.63] 11.2% 40.9% 0.0973 
 Death/Stroke/MI, Any 23.8% (20) 24.3% (22) 1.05 [0.57, 1.92] 0.5% 2.1% 0.8796 
  Death, Any 18.2% (15) 18.8% (17) 1.09 [0.54, 2.18] 0.6% 3.1% 0.8095 
  Cerebrovascular Event 
 (Stroke), Any 7.2% (6) 3.8% (3) 0.47 [0.12, 1.89] -3.4% -47.0% 0.2780 
  MI, Any 3.4% (3) 9.5% (8) 2.64 [0.70, 9.95] 6.1% 179.2% 0.1358 
 Revascularization, Any 3.9% (3) 25.5% (21) 7.35 [2.19, 24.63] 21.5% 548.4% 0.0001 
  PCI 3.9% (3) 22.1% (18) 6.19 [1.82, 21.01] 18.2% 463.7% 0.0008 
  CABG 0.0% (0) 3.6% (3) NA [NA, NA] 3.6% NA 0.0845 
Post-Procedure Stent 
Thrombosis/Graft 
Occlusion 
0.0% (0) 3.5% (3) NA [NA, NA] 3.5% NA 0.0895 
Table 8 
Principal effectiveness and safety results, summary of time-to-event analyses intent-
to-treat, comparing GRCHIGH for the Randomised LMS population (N=93). 
Event 
CABG 
(N=50) 
TAXUS 
(N=43) 
Hazard Ratio 
[95% CI] Difference 
Relative 
% 
Change p-Value1 
3 Year       
Post-Allocation MACCE  28.9% (14) 39.5% (17) 1.46 [0.72, 2.97] 10.6% 36.6% 0.2880 
 Death/Stroke/MI, Any 26.8% (13) 25.6% (11) 0.94 [0.42, 2.10] -1.3% -4.7% 0.8859 
  Death, Any 18.9% (9) 18.6% (8) 1.05 [0.41, 2.72] -0.3% -1.5% 0.9193 
  Cerebrovascular Event 
 (Stroke), Any 10.6% (5) 5.4% (2) 0.45 [0.09, 2.34] -5.2% -49.2% 0.3315 
  MI, Any 6.0% (3) 5.7% (2) 0.77 [0.13, 4.61] -0.3% -4.8% 0.7773 
 Revascularization, Any 2.3% (1) 24.3% (9) 11.67 [1.48, 92.11] 22.1% 970.9% 0.0031 
  PCI 2.3% (1) 21.7% (8) 10.13 [1.27, 81.01] 19.4% 853.4% 0.0069 
  CABG 0.0% (0) 2.6% (1) NA [NA, NA] 2.6% NA 0.2712 
Post-Procedure Stent 
Thrombosis/Graft 
Occlusion 
0.0% (0) 0.0% (0) NA [NA, NA] 0.0% NA Undef 
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Table 9 
Principal effectiveness and safety results, summary of time-to-event analyses intent-
to-treat, comparing GRCHIGH for the Randomised 3VD population (N=88). 
Event 
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(N=40) 
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Change p-Value1 
3 Year       
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  Death, Any 17.1% (6) 19.0% (9) 1.16 [0.41, 3.26] 1.9% 11.3% 0.7772 
  Cerebrovascular Event 
 (Stroke), Any 2.8% (1) 2.3% (1) 0.76 [0.05, 12.20] -0.5% -16.3% 0.8480 
  MI, Any 0.0% (0) 12.7% (6) NA [NA, NA] 12.7% NA 0.0253 
 Revascularization, Any 6.0% (2) 26.1% (12) 4.87 [1.09, 21.76] 20.1% 332.2% 0.0217 
  PCI 6.0% (2) 22.2% (10) 4.01 [0.88, 18.30] 16.2% 268.1% 0.0525 
  CABG 0.0% (0) 4.4% (2) NA [NA, NA] 4.4% NA 0.2090 
Post-Procedure Stent 
Thrombosis/Graft 
Occlusion 
0.0% (0) 6.3% (3) NA [NA, NA] 6.3% NA 0.1341 
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V. Reclassification Analyses for Randomised SYNTAX Population                                                                                                                                      
Tables 10-11: Reclassification Analyses 
Table 10 
Reclassification analyses (intermediate SXscore and low-intermediate EuroSCORE 
reclassified to GRCLOW) within the randomised SYNTAX Population: Kaplan-Meier 
event rates in reclassified PCI and CABG patients are shown.  
 
 
Table 11 
Reclassification analyses (low SXscore and high EuroSCORE reclassified to GRCINT) 
within the randomised SYNTAX Population: Kaplan-Meier event rates in the 
reclassified CABG and PCI patients are shown. 
 
 
 
 
Reclassified SYNTAX 
Population 
 
Outcome Event Rates/Total 
Reclassified  
CABG Patients  
Event Rates/Total 
Reclassified  
PCI Patients  
Randomised 3-Year MACCE 18.7% (39/222) 23.0% (55/242) 
3-Year death 6.4% (13/222) 5.4% (13/242) 
Randomised LMS 3-Year MACCE 24.4% (16/68) 15.6% (12/77) 
3-Year Death 10.8% (7/68) 1.3% (1/77) 
Randomised 3VD 3-Year MACCE 16.1% (23/154) 26.4% (43/165) 
3-Year Death 4.3% (6/154) 7.4% (12/165) 
Reclassified SYNTAX 
Population 
 
Outcome Event Rates/Total 
Reclassified  
CABG Patients  
Event Rates/Total 
Reclassified  
PCI Patients  
Randomised 3-Year MACCE 24.8% (12/53) 32.1% (20/63) 
3-Year Death 10.1% (5/53) 14.5% (9/63) 
Randomised LMS 3-Year MACCE 28.6% (5/19) 24.1% (7/29) 
3-Year Death 11.1% (2/19) 6.9% (2/29) 
Randomised 3VD 3-Year MACCE 22.5% (7/34) 39.1% (13/34) 
3-Year Death 9.6% (3/34) 21.3% (7/34) 
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VI. Additional Analyses for the All-Comers (Entire Population and 
LMS/3VD Cohorts) SYNTAX Population  
Figure 9: Kaplan Meier curves for cumulative rate of Death (upper), and MACCE 
(lower) in the Global ‘All-Comers’ SYNTAX population at 3-year follow-up 
stratified according to the group of Global Risk, event rate ±1.5 SE.  
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Figure 11 
Comparison of different risk models for the ‘All-Comers’ LMS and 3VD populations 
for Death (upper) and MACCE (lower) at 3-Years. A smaller Brier score (x-axis) and 
larger c-statistic (y-axis) represents a better predictive ability of the risk model.(17) 
Yellow arrows represent the incremental predictive benefit of the GRC compared to 
the SXscore and additive EuroSCORE within the LMS PCI population, not evident 
within the 3VD PCI population with comparability of the GRC and additive 
EuroSCORE.  
Striped circles represents calibrated additive EuroSCORE  and non-calibrated logistic 
EuroSCORE in the LMS CABG (MACCE) population and calibrated additive EuroSCORE 
and non-calibrated GRC within the 3VD CABG (MACCE) population. 
The renal function was not collected in all nested registry patients, consequently the 
ACEF based scores were excluded from the analysis below. 
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Figure 10 
Comparison of different risk models for the Global ‘All-Comers’ SYNTAX 
population Death (left) and MACCE (right), utilising calibration (Hosmer-Lemeshow 
test), discrimination (c-statistic) and overall model performances (Brier score). Renal 
function was not collected in all nested registry patients, consequently the ACEF 
based scores were excluded from the analysis below.  
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Tables 12-14: Comparisons (CABG and PCI) of low Global Risk Groups (GRCLOW)  
Table 12 
Principal effectiveness and safety results, summary of time-to-event analyses intent-
to-treat, all low Global Risk groups (GRCLOW) for ‘All-Comers’ CABG and ‘All-
Comers’ PCI patients (N=1156) 
Event 
CABG 
(N=626) 
PCI 
(N=530) 
Hazard Ratio 
[95% CI] Difference 
p-
Value 
3 Year      
Post-Allocation MACCE  18.0% (108) 22.3% (117) 1.28 [0.98, 1.66] 4.4% 0.067 
 Death/Stroke/MI, Any 10.3% (62) 8.8% (46) 0.84 [0.57, 1.23] -1.5% 0.38 
  Death, Any 5.2% (31) 4.8% (25) 0.92 [0.54, 1.56] -0.4% 0.76 
  Cerebrovascular Event 
 (Stroke), Any 3.5% (21) 1.2% (6) 0.32 [0.13, 0.80] -2.4% 0.01 
  MI, Any 2.8% (17) 4.8% (25) 1.70 [0.92, 3.15] 2.0% 0.088 
 Revascularisation, Any 9.7% (57) 17.2% (89) 1.87 [1.34, 2.61] 7.5% 0.0002 
  PCI 9.2% (54) 14.7% (76) 1.67 [1.18, 2.37] 5.5% 0.0035 
  CABG 0.8% (5) 3.7% (19) 4.41 [1.65, 11.82] 2.9% 0.0012 
Post-Procedure Stent 
Thrombosis/Graft Occlusion 3.4% (20) 3.5% (18) 1.03 [0.55, 1.95] 0.1% 0.92 
 
Table 13 
Principal effectiveness and safety results, summary of time-to-event analyses intent-
to-treat, comparing GRCLOW groups for ‘All-Comers’ LMS CABG and ‘All-
Comers’ LMS PCI patients (N=419). 
Event 
CABG 
(N=234) 
PCI 
(N=185) 
Hazard Ratio 
[95% CI] Difference 
p-
Value 
3 Year      
Post-Allocation MACCE  18.0% (41) 18.5% (34) 1.02 [0.65, 1.60] 0.6% 0.94 
 Death/Stroke/MI, Any 9.6% (22) 6.6% (12) 0.65 [0.32, 1.32] -3.1% 0.23 
  Death, Any 5.3% (12) 2.7% (5) 0.51 [0.18, 1.44] -2.6% 0.19 
  Stroke, Any 4.0% (9) 0.6% (1) 0.13 [0.02, 1.05] -3.5% 0.025 
  MI, Any 0.9% (2) 3.9% (7) 4.30 [0.89, 20.69] 3.0% 0.047 
 Revascularisation, Any 10.7% (24) 14.8% (27) 1.40 [0.81, 2.42] 4.1% 0.23 
  PCI 9.8% (22) 12.0% (22) 1.23 [0.68, 2.22] 2.2% 0.49 
  CABG 0.9% (2) 3.8% (7) 4.37 [0.91, 21.02] 3.0% 0.044 
Post-Procedure Stent 
Thrombosis/Graft Occlusion 4.0% (9) 2.3% (4) 0.54 [0.17, 1.74] -1.7% 0.29 
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VII. Reclassification Analyses for ‘All-Comers’ SYNTAX Population                                                                                                                                      
Tables 15-16: Reclassification Analyses 
Table 15 
Reclassification analyses (intermediate SXscore and low-intermediate EuroSCORE 
reclassified to GRCLOW) within the ‘All-Comers’ SYNTAX Population: Kaplan-
Meier event rates in reclassified PCI and CABG patients are shown.  
 
Table 16 
Reclassification analyses (low SXscore and high EuroSCORE reclassified to GRCINT) 
within the ‘All-Comers’ SYNTAX Population: Kaplan-Meier event rates in 
reclassified PCI and CABG patients are shown. 
 
 
 
 
 
 
Reclassified SYNTAX 
Population 
 
Outcome Event Rates/Total 
Reclassified  
CABG Patients  
Event Rates/Total 
Reclassified  
PCI Patients  
All-Comers 3-Year MACCE 16.7% (56/350) 23.3% (62/269) 
3-Year Death 4.8% (16/350) 6.0% (16/269) 
All-Comers LMS 3-Year MACCE 18.8% (21/114) 19.0% (16/84) 
3-Year Death 6.3% (7/114) 3.6% (3/84) 
All-Comers 3VD 3-Year MACCE 15.6% (35/236) 25.2% (46/185) 
3-Year Death 4.1% (9/236) 7.1% (13/185) 
Reclassified SYNTAX 
Population 
 
Outcome Event Rates/Total 
Reclassified  
CABG Patients  
Event Rates/Total 
Reclassified  
PCI Patients  
All-Comers 3-Year MACCE 21.1% (13/66) 30.8% (25/82) 
3-Year Death 8.1% (5/66) 13.6% (11/82) 
All-Comers LMS 3-Year MACCE 20.4% (5/26) 27.0% (10/37) 
3-Year Death 8.0% (2/26) 10.8% (4/37) 
All-Comers 3VD 3-Year MACCE 21.4% (8/40) 33.9% (15/45) 
3-Year Death 8.2% (3/40) 15.9% (7/45) 
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Table 14 
Principal effectiveness and safety results, summary of time-to-event analyses intent-
to-treat, comparing GRCLOW groups for ‘All-Comers’ 3VD PCI and ‘All-Comers’ 
3VD CABG patients (N=737). 
Event 
CABG 
(N=392) 
PCI 
(N=345) 
Hazard Ratio 
[95% CI] Difference 
p-
Value 
3 Year      
Post-Allocation MACCE  17.9% (67) 24.4% (83) 1.42 [1.03, 1.96] 6.4% 0.031 
 Death/Stroke/MI, Any 10.7% (40) 10.0% (34) 0.93 [0.59, 1.47] -0.7% 0.76 
  Death, Any 5.1% (19) 5.9% (20) 1.16 [0.62, 2.17] 0.7% 0.65 
  Stroke, Any 3.2% (12) 1.5% (5) 0.46 [0.16, 1.30] -1.7% 0.13 
  MI, Any 4.0% (15) 5.3% (18) 1.34 [0.67, 2.65] 1.3% 0.41 
 Revascularisation, Any 9.1% (33) 18.5% (62) 2.20 [1.44, 3.35] 9.5% 0.0002 
  PCI 8.8% (32) 16.2% (54) 1.96 [1.27, 3.04] 7.4% 0.0021 
  CABG 0.8% (3) 3.6% (12) 4.45 [1.26, 15.79] 2.8% 0.011 
Post-Procedure Stent 
Thrombosis/Graft Occlusion 3.0% (11) 4.2% (14) 1.41 [0.64, 3.10] 1.2% 0.40 
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VIII. Additional Material:  
Fig. 12 Vessel Distribution in the LMS Population According to SYNTAX Score 
Tertiles. 
Upper graphs: proportion of LMS population with isolated LMS disease, or 
associated with one (1VD), two (2VD) or three vessel disease (3VD).  
Middle graphs: proportion of LMS disease with non distal disease (non distal), distal 
bifurcation disease (distal) or both components (both). 
Lower graphs: proportion of non-total occlusion and total-occlusion disease within 
the coronary tree (not within the LMS).  
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Background The SYNTAX score (SXscore), an anatomical-based scoring tool reflecting the complexity of coronary anatomy, has
established itself as an important long-term prognostic factor in patients undergoing percutaneous coronary interven-
tion (PCI). The incorporation of clinical factors may further augment the utility of the SXscore to longer-term risk
stratify the individual patient for clinical outcomes.
Methods
and results
Patient-level merged data from .6000 patients in seven contemporary coronary stent trials was used to develop a
logistic regression model—the Logistic Clinical SXscore—to predict 1-year risk for all-cause death and major adverse
cardiac events (MACE). A core model (composed of the SXscore, age, creatinine clearance, and left ventricular ejec-
tion fraction) and an extended model [incorporating the core model and six additional (best performing) clinical vari-
ables] were developed and validated in a cross-validation procedure. The core model demonstrated a substantial
improvement in predictive ability for 1-year all-cause death compared with the SXscore in isolation [area under
the receiver operator curve (AUC): core model: 0.753, SXscore: 0.660]. A minor incremental benefit of the extended
model was shown (AUC: 0.791). Consequently the core model alone was retained in the final the Logistic Clinical
SXscore model. Validation plots confirmed the model predictions to be well calibrated. For 1-year MACE, the add-
ition of clinical variables did not improve the predictive ability of the SXscore, secondary to the SXscore being the
predominant determinant of all-cause revascularization.
Conclusion The Logistic Clinical SXscore substantially enhances the prediction of 1-year mortality after PCI compared with the
SXscore, and allows for an accurate personalized assessment of patient risk.
Introduction
The SYNTAX score1–4 (SXscore) has established itself as an im-
portant prognostic tool in risk stratifying patients in the Synergy
between Percutaneous Coronary Intervention with Taxus and
Cardiac Surgery (SYNTAX) pioneered Heart Team approach,
and has since been validated in patients undergoing percutaneous
coronary intervention (PCI) at a short and longer-term follow-
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296 Chapter 8.2
up.5–9 More recently the SXscore has been applied to contempor-
ary ‘All-Comers’ coronary stent trials, and has consistently been
shown to be an independent predictor of 1-year mortality and
major adverse cardiac events (MACE).10–12 In contrast, traditional
risk scores for patients undergoing PCI principally allow for the
estimation of procedural risk.13–18
The addition of clinical risk factors to the SXscore has been
shown to potentially further augment its utility to objectively
select the most appropriate revascularization strategy for patients
planning to undergo surgical or percutaneous revascularization.19–23
These approaches have involved the amalgamation of cardiac
surgery-based summary risk scores to the SXscore to form the
‘Global Risk’ (SXscore and additive EuroSCORE)23 and the ‘clinical
SXscore’ (SXscore and the modified ACEF score).19–22 As the in-
dividual clinical components of the cardiac surgery-based summary
risk scores were not incorporated into the development of the
combined risk models, and that these risk scores contained redun-
dant information not relevant to the prediction of mortality after
PCI—such as the chronic obstructive pulmonary disease and pul-
monary hypertension in the EuroSCORE—this may have limited
the predictive ability of the final risk models.23 Furthermore,
these approaches categorized patient risk without giving a more
personalized risk assessment—with the Clinical SXscore19–22
being able to identify a high-risk population only, and the Global
Risk23 a lower-risk population.
The aims of the present study are to combine the individual
components of the Clinical SXscore—namely the continuous vari-
ables age, creatinine or creatinine clearance (CrCl), left ventricular
ejection fraction (LVEF), and the SXscore—to form the Logistic
Clinical SYNTAX score (Logistic Clinical SXscore). The underlying
hypothesis being that the addition of these ‘Core’ clinical variables
would provide the majority of the improvement to the 1-year pre-
dictive ability of the SXscore compared with the addition of further
clinical variables. The second aim of this study was to allow for a
more personalized approach to risk stratification, compared with
the categorical approaches of previous risk models.19–23
Methods
Patients
Patient-level data from seven contemporary coronary stent trials3,24–29
incorporating 6508 patients with a calculated SXscore were pooled
for the present study and have previously been described.19 An add-
itional trial was excluded from the original database (n ¼ 187)30 due
to permission being unobtainable from the study sponsor, and a
further 12 patients excluded due to missing values for death, leading
to a total of 6309 patients in the present analysis. The endpoints
for the prognostic analyses were 1-year all-cause death and MACE
[a composite of all-cause death, myocardial infarction (MI) and all-
cause revascularization].
Predictors and model development
During the development phase, two risk models were defined: (i) a
core model that incorporated the SXscore and components of the
ACEF and modified ACEF scores31 (age, creatinine or CrCl and
LVEF); (ii) an extended model that included the core model and the
addition of best performing clinical variables that improved the
performance of the core model. The CrCl was defined by the Cock-
croft and Gault formula.32 The left ventricular ejection fraction was
defined as the percentage LVEF taken by transthoracic echocardiog-
raphy or left ventriculography taken at the time of the diagnostic cor-
onary angiogram.
As the Logistic Clinical SXscore was to be developed for predicting
future longer-term (1-year) clinical outcomes, relatively weaker predic-
tors (of borderline significance) were selected and retained in the
extended model only if there was an appropriate increase in AUC
when added to the core model in the multivariable logistic regression
model, in line with work described by Harrell and others.33,34
Within all the coronary stent trials predictor values generally were
.90% complete if the predictor was recorded. Multiple imputation of
missing values in the trials with predictors recorded was undertaken
using an advanced imputation strategy that takes the correlation
between all potential predictors into account [method of chained
equations (MICE algorithm in R software)].35–37
Statistical analysis
Logistic regression analyses were performed to examine individual and
joint relations between the core model, other clinical characteristics
(extended model), and the binary outcome of 1-year all-cause death
and MACE. Interaction terms between predictors were examined
with likelihood ratio tests, but none was of sufficient relevance to
extend the models beyond the main effects for each predictor. All ana-
lyses were stratified by the coronary stent trial.
Determining how the variables should be modelled was a vital step
in identifying which variables were most strongly related to 1-year clin-
ical outcomes. For the continuous predictors, possible non-linearity
with clinical outcomes was assessed with restricted cubic spline func-
tions. These are flexible functions that can accommodate curves in the
form of the association to assess the assumption that patient charac-
teristics are linearly related to the log odds of the outcome
event.33,34 To allow for a direct comparison of the prognostic value
of predictors recorded in different units or scales, the odds ratios
(ORs) for continuous predictors were scaled to correspond to a
change from the 25th to 75th percentile of the predictor distribu-
tion.37 Pooled ORs were estimated over the imputed data set, and
repeated using only the complete data, which gave similar results (un-
published data). Statistical analyses were performed with R software37
and SPSS Version 17.0 (SPSS, Inc., Chicago IL, USA).
Validation
The predictive performance of the model was cross-validated by the
omission of each of the coronary stent trials in turn, with the model
fitted on the remaining pooled population, and the resulting fit
tested on the omitted trial.38–40 This methodology allowed for the es-
timation of the extent to which the predictive accuracy of the model
(based on the entire sample) was affected by any differences
between the seven coronary stent trials.3,24–29 This form of cross-
validation by trial was hence a stronger test of validity than if, for
example, the study population had been divided at random into a de-
velopment and validation cohort.34,41,42
The measure of predictive discrimination used to characterize the
model performance in the original and the validation samples, was
by the area under the receiver operating characteristic curve (AUC),
and is equal to the c-statistic (the ability to distinguish a patient with
and without a clinical outcome—and ranges from 0.50 (no better
than flipping a coin) to 1.0 (model is 100% correct). Calibration—
the agreement between observed and predicted risks—was assessed
with the Hosmer–Lemeshow test and validation plots.33,40
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Model presentation
The final model is presented in a score chart with the scores based on
the original logistic regression coefficients and can be used to obtain
approximate predictions for individual patients.34,40 Scores were
based on rounding of the regression coefficients. A constant was sub-
tracted or added to rescale the scores in positive integers. The sum
scores were related to the risks of 1-year mortality with logistic regres-
sion. The score chart can be used to obtain approximate predictions
for individual patients.
Results
Development of the model
Within the analysed data set 175 all-cause deaths (2.8%) and 797
MACE (15.8%) were observed. The univariate associations of the
SXscore and clinical variables to 1-year all-cause death and
MACE are shown in Table 1. Creatinine clearance was
demonstrated to be a stronger univariate predictor of 1-year all-
cause death compared with serum creatinine and was therefore
incorporated into the core model (CrCl, OR: 2.2; 95% CI: 1.8–
2.8; creatinine, OR: 1.4; 95% CI: 1.2–1.6). Linear relationships
were a good approximation for the SXscore, age, CrCl, and
LVEF with 1-year mortality, except that constant risk was
evident at higher values for the LVEF (≥50%) and CrCl
(≥90 mL/min) (Supplementary material online, Appendix). The
four factors (SXscore, age, CrCl, and LVEF) were entered into a
multivariable logistic regression model (Table 2) and confirmed
to be strong independent predictors of 1-year mortality, thus
forming the core model.
Similar analyses were repeated with the core model and the best
performing clinical variables (six clinical variables: presentation,
body mass index (BMI), peripheral vascular disease, diabetes, pre-
vious MI, smoking) for 1-year mortality to form the extended
model.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Univariate associations between predictors of 1-year death and 1-year major adverse cardiac events in the
pooled database of seven contemporary coronary stent trials
Characteristics Coding Death (n5 6309) MACE (n 5 5048)a
Number (%) Univariateb Number (%) Univariateb
Core model
SYNTAX scorec 23 vs. 8 — 1.7 (1.6–1.8) — 1.8 (1.7–1.8)
Age (years)c 72 vs. 56 — 2.9 (2.7–3.1) — 1.2 (1.2–1.2)
CrClc 67 vs. 109 — 2.2 (1.8–2.6) — 1.2 (1.1–1.3)
Ejection fractiond 40 vs. 50 — 2.2 (1.8–2.8) — 1.3 (1.1–1.5)
Extended model
Presentation (%)
Stable 72 (2.4) 1.0 386 (15.1) 1.0
UA 32 (2.5) 1.0 (0.7–1.6) 185 (15.2) 1.0 (0.8–1.2)
NSTEMI 25 (3.1) 1.8 (1.1–2.9) 102 (16.5) 1.1 (0.8–1.4)
STEMI 46 (3.6) 1.7 (1.1–2.9) 97 (14.9) 1.0 (0.8–1.3)
Female 58 (3.7) 1.5 (1.1–2.1) 215 (17.1) 1.2 (1.0–1.4)
BMIc 30 vs. 25 — 1.1 (1.0–1.1) — 1.0 (1.0–1.1)
PVD 20 (6.9) 2.5 (1.5–4.1) 49 (20.6) 1.3 (0.9–1.8)
Diabetes (%)
Non-insulin treated 32 (3.8) 1.8 (1.2–2.8) 146 (17.4) 1.3 (1.1–1.6)
Insulin treated 27 (6.8) 3.1 (2.0–4.8) 101 (25.4) 2.1 (1.6–2.6)
Hypertension (%) 134 (3.1) 1.5 (1.1–2.2) 579 (16.1) 1.2 (1.0–1.5)
Hyperlipidaemia (%) 95 (2.3) 0.6 (0.5–0.9) 523 (15.3) 1.0 (0.9–1.2)
Glycoprotein 2b3a use (%) 57 (3.3) 1.2 (0.8–1.9) 173 (16.3) 1.1 (0.9–1.4)
Previous smoking (%) 48 (2.3) 0.8 (0.6–1.2) 259 (13.9) 1.0 (0.8–1.2)
Current smoking (%) 37 (2.2) 0.8 (0.5–1.1) 178 (14.3) 0.9 (0.7–1.1)
Previous MI (%) 68 (3.9) 1.8 (1.3–2.4) 250 (16.8) 1.2 (1.0–1.4)
Previous PCI (%) 23 (1.9) 0.7 (0.4–1.1) 179 (16.9) 1.2 (0.9–1.4)
TIA or CVA (%) 10 (5.5) 1.5 (0.7–2.8) 33 (22.8) 1.4 (0.9–2.1)
Stent generation (%) Newer generation 58 (2.1) 0.9 (0.5–1.6) 382 (14.1) 0.8 (0.6–1.1)
CrCl, creatinine clearance; Yrs, years; UA, unstable angina; NSTEMI, non-ST-elevation myocardial infarction; STEMI, ST-elevation myocardial infarction; BMI, body mass index;
PVD, peripheral vascular disease; MI, myocardial infarction; PCI, percutaneous coronary intervention; TIA, transient ischaemic attack; CVA, cerebrovascular accident.
an ¼ 5048 without STRATEGY/MULTI-STRATEGY24,28 and SIRTAX26 trials secondary to all-cause revascularization not being recorded in the trials.
bOdds ratio (95% confidence interval).
cOdds ratios for continuous variables are given for the inter-quartile range.
dOdds ratio for a decrease in 10% for values below 50%.
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Model performances
1-Year all-cause death (death)
The core model (SXscore, age, CrCl, and LVEF) demonstrated a
significantly better predictive ability for 1-year all-cause death com-
pared with the SXscore in isolation (Table 3). Within the pooled
population (combining all trials), the AUC was substantially
higher for the core model compared with the SXscore in isolation
(core model: 0.753, SXscore 0.660). A minor incremental benefit
of the extended model (AUC: 0.791) compared with the core
model was evident. Consequently, the core model was retained
in the final Logistic Clinical SXscore, and the extended model
excluded. The Hosmer–Lemeshow test confirmed that there
was no evidence of poor calibration for the core model in
pooled analyses of the seven trials (P ¼ 0.55). Validation plots of
the core model indicated a good agreement between the observed
and predicted risks in the three largest coronary stent trials
(n . 1000) (Figure 1). Within the SYNTAX trial recalibration of
the validation plots was necessary to prevent generalized under-
estimation of predicted risk, and involved resetting the intercept
of the calibration slope to zero.
1-Year major adverse cardiac events
For the outcome of 1-year MACE, the core and extended models
added little incremental increase in predictive ability compared
with the SXscore in isolation (AUC core model: 0.609, AUC
extended model: 0.618, SXscore: 0.605) (Tables 2 and 3).
Further analyses indicated that all-cause revascularization least
benefited from the addition of clinical variables compared with
death or MI (Supplementary material online, Appendix). Since
the Logistic Clinical SXscore conferred no major additional
benefit to the SXscore in predicting MACE, further analyses for
this endpoint are not reported.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Performances of the Logistic Clinical SYNTAX score (core model) at cross-validation
Study Death MACE
SYNTAX score Core model SYNTAX score Core model
ARTS II25 0.69 0.75 0.69 0.70
LEADERS27 0.63 0.74 0.62 0.61
STRATEGY24/MULTI-STRATEGY28 0.62 0.84 — —
RESOLUTE29 0.57 0.77 0.63 0.63
SIRTAX26 0.64 0.71 — —
SYNTAX3 0.67 0.73 0.58 0.59
Overalla 0.660 0.753 0.605b 0.609b
The core model was developed by omitting each study in turn, with the model fitted on the remaining pooled population, and validated by testing the resulting fit on the omitted
trial.38–40 Values shown are c-statistics for testing the resulting fit on the omitted trial (cross-validation).
LEADERS, biolimus-eluting stent with biodegradable polymer vs. sirolimus-eluting stent with durable polymer for coronary revascularization trial;27 MACE, major adverse cardiac
events; RESOLUTE, RESOLUTE all-comers trial;29 SIRTAX, the sirolimus-eluting vs. paclitaxel-eluting stents for coronary revascularization trial;26 SYNTAX, Synergy between PCI
with Taxus and cardiac surgery trial;3 ARTS II, the arterial revascularization therapies study part II trial;25 STRATEGY, the single high-dose bolus tirofiban and sirolimus-eluting
stent vs. abciximab and bare metal stent in myocardial infarction trial;24 MULTISTRATEGY, comparison of angioplasty with infusion of tirofiban or abciximab and with implantation
of sirolimus-eluting or uncoated stents for acute myocardial infarctiontrial.28
aPooled population (combining all trials).
bn ¼ 5048 without STRATEGY/MULTI-STRATEGY and SIRTAX secondary to all-cause revascularization not being recorded in the trial.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Multivariable associations [odds ratio (95% CI)], between the individual components of the core model, for
1-year death and 1-yearmajor adverse cardiac events in the pooled database of seven contemporary coronary stent trials
Characteristics Coding Death (n5 6309) MACE (n 5 5048)a
Core model
SYNTAX Scoreb 23 vs. 8 1.41 (1.15–1.73) 1.72 (1.54–1.91)
Age (years)b 72 vs. 56 2.06 (1.51–2.82) 1.06 (0.92–1.22)
CrCl (ml/min)b 67 vs. 109 1.53 (1.12–2.09) 1.11 (0.94–1.31)
LVEF (%)c 40 vs. 50 1.97 (1.61–2.41) 1.10 (0.93–1.30)
CrCl, creatinine clearance, LVEF, left ventricular ejection fraction; MACE, major adverse cardiac events.
an ¼ 5048 without STRATEGY/MULTI-STRATEGY24,28 and SIRTAX26 trials secondary to all-cause revascularization not being recorded in the trials.
bOdds ratios for continuous variables are given for the inter-quartile range (indicated in coding column).
cOdds ratio for a decrease in 10% for values ,50%.
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Score charts for 1-year all-cause death
A simple score chart for the bedside application of the final Logistic
Clinical SXscore for predicting 1-year all-cause death after PCI is illu-
strated (Figure 2). An extra score is included for a ‘‘SYNTAX-like’’
patient, i.e. a patient presenting with left main disease (isolated or
associated with 1, 2, or 3-vessel disease) or 3-vessel disease, due
to the need to recalibrate risks to the SYNTAX trial patients as
described previously. One-year mortality can be accurately esti-
mated by the summation of scores. Similar charts for the extended
model are enclosed in the Supplementarymaterial online, Appendix.
Discussion
The main findings from this study are that: (i) the Logistic Clinical
SXscore—consisting of four continuous variables (SXscore, age,
CrCl, LVEF)—substantially enhances the risk stratification of PCI
patients for the outcome of 1-year all-cause death compared
with the SXscore in isolation; (ii) the Logistic Clinical SXscore
was able to accurately distinguish patients with or without a clinical
outcome (discrimination) and could accurately predict individual
patient risk (calibration) without under or over-estimating risk;
(iii) the addition of further clinical variables to the four key predic-
tors of the Logistic Clinical SXscore (SXscore, age, CrCl, and
LVEF) did not substantially increase its predictive ability; (iv) an
individualized approach to the longer-term (1-year) risk stratifica-
tion of patients after PCI was achievable utilizing the SXscore and
(v) the SXscore in isolation was the predominant determinant of
1-year MACE with little additional predictive benefit of clinical
variables, predominantly secondary to the SXscore being the
main determinant of all-cause revascularization.
Figure 1 Validation plots at cross-validation for the three largest coronary stent trials (n . 1000). Plots are shown for the core model pre-
dicting 1-year all-cause death. The triangles indicate the observed frequencies by quintile of predicted probabilities with a 95% confidence inter-
val. Good agreement was evident between observed and predicted risks, indicating that the core model did not over or under-estimate 1-year
mortality (i.e. good calibration).
Figure 2 The Logistic Clinical SYNTAX score for the prediction of 1-year death. *SYNTAX-like patient defined as fulfilling the enrolment
criteria for the SYNTAX All-Comers trial, i.e. left main stem (isolated or associated with one-, two-, or three-vessel disease) or three-vessel
disease alone. CrCl, creatinine clearance, LV ejection fraction, left ventricular ejection fraction.
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The logistic clinical SYNTAX score:
predicting 1-year death
The findings of the Logistic Clinical SXscore, namely that a few
strongly predictive clinical variables leading to the accurate predic-
tion of 1-year all-cause death after PCI, are consistent with the
concepts of the ‘‘law of parsimony’’ or ‘‘Occam’s razor.’’ Age,
CrCl, and LVEF are objectively measured continuous clinical vari-
ables in line with the ACEF methodology, which has previously
been shown to match or even surpass the EuroSCORE (consisting
of 17 clinical variables) in predicting in-hospital mortality after
elective coronary artery bypass graft surgery.31,43,44 Explanations
for this comparability have included that the clinical variables of
the ACEF score were objectively defined and continuous.31
Notably the addition of a further six clinical variables to the Lo-
gistic Clinical SXscore to form the extended model lead to a minor
incremental increase in its predictive ability. This is likely related to
the inter correlation between the core model and the additional
clinical variables. Clear correlations were evident (Pearson correl-
ation coefficient 0.2 or greater, P, 0.001) for age and gender/
hypertension; CrCl and gender/BMI; LVEF and MI; SXscore and
prior PCI; BMI and diabetes mellitus. In addition the presence of
diabetes has historically been associated with adverse outcomes
after PCI.45,46 It is however likely that patients with more severe
diabetes were captured by the continuous variables in the Logistic
Clinical SXscore, in particular a reduced CrCl. Both a reduced
CrCl and proteinuria—a marker of diabetic nephropathy—have
previously been shown to be significant determinants of adverse
risk following PCI.47–49 Furthermore diabetics without evidence of
proteinuria have also previously been reported to have a similar
survival compared with non-diabetics.47
SYNTAX score
The SXscore calculation has previously been reported to have
moderate inter-observer variability when performed by interven-
tional cardiologists,4,50 which may be perceived as a limitation of
the Logistic Clinical SXscore. Appropriate training of SXscore
reporting has, however, been shown to substantially reduce in-
ter-observer variability.1,2,50 It has previously been suggested that
the SXscore is a reflection of the underlying co-morbidity of the
patient,23 for which the present study provides further supportive
evidence. This notion is also supported by the 10-year predicted
Framingham risk scores being recently shown to have a significant
and direct relationship with the prevalence and magnitude of
coronary artery calcium scores.51
Comparisons with the clinical SYNTAX
score
The Clinical SXscore, on which the Logistic Clinical SXscore is
based, multiplied a variant of the surgical-based ACEF (age, creatin-
ine, and ejection fraction) score (modified ACEF score) to the
SXscore. In doing so the Clinical SXscore was shown to over-
estimate predicted risks (i.e. relatively poor calibration) despite
modest increases in the discriminative ability of the Clinical
SXscore being obtained.20,23 The application of the Clinical
SXscore to the present study (full data not shown) showed that
it was able to identify a high-risk population only (mortality: 6.6%
of the study population), compared with the intermediate- and
low-risk groups (mortality: 2.3 and 1.1% of the study population,
respectively) consistent with the previously reported litera-
ture.19–23 Comparatively the Logistic Clinical SXscore within the
present study was demonstrated to accurately predict risk across
all risk groups (i.e. well calibrated) and importantly was able to
provide an individualized risk assessment.
Comparisons with other risk models
The recently reported Functional SXscore (FSS)—a fractional flow
reserve (FFR)-guided SYNTAX scoring methodology—has been
shown to potentially improve the predictive accuracy of the
SXscore.52 Within this study, the more objective assessment of
coronary stenoses compared with visual assessment (to form the
FSS) lead to incremental increases in the predictive accuracies
for the outcomes of 1-year MACE (AUC: SXscore, 0.630; FSS,
0.677), 1-year death or MI (AUC: SXscore, 0.621; FSS, 0.676)
and 1-year all-cause revascularization (AUC: SXscore, 0.627; FSS,
0.657).52 Notably, improvements in the predictive accuracy for
1-year death were not reported with the FSS. Comparatively the
Logistic Clinical SXscore in the present study demonstrated a sub-
stantial increase in the prediction of 1-year death (AUC: SXscore,
0.660; core model, 0.753), and improvements in the prediction of
1-year death or MI (AUC: SXscore, 0.594; core model, 0.657,
extended model 0.666—Supplementary material online, Appen-
dix) without the need for invasive pressure-wire coronary
assessment.
The longer-term (1-year) mortality predictions provided by the
Logistic Clinical SXscore are the principle differences compared
with other reported risk scores, namely the National Cardio-
vascular Data Registry16 score, the Mayo Clinical Risk score,13,15
the EuroHeart PCI score,18 and the New York PCI risk score,14
in that they report in-hospital Death14,16,18 or in-hospital
MACE,50,51 or at the most 30-day mortality16 after PCI. Other
risk scores that longer-term risk stratify patients include the
New Risk Stratification score (NERS).53 As previously described
with the Clinical SXscore, NERS categorized patients into levels
of risk (high and low risk) without giving an individualized assess-
ment of patient risk, which was achievable with the Logistic Clinical
SXscore. Furthermore NERS is a more complicated score that
consists of 17 clinical variables, 33 anatomical factors, and 4
procedural details, and was developed for patients with left main
coronary artery disease undergoing PCI.53
Potential clinical application
Although the patient and clinician may wish to know the short-
term risk of procedural complications associated with PCI, a
longer-term perspective may also be beneficial. Not only would
this appropriately inform the patient, but may also prove to be
of benefit in determining whether surgical or percutaneous re-
vascularization would be more appropriate as part of the Heart
Team consensus. As recently reported, high co-morbidity patients
may confer prognostic and morbidity benefits from undergoing
surgical revascularization compared with PCI provided a certain
threshold of operative risk is not exceeded.23
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Limitations
Although the Logistic Clinical SXscore was derived from ‘All-
Comers’ types patients in contemporary stent trials, each trial
still retained certain inclusion and exclusion criteria.11 These cri-
teria were, however, minimal which should legitimize the applica-
tion of the Logistic Clinical SXscore to contemporary clinical
practice. The authors recognize that further external validation
of the Logistic Clinical SXscore in ‘real-world’ ‘unrestricted’ regis-
try populations is necessary when these registries reporting the
SXscore become available. This would further strengthen the
results of this study, although the present analyses were already
undertaken in a pooled analysis of seven different contemporary
stent trials and internally validated with a cross-validation proced-
ure. Comparisons of the Logistic Clinical SXscore with the Global
Risk23 were not possible since the EuroSCORE was not collected
in the seven contemporary stent trials.
Cardiogenic shock is a risk variable that has consistently been
shown to be a powerful predictor of in-hospital mortality.13–18
This important subset of patients, although not an exclusion
criteria in the ‘All-Comers’ trials, by practice lead to the under-
recruitment of these patient types predominantly due to the inabil-
ity to gain appropriate informed consent or refusal to participate.54
Consequently, the Logistic Clinical SXscore should at present not
be applied to these patients where other risk scores would be
better suited.13–18
Future directions
Potentially the integration of the Logistic Clinical SXscore into an
online algorithm with the currently available SXscore1 may serve
to simultaneously allow for risk stratification of patients based on
anatomical and clinical variables. In addition, the application of
the Logistic Clinical SXscore in place of the SXscore to aid in
determining the optimal revascularization modality in patients
with complex coronary disease is a potential future application.
The incorporation of the FSS as previously described,52 to
allow for a more objective assessment of the coronary
anatomy, may enhance the predictive accuracy of the Logistic
Clinical SXscore even further. Future direction with non-invasive
imaging and FFR calculation55—utilizing computational fluid dynam-
ics applied to coronary computed tomography angiography—may
be feasible. The expansion of other risk variables to the Logistic
Clinical SXscore such as the haemodynamic status as previously
discussed may expand the use of this risk score to other patient
types.
Conclusion
Compared with the SXscore in isolation, the Logistic Clinical
SXscore substantially enhances the risk stratification of PCI
patients for death at 1-year and allows for an accurate individua-
lized assessment of patient risk. The use of the Logistic Clinical
SXscore may also further aid in the Heart Team consensus in
determining the optimal revascularization modality.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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2 
Figures 
Figure 1 
Plots showing univariate associations between the continuous Core Model predictors 
and 1-year all-cause Death: a) SYNTAX Score, b) Age, c) Left Ventricular Ejection 
Fraction and d) Creatinine Clearance. Each panel depicts the risk of 1-year death 
(solid curve) with 95% CIs (dotted curves). 
Figure 2 
Receiver-operator characteristic (ROC) curve analysis for the SXscore and the 
Logistic Clinical SXscore (Core and Extended Model) for 1-year clinical outcomes. 
Figure 3 
Core and Extended Models of the Logistic Clinical SYNTAX Score for the prediction 
of 1-Year Death. 
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Combined Anatomical and Clinical Factors for the Long Term Risk 
Stratification of Patients Undergoing Percutaneous Coronary 
Intervention: The Logistic Clinical SYNTAX Score 
Supplementary Appendix 
 
Table 1 
Multivariable associations (odds ratio [95% confidence interval]) between the best 
performing predictors of 1-year Death and 1-year MACE in the pooled database of 7 
contemporary coronary stent trials. 
Table 2 
Performances of the Logistic Clinical SYNTAX Score (Core and Extended models) at 
cross validation: models were developed by omitting each study in turn, and validated 
by each study in turn.  
Table 3 
Logistic regression formula to predict 1-Year Death 
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3 
Table 1 
Multivariable associations (odds ratio [95% confidence interval]) between the best 
performing predictors of 1-year Death and 1-year MACE in the pooled database of 7 
contemporary coronary stent trials  
 
1 n=5048 without STRATEGY/MULTI-STRATEGY1, 2 and SIRTAX3 Trials secondary to all-cause revascularisation not being 
recorded in the trials. 
 †Odds Ratios for continuous variables are given for the interquartile range (indicated in Coding column) 
‡Odds Ratio for a decrease in 10% for values below 50%  
Abbreviations: NSTEMI non ST elevation myocardial infarction, STEMI ST elevation myocardial infarction, BMI body mass 
index, PVD peripheral vascular disease, MI myocardial infarction, PCI percutaneous coronary intervention, TIA transient 
ischaemic attack, CVA cerebrovascular accident. 
 
 
 
 
 
Characteristics Coding Death (n=6309) MACE (n=5048)1 
  Core Model Extended Model Core Model Extended Model 
 
CORE MODEL 
SYNTAX Score† 
Age (Years)† 
 
 
23 vs. 8 
72 vs. 56 
 
 
1.41 (1.15, 1.73) 
2.06 (1.51, 2.82) 
 
 
1.50 (1.17, 1.92) 
1.77 (1.20, 2.61) 
 
 
1.72 (1.54, 1.91) 
1.06 (0.92, 1.22) 
 
 
1.72 (1.55, 1.92) 
1.01 (0.87, 1.17) 
CrCl (ml/min)† 
LVEF (%)‡ 
67 vs. 109 
40 vs. 50 
1.53 (1.12, 2.09) 
1.97 (1.61, 2.41) 
1.59 (1.10, 2.30) 
1.58 (1.21, 2.03) 
1.11 (0.94, 1.31) 
1.10 (0.93, 1.30) 
1.09 (0.90, 1.32) 
1.12 (0.96, 1.29) 
      
EXTENDED MODEL 
Presentation 
   
BMI† 
PVD 
Previous MI 
Current Smoking 
Diabetes 
  
 
Hypertension 
Stent Generation 
Female 
 
NSTEMI 
STEMI 
30 vs. 25 
 
 
 
Non-Insulin 
Treated  
Insulin Treated  
 
 
- 
- 
- 
- 
- 
- 
- 
 
- 
- 
- 
- 
 
1.33 (0.66, 2.69) 
1.80 (1.10, 2.94) 
1.27 (1.02, 1.59) 
1.83 (1.08, 3.12) 
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Table 1 
Multivariable associations (odds ratio [95% confidence interval]) between the best 
performing predictors of 1-year Death and 1-year MACE in the pooled database of 7 
contemporary coronary stent trials  
 
1 n=5048 without STRATEGY/MULTI-STRATEGY1, 2 nd SIRTAX3 Trials secondary to all- use revascularisation not being 
recorded in the trials. 
 †Odds Ratios for continuous variables are given for the interquartile range (indicated in Coding column) 
‡Odds Ratio for a decrease in 10% for values below 50%  
Abbreviations: NSTEMI non ST elevation myocardial infarction, STEMI ST elevation myocardial infarction, BMI body mass 
index, PVD peripheral vascular disease, MI myocardial infarction, PCI percutaneous coronary intervention, TIA transient 
ischaemic attack, CVA cerebrovascular accident. 
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Table 2 
Performances of the Logistic Clinical SYNTAX Score (Core and Extended models) at 
cross validation: models were developed by omitting each study in turn, and validated 
by each study in turn.  
 Death MACE 
 
Study 
SYNTAX 
Score 
Core 
Model 
Extended 
Model 
SYNTAX 
Score 
Core 
Model 
Extended 
Model 
ARTS II4 0.69 0.75 0.80 0.69 0.70 0.71 
LEADERS5 0.63 0.74 0.74 0.62 0.61 0.60 
STRATEGY2/MULTI-
STRATEGY1 
0.62 0.84 - - - - 
RESOLUTE6 0.57 0.77 - 0.63 0.63 0.63 
SIRTAX3 0.64 0.71 0.72 - - - 
SYNTAX7 0.67 0.73 0.76 0.58 0.59 0.61 
Overall* 0.660 0.753 0.7911 0.6052 0.6092 0.6182 
 
Values are c-statistics for models. 
*Pooled population (combining all trials) 
1 n=3880 without STRATEGY/MULTI-STRATEGY and RESOLUTE, secondary to body mass index (BMI) and 
peripheral vascular disease (PVD) not being recorded in the respective trial.  
2 n=5048 without STRATEGY/MULTI-STRATEGY and SIRTAX secondary to all-cause revascularisation not being 
recorded in the trial. 
Abbreviations: LEADERS, biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with 
durable polymer for coronary revascularisation trial;5 RESOLUTE, RESOLUTE all-comers trial;6 SIRTAX: the 
sirolimus-eluting versus paclitaxel-eluting stents for coronary revascularisation trial;3 SYNTAX: Synergy between PCI 
with Taxus and cardiac surgery trial;7 ARTS II: the arterial revascularisation therapies study part II trial;4 STRATEGY: 
the single high dose bolus tirofiban and sirolimus eluting stent vs abciximab and bare metal stent in myocardial 
infarction trial;2 MULTISTRATEGY: comparison of angioplasty with infusion of tirofiban or abciximab and with 
implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction trial.1 
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Table 3 
Logistic regression formula to predict 1-Year Death 
 
Logistic Clinical SXscore - Core Model: 1-Year Death 
Logit (Death) = -7.5478 + 0.0241 * SXscore + 0.0396 * age + 0.0748 * (50-LVEF)+ + 
0.0235 * (90-CrCl)+ + 0.3649 * SYNTAX-like 
 
Logistic Clinical SXscore - Extended Model: 1-Year Death 
Logit (Death) = -9.3818 + 0.0276 * SXscore + 0.0325 * age + 0.0536 * (50-LVEF)+ + 
0.0248 * (90-CrCl)++ 0.5440 * SYNTAX-like + 0.4813 * NSTEMI + 0.7937 * 
STEMI + 0.0570 * BMI + 0.5689 * PVD + 0.4568* Diabetes + 0.7422* DiabInsul + 
0.3673 * PrevMI + 0.4279 * CurrSmok 
 
Risk of 1-Year Death = 1/[1+exp(-Logit(Death)] 
 
Key: 
SXscore              = SYNTAX Score 
Age   = Age (Years) 
LVEF   = Left Ventricular Ejection Fraction  
CrCl   = Creatinine Clearance (ml/min)  
SYNTAX-like  = SYNTAX Trial Patient  (Yes=1/No=0) 
NSTEMI  = Non ST-Elevation Myocardial Infarction (Yes=1/No=0) 
STEMI   = ST-Elevation Myocardial Infarction (Yes=1/No=0) 
BMI    = Body Mass Index (kg/m2) 
PVD    = Peripheral Vascular Disease (Yes=1/No=0) 
Diabetes   = Diabetes: Not Insulin Treated (Yes=1/No=0) 
DiabInsul   = Diabetes: Insulin Treated  (Yes=1/No=0) 
PrevMI   = Previous Myocardial Infarction (Yes=1/No=0) 
CurrSmok  = Current smoker  (Yes=1/No=0) 
(50-LVEF)+   indicates 50-LVEF for positive values, 0 for negative values 
(90-CrCl) +                  indicates 90-CrCl for positive values, 0 for negative values 
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Figure 1 
Plots showing univariate associations between the continuous Core Model predictors 
and 1-year all-cause Death: a) SYNTAX Score, b) Age, c) Left Ventricular Ejection 
Fraction and d) Creatinine Clearance. Each panel depicts the risk of 1-year death 
(solid curve) with 95% CIs (dotted curves). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figur  1.  
Univariate associations of the core predictors a) Syntax score, b) Age, c) Ejection fraction and d) 
Creatinin clearance with the risk of 1-year death. 
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Figure 2 
Receiver-operator characteristic (ROC) curve analysis for the SXscore and the 
Logistic Clinical SXscore (Core and Extended Model) for 1-year clinical outcomes. 
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Figure 3 
 Core and Extended Models of the Logistic Clinical SYNTAX Score for the 
prediction of 1-Year Death. 
  
 
 
 
 
 
 
 
 
 
 
 
*SYNTAX-like Patient defined as fulfilling the enrolment criteria for the SYNTAX All-Comers trial i.e. left 
main stem (isolated or associated with one, two or three vessel disease) or three vessel disease alone. 
Abbreviations. CrCl: creatinine clearance, STEMI: ST elevation myocardial infarction, BMI: body mass index, LV 
Ejection Fraction: left ventricular ejection fraction, PVD: peripheral vascular disease, DM: diabetes mellitus, MI: 
myocardial infarction. 
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Prediction of 1-Year Mortality in Patients
With Acute Coronary Syndromes Undergoing
Percutaneous Coronary Intervention
Validation of the Logistic Clinical SYNTAX (Synergy Between Percutaneous
Coronary Interventions With Taxus and Cardiac Surgery) Score
Vasim Farooq, MBCHB,* Yvonne Vergouwe, PHD,y Philippe Généreux, MD,z
Christos V. Bourantas, MD, PHD,* Tullio Palmerini, MD,z Adriano Caixeta, MD,z
Hector M. Garcìa-Garcìa, MD, PHD,* Roberto Diletti, MD,* Marie-angèle Morel, BSC,x
Thomas C. McAndrew, MS,z Arie Pieter Kappetein, MD, PHD,jj Marco Valgimigli, MD,{
Stephan Windecker, MD,# Keith D. Dawkins, MD,** Ewout W. Steyerberg, PHD,y
Patrick W. Serruys, MD, PHD,* Gregg W. Stone, MDz
Rotterdam, the Netherlands; New York, New York; Ferrara, Italy; Bern, Switzerland; and
Natick, Massachusetts
Objectives This study sought to validate the Logistic Clinical SYNTAX (Synergy Between Percutaneous
Coronary Intervention With Taxus and Cardiac Surgery) score in patients with non–ST-segment
elevation acute coronary syndromes (ACS), in order to further legitimize its clinical application.
Background The Logistic Clinical SYNTAX score allows for an individualized prediction of 1-year
mortality in patients undergoing contemporary percutaneous coronary intervention. It is composed
of a “Core” Model (anatomical SYNTAX score, age, creatinine clearance, and left ventricular ejection
fraction), and “Extended” Model (composed of an additional 6 clinical variables), and has previously
been cross validated in 7 contemporary stent trials (>6,000 patients).
Methods One-year all-cause death was analyzed in 2,627 patients undergoing percutaneous coronary
intervention from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
Mortality predictions from the Core and Extended Models were studied with respect to discrimination,
that is, separation of those with and without 1-year all-cause death (assessed by the concordance [C]
statistic), and calibration, that is, agreement between observed and predicted outcomes (assessed with
validation plots). Decision curve analyses, which weight the harms (false positives) against benefits (true
positives) of usinga risk score tomakemortality predictions,wereundertaken to assess clinical usefulness.
Results In the ACUITY trial, the median SYNTAX score was 9.0 (interquartile range 5.0 to 16.0);
approximately 40% of patients had 3-vessel disease, 29% diabetes, and 85% underwent drug-eluting
stent implantation. Validation plots confirmed agreement between observed and predicted mortality.
The Core and Extended Models demonstrated substantial improvements in the discriminative ability
for 1-year all-cause death compared with the anatomical SYNTAX score in isolation (C-statistics:
SYNTAX score: 0.64, 95% confidence interval [CI]: 0.56 to 0.71; Core Model: 0.74, 95% CI: 0.66 to 0.79;
Extended Model: 0.77, 95% CI: 0.70 to 0.83). Decision curve analyses confirmed the increasing ability to
correctly identify patients who would die at 1 year with the Extended Model versus the Core Model
versus the anatomical SYNTAX score, over a wide range of thresholds for mortality risk predictions.
Conclusions Compared to the anatomical SYNTAX score alone, the Core and Extended Models of the
Logistic Clinical SYNTAX score more accurately predicted individual 1-year mortality in patients
presenting with non–ST-segment elevation acute coronary syndromes undergoing percutaneous
coronary intervention. These findings support the clinical application of the Logistic Clinical SYNTAX
score. (J Am Coll Cardiol Intv 2013;6:737–45) ª 2013 by the American College of Cardiology
Foundation
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The SYNTAX (Synergy Between Percutaneous Coronary
Intervention With Taxus and Cardiac Surgery) score is as an
objective, anatomical-based tool to determine the complexity of
coronary artery disease and guide decision making between
cardiac surgery and percutaneous coronary intervention (PCI)
(1–5). Since the SYNTAX trial, numerous validation studies
have confirmed the SYNTAX score to be an independent
predictor of long-termmortality in abroad rangeof patient types
(6–8). The use of the SYNTAX score is now advocated in both
the U.S. and European revascularization guidelines (9,10). In
addition, theU.S.Food andDrugAdministrationmandates the
SYNTAX score as entry criteria in ongoing contemporary stent
and structural heart disease trials, investigating percutaneous left
main coronary intervention (EXCEL [Evaluation of XIENCE
PRIME Everolimus Eluting Stent System (EECSS) or
XIENCE V EECSS Versus Coronary Artery Bypass Surgery
for Effectiveness of Left Main Revascularizations] Clinical
Trial; NCT01205776) (11) and transcatheter aortic valve
implantation (SURTAVI [Safety and Efficacy Study of the
Medtronic CoreValve System in
the Treatment of Severe, Symp-
tomatic Aortic Stenosis in Inter-
mediate Risk Subjects Who Need
Aortic Valve Replacement];
NCT01586910).
The lack of clinical variables,
and the lack of a more individual-
ized approach of the SYNTAX
scoredwithpatients categorized as
“low,” “intermediate,” or “high”
riskdhas recently been shown to
be potentially misleading. In a post
hoc analysis of the SYNTAX trial
(12), relatively higher- and lower-
risk patients were identified in
the low and high SYNTAX score groups, respectively. The
Logistic Clinical SYNTAX score (13) was designed to
overcome these limitations, by augmenting the anatomical
SYNTAX score with clinical variables, and to individualize
long-term (1-year) mortality predictions in patients undergoing
contemporary PCI.
The purpose of this study was to validate the Logistic
Clinical SYNTAX score in patients with non–ST-segment
elevation acute coronary syndromes (ACS), in order to
further establish its clinical utility.
Methods
Study population. TheACUITY (AcuteCatheterization and
Urgent Intervention Triage Strategy) trial design has previ-
ously been described (14). In brief, this was a multicenter,
prospective, randomized trial of patients with moderate-
and high-risk non–ST-segment elevation ACS, managed
with an early invasive strategy. Coronary angiography was
performed in all patients within 72 h of randomization to
a specific anticoagulation regime undertaken during the
intervention. The choice of either bare-metal (BMS) or
drug-eluting stents (DES) was per operator discretion;
approximately 85% of the PCI population underwent DES
implantation. First-generation sirolimus-eluting or paclitaxel-
eluting stents were exclusively used ifDESwas to be implanted.
Dual antiplatelet therapy with aspirin and clopidogrel was
strongly recommended for at least 1 year. All major adverse
events were adjudicated by an independent clinical events
committee blinded to treatment assignment. In line with
a previous validation study of the anatomical SYNTAXscore in
the ACUITY trial (8), the subgroup of PCI patients in whom
quantitative coronary angiography was performed in the formal
angiographic substudy of the ACUITY trial (n ¼ 2,627) was
used for validation in the present study (15). All patients
underwent anatomical SYNTAX score analyses by 3 inter-
ventional cardiologists, appropriately trained for SYNTAX
score reading and blinded to the clinical outcomes (16).
Logistic Clinical SYNTAX score. The Logistic Clinical
SYNTAX score has previously been developed and cross-
validated (13) in a pooled population of 7 contemporary DES
trials (n ¼ 6,309) (2,17–23). It is composed of a Core Model
(consisting of the anatomical SYNTAX score, age, creatinine
clearance [CrCl], and left ventricular ejection fraction
[LVEF]), and an Extended Model (consisting of an addi-
tional 6 clinical variables) to improve the accuracy of 1-year
mortality predictions. During development and cross-
validation (13), the Core Model was shown to substantially
improve the predictive ability of the anatomical SYNTAX
score, with a minor incremental benefit in improving
mortality predictions for the Extended Model.
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Abbreviations
and Acronyms
ACS = acute coronary
syndromes
BMS = bare-metal stent(s)
CrCl = creatinine clearance
DES = drug-eluting stent(s)
IQR = interquartile range(s)
LVEF = left ventricular
ejection fraction
PCI = percutaneous coronary
intervention
PVD = peripheral vascular
disease
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For validation purposes, all predictor values in the Core
Model were present in >85% of patients. For the additional
predictors of the Extended Model, all values were present in
>90% of patients, except peripheral vascular disease (PVD)
(not recorded) and body mass index (weight [100%,
n ¼ 2,627], height [36%, n ¼ 945]). The definition of PVD
was expanded to include previous transient ischemic attack
or cerebrovascular accident, because these variables repre-
sented extracardiac arteriopathy. This modification to the
variable was rerun in the original development and cross-
validation population (13), with no change in predictive
performance of the Logistic Clinical SYNTAX score
(Fig. 1). Multiple imputation (5�) of missing values was
undertaken using an imputation strategy that takes the
correlation between all potential predictors into account.
The method of chained equations with the Multivariate
Imputation by Chained Equations (MICE) algorithm in R
software (R Foundation for Statistical Computing, Vienna,
Austria) was used (23,24).
Statistical analysis. Continuous variables are expressed as
means �SD or medians and interquartile ranges (IQR), as
appropriate. Binary variables are expressed as counts and/or
percentages. The possible nonlinearity of the continuous
predictors of the Core Model with 1-year all-cause death in
the ACUITY trial were assessed with restricted cubic spline
functions. These are flexible functions that can accommo-
date curves in the form of the association to assess the
assumption that patient characteristics are linearly related to
the log odds of the outcome event (23,25). Statistical anal-
yses were performed with R software (24) and SPSS (version
17.0, SPSS Inc., Chicago, Illinois).
Calibration, discrimination, and clinical usefulness. Calibra-
tion, discrimination, and clinical usefulness (23) were
assessed for the Logistic Clinical SYNTAX score (Core and
Extended Models) and anatomical SYNTAX score in the
ACUITY trial. Calibration refers to the agreement between
observed and predicted outcomes. The possible over- or
underestimation of the predicted risks were graphically
Figure 1. The Logistic Clinical SYNTAX Score for the Prediction of 1-Year Death
Core (incorporating 4 variables) and Extended Model (incorporating a further 6 variables) are illustrated. *SYNTAX-like patient defined as fulfilling the enrollment
criteria for the SYNTAX All-Comers trial: that is, left main stem (isolated or associated with 1-, 2-, or 3-vessel disease) or 3-vessel disease alone. Adapted, with permission,
from Farooq et al. (13). BMI ¼ body mass index; CrCl ¼ creatinine clearance; CVA ¼ cerebrovascular accident; DM ¼ diabetes mellitus; LV ¼ left ventricular; MI ¼
myocardial infarction; Prev ¼ previous; PVD ¼ peripheral vascular disease; STEMI ¼ ST-segment elevation myocardial infarction; SYNTAX ¼ Synergy Between
Percutaneous Coronary Intervention With Taxus and Cardiac Surgery; TIA ¼ transient ischemic attack.
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assessed with validation plots. Discrimination was studied
with the concordance (C) index, which is identical to the
area under the receiver-operating characteristic curve. The
C-index estimates the probability that, of two randomly
chosen patients, the patient with the more favorable prog-
nostic score will outlive the patient with the less favorable
prognostic score, and ranges from 0.5 (no discrimination) to
a theoretical maximum of 1.
Clinical usefulness was assessed using decision curve
analyses (26–29). These analyses estimate a “net benefit” for
prediction models that provide individual risk estimates.
Patients are classified as high or low risk at a chosen
threshold value. The net benefit considers the benefit of
the classification (patients correctly classified as dying within
1 year) and the harms (patients wrongly classified as dying
within 1 year). The threshold value for classification is used
in the decision-curve analysis to weigh correctly classified
patients against wrongly classified patients. The references
were that everyone was classified as high risk (i.e., died at
1 year), or that everyone was classified as low risk (i.e., alive
at 1 year). The interpretation of the decision curve is that the
model with the highest net benefit, at a particular threshold
value, is the preferred model.
Results
The incidence of all-cause mortality in the quantitative
coronary angiography–PCI cohort of the ACUITY trial
(n ¼ 2,627) was 2.4% at 1 year (62 deaths). Baseline char-
acteristics are shown in Table 1 (30). The mean age was
60.7 � 11.7 years; 33% were women; 62% of patients pre-
sented with non–ST-segment elevation myocardial infarc-
tion and the remainder with unstable angina. Approximately
85% of patients were implanted with DES, and 14%
implanted with BMS. The median anatomical SYNTAX
score was 9.0 (IQR: 5 to 16) with a maximum value of 59.5.
Approximately 40% of the study population had 3-vessel
disease, and 28.5% had diabetes mellitus.
The univariate associations of the variables in the Core
Model (age, CrCl, LVEF, anatomical SYNTAX score) with
1-year mortality in the ACUITY trial are illustrated in Fig. 2.
Validation of the Logistic Clinical SYNTAX score. CALI-
BRATION. For the anatomical SYNTAX score, a good
agreement was found between observed and predicted
mortality outcomes (Fig. 3). For the Logistic Clinical
SYNTAX score (Fig. 3), the Core Model demonstrated
good agreement between observed and predicted mortality
outcomes at the lower risks, with some underestimation at
the higher risks (>5%). The Extended Model demonstrated
good agreement between observed and predicted mortality
outcomes across all recorded risk ranges.
DISCRIMINATION. The area under the receiver-operating
characteristic curve demonstrated a substantially higher
predictive accuracy of the Core and Extended Models for
1-year all-cause death, compared with the anatomical
SYNTAX score in isolation (Fig. 4).
CLINICAL USEFULNESS. The net benefit of the Core and
Extended Models, and the anatomical SYNTAX score, are
shown on the y-axis on the decision curves (Fig. 5). The net
benefit was highest for the Extended Model across all
potential threshold values of 1-year mortality. This was
followed by the Core Model, and then the anatomical
SYNTAX score.
Table 1. Baseline Characteristics of Patients in the ACUITY Trial
(N ¼ 2,627)
Clinical characteristics
Age, yrs 60.7 � 11.7 (2,627)
Male 67.5 (1,774/2,627)
Diabetes 28.5 (745/2,614)
Insulin-treated diabetes 7.8 (205/2,614)
Hypertension 65.6 (1,718/2,619)
Hyperlipidemia 56.2 (1,454/2,588)
Cerebrovascular event: previous stroke/transient
ischemic attack
5.8 (150/2,604)
Creatinine clearance, ml/min 99.2 � 51.8 (2,458)
History of renal insufficiency 15.5 (381/2,458)
Left ventricular ejection fraction, % 54.5 � 12.0 (2,231)
Current smoker 35.3 (925/2,618)
Previous PCI 44.0 (1,155/2,623)
Anatomical/procedural characteristics
Anatomical SYNTAX score 9.0 (IQR 5.0–16.0)*
3-vessel disease 39.7 (1,043/2,627)
Left anterior descending artery involvement 77.5 (2,036/2,627)
Left circumflex involvement 66.1 (1,737/2,627)
Right coronary artery involvement 73.8 (1,939/2,627)
Left main involvement 0.5 (12/2,627)
Bare-metal stent implantation 14.0 (369/2,627)
Drug-eluting stent implantation: Cypher or Taxusy 84.9 (2,230/2,627)
Cypher (sirolimus-eluting stent) only 46.8 (1,043/2,230)
Taxus (paclitaxel-eluting stent) only 49.6 (1,106/2,230)
Cypher and Taxus 1.6 (35/2,230)
Non–ST-segment elevation ACS characteristics
ST-segment deviation �1 mm 25.4 (667/2,627)
Baseline cardiac biomarker elevation 60.2 (1,470/2,442)
Non–ST-segment elevation myocardial infarction 62.2 (1,467/2,358)
Previous myocardial infarction 29.1 (749/2,576)
TIMI risk score (30)
Low: 0–2 16.2 (345/2,131)
Intermediate: 3–4 59.2 (1,261/2,131)
High: 5–7 24.6 (525/2,131)
Values are mean � SD (N), % (n/N), or median (IQR). *Data not normally distributed. yThe
Cypher stent is manufactured by Cordis (Miami Lakes, Florida) and Taxus is manufactured by
Boston Scientific (Natick, Massachusetts).
ACS ¼ acute coronary syndromes; ACUITY ¼ Acute Catheterization and Urgent Intervention
Triage Strategy; IQR ¼ interquartile range; PCI ¼ percutaneous coronary intervention;
SYNTAX ¼ Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac
Surgery; TIMI ¼ Thrombolysis In Myocardial Infarction.
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Discussion
In this study, the Logistic Clinical SYNTAX score was vali-
dated in a large, prospective, randomized trial of patients with
predominantly moderate- and high-risk non–ST-segment
elevation ACS undergoing PCI (8). These findings indicate
that the Logistic Clinical SYNTAX score is statistically
robust, having previously been cross-validated (“internal-
external” validation procedure [31]) during development in
>6,000 patients in 7 contemporary stent trials (13). The
current study provides further legitimacy toward the clinical
application of the Logistic Clinical SYNTAX score. In
addition, there are several notable findings: 1) In patients
with non–ST-segment elevation ACS, both the Core (age,
CrCl, LVEF, and anatomical SYNTAX score) and Extend-
ed Models (Core Model and additional 6 variables) substan-
tially improved the predictive accuracy of 1-year mortality
predictions, compared with the anatomical SYNTAX score
alone. 2) The Core and ExtendedModels were both shown to
discriminate well in the study population; the Core Model
underestimated mortality predictions in patients at higher
risk (>5%), which the Extended Model corrected for. 3)
Decision-curve analyses, a method to assess clinical useful-
ness, confirmed the progressive improvement in 1-year
mortality predictions over a wide range of thresholds, with the
Extended Model versus the Core Model versus the anatom-
ical SYNTAX score.
One of the main messages of the present study, and of
the previous development and cross-validation study of the
Logistic Clinical SYNTAX score (13), was that the Core
Model was shown to contain most of the predictive infor-
mation for 1-year mortality. The Extended Model, which
incorporates 6 additional clinical variables to the Core
Model, including diabetes and peripheral vascular disease,
yielded only modest incremental improvement for 1-year
mortality predictions. However, the Extended Model proved
to be of additional clinical value in patients with non–ST-
segment elevation ACS in improving the accuracy of higher
risk predictions (>5%), as shown by the validation plots
(Fig. 3). In addition, the decision-curve analyses showed
that the Extended Model provided additional clinical value
compared with the Core Model, by improving the accuracy
of 1-year mortality predictions across all considered risk
threshold values (Fig. 5).
Figure 2. Plots Showing the Form of the Univariate Associations Among the 4 Continuous Core Model Predictors and 1-Year Risk of Death in the ACUITY Trial
Each panel depicts the risk of 1-year death (solid curve)with 95% confidence intervals (dotted curves). A histogram illustrating the distribution of the data for each variable
in the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial is shown below each plot. Due to the rounding of some values of data by the study sites,
for example, left ventricular ejection fraction (often to the nearest 5% or 10%), age (nearest whole integer), or the maximum value being a whole or half point (SYNTAX
[Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery] score), gaps between the values in the histogram for these variables are seen.
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Decision-curve analyses were recently proposed as an
assessment of clinical usefulness and weigh the harms (false
positives) against the benefits (true positives) of using a risk
score to make treatment decisions (27,29). Comparatively,
the C-index is the probability of the correct ordering of risks
(i.e., of 2 randomly chosen patients, the patient with the
lower prognostic score will outlive the patient with the
higher prognostic score), and has previously been suggested
to be insensitive in detecting the clinical value of a risk
prediction score (23,29,32,33). Indeed, in the present study,
only a minor increase in the C-index was observed, when
comparing the Extended and Core Models (C-index:
Extended Model: 0.77, Core Model: 0.74) (Fig. 4).
Nevertheless, as the Core Model retained a substantial
superior ability over the anatomical SYNTAX score in
predicting 1-year mortality, the Core Model can be used
with reasonable accuracy, with the knowledge that the
Extended Model would improve the mortality predictions,
particularly in the higher-risk ranges.
Diabetic patients. The FREEDOM (Future Revasculariza-
tion Evaluation in Patients With Diabetes Mellitus: Optimal
Management of Multivessel Disease) trial has recently re-
ported that diabetics with multivessel disease (predominantly
3- vessel disease, without left main involvement), to confer
a mortality benefit in undergoing coronary artery bypass graft
surgery compared with PCI with DES (34). The present
study provides insights to the potential importance of dia-
betes as a risk factor for PCI. With the Logistic Clinical
SYNTAX score, diabetes added only minor improvement to
the predictive accuracy of the Core Model, as 1 of 6 other
variables in the ExtendedModel. Essentially the CoreModel
captures most of the patient comorbidity, with variables
such as CrCl, and is therefore likely to be a reflection of
the presence of systemic and coronary atherosclerotic
burden. Evidence to support this hypothesis comes from a
population-level cohort study, demonstrating that the rate
of myocardial infarction was substantially higher in nondia-
betics with chronic kidney disease than in diabetics without
chronic kidney disease (35). In addition, a recently published
large meta-analysis demonstrated the importance of kidney
disease as a predictor of clinical outcomes, including mor-
tality, irrespective of the presence or absence of diabetes (36).
Thus, the outcomes for patients with diabetes after PCI may
be favorable if end-organ manifestations of diabetes are not
yet present, such as chronic kidney disease (37).
Study limitations. The ACUITY trial population had rela-
tively low anatomical SYNTAX scores. This is likely to be
representative of real-world practice, because other contem-
porary, all-comer stent trials reported similarmean anatomical
SYNTAX scores to those of the ACUITY trial (17,19–22).
Despite this limitation, 3-vessel disease still represented
approximately 40% of the study population in the ACUITY
Figure 3. Validation Plots
Validation plots, comparing the anatomical SYNTAX score against the Core and Extended Models of the Logistic Clinical SYNTAX score. A histogram illustrating the
distribution of the predicted risks in the ACUITY trial are shown below each plot (scale not shown). The triangles indicate the observed frequencies by quintiles of the
predicted 1-year risk. Abbreviations as in Figures 1 and 2.
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trial. Second, BMS were used in only 14% of the study pop-
ulation, whereas the Logistic Clinical SYNTAX score was
developed and cross-validated in patients undergoing DES
implantation (13). The validation process was rerun in the
ACUITY trial with BMS patients excluded, and the predic-
tive performance of the Logistic Clinical SYNTAX score did
not change (data not shown). Third, because the present
study assessed first-generation DES, we cannot exclude the
possibility of improved mortality with newer generation
DES. In the original development and cross-validation study
of the Logistic Clinical SYNTAX score, composed of 7
contemporary stent trials and >6,000 patients, stent genera-
tion (first against newer generation) was not shown to have an
impact on 1-year mortality (13). Conversely, newer genera-
tion DES have been associated with reductions in definite
stent thrombosis and composite clinical outcomes; however,
improvements in mortality have not been shown (38,39). In
addition, we cannot exclude the possibility of newer genera-
tion antiplatelet therapy to have had an impact on clinical
outcomes (40). Fourth, cardiogenic shock is an important
subset of patients that cannot be assessed with the Logistic
Clinical SYNTAX score, due to under-recruitment of these
patient types in all-comer stent trials, predominantly due to
the inability to gain appropriate informed consent (13,41).
Lastly, we cannot exclude the possibility of the addition of
a functional component to the calculation of the anatomical
SYNTAX score to improve the predictive accuracy of the
Logistic Clinical SYNTAX score (42).
Conclusions
Compared with the anatomical SYNTAX score alone, the
Core and Extended Models of the Logistic Clinical
Figure 4. ROC Curves
Receiver-operating characteristic (ROC) curves for the anatomical SYNTAX
(Synergy Between Percutaneous Coronary Intervention With Taxus and
Cardiac Surgery) score and the Core and Extended Models of the Logistic
Clinical SYNTAX score, predicting 1-year mortality. The combination of vari-
ables in the Core (red) and Extended (green) Models improves the predictive
performance of the Logistic Clinical SYNTAX score for 1-year mortality.
AUC ¼ area under curve; CI ¼ confidence interval(s).
Figure 5. Decision Curves Demonstrating Identification of Patients Who
Will Die, Based on 1-Year Mortality Predictions of Logistic Clinical SYNTAX
Score, Compared With the Anatomical SYNTAX Score
The x-axis shows threshold values for 1-year mortality risk. The clinicianmay use
the threshold to classify patients as high or low risk at a value to proceed with
some action, such as, increased patient monitoring or additional medical
therapy. The y-axis represents the net benefit for the different threshold values
of 1-year mortality risk. The interpretation of the net benefit is in units of true
positives and is the sum of howmany patients are correctly identified to be high
risk (true positive, i.e., died within 1 year) minus a weighted number of patients
incorrectly identified as high risk (false positive, i.e., alive at 1 year). The slanted
gray line represents the classification of all patients as high risk (i.e., died within
1 year); the horizontal line represents the classification of all patients as low risk
(i.e., alive at 1 year), with the latter resulting in a net benefit of 0. The intersection
of the y-axis and the slanted gray line (as highlighted) represents the overall
1-year mortality risk in the ACUITY trial (2.4%). The prediction models that are
the farthest away from the slanted gray line (i.e., assume all died within 1 year)
and the horizontal line (i.e., assume all are alive at 1 year) demonstrate the
highest net benefit, namely the ExtendedModel (broken green line), followed
by the Core Model (broken red line), and then the anatomical SYNTAX score
(broken black line). For example, at a threshold value of 3%, the Extended
Model would correctly identify an extra 1 in 200 deaths, compared with the
anatomical SYNTAX score alone (difference in net benefit is 0.5%). At threshold
values of 5% or 10%, this value would be 1 in 300 (difference in net benefit
0.33%). Abbreviations as in Figures 1 and 2.
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SYNTAX score more accurately predict individual 1-year
mortality in patients presenting with non–ST-segment
elevation ACS undergoing PCI. These findings provide
further legitimacy toward the clinical application of the
Logistic Clinical SYNTAX score.
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APPENDIX
For the logistic regression formula used to predict 1-year death, please see
the online version of this paper.
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Table 1 
Logistic regression formula to predict 1-year Death 
 
Logistic Clinical SYNTAX Score - Core Model: 1-Year Death 
Logit (Death) = -7.5478 + 0.0241 * SYNTAX Score + 0.0396 * age + 0.0748 * (50-
LVEF)+ +0.0235 * (90-CrCl)+ + 0.3649 * SYNTAX-like 
 
Logistic Clinical SYNTAX Score - Extended Model: 1-Year Death 
Logit (Death) = -9.255 + 0.029 * SYNTAX Score + 0.033 * age + 0.050 * (50-LVEF)+ + 
0.023 * (90-CrCl)++ 0.457 * SYNTAX-like + 0.347 * NSTEMI + 0.684* STEMI + 0.051 * 
BMI + 0.358* PVD/Prev TIA or CVA + 0.457* Diabetes + 0.742* DiabInsul + 0.473 * 
PrevMI + 0.465 * CurrSmok 
 
Risk of 1-Year Death = 1/[1+exp(-Logit(Death)] 
 
Key: 
Age       = Age (Years) 
LVEF       = Left ventricular ejection fraction  
CrCl       = Creatinine Clearance (ml/min)  
SYNTAX-like      = SYNTAX Trial Patient  (Yes=1/No=0) 
NSTEMI      = Non ST-elevation myocardial infarction (Yes=1/No=0) 
STEMI       = ST-elevation myocardial infarction (Yes=1/No=0) 
BMI        = Body mass index (kg/m2) 
PVD/Prev TIA or CVA  = Peripheral vascular disease/Previous transient ischaemic          
                                           attack/cerebrovascular accident  (Yes=1/No=0) 
Diabetes       = Diabetes: not insulin treated (Yes=1/No=0) 
DiabInsul       = Diabetes: insulin treated  (Yes=1/No=0) 
PrevMI       = Previous myocardial infarction (Yes=1/No=0) 
CurrSmok      = Current smoker  (Yes=1/No=0) 
(50-LVEF)+      indicates 50-LVEF for positive values, 0 for negative values 
(90-CrCl) +                      indicates 90-CrCl for positive values, 0 for negative values 
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Anatomical and clinical characteristics to guide decision 
making between coronary artery bypass surgery and 
percutaneous coronary intervention for individual patients: 
development and validation of SYNTAX score II
Vasim Farooq*, David van Klaveren*, Ewout W Steyerberg, Emanuele Meliga, Yvonne Vergouwe, Alaide Chieff o, Arie Pieter Kappetein, 
Antonio Colombo, David R Holmes Jr, Michael Mack, Ted Feldman, Marie-Claude Morice, Elisabeth Ståhle, Yoshinobu Onuma; Marie-angèle Morel, 
Hector M Garcia-Garcia, Gerrit Anne van Es, Keith D Dawkins, Friedrich W Mohr, Patrick W Serruys
Summary
Background The anatomical SYNTAX score is advocated in European and US guidelines as an instrument to help 
clinicians decide the optimum revascularisation method in patients with complex coronary artery disease. The 
absence of an individualised approach and of clinical variables to guide decision making between coronary artery 
bypass graft surgery (CABG) and percutaneous coronary intervention (PCI) are limitations of the SYNTAX score. 
SYNTAX score II aimed to overcome these limitations.
Methods SYNTAX score II was developed by applying a Cox proportional hazards model to results of the 
randomised all comers SYNTAX trial (n=1800). Baseline features with strong associations to 4-year mortality in 
either the CABG or the PCI settings (interactions), or in both (predictive accuracy), were added to the anatomical 
SYNTAX score. Comparisons of 4-year mortality predictions between CABG and PCI were made for each patient. 
Discriminatory performance was quantifi ed by concordance statistics and internally validated with bootstrap 
resampling. External validation was done in the multinational all comers DELTA registry (n=2891), a heterogeneous 
population that included patients with three-vessel disease (26%) or complex coronary artery disease (anatomical 
SYNTAX score ≥33, 30%) who underwent CABG or PCI. The SYNTAX trial is registered with ClinicalTrials.gov, 
number NCT00114972.
Findings SYNTAX score II contained eight predictors: anatomical SYNTAX score, age, creatinine clearance, left 
ventricular ejection fraction (LVEF), presence of unprotected left main coronary artery (ULMCA) disease, peripheral 
vascular disease, female sex, and chronic obstructive pulmonary disease (COPD). SYNTAX score II signifi cantly 
predicted a diff erence in 4-year mortality between patients undergoing CABG and those undergoing PCI 
(pinteraction 0·0037). To achieve similar 4-year mortality after CABG or PCI, younger patients, women, and patients with 
reduced LVEF required lower anatomical SYNTAX scores, whereas older patients, patients with ULMCA disease, and 
those with COPD, required higher anatomical SYNTAX scores. Presence of diabetes was not important for decision 
making between CABG and PCI (pinteraction 0·67). SYNTAX score II discriminated well in all patients who underwent 
CABG or PCI, with concordance indices for internal (SYNTAX trial) validation of 0·725 and for external (DELTA 
registry) validation of 0·716, which were substantially higher than for the anatomical SYNTAX score alone 
(concordance indices of 0·567 and 0·612, respectively). A nomogram was constructed that allowed for an accurate 
individualised prediction of 4-year mortality in patients proposing to undergo CABG or PCI.
Interpretation Long-term (4-year) mortality in patients with complex coronary artery disease can be well predicted by 
a combination of anatomical and clinical factors in SYNTAX score II. SYNTAX score II can better guide decision 
making between CABG and PCI than the original anatomical SYNTAX score.
Funding Boston Scientifi c Corporation.
Introduction
The anatomical SYNTAX score is an important instru-
ment that can help clinicians to establish the optimum 
revascularisation approach in patients with complex 
coronary artery disease (with or without unprotected left 
main coronary artery [ULMCA] involvement).1–5 It is 
advocated in both European and US revascularisation 
guidelines.6,7 These guidelines also state that clinical 
variables should be taken into account during discussion 
between multidisciplinary teams consisting of a clinical 
cardiologist, cardiac surgeon, and interventional cardiol-
ogist (the so-called heart team approach) when deciding 
the best treatment method; absence of clinical variables 
is a limitation of the SYNTAX score.
In patients with ULMCA disease, a low-intermediate 
SYNTAX score (<33) was shown to have much the same 
long-term clinical outcomes—including all-cause mor-
tality and major cardiovascular and cerebrovascular 
Lancet 2013; 381: 639–50
See Comment page 605
See Articles page 629
*Contributed equally
Thoraxcenter (V Farooq MBChB, 
Y Onuma MD, 
H M Garcia-Garcia MD, 
Prof P W Serruys MD), 
Department of Public Health 
(D van Klaveren MSc, 
Prof E W Steyerberg PhD, 
Y Vergouwe PhD), and 
Department of Cardiothoracic 
Surgery (Prof A P Kappetein MD) 
Erasmus University Medical 
Center, Rotterdam, 
Netherlands; AO Ordine 
Mauriziano Umberto I, Turin, 
Italy (E Meliga MD); 
San Raff aele Scientifi c 
Institute, Milan, Italy 
(A Chieff o MD, A Colombo MD); 
Mayo Clinic, Rochester, MN, 
USA (Prof D R Holmes Jr MD); 
Heart Hospital Baylor Plano, 
Baylor Healthcare System, 
Dallas, TX, USA (M Mack MD); 
Evanston Hospital, Evanston, 
IL, USA (Prof T Feldman MD); 
Hôpital Privé Jacques Cartier, 
Massy, France (M-C Morice MD); 
University Hospital Uppsala, 
Uppsala, Sweden 
(Prof E Ståhle MD); Cardialysis, 
Rotterdam, Netherlands 
(M-A Morel BSc, 
H M Garcia-Garcia MD, 
G A van Es PhD); Boston 
Scientifi c Corporation, Natick, 
MA, USA (K D Dawkins MD); and 
Herzzentrum Universität 
Leipzig, Leipzig, Germany 
(Prof F W Mohr MD)
Correspondence to:
Prof Patrick W Serruys, Erasmus 
University Medical Centre, 
3015 CE Rotterdam, Netherlands
p.w.j.c.serruys@erasmusmc.nl
For the SYNTAX score see 
http://www.syntaxscore.com
328 Chapter 8.4
Articles
640 www.thelancet.com   Vol 381   February 23, 2013
events—with coronary artery bypass graft sur gery 
(CABG) and percutaneous coronary intervention (PCI) 
in the SYNTAX trial.1,4,8 This fi nding formed the basis for 
the US Food and Drug Administration’s decision to 
accept a SYNTAX score of less than 33 as an entry 
criterion to the ongoing international multicentre EXCEL 
(Evaluation of XIENCE prime versus Coronary artery 
bypass surgery for Eff ectiveness of Left main revas-
cularisation) trial, aiming to recruit 2600 patients with 
ULMCA disease (NCT01205776).9
In patients with three-vessel disease, a low SYNTAX 
score (<23) was shown to have much the same long-term 
clinical outcomes between CABG and PCI in the 
SYNTAX trial.1,8 A substudy of the SYNTAX trial10 has, 
however, suggested that patients with high clinical 
comorbidity (ie, additive EuroSCORE11 ≥6) with three-
vessel disease, irrespective of the anatomical complexity 
(SYNTAX score), might potentially derive a prognostic 
benefi t from undergoing CABG compared with PCI, 
provided an acceptable threshold of operative risk is not 
exceeded. Some researchers have therefore suggested 
that the SYNTAX score, and other category-based 
scores10,12–15 that labelled patients as low risk, intermediate 
risk, or high risk might be concealing higher risk patients 
in lower risk groups, or vice versa.
The purpose of our study was to augment the SYNTAX 
score with prognostically important clinical variables to 
form SYNTAX score II, to better guide decision making 
between CABG and PCI. Additionally, SYNTAX score II 
should provide the basis for individualised decision 
making between CABG and PCI, by contrast with the 
present strategy of grouping (low, intermediate, or high) 
risk to patients.
Methods
SYNTAX trial
The SYNTAX trial was a randomised, prospective, multi-
centre trial (85 centres in 18 countries) with an allcomers 
design.1,5,8 Exclusion criteria were minimal and consisted 
of previous coronary revascularisation, concomitant 
cardiac surgery (valve or resection of aortic or left 
ventricular aneurysm) or acute myocardial in farction, 
and cardiac enzymes more than twice as high as the 
normal limit. Patients with ULMCA disease (isolated or 
associated with one-vessel, two-vessel, or three-vessel 
disease) or de-novo three-vessel disease were randomised 
on a 1:1 basis to CABG or PCI with TAXUS Express 
paclitaxel-eluting stent (Boston Scien tifi c Corporation, 
Natick, MA, USA; n=1800). Random isation of patients 
was stratifi ed by clinical site, absence or presence of 
ULMCA disease, and medically treated diabetes (requir-
ing oral medications or insulin). Patients deemed 
unsuitable for randomisation by the cardiologist were 
nested in registries. An independent clinical events 
committee reviewed all primary clinical endpoints.1
The anatomical SYNTAX score1–3 combines the impor-
tance of a diseased coronary artery segment by vessel-
segment weighting (Leaman score), adverse lesion 
charac teristics (American College of Cardiology/American 
Heart Asso ciation lesion classifi cation, and total occlusion 
charac teristics from the European TOTAL Surveillance 
Study), and the Medina classifi  cation system for bifur-
cation lesions.14,16–18 Calculation of antomical SYNTAX 
score was done by the heart team before randomisation, 
and corroborated by an independent core laboratory 
(Cardialysis BV, Rotterdam, Netherlands), blinded to treat-
ment assign ment. Clinical variables were also prospec-
tively collected as part of the original SYNTAX trial.1 
Chronic obstructive pulmonary disease (COPD) was 
defi ned as the long-term use of bronchodilators or steroids 
for lung disease (EuroSCORE defi nition11). Peripheral 
vascular disease was defi ned as aorta and arteries other 
than coronaries, with exercise-related claudication, or 
revascularisation surgery, or reduced or absent pulsation, 
or angiographic stenosis of more than 50%, or com-
binations of these characteristics (Arterial Revascular-
isation Therapies Study Part I [ARTS I] defi nition19). 
Pre procedural left ventricular ejection fraction (LVEF) was 
taken by trans thoracic echo cardiography or diagnostic left 
ventricul ography, and categorised as good (≥50%), 
moderate (30–49%), or poor (<30%). Creatinine clearance, 
a measure of estimated glomerular fi ltration rate, was 
defi ned by the Cockcroft and Gault formula.20
Within the SYNTAX trial, most predictor values were 
more than 98% complete. Creatinine clearance was 91% 
complete, LVEF was 98·4% complete when recorded 
categorically (good, moderate, and poor) and 62·6% 
complete when recorded continuously (numerical value). 
An advanced multiple imputation strategy, which takes 
the correlation between all potential predictors (method 
of chained equations [Hmisc package version 3.8-3, in 
R software version 2.13.2]), and sensitivity analyses were 
done to account for missing values.21,22 For the multiple 
imputation of missing values of the continuous variable 
LVEF, categories of LVEF were additionally considered. 
All analyses were done for the imputed datasets, and 
repeated with only complete data, which gave much the 
same results. The SYNTAX trial is registered with 
ClinicalTrials.gov, number NCT00114972.
SYNTAX score II
Combination of anatomical SYNTAX score with three 
simple clinical variables (age, creatinine or creatinine 
clearance, LVEF) has been shown to contain most of the 
prognostic in formation in predicting mortality after PCI 
(including the SYNTAX score—logistic clinical SYNTAX 
score23) or CABG (excluding the SYNTAX score—ACEF 
score24,25). Consequently, we developed SYNTAX score II 
on the basis of a core model consisting of anatomical 
SYNTAX score, age, creatinine clearance, and LVEF. 
Other common independent predictors of mortality, 
using the baseline characteristics of the CABG and PCI 
cohorts of the SYNTAX trial, were screened and identifi ed 
with a multivariable Cox proportional hazards model 
329Chapter 8.4
Articles
www.thelancet.com   Vol 381   February 23, 2013 641
(appen dix), the fi ndings of which have been reported.24 
As a result, we added peripheral vascular disease to the 
core model. Notably, medically treated diabetes—despite 
being stratifi ed at randomisation in the SYNTAX trial5 
and reported in 26% of patients—was not added to the 
core model, because it was shown not to be an 
independent predictor of mortality in the CABG and PCI 
groups of the SYNTAX trial.24
The SYNTAX score aids decision making between 
CABG and PCI; it is more predictive of clinical 
outcomes in patients undergoing PCI than in those 
undergoing CABG, for whom it is not predictive.2,10 
This discrepancy means that the SYNTAX score has a 
signifi cant interaction eff ect25 with CABG and PCI in 
establishing long-term mortality. Interaction for a 
particular baseline characteristic was defi ned as the 
hazard ratio (HR) of mortality associated with that 
characteristic among patients undergoing PCI (HRPCI), 
divided by the HR for the same characteristic among 
patients undergoing CABG (HRCABG)—ie, HRPCI/HRCABG. 
Consistent with this principle, we screened baseline 
characteristics (appen dix), and added variables to the 
core model when they showed an interaction between 
CABG and PCI (p<0·10) in aff ecting 4-year mortality, 
using a multivariable Cox proportional hazards model. 
To aid visualisation of the interaction eff ects, we 
constructed graphs by plotting the log HR for 4-year 
mortality (CABG and PCI) on the y axis, and the 
predictors on the x axis.
Since the SYNTAX trial data originated from 18 coun-
tries, we assessed whether between-country hetero geneity 
existed using gamma frailty in the Cox pro por tional 
hazards model.26 Between-country hetero geneity had a 
negligible eff ect on parameter estimates (data not shown). 
Consequently we present pooled country results.
We constructed scatter plots to visualise how the 
SYNTAX score II predicted long-term mortality in each 
individual patient from the CABG and PCI cohorts of the 
SYNTAX trial (n=1800). On the basis of the Cox 
proportional hazards model parameter estimates, we 
made individual risk predictions for each patient as if 
they had undergone CABG or PCI. The predicted hazards 
(relative to the average predicted hazard) for CABG 
versus PCI were plotted. We used a log scale to allow for 
good separation of individual predicted risks. Bootstrap 
analyses (1000 resamples with replacement) were done to 
assess whether individual predictions for CABG were 
either higher or lower compared with the predictions for 
PCI with 95% confi dence (p<0·05), and are highlighted 
in the scatter plots.22 Similar scatter plots were produced 
for the SYNTAX score tertiles2 and clinical variables in 
SYNTAX score II to allow judgment of their collective 
eff ect on long-term mortality predictions.
We did reclassifi cation analyses (ie, what proportion of 
patients moved from high to low risk, and from low to 
high risk) following the principles of Net Reclassifi cation 
Improvement.27 The proportion of patients reclassifi ed 
was calculated with bootstrap analyses (1000 resamples), 
and are represented in the scatter plots.
External validation of SYNTAX score II
External validation was done in the Drug Eluting stent 
for LefT main coronary Artery disease (DELTA) registry.28 
Briefl y, this is a multinational (14 centres in Europe, the 
USA, and South Korea), non-randomised, allcomers 
registry (n=2891) of ULMCA disease (isolated, or asso-
ciated with single or multivessel disease) treated with 
CABG (n=902, 31·2%) or fi rst generation sirolimus-
eluting or paclitaxel-eluting stents (n=1989, 68·8%). 
SYNTAX scores of 33 or more were reported in 30% 
(n=871) of the study population and three-vessel disease 
in 26% (n=744). Previous CABG or PCI was permitted. 
Follow-up was similar to the SYNTAX trial, with a 
median period of 3·5 years (IQR 2·5–4·6 years). Data 
were reported by the study sites in 2039 of 2891 (70·5%) 
patients for the SYNTAX score, 2785 (96·3%) for age, 
2891 (100%) for creatinine (categorical variable [above 
150 μmol/L]) and sex, 2747 (95·0%) for LVEF (continuous 
variable), 1363 (47·1%) for peripheral vascular disease, 
and 1061 (36·7%) for COPD. Because renal function 
was collected categorically in the DELTA registry, 
median renal function from the SYNTAX trial data, with 
or without a creatinine concentration above 150 μmol/L, 
was used to replace creatinine with a continuous 
variable. Since renal function had only a weak inter-
action eff ect in aff ecting mortality between CABG and 
PCI, this ap proach was judged to be acceptable. Multiple 
imputation of missing values and sensitivity analyses, 
identical to that described earlier, yielded much the 
same results for the complete dataset. Specifi cally, 
sensitivity ana lyses21,22,29 testing the robust ness of the 
interaction eff ects for COPD and peripheral vascular 
disease gave similar results.
SYNTAX score II assessments
The most important aspects of the SYNTAX score II are 
the interaction eff ects, since they drive decision making 
between CABG and PCI. Other measures are needed to 
ensure the accuracy of individual mortality predictions 
for CABG and PCI, and the magnitude of their 
diff erences (eg, 10% vs 5% or 2% vs 1% predicted risks 
for CABG and PCI), which will further support decision 
making. These measures include discrimination with 
the concordance index, and calibration (agreement 
between predicted and observed risks) with validation 
plots. The concordance index estimates the probability 
that, of two randomly chosen patients, the patient with 
the higher prognostic score will outlive the one with the 
lower prognostic score.25 Values of the concor-
dance index range from 0·5 (no discrimination) to a 
theoretical maximum of 1. The concordance index 
was internally validated with a bootstrap procedure 
(100 resamples with replacement) to correct for opti-
mism in parameter estimates.22
See Online for appendix
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SYNTAX score II presentation
We present SYNTAX score II as a nomogram, with scores 
assigned for the presence and magnitude of each 
predictor directly based on the Cox proportional hazards 
model coeffi  cients.22 All statistical analyses were done 
with Harrell’s Regression Modelling Strategies (rms 
version 3.4-0) package in R software (version 2.13.2).21,30,31
Role of the funding source
SYNTAX trial design and conduct was overseen by the 
SYNTAX steering committee, on which representatives 
of the study sponsor served. Data analysis and inter-
pretation and writing of the report were independent 
from the study sponsor. The authors had unrestricted 
access to the full study database. PWS and EWS took 
the fi nal responsibility for the decision to submit 
for publication.
Results
In the randomised SYNTAX population (n=1800), base-
line demographics and clinical characteristics for the 
CABG (n=897) and PCI (n=903) groups were well 
balanced and have been described previously (appendix).1 
At 4-years follow-up, clinical data were available in 819 of 
897 patients in the CABG group and 879 of 903 patients 
in the PCI group. 178 all-cause deaths were recorded 
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Figure 1: Predictor eff ects for CABG and PCI in SYNTAX score II
Predictor eff ects are represented visually as a log HR for CABG and PCI on the y-axis for each predictor. Each predictor is expressed on the x-axis continuously 
(upper panels) or categorically (lower panels), for a person of mean baseline characteristics. Diabetes is included to show its absence of interaction when included in 
the analyses. Note the diff ering gradients of the hazards for PCI and CABG, leading to the hazards crossing at an anatomical SYNTAX score of 15. At this cross-over 
point of hazards, the mortality risk is much the same between CABG and PCI. This threshold of cross-over of hazards will vary according to the level of other variables, 
namely being lower for female sex, reduced LVEF, and younger age, and higher for COPD, left main disease, and older age. Because both peripheral vascular disease 
(p=1·00) and diabetes (p=0·67) lacked an interaction eff ect, as shown by almost parallel HRs (ie, similar increase in mortality risk), their presence would have no eff ect 
on decision making between CABG and PCI. Since diabetes was also not an independent predictor of mortality (appendix),24 it was excluded from SYNTAX score II. 
CABG=coronary artery bypass surgery. PCI=percutaneous coronary intervention. HR=hazard ratio. CrCl=creatinine clearance. LVEF=left ventricular ejection fraction. 
Left main=unprotected left main coronary artery disease. 3VD=three-vessel disease. LMS=left main stem. COPD=chronic obstructive pulmonary disease. 
PVD=peripheral vascular disease.
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(CABG 9·0%, 74 all-cause deaths; PCI 11·8%, 104 all-
cause deaths, log rank p value=0·063).
The fi nal developed SYNTAX score II consisted of two 
anatomical (SYNTAX score and ULMCA disease) and six 
clinical variables (age, creatinine clearance, LVEF, sex, 
COPD, and peripheral vascular disease). The interaction 
eff ect of the SYNTAX score II in collectively aff ecting 
long-term mortality predictions between CABG and PCI 
was signifi cant (pinteraction=0·0037). Figure 1 shows the 
interaction eff ects of the eight SYNTAX score II variables. 
Six of the eight SYNTAX score II variables—anatomical 
SYNTAX score, age, LVEF, ULMCA disease, COPD, and 
female sex—showed a moderate to strong interaction 
eff ect in aff ecting long-term mortality predictions with 
CABG and PCI (pinteraction<0·10; table). Creatinine clear-
ance (pinteraction=0·30) and peripheral vascular disease 
(pinteraction=1·00) showed weak or negli gible interaction 
eff ects. Diabetes was not included in the SYNTAX score 
II because it was not an independent predictor of 
mortality24 and did not have an interaction eff ect (p=0·67) 
with CABG and PCI for long-term mortality (fi gure 1).
Figure 2 shows scatter plots for individual patients in 
the left main cohort and three-vessel disease cohort of 
the SYNTAX trial, and by tertiles of the anatomical 
SYNTAX score. Individual predictions plotted to the left 
of the diagonal line favoured CABG, and to the right 
favoured PCI. Individual predictions for CABG and 
PCI that could not be separated with 95% confi dence 
(ie, p>0·05) are highlighted in grey, and had a similar 
4-year mortality in the SYNTAX trial (ie, could not be 
statistically separated).
For the left main cohort, on the basis of the numerical 
values of the mortality predictions, CABG was favoured 
in 50·1% (353) and PCI in 49·9% (352) of the SYNTAX 
population (fi gure 2). 62·8% (140) of patients in the low 
(0–22) SYNTAX score tertile, 61·7% (121) in the inter-
mediate (23–32) tertile, and 31·8% (91) in the high (>32) 
tertile had numerically lower 4-year mortality predictions 
for PCI compared with CABG. In 79·7% (562) of patients, 
4-year mortality predictions between CABG and PCI 
could not be signifi cantly separated (p>0·05). 18·8% (42) 
of patients in the low SYNTAX score tertile had mor-
tality predictions separated with statistical signifi cance 
(p<0·05) in favour of PCI, and 19·2% (55) of patients in 
the high SYNTAX score tertile, had statistically sig-
nifi cant mortality predictions in favour of CABG.
For the three-vessel disease cohort, on the basis of the 
numerical values of the mortality predictions, CABG was 
favoured in 84·2% (922) and PCI in 15·8% (173) of the 
SYNTAX population (fi gure 2). 29·1% (103) of patients in 
the low SYNTAX score tertile (0–22), 12·9% (54) in the 
intermediate tertile (23–32), and 5·0% (16) in the high 
tertile (>32) had numerically lower 4-year mortality 
predictions for PCI compared with CABG. In 58·8% 
(643) of patients, 4-year mortality predictions between 
CABG and PCI could not be signifi cantly separated 
(p>0·05); an eff ect that was more prevalent in the low to 
indeterminate SYNTAX score tertiles (0–32). In the high 
Multivariable adjusted HR (95% CI) Interaction eff ect (HRPCI/HRCABG); 
HR (95% CI; p value)
CABG 4-year mortality PCI 4-year mortality
Development population , SYNTAX trial (n=1800)
Anatomical SYNTAX score (per 10 point increase) 0·97 (0·79–1·18) 1·27 (1·08–1·50) 1·32 (1·01–1·71; p=0·039)
Age (per 10 year increase) 1·88 (1·34–2·64) 1·29 (0·97–1·71) 0·69 (0·44–1·07; p=0·095)
Creatinine clearance† (per 10 mL/min increase) 0·91 (0·77–1·07) 0·82 (0·72–0·93) 0·89 (0·73–1·10; p=0·30)
LVEF (per 10% increase) 0·84 (0·61–1·16) 0·56 (0·43–0·73) 0·67 (0·44–1·00; p=0·053)
Peripheral vascular disease* 2·79 (1·66–4·71) 2·79 (1·72–4·53) 1·00 (0·49–2·04; p=1·00)
ULMCA disease 1·47 (0·93–2·34) 0·82 (0·54–1·23) 0·56 (0·30–1·03; p=0·062)
Women 0·59 (0·32–1·10) 1·70 (1·11–2·60) 2·87 (1·35–6·07; p=0·0059)
COPD 2·84 (1·64–4·90) 1·35 (0·74–2·47) 0·48 (0·21–1·08; p=0·074)
External validation population, DELTA registry (n=2891)
Anatomical SYNTAX score (per 10 point increase) 1·12 (0·95–1·32) 1·32 (1·20–1·46) 1·18 (0·98–1·42; p=0·083)
Age (per 10 year increase) 1·46 (1·15–1·85) 1·34 (1·19–1·52) 0·92 (0·70–1·21; p=0·56)
Creatinine clearance (per 10 mL/min increase) 0·91 (0·78–1·06) 0·93 (0·86–1·00) 1·02 (0·86–1·21; p=0·82)
LVEF (per 10% increase) 0·59 (0·47–0·75) 0·57 (0·50–0·65) 0·96 (0·72–1·27; p=0·75)
Peripheral vascular disease 1·37 (0·68–2·79) 1·77 (1·01–3·09) 1·29 (0·51–3·22; p=0·59)
Women 0·52 (0·31–0·87) 1·09 (0·82–1·46) 2·09 (1·16–3·76; p=0·014)
COPD 3·63 (1·31–10·04) 1·97 (0·88–4·42) 0·54 (0·20–1·47; p=0·23)
Hazard ratios (HR) in a multivariable Cox proportional hazards model for SYNTAX score II are shown for the CABG and PCI cohorts, followed by the interaction eff ects 
(HRPCI/HRCABG) in aff ecting long-term mortality between CABG and PCI. CABG=coronary artery bypass graft. PCI=percutaneous coronary intervention. HR=hazard ratio. 
ULMCA=unprotected left main coronary artery. LVEF=left ventricular ejection fraction. COPD=chronic obstructive pulmonary disease. *Retained in SYNTAX score II to 
improve the predictive accuracy (discrimination) of the 4-year mortality predictions in the CABG and PCI cohorts.
Table: Development (SYNTAX Trial) and validation (DELTA Registry) data for SYNTAX score II
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Figure 2: Mortality predictions for CABG versus PCI for each individual patient in the randomised SYNTAX trial
The SYNTAX trial included 1800 participants, separated into LMS cohort and 3VD cohort (upper panels), and by tertiles of the anatomical SYNTAX score (lower 
panels). The diagonal line represents identical mortality predictions for CABG and PCI. Individual predictions plotted to the left of the diagonal line favour CABG 
(actual percentages shown in top left corner), and to the right favour PCI (actual percentages shown in bottom right corner). Individual mortality predictions for 
CABG or PCI that could be separated with 95% confi dence (p<0·05) are coloured black (actual percentage shown in parentheses in respective corners). Mortality 
predictions that could not be separated with 95% confi dence (p>0·05) are highlighted in grey, and identify patients with similar 4-year mortality. Percentages of 
patients in each category are shown. CABG=coronary artery bypass surgery. PCI=percutaneous coronary intervention. LMS=left main stem. 3VD=three-vessel disease.
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SYNTAX score tertile (>32), 68·1% (220) of patients had 
mortality predictions separated with statistical signifi -
cance (p<0·05) in favour of CABG.
Figure 3 displays scatter plots showing how the ana-
tomical SYNTAX score, presence of ULMCA disease, and 
clinical variables (tertiles of age, sex, COPD, poor LVEF 
[<30%]) collectively aff ect 4-year mortality predic tions. On 
the basis of the crossing of interaction eff ects between 
CABG and PCI for the anatomical SYNTAX score shown 
in fi gure 1, the presence of specifi c characteristics of 
patients altered the threshold value of the anatomical 
SYNTAX score at which CABG and PCI had much the 
same 4-year mortality. Younger age, female sex, and 
reduced LVEF favoured CABG compared with PCI. Thus, 
in patients with these characteristics, a lower anatomical 
SYNTAX score (compared with the rest of the population) 
would be required for the long-term mortality risk to be 
similar between CABG and PCI. By contrast, older age, 
COPD, or ULMCA disease favoured PCI compared with 
CABG and thus, in patients with these characteristics, a 
higher anatomical SYNTAX score (compared with the rest 
of the population) would be needed for the long-term 
mortality risks to be similar. These eff ects were more 
prominent in the low-intermediate SYNTAX score tertiles 
(0–32) than in the high tertile (>32).
On the basis of comparisons of interaction eff ects 
(HRPCI/HRCABG), and therefore decision making between 
CABG and PCI, all variables in the SYNTAX score II 
interacted in much the same way in the SYNTAX trial 
and DELTA registry, with the exception of age and LVEF, 
which had minimal interactions in the DELTA registry. 
SYNTAX score II discriminated well in all patients who 
underwent either CABG or PCI, with an internally 
(SYNTAX trial) validated concordance-index of 0·725 and 
an externally (DELTA registry) validated concordance-
index of 0·716, which were substantially higher than for 
SYNTAX score alone (internal concordance index 0·567, 
external concordance index 0·612). The SYNTAX score II 
was well calibrated (ie, a good agreement between 
predicted and actual risks) on validation plots in the 
SYNTAX trial and DELTA registry (appendix). Analyses 
in the stratum of patients with three-vessel disease (26% 
of the DELTA registry) yielded much the same results, 
with a con cordance index for the SYNTAX score II of 
0·763, and good calibration (expected 4-year survival 
88·2%, actual 4-year survival 86·2%).
A nomogram for the bedside application of the 
SYNTAX score II is detailed in fi gure 4. The nomogram 
can be used to obtain long-term mortality predictions for 
individual patients proposing to undergo CABG or PCI.
Discussion
The main fi ndings of this study are: fi rst, that a per-
sonalised, individual assessment of long-term mortality 
was achievable for patients with complex coronary artery 
disease (ULMCA or de-novo three-vessel disease) 
proposing to undergo CABG or PCI; second, that in 
Figures 3: Collective eff ect of SYNTAX score and other anatomical and clinical variables on mortality predictions
LMS cohort (A) 3VD cohort (B). Scatter plots are for illustrative purposes only. CABG=coronary artery bypass 
surgery. PCI=percutaneous coronary intervention. LMS=left main stem. 3VD=three-vessel disease.
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addition to the anatomical SYNTAX score, other factors 
had a direct eff ect on decision making between CABG 
and PCI, requiring lower (younger age, female sex, lower 
LVEF) and higher (older age, COPD, ULMCA disease) 
SYNTAX scores to achieve similar 4-year mortality, 
fi ndings that were validated in the DELTA registry, with 
the exception of age and LVEF; third, the presence of 
diabetes in itself was shown not to be important for 
decision making between CABG and PCI; fourth, that 
the SYNTAX score II clearly identifi ed patients for whom 
either CABG or PCI had a more favourable long-term 
outlook, and patients for whom long-term outlooks 
between CABG and PCI were much the same; and fi fth, 
that the individualised approach of the SYNTAX score II, 
using anatomical and clinical variables that directly 
improved decision making between CABG and PCI, was 
more useful than the anatomical SYNTAX score (panel).
During development of SYNTAX score II, we sug-
gested and then showed that the low, intermediate, 
and high categories of anatomical complexity in the 
SYNTAX score were concealing lower risk patients in 
the higher SYNTAX score groups, and vice versa. This 
principle is well established in epidemiological litera-
ture, and necessitates careful reclassifi cation analyses 
to ensure that patients with high or low risk are appro-
priately recategorised.22,27,37 With the individualised 
approach of SYNTAX score II, a subset of patients 
with low (<23), intermediate (23–32), or high (>32) 
anatomical SYNTAX scores were objectively identifi ed, 
that would have lower, similar, or higher 4-year 
mortality predictions for CABG or PCI. Importantly, 
these fi ndings were validated in the DELTA registry.28
Additionally, the present study shows the important 
principle of combination of anatomical and clinical 
variables, which interact with CABG and PCI to aff ect 
4-year mortality (ie, are more predictive of mortality in 
one or the other revascularisation methods), and 
therefore drive decision making between CABG and 
PCI. The presence of ULMCA disease drove mortality 
predictions in favour of PCI, requiring higher anatomical 
SYNTAX scores among PCI patients to achieve similarity 
in long-term prognosis between CABG and PCI. The 
main explanation for this fi nding is that a sizeable 
proportion of the SYNTAX score can be attributed to the 
presence of the left main disease. Conversely, in patients 
with three-vessel disease and no left main involve ment, 
the SYNTAX score would represent more complex 
downstream coronary anatomical disease, compared 
with a left main patient with an identical anatomical 
SYNTAX score, and therefore patients with three-vessel 
disease would derive a greater prognostic benefi t in 
undergoing CABG.9,10
Notably, diabetes was not a useful variable in the 
SYNTAX score II, despite medically treated diabetes being 
stratifi ed at randomisation in the SYNTAX trial and 
reported in more than a quarter of patients. Several 
reasons might explain this apparent paradox. First, 
diabetes in itself did not produce an interaction eff ect in 
aff ecting long-term mortality between CABG and PCI 
(fi gure 1). Second, diabetes is a metabolic, systemic 
disorder, the severity and duration of which has a specifi c 
eff ect on organs such as the heart, detected by complex 
coronary anatomy (anatomical SYNTAX score) and LVEF; 
Figure 4: SYNTAX Score II nomogram for bedside application
Total number of points for 8 factors can be used to accurately predict 4-year mortality for the individual patient 
proposing to undergo for CABG or PCI. For example, a 60 year old man with an anatomical SYNTAX score of 30, 
unprotected left main coronary artery disease, creatinine clearance of 60 mL/min, an LVEF of 50%, and COPD, would 
have 41 points (predicted 4-year mortality 16·3%) to undergo CABG and 33 points (predicted 4-year mortality 
8·7%) to undergo PCI respectively. The same example without COPD included would lead to identical points 
(29 points) and 4-year mortality predictions (6·3%) for CABG and PCI. COPD defi ned with EuroSCORE11 defi nition, 
long-term use of bronchodilators or steroids for lung disease. PVD defi ned according to ARTS I19 defi nition, aorta 
and arteries other than coronaries, with exercise-related claudication, or revascularisation surgery, or reduced or 
absent pulsation, or angiographic stenosis of more than 50%, or combinations of these characteristics. 
CABG=coronary artery bypass surgery. PCI=percutaneous coronary intervention. CrCl=creatinine clearance. 
LVEF=left ventricular ejection fraction. Left main=unprotected left main coronary artery disease. 3VD=three-vessel 
disease. COPD=chronic obstructive pulmonary disease. PVD=peripheral vascular disease. *Because of the rarity of 
complex coronary artery disease in premenopausal women, mortality predictions in younger women are 
predominantly based on the linear relation of age with mortality. The diff erences in mortality predictions in younger 
women between CABG and PCI will therefore be aff ected by larger 95% CIs than those in older women.
0 20 40 60 80 100
0
20
40
60
80
100
4-
ye
ar
 m
or
ta
lit
y 
(%
)
Total points
0·6% 1·3%
3%
6·8%
15·1%
31·5%
58·4%
SYNTAX score
0+
40 50 60 70 80 40 50 60
403020100 50 60
70 80
Age (years)
90 60 30 90 60 30
CrCl (mL/min)
50 40 30 20 50 40 30 20
LVEF (%)
Left main
0
1
1
0
Sex*
F
M
M
F
COPD
0
1
0
1
PVD
0
1
0
1
Points
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30
CABG PCI
335Chapter 8.4
Articles
www.thelancet.com   Vol 381   February 23, 2013 647
the brain, detected by the presence of peripheral vascular 
disease, a sign of systemic atherosclerosis; kidney 
function, de tected by the creatinine clearance; and age, 
older patients are representative of a longer duration of 
diabetes and its consequent multiorgan eff ect. The risk 
factors in the SYNTAX score II (predominantly the core 
model: SYNTAX score, age, creatinine clearance, and 
LVEF) are the dimensions that are relevant for the outlook 
for the patient, and are why diabetes falls out of the 
multivariable model. Although diabetes is the common 
denominator, it cannot be regarded as the one, direct, 
causative factor, in view of the many other risk factors 
associated with coronary artery disease, such as hyper-
cholesterolaemia and hypertension. These fi ndings are 
exemplifi ed by diabetes previously being shown not to be 
an inde pendent predictor of mortality in the CABG and 
PCI groups of the SYNTAX trial,24 and in a pooled analysis 
of seven contemporary stent trials (n>6000), after SYNTAX 
score, age, creatinine clearance, and LVEF were accounted 
for.23 Additionally, a large population-based cohort study 
and meta-analysis involving 128 505 indi viduals with 
diabetes showed that individuals without diabetes but 
with chronic kidney disease and proteinuria had a stronger 
association with the risk of myocardial infarction, and a 
higher rate of mortality, compared with those with 
diabetes,38 and that the relative risk of long-term mortality 
associated with chronic kidney disease was “much the 
same irrespective of the presence or absence of diabetes.”39 
Third, two meta-analyses of ran domised controlled 
trials40,41 comparing CABG against PCI before drug-eluting 
stents were available (balloon angioplasty or bare metal 
stents) have shown a survival advantage for individuals 
with diabetes undergoing CABG (compared with PCI) at 
4 years (but not at 6·5 years) in one study,40 and at a 
median follow up of 5·9 years in the other study.41 
Importantly, signifi cant selection bias in recruiting 
patients before randomisation occurred in most of these 
studies (eg, 2–12% of screened patients were randomised 
in most studies), whereas in the SYNTAX trial, selection 
of patients was mandated to be allcomers to overcome 
these issues. Furthermore, in these two meta-analyses,40,41 
most patients had sub stantially less complex coronary 
artery disease compared with those in the SYNTAX trial, 
with single or double vessel disease occurring in almost 
two-thirds41 of patients (without left main involvement). 
Consequently, most of these patients probably would have 
had anatomical SYNTAX scores that lay below the cross-
over point of 15 for the hazards for CABG and PCI 
(fi gure 1) in the present study.
Since drug-eluting stents became available, the 
FREEDOM Trial (n=1900)42 has shown a mortality benefi t 
for CABG compared with drug-eluting stents in 
individuals with diabetes with predominantly three-
vessel disease (without left main involvement) at a 
median follow-up of 3·8 years (minimum 2 years). 
Notably, FREEDOM showed an apparent absence of 
association of SYNTAX score with 5-year mortality. 
However, these analyses were underpowered to assess 
anatomical SYNTAX score, since the numbers at 5 year 
follow-up were less than a quarter (n=440) of the study 
population. Therefore, a signifi cant subset of lower risk 
patients might exist in FREEDOM, and in other reported 
studies examining multivessel disease (ASCERT 
registry43), in whom CABG and PCI would have much 
the same long-term clinical outcomes.
Female sex was shown to have a signifi cant interaction 
eff ect in the development (SYNTAX trial) and validation 
(DELTA registry) populations, requiring lower anatom-
ical SYNTAX scores for women to achieve similar long-
term mortality after CABG or PCI. Notably, female sex 
was recently reported to be an independent predictor of 
long-term mortality in the PCI group of the SYNTAX 
trial, despite adjustment for risk factors,24 and contrary to 
reported scientifi c literature.44,45 The main hypotheses put 
forward were that women in the SYNTAX trial 
had substantially higher anatomical SYNTAX scores 
(mean 26·5, SD 11·9), and therefore plaque burden, 
compared with contemporary stent trials (12·9, 8·4),45 
and that the plaque burden might be associated with 
more unfavour able plaque composition.24,46 Another 
perspective is that, because women with complex 
coronary artery disease are more likely to have greater 
clinical comorbidity,44 then a lower anatomical SYNTAX 
score is needed for women to achieve similar long-term 
mortality between CABG and PCI, as shown by the 
interaction analyses (fi gure 1).
SYNTAX score II provides an impartial, evidence-based 
assessment47 of the decision making process for clinicians 
weighing anatomical and clinical factors to establish the 
optimum revascularisation technique for individual 
patients with complex coronary artery disease. Such an 
instrument might help to more clearly and objectively 
defi ne the often uncertain line that separates patients for 
whom PCI or CABG should be considered, as reported in 
appropriate-use criteria for coronary revascularisation.48 
SYNTAX score II should be used by multidisciplinary 
teams consisting of a clinical cardi ologist, cardiac surgeon, 
and interventionalist to comply with inter national 
revascularisation guidelines (class 1 indication),6,7 and to 
remove any possibility of individual bias in interpretation.
Importantly, SYNTAX score II was externally validated 
in the DELTA registry (n=2891), a heterogeneous popu-
lation that included patients with complex coronary 
artery disease (anatomical SYNTAX score ≥33 existed in 
30% of the DELTA registry) who would have not been 
suitable for enrolment in the EXCEL trial,9 and three-
vessel disease (26% of the DELTA registry). Additionally, 
all the variables in SYNTAX score II, with the exception 
of age and LVEF, were externally validated in the DELTA 
registry. One of the major limitations, inherent to all 
observational registry studies, is that decision making 
between CABG and PCI had already been done by 
clinicians. These decisions, although not objective, are 
based on the clinical judgment of cardiologists and 
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cardiac surgeons, and thus lead to (often appropriate) 
selection bias. Evidence to support this notion comes 
from Hannan and colleagues49 who examined the New 
York State registries and showed much the same 
mortality outcomes between CABG and PCI with drug-
eluting stents in patients with multivessel disease when 
the data were not adjusted for baseline characteristics.49,50 
Notably, after adjustment of the data for baseline charac-
teristics, which included all clinical variables recorded in 
the SYNTAX score II, a mortality benefi t was shown for 
CABG. The inherent, unavoidable (and often appropriate) 
selection bias in registries might therefore be the pre-
dominant reason for not identifying an interaction eff ect 
for age and LVEF in the DELTA registry.
Future validation studies of the SYNTAX score II should 
ideally be done in suffi  ciently powered, ran domised, 
allcomers studies comparing CABG against PCI with 
drug-eluting stents, in which selection bias would be 
mini mised. Such so-called mega-trials are at present rare, 
and include the recently reported FREEDOM Trial 
(n=1900)42 and the ongoing EXCEL trial investigating 
ULMCA disease (n=2600).9 Prospective trials are being 
planned that will use SYNTAX score II to recruit patients, 
and include its further validation as one of the endpoints.
The SYNTAX score II nomogram (fi gure 4) provides 
individual mortality predictions for CABG and PCI, and 
a measure of the magnitude of their diff erences, with 
clinically applicable accuracy. It is, however, currently 
limited by being unable to provide an indicator as to 
whether the mortality predictions can be statistically 
separated. An online version of the SYNTAX score II is 
under development, which will provide this additional 
information. Some of the incomplete data in the DELTA 
registry might have aff ected validation of certain vari-
ables. This eff ect would have been minimised since 
multiple imputation and sensitivity analyses were 
done,22,29 as evidenced by COPD being shown to have 
similar interaction coeffi  cients in the SYNTAX trial and 
DELTA registry, and peripheral vascular disease not to 
have had an interaction eff ect in either study. Despite the 
SYNTAX trial being the only randomised, suffi  ciently 
powered, allcomers trial comparing CABG with PCI, 
with long-term follow-up, we cannot exclude the 
possibility that a larger sample size might have had an 
eff ect on interaction eff ects between CABG and PCI for 
certain factors. This uncertainty includes diabetes, 
although medically treated diabetes was prestratifi ed at 
randomisation as a powered subgroup in the SYNTAX 
trial, and was present in more than a quarter of the study 
patients (26%). Because of the rarity of complex coronary 
artery disease in premeno pausal women, mortality pre-
dictions in younger women with the SYNTAX score II 
are predominantly based on the linear asso ciation 
between age with mortality. The diff erences in mortality 
predictions in younger women between CABG and PCI 
will therefore be aff ected by larger 95% CIs. The 
interobserver variability of the SYNTAX score can 
potentially aff ect the mortality predictions. Appropriate 
training has been shown to limit this occurrence.51 Work 
is underway to develop a non-invasive calculated ana-
tomical SYNTAX score, using multislice CT that will 
incorporate non-invasive func tional assessment of 
lesions.14,52 The possibility of improved mortality cannot 
be excluded with newer gener ation drug-eluting stents, 
particularly since improve ments in drug-eluting stent 
design have shown reductions in the incidence of stent 
thrombosis and composite clinical outcomes.53,54 These 
fi ndings should be balanced by a study of a pooled 
analysis of more than 6000 patients in seven con-
temporary drug-eluting stent trials,23 showing stent 
generation (newer generation vs fi rst generation) not to 
be a predictor of mortality. Additionally, when deaths 
associated with the Academic Research Consor tium55 
defi nition of defi nite or probable stent thrombosis were 
removed from the SYNTAX trial (on the basis of the 
assumption that these patients would be alive), there was 
a 0·45% (defi nite stent thrombosis) or 1·5% (defi nite 
and probable stent thrombosis) reduction in mortality 
Panel: Research in context
Systematic review
We searched PubMed using the terms “drug-eluting stents” and “coronary artery bypass 
graft surgery” and “randomised controlled trials” or “registries,” with the last search done 
in January, 2013. Search results were fi ltered by hand and targeted studies which validated 
a score that stratifi ed the long-term risk for patients undergoing PCI or CABG, or that 
could potentially help with decision making between these procedures in patients with 
complex coronary artery disease. Most studies validated the anatomical SYNTAX score as 
an instrument to guide decision making between PCI and CABG in the context of 
unprotected left main or multivessel coronary artery disease.14,32 Two studies did not,33,42 
but seemed to be underpowered to allow for such assessment.9,32,34 Other studies 
amalgamated the anatomical SYNTAX score with cardiac-surgery-based risk scores to 
guide decision making between PCI and CABG.10,12,14,15 These studies were, however, limited 
by using risk scores previously developed for predicting in-hospital mortality after cardiac 
surgery. Additionally, they did not use an individualised approach to decision making 
between PCI and CABG, and instead were reliant on categorising risk into low, 
intermediate, or high-risk groups, which has previously been shown to be potentially 
misleading.10,15 Other studies focused on improvement of longer term clinical predictions 
in patients undergoing either PCI or CABG, without being specifi cally developed to 
directly improve decision making between these procedures.13,23,35,36 
Interpretation
Decision making between PCI and CABG with drug-eluting stents has traditionally been 
an area free from a compelling evidence base. The SYNTAX trial established that 
anatomical complexity—as assessed by the SYNTAX score—helped to guide decision 
making between PCI and CABG. The SYNTAX score II further improved decision making 
between PCI and CABG by augmenting the anatomical SYNTAX score with anatomical 
and clinical variables that would change the threshold value of the anatomical SYNTAX 
score in which PCI and CABG would off er comparable long-term mortality. Such a score 
would provide more objective, evidence-based decision making between PCI and CABG, 
when undertaken during multidisciplinary discussions between clinical cardiologists, 
cardiac surgeons, and interventional cardiologists, in working out the best possible 
revascularisation method in patients with complex coronary artery disease.
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(appendix). In view of the relative infrequency of these 
deaths, it is unlikely that they would have had a signifi cant 
eff ect on the coeffi  cients for the SYNTAX score II and its 
ability to aff ect decision making. The allcomers concept 
of the SYNTAX trial, although repre sentative of contem-
porary clinical practice, might be unavoidably limited by 
the inability to gain appropriate informed consent or 
refusal to participate from con secutive patients.56
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Table 1 
Baseline characteristics in the randomised SYNTAX Trial (n=1800).1 
Baseline Characteristic  PCI (N=903) CABG (N=897) P Value 
Age (years)  
Male gender 
Female gender 
Body-mass index (weight [kg]/height [metres]) 
Diabetes  
Medically treated diabetes* (%)  
  Any 
  Requiring insulin  
Metabolic syndrome (%) 
Current smoker (%) 
Previous myocardial infarction (%) 
Previous cerebrovascular accident (CVA) (%) 
Previous transient ischemic attack (TIA) (%) 
Peripheral vascular disease (%)**  
Blood pressure ≥130/85 mm Hg (%) 
Chronic obstructive pulmonary disease (COPD)***  
Congestive heart failure (%) 
Hyperlipidemia (%) 
Angina (%) 
  Stable (%) 
  Unstable  (%) 
Silent ischaemia 
Left ventricular ejection fraction (continuous) (%) 
Creatinine clearance (ml/min) (Cockcroft and Gault2) 
Anatomical SYNTAX Score3-6  
Unprotected left main coronary artery disease (%) 
De novo three vessel disease (without left involvement)  
 
65.2±9.7 
76.4 
33.6 
28.1±4.8 
28.2 
 
25.6 
9.9 
46.0 
18.5 
31.9 
3.9 
4.3 
9.1 
68.9 
7.9 
4.0 
78.7 
 
56.9 
28.9 
8.2 
59.9±12.9 
86.7±35.6 
28.4±11.5  
39.5 
60.5 
65.0±9.8 
78.9 
21.1 
27.9±4.5 
28.5 
 
24.6 
10.4 
45.5 
22.0 
33.8 
4.8 
5.1 
10.6 
64.0 
9.3 
5.3 
77.2 
 
57.2 
28.0 
8.2 
58.3±13.2 
85.6±29.4 
29.1±11.4  
38.8 
61.2 
0.55 
0.20 
0.20 
0.37 
0.89 
 
0.64 
0.72 
0.86 
0.06 
0.39 
0.33 
0.46 
0.28 
0.03 
0.29 
0.18 
0.44 
 
0.91 
0.66 
0.97 
0.32 
0.49 
0.19 
0.76 
0.76 
 
 
Continuous variables are expressed as means±SD. Categorical variables are expressed as percentages. 
*Medically treated diabetes was defined as diabetes for which the patient was receiving oral 
hypoglycaemic agents or insulin at the time of enrolment. 
**Aorta and arteries other than coronaries, with exercise related claudication, and/or revascularization 
surgery and/or reduced or absent pulsation and/or angiographic stenosis of more than 50% (ARTS I 
definition7).  
***Long term use of bronchodilators or steroids for lung disease (EuroSCORE definition8). 
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**Aorta and arteries other than coronaries, with exercise related claudication, and/or revascularization 
surgery and/or reduced or absent pulsation and/or angiographic stenosis of more than 50% (ARTS I 
definition7).  
***Long term use of bronchodilators or steroids for lung disease (EuroSCORE definition8). 
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**Aorta and arteries other than coronaries, with exercise related claudication, and/or revascularization 
surgery nd/or reduced or absent pulsation and/or angiogr phic stenosis of more th n 50% (ARTS I 
definition7).  
***Long term use of bronchodilators or steroids for lung disease (EuroSCORE definition8). 
 
 
 
 
 2 
Tables 2a-2b 
Independent predictors of 4-year mortality in the CABG (upper) and PCI (lower) 
cohorts. An entry/exit criteria of 0.05/0.05 were used in a Cox proportional hazards 
model. These findings have previously been reported.9  Used with permission from 
Farooq et al.9 
CABG Cohort (n=897) 
Independent Correlates of 4-Year Mortality 
(Variables with a p value >0.05 italicised) 
Hazard Ratio 95% C.I. p-value 
 
  Lack of discharge aspirin 
  Peripheral vascular disease 
  COPD 
  History of GI bleeding or peptic ulcer disease 
  Age per increase in 10 years  
  Pre-procedural poor LVEF 
  Amiodarone therapy on discharge 
  Serum creatinine (mg/dL) 
  Hypertension 
  Lack of pre-procedural aspirin 
 
3.56 
2.65 
2.44 
2.14 
1.95 
1.86 
1.79 
1.47 
1.28 
1.18 
 
2.04, 6.21 
1.49, 4.72 
1.30, 4.60 
0.90, 5.07 
1.41, 2.69 
0.65, 5.33 
0.95, 3.35 
1.17, 1.84 
0.62, 2.67 
0.64, 2.19 
 
<0.001 
0.001 
0.006 
0.085 
<0.001 
0.25 
0.070 
0.001 
0.51 
0.59 
 
 
PCI Cohort (n=903) 
Independent Correlates of 4-Year Mortality 
(Variables with a p value >0.05 italicised) 
Hazard Ratio 95% C.I. p-value 
 
  No post-procedural antiplatelet therapy* 
  Amiodarone therapy on discharge 
  Pre-procedural poor LVEF 
  History of GI bleeding or peptic ulcer disease 
  Peripheral vascular disease 
  Age per increase in 10 years 
  Female gender 
  Serum creatinine 
  Diabetes 
  SYNTAX Score per increase in 10 points 
 
 
152.16 
4.49 
3.31 
2.93 
2.13 
1.62 
1.60 
1.28 
1.28 
1.25 
 
53.57, 432.22 
1.36, 14.83 
1.03, 10.64 
1.41, 6.12 
1.26, 3.60 
1.26, 2.09 
1.01, 2.56 
0.95, 1.72 
0.83, 2.00 
1.06, 1.47 
 
 
<0.001 
0.014 
0.045 
0.004 
0.005 
<0.001 
0.048 
0.11 
0.27 
0.007 
* Neither aspirin nor thienopyridine  
Abbreviations: CABG coronary artery bypass graft surgery; COPD chronic obstructive 
pulmonary disease; CI confidence interval; GI gastrointestinal; LVEF left ventricular ejection 
fraction; PCI percutaneous coronary intervention. 
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Tables 2a-2b 
Independent predictors of 4-year mortality in the CABG (upper) and PCI (lower) 
cohorts. An entry/exit criteria of 0.05/0.05 were used in a Cox proportional hazards 
model. These findings have previously been reported.9  Used with permission from 
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Figure 2 
Title: Corrected Kaplan-Meier curves for ARC Definition stent thrombosis 
Legend: Kaplan-Meier estimates of cardiac death (black lines), cardiac death or myocardial infarction 
(MI) (green lines), and cardiac death, MI, or all cause revascularization, according to Academic 
Research Consortium (ARC)11 definition (reported by the Clinical Events Committee). Broken lines 
indicate corrected KM curves after ST related clinical event excluded. Definite stent thrombosis (ST) is 
superimposed on the Kaplan-Meier curves as a circle and probable ST as a square. If all these ST-
related events had been eliminated (broken lines), using ARC definite (upper) and ARC 
definite/probable (lower), the incidence of cardiac mortality would have decreased by 0.45% (definite 
ST) and 1.5% (definite/probable ST). Methodology adapted from Serruys et al.12 
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 3 
Figure 1 
Title: Validation plots for the SYNTAX Score II 
Legend: Validation plots in the development (SYNTAX Trial1) (a) and validation (DELTA Registry10) 
populations (b). The SYNTAX Score II was well calibrated in the SYNTAX Trial and DELTA 
Registry, as indicated by a good correlation between predicted and observed 4-year mortality. c-indices 
for the anatomical SYNTAX Score and SYNTAX Score II are indicated in each population (consisting 
of CABG and PCI treated patients). 
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Figure 2 
Title: Corrected Kaplan-Meier curves for ARC Definition stent thrombosis 
Legend: Kaplan-Meier estimates of cardiac death (black lines), cardiac death or myocardial infarction 
(MI) (green lines), and cardiac death, MI, or all cause revascularization, according to Academic 
Research Consortium (ARC)11 definition (reported by the Clinical Events Committee). Broken lines 
indicate corrected KM curves after ST related clinical event excluded. Definite stent thrombosis (ST) is 
superimposed on the Kaplan-Meier curves as a circle and probable ST as a square. If all these ST-
related events had been eliminated (broken lines), using ARC definite (upper) and ARC 
definite/probable (lower), the incidence of cardiac mortality would have decreased by 0.45% (definite 
ST) and 1.5% (definite/probable ST). Methodology adapted from Serruys et al.12 
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our report1 due to space limitations. 
The patient was thoroughly evaluated 
before enrolment, including a case 
review with her treating neurologist 
(GM) of more than 14 years. The 
patient fi rst noted stiff ness in her 
legs at age 36 years, 17 years before 
enrolment. Over several months, 
stiff ness pro gressed to fatigue, 
weakness in the legs, and then 
to weakness in the arms over the 
following year. 3 years after symptom 
onset, the patient was too weak to 
walk and used a wheelchair full time; 
she had also developed subtle sensory 
symptoms and urinary retention.
Upon presentation at the University 
of Pittsburgh, 4 years after symptom 
onset, pertinent examination fi ndings 
were left lateral gaze-evoked jerk 
nystagmus, mild left arm weakness, 
and severe right arm weakness. In 
the leg, there was complete paralysis 
except for knee fl exion, which was 
near normal, and hip fl exion, which 
showed severe weakness. She had 
increased tone in the legs with 
bilateral plantar refl exes present. She 
had mild to moderate vibratory sense 
loss to the knees, without pinprick 
loss. There were no cerebellar signs in 
the arm that moved and no obvious 
truncal ataxia for a patient who could 
not stand. She had no history of 
depression or signifi cant pain. She 
progressed with primarily motor 
dysfunction and became tetraplegic. 
Testing, at that time, failed to reveal 
a genetic disorder. After thorough 
evaluation for central and peripheral 
nervous system diseases, resulting 
in an unknown aetiology, it was 
determined she had a degenerative 
disorder diagnosed as spinal cerebellar 
syndrome. Her father had a very 
similar set of symptoms, with the 
addition of ataxia, and more recently, 
two of her siblings were diagnosed 
with multiple sclerosis.
At the time of enrolment in the 
study,1 she had 0/5 motor strength in 
all extremities, preserved—although 
subjectively slightly diminished— 
sensation, and decreased tone.
a common and genuine cause of 
physical disability.4 
The diagnosis could aff ect the 
generalisability of these techniques. 
It might be harder for a patient 
with a brain disease to control 
a neuroprosthetic device than 
someone with a structurally normal 
brain. Furthermore, someone with a 
functional tetraplegia, and an abnormal 
body image, might have superior 
ability to control a neuroprosthetic 
device compared with an amputee or 
spinal cord injured patient in whom 
neuroprosthetic ability must be 
superimposed over a potentially intact 
cognitive body image.
We do not detract from the authors 
considerable technical achievements, 
nor are we suggesting that this 
patient’s disability is anything other 
than genuine. However, clinical 
characterisation is essential in 
understanding the potential of this 
technology for patients with brain 
disease compared with patients with 
other causes of severe disability.
We declare that we have no confl icts of interest.
*Jon Stone, William Landau
jon.stone@ed.ac.uk
Department of Clinical Neurosciences, University of 
Edinburgh, Western General Hospital, Edinburgh 
EH4 2XU, UK (JS); and Washington University, 
School of Medicine, St Louis, MO, USA (WL)
1 Collinger JL, Wodlinger B, Downey JE, et al. 
High-performance neuroprosthetic control by 
an individual with tetraplegia. Lancet 2013; 
381: 557–64.
2 University of Pittsburgh Medical Center. One 
giant bite. https://www.youtube.com/
watch?v=76lIQtE8oDY (accessed March 13, 
2013).
3 60 Minutes. http://www.cbsnews.com/video/
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2013).
4 Stone J, Warlow C, Sharpe M. The symptom of 
functional weakness: a controlled study of 
107 patients. Brain 2010; 133: 1537–51. 
Neuroprosthetic control 
and tetraplegia
The neuroprosthetic achievements 
reported by Jennifer Collinger and 
colleagues (Feb 16, p 557)1 are 
remarkable. The diagnosis of the 
tetraplegic patient of the study 
is, however, puzzling. The patient 
has spinocerebellar ataxia without 
cerebellar features. Material available 
elsewhere2,3 suggests that her 
symptoms began rather suddenly 
13 years before taking part in the 
study. She describes relapsing 
weakness, has normal looking 
hands, and, head rest excepted, no 
symptoms above the neck. This is 
unusual for spinocerebellar ataxia, 
which typically has slow onset with 
gradual deterioration.
One of several alternative explan-
ations for this clinical picture, 
including cervical spinal cord 
pathology, is that the patient has a 
functional (psychogenic) tetraplegia, 
Authors’reply
Jon Stone and William Landau’s main 
concern is the possibility that the 
patient’s disorder might be functional 
(psychogenic) tetraplegia.
We welcome the opportunity 
to present details of the patient’s 
diagnosis, which were not included in 
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the new score versus those obtained 
with the original score for treatment 
decisions. To what extent does 
survival improve with the new score?4 
New purposes for prediction models 
require new performance statistics.
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SYNTAX score II
Vasim Farooq and colleagues1 
(Feb 23, p 639) developed and 
validated a new score (SYNTAX 
II) for the prediction of mortality 
after coronary artery bypass graft 
(CABG) and percutaneous coronary 
intervention (PCI) in patients with 
complex coronary artery disease. They 
added clinical characteristics to the 
anatomical SYNTAX score to improve 
individualised treatment decisions. 
They conclude that the new score 
can better guide the choice between 
CABG and PCI. It is very valuable that 
they used the SYNTAX trial not only 
to compare the treatment groups 
but also to develop a decision rule to 
guide treatment choice.
However, we have concerns about 
the use of the conventional measures 
of discrimination, calibration, and 
reclassifi cation to assess this score. 
These conventional statistics were 
developed to evaluate risk predictions 
under a single treatment or no 
treatment: discrimination, for 
example, tells us to what extent 
those who died had higher calculated 
mortality risks than those who 
survived. Here there is not one but 
two treatment options. To decide 
which of the two is preferable for 
a patient, one needs to estimate 
the mortality risk after CABG and 
the mortality risk after PCI for that 
individual, and then compare the 
two. The diff erence between these 
two risks is the estimated benefi t 
from one treatment compared 
with the other, and performance 
measures should assess how 
accurate the model is in predicting 
this benefi t.2,3 Using conventional 
statistics of model performance 
to assess the value of the model in 
estimating treatment benefi t and 
guiding treatment decisions could be 
potentially misleading. 
The score should be evaluated for 
outcome improvement. It would 
have been informative if the authors 
had presented results obtained using 
Authors’ reply 
We welcome the opportunity 
to expand on how to assess the 
performance of the SYNTAX score II.1 
First, interactions in the SYNTAX 
score II are central to more 
personalised decision making—ie, 
specifi c anatomical or clinical factors 
to be more predictive of mortality with 
percutaneous coronary intervention 
(PCI) compared with coronary artery 
bypass graft (CABG) surgery, or vice 
versa. All variables in the SYNTAX 
score II were validated, with the 
exception of age and left ventricular 
ejection fraction, which might relate to 
selection bias inherent to all registries. 
Hence randomised validation was 
proposed.1 Currently, validation of the 
SYNTAX score II is prespecifi ed as an 
endpoint in the ongoing randomised 
EXCEL trial (NCT01205776), and the 
planned SYNTAX trial II which will use 
the SYNTAX score II to recruit patients 
on the grounds of patient safety.
Second, substantial diff erences in 
treatment assignment (CABG or PCI) 
were evident using reclassifi cation 
analyses—ie, comparisons between 
the SYNTAX score II and conventional 
tertiles of the anatomical SYNTAX 
score.2 These were quantifi ed and 
presented in the manuscript, and 
cannot be deemed misleading, 
because they are an accepted 
and important step in assessing 
performance.3 
A further step to quantify eff ect 
on survival of the population under 
study requires a clear decision rule. If 
we simply select CABG or PCI based 
on a higher or lower expected survival 
(Kaplan-Meier analyses) with the 
SYNTAX score II, irrespective of the 
margin of diff erence, 4-year mortality 
would be 7·5% compared with 
8·4% using the anatomical SYNTAX 
score with existing myocardial 
revascularisation guidelines4 (equiva-
lent to using the SYNTAX score II in 
only 111 patients [100/0·9%] to have 
one more patient alive at 4 years). 
Similar analyses selecting CABG or 
PCI based on statistical comparisons 
of expected survival showed that 
4-year mortality remained unaltered 
at 8·2%. Notably, using either 
approach to decision making with 
the SYNTAX score II resulted in a 
similar 4-year survival (Kaplan-
Meier analyses) between CABG and 
PCI in both the development and 
validation populations. Additionally, 
and contrary to current myocardial 
revascularisation guidelines,4 patients 
were identifi ed in all tertiles of the 
anatomical SYNTAX score who would 
be potentially suitable for CABG, PCI, 
or both.
The choice between CABG and PCI 
would thus be down to individual 
patient preference, their perception 
of short-term and long-term risk, and 
health economics. We agree that the 
practical applications of performance 
statistics are complex, and future 
work in this evolving fi eld will prove 
to be of additional value in upcoming 
validation studies.
For more on expected survival 
see www.syntaxscore.com
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our report1 due to space limitations. 
The patient was thoroughly evaluated 
before enrolment, including a case 
review with her treating neurologist 
(GM) of more than 14 years. The 
patient fi rst noted stiff ness in her 
legs at age 36 years, 17 years before 
enrolment. Over several months, 
stiff ness pro gressed to fatigue, 
weakness in the legs, and then 
to weakness in the arms over the 
following year. 3 years after symptom 
onset, the patient was too weak to 
walk and used a wheelchair full time; 
she had also developed subtle sensory 
symptoms and urinary retention.
Upon presentation at the University 
of Pittsburgh, 4 years after symptom 
onset, pertinent examination fi ndings 
were left lateral gaze-evoked jerk 
nystagmus, mild left arm weakness, 
and severe right arm weakness. In 
the leg, there was complete paralysis 
except for knee fl exion, which was 
near normal, and hip fl exion, which 
showed severe weakness. She had 
increased tone in the legs with 
bilateral plantar refl exes present. She 
had mild to moderate vibratory sense 
loss to the knees, without pinprick 
loss. There were no cerebellar signs in 
the arm that moved and no obvious 
truncal ataxia for a patient who could 
not stand. She had no history of 
depression or signifi cant pain. She 
progressed with primarily motor 
dysfunction and became tetraplegic. 
Testing, at that time, failed to reveal 
a genetic disorder. After thorough 
evaluation for central and peripheral 
nervous system diseases, resulting 
in an unknown aetiology, it was 
determined she had a degenerative 
disorder diagnosed as spinal cerebellar 
syndrome. Her father had a very 
similar set of symptoms, with the 
addition of ataxia, and more recently, 
two of her siblings were diagnosed 
with multiple sclerosis.
At the time of enrolment in the 
study,1 she had 0/5 motor strength in 
all extremities, preserved—although 
subjectively slightly diminished— 
sensation, and decreased tone.
a common and genuine cause of 
physical disability.4 
The diagnosis could aff ect the 
generalisability of these techniques. 
It might be harder for a patient 
with a brain disease to control 
a neuroprosthetic device than 
someone with a structurally normal 
brain. Furthermore, someone with a 
functional tetraplegia, and an abnormal 
body image, might have superior 
ability to control a neuroprosthetic 
device compared with an amputee or 
spinal cord injured patient in whom 
neuroprosthetic ability must be 
superimposed over a potentially intact 
cognitive body image.
We do not detract from the authors 
considerable technical achievements, 
nor are we suggesting that this 
patient’s disability is anything other 
than genuine. However, clinical 
characterisation is essential in 
understanding the potential of this 
technology for patients with brain 
disease compared with patients with 
other causes of severe disability.
We declare that we have no confl icts of interest.
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Neuroprosthetic control 
and tetraplegia
The neuroprosthetic achievements 
reported by Jennifer Collinger and 
colleagues (Feb 16, p 557)1 are 
remarkable. The diagnosis of the 
tetraplegic patient of the study 
is, however, puzzling. The patient 
has spinocerebellar ataxia without 
cerebellar features. Material available 
elsewhere2,3 suggests that her 
symptoms began rather suddenly 
13 years before taking part in the 
study. She describes relapsing 
weakness, has normal looking 
hands, and, head rest excepted, no 
symptoms above the neck. This is 
unusual for spinocerebellar ataxia, 
which typically has slow onset with 
gradual deterioration.
One of several alternative explan-
ations for this clinical picture, 
including cervical spinal cord 
pathology, is that the patient has a 
functional (psychogenic) tetraplegia, 
Authors’reply
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concern is the possibility that the 
patient’s disorder might be functional 
(psychogenic) tetraplegia.
We welcome the opportunity 
to present details of the patient’s 
diagnosis, which were not included in 
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Revascularization Strategies in Patients with Diabetes
To the Editor: In reporting the results of the 
Future Revascularization Evaluation in Patients 
with Diabetes Mellitus: Optimal Management 
of Multivessel Disease (FREEDOM) trial, Farkouh 
et al. (Dec. 20 issue)1 suggest that in patients 
with diabetes and advanced coronary artery dis-
ease, coronary-artery bypass grafting (CABG) was 
superior to percutaneous coronary intervention 
(PCI). The benefit of CABG was driven by differ-
ences in rates of myocardial infarction and death 
from any cause. However, rates of cardiovascular 
death were similar in the two groups, whereas 
the rate of stroke was significantly higher after 
CABG.1 At 30 days, the primary outcome had oc-
curred in fewer patients after PCI. The main 
driver of the difference in the primary composite 
outcome was the higher incidence of myocardial 
infarction after PCI. However, beyond 30 days 
after any revascularization procedure, myocardial 
infarction was defined as only a typical increase 
in the troponin level (more than one value ex-
ceeding the necrosis boundary).1,2 Most of these 
late myocardial infarctions (accounting for 82% 
of those seen in the PCI group) might actually 
have been relatively minor episodes of myonecro-
sis. The clinical relevance of these events, as com-
pared with other major components of the pri-
mary outcome, including stroke, remains largely 
speculative. Accordingly, additional information 
on the types of myocardial infarction in the two 
groups would be critical to better interpret the 
study. Otherwise, the superiority of CABG over 
PCI could be questioned, even in this challenging 
scenario.
Fernando Alfonso, M.D. 
Rosana Hernandez, M.D.
Clínico San Carlos University Hospital 
Madrid, Spain 
falf@hotmail.com
No potential conflict of interest relevant to this letter was re-
ported.
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multivessel revascularization in patients with diabetes. N Engl J 
Med 2012;367:2375-84.
2. Farkouh ME, Dangas G, Leon MB, et al. Design of the Future 
REvascularization Evaluation in patients with Diabetes mellitus: 
Optimal management of Multivessel disease (FREEDOM) trial. 
Am Heart J 2008;155:215-23.
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To the Editor: The conclusion of Farkouh et al. 
that CABG was superior to PCI was driven by the 
difference in rates of myocardial infarction and 
death from any cause (with a substantial propor-
tion of deaths that occurred from cardiovascular 
causes) at 5 years after randomization. PCI was 
performed with the use of first-generation siro-
limus-eluting stents in 51% of the patients and 
paclitaxel-eluting stents in 43% of the patients. 
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To extrapolate the findings of the FREEDOM 
trial for current clinical practice, the incidence of 
cardiovascular death and myocardial infarction 
adjudicated to be due to probable or definite 
stent thrombosis is of great interest; PCI with 
contemporary stents might reduce the incidence 
of fatal or nonfatal stent thrombosis. We concur 
with the accompanying editorial by Hlatky1 that 
both revascularization strategies should be 
weighed by a multidisciplinary heart team to 
assess the benefit:risk ratio of each form of 
treatment. Patients with diabetes and multivessel 
disease should be informed about expected long-
term results after CABG (as shown in this trial) 
and about the estimated results after PCI with 
contemporary stent technology.
Jan J. Piek, M.D., Ph.D. 
Robbert J. de Winter, M.D., Ph.D. 
Jan G.P. Tijssen, Ph.D.
Academic Medical Center 
Amsterdam, the Netherlands 
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gery in patients with diabetes. N Engl J Med 2012;367:2437-8.
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To the Editor: Although they appear to show 
the superiority of CABG over multivessel PCI in 
patients with diabetes, the data presented in the 
article by Farkouh et al. suggest incomplete re-
vascularization in patients treated by means of 
PCI. In this group, the average number of lesions 
was 5.65 per patient, whereas the average num-
ber of lesions stented was 3.5 per patient. The 
completeness of revascularization in the CABG 
group was not reported. Incomplete revascular-
ization is known to be associated with an in-
creased risk of myocardial infarction, repeat 
revascularization,1 and cardiovascular death2 
and may have contributed to the worse outcomes 
in the PCI group in this trial. This issue needs 
to be clarified to be able to interpret this trial 
properly.
Alisdair Ryding, Ph.D.
Norfolk and Norwich University Hospital 
Norwich, United Kingdom 
alisdair.ryding@nnuh.nhs.uk
No potential conflict of interest relevant to this letter was re-
ported.
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vascularization on 10-year survival of patients with stable multi-
vessel coronary artery disease: MASS II trial. Circulation 2012; 
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DOI: 10.1056/NEJMc1301244
To the Editor: The suggestion of a lack of 
 association of the Synergy between PCI with 
TAXUS and Cardiac Surgery (SYNTAX) score 
(www.syntaxscore.com)1 with clinical outcomes 
in the FREEDOM trial should be interpreted with 
caution. Such conclusions are not consistent with 
the large volume of evidence that validates the 
SYNTAX score.2-5 Can the authors elaborate on 
how the SYNTAX score was used, since it became 
operational during the FREEDOM trial? Were the 
clinician and persons who conducted the core 
laboratory readings unaware of the clinical out-
comes? Furthermore, because of the numbers of 
patients at risk in the analysis of 5-year outcomes 
according to the SYNTAX score in the FREEDOM 
trial, the study was underpowered to draw any 
conclusions, since these patients composed less 
than a quarter (440 patients) of the study popula-
tion (1900 patients). The results of the FREEDOM 
trial are nevertheless consistent with the results 
in the subgroup of patients with diabetes and 
three-vessel disease in the SYNTAX trial (Fig. 1): 
namely, that in patients with a low SYNTAX score 
(i.e., ≤22), there was a minimal difference in 
long-term clinical outcomes between cardiac 
surgery and PCI with first-generation drug-elut-
ing stents. Consequently, no conclusions can yet 
be drawn from the FREEDOM trial with respect 
to how the SYNTAX score can influence decision 
making on the most appropriate form of revascu-
larization in patients with diabetes and complex 
coronary artery disease (without left main coro-
nary stenosis).
Patrick W. Serruys, M.D., Ph.D. 
Vasim Farooq, M.B., Ch.B.
Erasmus University Medical Center 
Rotterdam, the Netherlands 
p.w.j.c.serruys@erasmusmc.nl
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To extrapolate the findings of the FREEDOM 
trial for current clinical practice, the incidence of 
cardiovascular death and myocardial infarction 
adjudicated to be due to probable or definite 
stent thrombosis is of great interest; PCI with 
contemporary stents might reduce the incidence 
of fatal or nonfatal stent thrombosis. We concur 
with the accompanying editorial by Hlatky1 that 
both revascularization strategies should be 
weighed by a multidisciplinary heart team to 
assess the benefit:risk ratio of each form of 
treatment. Patients with diabetes and multivessel 
disease should be informed about expected long-
term results after CABG (as shown in this trial) 
and about the estimated results after PCI with 
contemporary stent technology.
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was 5.65 per patient, whereas the average num-
ber of lesions stented was 3.5 per patient. The 
completeness of revascularization in the CABG 
group was not reported. Incomplete revascular-
ization is known to be associated with an in-
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revascularization,1 and cardiovascular death2 
and may have contributed to the worse outcomes 
in the PCI group in this trial. This issue needs 
to be clarified to be able to interpret this trial 
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caution. Such conclusions are not consistent with 
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SYNTAX score.2-5 Can the authors elaborate on 
how the SYNTAX score was used, since it became 
operational during the FREEDOM trial? Were the 
clinician and persons who conducted the core 
laboratory readings unaware of the clinical out-
comes? Furthermore, because of the numbers of 
patients at risk in the analysis of 5-year outcomes 
according to the SYNTAX score in the FREEDOM 
trial, the study was underpowered to draw any 
conclusions, since these patients composed less 
than a quarter (440 patients) of the study popula-
tion (1900 patients). The results of the FREEDOM 
trial are nevertheless consistent with the results 
in the subgroup of patients with diabetes and 
three-vessel disease in the SYNTAX trial (Fig. 1): 
namely, that in patients with a low SYNTAX score 
(i.e., ≤22), there was a minimal difference in 
long-term clinical outcomes between cardiac 
surgery and PCI with first-generation drug-elut-
ing stents. Consequently, no conclusions can yet 
be drawn from the FREEDOM trial with respect 
to how the SYNTAX score can influence decision 
making on the most appropriate form of revascu-
larization in patients with diabetes and complex 
coronary artery disease (without left main coro-
nary stenosis).
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The Authors Reply: Alfonso and Hernandez 
state that more analysis of the data on myocar-
dial infarction is needed to interpret the results 
of the FREEDOM trial. This simply is not the 
case. Our randomized, controlled trial showed 
that survival among patients with diabetes and 
multivessel coronary disease who require revas-
cularization is increased if they undergo CABG 
rather than PCI. There is no complexity to this 
result, and no amount of analysis of the data on 
myocardial infarction will change the fact that 
patients who met the criteria for randomization 
in our trial were more likely to die sooner if they 
underwent PCI rather than CABG.
Piek and colleagues suggest that the use of 
newer stents could alter the outcome of our trial. 
The performance of the newer stents as com-
pared with earlier stents has been studied.1 The 
results of these analyses suggest, at most, very 
small absolute improvement in outcomes — far 
too little to affect the conclusions of the trial. 
The message of the trial is clear and actionable; 
speculation regarding the superiority of newer 
stents in producing the opposite result to that of 
our trial is not.
As Ryding points out, substantial data exist 
to suggest that more complete revascularization 
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Figure 1. Clinical Outcomes, According to Categories of the Anatomical 
SYNTAX Score.
Synergy between PCI with TAXUS and Cardiac Surgery (SYNTAX) scores in the 
subgroup of 297 patients with medically treated diabetes and three-vessel 
disease in the randomized SYNTAX trial are shown. The SYNTAX score cate-
gories are the following: 0 to 22, low anatomical complexity (Panel A); 23 to 
32, intermediate anatomical complexity (Panel B); and ≥33, high anatomical 
complexity (Panel C). Cumulative event rates of the composite outcome of 
major adverse cardiovascular and cerebrovascular events (death from any 
cause, myocardial infarction, revascularization for any cause, or stroke) are 
shown. I bars indicate 95% confidence intervals. CABG denotes coronary-
artery bypass grafting, and PCI percutaneous coronary intervention. Data 
are from the SYNTAX trial investigators.
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improves outcomes as compared with less com-
plete revascularization.2 However, our trial in-
volved highly experienced interventional cardiolo-
gists and surgeons who attempted to maximize 
the completeness of revascularization. Substan-
tially more complete PCI-based revascularization 
is therefore unlikely in other institutions.
Serruys and Farooq suggest that the SYNTAX 
score may have had a role in selecting patients 
in the FREEDOM trial in whom PCI may have 
been an appropriate procedure. In the group of 
patients with a low SYNTAX score, the incidence 
of the primary outcome of death, myocardial 
infarction, or stroke at 6 months was 6 percent-
age points lower in the CABG group than in the 
PCI group. In addition, the test for heterogeneity 
was nonsignificant and suggests that there was 
no significant interaction with the SYNTAX 
score in the comparison of PCI with CABG. 
Since the point estimates of all subgroups in 
Figure 2 of the article are trending in the same 
direction, the finding of the superiority of CABG 
is robust. Of course, subgroups can be defined 
for which inadequate power is available to fully 
study the question posed. Serruys and Farooq 
have defined such a subgroup.3 Even here, the 
data are consistent with the results in the full 
FREEDOM cohort.
Michael E. Farkouh, M.D. 
Michael Domanski, M.D. 
Valentin Fuster, M.D., Ph.D.
Icahn School of Medicine at Mount Sinai 
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Factor VIII Products and Inhibitors in Severe Hemophilia A
To the Editor: Gouw et al. (Jan. 17 issue)1 have 
provided a much-needed comparison of the risk 
of inhibitor development associated with differ-
ent factor VIII molecules in previously untreated 
children with severe hemophilia A. We anticipate 
obvious concerns in the hemophilia community 
regarding the unexpected finding of a higher rate 
of inhibitor development for second-generation 
recombinant factor VIII, and we would like to 
comment on the strength of the association. The 
absence of a biologic hypothesis, a risk ratio of 
less than 2 (unadjusted lower limit, 0.91; adjust-
ed, 1.09), and the omission of 20.4% of patients 
(74 eligible patients were excluded and 58 patients 
did not reach the study end point) leave the as-
sociation weak and questionable. A sensitivity 
analysis comparing the first and second half of 
patients enrolled should be performed to deter-
mine whether in such a long study any temporal 
trends influenced recombinant concentrate use 
and outcome assessment. Comparing the recom-
binant concentrates produced in baby-hamster–
kidney (BHK) cells and Chinese-hamster–ovary 
(CHO) cells would test a more plausible hypoth-
esis2 than the “generation” effect. We strongly 
agree with the authors in recommending extreme 
caution in transferring these unexpected research 
results to decision making in clinical practice.
Alfonso Iorio, M.D., Ph.D.
McMaster University 
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“Cherry-Picking” Patients for
Randomized, Controlled Trials—
Reliving the Past. . .
We read with interest the VA CARDS (Veterans Affairs Coronary
Artery Revascularization in Diabetes) study (1) comparing percu-
taneous coronary intervention (PCI) and coronary artery bypass
grafting (CABG) in subjects with diabetes. In our opinion, the
most notable finding of the study is not the outcome of the trial,
but the actual study design itself, that is, the stringent
angiography- and clinically based inclusion and exclusion criteria,
which makes application of the study’s findings to real-world
contemporary clinical practice highly questionable. Notably, of the
6,678 diabetic patients screened for this study, a staggering
6,080/6,678 (91%) of screened subjects did not meet angiographic
requirements for the study, and only 198 subjects (3%) were
randomly assigned to either CABG (n  97, 1.5%) or PCI with
drug-eluting stents (DESs) (n  101, 1.5%) and completed the
2-year follow-up. Such a trial design is reminiscent of the PCI
versus CABG randomized trials undertaken before the SYNTAX
(Synergy Between PCI With Taxus and Cardiac Surgery) trial
(2,3), where “cherry-picking” of patients before randomization was
a major confounding issue (2% to 12% of screened patients were
randomized in most trials) that effectively invalidated the results of
these trials (4,5). The SYNTAX trial was designed to overcome
these limitations by incorporating an all-comers design in which
practically no patient was refused entry, with subjects either
randomized (if determined by the Heart Team to achieve “equiv-
alent anatomical revascularization” between CABG and PCI) or
nested in registries (2,3). This was at the insistence of 7 cardiac
surgeons (dubbed the “magnificent 7”) during the design of
SYNTAX to prevent selection bias, a view that was fully endorsed
by the clinical and interventional cardiologists at the time. To give
an example of the potential dangers of using highly selected
populations in a clinical trial design, a recent meta-analysis of
randomized trials undertaken before SYNTAX comparing PCI
with CABG (6) showed CABG to be favored in older subjects and
PCI to be favored in younger subjects, findings that have since
been directly contradicted by the all-comers SYNTAX trial (where
the opposite was shown) (7). In addition, the analyses demonstrat-
ing the anatomic SYNTAX score in the VA CARDS study not to
show any treatment effect between CABG and PCI warrant
specific mention in that they were severely underpowered to draw
any conclusions, even if considered hypothesis generating (8).
Specifically, the majority of subjects in the VA CARDS study had
low (22) (CABG: n  47 vs. PCI: n  59) SYNTAX scores,
with few subjects in the intermediate (23 to 32) (CABG: n  33
vs. PCI: n  24) or high (33) (CABG: n  13 vs. PCI: n  12)
SYNTAX scores, presumably due to the overwhelmingly restric-
tive angiographic inclusion and exclusion criteria of the study as
described earlier, thus making any comparisons of the low with the
higher SYNTAX score tertiles practically meaningless. Even
within the FREEDOM (Future Revascularization Evaluation in
Patients With Diabetes Mellitus: Optimal Management of Mul-
tivessel Disease) trial, (9) analyses based on the SYNTAX score
tertiles appear to have been limited by power and were contra-
dicted by those reported in the pre-stratified and powered diabetic
subgroup of SYNTAX (10). The real lesson of the VA CARDS
study is that randomization of subjects in a clinical trial is not
enough and that an all-comers clinical trial design is warranted.
Anything less will take us back to the confusing era of randomized
trials performed before SYNTAX and will serve to cloud the
medical literature.
Vasim Farooq, MBChB
*Patrick W. Serruys, MD, PhD
*Erasmus Medical Center
=s-Gravendijkwal 230
3015 CE Rotterdam
the Netherlands
E-mail: p.w.j.c.serruys@erasmusmc.nl
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Reply
In the letter about our paper (1), Drs. Farooq and Serruys make the
assertion that the VA CARDS (Veterans Affairs Coronary Artery
Revascularization in Diabetes) study is not applicable to contem-
porary coronary revascularization based on: 1) the angiographic
inclusion criteria being too strict; 2) the small percentage of
screened patients who were enrolled; and 3) that our study was
underpowered to evaluate SYNTAX (Synergy Between PCI With
Taxus and Cardiac Surgery) scores. The letter completely misses
important aspects of our study.
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Our angiographic criteria were based on subsets of patients
known to have better survival with surgery than with medical
treatment. We deliberately excluded patients when the primary
role of revascularization would be symptom relief. These patients
were extensively studied in COURAGE (Clinical Outcomes
Utilizing Revascularization and Aggressive Drug Evaluation) and
BARI 2D (Bypass versus Angioplasty Revascularization Interven-
tion 2 Diabetes) (2,3). Including these subsets would have in-
creased enrollment but also would have diluted the power of the
study to find survival differences.
Our screened patients included all patients with diabetes re-
ferred for a diagnostic angiogram for any reason. To compare
VA-CARDS to SYNTAX, we need to know the total number of
patients having diagnostic angiography at the 85 sites over their
2-year enrollment (4). An average of 500 diagnostic angiograms
per year per SYNTAX site would yield a total of 85,000 diagnostic
coronary angiograms. The 1,800 patients enrolled in SYNTAX
would then represent 2.1% of this total, which is lower than our
study.
Our study was not designed or powered to examine SYNTAX
score subgroups. The SYNTAX scores in our study merely show
that there was no systematic bias in the distribution of scores to
explain the observed survival difference. If anything, low SYNTAX
scores were more frequent for PCI than surgery. It is important to
note in this discussion that the SYNTAX trial itself was not
powered to compare small subgroups based on SYNTAX terciles.
There is no SYNTAX score that leads to an absolute improvement
in outcome for percutaneous coronary intervention over surgery
among patients with 3-vessel coronary disease. The failure to find
a significant p value in the subanalysis of 352 patients with low
SYNTAX scores and 3-vessel coronary artery disease is likely to
represent a type II error (5). The SYNTAX investigators need to
report a power analysis of each of the subgroups that they analyze.
The assumption that the failure to find a difference means that
there is no difference is misleading.
*Masoor Kamalesh, MD
Thomas Sharp, MD
*Krannert Institute of Cardiology
1481 West 10th Street
Indianapolis, Indiana 46202
E-mail: mkamales@iupui.edu
http://dx.doi.org/10.1016/j.jacc.2013.03.017
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Observations from the CREDO-Kyoto three-vessel disease 
registry: can one adjust for the unadjustable?
Vasim Farooq, MBChB, MRCP; Patrick W. Serruys*, MD, PhD
Department of Interventional Cardiology, Erasmus University Medical Centre, Thoraxcenter, Rotterdam, The Netherlands
In this issue of EuroIntervention, results from the long-awaited three-
vessel-disease (3VD) subset of the CREDO-Kyoto PCI/CABG regis-
try cohort-2 (CREDO-Kyoto registry) are published1. These findings 
were first presented at the European Society of Cardiology Congress 
in Paris, France, in August 2011, and were controversial. Although 
the registry was retrospective in nature, given its size, the results are 
difficult to ignore, particularly the apparent finding of CABG being 
“best” for 3VD in lower SYNTAX-score patients2.
Over a three-year period (2005-2007), 15,939 consecutive 
patients were enrolled in 26 centres in Japan, of whom 2,981 
patients were identified with 3VD (PCI: n=1,825; CABG: n=1,156), 
and an impressive 2,812 patients (PCI: n=1,792; CABG: n=1,020) 
underwent retrospective SYNTAX score calculations. As expected, 
the adjusted primary endpoint of all-cause death, MI, or stroke was 
significantly lower in CABG-treated patients compared to PCI-
treated patients, reflecting recent findings from the ASCERT regis-
try3, and the randomised, all-comers SYNTAX trial4.
Interestingly, in the CREDO-Kyoto registry, unadjusted all-cause 
death was significantly greater for PCI compared to CABG (PCI: 11.7% 
vs. CABG: 9.3%, p=0.046), whereas unadjusted cardiac death was simi-
lar (PCI: 5.6% vs. CABG: 5.4%, p=0.41). Adjusted all-cause death 
(p=0.005) remained significantly in favour of CABG, whereas adjusted 
cardiac death remained neutral between CABG and PCI (p=0.28). 
The results stratified by the presence of tertiles of the SYNTAX 
score in the CREDO-Kyoto registry are of additional interest, since 
the European revascularisation guidelines5 advocate that, for 3VD 
disease with a low SYNTAX score (0-22), PCI is given a class IIA 
recommendation (weight of evidence/opinion in favour of useful-
ness/efficacy). This recommendation is based primarily on the 
results of the SYNTAX trial4. Conversely, for 3VD associated with 
higher SYNTAX scores (>22), PCI is given a class III recommen-
dation (not useful/effective and possibly harmful). Yet in the low 
SYNTAX score subset (0-22) of the CREDO-Kyoto study, the 
adjusted risk of the primary endpoint was higher for PCI compared 
to CABG (HR 1.66 [1.04-2.65], p=0.03), whereas the unadjusted 
risk of the primary endpoint was similar between CABG and PCI 
(HR 1.26 [0.86-1.925], p=0.24). Findings in the higher SYNTAX 
score tertiles were mixed, with only a high SYNTAX score (33) 
showing a trend towards treatment benefit for CABG compared to 
PCI on adjusted analyses (p=0.051). Given these contradictory 
findings, how is one to interpret them, particularly in the context of 
the current published evidence?
Interpreting the CREDO-Kyoto study
The main observation of the CREDO-KYOTO study is that the 
authors attempt to equalise the two treatment groups (CABG and 
PCI), through adjustment of data with simple clinical variables, and 
then undertake sensitivity analyses using propensity score matching 
to confirm the findings. What should be highlighted is that the authors 
endeavour to adjust an unadjustable characteristic, namely the clini-
cal judgement and decision-making process of the Heart Team in 
selecting the most appropriate revascularisation modality6. As the 
authors appropriately highlight in the limitations section, selection 
bias due to unmeasured confounders, such as patient frailty, cognitive 
dysfunction, active malignancy, and systemic infection, could not be 
controlled for, and may offer an explanation why all-cause death was 
higher for PCI, whereas cardiac death was similar between CABG 
and PCI, even after adjustment for baseline factors. 
Evidence to support these statements comes from the New York State 
registry6,7, in which survival after CABG or PCI was similar in unad-
justed curves, but showed a mortality benefit favouring CABG after 
adjustment for risk factors (Figure 1). Excessive comorbidities make 
CABG less attractive due to the operative risk, which can be prohibitive. 
In such scenarios, PCI becomes the default approach. In the SYNTAX 
trial, these types of patients were not randomised, since CABG and PCI 
could not be offered equally, and they were therefore nested in a PCI reg-
istry (n=198). Strikingly, at five years, the nested PCI registry of the 
SYNTAX trial reported a mortality rate of 30%4. By comparison, in the 
randomised SYNTAX trial, five-year all-cause mortality was 11.4% in 
the CABG arm and 13.9% in the PCI arm (p=0.10). The reasons to 
explain the more than doubling of mortality in the PCI registry of the 
SYNTAX trial may be related to a greater occurrence of incomplete 
revascularisation due to severe anatomical complexity, and the associ-
ated negative impact on long-term survival8,9, high EuroSCORE subjects 
being shown to have an excess of mortality after PCI10,11, and the hypoth-
esis12 that bypass grafts “protect” coronary vessels from future cardiac 
events for the lifespan of the graft, whereas PCI treats individual lesions 
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– particularly in very high-risk subjects where the chances of a future 
clinical event are likely to be substantial. 
In the higher SYNTAX scores in the CREDO-Kyoto study, at 
least a trend for a treatment benefit of CABG was seen in the high 
SYNTAX score tertile (>32). This is likely to be related to the data 
being underpowered, confounded by selection bias as discussed. 
SYNTAX score II
Recently, the SYNTAX score II was proposed and validated13, 
whereby the anatomical SYNTAX score was combined with clini-
cal variables shown directly to affect decision making between 
CABG and PCI based on interactions (Figure 2). For example, the 
anatomical SYNTAX score aids decision making between CABG 
and PCI because it is more predictive of clinical outcomes in 
patients undergoing PCI, compared to patients undergoing CABG 
(where it is not predictive). Based on this principle, other factors 
were included in the SYNTAX score II, that were shown to alter the 
threshold value of the anatomical SYNTAX score that would lead 
to similar long-term mortality between CABG and PCI. 
In essence, the SYNTAX score II adjusts the individual patient ana-
tomical and clinical characteristics to aid objective decision making 
between CABG and PCI for the Heart Team. In addition, by individu-
alising risk, the SYNTAX score II was shown to be able to identify 
higher and lower-risk subjects in all tertiles of the anatomical SYNTAX 
score who had a long-term mortality that favoured either CABG or 
PCI, or both revascularisation modalities. As compared to existing 
revascularisation guidelines using the conventional SYNTAX score, 
the selection of subjects based on a higher or lower expected survival 
using the SYNTAX score II was recently reported to be necessary only 
in approximately 110 patients in order to have one more patient alive at 
four years14.
Conclusion
What is required for validation of the effectiveness of the SYNTAX 
score and SYNTAX score II in decision making are prospectively 
run studies, or randomised validation studies, free from selection 
bias. Registry data, no matter how large, are confounded by (often 
appropriate) decision-making processes, and should therefore be 
interpreted with caution, as exemplified in the CREDO-Kyoto reg-
istry. The take-home message from the CREDO-Kyoto study is that 
the results actually appear to support current revascularisation 
guidelines, particularly with respect to the low SYNTAX score 
group, provided both anatomical and clinical factors are accounted 
for, as demonstrated in the SYNTAX score II.
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in older women but will be equally valid.
Figure 2. The SYNTAX score II nomogram for bedside application. 
Total number of points for 8 factors can be used for accurate prediction 
of 4-year mortality for the individual patient proposing to undergo 
CABG or PCI. Younger age, female gender and reduced LVEF 
favoured CABG compared to PCI on long-term prognostic grounds. 
Thus, in such patients a lower anatomical SYNTAX score would be 
required in order for the long-term mortality risk to be similar between 
CABG and PCI. By contrast, older age, chronic obstructive pulmonary 
disease or ULMCA disease favoured PCI compared to CABG. Thus, in 
this type of patient, a higher anatomical SYNTAX score would be 
needed for the long-term mortality risks to be similar. For example, 
a 60-year-old male with an anatomical SYNTAX score of 30, ULMCA 
disease, CrCl 60 ml/min, a LVEF of 50%, and COPD would have 41 
points (predicted 4-year mortality: 16.3%) and 33 points (predicted 
4-year mortality: 8.7%) to undergo CABG and PCI, respectively. The 
same example, without COPD included, would lead to identical points 
(29 points) and 4-year mortality predictions (6.3%) for CABG and PCI. 
Legend and image modified and reproduced with permission from 
Farooq et al11. CABG: coronary artery bypass graft surgery; 
PCI: percutaneous coronary intervention; CrCl: creatinine clearance 
(Cockcroft and Gault formula); LVEF: left ventricular ejection fraction; 
Left main: unprotected left main coronary artery disease; 
COPD: chronic obstructive pulmonary disease (long-term use of 
bronchodilators or steroids for lung disease [EuroSCORE definition]); 
PVD: peripheral vascular disease (aorta and arteries other than 
coronaries, with exercise-related claudication, and/or revascularisation 
surgery and/or reduced or absent pulsation and/or angiographic 
stenosis of more than 50%).
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To the Editor:
We read with interest the article by Farooq et al, “Quantification 
of Incomplete Revascularization and Its Association With Five-Year 
Mortality in the Synergy Between Percutaneous Coronary Intervention 
With Taxus and Cardiac Surgery (SYNTAX) Trial: Validation of the 
Residual SYNTAX Score,”1 in which the authors investigated the 
effect on long-term outcomes of the randomized patients receiving 
percutaneous coronary intervention in the SYNTAX study accord-
ing to the SYNTAX score (SS) of the residual coronary lesions once 
subjects had been revascularized (residual SS). They concluded that 
a residual SS >8 was associated with increasing adverse long-term 
clinical outcomes, including mortality. On the other hand, residual SS 
≤8 was associated with long-term mortality comparable with that of 
patients with complete revascularization (residual SS=0).
SS was used to stratify the comparison between coronary artery 
bypass graft and percutaneous coronary intervention in the SYNTAX 
trial,2 so that apparently the benefits of coronary artery bypass graft 
over percutaneous coronary intervention remained only in the high-
est SS tertiles. We cannot forget that these subgroup comparisons 
were performed post hoc and with small sample sizes. Furthermore, 
the alternative hypothesis had not been demonstrated. Therefore, we 
believe subgroup analysis results could be interpreted only as being 
hypothesis originating.2 On the other hand, SS reproducibility is 
limited. The SYNTAX Investigators assessed the reliability of SS 
by comparing the score obtained by different well-trained observers 
when calculating the SS for the same angiography.3 The weighted 
κ measures the agreement between ≥2 observations. Weighted κ 
>0.75 represents excellent agreement beyond chance; 0.40 to 0.75, 
fair to good agreement; and <0.40, poor agreement. In that study, 
Serruys et al3 reported a weighted κ for the observations of the global 
score of 0.45; the weighted κ for the number of lesions was 0.59; 
and weighted κ for bifurcations was 0.41. Although the weighted κ 
values were >0.4, in our opinion, the degree of agreement was still 
lower than desired.
Given the limited power of the SS to predict outcomes after coro-
nary artery bypass graft or percutaneous coronary intervention, SS II 
was developed by the SYNTAX Investigators.4 This new score added 
to the original SS some clinical items to improve the risk prediction 
among patients with complex coronary disease. Although it demon-
strated an accurate prediction of 4-year mortality (greater than the 
original SS), SS II was complex to calculate and, like the SS, had poor 
reproducibility. The more variables it has, the greater its complexity 
is, and the less parsimonious a score is, the less useful it becomes.
Before the present article by Farooq et al,1 a basic principle of 
coronary revascularization remained unchanged: Complete revas-
cularization is always better. After performing a (once again) non-
randomized subgroup analysis with limited sample sizes (and thus 
limited statistical power to detect differences), the authors concluded 
that some degree of incompleteness of revascularization (residual SS 
≤8) might be acceptable. We should be cautious when assuming these 
conclusions because they are, once again, hypothesis generating.
Although the 3 scores mentioned before are widely used in every-
day practice, we believe the decision on the optimal revascularization 
treatment must not completely rely on these scores yet. Further stud-
ies must be performed to prospectively assess their true accuracy and 
reproducibility
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First, the readership should be reminded that the anatomic Synergy 
Between Percutaneous Coronary Intervention With Taxus and Cardiac 
Surgery (SYNTAX) score was designed before the SYNTAX trial as 
a tool to force the interventional cardiologist and cardiac surgeon to 
systematically analyze the coronary angiogram and agree that “equiv-
alent anatomic revascularization” could be achieved on the basis of 
a vessel size of 1.5 mm. A vessel size of 1.5 mm was selected as this 
was the size of the vessel the cardiac surgeon stated they could revas-
cularize. Before the SYNTAX trial, the SYNTAX score was tested in 
the Arterial Revascularization Therapies Study (ARTS) II Study.2 In 
the SYNTAX trial protocol, outcomes related to the SYNTAX score 
were prespecified. Since the SYNTAX trial, numerous studies have 
validated the SYNTAX score.3
Second, criticisms related to the reproducibility of the SYNTAX 
score appear excessive. The simple interpretation of a coronary 
angiogram, on which most contemporary revascularization practice 
is based, has been reported as far back as the 1970s to have substantial 
intraobserver and interobserver variability in visual estimation (SD 
up to 18%),4 findings that are simply reflected in the SYNTAX score 
calculation. Suitable training to undertake the SYNTAX score, quan-
titative coronary angiography, and functional guidance have been 
shown to limit this issue.3 A semiautomated, computed tomography–
derived functional SYNTAX score is currently in development and is 
expected to further minimize this concern.3
Third, it is important to highlight that the SYNTAX score II is built 
on the principle of parsimony. The core factors in the SYNTAX score II 
(SYNTAX score and ACEF [age, creatinine clearance, and left ventricu-
lar ejection fraction]) contain the bulk of the prognostic information for 
predicting long-term mortality after coronary artery bypass graft surgery 
or percutaneous coronary intervention.3 The remaining factors added to 
the SYNTAX score II were based on the principle that they were shown 
to alter the threshold value of the SYNTAX score (interactions) for 
equipoise to be achieved between coronary artery bypass graft surgery 
and percutaneous coronary intervention for long-term mortality, thereby 
aiding decision making between revascularization modalities. An online 
calculator to simplify the calculation of the SYNTAX score II is planned 
for public release shortly (www.syntaxscore.com).
Finally, the authors assert that complete revascularization (CR) is 
always better. On which definition of CR is this assumption being 
made? This is particularly pertinent given the multiple definitions 
of CR that exist in the literature. Although too extensive incomplete 
revascularization is likely to have a negative impact on long-term 
clinical outcomes, too extensive surgical revascularization has been 
associated with the occurrence of major perioperative complications 
and acute myocardial infarction, with evidence to support a reasonable 
incomplete revascularization approach.5,6 Even within the SYNTAX 
trial, despite CR being mandated by the heart team, the reality was 
somewhat different, with only 56.7% and 63.2% of the percutane-
ous coronary intervention and coronary artery bypass graft surgery 
cohorts, respectively, achieving CR. In addition, CR is a clinical out-
come, not a baseline characteristic. Therefore, conducting a random-
ized trial directly examining this issue is difficult, particularly because 
incomplete revascularization was shown to be a surrogate marker for 
sicker patients, with a greater burden and complexity of coronary dis-
ease and clinical comorbidity.1
We fully agree that further prospective validation of these 
SYNTAX-based tools is required to further legitimize their use in 
clinical practice. This is currently occurring in the ongoing EXCEL 
(Evaluation of XIENCE PRIME Everolimus Eluting Stent System 
[EECSS] or XIENCE V® EECSS or XIENCE Xpedition EECSS or 
XIENCE PRO EECSS Versus Coronary Artery Bypass Surgery for 
Effectiveness of Left Main Revascularization) and SYNTAX II trials 
investigating unprotected left main and  3-vessel disease, respectively.3
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EDITORIAL COMMENT
Complex Coronary
Artery Disease
Would Outcomes From the SYNTAX (Synergy
Between Percutaneous Coronary Intervention With
Taxus and Cardiac Surgery) Trial Have Differed With
Newer-Generation Drug-Eluting Stents?*
Vasim Farooq, MB, CHB,
Patrick W. Serruys, MD, PHD
Rotterdam, the Netherlands
Newer-generation drug-eluting stents (DES) have un-
equivocally led to significant improvements in safety
compared with first-generation DES (1–8). Given the
substantial clinical benefits attained with newer-generation
DES, the obvious question remainsdwould outcomes from
the landmark SYNTAX (Synergy Between Percutaneous
Coronary Intervention With Taxus and Cardiac Surgery)
trial (9–12) have differed with newer-generation DES?
In this issue of JACC: Cardiovascular Interventions, Ribi-
chini et al. (13) present important findings from the
randomized, multicenter EXECUTIVE (Evaluating Xience-
V in Multi-Vessel Disease) pilot trial, comparing the newer-
generation everolimus-eluting stent (EES) (Xience V, Abbott
Vascular, Santa Clara, California) against the first-generation
paclitaxel-eluting stent (PES) (Taxus Express, Boston
Scientific, Natick, Massachusetts) in the treatment of multi-
vessel coronary artery disease. The primary outcome was
angiographic, namely, late lumen loss, and demonstrated the
superiority of EES (all lesions late lumen loss: EES 0.05 
0.51 mm vs. PES 0.24 0.50 mm, p< 0.001). Although the
study was clearly underpowered for clinical outcomes, obser-
vations of numerical differences in 1-year major ad-
verse cardiac events of 11.1% in the randomizedEES arm, and
16.5% in the randomized PES arm are difficult to ignore, and
offer a unique insight into the potential benefit of newer-
generation DES in the treatment of multivessel disease.
There are, however, a number of caveats to the EXECU-
TIVE trial that should be highlighted. Firstly, in keepingwith
the U.S. and European revascularization guidelines (14–16),
the EXECUTIVE trial focused primarily on low SYNTAX
score (<23) (11,17,18) subjects, having been recruited in
approximately 95% of the EES and PES treatment arms
(mean SYNTAX score: 12.7  5.2). How generalizable the
results of the EXECUTIVE trial are to subjects with more
complex multivessel disease, therefore, remains unclear.
Secondly, the EXECUTIVE trial lacked an all-comers
design, with clinical and angiographic inclusion and exclusion
criteria, which somewhat limits translation of the study’s
findings to contemporary clinical practice, even in low
SYNTAX score subjects. For example, a history of congestive
cardiac failure or a left ventricular ejection <30%dfactors
previously shown to alter the threshold value of the SYNTAX
score in favor of coronary artery bypass grafting (CABG)
(19)dwere exclusion criteria. In the pre-SYNTAX era, such
restrictive trial designs comparing CABG with percutaneous
coronary intervention (PCI) were heavily criticized for
“cherry-picking” patients for randomization, despite the
randomized nature of these studies (20,21). Thirdly, the
EXECUTIVE trial was clearly underpowered to assess clin-
ical outcomes, and showed numerical differences in clinical
outcomes that could not be statistically corroborated.
Fourthly, the fact that complete revascularization almost
uniquely appeared to have been achieved in all randomized
patients, with consequent favorable outcomes (22,23), and
that an arbitrarily defined limit of 4 planned stents per patient
was placed in the angiographic inclusion criteria, does imply
a further amount of selection bias in recruiting subjects.
The improved clinical outcomes with the EES in multi-
vessel disease (despite the described shortcomings of the
EXECUTIVE trial), coupled with similarly reported data
from the FLM Taxus (French Left Main Taxus) and the
LEMAX (LEft MAin Xience) registries, investigating left
main stenting with EES (24,25), and the known reductions
in stent thrombosis (ST) of newer-generation DES (1–8),
does imply that if newer-generation DES had been used in
the SYNTAX trial, there would have been a significant
reduction in clinical events, particularly repeat revasculari-
zation and myocardial infarction.
As to whether reductions in mortality would be seen with
newer-generation DES in patients undergoing contempo-
rary PCI is entirely plausible (8). Large-scale reductions in
ST and their clinical sequelae with newer-generation DES
are firmly established in the literature, although the expected
reduction in mortality awaits confirmation from randomized
trials (1–7). Conversely, in the SYNTAX trial, if the cardiac
mortality events related to ST were removed, based on
Academic Research Consortium (26) definitions of ST,
there would have been only a modest reduction in cardiac
mortality at 5 years. Namely, for definite ST, 5-year cardiac
mortality would be reduced from 9% to 8.5%, and for
*Editorials published in JACC: Cardiovascular Interventions reflect the views of the
authors and do not necessarily represent the views of JACC: Cardiovascular Interven-
tions or the American College of Cardiology.
From the Department of Interventional Cardiology, Erasmus University Medical
Centre, Thoraxcenter, Rotterdam, the Netherlands. Both authors have reported that
they have no relationships relevant to the contents of this paper to disclose.
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definite and probable ST, from 9% to 7.5% (27). The main
reason to account for this phenomenon may relate to the
hypothesis that bypass grafts protect coronary vessels from
future myocardial events for the lifespan of the graft,
particularly in more complex coronary artery disease where
the plaque burden and risk of a future cardiac event would
potentially be higher, compared with a subject with less
complex coronary artery disease. Conversely, stents would
only treat individual lesions (21,28).
The potential reduction in mortality with newer-genera-
tion DES in the SYNTAX trial would therefore be unlikely
to bridge the gap between CABG and PCI, particularly with
more complex coronary artery disease. This is exemplified in
the SYNTAX score II (19,29), in which the SYNTAX score
was combined with clinical variables that were shown to alter
the threshold value of the SYNTAX score so that equipoise
was achieved between CABG and PCI for long-term
mortality. Notably, subsets of patients were identified across
all tertiles of the SYNTAX score who would have
a mortality benefit from undergoing CABG or PCI (Fig. 1).
It should, however, be emphasized that increasing anatom-
ical complexity, particularly in subjects with 3-vessel disease,
lead to a greater likelihood of a mortality benefit to be
attained with CABG over PCI (Fig. 1).
In both the ongoing EXCEL (Evaluation of XIENCE
PRIME Everolimus Eluting Stent System [EECSS] or
XIENCE V EECSS Versus Coronary Artery Bypass
Surgery for Effectiveness of Left Main Revascularization)
trial (NCT01471522), investigating the treatment of
unprotected left main coronary artery disease, and the
Figure 1. Scatter Plots for Individual Patients in the Left Main and 3-Vessel Disease Cohorts of the Randomized SYNTAX Trial (N ¼ 1,800)
The scatter plots for the left main and 3-vessel disease cohorts of the SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery)
trial are based on the SYNTAX score II. The diagonal line represents identical mortality predictions for CABG and PCI. Individual mortality predictions plotted to the left
of the diagonal line favor CABG (actual percentages shown in top left corner), and to the right favor PCI (actual percentages shown in bottom right corner).
Individual mortality predictions for CABG or PCI that could be statistically separated with 95% confidence (p < 0.05) are colored black (actual percentage shown in
parentheses in respective corners). Mortality predictions that could not be statistically separated with 95% confidence (p > 0.05) are highlighted in gray, and identify
patients with similar 4-year mortality. 3VD ¼ 3-vessel disease; CABG ¼ coronary artery bypass grafting; LMS ¼ left main stem; PCI ¼ percutaneous coronary inter-
vention. Legend and image are adapted and reproduced, with permission, from Farooq et al. (19).
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planned SYNTAX Trial II, investigating the treatment of de
novo 3-vessel disease, the SYNTAX score and SYNTAX
score II, respectively, are being used to recruit subjects on the
grounds of patient safety (30). Further delineating the
boundaries between CABG and PCI is where further study
is heading to help best define the optimal revascularization
modality for individual patients with complex coronary
artery disease.
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Summary and Conclusions
As a direct result of the all-comers SYNTAX Trial, the boundaries between a percutaneous 
and a surgical based approach to coronary revascularisation in subjects with complex 
coronary artery disease has more clearly been defined. The present thesis has allowed 
for a greater understanding of the results of this landmark trial, and has developed/
validated several SYNTAX based tools to allow application of the findings to clinical 
practice, as summarised in Chapter 10. Within the Appendix is enclosed the SYNTAX II 
trial protocol, investigating the management of de novo three vessel disease, and will 
use the SYNTAX Score II as a tool to recruit subjects on the grounds of patient safety. As 
to whether the boundaries between the two revascularisation modalities will change 
with advances in technology with either technique is the subject of ongoing and future 
trials. Irrespective of the results of these trials, it should be emphasised that treatment 
recommendations for patients with complex coronary artery disease needs to be made 
by a heart team, in open dialogue with the patient, rather than an individual practitioner.
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Samenvatting en Conclusies
Als direct gevolg van de ‘all-comers’ SYNTAX Trial zijn de grenzen tussen een percutane 
en chirurgische benadering van coronaire revascularisatie bij patiënten met complexe 
kransslagaderziekte duidelijker gedefinieerd. Dit proefschrift heeft geleid tot een beter 
begrip van de resultaten van deze baanbrekende trial. De verschillende SYNTAX geba-
seerde tools, die zijn ontwikkeld en gevalideerd voor toepassing van de bevindingen in 
de klinische praktijk, zijn samengevat in hoofdstuk 10. Het SYNTAX II onderzoeksproto-
col in de appendix stuurt de behandeling van ‘de novo three vessel disease’ en gebruikt 
de SYNTAX Score II als een instrument voor selectie van patiënten die adequaat en 
veilig percutaan behandeld kunnen worden. De vraag of de grenzen tussen de twee 
revascularisatie technieken zullen verschuiven met de vooruitgang in beide technieken 
is het onderwerp van lopende en toekomstige trials. Ongeacht de resultaten van deze 
trials, moet worden benadrukt dat de aanbevelingen voor behandeling van patiënten 
met complexe kransslagaderziekte moeten worden gedaan door een hart team, in open 
dialoog met de patiënt, in plaats van door een individuele arts.
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ABSTRACT
The SYNTAX Score (http://www.syntaxscore.com) has
established itself as an anatomical based tool for
objectively determining the complexity of coronary artery
disease and guiding decision-making between coronary
artery bypass graft (CABG) surgery and percutaneous
coronary intervention (PCI). Since the landmark SYNTAX
(Synergy between PCI with Taxus and Cardiac Surgery)
Trial comparing CABG with PCI in patients with complex
coronary artery disease (unprotected left main or de
novo three vessel disease), numerous validation studies
have confirmed the clinical validity of the SYNTAX Score
for identifying higher-risk subjects and aiding decision-
making between CABG and PCI in a broad range of
patient types. The SYNTAX Score is now advocated in
both the European and US revascularisation guidelines
for decision-making between CABG and PCI as part of a
SYNTAX-pioneered heart team approach. Since
establishment of the SYNTAX Score, widening clinical
applications of this clinical tool have emerged. The
purpose of this review is to systematically examine the
widening applications of tools based on the SYNTAX
Score: (1) by improving the diagnostic accuracy of the
SYNTAX Score by adding a functional assessment of
lesions; (2) through amalgamation of the anatomical
SYNTAX Score with clinical variables to enhance
decision-making between CABG and PCI, culminating in
the development and validation of the SYNTAX Score II,
in which objective and tailored decisions can be made
for the individual patient; (3) through assessment of
completeness of revascularisation using the residual and
post-CABG SYNTAX Scores for PCI and CABG patients,
respectively. Finally, the future direction of the SYNTAX
Score is covered through discussion of the ongoing
development of a non-invasive, functional SYNTAX Score
and review of current and planned clinical trials.
INTRODUCTION
The SYNTAX Score (http://www.syntaxscore.com)
has emerged as an anatomically based tool for
objectively determining the complexity of coronary
artery disease and guiding decision-making
between coronary artery bypass graft (CABG)
surgery and percutaneous coronary intervention
(PCI).1–4 Since the landmark SYNTAX (Synergy
between PCI with Taxus and Cardiac Surgery)
Trial5–7 comparing CABG with PCI in patients with
complex coronary artery disease (unprotected left
main coronary artery (ULMCA) or de novo three
vessel disease (3VD)), numerous validation studies
have confirmed the clinical validity of the SYNTAX
Score for identifying higher-risk subjects and aiding
decision-making between CABG and PCI in a
broad range of patient types.4 8 The SYNTAX
Score is now advocated in both the European and
US revascularisation guidelines9–11 as part of the
SYNTAX-pioneered heart team approach.12 In
addition, the US Food and Drug Administration
mandates the SYNTAX Score as an entry criterion
in ongoing contemporary stent and structural heart
disease trials—namely, the EXCEL (Evaluation of
XIENCE PRIME or XIENCE V Everolimus
Eluting Stent System Versus Coronary Artery
Bypass Surgery for Effectiveness of Left Main
Revascularisation) Trial (ClinicalTrials.gov identi-
fier: NCT01205776)13 and SURTAVI (Safety and
Efficacy Study of the Medtronic CoreValve System
in the Treatment of Severe, Symptomatic Aortic
Stenosis in Intermediate Risk Subjects Who Need
Aortic Valve Replacement) Trial (ClinicalTrials.gov
identifier: NCT01586910).
Since establishment of the SYNTAX Score,
widening clinical applications of this clinical tool
have emerged (table 1). The purpose of this review
is to give the clinician a concise overview of the
widening applications of the SYNTAX Score, from
improving its diagnostic accuracy by incorporation
of a functional component, augmenting the ana-
tomical SYNTAX Score with clinical variables to
enhance decision-making between CABG and PCI,
moving towards individualised decision-making
between CABG and PCI, to assessment of the com-
pleteness of revascularisation and its prognostic
implications. Lastly, the future direction of the
SYNTAX Score is explored.
ANATOMICAL AND FUNCTIONAL APPROACH
SYNTAX Score
The SYNTAX Score was developed during the
design of the SYNTAX Trial as a tool to force the
interventional cardiologist and cardiac surgeon to
systematically analyse the coronary angiogram and
to specify the number of coronary lesions requiring
treatment, their angiographic location and anatom-
ical complexity.1–5 8 The SYNTAX Score combines
the importance of a diseased coronary artery
segment in terms of its severity (ie, obstructive or
occlusive), anatomical location and importance in
supplying blood to the myocardium (‘vessel-
segment weighting’ based on the Leaman Score14),
adverse lesion characteristics (American College of
Cardiology (ACC)/American Heart Association
(AHA) lesion classification),15 bifurcation lesion
characteristics (Medina classification16) and total
occlusion characteristics from the European
TOTAL Surveillance Study.17 Each vessel segment,
1.5 mm in diameter or greater (figure 1A, labelled
1–16), with a ≥50% diameter stenosis by visual
estimation, is awarded a multiplication factor
related to coronary lesion location and severity
(figure 1A). Further characterisation of the coron-
ary lesions leads to the addition of more points
(figure 1B), which includes features of total occlu-
sions (duration, length, blunt stump, presence of
bridging collaterals or side branch), bifurcation
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(Medina classification16) or trifurcation (number of diseased
branches involved), side branch angulation, aorto-ostial lesion,
severe tortuosity, lesion length >20 mm, heavy calcification,
thrombus, and diffuse or small vessel disease. An online
SYNTAX Score algorithm1 automatically summates each of
these features to calculate the total SYNTAX Score.
Based primarily on the results of the SYNTAX Trial,5–7
current European revascularisation guidelines9 give subjects with
3VD and low SYNTAX Scores (0–22) a level of evidence of IA
for CABG and IIa B for PCI. In subjects with ULMCA disease
and low to intermediate SYNTAX Scores (<33), a level of evi-
dence of IA is given for CABG and IIb B for PCI. Furthermore,
US guidelines now give surgical revascularisation for ULMCA
disease a Class 1B recommendation,10 11 compared with a Class
1A recommendation in previous guidelines.18
Functional SYNTAX Score
PCI guided by the assessment of the functional significance of a
lesion using fractional flow reserve (FFR) has been shown to
improve clinical outcomes.19 The functional SYNTAX Score
uses the principle of the functional assessment of coronary
lesions to determine the SYNTAX Score, rather than the angio-
graphic determination of the SYNTAX Score based on visual
assessment, as is undertaken in conventional SYNTAX Score cal-
culations. In a retrospective sub-analysis of almost 500 patients
(n=497) from the FFR-guided arm of the FAME (Fractional
Flow Reserve vs Angiography for Multivessel Evaluation) Study,
the primary benefit was reclassifying higher-risk groups into
lower-risk categories without any adverse sequelae in terms of
major adverse cardiac events (MACE) and death or myocardial
infarction (MI) at 1 year.20
Table 1 Outline of the SYNTAX Score and how it has progressed since its inception
Year
‘conceived’ Structure Remarks
Anatomical
SYNTAX Score5–8
2006 Score of angiographic variables—that is, anatomical complexity.
Developed during the design of the SYNTAX Trial3 5 as a tool to
force the heart team to systematically analyse the coronary
angiogram and agree that equivalent anatomical revascularisation
(CABG and PCI) could be achieved
First reported to be useful for decision-making between CABG
and PCI in the SYNTAX Trial in 2009.5 Categories of anatomical
complexity (low, intermediate and high), no clinical variables, no
individual predictions. Adding a functional component shown to
improve accuracy.20 Non-invasive multislice CT anatomical
SYNTAX Score in development,58 with integration of a
non-invasive functional component4
‘Development phase’—augmenting the anatomical SYNTAX Score with clinical variables and the move towards individualised decision-making
ACEF23 2009 Age, creatinine, ejection fraction Predicted individual in-hospital operative mortality after CABG.
Shown to be at least comparable to the EuroSCORE (composed of
17 variables) in predicting operative risk.21–23 Shown to aid in
long-term predictions of mortality after PCI or CABG36
Clinical SYNTAX
Score29
2010 Amalgamation of SYNTAX Score with modified ACEF Score
(creatinine replaced with CrCl, as shown to be more predictive of
mortality)
Similar to the SYNTAX Score; categorised patient risk. Could only
identify a high-risk group in PCI-treated patients. Provided little
help in decision-making between CABG and PCI. Not
individualised
Global Risk31 36 2010 Amalgamation of SYNTAX Score with surgical EuroSCORE
(composed of 17 variables)
Similar to the SYNTAX Score; categorised patient risk. Could
identify a low-risk group with comparable outcomes to CABG and
PCI in left main and 3VD patients. Not individualised. High
EuroSCORE patients identified to have a prognostic benefit in
undergoing CABG compared with PCI irrespective of the SYNTAX
Score, provided that an acceptable threshold of operative risk not
exceeded
Logistic Clinical
SYNTAX Score32 33
2011 Combination of age, SYNTAX Score, age, CrCl, LVEF shown to
contain the majority of the prognostic information for 1-year
mortality predictions after PCI
Individual 1-year mortality predictions in all PCI patients (STEMI,
NSTEMI) irrespective of clinical presentation (except cardiogenic
shock). Not designed for decision-making between CABG and
PCI. Cross-validated in seven contemporary stent trials and >6000
patients32 and further externally validated33
End result of this process leading to the development of the SYNTAX Score II
SYNTAX
Score II38 40
2012 Augmenting SYNTAX Score with clinical variables—based on the
principle that age, CrCl, LVEF and SYNTAX Score contained the
majority of the long-term prognostic information in CABG and
PCI patients. Additional variables added that directly influenced
decision-making between CABG and PCI
Individualised approach. Threshold of the SYNTAX Score in
guiding decision-making between CABG and PCI shown to alter
based on the presence of other risk factors. Validated in the
DELTA Registry,41 containing left main and 3VD (quarter of
population), with a third (30%) of the population with highly
complex disease (SYNTAX Scores ≥33). Prospective validation
studies underway in the EXCEL Trial (left main) and planned
SYNTAX II Trial (de novo 3VD)
Use of the SYNTAX Score as an objective marker of completeness of revascularisation
Residual SYNTAX
Score47 48
2012 Recalculation of the SYNTAX Score after PCI Developed and validated in the ACUITY47 and SYNTAX47 48 Trials
respectively. A residual SYNTAX Score >8 was shown to have an
adverse effect on long-term prognosis at up to 5 years follow-up.
Further prospectively run validation studies are awaited
Post-CABG
SYNTAX Score51 52
2013 Recalculation of the SYNTAX Score after CABG, with points
deducted on the basis of importance of the diseased coronary
artery segment (Leaman Score14) in patients who have a
functioning bypass graft anastomosed distally
Pilot study in angiographic substudy of the SYNTAX Trial
demonstrated the feasibility of this approach in identifying
subjects after CABG with an adverse long-term (5 year)
prognosis.51 52 Validation studies are awaited
3VD, three vessel disease; ACUITY, Acute Catheterisation and Urgent Intervention Triage Strategy; CABG, coronary artery bypass graft; LVEF, left ventricular ejection fraction; NSTEMI,
non-ST segment elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST segment elevation myocardial infarction.
Farooq V, et al. Heart 2014;100:276–287. doi:10.1136/heartjnl-2013-304273 277
Review
 group.bmj.com on January 27, 2014 - Published by heart.bmj.comDownloaded from 
389Chapter 10
It should be emphasised that subjects in the FAME Study had
substantially less complex coronary artery disease (mean±SD
SYNTAX Score 14.8±6.0) compared with the PCI arm of the
SYNTAX Trial (mean±SD SYNTAX Score 28.4±11.5), and that
subjects with left main coronary artery disease were not investi-
gated. Prospective validation studies of the functional SYNTAX
Score in complex coronary artery disease are awaited at the time
of writing.
AUGMENTING THE ANATOMICAL SYNTAX SCORE WITH
CLINICAL FACTORS AND THE PERSONALISATION OF
DECISION-MAKING: DEVELOPMENT OF THE SYNTAX
SCORE II
Since the SYNTAX Score was developed, limitations of this
scoring system in aiding decision-making between CABG and
PCI has become evident—namely, the lack of clinical variables
and lack of a personalised approach to decision-making. Below
is a brief overview of the ‘development phase’ leading to the
SYNTAX Score II, which was designed to overcome these limita-
tions (table 1).
The law of ‘parsimony’ and ‘ACEF’
ACEF
Ranucci et al21–23 developed a simple risk model consisting of
only three clinical variables (age, serum creatinine and left ven-
tricular ejection fraction (LVEF)), for assessing operative mortal-
ity risk in elective cardiac operations (ACEF Score—figure 2A).
Based on the ‘law of parsimony’ or ‘the Ockham razor’
concept, whereby a simple model can explain a phenomenon
with the same level of accuracy as complex models, ACEF was
shown to be least comparable to the EuroSCORE (composed of
17 variables)24 25 in predicting in-hospital mortality after
CABG.22 23
The three risk factors used in ACEF are natural continuous
variables that are objectively defined and not subject to personal
estimation (eg, is the patient diabetic? does the patient have
extra cardiac arteriopathy?). In addition, the variables of ACEF
are known independent risk factors for mortality, and it was
subsequently shown that the end organ manifestations of the
risk factor (as identified in ACEF) are more important than the
actual presence of the risk factor for predicting long-term
prognosis.21 26–28
Clinical SYNTAX Score/Logistic Clinical SYNTAX Score
Based on the principle of ACEF, the Clinical SYNTAX Score,29–31
and subsequently the Logistic Clinical SYNTAX Score (figure
2B),32 33 were developed and validated. Both the Clinical
SYNTAX Score and Logistic Clinical SYNTAX Score combined
ACEF with the SYNTAX Score, and were shown to improve
mortality predictions compared with the SYNTAX Score alone
in subjects with complex coronary artery disease.29–33 Similar to
the conventional SYNTAX Score, the Clinical SYNTAX Score
relied on categorisation of risk (low, intermediate and high) and
was able to only identify a high-risk group after PCI.29–31 The
Logistic Clinical SYNTAX Score was designed to individualise
risk and provide 1-year mortality predictions in an all-comers
PCI population irrespective of clinical presentation (except
cardiogenic shock).32 33
The Logistic Clinical SYNTAX Score was developed and
cross-validated (‘internal–external’ validation procedure34) in
>6000 subjects from seven contemporary coronary stent
trials,32 and further externally validated in 2627 subjects pre-
senting with non-ST elevation acute coronary syndrome and
undergoing PCI from the Acute Catheterisation and Urgent
Intervention Triage Strategy (ACUITY) Trial.33 Notably, the add-
ition of a further six additional clinical variables, including dia-
betes, to the Logistic Clinical SYNTAX Score led to only a
minor incremental improvement in risk predictions.32 33 Thus,
the Logistic Clinical SYNTAX Score was shown to follow the
law of parsimony, as seen with the surgical ACEF model dis-
cussed above21–23—namely, the end organ manifestations of the
risk factor were more important than the actual presence of the
risk factor for predicting long term prognosis.
Global risk
In the SYNTAX Trial, it was shown that, as well as the SYNTAX
Score in PCI subjects, the EuroSCORE (a surgery-based risk
score composed of 17 variables designed to predict in-hospital
mortality after CABG24 25) was an independent predictor of
MACE in subjects undergoing surgery- or percutaneous-based
Figure 1 Coronary tree segments and their importance in supplying blood flow to the left ventricle (vessel segment weighting—weighting factors
—Leaman Score14) based on the presence of a right or left dominant system (A). A multiplication factor of ×2 is used for non-occlusive (50–99%
diameter stenosis) lesions and ×5 for occlusive (100% diameter stenosis) lesions. For example, a stenotic proximal LAD lesion (segment 6) would
have a weighting factor of 3.5×2 (7 points), and an occlusive proximal LAD lesion a weighting factor of 3.5×5 (17.5 points). Other adverse lesion
characteristics considered in the SYNTAX score have an additive value (B). Images used with permission from the SYNTAX Trial Investigators.
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revascularisation. Subsequently, it was hypothesised that the
amalgamation of the SYNTAX Score with the EuroSCORE
could improve decision-making between CABG and PCI.4 5 The
feasibility of this ‘Global Risk’ approach was demonstrated in a
registry of 255 subjects with left main coronary artery disease
using tertiles of the SYNTAX Score and tertiles of the additive
EuroSCORE that reflected their study population.35
Subsequently, the Global Risk was validated in the SYNTAX
Trial using conventional tertiles of the SYNTAX Score and
EuroSCORE,36 and was shown to substantially enhance the
identification of low-risk patients with ULMCA disease or de
novo 3VD who could safely and efficaciously be treated with
CABG or PCI, compared with the SYNTAX Score alone.
One of the unexpected findings from the Global Risk was
that higher-risk subjects (high additive EuroSCORE ≥6) in all
tertiles of the SYNTAX Score (low, intermediate or high) were
shown to have a potential prognostic benefit from undergoing
CABG compared with PCI, irrespective of the SYNTAX Score,
provided that an acceptable threshold of operative risk was not
exceeded.36 For example, in the 3VD cohort of the SYNTAX
Trial, the 3-year mortality of subjects with a low SYNTAX Score
(<23) and a high EuroSCORE (≥6) was doubled when
undergoing PCI (15.9%) compared with CABG (8.2%). One
hypothesis used to explain these findings is that the bypass graft
would potentially ‘protect’ the entire treated coronary vessel
from future cardiac events for the lifespan of the graft in high-
risk subjects compared with PCI, which would treat the individ-
ual lesion.37 On the basis of these observations, it was hypothe-
sised by the investigators that potentially low (or high) risk
subjects were potentially concealed by high (or low) risk subjects
in all tertiles of the SYNTAX Score. This hypothesis is what
prompted the investigators to develop a more individualised
approach to decision-making between CABG and PCI, and sub-
sequently led to the development of the SYNTAX Score II,38 as
detailed below.
SYNTAX Score II
As previously discussed, the combination of the anatomical
SYNTAX Score with ACEF contained most of the prognostic
information for predicting mortality after CABG (excluding the
anatomical SYNTAX Score21–23 36) or PCI (including the ana-
tomical SYNTAX Score32 36). The SYNTAX Score II was built
on the ACEF ‘skeleton’, with the addition of risk factors that
were shown to directly affect decision-making between CABG
Figure 2 Side by side comparisons of
ACEF (A) and the Logistic Clinical
SYNTAX Score (B). Images used with
permission from Ranucci et al23 and
Farooq et al.32 *SYNTAX-like patient
defined as fulfilling the enrolment
criteria for the SYNTAX All-Comers
trial, i.e. left main stem (isolated or
associated with one-, two-, or three-
vessel disease) or three-vessel disease
alone. CrCl, creatinine clearance,
LV ejection fraction, left ventricular
ejection fraction.
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and PCI—that is, interaction effects, namely a risk factor being
more predictive of mortality in patients undergoing PCI com-
pared with CABG, or vice versa (figure 3).38 For example, the
anatomical SYNTAX Score aids decision-making between CABG
and PCI because it is more predictive of clinical outcomes in
patients undergoing PCI than in patients undergoing CABG
(where it is not predictive). On the basis of this principle,
younger age, female gender and reduced LVEF favoured CABG
over PCI on long-term prognostic grounds. Thus, in such
patients, a lower anatomical SYNTAX Score would be required
in order for the long-term mortality risk to be similar between
CABG and PCI. In contrast, older age, chronic obstructive pul-
monary disease (COPD) or ULMCA disease favoured PCI over
CABG, and thus, in this type of patient, a higher anatomical
SYNTAX Score would be needed for the long-term mortality
risks to be similar.
By adopting the individualised approach of the SYNTAX
Score II, augmented by clinical variables, it was shown that
subsets of patients existed in all tertiles of the SYNTAX Score in
which CABG or PCI would confer a mortality benefit, or offer
similar long-term prognosis.38 A nomogram was developed
(figure 4) that allowed an accurate individualised prediction of
4-year mortality in patients proposing to undergo CABG or
PCI, to objectively aid decision-making. For example, a
60-year-old man with an anatomical SYNTAX Score of 30,
ULMCA disease, CrCl of 60 mL/min, a LVEF of 50%, and
COPD would have 41 points (predicted 4-year mortality
16.3%) and 33 points (predicted 4-year mortality 8.7%) for
CABG and PCI, respectively. The same example, without COPD
included, would lead to identical points (29 points) and identi-
cal 4-year mortality predictions (6.3%) for CABG and PCI. An
online version of the SYNTAX Score II will soon appear along-
side the original SYNTAX Score calculator (http://www.
syntaxscore.com).
Diabetics
Notably, diabetes was not included in the final SYNTAX Score
II, despite medically treated diabetes being prestratified at ran-
domisation as a powered subgroup in the SYNTAX Trial, and
present in over a quarter of the study patients (26%). This in
spite of diabetics being perceived as a specific high-risk group
potentially warranting a different treatment strategy compared
with patients with other risk factors.9–11 39
The primary reason for the non-inclusion of diabetes in the
SYNTAX Score II was that it was shown to be equally predictive
of mortality in the CABG and PCI cohorts of the SYNATX
Trial, after adjustment for other risk factors (figure 3) —that is,
diabetes lacked an interaction effect and was therefore not
Figure 3 Predictor effects for coronary artery bypass graft (CABG) and percutaneous coronary intervention (PCI) in the SYNTAX Score II. These are
represented visually as log HR for CABG and PCI on the y-axis for each predictor. Each predictor is expressed on the x-axis continuously (upper) or
categorically (lower), for a person of mean baseline characteristics. Diabetes is included (highlighted in red) to illustrate its absence of interaction
when included in the analyses. Note the different gradients of the hazards for PCI and CABG, leading to the hazards crossing at an anatomical
SYNTAX Score of 15. At this ‘cross-over’ point of hazards, the mortality risk is comparable between CABG and PCI. This threshold of cross-over of
hazards will vary according to the level of other variables, namely being lower for female gender, reduced left ventricular ejection fraction (LVEF)
and younger age, and higher for chronic obstructive pulmonary disease (COPD), unprotected left main coronary artery disease and older age. As
both PVD (p=1.00) and diabetes (p=0.67) lacked an interaction effect, as indicated by almost parallel HRs (ie, comparable increase in mortality
risk), their presence would have no effect on decision-making between CABG and PCI. Legend and image reproduced with permission from Farooq
et al.3 38 3VD three vessel disease; LMS left main stem; CrCl creatinine clearance; COPD chronic obstructive pulmonary disease; PVD peripheral
vascular disease.
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important for decision-making between CABG and PCI (after
adjustment for the end organ manifestations of the risk factors).
As previously discussed for ACEF, the end organ manifestation
of diabetes was what affected long-term mortality in CABG and
PCI populations21–23 28 32—and therefore decision-making
between CABG and PCI in the SYNTAX Score II—and not the
actual presence of the risk factor. The findings of the lack of
inclusion of diabetes in the SYNTAX Score II are supported by
epidemiological data, in which non-diabetics with chronic
kidney disease and proteinuria had a stronger association with
the risk of MI, and a higher mortality, than diabetics, and that
the relative risk of long-term mortality associated with chronic
kidney disease was ‘much the same irrespective of the presence
or absence of diabetes’.26 27
Validation of the SYNTAX Score II
As compared with existing revascularisation guidelines using the
anatomical SYNTAX Score,9–11 it was shown that, if CABG or
PCI was selected on the basis of a higher or lower expected sur-
vival (irrespective of the margin of difference) with the
SYNTAX Score II in the SYNTAX Trial, the SYNTAX Score II
would only need to be used in 110 patients to have one more
patient alive at 4 years.40
Figure 4 The SYNTAX Score II nomogram for bedside application. The total number of points for eight factors can be used to accurately predict
4-year mortality for the individual patient proposing to undergo coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI).
Image reproduced with permission from Farooq et al.38 *Due to the rarity of complex coronary artery disease in pre-menopausal women, mortality
predictions in younger women are predominantly based on the linear relationship of age with mortality. The differences in mortality predictions in
younger women between CABG and PCI will therefore be affected by larger 95% confidence intervals than those in older women but will be equally
valid. 3VD three vessel disease; LMS left main stem; CrCl creatinine clearance; LVEF left ventricular ejection fraction; COPD chronic obstructive
pulmonary disease; PVD peripheral vascular disease.
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External validation of the SYNTAX Score II38 was performed
in the multinational Drug Eluting stent for Left main coronary
Artery disease (DELTA) Registry (14 centres in Europe, USA and
South Korea),41 composed of subjects with ULMCA disease
associated with or without multivessel disease (26% of the study
population had 3VD). All variables in the SYNTAX Score II
interacted in a similar way, and therefore influenced decision-
making between CABG and PCI, in the SYNTAX Trial and
DELTA Registry, with the exception of age and LVEF, which had
minimal interactions in the DELTA Registry—findings that may
relate to the unavoidable selection bias inherent to all registries,
since decision-making between CABG and PCI has already been
made and would be difficult to control for.42 Even randomised
trials lacking an all-comers design, with restrictive inclusion and
exclusion criteria, can potentially make application to clinical
practice questionable.37 43 44 This is exemplified in a recent
meta-analysis of randomised trials undertaken before SYNTAX
comparing PCI with CABG, where in most trials 2–12% of
screened subjects were randomised because of the highly
restrictive inclusion and exclusion criteria.45 In this
meta-analysis, CABG was shown to be favoured in older sub-
jects, and PCI in younger subjects45—findings that have since
been directly contradicted by the SYNTAX Score II in the all-
comers SYNTAX Trial (where the opposite was shown).38
Hence ‘randomised’ validation of the SYNTAX Score II was
proposed,38 in which its further validation would be conducted
in randomised controlled trials or prospectively run studies, as
discussed below under Future directions.
TOOLS FOR ASSESSMENT OF COMPLETENESS
OF REVASCULARISATION
Interpreting the long-term prognostic impact of incomplete
revascularisation in patients with complex coronary artery
disease has historically been difficult.46 The lack of standardised
definitions of incomplete revascularisation has confounded this
issue and made comparisons between studies difficult. The
residual and post-CABG SYNTAX Score were designed to over-
come this limitation as detailed.
Residual SYNTAX score
The residual SYNTAX Score is based on the principle of being a
measure of the myocardial ischaemia burden, dependent on the
location of the coronary disease, its importance in supplying
blood to the myocardium, and the anatomical complexity (eg,
calcification, bifurcation, long lesion) associated with the
obstructive disease. The residual SYNTAX Score is essentially
the SYNTAX Score recalculated after the PCI procedure, and
provides an objective, quantitative measure of the degree and
complexity of residual stenosis after revascularisation. More
proximal coronary artery disease scores more highly on the
residual SYNTAX Score since this is dependent on the vessel-
segment weighting as previously discussed (figure 1), particu-
larly if the obstructive disease is more complex.47 48
Genereux et al47 first demonstrated that a residual SYNTAX
Score of >8.0 after PCI was associated with adverse 1-year mor-
tality, in a post hoc analysis of the ACUITY Trial. The ACUITY
Trial consisted of subjects with moderate- to high-risk acute cor-
onary syndrome undergoing PCI, and substantially less complex
coronary artery disease (median SYNTAX Score 9.0, IQR 5.0–
16.0) compared with the SYNTAX Trial (median SYNTAX
Score 28, IQR 20.0–36.0).
The residual SYNTAX Score was subsequently validated in
the randomised, all-comers SYNTAX Trial, consisting of subjects
with complex coronary artery disease (ULMCA or de novo
3VD) at the final 5-year follow-up.48 The previous finding of a
residual SYNTAX Score of >8 being associated with adverse
long-term clinical outcomes in the ACUITY Trial47 was found to
be equally of importance in SYNTAX patients who underwent a
5-year follow-up. Notably, as the baseline SYNTAX Score
increased, the frequency of a residual SYNTAX Score >8
increased in unison, with an associated increase in long-term
mortality (figure 5). In addition, progressively higher residual
SYNTAX Scores were shown to be a surrogate marker of sicker
patients,49 with greater baseline clinical comorbidity and ana-
tomical complexity, with consequent adverse long-term clinical
outcomes, including all-cause mortality.
Stratified analyses in the powered subgroups of ULMCA
disease and medically treated diabetes showed a residual
SYNTAX Score of >8 to be associated with adverse long-term
clinical outcomes, including mortality. Stratified analyses in sub-
jects with reduced LVEF also showed the results to be equally
applicable, whereas, in subjects with total occlusions, a more
modest effect was shown that did not reach statistical signifi-
cance. The latter perhaps implied that appropriate viability
assessment was required to ensure that revascularisation of the
total occlusion was appropriate and clinically justified.50
In summary, the residual SYNTAX Score allowed the quantifi-
cation of the degree of revascularisation, and the determination
of an objective level of reasonable incomplete revascularisa-
tion,46 whereby a threshold value could be determined (≤8) that
would not have a negative effect on long-term mortality and
other clinical outcomes.
Post-CABG SYNTAX Score
The CABG equivalent of the residual SYNTAX Score—post
CABG SYNTAX Score—has recently been shown to be linked to
adverse 5-year clinical outcomes, including mortality, in the angio-
graphic substudy of the SYNTAX Trial (SYNTAX-LE MANS)
(figure 6A).51 52 Owing to the inherently different mechanisms of
treatment of coronary artery disease with CABG and PCI, calcula-
tion of the residual SYNTAX Score (ie, burden of coronary disease
removed by PCI) differs from that of the post-CABG SYNTAX
Score (ie, coronary disease bypassed with a graft). The basic prin-
ciple of the post-CABG SYNTAX Score is that it deducts points
from the ‘native’ baseline SYNTAX Score based on the level of
‘protection’ conferred by the bypass grafts, through deduction of
the vessel-segment weighting (Leaman Score14—figure 1) that the
bypass graft provides (figure 6B). Since the post-CABG SYNTAX
Score is based on validated physiological principles of blood flow
(Leaman Score14), it does not arbitrarily deduct points for the type
of bypass graft anastomosed. Points related to native coronary
disease (eg, bifurcation disease, calcification, total occlusions, long
lesions, diffuse disease) remain unaltered.
Historical evidence to back up the findings from the
post-CABG SYNTAX Score being linked to adverse long-term
prognosis comes from the CASS (Coronary Artery Surgery
Study)53 and Rotterdam54 registries. First, in both studies, more
extensive preoperative coronary artery disease was linked to the
higher prevalence and severity of other clinical risk factors and
adverse long-term prognosis, compared with subjects with less
complex coronary artery disease. Second, 5 years follow-up of
the Bypass Angioplasty Revascularisation Investigation (BARI)
Trial demonstrated that native coronary disease progression (and
not the extent of initial revascularisation) was the predominant
determinant of the recurrence of angina and jeopardised myo-
cardium in percutaneous and surgically revascularised subjects.55
Lastly, coronary artery calcification has been linked to adverse
all-cause mortality at 10 years, independent of other risk
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factors.56 57 Validation studies of the post-CABG SYNTAX
Score are awaited at the time of writing.
FUTURE DIRECTIONS
Non-invasive SYNTAX Score
Multislice CT SYNTAX Score
Papadopoulou et al58 first described the feasibility and reproduci-
bility of a multislice CT (MSCT)-derived SYNTAX Score in
80 consecutive patients with symptomatic angina, using defini-
tions of the angiographically defined SYNTAX Score adapted for
the MSCT capabilities. The underlying concept was to allow the
SYNTAX Score to be calculated before the intervention, to
potentially aid decision-making and optimise patient manage-
ment. In this study, the MSCT SYNTAX Score was shown to be
feasible, with results comparable to the SYNTAX Score calculated
with conventional coronary angiography. While this study was
shown to be highly reproducible,58 a subsequent validation study
of similar size (n=104) found only fair agreement between
MSCTand angiography-derived SYNTAX Scores,59 although this
did improve substantially when analyses were restricted to good
quality MSCT. Notably, both studies investigated subjects with
predominantly less complex coronary artery disease (low
SYNTAX Scores <23).58 59 Larger scale validation studies, par-
ticularly in more complex ‘SYNTAX-like’ patients, are awaited.
Non-invasive FFR
The addition of a non-invasive FFR component (Heartflow,
Redwood City, California, USA) has the potential to allow the
Figure 5 The residual SYNTAX Score in the SYNTAX Trial. Complete (residual SYNTAX Score 0) and incomplete (tertiles of the residual SYNTAX
Score (residual SYNTAX Score >0)) revascularisation, stratified according to tertiles of the baseline SYNTAX Score (A). Kaplan–Meier curves showing
cumulative event rates through to 5 years, based on complete (residual SYNTAX Score 0) and incomplete (tertiles of residual SYNTAX Score)
revascularisation, in the low (0–22), intermediate (23–32) and high (≥33) baseline SYNTAX Scores (B). Note the progressive increase in the
frequency of a residual SYNTAX Score >8 across the tertiles of the baseline SYNTAX Score (A) and its association with adverse long-term mortality
(B). Legend and image reproduced with permission from Farooq et al.48
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non-invasive calculation of a functionally based MSCT
SYNTAX Score. This technology is based on using computa-
tional fluid dynamic techniques applied to the MSCT angiog-
raphy.58 Validation data from the non-invasive FFR MSCT have
been reported in the DISCOVER FLOW and multicentre
DeFACTO (Determination of Fractional Flow Reserve by
Anatomic Computed Tomographic Angiography) Trials.4 60–62
In both studies, non-invasive FFR MSCTwas shown to substan-
tially improve the diagnostic accuracy in detecting haemo-
dynamically significant coronary artery disease in subjects with
suspected coronary artery disease. Application of this technol-
ogy in subjects with more complex coronary artery disease has
recently been undertaken (figure 7). At the time of writing,
work to derive a non-invasive functional MSCT SYNTAX Score
using this technology is in progress.
Ongoing and future studies
EXCEL Trial
The ongoing international multicentre EXCEL Trial is aiming to
recruit 2600 patients with ULMCA disease and a SYNTAX
Figure 6 (A) The post-coronary
artery bypass graft (CABG) SYNTAX
Score in the angiographic substudy of
the SYNTAX Trial (SYNTAX-LE MANS).
Outcomes (Kaplan–Meier curves)
separated by the median of the
post-CABG SYNTAX Score into low (0–
21; n=58) and high (≥22; n=55) score
groups. At 5 years, significantly greater
all-cause mortality, significantly greater
all-cause death/CVA/myocardial
infarction (MI) and major adverse
cardiovascular and cerebrovascular
events (MACCE) were evident in the
high post-CABG SYNTAX Score group
compared with the low post-CABG
SYNTAX Score group. Note the peak in
MACCE at approximately 18 months
secondary to patients undergoing
scheduled coronary angiography, the
findings of which triggered repeat
revascularisation. (B) Example of the
calculation of the post-CABG SYNTAX
Score. Occluded left main (#) in a left
dominant system gave a native
SYNTAX Score of 39 (upper image).
A patent left internal mammary artery
(LIMA) inverse Y graft anastomosed to
the mid LAD (upper white arrow), with
sequential anastomoses to the 1st, 2nd
and 3rd obtuse marginal (OM)
branches (lower three white arrows)
are shown. Based on the vessel
segment weighting (refer to figure 1),
17.5 (occluded proximal LAD) and 12.5
(occluded proximal left circumflex
(LCx)) points were deducted from the
native SYNTAX Score. Post-CABG
SYNTAX Score was therefore 39−17.5
−12.5=9 points. Legend and images
reproduced with permission from
Farooq et al.51 52
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Score <33, randomised to CABG (n=1300) or PCI with con-
temporary stents (n=1300).13 The primary end point is a com-
posite measure of all-cause death, MI or stroke 3 years after
revascularisation. As part of the EXCEL Trial, validation of the
SYNTAX Score II has recently been prespecified as an end
point.
SYNTAX II trial
The planned SYNTAX II single-arm trial will use the SYNTAX
Score II38 as a tool to recruit subjects with de novo 3VD
(without left main involvement) on the grounds of patient safety
—that is, subjects with a similar long-term mortality between
CABG and PCI, as determined by the SYNTAX Score II in con-
junction with the heart team. Notably, subjects from all tertiles
of the SYNTAX Score will be eligible. The PCI procedure will
be guided by a functional assessment of all three vessels (func-
tional SYNTAX Score20), a newer generation stent platform
with a biodegradable polymer,63 64 and intravascular
ultrasound-guided stent implantation.65 The PCI and CABG
arms of the SYNTAX Trial5–7 will act as control arms. Validation
of the SYNTAX Score II will be prespecified as an end point.
Recruitment of patients is expected to begin towards the end of
the year.
SUMMARY
Since the founding of the original SYNTAX Score, a multitude
of clinical applications have emerged as discussed in this review.
It is, however, important to recognise that randomised trials
lacking an all-comers trial design, and registries (however well
designed), have their inherent limitations as discussed, and
further validation of SYNTAX-based tools in these populations
should be interpreted with caution. So-called ‘randomised valid-
ation’ may prove to be the better technique in further validating
these tools to remove any form of selection bias, particularly in
registries, where decision-making between CABG and PCI has
already been undertaken. Moreover, the move away from cat-
egorisation of risk (ie, low, intermediate or high) to individual
risk profiling, culminating in the development of the SYNTAX
Score II, is a significant step forward, provided that it is under-
taken in the context of the heart team in open dialogue with the
patient, whose individual perception of short- and long-term
risk would prove to be an important factor in decision-making.
SYNTAX-based tools (residual and post-CABG SYNTAX
Scores), as measures of completeness of revascularisation, show
significant promise, and may aid the heart team in determining
a reasonable level of revascularisation. The ongoing develop-
ment of a non-invasive functional SYNTAX Score would
undoubtedly prove to be a significant development in streamlin-
ing and simplifying the heart team process.
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Getting to Rotterdam
My decision to enter interventional cardiology happened more by chance than actual 
planning. Shortly after I graduated, personal events drew me towards realising that 
cardiology, and at that interventional cardiology, was where my career ambitions firmly 
lay. I still vividly remember being amazed at the immediate impact that the insertion of 
a small piece of metal (coronary stent) had in the treatment of a myocardial infarction. 
“You must do the thing you think you cannot do.” [Eleanor Roosevelt] 
Several years later I picked up the PhD thesis of an ex fellow of Professor Serruys on 
coronary bifurcations and chronic total occlusions at a PCI meeting in Leeds UK, and 
literally read it cover to cover. I still remember saying to myself, don’t even bother trying 
to get to Rotterdam, it’s too far away, and I won’t be good enough…
“Expect the best, prepare for the worst.” [Muhammad Ali Jinnah]
My decision to come to Rotterdam again happened more by chance rather than actual 
planning. I was extremely motivated to undertake interventional research, particularly in 
relation to the bioabsorbable scaffolds – the so called next ‘revolution’ in interventional 
cardiology – and was going through the process of writing research grants to set up a 
project up in the UK. We were however struggling to secure the backing of industry on 
which the foundations of the project lay. 
“Screw it, Let’s do it!” [Sir Richard Branson]
Towards the end of 2009, several of my colleagues suggested I should write to Professor 
Serruys about an interventional research fellowship at the Thoraxcenter in Rotterdam. 
Rather unexpectedly I got an immediate offer of a series of interviews, which I attended 
in December 2009 at the Thoraxcenter. I had very little expectation at the interviews and 
remember telling myself, you have nothing to lose, just go for it... I had interviews firstly 
with the late Professor Willem van der Giessen, Dr Eric Duckers, Dr Peter de Jaegre, and 
at the end of the day, Professor Serruys, who were all very enthusiastic and positive. This 
was subsequently followed up by a personal phone call from Professor Serruys inviting 
me to join his team at Rotterdam. I still remember, I rather embarrassingly repeatedly 
asked (in more than one phone call when I was dealing with the logistics in coming to 
Thoraxcenter) “are you really offering me a position?” 
At the time of accepting the position to come to Rotterdam, I was working at Man-
chester Royal Infirmary. I am grateful to the entire team here for their advice and support 
during this period, in particular, Faz, Doug, Magdi, Raj, Bernard, Mahadevan, Helen and 
Mamas. In addition, I am grateful to Dr Lawrence Cotter and Dr Ngozi Edi-Osagie, past 
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and present chairman of The Dickinson Trust Traveling Scholarship Fund, Manchester 
Royal Infirmary, the Dickinson Trustees, Michael Pate, and Salley Hussey, for a financial 
grant that contributed to supporting my time in Rotterdam. I am grateful to Dr Peter 
Clarkson, Dr Amir Zaidi, and Dr Andy Jones from the North Western Deanery for their 
support in allowing me to take time out of my interventional cardiology training in 
Manchester to go to Rotterdam.
Rotterdam
“Attitude is a little thing that makes a big difference.” [Sir Winston Churchill]
I settled in a modest place in Rotterdam in Aug 2010 with the invaluable assistance 
of my dear brother Javad who took time out of his busy job abroad to help me with 
the move. I remember turning up to work for the first time and meeting the Professor. 
His enthusiasm was unbounded and he literally threw me into multiple meetings and 
research proposals. As the professor used to say, “total immersion” in all the fields was 
required. At first it was overwhelming. The best analogy is being a novice swimmer and 
being politely nudged in at the deep end and just expected to swim! Of course the 
support was there – I just had not yet realised…
“Never, never, never give up.” [Sir Winston Churchill] 
The beginning was however tough. I had to learn to develop a thick skin and take criti-
cism and rejections constructively. Professor Serruys used to advise me, no one knows 
“who this Vasim Farooq is,” and that you are “travelling in well chartered waters.” In my 
first 18 months I made steady progress, and had the pleasure to work with multiple 
teams on various projects ranging from preclinical to clinical research. In addition, we 
formed a friendly collaboration with Professor Ewout Steyerberg and his team (Yvonne 
and David). 
“Your assumptions are your windows on the world. Scrub them off every once in a while, or 
the light won’t come in.” [Isaac Asimov]
At each stage, our knowledge and understanding of the field continued to evolve, 
previously held assumptions challenged, and we collectively went on to prove our 
hypotheses. The frequent occasions to personally present our work at major interna-
tional meetings, such as the European Society of Cardiology (ESC), American College of 
Cardiology (ACC), EuroPCR, Transcatheter Cardiovascular Therapeutics (TCT) congresses, 
followed by acceptance in reputable scientific journals proved to be a major vindication 
of our efforts.
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“Alone we can do so little; together we can do so much…” [Helen Keller]
There are multiple people I need to thank for my time in Rotterdam, far too many to list 
below. If I have missed anyone of – I apologise. I truly believe that the friends I made in 
Rotterdam were like an extended family and still regard the city as my second home…
Thoraxcenter and Department of Public Health, Erasmus MC
I am indebted to Professor Patrick Serruys and Professor Felix Zijlstra to allow me the 
honour of undertaking and continuing my fellowship at the Thoraxcenter, Rotterdam. 
Hector’s wise counsel, friendship and frequent dinners with his family; the energy and 
vibrancy of my good friend Pascal Vranckx – a rare breed of being an interventional-
ist, an intensivist and a thoroughly nice chap; Yoshi – in particular for his passion of 
all things interventional – and for just being Yoshi (he will understand); Osama – your 
friendship, good humour, unique insights into all things TAVI, and regular socialising; the 
guidance and kind words of Carl Schultz and Nicolas van Mieghem; the counsel of the 
late Professor Willem van der Giessen, Robert-Jan van Geuns, Arie-Pieter Kappetein, Eric 
Duckers, Pim J. de Feyter; the invaluable help from Jurgen Ligthart and colleagues; the 
collaboration with Heleen van Beusekom, Koen Nieman and Eric Boersma; the friend-
ship and good humour of Joost Daemen and Nico Bruining; the unique opportunity 
to collaborate with my other mentor and friend Professor Ewout Steyerberg – from our 
very first meeting your enthusiasm was limitless, your unwavering support appreciated; 
Yvonne Vergouwe  – with her rather large motorcycle…I do miss our regular meetings; 
my dear friend David van Klaveren, your professionalism and friendship are something 
I miss dearly.
Interventional Fellows (in order of meeting) – a truly international team!
Josep Gomez Lara (Spain), Joanna Wykrzykowska (US), Roberto Diletti (Italy), Bill 
“Vasileios” Gogas (and his wife Katerina) (Greece), Salvatore Brugaletta (Italy), Juan 
Luis Gutiérrez Chico (Spain), Maria Radu (Denmark), Chrysafios Girasis and Stella-Lida 
(Greece), Michael Magro (Malta), Cihan Simsek (The Netherlands), Stuart Head (The 
Netherlands), Nienke van Ditzhuijzen (The Netherlands), Jung Ho Heo (South Korea), 
Lorenz Räber (Switzerland), Takashi Muramatsu (and his wife Yuko) (Japan), Il Soo Lee 
(and his wife Mijung) (South Korea), Alexander Kharlamov (Russia), Christos Bourantas 
and Thekla Geragotou (Greece), Yaojun Zhang (China), Javaid Iqbal (UK), Shimpei Naka-
tani (Japan), Carlos Campos (Brazil).
It is difficult to know where to start in acknowledging the countless fellows I had the 
pleasure to work with and can truly call my friends. We shared the highs and lows of re-
search together, we learnt from each other, we socialised together, travelled to national 
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and international congresses together, we spent so much time together that it was 
practically like an extended family. It was always difficult when friends returned to their 
mother countries; this was however offset by the new blood that inevitably occurred. 
I can never forget the first social event in Rotterdam. A delicious Spanish meal at Hec-
tor’s house, with paella prepared by my Spanish friends; countless lunch and evening 
meals at each others apartments; the culinary and somewhat odd linguistic skills of 
Josep (I think he had similar views about my English accent…); the passion of my Italian 
and Spanish friends Roberto, Salvatore and Juan Luis; larger than life, straight-talking 
Bill and his music and friendship; my dear friends Maria and Lorenz  – your good humour 
and friendship are sorely missed; Chrysafios (Chris) and my Maltese friend Michael, we 
worked extremely well together, I still have the recording of the only time Chris ever 
admitted he was wrong!; my Dutch friends Stuart, Cihan, and Nienke – as you may well 
know at first Rotterdam did not quite agree with me, but I grew to love the city (similar to 
the feelings I had when I first went to Manchester); the hospitality and friendship of Jung 
Ho and Il Soo – Jung Ho the busy researcher/photographer and Il Soo, the gentle, man of 
peace – I pray your son (Sang Joon) continues to make a speedy recovery; Takashi (and 
Yuko) – at first we did not understand what each other were saying, yet after 3 months 
we passed that barrier and became great friends (I later found it took you 6 months be-
fore you finally understood my English accent! – qualities that simply underlie the true 
gentleman that you are…); my dear friends Chris Bourantas (with whom I had briefly 
met in the UK many years previously at the start of my training in cardiology) and Thekla 
– your wedding in an olive garden in Athens was inspirational…truly unforgettable…
your country beautiful…and I even managed a Greek dance (albeit very poorly as the 
videos well prove!); Yaojun, your enthusiasm and energy were inexhaustible; my dear 
friend Javaid, am sure you have now settled in Rotterdam; Shimpei and Carlos, I only 
briefly met you before I left Rotterdam but could see we would have been great friends.
Cardialysis
I must consider the organizer as more important than the discoverer. [Carl Wilhelm Wolfgang 
Ostwald]
Gerritt-Anne van Es, Coen van Kalken, Hanny Boutkan, Marie-angèle Morel, Teun Smits, 
Ana Guimaraes (and her little ones), Ton de Vries, Jolanda de Groot, Glenda van Bochove, 
Linda Korthout, Ravindra Pawar, Jamal, Bianca Backx, Anne-Marie Bruinsma, Anne-Marie 
Hoogenboom, Yvonne, Arja, Eliane Lopes dos Santos, Marije, Marieke Tuinman, Peter 
Paul Kint, Mandy Hartwig, Janette Symons, Linda Roest, Monique Schuijer, Jeannette 
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Fong-Pien-Joe, Ad Meijer, Andre Boogaards, Tessa Rademaker, Michael Swart, Marco 
Bressers, Eric van Remortel, Wietze Lindeboom, Pierre Gobbens.
It is difficult to know where to start thanking the people of Cardialysis for their time 
and hospitality. All I can say is that they are a truly wonderful, friendly, and highly profes-
sional team. I learnt so much from you all, and left regarding many of you as my friends. 
You are all missed. 
Gerritt-Anne, a personal thank you for your support during my time in Rotterdam. 
Teun, Ana and Marie-angèle – I do miss our daily early morning banter, Teun your dry 
sense of humour was unforgettable, and I was truly flattered by your leaving present, 
Ana it was always a real delight talking to you and seeing your little ones – thank you 
for introducing me to haring at Schmidt’s place and the good advice of the need to 
chew the haring to prevent any sickness…; Ton, Tessa, Michael, Marco, Eric, Wietze and 
Pierre – in my eyes the “magnificent seven” who I learnt so much from and was truly 
a wonderful experience working with; Ton even in times of tight deadlines you were 
always a great friend and a true gentlemen, you would always make time to help us out 
with problems no matter how busy you were; Glenda you were always great company, 
a dear friend, and would provide us with invaluable technical support – you were very 
missed when you left Cardialysis to pursue your dreams; Jolanda you were always great 
company and your countless trips to the pub quiz and odd times to the Pleinbioscoop 
with Marie-angèle and the team looked forward to; Ravindra, Jamal, Yvonne, Marieke 
and Marije, your warm and friendly nature, good humour and patience were greatly 
appreciated; Monique, Bianca, Linda, Eliane, Anne Marie, Janette, and others – it was 
always a real delight working with you individually on differing trials; Ad I always ap-
preciated your friendliness and ability to solve multiple problems – thank you; Peter Paul 
your warm and friendly nature was always appreciated; the list of personal thanks could 
go on and on…
Pub (O’Sheas) quiz team: “Cardiac B*stards”
Our pub quiz team name was dreamt up by my good friend master Ton de Vries, in rec-
ognition of the film “Inglorious B*stards,” a name that admittedly took a while to grow 
on me... I looked forward to going to the weekly pub quizzes, particularly in my last 6 
months at Rotterdam, it was a welcome break from everything. We formed a great team, 
and if I remember correctly, the highest position we got was second, which was fantastic 
considering the team that beat us were made up of die-hard quiz fanatics. Everything 
from elephants being unable to jump, eclectic music (Ton and Andre), contemporary 
music (Sylvie), sports and football (Marie-angèle), knowledge of travel and just odd facts 
(Jolanda, Linda, Janette, Eliane), always being invited but never actually making it to 
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the quiz because of her little ones (Ana), being always highly confident in her answers 
whether right or wrong but great fun all the same (Jolanda), never 100% sure of any an-
swer (me), forgetting the name of the main street in central Paris by the only Parisienne 
on the team (name withheld)... 
EuroIntervention/Europa Organisaton
It was a great pleasure to be part of the editorial board with the EuroIntervention team 
in Rotterdam, in particular, Paul Cummins, Sylvie L’Hoste, Wendel van der Sluis, and the 
editor-in-chief Professor Serruys. My lasting impression of Paul is a work hard, play hard, 
electric guitar playing, Guinness loving Irish friend. Sylvie, my gratitude to you is detailed 
below. The calm Wendel – in the short time I met you we became good friends – thank 
you for the book you gave me when I left, I am still reading it! Warm thanks go to Wil-
liam Wijns, Frédéric Doncieux and Rodney de Palma for their friendliness and invaluable 
reviews of the two chapters we co-authored in the PCR-EAPCI Textbook.
 Hanny, Sylvie and Marie-angèle 
My three ‘rocks’ in Rotterdam. I am enormously grateful for all the help, support and 
friendship we shared together in Rotterdam, you were all there from the very beginning, 
during the low and high times. Firstly the wonderful Hanny, thank you for just being 
Hanny – I am not sure what I would have done without you. Your cheerfulness, good 
humour and philosophy are something I miss very much. What can I say but you were 
always there, even during the times when you were off work…thank you! I still have your 
leaving card with your famous last words of wisdom written on it “The way is the GOAL…
because very often the goal is IN THE WAY.” Secondly, my dear friend Mademoiselle Perdue 
(Sylvie) what can I say, I would have been ‘lost’ without you. I will never forget when you 
took the entire team out for a day in the windmills in Rotterdam, the concert where Paul 
Cummins was the lead guitarist, your tireless efforts in helping us make the illustrations 
for the left main chapter of the PCR - EAPCI textbook in collaboration with Catherine 
Meunier (French illustrator) and putting up with me in the process, the frequent socialis-
ing with the team, and er… your driving skills… merci beaucoup! Thirdly, the delightful 
Marie-angèle Morel, senior author of the BENESTENT trial, ‘queen’ of the SYNTAX Score, a 
wealth of new ideas, a problem solver (no matter how big or small), football – Feyenoord 
– crazy, and wonderful company. The move of the local Rotterdam footballer Robin Van 
Persie to Manchester United cemented our friendship. When I could not get home for 
New Year’s day in my last 6 months in Rotterdam, you threw us an amazing New Year 
Eve’s party... Dank u to you all, Hanny, Sylvie and Marie-angèle, the leaving party you 
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threw me was unforgettable, the Feyenoord van Persie shirt unique, you truly are all very 
special, and I miss you all very dearly.
SYNTAX Investigators
“There are in fact two things, science and opinion; the former begets knowledge, the latter 
ignorance.” [Hippocrates]
Patrick W Serruys, Marie-Claude Morice, Arie-Pieter Kappetein, Antonio Colombo, David 
R. Holmes, Michael J. Mack, Elisabeth Ståhle, Ted E. Feldman, Marie-angèle Morel, Keith 
D. Dawkins, and Friedrich W. Mohr. 
I am grateful to all the SYNTAX Investigators for their friendly and helpful advice, sup-
port and critical review of all the manuscripts based on the SYNTAX Trial. Indeed, it was 
a great honour and privilege to work alongside such a unique and inspirational team. 
Special thanks go to Dr Keith Dawkins for his advice, support, frank and honest reviews 
of our manuscripts, and unique insights into the SYNTAX Trial – they were always very 
well received and appreciated; Professor Kappetein, I enjoyed our friendly debates on 
all things SYNTAX; Professor Mohr, I had the unique opportunity to present alongside 
you at the ESC Congress in Munich on the SYNTAX Trial, and was very flattered by your 
personal invite to present at the “Hands Across the Ocean” conference in Leipzig last 
December  – and was simply blown away by the friendliness and hospitality in Leipzig; Dr 
Colombo, we were truly humbled by your enthusiasm of the SYNTAX Score II and dem-
onstration of its first public clinical use with Alaide Chieffo during a live case on board 
the SS Rotterdam; Dr Morice, Dr Holmes, Dr Mack, Dr Ståhle and Dr Feldman – your kind 
and learned comments were always very much appreciated, whenever we received your 
positive comments we always knew we were winning…
Industry
“Research is four things: brains with which to think, eyes with which to see, machines with 
which to measure, and fourth, money.” [Albert Szent-Gyorgyi]
I am grateful to Boston Scientific for their unwavering support, in particular, Keith 
Dawkins, Peggy Pereda, Jian Huang, Vicki Houle, Kristine Roy, and Nic van Dyck; Michel 
Lussier and Egon Wülfert of Volcano Corporation; the friendly support of John Stevens 
and Campbell Rogers of Heartflow, Inc; the multiple face to face meetings and support 
of Abbott whilst working on the ABSORB programme, in particular Richard Rapoza, 
Susan Veldhof, Ann Snoeijs, Laura Perkins, Jennifer Powers; the enthusiasm and sup-
port of Dragica  Paunovic of Terumo, in particular when working in the evolving field 
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of three-dimensional optical coherence tomography; Susanne Meis and colleagues of 
Biosensors; Manish Doshi of Envision Scientific. 
My Mentors
“If I have seen further it is by standing on the shoulders of Giants.” [Sir Isaac Newton]
Professor Steyerberg. I am grateful for all your support and mentorship you provided 
during my time in Rotterdam. From our very first meeting it was clear that we would 
work tremendously well together. You were always extremely enthusiastic and encour-
aging, would never allow us accept defeat, and pushed us to excel. We were uniquely 
privileged to work alongside your gifted team, in particular my dear friends Yvonne and 
David, and to allow us to brainstorm thoughts and ideas in meetings with your entire 
department. Special thanks go out to Sanne in dealing with the all-important logistics. 
If ever there was an example of a warm and friendly collaboration this was it. I still have 
your famous book you loaned to me – I promise to return it very soon!
Professor Serruys. It is difficult to know where to acknowledge my gratitude for the 
unique opportunity and mentorship you provided to me in Rotterdam. As you know I 
came to Rotterdam to work on the bioresorbable scaffold programme, which I achieved, 
but simultaneously got working in SYNTAX (forming the basis of my thesis), intravascular 
imaging, contemporary coronary stents, and multiple other branches of interventional 
cardiology – such was the philosophy you instilled to us of being positive, enthusiastic, 
a team player, open to new ideas and the pursuit of the truth, however difficult it was 
to find. Sometimes I felt like a piece of metal being hammered into shape, but realise 
this was simply the nature of research and the need to reach the very highest standards. 
Special thanks also go out to your amazing wife Danielle, her strength and courage are 
an inspiration to us all. Danielle was always welcoming on the countless visits to your 
home in the evenings and weekends, particularly on those cold winter days, when Rot-
terdam was hit by snow blizzards and under a blanket of snow. Professor Serruys you 
gave me, a simple interventional fellow, the unique opportunity to share thoughts and 
ideas with cardiologists and cardiac surgeons from around the world. Your mentorship 
and guidance culminated in me unexpectedly winning the Thomas J. Linnemeier Spirit 
of Interventional Cardiology Young Investigator Award at the TCT 2013 in San Francisco, 
United States. Looking ahead, I am uniquely privileged to continue to working with you 
on the SYNTAX II Trial. Thank you for opening my eyes…thank you for everything!
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Future 
“Learn from yesterday, live for today, hope for tomorrow. The important thing is to not stop 
questioning.” [Albert Einstein]
I got to Rotterdam, not really knowing what to expect, unsettled and uneasy of the 
future; its ironic that on leaving Rotterdam and returning home, I felt exactly the same 
way. It’s a great feeling and I wouldn’t change it for the world…
Final words 
“I sustain myself with the love of family.” [Maya Angelou]
Final words go to my family, in particular my mother and father, all I can say is thank 
you…
Vasim Farooq, 17th February 2014
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1 PROTOCOL SYNOPSIS 
 
Protocol Number ECRI-002 
Title A single-arm trial to evaluate the effectiveness of PCI of de novo 3-vessel 
disease applying the SYNTAX Score II with pressure wire functional 
assessment and IVUS guidance, using an everolimus-eluting stent with a 
biodegradable abluminal coating. 
  
Objective • To evaluate the effectiveness of contemporary PCI treatment of de 
novo 3-vessel disease following the heart team selection applying the 
SYNTAX Score II with pressure wire functional assessment and 
IVUS guidance (SYNTAX II strategy) • To establish superiority of the SYNTAX II strategy compared to the 
PCI arm of the SYNTAX I study (Primary endpoint) • To prospectively assess the effectiveness of the SYNTAX Score II for 
heart team decision making • To prospectively validate the SYNTAX Score II for all-cause death at 
1 and 2 year and 5 year follow-up; • To retrospectively validate the residual SYNTAX Score (academic 
research) 
 
Treatment SYNTAX II strategy consists of contemporary PCI of de novo 3-vessel 
disease following the heart team consensus applying the SYNTAX Score 
II for the heart team selection of patients, pressure wire functional 
assessment of lesions and IVUS optimization of DES implantation. 
 
Study design The SYNTAX II Trial is a multicenter, 3-vessel disease, all-comers, open-
label, single-arm trial of approximately 450 patients in approximately 25 
interventional cardiology centres in Europe. All patients will be treated 
with an everolimus-eluting stent with a biodegradable abluminal coating. 
 
Comparisons will be undertaken using the completed SYNTAX I Trial as 
a control: Primary endpoint: comparison with PCI (TAXUS Express2);. 
 
Number of Subjects 450 subjects in total 
 
Investigational Sites Up to approximately 25 sites in Europe 
 
Follow-up In-hospital and additional follow-up visits at 1 month, 6 months and 12 
months after enrolment.  
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In addition, patients will be contacted annually by telephone up to 5 years 
to check survival status and other MACCE components (patient reported). 
 
Primary Endpoint The primary endpoint is a composite of MACCE rate (all-cause death, 
cerebrovascular event (stroke), documented myocardial infarction, or all-
cause revascularization) at 1 year follow-up (SYNTAX I definition) 
compared to PCI arm of the SYNTAX I Trial (Patient Oriented Clinical 
Endpoint).  
 
Secondary Endpoints • Composite of all-cause death, cerebrovascular event (stroke), 
documented myocardial infarction at 1 year follow-up compared 
to the  PCI arm of SYNTAX I; (Safety Endpoint) • Composite of cardiovascular death, documented target-vessel 
myocardial infarction and repeat target lesion revascularization at 
1 year follow-up compared to the  PCI arm of SYNTAX I; 
(Device Oriented Clinical Endpoint) • Rates of individual components of MACCE (all-cause death, 
cerebrovascular event (stroke), documented myocardial infarction 
and repeat revascularization) at 1 year;  • The composite of MACCE and its individual components at 2-5 
years follow-up (patient reported);  • Myocardial Infarction – according to Universal MI definition 2012 
at all timepoints;  • Stent Thrombosis – according to ARC definitions at all 
timepoints; 
 
Exploratory Endpoint • Composite of MACCE (all-cause death, cerebrovascular event 
[stroke], documented myocardial infarction or all-cause 
revascularization) at 5 years follow-up compared to CABG arm of 
the SYNTAX I Trial. 
 
General Inclusion and 
Exclusion Criteria 
Inclusion Criteria: 
1. At least 1 stenosis (angiographic, visually determined de novo 
lesions with ≥50% DS) in all 3 major epicardial territories (LAD 
and/or side branch, CX and/or side branch, RCA and/or side branch) 
supplying viable myocardium without left main involvement; 
(Patients with ostial LAD or ostial CX - Medina 0,0,1 or Medina 0,1,0 – 
may be enrolled) 
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2. Patients with hypoplastic RCA with absence of descending posterior 
and presence of a lesion in the LAD and CX territories may be 
included in the trial as a 3VD equivalent; 
3. Vessel size should be at least 1.5 mm in diameter as visually 
assessed in diagnostic angiogram; 
4. Patients with 
a) stable (Canadian Cardiovascular Society Class 1, 2, 3 or 4) angina 
pectoris; 
b) or unstable (Braunwald class IB, IC, IIB, IIC, IIIB, IIIC) angina 
pectoris and ischemia; 
c) or patients with atypical chest pain or those who are asymptomatic 
provided they have myocardial ischemia (e.g. treadmill exercise test, 
radionuclide scintigraphy, stress echocardiography); 
5. All anatomical SYNTAX Scores are eligible for initial screening 
with the SYNTAX Score II; 
6. Patient has been informed of the nature of the study and agrees to its 
provisions and has provided written informed consent as approved 
by the Ethical Committee of the respective clinical site; 
7. Signed Heart Team Decision Form between local cardiologist and 
surgeon that the selected case meets all of the inclusion and 
exclusion criteria; 
 
Exclusion Criteria: 
Candidates will be ineligible for enrolment in the study if any of the 
following conditions apply: 
1. Under the age of 21 years; 
2. Known pregnancy at time of enrolment. Female of childbearing 
potential (and last menstruation within the last 12 months), who 
are not taking adequate contraceptives. Female who is 
breastfeeding at time of enrolment; 
  
3. Prior PCI or CABG; 
4. Ongoing acute myocardial infarction and enzymes CKMB >2x 
upper limit of normal; 
5. Concomitant cardiac valve disease requiring surgical therapy 
(reconstruction or replacement); 
6. Single or two-vessel disease (at time of Heart Team consensus); 
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7. Participation or planned participation in another cardiovascular 
clinical study before one year follow up is completed; 
8. Mental condition (psychiatric or organ cerebral disease) rendering 
the subject unable to understand the nature, scope, and possible 
consequences of the study or mental retardation or language 
barrier such that the patient is unable to give informed consent and 
potential for non-compliance towards the requirement in the study 
protocol. 
Antiplatelet 
Medication 
Dual Antiplatelet treatment is mandatory for at least 6 months; aspirin 
indefinitely. 
Loading dose: • All patients must receive aspirin ≥300 mg/day starting 12-24 hours 
prior to the procedure (even if the subject is on chronic aspirin 
therapy). • Clopidogrel loading dose must be 600 mg, starting 12-24 hours 
prior to the procedure (even if the subject is on chronic clopidogrel 
therapy). 
Alternatively: • Prasugrel 60 mg >1 hr before PCI; or • Ticagrelor 180 mg >1 hr before PCI if approved by the local 
regulatory authorities during the enrolment period of this protocol. 
 
Maintenance dose: 
Starting from the day after the procedure, aspirin 75-100 mg/day will be 
prescribed to all patients indefinitely. 
Additionally, all patients must receive platelet aggregation inhibition 
therapy for at least 6 months as currently recommended by the 
ESC/AHA/ACC guidelines which includes: • Clopidogrel 75 mg once daily. 
Alternatively: • Prasugrel 10 mg once daily; or 
(The dose of prasugrel may be decreased to 5mg od in patients with a weight 
<60 kg or age >75 years).  • Ticagrelor (90mg bid) 
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2 INTRODUCTION 
 
 
The anatomical-based SYNTAX Score (http://www.syntaxscore.com) has established itself as a 
tool to aid the Heart Team consensus in determining the optimal revascularization modality in 
patients with unprotected left main coronary artery (ULMCA) disease or de novo three vessel 
disease (3VD).1-10 The anatomical based SYNTAX Score was designed and implemented in the 
landmark SYNTAX Trial,4, 7, 10 as an instrument to force the interventional cardiologist and 
cardiac surgeon to examine the coronary angiogram, and agree that equivalent anatomical 
revascularisation could be achieved. Only after the publication of the SYNTAX Trial did the 
importance of the anatomical SYNTAX Score become clear. Namely, in appropriately guiding 
decision making between coronary artery bypass graft (CABG) surgery and percutaneous 
coronary intervention (PCI) for the treatment of complex coronary artery disease. Since 
publication of the SYNTAX Trial, the anatomical-based SYNTAX Score, has been validated in 
multiple studies, and has recently been advocated in both the US and European revascularization 
guidelines, as a tool to guide the clinician in determining the optimal revascularization modality 
(CABG or PCI) in patients with complex coronary artery disease.8, 9, 11-13 
 
Dedicated studies in the post SYNTAX Trial era investigating 3VD remain scarce. As of present, 
current revascularization guidelines recommend that a low SYNTAX Score (0-22) may offer 
similar clinical outcomes between percutaneous coronary intervention (PCI) with drug eluting 
stents (DES) and coronary artery bypass graft (CABG) surgery.11-13  
Diabetes 
Outcomes in diabetic patients have historically lacked suitably powered randomized trials. Meta-
analyses of trials comparing CABG against PCI in the pre-DES era (balloon angioplasty and bare 
metal stents) have shown a potential prognostic advantage of CABG compared to PCI.14, 15 A 
major limitation of these studies were however that the studies were not all-comers in design, 
with patients ‘cherry-picked’ for randomisation based on restrictive inclusion and exclusion 
criteria, making application to clinical practice questionable.16, 17 
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In the DES era, the Future Revascularization Evaluation in Patients with Diabetes Mellitus: 
Optimal Management of Multivessel Disease (FREEDOM) Trial,18, 19 consisting of 1900 patients 
with two or 3VD, randomised to CABG or PCI with first generation DES, showed a prognostic 
advantage for CABG at a median follow up of 3.8 years. At 5 years follow up, only 678/1900 
patients reached this time point, with 197 deaths recorded. In this subset of patients, there was no 
interaction between the SYNTAX Score and treatment (p=0.58). There was however a stepwise 
increase in death, MI, or stroke in patients that underwent PCI (low SYNTAX Score: 19.4%, 
intermediate SYNTAX Score: 22.2%, high SYNTAX Score: 31.0%), but not in those treated 
with CABG (low SYNTAX Score: 20.1%, intermediate SYNTAX Score: 21.5%, high SYNTAX 
Score: 16.0%). The FREEDOM Trial was however underpowered to assess the SYNTAX Score 
at 5 years.9, 20 
Conversely, diabetics in the SYNTAX Trial (a pre-stratified powered subgroup), has shown that 
low SYNTAX Scores to be associated with comparable long term mortality and composite 
clinical outcomes (major adverse cardiac and cerebrovascular events [MACCE]).20-22  
Left Main Coronary Artery Disease 
Based on the results of the SYNTAX Trial, in which short and long term outcomes were similar 
between CABG and PCI in subjects with unprotected left main coronary artery (ULMCA) 
disease with an anatomical SYNTAX Score <33,4, 7, 10 the EXCEL (Evaluation of Xience Prime 
versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) trial 
was conceived (ClinicalTrials.gov Identifier: NCT01205776). EXCEL is an ongoing, 
international, multicentre trial, aiming to recruit 2600 patients with ULMCA disease and a 
SYNTAX Score <33 – randomized to surgical (n=1300) or percutaneous (with the XIENCE 
PRIME or XIENCE V DES [n=1300]) revascularization.23 Notably the US Food and Drug 
Administration (FDA) mandated the anatomical-based SYNTAX Score as entry criteria within 
the EXCEL Trial. 
 
 
455Appendix
 
SYNTAX II 
Protocol 
Protocol ECRI-002 
Version 2.0 
Page 13 of 93 
 
 
Confidential and Proprietary 
Do not distribute or reproduce without the prior written permission of ECRI. 
CIP Version 2.0 - 27 November 2013 
 
SYNTAX Score II 
The category based risk approach of the anatomical-based SYNTAX Score – i.e. “low”, 
“intermediate,” or “high” SYNTAX Scores – to guide decision making between CABG or PCI, 
has been shown to be potentially misleading in a post hoc analysis of the SYNTAX Trial.24 
Within this study, it was shown that low and high risk subjects existed in higher and lower 
SYNTAX Score tertiles, which appeared to have implications for the most appropriate 
revascularisation modality (CABG and PCI); e.g. there was a doubling of 3-year mortality in 
subjects with 3VD – with a low SYNTAX Score (<23) and a high additive EuroSCORE (≥6) – 
who underwent PCI compared to CABG.24 In addition, a recent study pooling over 6000 PCI 
subjects treated with DES, demonstrated that the addition of clinical variables to the anatomical 
SYNTAX Score, substantially increased the accuracy of identifying low (and high) risk patients 
compared to the anatomical SYNTAX Score alone.25 
 
The SYNTAX Score II26, 27 was designed to improve decision making between CABG and PCI, 
by allowing for a long term, individualized risk assessment of patients with complex coronary 
artery disease. The SYNTAX Score II combined the anatomical based SYNTAX Score with 
clinical variables, that were shown to alter the threshold value of the SYNTAX Score so that 
equipoise was achieved between CABG and PCI for long term mortality. These included the 
presence of unprotected left main coronary artery disease, female gender,28 chronic obstructive 
pulmonary disease, age and left ventricular ejection fraction. The SYNTAX Score II was 
developed in the randomized SYNTAX Trial (n=1800), and validated in the multicentre Drug 
Eluting stent for LefT main coronary Artery disease (DELTA) Registry (n=2891).29 Importantly 
the DELTA Registry was a multinational, non-randomised, all-comers registry, conducted in 14 
centres in Europe, US and South Korea. The study population was heterogeneous, and included 
complex coronary artery disease – anatomical SYNTAX Score ≥33 existed in 30%, and 3VD in 
26%, of the DELTA Registry. 
During development and validation of the SYNTAX Score II, it was shown that diabetes did not 
improve decision making between CABG and PCI. Findings that were consistent with a previous 
study of over 6000 patients treated with DES, where it was shown that the presence of diabetes 
minimally affected long term mortality predictions after PCI with DES, when age, kidney 
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function and left ventricular ejection fraction were accounted for.25 Subsequent 
epidemiology/population based studies have further supported these findings.30, 31  
By utilizing the individualized approach of the SYNTAX Score II, in contrast to the anatomical-
based SYNTAX Score tertiles, a subset of patients with low, intermediate or high SYNTAX 
Scores were identified, that would have lower, similar, or higher 4-year mortality predictions for 
CABG or PCI. Specifically for 3VD, approximately 80%, 60% and 30% of patients in the 
respective low, intermediate and high SYNTAX Score tertiles of the randomised SYNTAX 
population would have similar long-term mortality between CABG and PCI (Appendix II).  
Contemporary PCI Practice and the SYNTAX Trial 
Overall, the amount of information gathered in the SYNTAX Trial has helped shape both clinical 
practice and international guidelines in the management of complex coronary artery disease.  The 
conclusions drawn in the SYNTAX Trial since its publication do however not take into account 
areas in which the progress has been made in more contemporary interventional practice. Some 
of these are discussed in the following paragraphs: 
1) Chronic total occlusion recanalization: In SYNTAX, the presence of a (chronic) total 
occlusion (C)TO was identified to be the strongest independent predictor of incomplete 
revascularisation in the PCI arm of the SYNTAX Trial.32, 33 Over the last 10 years the practice of 
(C)TO recanalization has been largely modified by the systematisation in the approach to (C)TO 
recanalization and the development of new devices. Although acquaintance with these 
techniques is still limited among interventional cardiologists, international registries have 
consistently reported that skilled, dedicated (C)TO operators have success rates of 85-95%, a 
much higher success rate that that observed in SYNTAX operators (approximately 50%).34 
Major technical improvements include the development of new coronary wires, dedicated 
intracoronary cathethers (Corsair,Ⓡ Tornus,Ⓡ CrossBossTM) and re-entry devices (The 
Stingray™ CTO Re-Entry System).35 Contemporary (C)TO procedures are performed both in 
anterograde or retrograde fashion (through collateral channels), frequently with the concourse of 
IVUS imaging. Virtually all these developments were not applied to (C)TO recanalization in 
SYNTAX. It will therefore be encouraged that each participating centre should select an expert 
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in (C)TO revascularisation who should be involved in the procedure whenever a (C)TO is 
involved. 
2) Ischemia-driven revascularisation: A large body of evidence, largely based on the use of 
fractional flow reserve (FFR), has demonstrated that, compared with angiography, decision 
making of coronary revascularisation based on physiological assessment of stenosis severity 
results in improved patient outcomes.36-39 Recalculation of the SYNTAX score by incorporating 
FFR-derived information of stenosis severity (functional SYNTAX score40) may decrease the 
number of higher-risk patients with multivessel disease undergoing PCI and contribute to a better 
discrimination of risk for adverse events in this subset of patients. A new pressure-derived index, 
instantaneous wave-free ratio (iFR), that allows faster adenosine-free assessment may be more 
ideally suited for multiple measurements performed in the context of multivessel disease.41  
3) Imaging guidance of PCI procedures: While the proposal of using intravascular ultrasound 
(IVUS) to tackle restenosis made in the bare metal stent (BMS) era was virtually abandoned with 
the arrival of drug eluting stents (DES), a growing body of evidence suggests that DES 
implantation with IVUS guidance in complex anatomical subsets may contribute to better patient 
outcomes. Specifically, a recent meta-analysis of IVUS guided DES implantation in almost 20 
000 subjects has reported significantly reductions in stent thrombosis and mortality.42, 43 
 
4) Newer generation DES: Compared to first generation DES, newer generation DES have 
proven reductions in stent thrombosis and other clinical outcomes. This has largely been through 
the design of more biocompatible polymers, biodegradable polymers, limus based drugs, thinner 
stent struts through the incorporation of metallic alloys with greater radial strength, and increased 
deliverability of the devices.44-49 Outcomes of the SYNTAX Trial related to newer generation 
DES are therefore unknown and will be investigated in the current study. 
  
458 Appendix
 
SYNTAX II 
Protocol 
Protocol ECRI-002 
Version 2.0 
Page 16 of 93 
 
 
Confidential and Proprietary 
Do not distribute or reproduce without the prior written permission of ECRI. 
CIP Version 2.0 - 27 November 2013 
 
 
Purpose of Study 
The purpose of the planned SYNTAX II Trial is to investigate the management of de-novo 3VD 
in order to prospectively assess which patients would have at least comparable short and long 
term clinical outcomes between CABG and PCI, using contemporary PCI practice. In SYNTAX 
II the effectiveness of a contemporary stent (the new generation SYNERGYTM DES, designed 
with thinner struts, biocompatible and biodegradable polymer, and a limus based drug50, 51), the 
use of pressure wire assessment of lesions to allow for ischemia-driven revascularisation, IVUS 
guidance to optimise DES deployment, and the treatment of (C)TO lesions with contemporary 
techniques, will be compared against PCI practice in the original SYNTAX trial. The proposed 
study would involve the SYNTAX Score II to prospectively recruit subjects on the grounds of 
patient safety.26, 27  
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3 OBJECTIVE  
 • To evaluate the effectiveness of contemporary PCI treatment of de novo 3-vessel disease 
following the heart team selection applying the SYNTAX Score II with pressure wire 
functional assessment and IVUS guidance (SYNTAX II strategy). 
• To establish superiority of the SYNTAX II strategy compared to the PCI arm of the 
SYNTAX I study (Primary Endpoint). 
• To prospectively assess the effectiveness of SYNTAX Score II for heart team decision 
making. 
• To prospectively validate the SYNTAX Score II for all-cause death at 1 and 2 year and 5 
year follow-up. 
• To retrospectively validate the residual SYNTAX Score (academic research)52, 53. 
 
Comparisons will be undertaken using the completed SYNTAX I Trial as a historical control:4 
Primary Endpoint – PCI cohort (TAXUS Express2); 
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4 STUDY DESIGN  
 
 
The SYNTAX-II Trial is a multicenter, 3-vessel disease, all-comers, open-label, single arm trial 
of approximately 450 patients in approximately 25 interventional cardiology centres in Europe. 
All patients will be treated with the Boston Scientific SYNERGY™ Everolimus-Eluting 
Platinum Chromium Coronary Stent System. 
 
 
Heart Team Discussion
Confirm SYNTAX Score II calculation, and that recruitment of patients for PCI is based on 
safety (long term mortality comparisons between CABG and PCI)
SYNTAX Trial II 
Inclusion: All-Comers, angiographic, de-novo 3-vessel disease without 
left main involvement (visual % diameter stenosis ≥50%)
Screening according to
SYNTAX Score II
Low (0-22) anatomical 
SYNTAX Score
Interm (23-32) anatomical 
SYNTAX Score
High (≥33) anatomical 
SYNTAX Score
Patient ‘Signed Off’ by Heart Team for PCI
SYNTAX Score II 
Favours CABG*
*Index revascularisation
procedure type collected (CABG, 
PCI or medical or refusal).. 
SYNTAX Score II 
Offers equipoise for PCI and CABG
YES
NO
Can ‘equivalent’ anatomical revascularisation be 
achieved*
*Surgeon and interventional cardiologist in agreement
Exploratory study: MsCT scan → non-invasive computation of FFRCT
Not 
“eligible”
for PCI
 
Study Flowchart: Part-1: Heart Team algorithm  
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1. All patients with de-novo 3-vessel disease (DS ≥50%), with no left main involvement, 
will be screened by the local Heart Team (interventional cardiologist and cardiac 
surgeon). Initial enrolment criteria will be unrestrictive and similar to the SYNTAX 
Trial.3, 4 As per the original SYNTAX Trial, prior CABG or PCI will be one of the very 
few exclusion criteria. 
2. All patients will have anatomical SYNTAX Scores and EuroSCOREs (I and II)54-58 
undertaken, and will undergo further assessment by the Heart Team for enrolment in the 
study. 
3. All patients will have the SYNTAX Score II prospectively determined by the Heart Team 
using an online calculator (Appendix III). The SYNTAX Score II will be used to 
objectively determine if the patient is suitable for PCI, CABG, or both revascularization 
modalities. Based on SYNTAX Score II in the SYNTAX Trial, approximately 80%, 60% 
and 30% of patients in the low, intermediate and high SYNTAX Score tertiles 
respectively, would have at least similar long-term mortality between CABG and PCI 
(Appendix II). Patients not suitable for PCI based on the SYNTAX Score II assessment 
will undergo CABG, unless contraindicated. In patients not eligible for SYNTAX II trial, 
the index revascularisation procedure type will be collected (i.e. CABG, PCI, medical 
treatment or refusal). 
 
Equivalent Anatomical Revascularization 
As per the SYNTAX Trial, patients must be able to undergo “equivalent anatomical 
revascularization,” based on the SYNTAX Trial definition of 1.5 mm vessels being 
revascularised, as agreed by the cardiac surgeon and interventional cardiologist during the Heart 
Team meeting.3 Patients not suitable for equivalent anatomical revascularization will undergo 
CABG, unless contraindicated. For patients not eligible for SYNTAX II trial, the index 
revascularisation procedure type will be collected (i.e. CABG, PCI, or medical treatment or 
refusal). 
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Exploratory sub-study 
After the Heart Team consensus, but prior to PCI procedure, a multislice computed tomography 
(MSCT) scan should be obtained (documentary only). MSCT will not be used in process of 
Heart Team discussion. The MSCT scan will be processed by HeartFlow Inc. (Redwood city, 
California, USA). HeartFlow’s technology enables the computation of FFRCT in a non-invasive 
manner.8, 59-62 Results will only become available after completion of the SYNTAX II study.  
 
Reporting of Study Endpoints 
The primary endpoint will be reported at 1 year. At 2-5 years follow-up, all patients will be 
contacted by telephone to check survival status and other MACCE components (patient reported). 
From all screened patients the index treatment type (i.e. CABG, PCI, medical, other) will be 
collected. 
 
Clinical data will be adjudicated by an independent Clinical Event Committee (CEC). Ongoing 
safety monitoring will be performed by a Data Safety Monitoring Board (DSMB). 
 
4.1 Risk Factor Modification 
 
Tight control of risk factors will be mandated in line with the European and US revascularisation 
guidelines.11, 12 Cholesterol reduction, with a LDL ≤1.8, will be an additional protocol defined 
target the operator will be recommended to record and control.  
In summary, patients (de-novo 3VD) will be treated according to ACC/AHA/ESC guidelines, i.e. 
Heart Team discussion (Ia); functional evaluation for diagnosis in absence of objective evidence 
of ischemia (Ia); and LDL levels ≤1.8mmol (Ia). 
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5 ENDPOINTS 
 
5.1 Primary Endpoint 
 
The primary endpoint is a composite of MACCE at 1 year follow-up compared to PCI arm of the 
SYNTAX I Trial (acting as a historical control) (Patient Oriented Clinical Endpoint) 
MACCE is defined as: all-cause death; cerebrovascular event (stroke); documented myocardial infarction or all-
cause revascularization). 
 
5.2 Secondary endpoints 
 
Secondary endpoints of this study are to assess: 
• Composite of all-cause death, cerebrovascular event (stroke), documented myocardial 
infarction at 1 year follow-up compared to the  PCI arm of SYNTAX I; (Safety Endpoint) 
• Composite of cardiovascular death, documented target-vessel myocardial infarction and 
repeat target lesion revascularization at 1 year follow-up compared to the  PCI arm of 
SYNTAX I; (Device Oriented Clinical Endpoint) 
• Rates of individual components of MACCE (all-cause death, cerebrovascular event 
(stroke), documented myocardial infarction and repeat revascularization) at 1 year;  
• The composite of MACCE rate and its individual components at 2-5 years follow-up 
(patient reported);  
• Myocardial Infarction – according to Universal MI definition 2012 at all timepoints;  
• Stent Thrombosis – according to ARC definitions at all timepoints; 
 
5.3 Exploratory endpoint • Composite of MACCE (all-cause death, cerebrovascular event (stroke), documented 
myocardial infarction or all-cause revascularization) at 5 years follow-up compared to 
CABG arm of the SYNTAX I Trial 
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6 SUBJECT SELECTION   
 
Patient selection will be from all-comers de novo 3VD patients. Anatomical SYNTAX and 
SYNTAX II Scores, will be undertaken to objectively determine if CABG or PCI offer a least 
similar long term mortality.  
 
Approximately 450 3-vessel disease all-comers patients will be enrolled. The recruitment will be 
competitive. 
 
6.1 Inclusion Criteria 
 
1. At least 1 stenosis (angiographic, visually determined de novo lesions with ≥50% DS) in 
all 3 major epicardial territories (LAD and/or side branch, CX and/or side branch, RCA 
and/or side branch) supplying viable myocardium without left main involvement; 
(Patients with ostial LAD or ostial CX - Medina 0,0,1 or Medina 0,1,0 – may be enrolled) 
2. Patients with hypoplastic RCA with absence of descending posterior and presence of a 
lesion in the LAD and CX territories may be included in the trial as a 3VD equivalent; 
3. Vessel size should be at least 1.5 mm in diameter as visually assessed in diagnostic 
angiogram; 
4. Patients with 
a) stable (Canadian Cardiovascular Society Class 1, 2, 3 or 4) angina pectoris; 
b) or unstable (Braunwald class IB, IC, IIB, IIC, IIIB, IIIC) angina pectoris and 
ischemia; 
c) or patients with atypical chest pain or those who are asymptomatic provided they 
have myocardial ischemia (e.g. treadmill exercise test, radionuclide scintigraphy, 
stress echocardiography); 
5. All anatomical SYNTAX Scores are eligible for initial screening with the SYNTAX 
Score II; 
6. Patient has been informed of the nature of the study and agrees to its provisions and has 
provided written informed consent as approved by the Ethical Committee of the 
respective clinical site; 
7. Signed Heart Team Decision Form between local cardiologist and surgeon that the 
selected case meets all of the inclusion and exclusion criteria; 
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6.2 Exclusion Criteria 
 
Candidates will be ineligible for enrolment in the study if any of the following conditions apply: 
1. Under the age of 21 years; 
2. Known pregnancy at time of enrolment. Female of childbearing potential (and last 
menstruation within the last 12 months), who are not taking adequate contraceptives. Female 
who is breastfeeding at time of enrolment; 
3. Prior PCI or CABG; 
4. Patients with ongoing acute myocardial infarction and enzymes CKMB >2x upper limit of 
normal;  
5. Concomitant cardiac valve disease requiring surgical therapy (reconstruction or replacement); 
6. Single or two-vessel disease at the time of Heart Team consensus; 
7. Participation or planned participation in another cardiovascular clinical study before one year 
follow up is completed; 
8. Mental condition (psychiatric or organ cerebral disease) rendering the subject unable to 
understand the nature, scope, and possible consequences of the study or mental retardation or 
language barrier such that the patient is unable to give informed consent and potential for non-
compliance towards the requirement in the study protocol. 
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7 STUDY PROCEDURES 
 
7.1 Patient Information and Informed Consent 
 
All potential subjects must be consented prior to undergoing any study-specific procedures. Once 
the subject’s general eligibility for the study is met, the background of the proposed study and 
the benefits and risks of the procedures and study must be explained to the subject prior to 
obtaining informed consent. Only those subjects who sign the Ethics Committee approved 
informed consent form prior to any study-specific procedures are candidates for actual enrolment 
in the study. Failure to provide written informed consent renders the subject ineligible for the 
study. 
 
The investigator and/or designee must also clearly document the process of obtaining informed 
consent in the subject’s source documents. The voluntary process of obtaining informed consent 
confirms the subject’s willingness to participate in the study. It is the investigator’s responsibility 
to ensure that the informed consent process is performed in accordance with ISO14155, EC 
requirements and country specific regulations.  
 
7.2 Baseline evaluation 
 
The following routine tests will be performed: 
a) Routine laboratory tests prior to the procedure according to local hospital practice. 
Creatinine and creatinine clearance (Cockcroft and Gault63) are mandated to be 
performed prior to procedure. Cardiac enzymes must be sampled prior to the PCI 
procedure in order to detect acute myocardial infarction (AMI) patients. Prior to the PCI 
procedure the cardiac enzymes (CK-MB or Troponin) must be less than 2-times the upper 
limit of normal (<ULN). 
b) 12-lead electrocardiogram pre, and post procedure and at discharge 
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7.3 Anatomical, residual and functional SYNTAX Scores  
 
The baseline anatomical SYNTAX Score and SYNTAX Score II will be recorded in the eCRF. 
All procedural coronary angiograms will be collected and allowances made for the export of this 
data to Cardialysis, Rotterdam. No analyses will be performed by the Core Laboratory. At a later 
stage post hoc analysis of the baseline anatomical SYNTAX Score, residual SYNTAX Score52, 53 
and functional SYNTAX Score40 will be undertaken (academic research).  
7.3.1 EuroSCORE and EuroSCORE II 
 
EuroSCORE and EuroSCORE II will be collected and recorded in the eCRF. 
 
7.4 Patient Allocation  
 
Calculation of the  SYNTAX Score II and prognostic outcomes (mortality predictions) following 
CABG or PCI will be determined at 4 years using the SYNTAX Score II online calculator. 
Individual mortality predictions for CABG and PCI that can be separated with 95% confidence 
(ie, that can be statistically separated, p<0•05) will have a treatment recommendation for either 
CABG alone or PCI alone. Individual mortality predictions for CABG and PCI that cannot be 
separated with 95% confidence (i.e., could not be statistically separated, p>0•05) will have a 
treatment recommendation for either CABG or PCI. 
Comparisons of 4 year mortality predictions will be undertaken using the SYNTAX Score II 
online calculator, which will incorporate statistical comparisons of mortality predictions for 
CABG and PCI (as previously highlighted). The online calculator will provide the heart team 
with an objective treatment recommendation, namely, CABG is recommended, PCI is 
recommended, or either CABG or PCI is recommended. Final decision of treatment 
recommendation will be left at the discretion of the heart team after formal dialogue with the 
patient and provision of the prognostic information. The heart team may overrule the treatment 
recommendation made by the online calculator. Reasons for undertaking this should be clearly 
documented in the eCRF.  
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Having established that the patient could be potentially recruited based on the SYNTAX Score II 
on the grounds of patient safety, subjects will be assessed by the heart team as to whether 
“equivalent anatomical revascularization” could be potentially achieved between CABG and 
PCI. Secondly, the heart team must clearly establish that both CABG and PCI would be equally 
offered to the patient. If the patient fulfils both criteria then the patient may be recruited in the 
SYNTAX II Trial.  
The decision for the subject’s inclusion into SYNTAX II will be documented and ‘signed off’ by 
both members of the local Heart Team (Heart Team Worksheet) - subsequently investigator will 
receive patient allocation number. 
 
7.5 MSCT  
 
After Heart Team consensus, but prior to the planned PCI procedure, a MSCT scan should be 
obtained (documentary only). Refer to Appendix VI for MSCT acquisition protocol. The MSCT 
results and results of MSCT-derived FFR will only become available after completion of the 
SYNTAX II study, and therefore investigators will be blinded to its results during the study. 
Furthermore, the analysis of MSCT and FFRCT will be performed by analysts blinded to 
iFR/FFR and angiographic data.  
 
7.5.1 MSCT and angiographic SYNTAX Score: Exploratory Endpoint 
 • To prospectively examine the value of an objective anatomic SYNTAX Score based on 
non-invasive MSCT imaging - compared to conventional angiographic SYNTAX Score 
as visually assessed by the Heart Team. 
 
 
 
 
 
469Appendix
 
SYNTAX II 
Protocol 
Protocol ECRI-002 
Version 2.0 
Page 27 of 93 
 
 
Confidential and Proprietary 
Do not distribute or reproduce without the prior written permission of ECRI. 
CIP Version 2.0 - 27 November 2013 
 
7.5.2 MSCT and non-invasive FFRCT: Exploratory Endpoints 
 • To prospectively compare, in a population of patients with multi-vessel disease, 
functional stenosis severity assessed with non-invasive FFRCT with invasive functional 
assessment with iFR/FFR, using per-vessel comparisons. Per vessel analysis will be 
performed to calculate the percentage of vessels properly classified by MSCT-FFR, in 
terms of haemodynamic stenosis severity, compared to invasive iFR/FFR measurements. 
• To prospectively compare, in a population of patients with multi-vessel disease, 
functional SYNTAX scores calculated from a) multi-slice computed tomography 
coronary angiography and non-invasive FFR, and b) conventional angiography and 
iFR/FFR. In both a) and b), functional SYNTAX score is defined as anatomical 
SYNTAX scoring limited to vessels with haemodynamically significant stenoses (as 
estimated by HeartFlow [non-invasive functional SYNTAX score] or iFR/FFR [invasive 
functional SYNTAX score]) 
 
7.6 Index Procedure 
 
7.6.1 iFR/FFR 
 
All centres must be experienced in PCI of complex coronary artery disease, utilizing functional 
(iFR/FFR) and IVUS guidance. 
 
iFR is a recently introduced pressure-derived index for the assessment of coronary stenosis 
severity that, at difference to FFR, does not require adenosine administration and provides an 
estimation of stenosis severity a few seconds after crossing the stenosis with the pressure guide- 
wire.41 These characteristics make iFR a more ideal method to apply ischemia driven 
revascularisation in patients with 3VD, in whom multiple measurements are required.   
The subject will undergo invasive adenosine-free iFR® assessment of all 3 major epicardial 
vessels. All lesions intended to be treated should be interrogated, including side-branches. Total 
occlusions and culprit lesions of acute coronary syndromes64-66 preclude iFR measurements. iFR 
values will be collected with the PrimeWire Prestige Plus with AccuesenseTM technology. In 
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place of the PrimeWire Prestige Plus wire, the VerrataTM wire will be permitted to be used in the 
study once the wire has received an expected CE-mark. 
In SYNTAX II ischemia driven revascularisation will be performed following a hybrid decision-
making strategy of coronary revascularisation with iFR and FFR.67 The use of a hybrid iFR/FFR 
approach, currently undergoing testing in the ADVISE II study (ClinicalTrials.gov Identifier: 
NCT01740895) has the potential of significantly reducing the need for adenosine administration, 
whilst maintaining a 95% classification agreement to the FFR-only strategy.67 
iFR in all intended to treat vessels 
iFR <0.86*
Implantation of 
SYNERGYTM stent(s)
iFR >0.93
No stent implantation
in lesion
Optimization by IVUS 
guidance (modified MUSIC 
Criteria) 
Optimal medical therapy with a strict control of LDL (≤1.8 mmol)
Patient ‘Signed Off’ by 
Heart Team for PCI
* Consider FFR pullback with sequential lesions
iFR 0.86-0.93
FFR
FFR≤0.80 FFR>0.80
 Study Flowchart: Part-2: PCI procedure  
 
iFR values will be collected with the PrimeWire Prestige Plus (or VerrataTM wire) with 
AccusenseTM technology.  
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In case of iFR <0.86 the lesion will be treated by PCI. If iFR is ≥0.86 and ≤0.93, FFR is 
mandated to be measured using i.v. or i.c. adenosine, and the decision to treat will be based on an 
FFR cutoff of 0.80. iFR >0.93 the stenosis should not be treated.  
In subjects with contraindications to adenosine administration, revascularisation will be 
performed using iFR as a dichotomous index, using most recently reported cutoff value of iFR 
<0.89 for haemodynamic significance.67 
In case of sequential lesions, the procedure depicted in the flowchart should be followed. 
Treat visually most severe lesion
Sequential Lesions:
iFR <0.86 or FFR <0.80 in distal vessel beyond all lesions 
Reassess vessel with iFR
iFR <0.86*
Implantation of further 
SYNERGYTM stent(s)
iFR >0.93
No further stent 
implantation
Optimization by IVUS 
guidance (modified MUSIC 
Criteria) 
iFR 0.86-0.93
FFR
FFR≤0.80 FFR>0.80
FFR hyperaemic pullback to guide sequential lesion 
treatment can be alternatively performed at the 
discretion of the operator
 Study Flowchart: Part-2a: PCI procedure (sequential lesions) 
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iFR/FFR values will be recorded in the eCRF. No analysis will be performed by the core 
laboratory. Export of recordings to Cardialysis will be performed for post hoc analysis at a later 
stage (academic research). 
7.6.2 Stent implantation 
 
Stent implantation will be performed according to routine local clinical practice using the 
femoral, brachial or radial approach with the intention of achieving equivalent anatomical 
revascularization to CABG. The radial approach, although not mandated, will be strongly 
recommended.68 
Patients will exclusively be implanted with the SYNERGYTM stent.50, 51 Stenting should be 
attempted for each lesion in a vessel with a >1.5 mm in diameter as assessed on the diagnostic 
angiogram and agreed to be revascularised by the Heart Team in order to achieve equivalent 
anatomical revascularization. 
IVUS use at pre-PCI is left to the discretion of the investigator. IVUS assessment post stent 
implantation for optimisation of stent deployment is mandated (see part 7.5.3). 
If the implantation of the SYNERGY stent was not successful, the reason should be recorded in 
the CRF. 
 
7.6.2.1 Treatment of Bifurcations 
 
All types of bifurcation may need stenting of the main vessel, and/or the side branch, followed 
by kissing balloon post-implantation if a two stent approach is adopted. The treatment goal is to 
avoid gaps whenever more than one stent is used. Bifurcation techniques will be selected 
depending on the anatomy and morphology, although it is expected that most lesions would 
require a simple (provisional) approach, in keeping with recommendations from the European 
Bifurcation Club.69, 70  
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Stent sizing in bifurcation stenoses should take into account vessel diameter mismatch between 
mother and daughter vessels, following the recommendations of the European Bifurcation Club69, 
70
 (see also Appendix V for detailed treatment of bifurcations – mandated and recommended 
strategies). 
 
7.6.2.2 Treatment of Total Occlusions 
 
It has recently been shown that the presence of a total occlusion (TO) to be the strongest 
independent predictor of incomplete revascularisation in the PCI arm of the SYNTAX Trial.32, 33 
Operator skill and use of specific techniques and devices are key determinants PCI success in 
CTOs.34 A dedicated chronic total occlusion (CTO) operator is recommended to be made 
available in all participating centres. Staging of the revascularisation procedure should be 
encouraged, to ensure CTOs are appropriately revascularised. CTO recanalization can be 
performed using the antegrade or retrograde approach, as well as using specific re-entry 
techniques such as the StingRay device 71 Selection of stent length can be based on IVUS 
imaging. Viability assessment of total occlusions will be left at the discretion of the operator.72-77  
A tolerant attitude, refraining stenting towards moderate stenoses located distal to the occluded 
segment should be followed, on the grounds of important vessel diameter shift after vessel 
recanalization.78  
 
7.6.3 Intravascular Ultrasound (IVUS) 
 
In SYNTAX II Trial, mechanical IVUS catheters (Revolution® Rotational Imaging Catheter / 
Volcano Therapeutics or AtlantisTM SR Pro or SR Pro2 Imaging Catheter or OpticrossTM / 
Boston Scientific Corp) or phase array IVUS catheters (EagleEye®  Platinum Digital IVUS 
Catheter / Volcano Therapeutics) will be used to guide SYNERGY implantation. Use of either 
motorised or manual IVUS pullback will be allowed, although motorised pullback is 
recommended. 
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Both Boston and Volcano IVUS consoles have incorporated simplified software algorithms into 
their consoles to allow for the operator to undertake these calculations, and allow export of the 
data for post hoc analysis at a later stage. The following are the recommendations made on the 
grounds of evidence collected in the DES era:  
• Plaque preparation based on pre-procedural IVUS. Rotational atherectomy or cutting 
balloon should be considered if a >270° arc of superficial calcium is evident in IVUS.79 
Pre-procedural IVUS is left to the discretion of the investigator (not mandatory). 
• Selection of SYNERGY dimensions. Separate recommendations are given for selecting 
SYNERGY stent diameter in bifurcation and non-bifurcation stenoses.  
o In non-bifurcation stenoses: stent diameter matching distal vessel diameter or 
area (See table in Appendix IV). 
o In bifurcation stenoses: stent diameter matching distal (daughter) branch, with 
mandatory post-dilation of the proximal (mother) segment and polygon of 
confluence (POC) with a larger balloon size according to IVUS imaging. 
Regarding stent length, IVUS can be useful in outlining the presence of 
significant neighbour stenoses that might cause in-flow or out-flow narrowing 
after DES implantation, a very common finding in cases of DES thrombosis that 
is believed to be causative.  
o Incomplete stent expansion: See IVUS criteria Appendix IV. 
o Incomplete stent apposition. A non-compliant balloon sized with IVUS to vessel 
luminal diameter or area will be used in segments with malapposition (See table 
in Appendix IV) 
 
No analyses will be performed by the Core Laboratory. However, allowances will be made 
for export of IVUS data to Cardialysis, Rotterdam for potential post hoc analysis at later 
stage (academic research). 
The operator will record the numerical values of the IVUS targets in the eCRF. 
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7.6.4 Staged procedures 
 
Staged procedures are permitted, and will be encouraged for more complex cases – e.g. 
revascularization of total occlusions – to increase the likelihood of complete revascularization 
and to decrease the risk of contrast induced nephropathy. 
The recommended timing of a planned elective staged second PCI procedure is within 2 weeks 
post index procedure (with an upper limit allowed for 4 weeks in exceptional circumstances). 
The need for staging, and all specific lesions planned to be treated during the staged procedure 
should be captured beforehand in the eCRF. Staged procedures are only allowed in non-target 
vessels. Stented index segments or immediately adjacent segment(s), including adjacent branch 
segment(s) should not be manipulated again. The staged procedures will not affect the original 
follow-up schedule. Staged procedures should be performed in the exact same manner as the 
index procedure, including iRF/FFR, IVUS, medications, etc. 
 
7.7 Concomitant Medications 
 
Optimal medical therapy will be mandated in all patients and will be assessed at clinical follow-
up visits.  
 
7.7.1 Anti-Platelet Medication 
 
Dual antiplatelet (aspirin + clopidogrel/ticagrelor/prasugrel) will be mandated for at least 6 
months, aspirin indefinitely. Ticagrelor therapy will be encouraged to be continued in patients 
already receiving this therapy, based on this regime having been shown to have the best safety to 
efficacy ratio.80, 81  
Loading dose: 
• All patients must receive aspirin ≥300 mg/day starting 12-24 hours prior to the procedure 
(even if the subject is on chronic aspirin therapy). 
• Clopidogrel loading dose must be 600 mg, starting 12-24 hours prior to the procedure 
(even if the subject is on chronic clopidogrel therapy). 
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On the rare occasion of a patient not receiving aspirin or clopidogrel as outlined above, the 
procedure is to be deferred until appropriate administration of antiplatelet therapy has been 
attained. Loading of antiplatelet therapy immediately prior to PCI should be discouraged, 
since lack of pre-procedural anti-platelet therapy was linked to creatine kinase (CK) cardiac 
enzyme rises >2 x upper limit of normal post PCI and adverse mortality in the SYNTAX 
Trial.28, 82 
Alternatively: 
• Prasugrel 60 mg >1 hr before PCI; or 
• Ticagrelor 180 mg >1 hr before PCI if approved by the local regulatory authorities during 
the enrolment period of this protocol. 
Maintenance dose: 
Starting from the day after the procedure, aspirin 75-100 mg per will be prescribed to all patients 
indefinitely. 
Additionally, all patients must receive platelet aggregation inhibition therapy for at least 6 
months as currently recommended by the ESC/AHA/ACC guidelines which includes: 
• Clopidogrel 75 mg once daily. 
Alternatively: 
• Prasugrel 10 mg once daily; or 
(The dose of prasugrel may be decreased to 5mg od in patients with a weight <60 kg or age >75 years).  
• Ticagrelor (90 mg bid) 
 
7.7.2 Other medication 
 
- Unless contraindicated, peri-procedural IIb/IIIa inhibitor will be given according to the 
guidelines.11-13  
- The use of other medications (e.g. beta-blockers, ACE inhibitors) should be given in 
accordance to the guidelines.11-13  
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7.7.3 PCI Statin therapy 
 
Optimal medical therapy with strict control of LDL (target of ≤1.8 mmol/l) is strongly 
recommended, along with optimization of all medical therapy – rosuvastatin/atorvastatin 
(according to the guidelines). Strict control of LDL levels is recommended  
aiming for a target of ≤1.8 mmol. 
Several randomized trials have demonstrated that high dose statin therapy decreases PCI-related 
myonecrosis in subjects undergoing stent implantation, whether or not the subject is already 
taking chronic statin therapy.83-87 Therefore, in the absence of absolute contraindications to statin 
use (e.g. severe allergy with prior use), one of the following statin regimens must be 
administered at least 12 hours (at least one dose) before the PCI, regardless of LDL level and 
history of prior statin use. 
• atorvastatin 80 mg daily 
• rosuvastatin 40 mg daily 
Risk Factor Modification 
Tight control of risk factors will be mandated in line with the European and US revascularisation 
guidelines.11-13 Cholesterol reduction, with a LDL ≤1.8, will be an additional protocol defined 
target the operator will be recommended to record and control.  
In summary, patients (de novo 3VD) will be treated according to ACC/AHA/ESC guidelines, i.e. 
Heart Team discussion (Ia); functional evaluation for diagnosis in absence of objective evidence 
of ischemia (Ia); and LDL levels ≤1.8mmol (Ia). 
 
 
7.8 Hospital Discharge (post-PCI to hospital discharge) 
At discharge from the hospital where the index procedure took place, an assessment of the 
patient’s clinical status will be performed. Assessment of the cardiovascular drug use and any 
Serious Adverse Events will be recorded. An ECG will be performed and an anonymised copy of 
the ECG (showing patient ID and recording date) should be sent to the CRO. 
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7.9 Follow-up Period 
 
7.9.1 Hospital visits at 1 month (± 7 days), 6 months (± 14 days) and 1 year (± 30 days) 
post-procedure 
 
An assessment of the angina status, cardiovascular drug use and any Serious Adverse Events 
will be recorded during clinical follow-up visits.  
An anonymised copy of the ECG (showing patient ID and recording date) should be sent to 
the CRO. 
 
7.9.2 Telephone contacts at 2 years (± 30 days), 3 years (± 30 days), 4 years (± 30 days) and 
5 years (± 30 days)  
 
During these telephone contacts information from the patient will be gathered on any Major 
Adverse Cardiac or Cerebrovascular Events (MACCE). Patients will also be asked for 
angina status and cardiovascular drug use. 
 
7.10 Withdrawal from the Study 
After entering into the study, the patients are asked to complete all scheduled follow-up visits. 
Patients will be exempt from follow-up only if they withdraw their consent. 
  
All subjects should be encouraged to remain in the study until he/she has completed the protocol 
requirements during the 5-year follow-up period.  
 
Possible reasons for premature discontinuation may include, but are not limited to, the following:  
• Withdrawal of consent: Patient decides to withdraw from the study. The decision must be an 
independent decision that is documented in the patient study files.  
• Physician discretion: The investigator may choose to withdraw a patient from the study if 
he/she considers follow-up too burdensome for the patient.  
• Lost to follow-up: All patients should be encouraged to return for all scheduled follow-up 
visits, and to provide appropriate contact information to accommodate completion of required 
telephone follow-ups. The investigator will attempt to contact the patient at each follow-up 
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visit, independent of any missed follow-ups. The investigator should make 3 documented 
attempts per required follow-up visit.  
 
Patients who have discontinued the trial prematurely will not be replaced.   
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8  STATISTICAL DESIGN AND ANALYSIS 
 
 
8.1 Introduction 
 
This trial is a non-randomized single arm study that aims to perform a comparative analysis with 
historical controls. Patient recruitment in the current trial will be using the SYNTAX Score II, 
and the historical control will be with similarly selected patients from the randomised SYNTAX 
Trial.  
The analytical plan will be split into two sections: 
1. Descriptive statistical methodology: to describe the results of the current trial by itself.  
2. Comparative statistical methodology: to describe the comparison between the SYNERGYTM 
Everolimus Eluting Stent (EES) results of this trial and similar selected patients from the PCI 
and CABG cohorts of the randomised SYNTAX Trial. 
 
8.2 Patient Selection  
 
Patients will be prospectively recruited in the current trial with the SYNTAX Score II.  Similarly 
selected subjects (using the SYNTAX Score II) will be undertaken from the PCI and CABG 
cohorts of the randomised SYNTAX Trial and will act as control groups for the current trial. 
The study populations of SYNTAX II and the de-novo 3-vessel disease patients of SYNTAX I 
will be ‘matched’ based on the SYNTAX Score II. During the recruitment of the SYNTAX II 
study it will be monitored whether the populations sufficiently overlap. 
No reference data for multivessel disease can be found in the published literature for the 
SYNERGY EES; thus the data is inferred from the Italian EXECUTIVE Pilot Trial (Ribichini et 
al)88 in which the XIENCE EES was compared to the Taxus Liberte (paclitaxel eluting stent 
[PES]) in multivessel coronary disease. In the current trial, EES will be compared to the selected 
PES arm (superiority) and the selected CABG arm (non inferiority) of the SYNTAX Trial. 
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8.3 Assumptions for comparative analysis 
 
In the EXECUTIVE Trial, the PES arm had an event rate for MACE (major adverse cardiac 
events) at 1 year of 16.5%, and 11.1% for the EES arm. This implies a ratio of 11.1/16.5 i.e. 
0.67. 
We assume the same ratio as the margin of effect of the new device in the current trial. We 
assume the incidence of stroke will be low and unchanged in the current trial as compared to the 
SYNTAX Trial, therefore the outcome of major adverse cardiac and cerebrovascular events 
(MACCE) will be assessed in order to allow comparisons with the CABG arm. The incidence of 
MACCE at 1 year for the selected PES arm was 17.1%; assuming a ratio of 0.67, we estimate 
11.5% as the incidence of MACCE in the current trial. The incidence of MACCE at 1 year for 
the selected CABG arm was 10.8%. In our assumptions - as factor of benefit - we only 
considered the hazard ratio of Synergy vs. Taxus. We did not introduce reduction in the hazard 
ratio due to functional/IVUS assessment. 
 
SYNTAX II will not consider CABG as a separate arm and therefore we need to define the 
uncertainty margins in advance. The point estimate of 10.8% for the selected CABG arm is 
accompanied with a 95% confidence interval of 7.7-14.6% (Clopper-Pearson Exact Test). It is 
assumed that there have been minimal changes of CABG over the time since the recruitment of 
the SYNTAX Trial. 
 
8.4 Sample size 
 
8.4.1 Superiority testing (PCI) for the primary endpoint 
 
A sample size of 416 patients will guarantee a power of 90% to show superiority of the EES arm 
of the current trial to the historical PES control group. The assumptions used are: 
1) a 5% 2-sided level of significance (alpha) 
2) a 11.5% MACCE rate at 360 days for the EES arm, compared to the historical control of 
17.1% in the selected patients from the PES arm of the SYNTAX Trial. 
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8.4.2 Non-inferiority testing (CABG) for the exploratory endpoint 
 
A sample size of 416 patients will guarantee a power of 80% to show non-inferiority of the EES 
arm of the current trial to the historical CABG control group. The assumptions used are: 
1) a 5% 1-sided level of significance (alpha) 
2) a 11.5% MACCE rate at 360 days for the EES arm, compared to the historical control of 
10.8% in the selected patients from the CABG arm of the SYNTAX Trial 
3) a non-inferiority margin of 5%, as was used in the SYNTAX Trial. 
8.4.3 Sample size justification 
 
For the comparison with the selected PCI arm a sample size of 450 patients is chosen to obtain a 
power of at least 90%. 
8.5 Analytical plan 
 
The primary analysis will be based on the intention-to-treat principle. More details will be 
described in the statistical analysis plan. 
All statistical analyses will be done using the SAS System software, version 9.2 or above (SAS 
Institute Inc., SAS Campus Drive, Cary, North Carolina 27513, USA. All rights reserved). 
 
8.5.1 Descriptive statistical methodology 
 
Continuous variables will be presented using mean, standard deviation, median, minimum and 
maximum. Discrete variables will be presented in terms of frequencies and percentages. 
 
8.5.2 Comparative statistical methodology 
 
For the primary endpoint (MACCE at 360 days) the log rank test will be applied to compare the 
SYNTAX II with the historical control of the selected PCI arm. 
For the comparison to the selected CABG arm a 90% CI for the incidence of MACCE at 360 
days will be constructed. If the upper limit of 90% CI in the current trial is less than 15.8%, the 
SYNERGY EES will be declared non-inferior to the selected CABG arm. 
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For the current trial day 0 will be the day of patient allocation, i.e. the day of patient “signed off” 
by the Heart Team.  
8.6 Validation of SYNTAX Score II 
 
Prospective validation of the SYNTAX Score II for all-cause death at 1, 2 and 5 year will be 
undertaken. 
 
  
484 Appendix
 
SYNTAX II 
Protocol 
Protocol ECRI-002 
Version 2.0 
Page 42 of 93 
 
 
Confidential and Proprietary 
Do not distribute or reproduce without the prior written permission of ECRI. 
CIP Version 2.0 - 27 November 2013 
 
9 SAFETY REPORTING 
 
The investigator will monitor the occurrence of Serious Adverse Events (SAEs) for each subject 
during the course of the study. For the purpose of this protocol, the reporting of SAEs begins 
directly after patient has signed Informed Consent.  
An SAE form should be completed within 24 hours of the investigator’s and study staff’s 
awareness of the event. 
 
9.1 Serious Adverse Events (SAEs) Definitions 
An AE is defined as any untoward medical occurrence, unintended disease or injury, or untoward 
clinical signs (including abnormal laboratory findings) in subjects, users or other persons, 
whether or not related to the investigational medical device.  
 
An AE is classified as “serious” if the event: 
• Led to death; 
• Led to serious deterioration in the health of a patient that: 
o Resulted in a life threatening illness or injury; 
o Resulted in a permanent impairment of a body structure or a body function; 
o Required in patients hospitalisation or prolongation of existing hospitalisation; 
o Resulted in medical or surgical intervention to prevent permanent impairment to a body 
structure or a body function. 
• Led to foetal distress, foetal death or a congenital abnormality or birth defect. 
All SAEs will be followed until the event has been resolved (with or without sequelae). 
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9.2 Anticipated Adverse Device Effects 
 
Anticipated adverse device effects for Synergy, IVUS, iFR/FFR procedures are described in the 
Instructions For Use (IFU).  
 
If the investigator observes device malfunctions that led or might have led to a death or serious 
deterioration in health of a patient, user or other person or has complaints with regard to defects 
in the medical devices, the investigator shall, within 24 hours of such observation, report such 
device malfunction or complaint to the device company. Company shall be responsible for 
handling all complaints and reported device malfunctions in respect of the quality of medical 
devices, for determining the measures to be taken due to such observations or complaints and for 
ensuring that all necessary actions are taken including, but not limited to, any necessary action in 
connection with the recall of the medical devices or the reporting of incidents to competent 
authorities if deemed appropriate by the Company. Discussions regarding such device 
malfunction or complaints will be held between the Company and the Participating Site. 
 
9.3 Reporting to Ethics Committee (EC)  
Safety reporting to local ECs will be in accordance with the “guidelines on a medical device 
vigilance system” by the European Commission (MEDDEV2.12 rev 6, Dec 2009) and in 
compliance with local country law.  
 
If an event fulfils the criteria for SAE, then this shall be reported in the eCRF within 24 hours of 
the clinic study staff having become aware of this. At the time the event is reported in the eCRF, 
no event-supporting source documentation needs to be sent. Event supporting source documents 
will be requested by the sponsor (via monitoring organisation and/or CRO) for the purpose of 
clinical event adjudication. 
 
Clinical study staf must report device malfunctions directly to the manufacturer, who will then 
perform vigilance reporting to Competent Authorities, if applicable. 
 
. 
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All (S)AEs will be MedDRA coded by the Safety Group. This allows categorising them by body 
system, which facilitates their reporting as frequency counts to local ethics committees, as well 
as to the Data Safety Monitoring Board (DSMB). 
 
9.4 Data Safety Monitoring Board (DSMB) 
Serious adverse events (events leading to serious disability or admission to hospital, life-
threatening events or death) will be periodically reviewed and analysed by an independent 
DSMB. Members of this board are not affiliated with any (interventional) cardiology site 
enrolling patients into the trial, are not participating in the trial, and will declare any conflicts of 
interest should they arise. 
 
The composition, guiding policies, and operating procedures governing the DSMB are described 
in a separate DSMB Charter. Based on safety data, the DSMB may recommend that the Steering 
Committee modify or stop the clinical trial. All final decisions regarding clinical 
trial/investigation modifications, however, rest with the Steering Committee.  
 
All analyses are carried out aiming to protecting the safety of the trial participants. If the data at 
hand suggests a substantial safety concern about the experimental treatment strategy, the DSMB 
will carefully balance the observed risk profile against possible signs of improved efficacy.  
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9.5 Risk Analysis 
There is extensive clinical and commercial experience worldwide with cardiac catheterization 
and interventional procedures and it is expected that the procedural risks in this study and 
existing stenting procedure will not be significantly different. Known adverse events that may 
result from stent intervention (incorporating IVUS/FFR assessments) include but may not be 
limited to: 
• Allergic reaction or hypersensitivity to device material and its degredants (everolimus, 
platinum, chromium, poly-lactide-co-glycolide (PLGA)) 
• Shortness of breath/dyspnea 
• Distal embolism (air, tissue, or thrombotic) 
• Nausea/Vomiting 
• Coronary and stent thrombosis 
• Coronary and stent embolism 
• Coronary dissection 
• Total coronary occlusion 
• Abrupt coronary closure/threatened abrupt closure 
• Coronary injury 
• Coronary spasm 
• Coronary perforation 
• Coronary rupture 
• Pseudoaneurysm 
• Angina (stable or unstable) 
• Urgent or non-urgent coronary artery bypass graft surgery 
• Vascular complications including at the entry site which may require vessel repair and 
vessel dissection 
• Hematoma 
• Respiration cease 
• Hypertension 
• Death 
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• Bleeding 
• Bleeding complication (that may require transfusion) 
• Shock 
• Myocardial ischemia 
• Cardiac enzyme level elevation 
• Myocardial infarction 
• Cardiac tamponade 
• Cardiac arrest 
• ECG change 
• Heart failure 
• Renal failure 
• Stent implanted in unintended location 
• Restenosis of lesion/vessel treated with stent 
• Access site infection or pain 
• Access site hematoma or bleeding 
• Cerebral stroke/cerebral vascular accident (CVA) 
• Hypotension 
• Palpitation 
• Aneurysm 
• Arteriovenous fistula 
• Pulmonary edema 
• Fever 
• Arrhythmia (atrial or ventricular) 
• Peripheral ischemia (due to vascular injury) 
• Adverse reaction to drug (to everolimus, antiplatelets or contrast agent) 
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10 QUALITY CONTROL AND QUALITY ASSURANCE 
10.1 Compliance to Standards and Regulations 
The protocol, informed consent form and other study-related documents will be submitted to the 
Ethics Committee (EC) / Institutional Review Board (IRB). The study will be performed in 
accordance with the Declaration of Helsinki and Good Clinical Practices (GCP). 
 
The trial will only start at a clinical site after written approval of the study has been obtained 
from the appropriate national EC/IRB.  
 
10.2 Data Recording 
It is the expectation of the Sponsor that all data entered into the eCRF has source documentation 
available at the clinical site. The site must implement processes to ensure this happens.   
 
10.3 Quality Assurance and Monitoring  
Monitoring the clinical investigation at the study site is the responsibility of the monitoring 
organisation through trained and qualified Clinical Research Associates (CRAs).  
 
A baseline monitoring visit will be scheduled when first patients have been enrolled and data 
have been entered into the eCRF. This serves to confirm the quality of site study execution and 
to discuss practicalities with the site study staff. During on-site monitoring, the Informed 
Consent Forms will be checked and a sample of clinical data will be verified against eCRF data. 
Subject confidentiality will be maintained at all time. Emphasis will be on the complete reporting 
by the study staff of SAEs as well as the availability of baseline angiograms, iFR, IVUS 
recordings and per protocol required 12-lead ECGs. 
 
Each clinical site will be visited several times during the study to ensure a high degree of data 
quality. These site monitoring visits will be conducted to verify that the data are authentic, 
accurate and complete, that the safety and rights of subjects are protected, that the study is 
conducted according to the protocol, and that any other study agreements, GCP and all 
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applicable regulatory requirements are met. The investigator and the head of the medical 
institution (where applicable) agree to allow the CRA direct access to all relevant documents. It 
is important that the investigator and the study staff are available during the monitoring visit and 
possible audits and that sufficient time is devoted to the process. Findings from the review and 
source documents will be discussed with the investigator. The number of monitoring visits will 
depend on Key Performance Indicators (KPI) derived from data management. 
 
Remote site monitoring will also be performed to ensure complete quality study data and patient 
adherence to the protocol. On a regular basis, the monitoring organisation will contact each site 
to discuss the progress of the study with respect to patient enrolment, timely attendance of 
patients to their follow-up visits and other relevant study aspects such as data query resolution.  
 
Each participating clinic will receive a close-out visit to resolve any outstanding issues and to 
perform the final source data verification. 
 
There will be regular teleconferences between the Sponsor and the monitoring organisation to 
discuss site management issues. 
 
10.4 Quality Assurance and Data management 
 
The data collection will be performed through an electronic CRF (eCRF). The investigator or an 
authorised member of the investigational team must sign all completed eCRFs by using an 
electronic signature (a password will be provided by the data management centre at the start of 
the study).  
 
Clinical data management will be performed in accordance with data cleaning procedures. This 
is applicable for data recorded in the eCRF as well as for data from other sources (e.g. 
angiographies, ECGs, etc.). Appropriate computer edit programs will be run to verify the 
accuracy of the database. The investigator will be queried on incomplete, inconsistent or missing 
data. 
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10.5 On-site Audits 
 
To ensure compliance with GCP and regulatory requirements, a member of the Sponsor’s (or a 
designated CRO’s) quality assurance unit, may arrange to conduct an audit to assess the 
performance of the study at the study site and of the study documents originating there. The 
investigator agrees to cooperate with the Sponsor and/or its designee in the conduct of these 
audits and provide access to medical records and other relevant documentation, as required. The 
investigator/institution will be informed of the audit outcome.  
 
Regulatory authorities worldwide may inspect the investigator during and after the study. The 
investigator should contact the sponsor immediately if this occurs, and must cooperate with the 
regulatory authority inspections as required.  
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11 ORGANISATION  
11.1 Sponsor 
In this investigator-initiated trial, the European Cardiovascular Research Institute (ECRI) will act 
as Sponsor (ECRI-Trials B.V., PO Box 2125, 3000 CC Rotterdam, The Netherlands,). The 
Sponsor’s responsibilities are described in chapter 18. 
 
11.2 Steering Committee 
The Steering Committee is responsible of the overall management of the study at the highest 
level. The Steering Committee is comprised of a Chairman, Deputy Study Chair, PIs, Co-PIs, 
ECRI). Their names, roles and responsibilities are described in a separate Steering Committee 
Charter. 
 
11.3 Clinical Event Committee (CEC) 
The composition, events to be adjudicated, the minimum amount of data required, and the 
algorithm followed in order to classify the events are described in a separate CEC Charter.  
 
11.4 Data Safety Monitoring Board (DSMB) 
The composition, guiding policies and operating procedures governing the DSMB are described 
in a separate DSMB Charter.  
 
11.5 Data Management 
Data management will be conducted by the Clinical Research Organisation (CRO) Cardialysis 
(Cardialysis B.V., PO Box 2125, 3000 CC Rotterdam, The Netherlands). 
 
11.6 Site Management and Monitoring 
The CRO Cardialysis (Cardialysis B.V., PO Box 2125, 3000 CC Rotterdam, The Netherlands) 
will be responsible for site management and monitoring.  
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11.7 Safety Reporting 
Sites are responsible for reporting of incidents, including device malfunctions, to the 
manufactures. Manufacturers are responsible for vigilance reporting of device malfunctions to 
competent authorities according to the “guidelines on medical devices vigilance system” by the 
European Commission (MEDDEV2.12 rev 6, Dec 2009). 
No expedited safety reporting is foreseen. 
The CRO Cardialysis (Cardialysis B.V., PO Box 2125, 3000 CC Rotterdam, The Netherlands) is 
responsible for event reporting to the EC/IRB  according to local  and national requirements. 
 
11.8 Statistical Analysis 
The CRO Cardialysis (Cardialysis B.V., PO Box 2125, 3000 CC Rotterdam, The Netherlands) is 
responsible for the statistical analysis. 
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12 DATA HANDLING AND RECORD KEEPING 
12.1 Source Documentation (SD) 
Regulations require that investigators maintain information in the patient’s medical records that 
corroborate data collected in the electronic Case Report Form (eCRF). In order to comply with 
these regulatory requirements, at minimum, the following is a list of information that should be 
maintained and made available as required by monitors and/or regulatory inspectors:  
 
• Medical history/physical condition of the study patient before involvement in the study 
sufficient to verify investigational plan entry criteria;  
• Dated and signed notes on the day of entry into the study, protocol number, clinical site, 
patient number assigned and a statement that informed consent was obtained; 
• Notations on abnormal lab results; 
• Adverse events reported and their resolution, including supporting documents such as 
discharge summaries, cath lab reports, ECGs, lab results; 
• Study patient’s condition upon completion of or withdrawal from the study.  
 
12.2 Case Report Form Completion 
All required data will be accurately recorded by authorised personnel documented on the 
authorised signature log in the eCRF.  
 
12.3 Record Retention  
All eCRF information, study records, reports and source documents that support the eCRF must 
be retained in the files of the responsible investigator according to the national requirements 
following notification by the Sponsor or designee that all investigations have been completed, 
and will further be retained in accordance with local and international guidelines as identified in 
the Investigator Site Agreement. This documentation must be accessible upon request by 
international regulatory authorities or the Sponsor (or designee). The Sponsor or designee must 
approve archiving or transfer of the documentation for relocation purpose of premises, in writing, 
prior to the actual file transfer. The investigator must notify the Sponsor, in writing, of transfer 
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location, duration, and the procedure for accessing study documentation. The investigator must 
contact the Sponsor, or designee, before the destruction of any records and reports pertaining to 
the study to ensure they no longer need to be retained.  
 
If the investigator retires, relocates, or for other reasons withdraws from assuming primary 
responsibility for keeping the study records, custody per written notice must be submitted to the 
Sponsor, or designee, indicating the name and address of the person accepting primary 
responsibility. The EC/IRB must be notified in writing of the name and address of the new 
custodian.  
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13 PUBLICATION POLICY 
The Steering Committee and investigators are committed to the publication and widespread 
dissemination of the results of the study. Data from this study will not be withheld regardless of 
the findings.  
 
The SYNTAX II trial is an investigator-initiated and scientifically driven study nested within the 
European Cardiovascular Research Institute (ECRI) and set up in collaboration with Boston 
Scientific and Volcano. All public presentations and manuscript generation and submissions will 
be led under the auspices of the Principal Investigators who will organise and lead a Publications 
Committee. However, this study represents a joint effort between investigators, ECRI and 
collaborators, and as such, the parties agree that the recommendation of any party concerning 
manuscripts or text shall be taken into consideration in the preparation of final scientific 
documents for publication or presentation. 
 
The final locked database will be housed at the data management centre, Cardialysis. Cardialysis 
will not publicly release data or study-related material, presentations, or manuscripts without the 
express permission of the Principal Investigators. All Principal Investigators will be listed as 
authors on all abstracts and publications, and as such must agree to their submission. The 
publication and/or presentation of results from a single trial site are not allowed until publication 
and/or presentation of the multi-centre results. All single site data for public dissemination must 
be generated from the central database – local database projects are not permitted. All proposed 
publications and presentations resulting from or relating to the study (whether from multicenter 
data or single site analysis) must be submitted to the Publications Committee for review and 
approval prior to submission for publication or presentation. 
 
The Steering Committee will receive any proposed publication and/or presentation materials 
prior to submission of the presentation or the initial submission of the proposed publication in 
order for the materials to be timely reviewed by all parties.  
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14 INVESTIGATOR RESPONSIBILITIES 
14.1 Investigator Responsibility/Performance 
Prior to starting enrolment of patients, the investigator must read and understand this study 
protocol, and must sign and date the Protocol Signature page. The Investigator Site Agreement 
documents agreement to all conditions of the study protocol and agreement to conduct the study 
accordingly. This study will be conducted in accordance the Declaration of Helsinki and other 
applicable regulatory requirements or any conditions of approval imposed by the IRB/EC or 
regulatory authorities.  
 
14.2 Required Documents 
The following documents must be submitted to Sponsor, or designee prior to patient enrolment:  
• Signed Protocol Signature Page  
• Recent signed and dated English Curriculum Vitae (CVs) of the Principal Investigator and co-
investigators of the clinical site. These CVs should clearly show the investigator’s and co-
investigators’ qualifications and experience.  
• Copy of the written confirmation of the EC/IRB regarding approval of the protocol including 
version number and date, patient information sheet and informed consent form, including 
version and date and other adjunctive patient material.  
• List of EC/IRB members, including name, title, occupation and any institutional affiliation of 
each member. If the EC/IRB member list is not available, the General Assurance or EC/IRB 
Recognition Number should be provided.  
• Signed Investigator Site Agreement. 
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14.3 Ethics Committee (EC) / Institutional Review Board (IRB) Approval 
According to the local regulations, the investigator must have all necessary approvals, including 
written approval from the EC/IRB of the clinical site or other accepted EC/IRB prior to enrolling 
patients in the study. A copy of the written approval must be provided to Sponsor and should 
include the following:  
• Statement of EC/IRB approval for the proposed study at the clinical site  
• Date the study was approved and the duration of the approval  
• Listing of any conditions attached to the approval  
• Identification of the approved Primary Investigator  
• Signature of the EC/IRB chairperson  
• Acknowledgement of the Co-Investigators  
• EC/IRB approval of the informed consent form (if applicable)  
• EC/IRB approval of the final protocol (if applicable).  
 
Any substantial amendments to the protocol, as well as associated consent form changes, will be 
submitted to the EC/IRB and written approval obtained prior to implementation. Minor changes 
which do not affect the subject’s safety will be subject to notification.  
 
Serious Adverse Event (SAE) reports will be submitted to the EC/IRB as requested by the 
Sponsor, EC/IRB and/or local regulations. Annual and final reports will be provided to the 
EC/IRB as required.  
 
14.4 Informed Consent 
Study subjects must provide written informed consent using an EC/IRB-approved informed 
consent form. The study must be explained to the study subjects in lay language. The 
investigator, or representative, must be available to answer all of the study subject’s study-
related questions. Study subjects will be assured that they may withdraw from the study at any 
time for any reason and receive alternative conventional therapy as indicated.  
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14.5 Protocol Deviation 
The CRA/monitor will report all protocol deviations to the Sponsor. The investigator will review 
all protocol deviations  and will inform the EC/IRB according to the EC/IRB requirement.  
 
14.6 Reporting Requirements 
The investigator should notify the EC/IRB in writing within three months after completion, 
termination, or discontinuation of the study at the site. The same procedure will be applied to 
Competent Authority where required.  
 
Site responsibilities for submitting data and reports:  
Type of CRF/Report  Completed by Site Within  Process  
Serious Adverse Event Notification 
eCRF (including death, MACE)  
24 hours  Enter eCRF pages within 
24 hours of knowledge of 
event  
   
eCRF (Baseline, In-hospital summary, 
Follow-up, Patient Withdrawal)  
Ongoing basis  Collected in the eCRF 
Angiographic Films, ECGs, IVUS and 
iFR/FFR recordings. 
MSCT scans (if applicable). 
Ongoing basis  Collected by site and 
shipped to Core lab 
within 7 days  
Device malfunctions Ongoing basis Collected by site and 
provided to manufacturer 
Annual Reports  Forward as requested by 
EC/IRB  
Copy  provided by 
Sponsor to be send to 
EC/IRB  
Final Report  Forward within 3 months of 
study completion or 
termination  
Copy  provided by  
Sponsor to be send to 
EC/IRB  
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14.7 Audits / Inspection 
In the event that audits are initiated by the Sponsor (or its designee) or national/international 
regulatory authorities, the investigator allows access to the original medical records and provides 
all requested information. In the event that audits are initiated by a regulatory authority, the 
investigator will immediately notify the Sponsor. 
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15 SPONSOR RESPONSIBILITIES  
 
15.1 Role of ECRI 
As Sponsor, ECRI has the overall responsibility for the conduct of the study, including assurance 
that the study satisfies international standards and the regulatory requirements of the relevant 
competent authorities.  
 
General duties  
Prior to allowing the sites to start enrolling patients into the study, the Sponsor is responsible for 
selecting investigators, ensuring EC/IRB approvals are obtained where applicable, and signing 
the Investigator Site Agreement with the investigators and/or hospitals. It is the Sponsor’s 
responsibility to ensure that the study is conducted according to ISO 14155, the Declaration of 
Helsinki, and other applicable regulatory requirements, the study protocol, and any conditions of 
approval imposed by the EC/IRB or regulatory authorities. Additionally, the Sponsor will ensure 
proper clinical site monitoring.  
 
Selection of clinical investigators and sites  
The Sponsor together with the Steering Committee will select qualified investigators and 
facilities which have adequate study patient population to meet the requirements of the 
investigation.  
 
Training of investigator and site personnel and site monitoring  
The training of the investigator and appropriate clinical site personnel will be the responsibility 
of the Sponsor, or designee, and may be conducted during an investigator meeting, a site 
initiation visit, or other appropriate training sessions.  
Periodic monitoring visits will be conducted frequently enough to ensure that all clinical patient 
data are properly documented and that the study is properly conducted.  
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Documentation  
The Sponsor will collect, store, guard and ensure completion by the relevant parties of the 
following documents;  
• All study relevant documents (protocol, EC/IRB approval and comments, patient information 
and informed consent template, relevant correspondence, etc.)  
• Signed and dated Case Report Form  
• Records of any Serious Adverse Events (SAEs) reported to the Sponsor during the clinical 
investigation  
• Any statistical analyses and underlying supporting data  
• Final report of the clinical investigation  
 
 
15.2 Supplemental Applications 
As appropriate, the Sponsor will submit changes to the study protocol to the investigators to 
obtain EC/IRB re-approval. 
 
15.3 Submitting Reports 
The Sponsor will submit the appropriate reports identified by the regulations. This includes 
withdrawal of any EC/IRB approval, interim (if any) and final reports. 
 
15.4 Maintaining Records 
The Sponsor will maintain copies of correspondence, data,  SAEs and other records related to the 
clinical study. The Sponsor will maintain records related to the signed Investigator Site 
Agreements according to requirements set forth by ISO14155.  
 
All Core Laboratories and clinical sites will maintain study records according to local 
requirements for this type of study. 
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15.5 Audit 
The Sponsor is responsible for auditing the study to ensure compliance with GCP and regulatory 
requirements, a member of the Sponsor’s (or a designated CRO’s) quality assurance unit and 
may arrange to conduct an on-site audit to assess the performance of the study at the study site 
and of the study documents originating there.  
 
15.6 Confidentiality  
All data and information collected during this study related to the participating subject will 
comply with the standards for protection of privacy based on applicable local/ national 
requirements for subject’s confidentiality. All data used in the analysis and summary of this 
study will be anonymous, and without reference to specific study subjects’ names. Access to 
study subject files will be limited to authorised personnel of the Sponsor, the investigator, and 
research staff. Authorised regulatory personnel have the right to inspect and copy all records 
pertinent to this study, but all efforts must be made to remove the subject’s personal data. 
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17 APPENDIX I: SCHEDULE OF EVENTS 
 
Event Screen Procedure Post -
Procedure 
to Hospital 
D/c 
1 Mo 
±7 days 
6 Mo 
±14 days 
1 Yrs 
±30 days 
2-5Yrs 
±30 days 
Type of contact    Visit Visit Visit Phone 
Local Heart Team 
conference 
- Inclusion/ 
exclusion Criteria  
-  SYNTAX Score II  
- EuroSCORE 
- EuroSCORE II 
X       
Informed consent X       
Physical examination X       
Medical and Cardiac 
history 
X       
Anginal Status X  X X X X X 
1CBC, blood 
chemistry, lipids 
X       
CK-MB  X2  X3     
Troponin X2  X3     
12 lead ECG7 X4  X5 X X X  
Medication regimen X X X X X X X 
Angiography6, 7  X      
IVUS7  X      
FFR/(iFR)7  X      
MSCT7 X       
Serious Adverse Event 
monitoring 
 X X X X X X 
1
 within 7 days prior to procedure 
2
 CK-MB/Troponin is drawn at least 24 hours prior to PCI. 
3
 CK-MB/Troponin is determined pre-discharge or within 48 hours whatever comes first 
4  ECG at time of screening should be at least 24 hours prior to PCI 
5  within 24 hours post-procedure or at discharge, whichever comes first 
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6  In index angiograms for anatomical SYNTAX Score assessment both the right coronary artery (RCA) and left     
   coronary artery (LCA, incl. LAD and LCX) must be imaged. 
7  Collect and forward to central Core Lab (material collection only).  
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18 APPENDIX II: PROPORTION OF 3VD PATIENTS SUITABLE FOR PCI  
 
Mortality predictions for CABG versus PCI for each individual patient in the randomised 
SYNTAX trial (n=1800). Scatter plots illustrating mortality predictions for the left main (upper 
panel) and 3VD (lower panel) cohorts separated by conventional tertiles of the SYNTAX Score. 
The diagonal line represents identical mortality predictions for CABG and PCI. Individual 
predictions plotted to the left of the diagonal line favour CABG (actual percentages shown in top 
left corner), and to the right favour PCI (actual percentages shown in bottom right corner). 
Individual mortality predictions for CABG or PCI that could be separated with 95% confidence 
(p<0·05) are coloured black (actual percentage shown in parentheses in respective corners). 
Mortality predictions that could not be separated with 95% confidence (p>0·05) are highlighted 
in grey, and identify patients with similar 4-year mortality. Percentages of patients in each 
category are shown. CABG=coronary artery bypass surgery. PCI=percutaneous coronary 
intervention. LMS=left main stem. 3VD=three-vessel disease. Adapted and reproduced from 
Farooq et al.26 
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19 APPENDIX III: SYNTAX SCORE II 
 
SYNTAX Score II nomogram for bedside application. An online version will be made available 
online at the original SYNTAX Score website (www.syntaxscore.com).1 
Total number of points for 8 factors can be used to accurately predict 4-year mortality for the 
individual patient proposing to undergo for CABG or PCI. For example, a 60 year old man with 
an anatomical SYNTAX score of 30, unprotected left main coronary artery disease, creatinine 
clearance of 60 mL/min, an LVEF of 50%, and COPD, would have 41 points (predicted 4-year 
mortality 16·3%) to undergo CABG and 33 points (predicted 4-year mortality 8·7%) to undergo 
PCI respectively. The same example without COPD included would lead to identical points (29 
points) and 4-year mortality predictions (6·3%) for CABG and PCI. 
COPD defined with EuroSCORE definition,54 long-term use of bronchodilators or steroids for 
lung disease. PVD defined according to ARTS I definition,89 aorta and arteries other than 
coronaries, with exercise-related claudication, or revascularisation surgery, or reduced or absent 
pulsation, or angiographic stenosis of more than 50%, or combinations of these characteristics.  
Adapted from Farooq et al.26 
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*Because of the rarity of complex coronary artery disease in premenopausal women, mortality predictions in 
younger women are predominantly based on the linear relation of age with mortality. The differences in mortality 
predictions in younger women between CABG and PCI will therefore be affected by larger 95% CIs than those in 
older women.  
518 Appendix
 
SYNTAX II 
Protocol 
Protocol ECRI-002 
Version 2.0 
Page 77 of 93 
 
 
Confidential and Proprietary 
Do not distribute or reproduce without the prior written permission of ECRI. 
CIP Version 2.0 - 27 November 2013 
 
A. Symmetry check: LD min/LD max is close to 1, thus is symmetric; Expansion check: The 
minimum lumen area within the stent should be compared to that of the reference 
segments; Apposition check: there is a space behind the struts, thus the stent is not lying 
on the vessel luminal wall and therefore is not well apposed. We recommend 
postdilation, preferably with a non compliant balloon according the inflation chart. 
B. Symmetry check: LD min/LD max is far from 1, thus is asymmetric. We recommend 
postdilation preferably with a non compliant balloon according the inflation chart; 
Expansion check: The minimum lumen area within the stent should be compared to that 
of the reference segments; Apposition check: there is a space behind the struts, thus the 
stent is not lying on the vessel luminal wall and therefore is not well apposed. We 
recommend postdilation, preferably with a non compliant balloon according the 
inflation chart.  
C. Symmetry check: LD min/LD max is 1, thus is symmetric; Expansion check: The 
minimum lumen area within the stent should be compared to that of the reference 
segments; Apposition check: there is NO space behind the struts, thus the stent is lying on 
the vessel luminal wall and therefore is well apposed and therefore no extra actions are 
needed. 
D. Symmetry check: LD min/LD max is far from 1, thus is asymmetric. We recommend 
postdilation, preferably with a non compliant balloon according the inflation chart.; 
Expansion check: The minimum lumen area within the stent should be compared to that 
of the reference segments; Apposition check: there is NO space behind the struts, thus the 
stent is lying on the vessel luminal wall and therefore is well apposed and therefore no 
extra actions are needed.  
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20 APPENDIX IV: IVUS CRITERIA 
 
IVUS Criteria (Modified MUSIC Criteria90): for evaluation of appropriate stent apposition: 
1). Complete apposition against the vessel wall of the entire stent AND 
2). a) ≥90% of the average reference lumen area or ≥100% of lumen area of the 
 reference segment with the lowest lumen area; or 
 b) MLA >between 5.5 mm2; or 
 c) MLA ≥80% of the average reference lumen area or ≥90% of lumen area of the 
 reference segment with the lowest lumen area. AND 
3). Symmetric stent expansion. 
 
ISA
No
ISA
Yes
Symmetry >0.7-NoSymmetry >0.7-Yes
LD 
min
LD 
max
LD 
min
LD 
max
LD 
min
LD 
max
LD 
min
LD 
max
Malapposition area Malapposition area
Reference Reference
Reference Reference Reference Reference
Reference Reference
A
C
B
D
Figure: Stent Symmetry, Expansion and Apposition
ISA: Incomplete Stent Apposition
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A. Symmetry check: LD min/LD max is close to 1, thus is symmetric; Expansion check: The 
minimum lumen area within the stent should be compared to that of the reference 
segments; Apposition check: there is a space behind the struts, thus the stent is not lying 
on the vessel luminal wall and therefore is not well apposed. We recommend 
postdilation, preferably with a non compliant balloon according the inflation chart. 
B. Symmetry check: LD min/LD max is far from 1, thus is asymmetric. We recommend 
postdilation preferably with a non compliant balloon according the inflation chart; 
Expansion check: The minimum lumen area within the stent should be compared to that 
of the reference segments; Apposition check: there is a space behind the struts, thus the 
stent is not lying on the vessel luminal wall and therefore is not well apposed. We 
recommend postdilation, preferably with a non compliant balloon according the 
inflation chart.  
C. Symmetry check: LD min/LD max is 1, thus is symmetric; Expansion check: The 
minimum lumen area within the stent should be compared to that of the reference 
segments; Apposition check: there is NO space behind the struts, thus the stent is lying on 
the vessel luminal wall and therefore is well apposed and therefore no extra actions are 
needed. 
D. Symmetry check: LD min/LD max is far from 1, thus is asymmetric. We recommend 
postdilation, preferably with a non compliant balloon according the inflation chart.; 
Expansion check: The minimum lumen area within the stent should be compared to that 
of the reference segments; Apposition check: there is NO space behind the struts, thus the 
stent is lying on the vessel luminal wall and therefore is well apposed and therefore no 
extra actions are needed.  
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21 APPENDIX V: BIFURCATION MANAGEMENT CRITERIA 
 
Principals - consistent with European Bifurcation club 
1) Provisional T is preferred strategy 
2) 2 wires from the outset are recommended when branch is of sufficient size for the 
lesion to be considered a bifurcation and it has some disease 
3) Probable 2 stents (operators choice of technique) when disease is in a suitably sized 
side branch and branch disease extends >5mm  
4) When 2 stents are used kissing balloon post dilatation is mandatory at completion 
5) When  1 stent used-  kissing balloon post dilatation is not mandatory at completion 
6) Large side branch with proximal disease and very challenging access should be 
stented once accessed - (no iFR/FFR required of branch before treatment) - these are 
exceptional cases. 
 
Performance/technique- pre stent 
7) Plan to perform iFR/FFR to main vessel prior to PCI – mandatory  
8) When performing elective 2 stents strategy-  iFR/FFR to main vessel prior to PCI – 
mandatory and branch iFR/FFR at operators discretion 
9) Plan to perform provisional approach and branch appears diseased and may require 
stenting – iFR/FFR of branch recommended 
10) In 0,0,1 lesion iFR/FFR of main vessel mandatory and branch recommended  
 
Performance/technique- post stent 
11) Post stent deployment in main vessel iFR/FFR recommended of main vessel  
12) Post stent deployment in main vessel – treatment of branch vessel 
a. Normal flow in branch with discrete pinched ostium – operators discretion 
either leave it or iFR/FFR prior to stenting – mandatory 
b. Reduced flow / dissection in significant branch - bail out strategy at operators 
discretion- can do  iFR/FFR at completion at operators discretion. If 2 stents 
placed final kissing is mandatory. 
 
 
Angiographically 1,1,0 LAD D1 bifurcation 
iFR/FFR of the LAD confirms need for stent  
stent placed, discrete ostial pinch of D1 but normal flow 
iFR/FFR mandatory if further stent to D1 considered 
iFR/FFR of LAD at completion 
 
Angiographically 1,1,0 LAD D1 bifurcation 
iFR/FFR of the LAD confirms need for stent  
LAD stent placed , but TIMI II flow in D1 
wire with any wire chosen by operator and proceed as per usual practice including additional 
stent if considered necessary  
iFR/FFR of LAD at completion and D1 if possible 
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Angiographically 1,0,1 LAD D1 bifurcation 
iFR/FFR of the LAD confirms need for stent  
unable to comment on D1 ostium in presence of proximal stenosis using iFR/FFR 
if disease >5mm in D1- 2 stent strategy of operators choice with kissing to complete procedure 
if disease <5mm in D1- stent LAD and then iFR/FFR of D1 is further stent considered 
iFR/FFR of LAD at completion 
 
Angiographically 0,0,1 LAD D1 bifurcation 
iFR/FFR of the LAD confirms no requirement for LAD stent  
iFR/FFR of the D1 confirms requirement for stent (unusual)  
stent strategy of operators choice 
iFR/FFR of LAD and D1 at completion 
 
Angiographically 0, 1, 0  LAD D1 bifurcation 
iFR/FFR of the LAD confirms requirement for LAD stent  
stent to LAD – will usually cover bifurcation 
stent strategy of operators choice 
discrete ostial pinch of D1 but normal flow iFR/FFR mandatory if further stent to D1 considered 
iFR/FFR of LAD and ideally D1 at completion 
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22 APPENDIX VI: DEFINITIONS 
 
 
I. According to SYNTAX I Trial, MACCE is defined as: 
 
• All cause death 
• Cerebrovascular event (stroke) 
• Documented myocardial infarction 
• Repeat revascularization (PCI and/or CABG). 
 
DEATH 
All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. 
Cardiac Death: any death due to immediate cardiac causes (e.g. MI, low-output failure, fatal 
arrhythmia). Unwitnessed death and death of unknown cause will be classified as cardiac death. 
Vascular Cause death: death due to cerebrovascular disease, pulmonary embolism, ruptured 
aortic aneurysm, dissecting aneurysm, or other vascular cause. 
Non-Cardiovascular death: any death not covered by the above definitions, including death due 
to infection, sepsis, pulmonary causes, accident, suicide or trauma. 
 
STROKE 
A focal neurological deficit of central origin lasting more than 72 hours and results in 
irreversible brain damage or permanent body impairment. Type and severity of symptoms is 
dependent on the location and extent of brain tissue whose circulation has been involved. Strokes 
will be further classified as ischemic or hemorrhagic based on imaging studies. When blood flow 
to the brain is interrupted because of rupture of a vessel causing bleeding into or around the brain, 
it is considered hemorrhagic. When a vessel that supplies the brain is blocked, the event is 
considered ischemic. 
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MYOCARDIAL INFARCTION 
A myocardial infarction will be considered whether it occurred spontaneously or in association 
with angioplasty or coronary bypass graft surgery procedures. A definite diagnosis of myocardial 
infarction is made: 
 
Definition I: Within the first 7 days post intervention: 
New Q-waves (*) and one plasma level of CKMB 5x upper limit for normal. 
 
Definition II: At least 7 days after any intervention procedure: 
Either a. New Q-waves (*) 
Or one plasma level of CKMB 5x upper limit for normal  
 
(*) development of new abnormal Q-waves not present on the patient’s baseline (i.e. before 
allocation) ECG. The Minnesota Code for pathological Q-waves will be used. 
(*) In cases of ECG diagnosis of MI in the presence of a complete left bundle branch block, peak 
CKMB levels should be obtained locally. 
 
TLR 
Target Lesion Revascularization is defined as any ischemia-driven repeat percutaneous 
intervention of the target lesion or bypass surgery of the target vessel due to any of the 
following: 
1. the patient had a positive functional study corresponding to the area served by the target lesion. 
2. ischemic ECG changes at rest in a distribution consistent with the target vessel 
3. ischemic symptoms referable to the target lesion. 
 
TVR 
Target Vessel Revascularization is defined as any ischemia-driven repeat percutaneous 
intervention of the target vessel or bypass surgery of the target vessel due to any of the 
following: 
1. the patient had a positive functional study corresponding to the area served by the target vessel 
2. ischemic ECG changes at rest in a distribution consistent with the target vessel 
3. ischemic symptoms referable to the target lesion. 
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A. If the acute focal signs represent a worsening of a previous deficit, these signs must have 
either 
1. Persisted for more than one week, or 
2. Persisted for more than 24 hours and were accompanied by an appropriate new CT or 
MRI finding 
B. Strokes may be sub-classified as follows:  
1. Ischemic (Non-hemorrhagic):  a stroke caused by an arterial obstruction due to 
either a thrombotic (e.g., large vessel disease/atherosclerotic or small vessel 
disease/lacunar) or embolic etiology. 
2. Hemorrhagic:  a stroke due to a hemorrhage in the brain as documented by 
neuroimaging or autopsy.  This category will include strokes due to primary 
intracerebral hemorrhage (intraparenchymal or intraventricular), ischemic strokes 
with hemorrhagic transformation (i.e., no evidence of hemorrhage on an initial 
imaging study but appearance on a subsequent scan), subdural hematoma,* and 
primary subarachnoid hemorrhage. 
*All subdural hematomas that develop during the clinical trial should be recorded 
and classified as either traumatic versus nontraumatic. 
3. Unknown:  the stroke type could not be determined by imaging or other means (e.g., 
lumbar puncture, neurosurgery, or autopsy) or no imaging was performed. 
C. Stroke Disability 
All strokes with stroke disability of Modified Rankin Scale (mRS) ≥1 will be included 
in the primary endpoint. All diagnosed strokes (even with mRS 0) will also be tabulated. 
Stroke disability will be classified using an adaptation of the modified Rankin Scale.  
 Scale Disability 
0 No stroke symptoms at all.  (May have other complaints) 
1 No significant disability; symptoms present but no physical or other limitations. 
2 Slight disability;  limitations in participation in usual social roles, but 
independent for activities of daily living (ADL) 
3 some need for assistance but able to walk without assistance 
4 Moderately severe disability; need for assistance with some basic ADL, but not 
requiring constant care  
5 Severe disability requiring constant nursing care and attention. 
  
Stroke: Modified Rankin score  ≥1 and increase by ≥1 from baseline 
D. Transient Ischemic Attack (as compared to stroke) is defined as: 
• New focal neurologic deficit with rapid symptom resolution, usually 1-2 hours, 
always within 24 hours 
• Neuroimaging without tissue injury 
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II. Contemporary definitions 
 
Death (Per ARC Circulation 2007; 115: 2344-2351) 
 
The deaths will be adjudicated per the ARC definition. All deaths are considered cardiac unless 
an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in 
patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be 
classified as cardiac.  
 • Cardiac death: 
Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), 
unwitnessed death and death of unknown cause, all study procedure related deaths including 
those related to concomitant treatment. 
 • Vascular death: 
Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary 
embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. 
   • Non-cardiovascular death: 
Any death not covered by the above definitions such as death caused by infection, 
malignancy, sepsis, pulmonary causes, accident, suicide or trauma. 
 
Stroke 
1. Duration of a focal/global neurological deficit  ≥24 hours or<24 hours if any of the 
following conditions exist: 
i. at least one of the following therapeutic interventions: 
a. Pharmacologic (i.e., thrombolytic drug administration) 
b. Non-pharmacologic (i.e., neurointerventional procedure such as 
intracranial angioplasty) 
ii. Available brain imaging clearly documents a new hemorrhage or infarct 
iii. The neurological deficit results in death 
2. No other readily identifiable non-stroke cause for the clinical presentation (e.g., brain 
tumor, trauma, infection, hypoglycemia, other metabolic abnormality, peripheral 
lesion, or drug side effect). Patients with non-focal global encephalopathy will not be 
reported as a stroke without unequivocal evidence based upon neuroimaging studies. 
3. Confirmation of the diagnosis by a neurology or neurosurgical specialist and at least 
one of the following: 
a. Brain imaging procedure (at least one of the following): 
i. CT scan 
ii. MRI scan 
iii. Cerebral vessel angiography 
b. Lumbar puncture (i.e. spinal fluid analysis diagnostic of intracranial hemorrhage) 
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A. If the acute focal signs represent a worsening of a previous deficit, these signs must have 
either 
1. Persisted for more than one week, or 
2. Persisted for more than 24 hours and were accompanied by an appropriate new CT or 
MRI finding 
B. Strokes may be sub-classified as follows:  
1. Ischemic (Non-hemorrhagic):  a stroke caused by an arterial obstruction due to 
either a thrombotic (e.g., large vessel disease/atherosclerotic or small vessel 
disease/lacunar) or embolic etiology. 
2. Hemorrhagic:  a stroke due to a hemorrhage in the brain as documented by 
neuroimaging or autopsy.  This category will include strokes due to primary 
intracerebral hemorrhage (intraparenchymal or intraventricular), ischemic strokes 
with hemorrhagic transformation (i.e., no evidence of hemorrhage on an initial 
imaging study but appearance on a subsequent scan), subdural hematoma,* and 
primary subarachnoid hemorrhage. 
*All subdural hematomas that develop during the clinical trial should be recorded 
and classified as either traumatic versus nontraumatic. 
3. Unknown:  the stroke type could not be determined by imaging or other means (e.g., 
lumbar puncture, neurosurgery, or autopsy) or no imaging was performed. 
C. Stroke Disability 
All strokes with stroke disability of Modified Rankin Scale (mRS) ≥1 will be included 
in the primary endpoint. All diagnosed strokes (even with mRS 0) will also be tabulated. 
Stroke disability will be classified using an adaptation of the modified Rankin Scale.  
 Scale Disability 
0 No stroke symptoms at all.  (May have other complaints) 
1 No significant disability; symptoms present but no physical or other limitations. 
2 Slight disability;  limitations in participation in usual social roles, but 
independent for activities of daily living (ADL) 
3 some need for assistance but able to walk without assistance 
4 Moderately severe disability; need for assistance with some basic ADL, but not 
requiring constant care  
5 Severe disability requiring constant nursing care and attention. 
  
Stroke: Modified Rankin score  ≥1 and increase by ≥1 from baseline 
D. Transient Ischemic Attack (as compared to stroke) is defined as: 
• New focal neurologic deficit with rapid symptom resolution, usually 1-2 hours, 
always within 24 hours 
• Neuroimaging without tissue injury 
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Myocardial Infarction 
 
New Universal Definition 2012 
 
Type 1: Spontaneous myocardial infarction 
Spontaneous myocardial infarction related to atherosclerotic plaque rupture, ulceration, fissuring, 
erosion, or dissection with resulting intraluminal thrombus in 
one or more of the coronary arteries leading to decreased myocardial blood flow or distal platelet 
emboli with ensuing myocyte necrosis. The patient may have 
underlying severe CAD but on occasion non-obstructive or no CAD. 
 
Type 2: Myocardial infarction secondary to an ischemic imbalance 
In instances of myocardial injury with necrosis where a condition other than CAD contributes to 
an imbalance between myocardial oxygen supply and/or demand, 
e.g. coronary endothelial dysfunction, coronary artery spasm, coronary embolism, tachy-/brady-
arrhythmias, anemia, respiratory failure, hypotension, and 
hypertension with or without LVH. 
 
Type 3: Myocardial infarction resulting in death when biomarker values are unavailable 
Cardiac death with symptoms suggestive of myocardial ischemia and presumed new ischemic 
ECG changes or new LBBB, but death occurring before blood 
samples could be obtained, before cardiac biomarker could rise, or in rare cases cardiac 
biomarkers were not collected. 
 
Type 4a: Myocardial infarction related to percutaneous coronary intervention (PCI) 
Myocardial infarction associated with PCI is arbitrarily defined by elevation of cTn values>5 x 
99th percentile URL in patients with normal baseline values (≤99th percentile URL) or a rise of 
cTn values >20% if the baseline values are elevated and are stable or falling. In addition, either 
(i) symptoms suggestive of myocardial ischemia, or (ii) new ischemic ECG changes or new 
LBBB, or (iii) angiographic loss of patency of a major coronary artery or a side branch or 
persistent slow- or no-flow or embolization, or (iv) imaging demonstration of new loss of viable 
myocardium or new regional wall motion abnormality are required. 
 
Type 4b: Myocardial infarction related to stent thrombosis 
Myocardial infarction associated with stent thrombosis is detected by coronary angiography or 
autopsy in the setting of myocardial ischemia and with a rise and/ 
or fall of cardiac biomarkers values with at least one value above the 99th percentile URL. 
 
Type 5: Myocardial infarction related to coronary artery bypass grafting (CABG) 
Myocardial infarction associated with CABG is arbitrarily defined by elevation of cardiac 
biomarker values >10 x 99th percentile URL in patients with normal 
baseline cTn values (≤99th percentile URL). In addition, either (i) new pathological Q waves or 
new LBBB, or (ii) angiographic documented new graft or new 
native coronary artery occlusion, or (iii) imaging evidence of new loss of viable myocardium or 
new regional wall motion abnormality. 
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Revascularization 
 
The revascularizations will be adjudicated per the ARC definition. 
 • Location of Revascularization: 
 • Target Lesion Revascularization (TLR)  
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass 
surgery of the target vessel performed for restenosis or other complication of the target 
lesion. The target lesion is defined as the treated segment from 5 mm proximal to the 
stent and to 5 mm distal to the stent. 
 • Target Vessel Revascularization (TVR) 
TVR is defined as any repeat percutaneous intervention or surgical bypass of any 
segment of the target vessel. The target vessel is defined as the entire major coronary 
vessel proximal and distal to the target lesion which includes upstream and downstream 
branches and the target lesion itself  
 • Non Target Lesion Revascularization (Non-TLR) 
Any revascularization in the target vessel for a lesion other than the target lesion is 
considered a non-TLR. 
 • Non Target Vessel Revascularization (Non-TVR) 
Revascularization of the vessel identified and treated as the non-target vessel at the time 
of the index procedure.  
 
 
Stent Thrombosis (Per ARC Circulation 2007; 115: 2344-2351) 
 
Stent thrombosis should be reported as a cumulative value at the different time points and with 
the different separate time points. Time 0 is defined as the time point after the guiding catheter 
has been removed and the subject left the catheterization lab.  
 • Timing:  • Acute stent thrombosis*:   0 - 24 hours post stent implantation  • Subacute stent thrombosis*:   >24 hours . 30 days post stent implantation  • Late stent thrombosis†:   30 days - 1 year post stent implantation  • Very late stent thrombosis†:   >1 year post stent implantation  
 
*  Acute/subacute can also be replaced by early stent thrombosis. Early stent thrombosis (0 - 
30 days) - this definition is currently used in the community.  
† Including “primary” as well as “secondary” late stent thrombosis; “secondary” late stent 
thrombosis is a stent thrombosis after a target segment revascularization.  
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• Categories: • Definite • Probable • Possible 
 
Definitions of each category are as follows. 
 • Definite stent thrombosis 
Definite stent thrombosis is considered to have occurred by either angiographic or 
pathologic confirmation. 
  
Angiographic confirmation of stent thrombosis* 
The presence of a thrombus† that originates in the stent or in the segment 5 mm proximal 
or distal to the stent and presence of at least one of the following criteria within a 48-hour 
time window:  
o Acute onset of ischemic symptoms at rest  
o New ischemic ECG changes that suggest acute ischemia  
o Typical elevation or depression in cardiac biomarkers (refer to definition of 
spontaneous MI)  
o Nonocclusive  thrombosis 
o Thrombus Intracoronary thrombus is defined as a (spheric, ovoid, or 
irregular) noncalcified filling defect or lucency surrounded by contrast 
material (on 3 sides or within a coronary stenosis) seen in multiple 
projections, or persistence of contrast material within the lumen, or a 
visible embolization of intraluminal material downstream.  
o Occlusive thrombus  
o TIMI 0 or TIMI 1 in-stent or proximal to a stent up to the most adjacent 
proximal side branch or main branch (if originates from the side branch).  
 
    * The incidental angiographic documentation of stent occlusion in the absence of 
clinical signs or symptoms is not considered a confirmed stent thrombosis. 
     † Intracoronary thrombus. 
 
Pathological confirmation of stent thrombosis  
Evidence of recent thrombus within the stent determined at autopsy or via examination of 
tissue retrieved following thrombectomy.  
 • Probable stent thrombosis 
Either of the following occurred after stent implantation will be considered a probable 
stent thrombosis: 
o Any unexplained death within the first 30 days  
o Irrespective of the time after the index procedure, any MI that is related to 
documented acute ischemia in the territory of the implanted stent without 
angiographic confirmation of stent thrombosis and in the absence of any other 
obvious cause  
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 • Possible stent thrombosis 
Clinical definition of possible stent thrombosis is considered to have occurred with any 
unexplained death from 30 days following intracoronary stenting until end of trial follow 
up. 
 
 
III. Other definitions 
 
ACUTE SUCCESS DEFINITIONS 
 
Clinical Device Success (Lesion Basis) 
Successful delivery and deployment of the assigned device at the intended target lesion and 
successful withdrawal of the delivery system with attainment of final in-stent residual stenosis of 
< 30% by QCA (by visual estimation if QCA unavailable).  
 
Clinical Procedure Success (Patient Basis) 
Achievement of final in-stent residual stenosis of < 30% by QCA (by visual estimation if QCA 
unavailable) with successful delivery and deployment of the assigned device at the intended 
target lesion and successful withdrawal of the delivery system without the occurrence of 
MACCE during the hospital stay (maximum of 7 days), and with or without use of other 
therapeutic device. 
 
In multiple target lesion setting all lesions must meet clinical procedure success criteria to have a 
patient level procedure success. 
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ADVERSE EVENT DEFINITIONS 
 
Adverse Event (AE) 
An adverse event (AE) is any untoward medical occurrence in a subject or clinical investigation 
when subject was treated with a study product and which does not necessarily have a causal 
relationship with the treatment. An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease temporally associated with the 
use of an investigational product whether or not related to the investigational device. 
 
Serious Adverse Event (SAE) 
If an adverse event meets any of the criteria below, it is regarded as a serious adverse event 
(SAE).  
 • Led to death; 
• Led to serious deterioration in the health of a patient that: 
o Resulted in a life threatening illness or injury; 
o Resulted in a permanent impairment of a body structure or a body function; 
o Required in patients hospitalisation or prolongation of existing hospitalisation; 
o Resulted in medical or surgical intervention to prevent permanent impairment to a body 
structure or a body function. 
• Led to foetal distress, foetal death or a congenital abnormality or birth defect. 
 
Adverse Device Effect 
 
Adverse device effects include issues related to its specifications, product experiences and device 
malfunctions, insufficient contents of instruction for use and adverse device effects. It also 
includes inevitable adverse events potentially occurs even if a device is properly used. This 
means that an adverse device effect is defined as any adverse event that is related to the study 
device, or whose relationship to the study device is unknown. 
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Unanticipated Adverse Device Effect (UADE) 
 
An unanticipated adverse device effect is an adverse device effect (including infection that is 
suspected to relate to use of the device) of which occurrence and the occurrence trend such as 
number and frequency of the occurrences, and conditions on the occurrence cannot be predicted 
from the Investigator’s Brochure of the investigational device. 
 
 
Angina Pectoris 
 • Braunwald Classification of Unstable Angina: 
I. New onset of severe or accelerated angina. Patients with new onset (≤ 2 months in 
duration) exertional angina pectoris that is severe or frequent (> 3 episodes/day) or patients 
with chronic stable angina who develop accelerated angina (that is, angina distinctly more 
frequent, severe, longer in duration, or precipitated by distinctly less exertion than 
previously) but who have not experienced pain at rest during the preceding 2 months. 
II. Angina at rest, subacute. Patients with one or more episodes of angina at rest during the 
preceding month but not within the preceding 48 hours. 
III. Angina at rest, acute. Patients with one or more episodes of angina at rest within the 
preceding 48 hours. 
 • Canadian Cardiovascular Society [CCS] Classification of Stable Angina: 
I. Ordinary physical activity does not cause angina; for example walking or climbing stairs, 
angina occurs with strenuous or rapid or prolonged exertion at work or recreation. 
II. Slight limitation of ordinary activity; for example, angina occurs walking or stair 
climbing after meals, in cold, in wind, under emotional stress or only during the few 
hours after awakening, walking more than two blocks on the level or climbing more than 
one flight of ordinary stairs at a normal pace and in normal conditions. 
III. Marked limitation of ordinary activity; for example, angina occurs walking one or two 
blocks on the level or climbing one flight of stairs in normal conditions and at a normal 
pace. 
IV. Inability to carry on any physical activity without discomfort - angina syndrome may be 
present at rest. 
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TIMI (Thrombosis in Myocardial Infarction) Flow Grades 
 
0. No contrast flow through the stenosis.   
1. A small amount of contrast flows through the stenosis but fails to fully opacify the artery 
beyond. 
2. Contrast material flows through the stenosis to opacify the terminal artery segment. 
However, contrast enters the terminal segment perceptibly more slowly than more 
proximal segments. Alternatively, contrast material clears from a segment distal to a 
stenosis noticeably more slowly than from a comparable segment not preceded by a 
significant stenosis. 
3. Anterograde flow into the terminal coronary artery segment through a stenosis is as 
prompt as anterograde flow into a comparable segment proximal to the stenosis. Contrast 
material clears as rapidly from the distal segment as from an uninvolved, more proximal 
segment. 
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23 APPENDIX VI: MSCT ACQUISITION GUIDELINES 
 
[Optimizing Imaging Quality for MSCT and FFRCT] 
 
Introduction 
• Please utilize 64 Slice CT Scanner. 
• Imaging the entire coronary tree allows for the most accurate FFRCT computation. 
 
Preparation 
• Assess heart rate and rhythm. Heart rate control (below 60 beats per minute) reduces 
misregistration and motion artifacts. 
• Heart rate modulation for heart rates >60/min during breath holding. 
o Oral:  metoprolol tartrate 100 mg, one hour before the exam. 
           atenolol 50 mg, one hour before the exam. 
o IV: metoprolol 5 mg, repeated up to 3 times. 
o Contraindications: conduction delays, hypotension, severe asthma, allergy to 
betablockers. 
o Consider ivabradin or calcium antagonist for patients with contra-indications to 
betablockers. 
• Full explanation of exam, and practice breath hold. Ensure breath hold time will be 
sufficient for scan time. Evaluate impact of breath holds on heart rate. 
 
Nitrates and FFRCT.  
• use NTG preferably 3 minutes prior to CT image acquisition; 
• use 1-2 sprays (0.4mg-0.8mg) 
• use beta-blocker with it to avoid reflex tachycardia/vasoconstriction 
• ask patients not to take any nitrates 12-14 hours prior to CT acquisition 
• additional Beta blockade may be given after nitroglycerin to counteract the reflex tachycardia 
 
o Confirm absence of allergy to contrast media (consider prophylaxis for patients with 
doubtful or mild reactions to contrast in the past). 
o No caffeine (coffee, tea, energy drinks, and most soda) products <12h pre-scan. 
o No smoking 5 minutes prior to scan. 
 
Patient installation 
o Attach ECG leads, avoid respiratory muscles, check signal stability during breath hold. 
o Placement of an IV catheter that allows a flow of at least 4 ml/s. 
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Data acquisition 
o Overview/scout of the entire chest. 
o Contrast enhancement:  
o ≥300 g/L iodine contrast medium. 
o Injection rate: 4-6 ml/s. 
o Total amount depends on the patient size, the scan mode and the scan duration.  
o Contrast-scan timing: 
o Test bolus acquisition: 15-20 ml of contrast is injected, preferably followed by a 
bolus chaser. The time of (maximum) enhancement is used as the delay of the 
data acquisition after start of contrast injection.   
o Bolus tracking: arrival of the (entire) bolus is monitored in the ascending aorta. 
To avoid premature triggering of the scan the ROI should be sufficiently large and 
placed away form the superior vena cava. 
o A saline bolus of ≈50 ml is injected after the contrast medium at the same rate. 
o Scan mode (depending on the available CT equipment and local experience): 
o ECG-gated spiral scan mode. ECG-triggered tube modulation: use and nominal 
output width depending on the heart rate and rate stability. Full-output window 
wider, to include both end-systolic and diastolic phase, for heart rates >70/min.   
o ECG-triggered sequential (step-and-shoot) scan mode can be used by experienced 
sites for patients with a modest heart rate (<70-75/min) without rhythm 
irregularities. Scan window preferably widened to allow reconstruction of more 
phases, wider for faster heart rates (>65/min).  
o High-pitch spiral scans (Definition Flash®) not recommended.  
o Acquisition parameters: 
o Thinnest detector width. 
o Tube current (mA), depending on the size of the patient.  
o Tube voltage 120 kV, 100 kV can be considered for (very) small patients (<70 kg).  
o Scan range: from 1-2 cm below the carina until the caudal border of the heart. 
 
Image reconstruction (appropriately labelled): 
1) Standard reconstructions: 
o Standard medium-sharp convolution kernel. 
o ECG-editing, if necessary. 
o Field-of-view enclosing the entire heart (cover inferior carina to lower heart border) 
(approx. 18 x 18 cm). 
o Reconstructed slice thickness equal or slightly wider than the individual detector 
width. In case of noisy images (obesity), thicker-slice reconstructions may be added.  
o Reconstructions of at least three different phases. Depending on the scan protocol 
both diastolic and systolic reconstructions should be performed.  
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o Reconstructions should be optimized for the segments of interest (ROI). In case of 
suboptimal image quality other phases should be explored.  
o In case of slab artifacts at the level of the lesions/segments of interest, ECG editing 
may improve image quality.  
2) Sharp-kernel reconstructions:  
o Thinnest slice thickness 
o One or two reconstructions at the best phase for each of the one or two stented 
segments, based on the standard reconstructions. 
 
DVD recording:  
o Topogram. 
o ECG file. 
o Scan protocol file containing: scan mode, mA, kV, DLP, etc.  
o Standard kernel reconstructions, at least one (or the same) optimal phase for each 
diseased coronary segment, preferably three or more datasets including both systolic and 
diastolic phases. 
o Sharp kernel reconstructions (dedicated stent reconstruction), at least one (or the same) 
optimal phase for each diseased segment.  
 
 
 
 
 
Summary 
 
• FFRCT is derived from precise modelling of the coronary tree, not just areas of 
disease 
 
• cCTA best practices = best practices for FFRCT data 
J Cardiovasc Comput Tomogr. 2009 May-Jun;3(3):190-204 
 
• Scan optimization is essential in unlocking the potential of FFRCT 
 
 
 
 
 
